<SEC-DOCUMENT>0001798749-23-000015.txt : 20230329
<SEC-HEADER>0001798749-23-000015.hdr.sgml : 20230329
<ACCEPTANCE-DATETIME>20230329170443
ACCESSION NUMBER:		0001798749-23-000015
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230329
DATE AS OF CHANGE:		20230329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aerovate Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001798749
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831377888
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40544
		FILM NUMBER:		23776053

	BUSINESS ADDRESS:	
		STREET 1:		930 WINTER STREET
		STREET 2:		SUITE M-500
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-443-2400

	MAIL ADDRESS:	
		STREET 1:		930 WINTER STREET
		STREET 2:		SUITE M-500
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tmb-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/29/2023 8:26:16 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: ce1f72e0-9ee2-4d12-96d4-ea1a8698cc05 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:avte="http://aerovatetx.com/20221231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_RaXIuauWqku0Xun2qBu32g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_-DTqJjWD8U-hAZ9Yia9iSQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" name="us-gaap:PreferredStockValue" id="Hidden_bJuePYP0z0enEK1t8naDBw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" name="us-gaap:PreferredStockValue" id="Hidden_nnISsMCKK0SB6DzIZRp3nQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i_IWKm7ZUkG0SD8gBMvkNg" name="us-gaap:StockholdersEquity" id="Hidden_z_7Smwx-xk6PNyccCkFacw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IdoElH_PsUqt48Em-48oBQ" name="us-gaap:StockholdersEquity" id="Hidden_FgzULbdEkEmMgengviJ06w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" id="Hidden_vGST7hUNHUyjx-QRVKVB1A"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" id="Hidden_PVPYhzV1KUSipoQZo14khg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" id="Hidden_p1B0cgyja0eXXB8mJzHwhA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" id="Hidden_zcK2QswtF0-XQisdNE1kTQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" id="Hidden_8gXmbsc5V0WGwB8z3WrE4w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" id="Hidden_oWEmnNhdQEiWCw4bOf86UQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" id="Hidden_0eG-SoEK5kuF1ShBTbmZBA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" id="Hidden_vYbLbfdpEUebrPRsjQkIrg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" id="Hidden_9TlgPwHWh0uwDbto1Gn0ag"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" id="Hidden_CF5UUFhDtkuwemyNcYLVqg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA" name="avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" id="Hidden_GU_-C10K_kufCNxbtEHvYw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g" name="avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" id="Hidden_xUSK3YkFk0WkQFu1WRz5ng"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Hidden_912yMiQA6EuoTS2GqOOWZg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Hidden_SPYadEtbxUyiMyoMbj-zGw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Hidden_kME_VnS40Ey8bN1ipvIIgg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Hidden_O4BKDDh0GkaxTRKHLBJZgQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" id="Hidden_cd88Enej1kGdiFZxGBTS-w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" id="Hidden_3AeL89uIOUWv41QC_R_viQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" id="Hidden_1_lGy5tgq0Cu3RjgvjBrwA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" id="Hidden_jf-F9WUfIkyExXtG1HLbpA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" id="Hidden_q6gqT2ZUikaTPHXP0K2tnw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Hidden_nj82nS1K_EyhUa226xKdDw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Hidden_shlVgBLiW06hH9N0n9n3nA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Hidden_4BYXfP_Jb0SBZ-QiJJauxA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Hidden_-htaxShuM0mu9hvSRX9XlA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Hidden_WdzbLmCHVkKzYMBb7IboLQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA" name="us-gaap:NetIncomeLoss" id="Hidden_xugVTio6i0afQ8eJushCTw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg" name="us-gaap:NetIncomeLoss" id="Hidden_Tfghgj6ncUaJhMrK7Zddcg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw" name="us-gaap:NetIncomeLoss" id="Hidden_bUCrvbpg-UOAq0-Dzxstgw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g" name="us-gaap:NetIncomeLoss" id="Hidden_Zab77IL0sEuX-g4J7QAoxw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA" name="us-gaap:NetIncomeLoss" id="Hidden_g0jXDBz0lEqllR8Gr6oWSA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" xs:nil="true" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjitDg4W4EOE9Yf-R3ycdQ" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_V7_LcdS0EE6yymFDgcmfhA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjitDg4W4EOE9Yf-R3ycdQ" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Hidden_V0VRYutPckKpqgmFqtDXwA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" xs:nil="true" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Qt-J82d3_02alNEkJwIh1g" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_89y_KHQk9EymnrvTUUnZ4g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Qt-J82d3_02alNEkJwIh1g" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Hidden__cF4v94lHEyR31ih6-E_WQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_hkNcRgCMlEqt8tgDQQSL_A" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" id="Hidden_OmhxfVgQCESxlgDb4_pJpA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8bQICbmQLU2n6JGchvzzOQ" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" id="Hidden_q7BbjAy1H0GnnYjlqlNn1Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" id="Hidden_Ze7UL0SREU-ymT6vUXcLKw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxaL35pKjEOanh6iG7wiBQ" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" id="Hidden_cemoZSwJvUGon3ssmaX5Sw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KD9Fb9Ua2k--d7ATP52t5w" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" id="Hidden_QGA3oU86m0uadUBtG201gA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_hkNcRgCMlEqt8tgDQQSL_A" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Hidden_pfuZVQLFS0iQYSds25WBYg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8bQICbmQLU2n6JGchvzzOQ" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Hidden_BAqDeljnCUWK-LcCFz5e8g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Hidden_DW-qWgX6KUGWwHIIOUBVYQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yReDKtcgo0KOffS55fF_QQ" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Hidden_YZqCbmXx5EO_3uRH4nk_Uw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KD9Fb9Ua2k--d7ATP52t5w" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Hidden_DraQ_PjnZ06wPW8F-PJ8Fw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_hkNcRgCMlEqt8tgDQQSL_A" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Hidden_SkywTp5LwEarI0V2Akphrg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8bQICbmQLU2n6JGchvzzOQ" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Hidden_Rve_yEtVik-IvzJJRRL0XA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Hidden_WWFZwnrdM0ySldpeT4dC9A"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yReDKtcgo0KOffS55fF_QQ" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Hidden_voeCO464H0uFQ8dGV2vLbg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KD9Fb9Ua2k--d7ATP52t5w" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Hidden_ttimKTVVBE-5HnXVZ5mGvw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_hkNcRgCMlEqt8tgDQQSL_A" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Hidden_9Z36iEtH-U6auxzWMeR0kA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8bQICbmQLU2n6JGchvzzOQ" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Hidden_JRtInkjAkUuk9CReiPXp-Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Hidden_5WQjntt1FkWeCko6wgN7qA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yReDKtcgo0KOffS55fF_QQ" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Hidden_ji1TW4Zr2kqi-qIrB_6mwg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KD9Fb9Ua2k--d7ATP52t5w" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Hidden_d3SsXOCB50K_JnEqsVSgLg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_hkNcRgCMlEqt8tgDQQSL_A" name="us-gaap:NetIncomeLoss" id="Hidden_A62rI6HNkUCVIRjAlLZg0Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8bQICbmQLU2n6JGchvzzOQ" name="us-gaap:NetIncomeLoss" id="Hidden_CVAmf7WadUq49f3TtsN3IQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ" name="us-gaap:NetIncomeLoss" id="Hidden_CGyXEL1XvUqkgQurGsmk1A"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxaL35pKjEOanh6iG7wiBQ" name="us-gaap:NetIncomeLoss" id="Hidden_JxIe_etIgESVo40crkG05w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yReDKtcgo0KOffS55fF_QQ" name="us-gaap:NetIncomeLoss" id="Hidden_UFXC1_PXnEOl3UAe3rfe4Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" xs:nil="true" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ox5viBwu-U-6f6s2IgjvBg" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_b1yO5jQyE0u1XcHo2dnzDQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ox5viBwu-U-6f6s2IgjvBg" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Hidden_vgAee7eWOkaa4ZB8w02AzA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" xs:nil="true" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_k2O0Ht8ZSEm2brOMJb52XA" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_7aPy-MGM50yJ2UV_65neTQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_k2O0Ht8ZSEm2brOMJb52XA" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="Hidden_ao9WX4t1XEmuc3Xz8JS1ow"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Hidden_P4znHQF3GUSWjTutnltemQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" name="avte:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" id="Hidden_E0ae-PWvkE-yL5o9JZGx5w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Hidden_nezSGvSzDU6xkqS5dwZsuQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" id="Hidden_8vjjWyCvikyedSLToWmJjA"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityWellKnownSeasonedIssuer" id="Hidden_ItY5_fvRF0q33fgyjXsiMQ">No</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityVoluntaryFilers" id="Hidden_951k_fTdP0-aD5ub2vV5Ww">No</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityCurrentReportingStatus" id="Hidden_4PoK6XCve0q_m0oUzP4FUg">Yes</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityInteractiveDataCurrent" id="Hidden_G02T1cY-L02zTAI_qfAWFw">Yes</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityCentralIndexKey" id="Tc_z0txTyMl102jua1CHGpErw_2_1">0001798749</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:DocumentFiscalPeriodFocus" id="Tc_Xw4qNEvuHUSOT6cIiMx_SQ_4_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:AmendmentFlag" id="Tc_HDKCuFaf3U6Ijvfa7Z3--A_5_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_GAre_n3AxkK4BhXuL_0rVg">24410393</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_dQ_Cvl9mWESujqCYmrqZLQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_H-3bEaFh4E-Fr641fpNCcQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_6_22_2021_To_6_22_2021_bf3_5zAtv0aORHhCRdPPag" decimals="6" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_AH0m-scr1ESIQqpsOnDeyg">0.321956</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_KeaWaOuYKEmKgtUe5KHG_A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_uKh2d8qoz0GftAIlA0yOkQ">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_aiS3g6rqK0C4IYQ7jBBLcw" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_bBazvaq5mUO3D78wc3eoZQ">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_L6Aulrv6skCjIRhGAQFN1w" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_Ha-ILLgVZUue-n7HxT3H2Q">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_NQg-uPEboUy3bkc7fClBSQ">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_yRE9VHYos06cYhHQPpwzYQ">24722974</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_32nsRXZZeE2LhzKjEdHwoQ" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_gWG-e8KNUkuG8sHbxrnFJA">P1Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tmb-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_6_3_2021_To_6_4_2021_avte_MilestoneAxis_avte_SecondAndThirdMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_rGO8UuK3d0mu99ddFv5hjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="avte:MilestoneAxis">avte:SecondAndThirdMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-03</xbrli:startDate><xbrli:endDate>2021-06-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_30_2021_To_2_1_2021_avte_MilestoneAxis_avte_FirstMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_hfGGAslhNEeVOwN6WrF5gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="avte:MilestoneAxis">avte:FirstMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-30</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_4_2020_To_8_5_2020_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_Dv12U9pPlk25gS6TpZJscg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_4_2020_To_8_5_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_KQ7-UIfWqUG1_y4Ju1lXmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_vnUkVXoGN0-57YWUs8EYpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_4_2021_avte_MilestoneAxis_avte_SecondAndThirdMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_GDEihDdvTUyXLABx1mfHnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="avte:MilestoneAxis">avte:SecondAndThirdMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_1_2021_avte_MilestoneAxis_avte_FirstMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_wwresvhtM0-V7mH5Vgo-hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="avte:MilestoneAxis">avte:FirstMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_crMw-EmKcUeuKdVO9DDyyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_No7St9Lvr0y96G_5EWC44g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_W0a55wDra0WelJUBZUsesw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_k2O0Ht8ZSEm2brOMJb52XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ox5viBwu-U-6f6s2IgjvBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Qt-J82d3_02alNEkJwIh1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_9gGeJ_r-oESMCylkTiaQrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8aHpRkxHpkCDJdb7yykJBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_qthA2_MWG0-O-o6csyodmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_45gK5TQqjU22PAv52bixOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_StockCompensationPlanMember_gpUHdU7SI0iF5rb9E2h1XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2021_To_6_22_2021_bf3_5zAtv0aORHhCRdPPag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-22</xbrli:startDate><xbrli:endDate>2021-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wX9u88nSX0ugu2QhP2n3ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KBAJsq8X1UePf0wtOE4-gA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ONawfJkraU2j7s81xUzW8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HN0Xoks5e0ezwLw29ZL8OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3CjGTVHCT0eUwawBJaweUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6B2XB2kFVUWrsHm32rtreg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FlYzV5V60kKR3Xb49ZQI6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PcOQWpSW2EGd9KpeiSRIIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IdoElH_PsUqt48Em-48oBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_rPrkP4ujk0W_7H8LCrqXLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_zemR5DkqREKFgJjFkN8qqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VJ2CIL3_20mu--166dWxVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_zqKb8DAZgESt_eax0wleGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_aQq0ijr06kSW_SZprlK7sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_USRDgmPtwkOyBzlosVP3AQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_tGjRsdl680qEsQ3mUldJJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8VmyKaoxLEOzzbfyzwCJ2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_RR9WWKOeMEOQdAup8Pv4AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_y6dmyknKUU-SGERHF0Dc_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YwXIEvLewkaQioMwjwbsbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ok3TV3BnH0eWo3UW7uDQug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i_IWKm7ZUkG0SD8gBMvkNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjitDg4W4EOE9Yf-R3ycdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_5_2020_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_oObJ-Nmc4UqeH2X0G6kfiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyEighteenStockOptionAndIncentivePlanMember_xoITfiC24kGgUX1H39EHoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_vrB-dEU-EE2kBgR4L-Vkig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_U-Vimp94EE-Vhg_ROQBzFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_KW9jG2TQGUqptBykLu-x_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_8KFv4vg0cUCOT78XuWQJLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_hoI7V65KHEG5GkLS5GdTEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_VdsnaK6Ohkqmx-_Z9SCPxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ZEq1R1quB0CHCsbXWqAwWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_jKuzK2N-lk6r-oAi8Vk34Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_tvsHVVkheEq71hXbwUCgSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_Cyq09hAZqUesspxvNiCeCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_StqYaHLjzEKZmEQ6yLvUGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_iezkj5eDqUCfolKO8YRv0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_KeaWaOuYKEmKgtUe5KHG_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_9FuVdbUhV0uvrx8hBa_1RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_32nsRXZZeE2LhzKjEdHwoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fJh_ywGZikyIQAcBTW536A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8pxhy8PI8Ei91_HCoX_sIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_38m67FS0GEuKtolLvc65gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_GUwnxPWZUk-8QC102OTn9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_avte_JefferiesMember_XuFYdSUixkyetwSnndM8uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_15_2022_To_8_15_2022_srt_CounterpartyNameAxis_avte_JefferiesMember_FWTe7abbGk2o3kC0iODEaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-15</xbrli:startDate><xbrli:endDate>2022-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeStatementLocationAxis_avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_6iVtOxWY10m-DhjKq-psJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">avte:ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_qimOehD_5ke94_ayOtSdCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">avte:ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_aiS3g6rqK0C4IYQ7jBBLcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_L6Aulrv6skCjIRhGAQFN1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_f35-tn37YkSEpT0jtT5KhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_rRDeb8AKE02Eu6qsh0BInw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember__U571LHq90ebMUCnu-8gKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bX05x-nRLk2IigYinMKBjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_Gyry4bLRNEOzHxfxq7X4iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_c5GfZjqasEeR4_aZW3f6NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_gjNW4nJ7gUG3lYvOm_OCOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ffQ1QIahIk-nBDBoGTbC3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_3BpSFz349EKBC1pez2vW1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_uqnI7J_-ykeUEvSi8eqaBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_2_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_xbOuftPGHkeAHGLhw_3HrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_djafJWnh40CLwBS3AvdTBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_22_2021_zuE5gWkeyk2gMuDMHkgnlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BFKtiMbYKEWGiX8enBMhZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_7kFZeYf8XkSj3t3wwiM5lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_CommonStockMember_aFm9TwWFNkWt1zWekbZnjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_TXk4moIa40GbN1BvRlu_JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BZC2smINzEqMpJkFZy61dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__I6MyJ-3P0WLSD1L0CQLMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_btTJ7hB3m0msnUE_XEjudA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XKXReW8Iv0iqNoVsfOn3wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1EYoksMxjEatDkF4HraTtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_X-cBBwKLukqd96ZZFzoANQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_lex_lE13Tka9RtZYzaRxrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6Vn0yOonI0i5051pthm-IQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ydsgvjwLrUe_yWrw82jE-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CkuAokZFEE6-3rAKVgGLlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tuJ-pg1BnECbTpf6Uk40Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fkQ2x2flakWcJsOn3HTX-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_h7PXcaYot0um0bjFUh0YmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_nM5HHKPZJk6bkcFB2fyHpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:FosterCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_I5wcShJpG0OhjXjvlcq-_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_o4StUCQIc0a31cjpbHrNkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2u36RAc4eEiBYcmpsvX8AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_rJ1OBbHLXUyHKgkaKxW57Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2skYMq1PvUmc9GZXaVoMzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_fPutlC_Wlkew2sr7ZE8ROQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_BRUvW3FPrk2wFPzvj1avag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_PUAKc7nXUEaEH4mxzoylkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8bQICbmQLU2n6JGchvzzOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_hkNcRgCMlEqt8tgDQQSL_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KD9Fb9Ua2k--d7ATP52t5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxaL35pKjEOanh6iG7wiBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yReDKtcgo0KOffS55fF_QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_KRknw7U1FU-LFYLG7DaGWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_VCaJi4v2YU2yhYi2bTbHgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_IosAfoWctk-rd00ZZE-fvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2023_ZaOeJvmGG0W1uFVcFuGpRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_5_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_pNNDYw-rNUWvdmmuAHZlsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_0fmPIdzRUE-bEqICdqsXyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_7_31_2019_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_524LLIpT_U62C9wdu6QZ1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_PvcTYb2K9UG6ACE8durCkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_efAf7fiBWUqdDgHCEPGdfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_mp5ueIyU6EupPXatRN7igQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:FosterCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_YaLLcUjHZki458JcBBF_AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_PvqmJS3bP0uIcfv-_n2kqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7ZoMrQXRJk2hJ6cbQPFKvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xiCQZvKWqESmhAB-Ehu1tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_7nzerVxUhkyRb7q9DTrxjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_j8WxaSALUESwMgXMefh0UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_mt2q9GoKi0-AvNO-EXkZnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_U58quFcv5ki9AFPMBo9uqw"><xbrli:measure>avte:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_UveSBE_izUeNb4VPRsSftw"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_4id_vXrVjkay3ChrkF2qUA"><xbrli:measure>avte:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_6fafb4fa_9935_41d6_abbf_a23f47f8c9dc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:DocumentType" id="Narr_bxJu0DrASEKavvqHUGDwPA"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">(Mark One)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:DocumentAnnualReport" id="Narr_fmRJmnKK5EuazSWj_qcHrA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4pt;margin-top:0pt;"><b style="font-size:8pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:DocumentPeriodEndDate" id="Narr_Gk3GxdSUiU-5DEPfIn6LzA"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:CurrentFiscalYearEndDate" id="Narr_Zcc_EcwdN0GpE5ry0pgC6Q"><b style="font-size:8pt;font-weight:bold;">December&#160;31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">,&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:DocumentFiscalYearFocus" id="Narr_QJgK4defjUiYfnmb5wvxgQ"><b style="font-size:8pt;font-weight:bold;">2022</b></ix:nonNumeric></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:DocumentTransitionReport" id="Narr_DcXGMCXJokWebZOTZfwTzg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4pt;margin-top:0pt;"><b style="font-size:8pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityFileNumber" id="Narr_rPxpwea9IUaU6ZLJQa9JzA"><b style="font-size:8pt;font-weight:bold;">001-40544</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityRegistrantName" id="Narr_b0_GqEKlqEWepekGg5s7pw"><b style="font-weight:bold;">Aerovate Therapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of Registrant as specified in its Charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f5a727b6_33ea_4b76_98a4_e92025f44735"></a><a id="Tc_BEuxB4ks5ke6myeeNdrCGg_2_0"></a><a id="Tc_o0Ebrjfu7kOWmq_mUOg9tQ_2_1"></a><a id="Tc_NbkmH00nXUSXEgXmrEm30A_3_0"></a><a id="Tc_u8tOaPpOJE-M49A5Wp6J6g_3_1"></a><a id="Tc_WhFcIp_c-0KuBDj8nOdyeg_5_0"></a><a id="Tc_Js2P_eCK5EO-10OHxXZ1xA_6_0"></a><a id="Tc_Y8kUv3YOWEm2xZmnTuHKcg_7_0"></a><a id="Tc_-hbULQUg506UD_ag3hny-Q_7_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityIncorporationStateCountryCode" id="Tc_aesgckgwxU6XQNPwkwnaRA_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityTaxIdentificationNumber" id="Tc_hzXkZKkGek2BvcENovEgjg_1_1"><b style="font-size:8pt;font-weight:bold;">83-1377888</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b></p></td><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityAddressAddressLine1" id="Narr_YPngDXHlZEKrYu711HJTng"><b style="font-size:8pt;font-weight:bold;">930 Winter Street</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityAddressAddressLine2" id="Narr_f3vZT0ztKECSK0ez7tJV0A"><b style="font-size:8pt;font-weight:bold;">Suite&#160;M-500</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityAddressCityOrTown" id="Narr_A3XL1gLaQ0i1Nj1gJNVhjw"><b style="font-size:8pt;font-weight:bold;">Waltham</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityAddressStateOrProvince" id="Narr_HdvTLLpr20u3271TWWhIxg"><b style="font-size:8pt;font-weight:bold;">MA</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityAddressPostalZipCode" id="Narr_cg6I6awGjUygzsLZ45J16g"><b style="font-size:8pt;font-weight:bold;">02451</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityAddressPostalZipCode" id="Tc_xnefd11PlEWAeyw0S-WftA_6_1"><b style="font-size:8pt;font-weight:bold;">02451</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:CityAreaCode" id="Narr_GedMZUOVCk2ZrYJViqlmxw"><b style="font-size:8pt;font-weight:bold;">617</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:LocalPhoneNumber" id="Narr_NfYxuY1eTU2yuAXU8Ef5tA"><b style="font-size:8pt;font-weight:bold;">443-2400</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_c849976f_deb5_44dd_bf71_e50044354ec1"></a><a id="Tc_kWZ7v7vEdkqwNcH2S2bRJg_0_0"></a><a id="Tc_dcI86FuCDEmm2V27rQkuQA_0_2"></a><a id="Tc_p2clfpkHJk-vO_BLJzaSjQ_0_4"></a><a id="Tc_uBHkjBLwLEekQ17Te2voXg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:5.85pt;"><td style="vertical-align:bottom;width:28.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:29.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:29.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:Security12bTitle" id="Tc_8M8mjX31602kHlXRLwyUZA_1_0"><span style="font-size:8pt;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:TradingSymbol" id="Tc_sRvzthd8nEChtJMeX8dgGQ_1_2"><span style="font-size:8pt;">AVTE</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:SecurityExchangeName" id="Narr_T1u6SVLldEGn9nipcxDdSg"><span style="font-size:8pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:8pt;"> Global Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Securities registered pursuant to Section 12(g) of the Act: <b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. YES </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><span style="-sec-ix-hidden:Hidden_ItY5_fvRF0q33fgyjXsiMQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">NO</span></span><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act. YES </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><span style="-sec-ix-hidden:Hidden_951k_fTdP0-aD5ub2vV5Ww;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">NO</span></span><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><span style="-sec-ix-hidden:Hidden_4PoK6XCve0q_m0oUzP4FUg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">YES</span></span><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> NO </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). </span><span style="-sec-ix-hidden:Hidden_G02T1cY-L02zTAI_qfAWFw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">YES</span></span><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> NO </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c24ac06d_2cef_48af_93f4_d7d3d27643e9"></a><a id="Tc_V0L_Ry-BmEeaQpHzAPNmUw_1_0"></a><a id="Tc_-0y-yseIiUKVIcKOcUqlNw_1_1"></a><a id="Tc_5eNwbAFVlUGt2p2jd5MMsw_1_2"></a><a id="Tc_hoaKFzlMxU20tps2VV54QQ_1_3"></a><a id="Tc_UrUdcuZTuUaXRXEqN9JAqg_2_1"></a><a id="Tc_jexQFgavCEuP1Lfm_420nA_2_2"></a><a id="Tc_UY2QT9O5REeNE368fS4o3A_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 16pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 80pt;">Accelerated filer</p></td><td style="vertical-align:bottom;width:16.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 87pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityFilerCategory" id="Tc_NYzZEOQvdUuM2rtHDqloSw_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 16pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 80pt;">Smaller reporting company</p></td><td style="vertical-align:bottom;width:16.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 87pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntitySmallBusiness" id="Tc_rBwI0A5xMUmmWBDVrJQ3qw_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:41.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 80pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:16.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 87pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityEmergingGrowthCompany" id="Tc_IcTEKYC2W0uGJkCW6sX9Xw_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityExTransitionPeriod" id="Narr_ruT7_OtHMkeUwZTRUWP62w"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:IcfrAuditorAttestationFlag" id="Narr_K0bKagzOWEmq_PyRQKDHLA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). YES </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> NO </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:EntityShellCompany" id="Narr_j516FwJUTUeVLj7Arlixfg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">As of June 30, 2022 (the last business day of the Registrant&#8217;s most recently completed second quarter) the aggregate market value of the Registrant&#8217;s common stock held by non-affiliates of the Registrant was $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2022_IosAfoWctk-rd00ZZE-fvg" decimals="-5" name="dei:EntityPublicFloat" id="Narr_PAkVaPg2KUaA6S_1PFH8fw">157.3</ix:nonFraction> million, based on the closing price of the Registrant&#8217;s common stock as reported on the Nasdaq Global Market of $15.63 per share. In determining the market value of non-affiliate common stock, shares of the Registrant&#8217;s common stock beneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 4pt 0pt;">The number of shares of Registrant&#8217;s Common Stock outstanding as of March&#160;27, 2023 was <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_27_2023_ZaOeJvmGG0W1uFVcFuGpRQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_ciwI8IpWXEaonpr_wX2Z4w">24,812,418</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="Tb_Bm2H4YMdY0u_6YZqU9zoDw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 4pt 0pt;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2023 Annual Meeting of Stockholders within 120&#160;days of the end of the registrant&#8217;s fiscal&#160;year ended December&#160;31, 2022. Portions of such definitive proxy statement are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K to the extent stated herein.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_47ce07b9_9ff3_44de_9d89_766fa039c400"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="TOC"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0pt 38pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Table of Contents</b></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTI_316884"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1Business_794628"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item1Business_794628"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1ARiskFactors_707099"><span style="font-style:normal;font-weight:normal;">Item 1A.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item1ARiskFactors_707099"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">48</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_255070"><span style="font-style:normal;font-weight:normal;">Item 1B.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_255070"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">97</p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item2Properties_265850"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item2Properties_265850"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">97</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item3LegalProceedings_561652"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item3LegalProceedings_561652"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">97</p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_480642"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item4MineSafetyDisclosures_480642"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">97</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTII_103847"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">97</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">97</p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item6Reserved_387707"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item6Reserved_387707"><span style="font-style:normal;font-weight:normal;">Reserved</span></a></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">98</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item 7.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">98</p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item 7A.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">105</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">105</p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementsWithAccoun"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item9ChangesinandDisagreementsWithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">105</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item9AControlsandProcedures_752435"><span style="font-style:normal;font-weight:normal;">Item 9A.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item9AControlsandProcedures_752435"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">106</p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item9BOtherInformation_913298"><span style="font-style:normal;font-weight:normal;">Item 9B.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item9BOtherInformation_913298"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTIII_336999"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item 10.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_18647"><span style="font-style:normal;font-weight:normal;">Item 11.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item11ExecutiveCompensation_18647"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item 12.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item 13.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Item 14.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTIV_243698"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item15ExhibitsFinancialStatementSchedule"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item15ExhibitsFinancialStatementSchedule"><span style="font-style:normal;font-weight:normal;">Exhibits, Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item16Form10KSummary_747275"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:83.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item16Form10KSummary_747275"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0pt 31pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#SIGNATURES_810279"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">104</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c15b4906_2412_4ddd_9886_c8e04add1cb9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SUMMARY OF THE MATERIAL AND OTHER RISKS ASSOCIATED WITH OUR BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are a clinical-stage biopharmaceutical company with a limited operating history.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant operating losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have no products approved for commercial sale and have not generated any revenue from product sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business is entirely dependent on the successful development, regulatory approval and commercialization of AV-101, our only product candidate under development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The ongoing COVID-19 pandemic, or a similar pandemic, epidemic, or outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of AV-101. As a result of medical complications associated with pulmonary arterial hypertension, or PAH, the patient populations that AV-101 targets may be particularly susceptible to COVID-19 and its variants, which may make it more difficult for us to identify patients able to enroll in our current and future clinical trials and may impact the ability of enrolled patients to complete any such trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are conducting our first late-stage clinical trial of AV-101, a dry powder formulation of imatinib for the treatment of PAH administered using a dry powder inhaler, to assess its safety and tolerability. Although we believe that AV-101 has therapeutic potential for PAH based on oral imatinib&#8217;s results in the Phase 3 IMPRES trial, we are utilizing a novel dry powder formulation which may not achieve better or similar levels of clinical activity or may have similar tolerability challenges as oral imatinib. The results of earlier studies and trials of oral imatinib in PAH patients and our Phase 1 clinical trial of AV-101 in healthy volunteers may not be predictive of future trial results for AV-101.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we continue to encounter difficulties with site activation and patient enrollment in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face, and will continue to face, significant competition and our failure to effectively compete may prevent us from achieving significant market penetration for AV-101, if approved. Most of our competitors have significantly greater resources than we do and we may not be able to successfully compete.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely, and intend to continue to rely, on qualified third parties to supply all components of AV-101. As a result, we are dependent on several third parties, some of which are sole source suppliers, for the manufacture of AV-101 and our supply chain, and if we experience problems with any of these suppliers, or they fail to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, it would materially and adversely affect our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely, and intend to continue to rely, on third parties in the conduct of all of our clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for AV-101.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have four issued U.S. patents and many pending patent applications with respect to AV-101. We can provide no assurance that any of our other current or future patent applications will result in issued patents. If we cannot protect our patent rights or our other proprietary rights, others may develop products similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any product candidates we may develop.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be unable to obtain regulatory approval for AV-101 under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of AV-101 and adversely impact our potential to generate revenue, our business and our results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AV-101 is a drug-device combination product, which may result in additional regulatory risks.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are currently conducting, and may in the future conduct clinical trials for AV-101 outside the United States, and the U.S. Food and Drug Administration, European Medicines Agency, and applicable foreign regulatory authorities may not accept data from such trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, our business may be materially and adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The material and other risks summarized above should be read together with the text of the full risk factors below and in the other information set forth in this Annual Report on Form&#160;10-K, including our consolidated financial statements and the related notes, as well as in other documents that we file with the U.S. Securities and Exchange Commission, or the SEC. If any such material and other risks and uncertainties actually occur, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks summarized above or described in full under Item&#160;1A of this Annual Report on Form&#160;10-K are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b1fe2147_e5d8_4b44_a0b0_11b94dd15e56"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Annual Report on Form&#160;10-K include, but are not limited to, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, timing, progress, results and cost of our research and development program for AV-101 and our current and future clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work and the period during which the results of the trials will become available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the potential market size and size of the potential patient populations for AV-101, if approved for commercial use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our clinical and regulatory development plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations with regard to the data to be derived from our ongoing global Phase 2b/Phase 3 clinical trial, or any other product candidates that we may identify or develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing or likelihood of regulatory filings and approvals for AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to commercialize AV-101, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the pricing and reimbursement of AV-101, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the implementation of our business model and strategic plans for our business and AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimates of our future expenses, revenues, capital requirements and our needs for additional financing, and our ability to obtain additional capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of protection we are able to establish and maintain for intellectual property rights covering AV-101, including the projected terms of patent protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the United States and foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enter into strategic collaborations, including for the commercialization of AV-101 outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate and degree of market acceptance of AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to contract with third-party suppliers, manufacturers and contract research organizations, or CROs, and their ability to perform adequately;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competing therapies for PAH that are or may become available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry, including the impact of government regulation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract and retain key scientific or management personnel;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain additional funding for our operations, when needed, including funding necessary to complete further development and commercialization of AV-101, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our financial performance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of the ongoing COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our clinical trials and any future studies or trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risks and uncertainties, including those listed under the section titled &#8220;Risk Factors.&#8221;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed above under &#8220;Summary of the Material Risks Associated with Our Business&#8221; and under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form&#160;10-K. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Annual Report on Form&#160;10-K and the documents that we reference in this Annual Report on Form&#160;10-K and have filed with the Securities and Exchange Commission, or the SEC, as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The forward-looking statements in this Annual Report on Form&#160;10-K represent our views as of the date of this Annual Report on Form&#160;10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Annual Report on Form&#160;10-K, their estimates, in particular as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e2557163_5038_4f88_bba3_212d4b3430a1"></a><a id="PARTI_316884"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I</p><a id="Item1Business_794628"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unless the context requires otherwise, references in this Annual Report on Form&#160;10-K to &#8220;Aerovate&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to Aerovate Therapeutics,&#160;Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Our initial focus is on advancing AV-101, our dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, or PAH, a devastating disease impacting approximately 70,000 people in the United States and Europe. Imatinib, marketed as Gleevec tablets, was originally developed for the treatment of multiple cancers. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients in an international Phase 3 trial conducted by Novartis but was poorly tolerated due to adverse events, or AEs, and never approved for the treatment of PAH. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. We have completed a Phase 1 clinical trial in healthy volunteers and AV-101 was generally well-tolerated with no serious adverse events reported. We are enrolling patients in Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), our global Phase 2b/Phase 3 trial of AV-101 in adults with PAH, and we have assembled a team with deep expertise in developing innovative PAH and inhaled therapies and commercializing novel drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PAH is an orphan disease with unmet medical need and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs. This high pressure is caused by abnormal cellular hyperproliferation and resistance to apoptosis, driven by improper signaling in cells of the distal pulmonary arteries, which over time results in narrowing of the pulmonary vessels and forces the heart to work harder to pump blood through the lungs. The severe blood flow restriction and strain on the heart becomes increasingly severe over time and ultimately leads to heart failure that is often fatal. We estimate there are between 30,000-40,000 patients treated with approved PAH therapies in the U.S. alone, many of whom are on two or more approved PAH therapies. It is estimated that the combined global sales for PAH products in 2022 was $6.1 billion. Despite the availability of multiple approved therapies, PAH has a five-year survival rate for newly diagnosed and prevalent patients between 61% and 65%. None of the approved therapies directly address the abnormal cellular hyperproliferation of the pulmonary vasculature that causes the increased resistance to blood flow. We believe that novel treatments that primarily address abnormal cellular hyperproliferation may provide therapeutic benefit to PAH patients and lead to improved quality of life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our focus on developing AV-101 is driven by historical results from the Phase 3 IMPRES clinical trial of oral imatinib for the treatment of PAH patients. Oral imatinib is a well-characterized targeted kinase inhibitor and approved oncology treatment, but clinical trials also supported its potential for the treatment of PAH. The Phase 3 IMPRES trial was a placebo-controlled clinical trial of oral imatinib, conducted globally by Novartis, in 202 PAH patients whose disease was not adequately controlled by two or all three classes of approved PAH therapies. After 24 weeks of treatment with oral imatinib, patients achieved on average an increase of 32 meters (p=0.002) compared to placebo in the distance they could walk in six minutes, a measure known as the 6MWD. A key secondary endpoint in the IMPRES trial was pulmonary vascular resistance, or PVR, which is an objective measure of hemodynamic disease severity in PAH patients. After 24 weeks of treatment with oral imatinib, patients achieved an average PVR improvement (reduction) of 32% (p&lt;0.001) compared to placebo with a significant increase in cardiac output (p&lt;0.001). The magnitude of improvement in both 6MWD and PVR is notable because no approved PAH drug has shown such an improvement in a Phase 3 trial on top of at least two background therapies. However, treatment with oral imatinib was also associated with significant tolerability issues and adverse events, including nausea, edema, diarrhea and vomiting. Patients taking oral imatinib also experienced serious adverse events, the most frequent of which were anemia (7%), worsening of pulmonary hypertension (6%), dyspnea (6%), peripheral edema (6%), presyncope (5%), diarrhea (3%), device-related infection (3%), subdural hematoma (2%) and syncope (1%). Despite the clinical effects of oral imatinib 26% of patients on oral imatinib, compared to 7% on placebo, discontinued due to AEs by 24 weeks.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our company was formed to develop an inhaled formulation of imatinib as a means of delivering therapeutically relevant drug concentrations to the lungs while minimizing systemic exposure, which we believe is the source of the observed intolerability of oral imatinib. We have brought together leaders both in the field of PAH drug development as well as in the area of inhaled drug formulation to invent AV-101, a drug/device combination designed to deliver imatinib directly to the lungs. We have completed a Phase 1 clinical trial of AV-101 in 82 healthy adults. Repeat inhaled doses of up to 90 mg were well-tolerated and resulted in systemic plasma levels that were below those observed with the 400 mg oral dose of imatinib (Gleevec) used in the IMPRES trial. According to pharmacokinetic models of lung exposure to imatinib as applied to our Phase 1 dose range, the predicted lung concentrations of imatinib delivered by AV-101 overlapped or surpassed those predicted from the 400 mg dose of oral imatinib in our Phase 1 clinical trial. There were no serious adverse events associated with AV-101. The most common adverse event was a transient cough primarily in the highest dose cohort, which was generally mild, and resolved within 30 minutes of dosing. There were no discontinuations due to cough. The intended Phase 2b dose range with AV-101 will only include doses that use 40% or less of the amount of dry powder that was inhaled at the highest Phase 1 dose and, based on the results of our Phase 1 clinical trial and our modeling, we expect lung concentrations of imatinib delivered by AV-101 in the 35 mg and 70 mg doses, both twice a day, or BID, selected for the Phase 2b portion of our Phase 2b/Phase 3 trial to overlap or surpass the lung concentrations predicted with the 400 mg oral dose in our Phase 1 clinical trial, which was the same target dose used in the Phase 3 IMPRES trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2021, we announced the initiation of IMPAHCT, our global double-blinded, placebo-controlled, randomized Phase 2b/Phase 3 trial of AV-101 in adults with PAH taking at least two background therapies. We are enrolling patients in the Phase 2b portion of this trial and will enroll approximately 200 PAH patients. The Phase 2b portion of the trial is designed to assess safety, tolerability and inform dose selection for the Phase 3 portion using changes in PVR, an objective measure of the effect of AV-101 on hemodynamic function in PAH patients, as the primary endpoint. We will measure 6MWD as a secondary endpoint in the Phase 2b portion of this trial. We anticipate that topline data from the Phase 2b portion of this trial will be available in the fourth quarter of 2023 or first quarter of 2024. In the Phase 3 portion of the trial improvement in 6MWD will be the primary endpoint. If the results of the Phase 3 trial show a statistically significant increase in 6MWD, we plan to submit a New Drug Application, or NDA, with the United States Food and Drug Administration, or FDA, and Marketing Authorisation Application, or MAA, with the European Commission for AV-101 for the treatment of PAH. These applications will leverage the existing safety data for Gleevec oral tablets allowing the company to save time and money. If AV-101 is approved, we believe it has the potential to become an important addition to existing therapies for PAH in both the United States and Europe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are pursuing a clinical development program utilizing established endpoints for development of previous PAH drugs, as well as enrollment criteria and dosing duration previously studied in oral imatinib PAH trials. At our April&#160;14, 2021 end-of-Phase 1 meeting with the FDA, we received regulatory guidance that our clinical program could support an NDA submission; however, the process of clinical development is inherently uncertain and there can be no guarantee that we will obtain marketing approval. AV-101 has been granted orphan drug designation by the FDA and the EMA for the treatment of PAH. We own four issued U.S. patents and several U.S. and foreign patent applications for patent protection of the composition of the aerosol, drug product, manufacturing and methods of use. We retain worldwide commercial rights to AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Team</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our executive management team has extensive experience in the clinical development and the commercialization of orphan drug indications. Timothy P. Noyes, our Chief Executive Officer, was a senior executive at GelTex Pharmaceuticals,&#160;Inc., or GelTex, and Genzyme Corporation, or Genzyme, where he headed all launch planning and the commercialization of Renagel, a treatment for hemodialysis patients that resulted in Genzyme&#8217;s acquisition of GelTex for more than $1 billion. Benjamin T. Dake, Ph.D., our Founder, President, Chief Operating Officer and Secretary, a cancer biologist, investor and entrepreneur, recognized the potential benefits of developing a lung-targeted imatinib and secured multiple rounds of funding to build the team at Aerovate with experts like Ralph Niven, Ph.D., our Chief Development Officer, who has over 30&#160;years of expertise in translational medicine and inhalation dosage forms, and Hunter Gillies, M.B.Ch.B., our Chief Medical Officer, who has led Phase 2 and Phase 3 PAH trials at Pfizer&#160;Inc., or Pfizer, and Gilead Sciences,&#160;Inc., or Gilead, and has designed and executed PAH trials with several smaller biotechnology companies. George A. Eldridge, our Chief Financial Officer, has served as CFO for several biotechnology companies, leading four of these companies to the public markets. Marinus Verwijs, our Senior Vice President of CMC, has over 15&#160;years of product development and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">manufacturing experience. He has worked on multiple commercial products, leading them from clinical product development to NDA filing and commercial launch. Timothy Pigot, our Chief Commercial Officer, has over 25&#160;years of industry experience working to launch and commercialize a range of products over multiple therapeutic areas. Mr.&#160;Pigot gained significant experience in PAH during his 12&#160;years at Gilead and 11&#160;years at Pfizer, where his responsibilities included the launches of Revatio and Letairis for the treatment of PAH. Donna Dea, our Head of Regulatory Affairs, has over 30&#160;years of global regulatory experience designing and implementing regulatory strategies resulting in the approval of treatments for asthma, COPD, rhinitis and others, for which several of these drugs involved inhaled formulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Strengths</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that our company and AV-101 possess the following attributes that may potentially increase the likelihood that we will be successful in developing and commercializing AV-101:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Significant efficacy for oral imatinib</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. In the global Phase 3 IMPRES trial, oral imatinib demonstrated statistically and clinically significant efficacy following 24 weeks of treatment on top of PAH standard of care. These results were notable for achieving statistically significant improvements in the study&#8217;s primary efficacy endpoint, 6MWD, and a key secondary endpoint, PVR, but also for hitting statistical significance on other clinically relevant efficacy endpoints on top of standard of care, which included at least two background PAH therapies. The primary endpoint of the Phase 2b portion of our Phase 2b/Phase 3 trial is the change in PVR following 24 weeks of treatment. The primary endpoint of the Phase 3 portion of our Phase 2b/Phase 3 trial is the change in 6MWD following 24 weeks of treatment. Our Phase 2b/Phase 3 trial is designed to treat a similar patient population to the IMPRES trial, patients in WHO Functional Classes II-IV taking at least two background PAH therapies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Distinct PAH treatment mechanism</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Unlike all approved treatments for PAH, which act primarily through vasodilation, AV-101 is designed to directly address the abnormal cellular hyperproliferation in the pulmonary vasculature that causes the increased resistance to blood flow and heart failure. We believe AV-101&#8217;s mechanism uniquely positions our product candidate, if approved, for combination therapy with existing vasodilator treatments.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Adaptive development path</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We have designed an innovative global Phase 2b/Phase 3 clinical trial based on an adaptive design that could lead to a potential NDA filing. Our development plan also benefits from our ability to leverage prior toxicology work done with oral imatinib.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Improved tolerability based on route of administration</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Our inhaled administration is designed to minimize systemic exposure and limit the safety and tolerability concerns observed in the IMPRES trial of oral imatinib in PAH. Our Phase 1 clinical trial results in healthy volunteers demonstrated that plasma levels of imatinib were significantly lower than those observed with the 400 mg oral dose of imatinib used in the IMPRES trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Expected comparability of concentrations of drug delivered</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Based on the results of our Phase 1 clinical trial and our modeling, we expect lung concentrations of imatinib delivered by AV-101 in the 35 mg and 70 mg doses, both BID, selected for the Phase 2b portion of our Phase 2b/Phase 3 trial to overlap or surpass the lung concentrations predicted with the 400 mg oral dose in our Phase 1 clinical trial, which was the same target dose used in the Phase 3 IMPRES trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Powerful barriers to entry</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We have generated strong intellectual property claims and other barriers to entry. We own four issued U.S. patent and several U.S. and foreign patent applications to protect our proprietary imatinib formulation, our drug product and methods of use. In addition, we have obtained exclusive access to a commercially available dry powder delivery device which we believe will create a substantial competitive advantage.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Substantial and readily addressable market opportunity. </b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If AV-101 is approved, we believe there is a substantial medical need and market opportunity for combining AV-101 with existing standard of care, which is </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">often two or three background agents. Beyond this base case, we also believe that AV-101, if approved, could benefit a larger group of PAH patients with earlier-stage disease such as those patients receiving only one other PAH therapy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Strong leadership in PAH</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Our executive management team has extensive experience in the clinical development of treatments for PAH, including Dr.&#160;Gillies who has been developing drugs for PAH for more than 20&#160;years and recently ran the AMBITION trial that established the current first-line PAH combination therapy and Dr.&#160;Niven&#8217;s experience in manufacturing and development for inhaled small molecules. In addition, our Clinical Advisory Board includes several of the premier thought leaders in PAH who have extensive experience developing drugs and caring for patients suffering from PAH.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our strategy is to develop and commercialize AV-101 for patients suffering from PAH. Key elements of our strategy include our plans to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Complete regulatory discussions for AV-101 in the United States and Europe</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. At our April 14, 2021 end-of-Phase 1 meeting with the FDA, we received regulatory guidance that our Phase 2b/Phase 3 trial, if successful, could support a NDA submission using the change in 6MWD compared to placebo as the primary endpoint in the Phase 3 portion of the trial; however, the process of clinical development is inherently uncertain and there can be no guarantee that we will obtain marketing approval even if we successfully achieve our primary endpoint. We have been granted orphan designation for the treatment of PAH from the FDA and from the European Commission in the European Union. We completed the formal process of seeking scientific advice and regulatory guidance from the European Medicines Agency, or EMA, regarding its requirements for regulatory approval and we believe that, if successful, our existing clinical program could support a MAA submission for regulatory approval in Europe.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Advance AV-101 through NDA submission</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. In December&#160;2021, we announced initiation of IMPAHCT, our Phase 2b/Phase 3 trial of AV-101 in adults with PAH taking at least two approved PAH therapies. The Phase 2b portion of this trial is enrolling patients and will be a dose-ranging trial in which PVR will be the primary endpoint. The Phase 3 portion of the trial will be based on the optimal dose selected in the Phase 2b portion and 6MWD will be the primary endpoint.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Commercialize AV-101 directly in the United States</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. If AV-101 is approved by the FDA, we intend to commercialize it ourselves in the United States with a specialty sales force focused primarily on pulmonologists and cardiologists treating adult patients suffering from PAH. We will consider entering into collaborations for the development and commercialization of AV-101 in Europe, Asia or other geographic regions, if approved by foreign regulatory authorities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Pursue additional indications for AV-101</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We believe that AV-101 could have clinical applications in other groups of PAH patients, such as those with earlier-stage disease who may be receiving only one other PAH therapy. We also may consider the potential use of AV-101 in other types of pulmonary vascular disease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Expand our pipeline by accessing additional product opportunities</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We plan to search for additional product opportunities available for license or acquisition that could be supported by the commercial infrastructure we build to successfully launch AV-101 in the United States if it is approved for marketing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PAH Background and Limitations of Current Treatments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PAH is a progressive, life-threatening orphan disease characterized by increased pressure in the pulmonary arteries, vessels responsible for carrying deoxygenated blood from the heart to the lungs. This increased pressure is caused by narrowing of these blood vessels as a result of dysregulation of cells of the arterial wall, leading to excessive growth and proliferation. Over time, blood flow worsens as inflammatory cells are recruited and inflammatory cytokines further stimulate the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:210.6pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">proliferation of blood vessel cells. This ultimately leads to tissue scarring, fibrosis and blood vessel remodeling, resulting in severe restriction of blood flow (as illustrated in the figure below) and increased risk of developing blood clots and heart failure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k001.jpg" alt="Graphic" style="display:inline-block;height:210.6pt;width:452.25pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 1. Increased pulmonary resistance is caused by cell proliferation that obstructs blood flow.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This severe restriction of blood flow also causes the heart to work harder to circulate blood through the lungs causing abnormal strain on the right ventricle of the heart resulting in PAH symptoms that worsen over time; these commonly include breathlessness, fatigue, chest pain, fainting or light headedness, as well as abdominal distension. Four PAH functional classes categorize patient symptom severity and ability to carry out physical activity. Higher numbered functional classes indicate worsening symptoms and are associated with higher mortality. The four functional classes established by the World Health Organization, or WHO, are detailed in the figure below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FIGURE 2. WHO PAH FUNCTIONAL CLASSES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:22.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:22.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">FUNCTIONAL CLASS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:74.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:22.13%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">I</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:74.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">No limitation of physical activity, and ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:22.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:22.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">II</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Slight limitation of physical activity, but patients are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:22.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:22.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">III</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">Marked limitation of physical activity, but patients are still comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:22.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:22.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">IV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">Patients are unable to carry out any physical activity without symptoms, and discomfort is increased by any physical activity. Signs of right heart failure manifest, and dyspnea and/or fatigue may even be present at rest.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prevalence of PAH and Unmet Need</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on third-party estimates, the number of PAH patients diagnosed is between 30,000 and 40,000 in the United States with an average age at diagnosis of 53&#160;years old and 65% to 80% of those diagnosed being women. The exact prevalence of PAH worldwide is not known but it has been estimated to be between 10 to 52 cases per million. Many drugs have been </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">developed and made commercially available for the treatment of PAH, such as vasodilators, and it is estimated that the combined global sales for PAH products in 2022 was $6.1 billion. While advances in the treatment of PAH using vasodilatory agents over the last two decades have markedly improved survival, PAH patients still face significant disease burden and premature death. The five-year survival rate for newly diagnosed and prevalent patients is between 61% and 65%. Clearly there is unmet need for new therapies beyond the standard of care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Limitations of Current Therapies for PAH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The current standard of care in PAH consists of drugs that act primarily as pulmonary vasodilators, which relax the muscles in the pulmonary arterial walls, thereby reducing the degree of blood vessel constriction. Although the current standard of care provides some benefit to patients, it is clear from the pathology of PAH that abnormal cellular hyperproliferation causes progressive narrowing of the pulmonary vasculature. This abnormal hyperproliferation is not addressed by therapies currently used to treat PAH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Three classes of pulmonary vasodilators are currently used to treat PAH: endothelin receptor antagonists, nitric oxide pathway modulators and prostacyclins.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Endothelin Receptor Antagonists</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Some treatments currently approved for PAH work by blocking the action of endothelin-1, a potent vasoconstrictor, and are referred to as endothelin receptor antagonists, or ERAs. These drugs include bosentan, macitentan and ambrisentan. All three of these drugs are orally administered and improve blood flow to the lungs as determined by measures of hemodynamics such as pulmonary vascular resistance and cardiac output, which translates to improvements in exercisability as measured by the distance that patients can walk in a fixed period of time (6MWD).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Nitric oxide pathway modulators such as PDE5 inhibitors and sGC&#8217;s</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Nitric oxide is a naturally occurring molecule that is widely recognized as important in a number of biological processes. It causes blood vessels to relax and widen via the second messenger cGMP, resulting in an increase in blood flow. Two common modalities utilize the nitric oxide pathway to result in vasodilation: Phosphodiesterase type 5, or PDE5, inhibitors prevent the breakdown of cGMP and soluble guanylate cyclase stimulators, or sGC&#8217;s, increase the production of cGMP independent of nitric oxide. Several oral PDE5 drugs are available, such as sildenafil and tadalafil. Additionally, riociguat is the only sGC approved for PAH.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Prostacyclin pathway modulators</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Patients with PAH have been shown to have reduced levels of prostacyclin, a naturally occurring lipid that has the effect of relaxing the smooth muscles surrounding arteries, resulting in vasodilation. Prostacyclin analogues, such as iloprost, epoprostenol, and treprostinil, are approved therapies for PAH. Selexipag is an oral prostacyclin-like drug approved for PAH. In addition to the challenges associated with dosing, prostacyclin therapy can be difficult to tolerate. In clinical trials subcutaneous infusion of these agents has shown severe infusion site adverse events requiring narcotics for these symptoms. The oral prostacyclins also have a high incidence of headache and diarrhea, nausea, vomiting, and flushing, which can lead to discontinuations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PAH patients are often treated with more than one of these drugs and new therapies are typically added to existing therapies rather than replacing drugs that are providing insufficient benefit. Based on both primary research and third party sources, we estimate that a majority of patients are taking two or three FDA approved drugs for the treatment of PAH. Oral therapies are commonly prescribed first-line, typically consisting of an ERA and PDE5 inhibitor. As patients progress in their disease severity, a prostacyclin can typically be added as a third agent. Although these therapies have been shown to improve exercise capacity, quality of life, pulmonary pressure and short-term survival, none of the current treatments are curative and patients remain on life-long therapy with poor long-term prognosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Approach, AV-101</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are developing AV-101 as a drug-device combination product that delivers imatinib directly to the lungs via inhalation. The product consists of capsules of particulate imatinib that will be used in conjunction with a dry powder inhaler device. We believe that delivery of imatinib directly to the lungs will maximize the amount of drug in the targeted tissues while </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">minimizing systemic exposure. Furthermore, we believe that delivering imatinib in this way may improve the tolerability of treatment while maintaining imatinib&#8217;s known effects on exercise capacity and hemodynamics. AV-101 has been granted orphan drug designation by the FDA and the European Commission for the treatment of PAH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Potential of Imatinib to Treat PAH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The molecule in AV-101, imatinib, has demonstrated improvement on the primary and multiple secondary endpoints in a global Phase 3 trial (IMPRES) conducted by Novartis in PAH patients on top of at least two standard of care PAH drugs. However, when administered orally, serious adverse events, and discontinuations were high and the oral version was never approved for PAH. We believe imatinib is unique amongst tyrosine kinase inhibitors for its specificity and potency. At pharmacologically achievable levels, it inhibits only a handful of kinases, such as PDGFR, KIT, DDR and ABL, which have been implicated in PAH disease processes. Other tyrosine kinase inhibitors that target the same binding pocket are more promiscuous. Recent academic focus on kinase inhibition in PAH has been on PDGFR. However, other kinase inhibitors that hit PDGFR also inhibit the closely related SRC and VEGFR kinases. These drugs have been shown to induce or exacerbate PAH. Thus, we believe clinical success with kinase inhibition in PAH is not dictated by inhibiting PDGFR alone, but rather by the overall kinase inhibition profile. We are encouraged that imatinib, the molecule in AV-101, has shown clinical effects in the IMPRES trial, and we believe inhaled delivery of AV-101 limits systemic exposure and may mitigate the tolerability issues observed with oral imatinib.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Kinase inhibitors have been approved for the treatment of various cancers. Case reports of improvements in PAH in patients receiving oral imatinib, marketed as Gleevec by Novartis, led to several clinical trials designed to test the efficacy of imatinib for PAH. The IMPRES trial was a randomized, double-blind global Phase 3 trial conducted by Novartis that enrolled 202 PAH patients. Most of these patients had Functional Class&#160;II or Class&#160;III PAH and were already on at least two background therapies. Patients were randomized to receive oral imatinib or placebo for 24 weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patients enrolled in the IMPRES trial had reduced exercise capacity compared to healthy adults as measured by the six-minute walk distance, or 6MWD, a simple test that has been used as a primary endpoint for the approval of multiple drugs to treat PAH. The mean baseline 6MWD for patients in this trial was 361 meters, whereas for healthy adults it has been reported to be approximately 600 meters The baseline 6MWD values in these patients upon enrollment was below normal for healthy adults despite the fact that they were all on treatment with at least two PAH therapies and 41% were on triple therapy, the maximal standard of care for PAH. Patients remained on their respective pre-trial PAH therapies throughout the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The target dose of oral imatinib in the IMPRES trial was 400 mg/day which is an approved dose of oral imatinib for the treatment of cancers such as chronic myelogenous leukemia, or CML, and metastatic malignant gastrointestinal stromal tumors, or GIST, containing specific genetic alterations. Treatment of PAH patients with 400 mg oral imatinib led to a significant improvement in 6MWD over baseline compared to placebo. This difference was significant at 12 weeks with significance observed at all consecutive timepoints through the end of the trial at 24 weeks, at which point the oral imatinib-treated patients achieved an average improvement of 32 meters vs placebo in the 6MWD (p=0.002). The magnitude of this improvement is notable because no approved PAH drug has shown such an improvement in a Phase 3 trial on top of at least two background therapies. The most recently approved oral PAH drug in the U.S., Uptravi (Selexipag), showed a 12-meter treatment effect in the Phase 3 GRIPHON trial. The patients in this trial were not as heavily treated as those in the IMPRES trial, with one third on double therapy and none on triple therapy. The figure below shows the improvement </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:243.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">over time in 6MWD of PAH patients treated with oral imatinib on at least two standard of care therapies as compared to the placebo group in the Phase 3 IMPRES trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><img src="tmb-20221231x10k002.jpg" alt="Graphic" style="display:inline-block;height:243.75pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:402.98pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure 3. Imatinib led to a significant increase in 6MWD on top of at least two standard of care therapies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The improvement in 6MWD with oral imatinib treatment was observed across all patient subgroups regardless of treatment with other PAH therapies (as seen in the figure below). We believe this observation suggests that oral imatinib improved 6MWD through a mechanism that was independent of patients&#8217; background therapies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:279.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><img src="tmb-20221231x10k003.jpg" alt="Graphic" style="display:inline-block;height:279.75pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:434.88pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 4. Imatinib led to improvements in 6MWD compared to placebo regardless of patients being treated concurrently with at least two approved PAH therapies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to improvements in 6MWD, patients treated with imatinib had greater improvements in multiple secondary endpoints, including measures of hemodynamics. Importantly, there was a significant improvement at 24 weeks in PVR (p&lt;0.001), a measure of how difficult it is for blood to circulate through the lungs. Damaged pulmonary blood vessels make it more difficult for the heart to pump blood through the lungs, leading to increased pulmonary arterial pressure, increased workload on the heart, and if not resolved, heart failure. PVR is frequently used as a quantitative measure in PAH Phase 2 trials to determine the appropriate dose for registrational Phase 3 trials that directly measure changes in patient exercise capacity, such as 6MWD. Patients treated with imatinib had a significant reduction in PVR at 24 weeks, as noted in the blue box in the figure below. PVR was virtually unchanged compared to baseline in placebo treated patients. Consistent with the improvements in PVR, significant improvements compared to placebo treated patients, as shown in the figure below, were also observed in mean pulmonary artery pressure, or mPAP, which was decreased by 5.2 mm Hg; cardiac output, or CO, which was increased by 0.88 liter/min; and right arterial pressure, or RAP, which was decreased by 1.7 mm Hg. An echocardiography sub-study of 74 IMPRES patients showed that patients randomized to oral imatinib showed significant improvements in certain measures of right ventricle function after 24 weeks compared with placebo. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:313.85pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant and consistent changes across hemodynamic and echo measures suggest a benefit of imatinib for the treatment of PAH with the potential to result in long-term improvements in pulmonary and cardiac function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k004.jpg" alt="Graphic" style="display:inline-block;height:313.85pt;width:354.35pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 5. Imatinib treatment led to significant improvements across multiple secondary endpoints including PVR (highlighted), an endpoint frequently used in Phase 2 dose-finding trials </b>(Patients included in analyses of hemodynamic parameters include those who completed the study plus those who discontinued early but had a right heart catheterization performed at discontinuation.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Long-Term Extension Study</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patients who completed the 24 week trial were eligible to be enrolled in an open label long-term extension study. The improvements in 6MWD achieved at 24 weeks were sustained during this extension and the mean difference in 6MWD compared to baseline improved up to 144 weeks in patients that were able to tolerate the treatment. Although these results were very encouraging, data from the extension trial also highlighted the major limitation in using oral imatinib to treat PAH, which was drug tolerability. Of the 103 patients originally randomized to the imatinib arm of the core trial, only 21 remained on therapy after 180 weeks of dosing. The patients who were able to tolerate the drug long term showed a durable continued improvement in 6MWD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Safety and Tolerability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The relatively poor tolerability of oral imatinib poses challenges for the potential use in PAH patients. The AEs observed in the IMPRES trial were consistent with the AE profile observed in cancer trials, with the exception of subdural hematoma, and led to a significant number of discontinuations, which limited oral imatinib&#8217;s potential as a therapy for PAH. Specifically, 44% of patients treated with oral imatinib in the IMPRES trial experienced fluid retention, which is of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:309.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">particular concern in PAH patients who suffer from heart failure. The figure below lists the AEs reported in the 24-week Phase 3 IMPRES trial of oral imatinib in PAH patients on two or more standard-of-care therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k005.jpg" alt="Graphic" style="display:inline-block;height:309.15pt;width:330.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 6. Adverse events reported in &gt;10% of the Imatinib group in the 24-week IMPRES trial, not including the trial extension</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the IMPRES trial, there were 45 serious adverse events reported in imatinib treated patients, including some that were of particular concern for PAH patients, who already have compromised cardiac function. These included worsening of PAH; anemia; dyspnea, or shortness of breath; peripheral edema; and presyncope, or lightheadedness. Of note, subdural </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:237.6pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">hematoma occurred in eight patients (two in the core study (1.9%), six in the trial extension (4.2%)) receiving imatinib and anticoagulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="tmb-20221231x10k006.jpg" alt="Graphic" style="display:inline-block;height:218.54pt;width:316.25pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Figure 7. Serious adverse events reported in the IMPRES 24-week trial publication, not including the trial extension</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Patients enrolled in the IMPRES trial that were not able to tolerate 400 mg/day of imatinib did not see a significant improvement in 6MWD after 24 weeks. As shown in the figure below, those patients who were not dosed with 400 mg/day for more than half of the time did not achieve the improvements in 6MWD that were significantly distinguished from those achieved by placebo treated patients. These results suggest that addressing the adverse events and tolerability of imatinib in PAH patients cannot be achieved by lowering the oral dose without sacrificing this improvement. Further development of oral imatinib for the treatment of PAH was discontinued by Novartis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="tmb-20221231x10k007.jpg" alt="Graphic" style="display:inline-block;height:237.6pt;width:205.2pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 8. Patients who were dosed with 400 mg/day for less than half of the duration of the trial did not achieve a significant improvement in 6MWD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">AV-101, an inhaled formulation of imatinib</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">AV-101 is designed to deliver imatinib directly to the lungs to maximize the amount of drug in the targeted tissues while minimizing systemic exposure. We believe that delivering imatinib in this way may maintain imatinib&#8217;s potential therapeutic benefits while improving the tolerability of treatment. The oral version of imatinib, marketed as Gleevec, is delivered as tablets containing imatinib mesylate which is a salt of imatinib. Imatinib mesylate is not readily amenable to being used in an inhaled formulation because it absorbs water from the atmosphere if not stored in a rigorously controlled environment. Moisture uptake would lead to potential stability concerns and a high likelihood of poor delivery performance when inhaled from any dry powder inhaler device. We also believe mesylate salt would be a poor choice for an inhaled PAH therapy for additional reasons: (i)&#160;the mesylate group introduces a genotoxic risk; (ii)&#160;it increases the formulation risk due to the existence of multiple crystal forms; and (iii)&#160;delivery using the mesylate salt has the potential to release the acidic mesylate upon deposition on the lung surface which could lead to transient irritation and increase the propensity for cough. We therefore explored other salt and polymorphs of imatinib to identify a more suitable formulation for an inhaled therapy without altering the active molecule. We discovered a form that exhibited what we believe to be almost ideal physical chemical properties for development as a dry powder for inhalation using capsules in a simple dry powder inhaler, or DPI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also believe that dry powder inhalation is the most convenient mode of delivery to the lungs for patients. The prospective advantages of dry powder inhalation include that such formulations (i)&#160;can be delivered via a convenient, portable and easy-to-use delivery system; (ii)&#160;avoid the cords or batteries or bulky equipment that may be needed with nebulizers; (iii)&#160;carry less risk of microbial contamination due to the low moisture content powder; (iv)&#160;have better anticipated shelf stability of the drug product compared to a solution dosage form; and (v)&#160;can potentially improve lung retention of the powder imatinib compared to an aqueous nebulizer formulation, which may result in reduced dose, dose frequency and peak exposure in the circulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">AV-101 Phase 1 Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have completed a placebo-controlled, randomized, double-blinded, single ascending dose and multiple ascending dose Phase 1 clinical trial of AV-101 in 82 healthy adult volunteers. Doses tested in the single ascending dose, or SAD, portion ranged from 1 to 90 mg of AV-101. A 400 mg dose of oral imatinib was included as a comparator. The multiple ascending dose, or MAD, portion tested 10 mg, 30 mg and 90 mg BID (<i style="font-style:italic;">bis in die</i>; or twice a day) for seven&#160;days. The purpose of the trial was to establish safety and tolerability of AV-101 and to demonstrate that systemic levels of AV-101 were lower than oral imatinib.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All doses resulted in lower systemic plasma levels of imatinib compared to those observed following a single 400 mg oral dose. In the figure below, the blue dashed line shows simulated steady state levels of oral imatinib in the blood extrapolated from the 400 mg cohort in the SAD potion of our Phase 1 clinical trial. These levels are consistent with multiple publications on oral imatinib pharmacokinetics. The other lines show the blood concentrations following the final dose of AV-101 in the MAD portion of our Phase 1 clinical trial, on day 7, when steady state concentrations had been achieved. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:263.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The dotted part of the 90 mg dose shows a simulated representation of an additional dose twelve hours later to illustrate steady state BID dosing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k008.jpg" alt="Graphic" style="display:inline-block;height:263.9pt;width:421.2pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 9. Phase 1 systemic exposure of AV-101 vs 400 mg oral imatinib.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We also predicted lung exposures using a physiologically based pharmacokinetic, or PBPK, model built from a published method to extrapolate lung exposures from blood levels, which was informed by our Phase 1 plasma data. Although there is inherent uncertainty associated with all models that extrapolate data, we expect the exposures of imatinib obtained in the lungs at the dose range we intend to use in the Phase 2b portion of our Phase 2b/Phase 3 trial of 35 mg and 70 mg, all BID, to overlap or surpass lung levels predicted from 400 mg oral imatinib. The dashed blue line in Figure 11 shows lung </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:257.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">exposures extrapolated from published steady state PK data and informed by our Phase 1 plasma data for oral imatinib at 400 mg. The solid lines show extrapolated lung levels of AV-101 doses using our PBPK model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k009.jpg" alt="Graphic" style="display:inline-block;height:257.15pt;width:402.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 10. Predicted Phase 2b lung exposures from dosing of 10, 35 and 70 mg AV-101. We expect the lung exposures of imatinib delivered by AV-101 in the dose range to overlap or surpass the predicted lung exposures from 400 mg oral imatinib</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Safety and Tolerability in Phase 1 Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There were no serious adverse events reported in our Phase 1 clinical trial. Adverse events reported in the Phase 1 clinical trial were classified as mild or moderate. There were no changes in vital signs including pulmonary function testing and oxygen saturations. Of the less severe adverse events, there was one discontinuation at the highest dose due to vomiting and the most frequent adverse event was a cough that was reported in 55% of volunteers at the highest 90 mg dose. This cough was transient, predominantly mild in nature, resolved on its own within 30 minutes and did not lead to any discontinuations. We believe that the cough may be a function of the total amount of powder delivered in the high Phase 1 dose. The intended dosing for the Phase 2b/Phase 3 trial will use less than 40% of the amount of powder that was inhaled </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:255.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">at the highest Phase 1 dose. The figure below shows the adverse events reported in our Phase 1 MAD trial of AV-101 in healthy volunteers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k010.jpg" alt="Graphic" style="display:inline-block;height:255.8pt;width:313.2pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 11. Adverse events reported in the Phase 1 MAD trial of AV-101 in healthy volunteers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We submitted to the FDA summaries of the safety and tolerability findings from our Phase 1 clinical trial along with the systemic plasma levels for the participants from the trial. We also submitted information on our drug substance and drug product. At our April&#160;2021 meeting, we reached alignment with the FDA that our Phase 2b/Phase 3 trial design was acceptable and could, if successful with strong results, support a NDA submission using the change in 6MWD compared to placebo over 24 weeks as the primary endpoint in the Phase 3 portion of our trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">AV-101 Phase 2b/Phase 3 IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December&#160;2021, we announced the initiation of IMPAHCT, our global Phase 2b/Phase 3 trial in adults with Functional Class&#160;II through Class&#160;IV PAH with inadequate disease control on at least two approved PAH therapies. This clinical trial, currently enrolling patients in the Phase 2b portion, will establish the target dose in the Phase 2b portion then continue into a Phase 3 efficacy trial using the selected dose. The Phase 2b portion of this double-blind, placebo-controlled randomized trial is designed to assess safety and tolerability using change in PVR, an objective measure of the effect of AV-101 on hemodynamic function in PAH patients, as the primary endpoint to inform the selection of the appropriate dose for the Phase 3 portion of the trial. Change in 6MWD compared to placebo will be a secondary endpoint, and all efficacy endpoints will be measured following 24 weeks of treatment. The Phase 3 portion of the trial will use the change in 6MWD compared to placebo at 24 weeks as the primary endpoint. Secondary endpoints in the Phase 2b/Phase 3 trial will include N-terminal pro B-type natriuretic peptide, or NT-proBNP, a biomarker associated with heart failure; hemodynamic parameters; clinical worsening; clinical improvement; change in functional class; change in risk score; and quality of life measures. All patients completing the Phase 2b or Phase 3 portions will be invited to enter a long-term extension trial of AV-101.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:157.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Phase 2b/Phase 3 Enrollment and Timing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Phase 2b/Phase 3 trial employs an operationally seamless, adaptive design consisting of three parts.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are currently in Part 1, which is the Phase 2b enrollment portion of the trial. Approximately 200 patients will be enrolled across four treatment arms, which include three dose groups of AV-101 and one placebo group. The primary endpoint is the change in PVR compared to placebo at 24 weeks. Data from the Phase 2b portion will inform the selection of an optimal dose of AV-101 for Phase 3. We anticipate that topline Phase 2b data will be available in fourth quarter of 2023 or the first quarter of 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Part 2 begins as soon as enrollment completes in the Phase 2b portion of the trial. This second part signifies the start of enrollment in the Phase 3 portion of the trial. We expect to complete enrollment of the Phase 2b portion of the trial in the middle of 2023 and commence enrollment of the Phase 3 portion thereafter.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Part 3 begins once the optimal dose is selected and will then only enroll across two treatment arms, the optimal dose of AV-101 and the placebo arm. Once the final patient enrolled has completed 24 weeks on study, the Phase 3 portion of the trial is complete.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k011.jpg" alt="Graphic" style="display:inline-block;height:156.96pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:452.16pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 12. Design of the Phase 2b/Phase 3 trial of AV-101 in adults with PAH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the results of the Phase 3 portion of this trial show a statistically significant and potentially clinically meaningful benefit in 6MWD, we plan to submit a NDA, with the FDA for AV-101 for the treatment of PAH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Confirmation of the Potential of Antiproliferative Medicines as a Novel Class&#160;of PAH Therapeutics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although no approved PAH therapy directly addresses the underlying cell proliferation that leads to increased pulmonary arterial pressure, the concept behind targeting cell proliferation to treat PAH is not new. The most advanced investigational antiproliferative compound in the clinic is sotatercept, a molecule that blocks signaling of members of the TGF-beta family of growth factors. Results from a Phase 3 clinical trial in PAH showed that sotatercept led to a statistically significant improvement in 6MWD with a safety profile reported to be generally consistent with what was observed with sotatercept in the previous Phase 2 study, providing further support for the therapeutic potential of antiproliferative product candidates in PAH. We are encouraged by these results as they provide independent confirmation of the importance of antiproliferative products as a potentially broad class of PAH therapeutics to complement vasodilators. Similar to the vasodilator field, we believe that PAH patients may benefit from treatment with multiple antiproliferative therapies directed against different targets.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing and Supply</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We use third-party contract manufacturers for the production of AV-101. Our active pharmaceutical ingredient, or API, can be purchased from multiple contract manufacturers in compliance with the FDA&#8217;s current Good Manufacturing Practice, or current GMP, regulations and European Pharmacopoeia, or EP, standards. The final step in the manufacture of API is completed at one of two contract manufacturing organizations that comply with the FDA&#8217;s current GMP regulations. AV-101 finished product is processed for aerosol use and filled into capsules by our contract fill/finish provider in the United States, which is required to comply with current GMP regulations. As AV-101 is a drug-device combination product, we have contracted with a third-party to manufacture the single-dose inhaler device that we use for delivering inhaled AV-101 to patients in our Phase 2b/Phase 3 clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Release and stability testing to date supports stability of at least 36 months for API under ambient conditions and supports stability of at least 30 months for drug product also under ambient conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At our April&#160;2021 meeting, the FDA confirmed that our API, finished product, and single-dose inhaler producers are acceptable for use in a Phase 2b/Phase 3 clinical trial. We have completed the manufacture of the initial clinical supply and have the finished product, device and ancillary supplies positioned at our global distribution partner and drug supply has been delivered to the active clinical sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In anticipation of a potential NDA filing, we plan to manufacture a minimum of three batches of API, finished product, and single-dose inhaler devices for registration purposes and to test these batches for stability with a goal of establishing a commercial shelf life of at least two&#160;years for finished product and bulk API.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales and Marketing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercialization strategy is to develop AV-101 into a leading therapy worldwide for the treatment of PAH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Chief Executive Officer and Chief Commercial Officer have significant commercial experience, but beyond that we have not yet established a sales and marketing organization. We intend to recruit our own specialty sales force in the United States focused on promoting AV-101. We plan to target our marketing and sales efforts to pulmonologists and cardiologists who specialize in treating PAH. We believe a specialty sales force of approximately 75-100 representatives, supported by reimbursement specialists and a medical affairs team, will enable us to call on the pulmonologists and cardiologists who specialize in treating PAH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that the market for AV-101 in the five largest countries in the European Union represents the bulk of the potential European market and that China and Japan represent the bulk of the potential Asian market. We plan to enter one or multiple collaborations to commercialize AV-101 in Europe and Asia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe AV-101 will receive coverage and reimbursement by public and commercial payors, but we cannot guarantee this will happen. For more information regarding these risks, please see &#8220;Risk Factors&#8212;Risks Related to Commercialization&#8212;The successful commercialization of AV-101 will depend in part on the extent to which governmental authorities, private health insurers, and other third-party payors provide coverage and adequate reimbursement levels. Failure to obtain or maintain coverage and adequate reimbursement for AV-101, if approved, could limit our ability to market our product and decrease our ability to generate revenue.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our products, novel discoveries, drug development technologies and know-how; to operate without infringing on or otherwise violating the proprietary rights of others; and to prevent others from infringing or otherwise violating our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing or in-licensing U.S. and foreign patents and patent applications related to our products and other proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trademarks, trade secrets, know-how, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our intellectual property portfolio includes issued patents in the United States, pending patent applications in the United States, under the Patent Cooperation Treaty (PCT international applications), and in commercially relevant foreign jurisdictions for our products. The PCT international applications preserve all of our rights to file patent applications in commercially relevant foreign jurisdictions for our products. As of March 27, 2023, we own four U.S. patents, eight U.S. patent applications, three pending PCT international applications, and twenty foreign patent applications. Our U.S. patent portfolio is expected to expire between May 14, 2040 and February 15, 2042, excluding any extension of patent term that may be available and assuming that the filed patent applications will issue as patents. Our foreign patent portfolio is expected to expire between May 14, 2040 and February 15, 2042, excluding any extension of patent terms that may be available and assuming that filed applications will issue as patents and that the foreign patent terms are calculated similarly to the calculation of U.S. patent terms for the corresponding U.S. portion of the patent portfolio. Our patent portfolio is summarized in the following table.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">APPLICATION/ PATENT NO.</b></p></td><td style="vertical-align:bottom;width:1.99%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:10%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">RELATED PRODUCT</b></p></td><td style="vertical-align:bottom;width:1.99%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROTECTION SOUGHT</b></p></td><td style="vertical-align:bottom;width:1.99%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:15%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROJECTED EXPIRATION*</b></p></td><td style="vertical-align:bottom;width:1.99%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:16%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">JURISDICTION</b></p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">62/849,054 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">11,229,650 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">17/582,599</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US</p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">PCT/US20/32872 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">International PCT </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">62/849,056 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">11,298,355</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">62/849,058 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">11,413,289</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Process</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">17/887,866</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">62/849,059 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">16/874,128 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">62/877,575 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Process</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">16/874,143 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">62/942,408 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">11,464,776</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">17/963,607</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">62/984,037 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Use; Kit</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">16/874,168 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Use; Kit</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">17/685,704</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Use; Kit</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">62/958,481 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Use</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">16/874,190 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Use</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">PCT/US20/32874 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Use</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">International PCT </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">20806763.7</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Use</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Europe</p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">63/117,258 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">63/150,731 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US </p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">PCT/US21/60526</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">International PCT</p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">63/149,446</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Process; Composition of Matter</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">US</p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">PCT/US22/16422 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Process; Composition of Matter</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">International PCT </p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">20806383.4</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Europe</p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">202080051359.5 </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">China</p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2021-568694</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Japan</p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2020274521</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Australia</p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3140641</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Canada</p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">288111</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Israel</p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">202117055928</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">India</p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">11202112719X</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Singapore</p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10-2021-7041312</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Republic of Korea</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">MX/A/2021/104029</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Mexico</p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">BR1120210230149</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Brazil</p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2021/09070</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">South Africa</p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">20210285</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Bahrain</p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">305/2021</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Jordan</p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">KW/P/2021/466</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Kuwait</p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">OM/P/2021/00467</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Oman</p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">QA/202111/000655</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Qatar</p></td></tr><tr><td style="vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">521430873</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Saudi Arabia</p></td></tr><tr><td style="vertical-align:top;width:17.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">P6002085/2021</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AV-101</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Composition of Matter; Use; Process</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/14/2040</p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">UAE</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Projected patent expiration dates were calculated for pending U.S. Nonprovisional Applications and Foreign Applications based on filing date. These calculations do not take into account any terminal disclaimers or patent term adjustments that may occur during prosecution or for pharmaceutical patents in Australia. U.S. Provisional and International PCT filings will not issue as patents and therefore do not have a projected expiration date. European filings will issue only in validated European countries and the projected expiration date will apply to those individual country patents.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our intellectual property estate strategy is designed to provide multiple layers of protection, including: (1)&#160;proprietary patent rights with claims directed to our drug product; (2)&#160;proprietary patent rights covering methods of treatment using our drug product; and (3)&#160;proprietary patent rights covering innovative manufacturing processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While we seek broad coverage under our pending patent applications, there is always a risk that a modification of the product or manufacturing process may allow a competitor to avoid infringement claims. In addition, patents, if granted, expire, and we cannot provide any assurance that any patents will be issued from our pending or any future applications or that any issued patents will adequately protect our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have conducted freedom to operate, or FTO, analyses of the current patent landscape with respect to our lead product candidates. In doing so, we have strived to ensure our ability to operate freely within the complex patent landscape of inhalable kinase inhibitors and the use of such products in the field of PAH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also working to develop new formulations of our drug products and new uses for such products, for which we intend to seek patent protection on our own to expand the layers of protection provided by our intellectual property estate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patent Protection and Terms</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued from regularly filed applications in the United States are granted a term of 20&#160;years from the earliest effective filing date. In addition, in certain instances, a patent term can be adjusted to recapture a portion of the United States Patent and Trademark Office, or the USPTO, delay in issuing the patent, and extended to recapture a portion of the patent term effectively lost as a result of the FDA regulatory review period of the drug covered by the patent. However, as to the FDA component, the restoration period cannot be longer than five&#160;years, the total patent term including the restoration period must not exceed 14&#160;years following FDA approval of the drug, and the extension may only apply to one patent that covers the approved drug (and to only those patent claims covering the approved drug, a method for using it, or a method for manufacturing it). There can be no assurance that any such patent term adjustment or extension will be obtained. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20&#160;years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furthermore, the patent positions of biotechnology and pharmaceutical products and processes like those we intend to develop and commercialize are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in such patents has emerged to date in the United States. The patent situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the United States and other countries can diminish our ability to protect our inventions and enforce our intellectual property rights, can make it easier to challenge the validity, enforceability or scope of any patents that may issue, and, more generally, could affect the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Third-Party Patent Filings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Numerous U.S. and foreign issued patents and patent applications owned by third parties exist in the fields in which we are developing products. In addition, because patent applications can take many&#160;years to issue, there may be applications unknown to us, which may later result in issued patents that our products or proprietary technologies may infringe. Moreover, we may be aware of patent applications, but incorrectly predict the likelihood of those applications issuing with claims of relevance to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under U.S. law, a person may be able to patent a discovery of a new way to use a previously known compound, even if such compound itself is patented, provided the newly discovered use is novel and non-obvious. Such a method-of-use patent, however, if valid, only protects the use of a claimed compound for the specified methods claimed in the patent. This type of patent does not prevent persons from using the compound for any previously known use of the compound. Further, this type of patent does not prevent persons from making and marketing the compound for an indication that is outside the scope of the patented method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Trade Secrets and Other Protections</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the protections afforded by patents and other regulatory protections, we may rely, in some circumstances, on trade secrets to protect our technology. Trade secrets may be useful to protect proprietary know-how that is not patentable or which we elect not to patent. Trade secrets may also be useful for processes or improvements for which patents are difficult to enforce.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also protect our products and proprietary technology through confidentiality agreements with employees, consultants, advisors, contractors and collaborators. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Infringement of Third-Party Proprietary Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend in part on not infringing upon or otherwise violating the intellectual property and proprietary rights of third parties. If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could also be forced, including by court order, to cease commercializing the infringing product or technology. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our products or force us to cease some of our business operations. For more information regarding these risks, please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Some of our potential competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The key competitive factors that will differentiate AV-101, if approved, are likely to be its efficacy, safety, convenience, price, and the availability of reimbursement from commercial, government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We intend to seek approval for AV-101 initially for the treatment of PAH in patients taking two or more approved PAH therapies. We recognize that physicians have many treatment options for patients already taking two or more treatments for PAH, including prostanoids available in oral form as Orenitram (United Therapeutics Corporation, or United Therapeutics) and Uptravi (Janssen Pharmaceuticals, Inc., or Janssen), by inhalation as Tyvaso and Tyvaso DPI (United Therapeutics), Ventavis (Janssen), and by infusion as Remodulin (United Therapeutics), Flolan (GlaxoSmithKline plc) and Veletri (Janssen). We believe that AV-101, if approved, could be used prior to or in combination with prostanoids, and in combination with existing front-line agents such as the oral PDE5 inhibitors, including Revatio (Pfizer) and Adcirca (United Therapeutics); the sGC stimulator Adempas (Bayer AG); and oral ERAs, including Tracleer (Janssen), Letairis (Gilead) and Opsumit (Janssen). PAH is also an active indication for investigational drugs, and we may face competition in the future from sotatercept (Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck &amp; Co., Inc.), seralutinib (Gossamer Bio, Inc.), and/or rodatristat (Enzyvant, Inc.). To our knowledge, Tenax Therapeutics, Inc. and Aerami Therapeutics, Inc. are developing other formulations of imatinib for PAH, and both companies have completed Phase 1 clinical trials and indicated they each intend to pursue further clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">United States&#8212;FDA Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The FDCA and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory authorities of the countries in which we wish to conduct studies or seek approval of our product candidates. Failure to comply with applicable United States requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs, withdrawal of an approval, warning or untitled letters, clinical holds, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, civil penalties, and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">FDA approval is required before any new unapproved product or a product with certain changes to a previously approved product, including a new use of a previously approved drug, can be marketed in the United States. The steps required to be completed by the FDA before a drug may be marketed in the United States generally includes the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests, animal studies, and formulation studies performed in accordance with the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an investigational new drug, or IND, application for human clinical testing, which must become effective before human clinical trials may begin and must be updated annually or when significant changes are made;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before the clinical trial is commenced;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, GCP, requirements and other clinical-trial related regulations to establish the safety and efficacy of the proposed drug for each indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation and submission to the FDA of a NDA after completion of all pivotal clinical trials, which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60&#160;days of its receipt of an NDA to file the application for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed drug is produced to assess compliance with current GMP regulations and of selected clinical trial sites to assess compliance with GCPs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Satisfaction of FDA pre-market approval requirements typically takes many&#160;years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Preclinical and Clinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLPs. The results of preclinical testing are submitted to the FDA as part of an IND application along with other information, including information about the product candidate, chemistry, manufacturing and controls, any available human data or literature to support the use of the product candidate and a proposed clinical trial protocol. Long term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions relating to one or more proposed clinical trials and places the clinical trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns, non-compliance or other issues affecting the integrity of the trial. Accordingly, submission of an IND may or may not result in the FDA allowing clinical trials to commence and, once begun, issues may arise that could cause the trial to be suspended or terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Clinical trials involve the administration of the investigational drug product to human subjects under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations; (ii)&#160;in compliance with GCP, an international standard meant to protect the rights and health of clinical research participants and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&#160;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on United States patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, an independent IRB or ethics committee for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objects. The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements. Further, an IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. Some trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may recommend a clinical trial to be halted if it determines that there is an unacceptable safety risk for subjects or other grounds, such as futility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials to support an NDA for marketing approval are typically conducted in three sequential phases, but the phases may overlap or be combined. In Phase 1 clinical trials, the investigational product is typically introduced into a limited population of healthy human subjects or patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, pharmacokinetics and pharmacological actions of the investigational product, to identify side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials usually involve administering the investigational product to a limited patient population with the specified disease or condition to evaluate the preliminarily efficacy, dosage tolerance, and optimum dosage, and to identify possible adverse effects and safety risks. Phase 3 clinical trials are typically undertaken in a larger number of patients, typically at geographically dispersed clinical trial sites, to provide substantial evidence of clinical efficacy and to further test for safety in an expanded and diverse patient population. These clinical trials are intended to permit the FDA to evaluate the overall benefit-risk relationship of the investigational product and to provide adequate information for the labeling of the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In reviewing an NDA, the FDA will consider all information submitted in the NDA, including the results of all clinical trials conducted. In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the NDA. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and further document clinical benefit in the case of drugs approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in the withdrawal of approval for products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with current GMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical study investigators. Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the product candidate, findings from animal or in vitro testing that suggest a significant risk for human subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">NDA Submission and Review</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of the required clinical testing in accordance with all applicable regulatory requirements, an NDA application which includes, among other information, the results of product development, preclinical studies and clinical trials are submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the United States. The NDA must include, among other things, the results of all trials and preclinical testing, and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, controls and proposed labeling. The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee, unless a waiver or exemption applies, currently $3,242,026, as well as an annual program fee, currently $339,933. These fees are typically increased annually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA has 60&#160;days from its receipt of an NDA to either issue a Refuse to File Letter or accept the NDA for filing, indicating that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs. Under the Prescription Drug User Fee Act, the FDA has a goal of responding to standard review NDAs within ten&#160;months after it accepts the application for filing, or, if the application qualifies for priority review, six&#160;months after the FDA accepts the application for filing, but this timeframe can be extended such as by the submission of major amendments by applicants during the review period. The FDA reviews an NDA to determine, among other things, whether the product is safe and effective and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee&#8212;typically a panel that includes clinicians and other experts&#8212;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. Additionally, the FDA will inspect the facility or the facilities at which the proposed product is manufactured. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates the NDA and conducts inspections of the manufacturing facilities where the investigational product and/or its drug substance will be produced, it issues either an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the drug with approved prescribing information for specific indications. A Complete Response letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response letter generally outlines the deficiencies in the submission, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may require substantial additional clinical data and/or other significant, expensive, and time-consuming requirements related to clinical trials, preclinical studies and/or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, withdraw the application or request a hearing. The FDA has committed to reviewing resubmissions of the NDA addressing such deficiencies in two or six&#160;months depending on the type of information included. Even if such data are submitted, however, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If regulatory approval of a product is granted, such approval will be granted for a particular indication(s)&#160;and may include limitations on the indicated use(s)&#160;for which such product may be marketed. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">patient registries. The requirement for REMS can materially affect the potential market and profitability of the product. Moreover, product approval may also be conditioned on substantial post-approval testing, such as Phase 4 post-market studies, and surveillance to monitor the product&#8217;s safety or efficacy, and FDA may limit further marketing of the product based on the results of these post-approval studies. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. As with new NDAs, the review process is often significantly extended by the FDA requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">505(b)(2)&#160;NDA Approval Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Section&#160;505(b)(2)&#160;of the FDCA provides an alternate regulatory pathway for the FDA to approve a new product and permits reliance for such approval on published literature or an FDA finding of safety and effectiveness for a previously approved drug product. Specifically, section 505(b)(2)&#160;permits the filing of an NDA where one or more of the investigations relied upon by the applicant for approval were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Typically, 505(b)(2)&#160;applicants must perform additional trials to support the change from the previously approved drug and to further demonstrate the new product&#8217;s safety and effectiveness. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, as well as for any new indication sought by the section 505(b)(2)&#160;applicant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Regulation of Combination Products in the United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain products may be comprised of components, such as drug components and device components, that would normally be regulated under different types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a drug, or device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, or device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any investigational drug, or device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under the FDCA and its implementing regulations, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. The designation of a lead center generally eliminates the need to receive approvals from more than one FDA component for combination products, although it does not preclude consultations by the lead center with other components of FDA. The determination of which center will be the lead center is based on the &#8220;primary mode of action&#8221; of the combination product. Thus, if the primary mode of action of a drug-device combination product is attributable to the drug product, the FDA center responsible for premarket review of the drug product would have primary jurisdiction for the combination product. The FDA has also established an Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A combination product with a drug primary mode of action generally would be reviewed and approved pursuant to the drug approval processes under the FDCA. In reviewing the NDA application for such a product, however, FDA reviewers in the drug center could consult with their counterparts in the device center to ensure that the device component of the combination product met applicable requirements regarding safety, effectiveness, durability and performance. In addition, under FDA regulations, combination products are subject to current GMP requirements applicable to both drugs and devices, including the Quality System, or QS, regulations applicable to medical devices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Once an NDA is approved, a product will be subject to pervasive and continuing regulation by the FDA including, among other things, requirements relating to current GMPs, quality controls, record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the practice of medicine by physicians or their choice of treatments. The FDA does, however, regulate manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, quality control, drug manufacture, packaging, and labeling procedures must continue to conform to current GMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA, and certain state agencies for compliance with current GMPs, which impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from current GMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. NDA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. Drug manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. The discovery of violative conditions, including failure to conform to current GMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with current GMPs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The FDA may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards or is not maintained, if problems occur following initial marketing, or if previously unrecognized problems are subsequently discovered. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">U.S. Patent Term Restoration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of the potential FDA approval of AV-101 and any future product candidates, some of our U.S. patents may be eligible for limited patent term extension. The Hatch-Waxman Amendments permit a patent restoration term, often referred to as patent term extension, of up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves or denies the application for any patent term extension or restoration. In the future, we intend to apply for extension of patent term for one of our patents covering AV-101 to add patent life beyond its current expected expiration date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">U.S. Marketing Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications, including 505(b)(2)&#160;applications. The FDA provides three&#160;years of marketing exclusivity for an NDA (including a 505(b)(2)&#160;application), or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. Three-year exclusivity is typically awarded to innovative changes to a previously-approved drug product, such as new indications, dosage forms or strengths. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving applications for drugs that do not have the innovative change, such as generic copies of the original, unmodified drug product. Three-year exclusivity blocks approval of 505(b)(2)&#160;applications and Abbreviated New Drug Applications, or ANDAs, but will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six&#160;months to existing exclusivity periods, including exclusivity attaching to certain patent certifications. This six-month exclusivity, which runs from the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">end of other exclusivity protection and patent terms, may be granted based on the voluntary completion within certain timeframes of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Orphan Drug Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition&#8212;generally a disease or condition with either a patient population that affects fewer than 200,000 individuals in the United States or a patient population greater than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and making available the drug will be recovered from sales of the drug in the United States. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the product and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same product for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of the patients with the disease or condition for which the product was designated. Orphan drug exclusivity does not prevent the FDA from approving a different product for the same disease or condition, or the same product for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA or BLA application user fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan drug designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fast Track Designation, Breakthrough Therapy Designation and Accelerated Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition which demonstrate the potential to address unmet medical needs for the condition. These programs include fast track designation, priority review and accelerated approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A product candidate is eligible for fast track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. Under the fast track program, the sponsor of a drug candidate may request that the FDA designate the candidate for a specific indication as a fast track product concurrent with, or after, the filing of the IND for the candidate. The FDA must determine if the product candidate qualifies for fast track designation within 60&#160;days of receipt of the sponsor&#8217;s request. Fast track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review of sections of a the applicant&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under the FDA&#8217;s breakthrough therapy program, a sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">substantial treatment effects observed early in clinical development. Breakthrough therapy designation comes with all of the benefits of fast track designation. The FDA may take other actions appropriate to expedite the development and review of the product candidate, including intensive guidance on an efficient product development program beginning as early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any product submitted to the FDA for marketing, including under the fast track or breakthrough designation program, may also be eligible for other types of FDA programs intended to expedite development and review, such as accelerated approval. Products are eligible for accelerated approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the conduct of Phase 4, or post-approval, clinical trials to confirm the effect on the clinical endpoint which must be conducted with due diligence and, under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA may require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date accelerated approval is granted. Additionally, under FDORA, the FDA has increased authority for expedited procedures to withdraw a product or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA unless otherwise informed by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Priority Review</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A product is eligible for priority review if it has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. A priority review means that the goal for the FDA to review an application is six&#160;months, rather than the standard review of ten&#160;months under current Prescription Drug User Fee Act, or PDUFA, guidelines. Under the current PDUFA agreement, these six and ten&#160;month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two&#160;months to the timeline for review and decision from the date of submission. Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Pediatric Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Pediatric Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Disclosure of Clinical Trial Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Sponsors of clinical trials of FDA-regulated products, including drugs and combination products, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government. The Final Rule&#160;on </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ClinicalTrials.gov registration and reporting requirements became effective in 2017, and both the National Institutes of Health and the FDA recently signaled the government&#8217;s willingness to begin enforcing those requirements against non-compliant clinical trial sponsors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">European Union&#8212;Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the European Union, or EU, our product candidate(s)&#160;may also be subject to extensive regulatory requirements governing, among other things, clinical trials and any commercial sales and distribution of our product candidate(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities located in the EU Member States prior to the commencement of clinical trials as well as EU or national regulatory approvals prior to marketing the product candidate(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Non-Clinical Studies and Clinical Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Similar to the United States, the various phases of non-clinical studies and clinical trials in the EU are subject to significant regulatory controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical substances. Non-clinical studies must be conducted in compliance with the principles of good laboratory practice, or GLP, as set forth in EU Directive 2004/10/EC. In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules&#160;and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials of medicinal products in the EU must be conducted in accordance with the EU Clinical Trials Regulation (EU) No 536/2014, or CTR, (which was adopted in April&#160;2014, and repealed the EU Clinical Trials Directive 2001/20/EC on January&#160;31, 2022), and the International Conference on Harmonization, or ICH, guidelines on GCP, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative (unless all EU Member States in which the trial is being conducted have chosen not to apply such rule, in which case it may be that only a contact person in the EU is required), who shall be responsible for ensuring compliance with the sponsor&#8217;s obligations under the CTR and be the addressee for all communications provided for under the CTR. The sponsor must take out a clinical trial insurance policy, and in most EU Member States, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The CTR is directly applicable in all Member States (meaning that no national implementing legislation in each EU Member State is required). Under the CTR, there is a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only limited involvement (instead of submitting applications separately to each national competent authority and ethics committee in the Member States in which the trial will be conducted, as was the case under the previous EU Clinical Trials Directive). The CTR also makes it more efficient for EU Member States to evaluate and authorize applications together, via the Clinical Trials Information System. Medicines used in clinical trials must be manufactured in accordance with GMP. Other national and EU-wide regulatory requirements may also apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Disclosure of Clinical Trial Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The CTR significantly enlarges the publication and transparency obligations for clinical trial sponsors from the previous position under the Clinical Trials Directive. Additionally, the CTR requires that EU Member States adopt specific measures, including penalties, to adequately sanction infringements of the relevant transparency obligations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Marketing Authorisations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the EU, medicinal products can only be placed on the market after obtaining a marketing authorisation, or MA. To obtain regulatory approval of a product in the EU, we must submit a MAA. The process for doing this depends, among other things, on the nature of the medicinal product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Centralized Procedure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the centralized procedure, the European Commission issues a single MA, based on the opinion of the European Medicines Agency&#8217;s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, which is valid across the entire territory of the EU, as well as Iceland, Liechtenstein and Norway (i.e. the European Economic Area, or EEA). The centralized procedure is compulsory for human medicines that are: (i)&#160;derived from biotechnology processes; (ii)&#160;advanced-therapy medicinal products (i.e. gene therapy, somatic cell-therapy or tissue-engineered medicines); (iii)&#160;contain a new active substance indicated for the treatment of certain diseases, such as HIV or AIDS, cancer, diabetes, neurodegenerative diseases, viral diseases or autoimmune diseases and other immune dysfunctions; and (iv)&#160;officially designated orphan medicines. For medicines that do not fall within these categories, an applicant has the option of submitting an application for a centralized MA to the EMA if the product contains a new active substance not yet authorized in the EU, or the medicine concerned is a significant therapeutic, scientific or technical innovation, or that the granting of a centralized authorization would be in the interest of public health at EU-level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a MA, which is issued within 67 days of receipt of the EMA&#8217;s recommendations. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. Accelerated assessment of an MAA might be performed by the CHMP in no more than 150 days (excluding clock stops) but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. Innovative products that target an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicine will bring a major therapeutic advantage) may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the breakthrough therapy designation in the United States. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment but this is not guaranteed. The benefits of a PRIME designation include the appointment of a CHMP rapporteur before submission of an MAA, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">National Authorisation Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There are also two other possible routes to authorize medicinal products in several Member States. National MAs are issued by the national competent authorities of the EU Member States and only cover their respective territory. They are available for products that fall outside the scope of the centralized procedure:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Decentralized</i><i style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:italic;font-weight:normal;"> </i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">procedure. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the product has not received a national MA in any Member State at the time of application, an applicant may apply for simultaneous MAs in more than one EU Member State. Under the decentralized procedure an identical dossier is submitted to the national competent authority of each of the Member States in which a MA is sought, one of which is selected by the applicant as the Reference Member State.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Mutual recognition procedure. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the mutual recognition procedure, a medicine that has already been authorized in one EU Member State, in accordance with the national procedures of that Member State, can be recognized in another Member State.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">MAs have an initial duration of five years. After these five years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Similar to the United States, there is a process for authorization of generic/biosimilar versions of innovator medicinal products authorized in the EU. Abridged applications for the authorization of generic/biosimilar versions of medicinal products authorized via the EU centralized procedure can be submitted to the EMA through the centralized procedure referencing the innovator&#8217;s data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Data and Market Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the EU, innovative medicinal products approved on the basis of a complete and independent data package qualify for eight years of data exclusivity upon grant of a MA and an additional two years of market exclusivity. Data exclusivity prevents generic and biosimilar applicants from referencing the innovator&#8217;s preclinical and clinical trial data contained in the dossier of the reference product when applying for a MA for a period of eight years from the date on which the reference product was first authorized in the EU. During the additional two-year period of market exclusivity, a generic or biosimilar MAA can be submitted and authorized, and the innovator&#8217;s data may be referenced, but no generic or biosimilar medicinal product can be marketed until the expiration of the market exclusivity period. The overall 10 year period will be extended to a maximum of 11 years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative medicinal product so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained MA based on an MAA with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Orphan Medicinal Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. A medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating conditions; (2)&#160;either (a)&#160;such condition affects no more than 5 in 10,000 persons in the EU when the application is made, or (b)&#160;it is unlikely that the marketing of the product, without the benefits derived from orphan status, would generate sufficient return in the EU to justify the necessary investment in its development; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU or, if such a method exists, the product in question would be of significant benefit compared to products available for that condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the EU, orphan designation entitles a party to financial incentives such as reduction of fees or fee waivers, regulatory assistance and the possibility to apply for a centralized MA. The application for orphan designation must be submitted before the application for an MA. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The grant of an MA for an orphan medicinal product leads to ten years of market exclusivity. During the ten-year market exclusivity period, the EMA cannot accept an MAA, or grant an MA, or accept an application to extend an MA, for the same therapeutic indication, in respect of a &#8220;similar medicinal product&#8221;. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity in the EU for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the orphan designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. At any time, a MA may be granted to a similar medicinal product for the same </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">therapeutic indication if: (i) a second applicant can establish that its product, although similar to the authorized product, is safer, more effective or otherwise clinically superior; (ii) the MA holder for the authorized product consents to a second orphan medicinal product application; or (iii) the MA holder for the authorized product cannot supply enough orphan medicinal product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Pediatric Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the EU, MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product for which an MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all Member States and study results are included in the product information, even when negative, the product is eligible for a six-months supplementary protection certificate, or SPC extension (provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to two years before the SPC expires) or, in the case of orphan medicinal products, a two-year extension of the orphan market exclusivity is granted. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure to comply with EU and Member State laws that apply to the conduct of clinical trials, manufacturing approval, marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant a MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Regulation of Combination Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The EU regulates medical devices and medicinal products separately, through different legislative instruments, and the applicable requirements will vary depending on the type of drug-device combination product. EU guidance has been published to help manufacturers select the right regulatory framework. In the case of drug-delivery products intended to administer a medicinal product where the device and the medicinal product do not form a single integral product, the medicinal product is regulated in accordance with the aforementioned rules while the device part is regulated as a medical device and will have to comply with all the requirements set by Regulation 2017/745, or the Medical Devices Regulation (which became applicable on May 26, 2021 and repealed the EU Council Directive 93/42/EEC, or the Medical Devices Directive). Where the medical device and medicinal product form a single integrated product (e.g. pre-filled inhalers), if the principal intended action is achieved by the medicine, the product is considered a medicinal product that includes a medical device and the entire product is regulated under the EU pharmaceutical legislation. However, the MAA for the product should include a CE certificate for the device in accordance with the Medical Devices Regulation or, if not CE marked but would need to be certified if marketed separately, the applicant must include an opinion from a notified body on the conformity of device (except for Class I non-sterile, non-measuring devices). This is a requirement under the new Medical Devices Regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The characteristics of non-integral devices used for the administration of medicinal products may impact the quality, safety and efficacy profile of the medicinal products. To the extent that administration devices are co-packaged with the medicinal product or, in exceptional cases, where the use of a specific type of administration device is specifically provided for in the product information of the medicinal product, additional information may need to be provided in the MAA for the medicinal product on the characteristics of the medical device(s) that may impact on the quality, safety and/or efficacy of the medicinal product. The requirements regarding quality aspects for integral drug-device combination products, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">including devices that are co-packaged with medicinal products, are outlined in an EMA guideline which came into effect on January 1, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The EU requires that all medical devices placed on the market in the EU must meet the relevant general safety and performance requirements laid down in Annex I of the Medical Devices Regulation. The most fundamental requirement is that a medical device must be designed and manufactured in such a way that it will not compromise the clinical condition or safety of patients, or the safety and health of users and others. In addition, the device must achieve the performances intended by the manufacturer and be designed, manufactured, and packaged in a suitable manner. To demonstrate compliance with the general safety and performance requirements laid down in Annex I to the Medical Devices Regulation, medical device manufacturers must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification. Conformity assessment procedures require an assessment of available clinical evidence, literature data for the product, and post-market experience in respect of similar products already marketed. Except for low-risk medical devices (Class I non-sterile, non-measuring devices), where the manufacturer can self-declare the conformity of its products with the general safety and performance requirements (except for any parts which relate to sterility or metrology), a conformity assessment procedure requires the intervention of a notified body. Notified bodies are independent organizations designated by EU countries to assess the conformity of devices before being placed on the market. If satisfied that the relevant product conforms to the relevant general safety and performance requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the CE mark to the device, which allows the device to be placed on the market throughout the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a general rule, demonstration of conformity of medical devices and their manufacturers with the general safety and performance requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The aforementioned EU rules&#160;are generally applicable in the EEA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Brexit and the Regulatory Framework in the United Kingdom</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The United Kingdom, or UK formally left the EU (commonly referred to as &#8220; Brexit&#8221;) on January&#160;31, 2020, and the EU and the UK have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January&#160;1, 2021 and has been formally applicable since May&#160;1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not provide for wholesale mutual recognition of UK and EU pharmaceutical or medical devices regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework continues to apply in Northern Ireland). The medicinal products regulatory regime in Great Britain therefore largely aligns with EU regulations, however it is possible that these regimes will diverge more significantly in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation. The new Medical Devices Regulation is not applicable in Great Britain following Brexit and the current legislation is based on the previous Medical Devices Directive. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since Brexit, Great Britain is no longer covered by centralized MAs (under the Northern Ireland Protocol, centralized MAs continue to be recognized in Northern Ireland). All medicinal products with a centralized MA were automatically converted to Great Britain MAs on January&#160;1, 2021. For a period of three&#160;years from January&#160;1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new MA in the centralized procedure, in order to more quickly grant a new Great Britain MA. A separate application will, however, still be required.<span style="font-size:12pt;"> </span>On January 24, 2023, the MHRA announced that a new international recognition framework will be put in place from January 1, 2024, which will have regard to decisions on the approval of MAs made by the European Medicines Agency and certain other regulators when determining an application for a new Great Britain MA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other International Markets&#8212;Drug Approval Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In some international markets (<i style="font-style:italic;">e.g.</i>, China or Japan), although data generated in United States or EU trials may be submitted in support of a MAA, additional clinical trials conducted in the host territory, or studying people of the ethnicity of the host territory, may be required prior to the filing or approval of MA within the country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pricing and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States and internationally, sales of products that we market in the future, and our ability to generate revenues on such sales, are dependent, in significant part, on the availability and level of reimbursement from third-party payors such as state and federal governments, managed care providers and private insurance plans. Substantial uncertainty exists as to the reimbursement status of newly approved healthcare products by third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States no uniform policy of coverage and reimbursement for drug products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor by payor basis. Private third-party payors tend to follow Medicare coverage policies and payment limitations in setting their own reimbursement rate to a substantial degree, but also have their own methods and approval process apart from Medicare determinations. As a result, coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Factors payors consider in determining reimbursement are based on whether the product is:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a covered benefit under its health plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safe, effective and medically necessary;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">appropriate for the specific patient;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost-effective; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">neither experimental nor investigational.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Increasingly, third party payors are implementing cost-cutting and reimbursement initiatives and likely will continue to do so in the future. These include establishing formularies that govern the drugs and biologics that will be offered and also the out-of-pocket obligations of member patients for such products. In addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. It is possible that future legislation in the United States and other jurisdictions could be enacted which could potentially impact the reimbursement rates for the products we are developing and may develop in the future and also could further impact the levels of discounts and rebates paid to federal and state government entities. Any legislation that impacts these areas could impact, in a significant way, our ability to generate revenues from sales of products that, if successfully developed, we bring to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. In the EU, governments influence the price of medicinal products through their pricing and reimbursement rules&#160;and control of national healthcare systems that fund a large part of the cost of those products to consumers. Member States are free to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. Member States may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market, including volume-based arrangements, caps and reference pricing mechanisms. To obtain reimbursement or pricing approval, some of the Member States may require the completion </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies that are considered the local standard of care. Other Member States allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription medicines, has become very intense. It is increasingly common in many EU Member States for MA holders to be required to demonstrate the pharmaco-economic superiority of their products as compared to products already subject to pricing and reimbursement in specific countries. In order for drugs to be evaluated positively under such criteria, pharmaceutical companies may need to re-examine, and consider altering, a number of traditional functions relating to the selection, study, and management of drugs, whether currently marketed, under development, or being evaluated as candidates for research and/or development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sales and Marketing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sales, promotion and other activities following product approval are subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers for Medicare&#160;&amp; Medicaid Services, other divisions of the Department of Health and Human Services, the U.S. Department of Justice, and similar foreign, state, and local government authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As described above, the FDA regulates all advertising and promotion activities for products under its jurisdiction both prior to and after approval. A company can make only those claims relating to safety and efficacy that are approved by the FDA in labeling. Physicians may prescribe legally available drugs for uses that are not described in the drug&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties, and often reflect a physician&#8217;s belief that the off-label use is the best treatment for the patients. The FDA does not regulate the behavior of physicians in their choice of treatments, but FDA regulations do impose stringent restrictions on manufacturers&#8217; communications regarding off-label uses. Failure to comply with applicable FDA requirements may subject a company to adverse publicity, enforcement action by the FDA, corrective advertising, consent decrees and the full range of civil and criminal penalties available to the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare Laws and Regulations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pharmaceutical companies are also subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business that may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, and transparency laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment. Such laws include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the United States federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any United States federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the United States federal civil monetary penalty and civil and criminal false claims laws, including the civil federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions, which prohibit, </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">among other things, individuals or entities from knowingly presenting, or causing to be presented, to the United States federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the United States federal government. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. Pharmaceutical manufacturers can cause false claims to be presented to the United States federal government by engaging in impermissible marketing practices, such as the off-label promotion of a product for an indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and services resulting from a violation of the United States federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious, or fraudulent statements or representations in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, including the Final Omnibus Rule&#160;published in January&#160;2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the United States Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care professionals (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists&#160;&amp; anesthesiologist assistants, and certified nurse-midwives), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous United States state laws, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the United States federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the United States Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, United States companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">similar healthcare laws in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Similar rigid restrictions are imposed on the promotion and marketing of medicinal products in the EU and other countries. Laws (including those governing promotion, marketing and anti-kickback provisions), industry regulations and professional codes of conduct often are strictly enforced. Even in those countries where we are not directly responsible for the promotion and marketing of our products, inappropriate activity by our international distribution partners can have adverse implications for us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare Reform and Legislation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases such as those we are developing. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. The Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers up to 2% per fiscal&#160;year. Subsequent legislation extended the 2% payment reduction which remains in effect through 2030. In addition, the American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. Additionally, in May&#160;2019, CMS issued a final rule&#160;to allow Medicare Advantage Plans the option of using step therapy for Part&#160;B drugs beginning January&#160;1, 2020. However, it is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">unclear whether the Biden administration will challenge, reverse, revoke or otherwise modify these executive and administrative actions after January&#160;20, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Inflation Reduction Act of 2022, includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket cap for Medicare Part D beneficiaries to $2,000 starting in 2025; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation, and delay the rebate rule that would limit the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one rare disease designation and for which the only approved indication is for that disease or condition. If a product receives multiple rare disease designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The effects of the IRA on our business and the healthcare industry in general is not yet known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent United States Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that it will continue to seek new legislative measures to control drug costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, on May&#160;30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the state level, individual states are increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Data Privacy and Security Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA and federal and state consumer protection laws and regulations (e.g., Section&#160;5 of the Federal Trade Commission Act) that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain state and non-U.S. laws, such as the CCPA, as modified by the CPRA and GDPR, govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to make compliance efforts more challenging, and can result in investigations, proceedings, or actions that lead to significant penalties and restrictions on data processing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other Laws and Regulatory Processes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will become subject to a variety of financial disclosure and securities trading regulations as a public company in the United States, including laws relating to the oversight activities of the SEC and, following the listing of our capital stock on The Nasdaq Global Market, we will be subject to the regulations of The Nasdaq Global Market. In addition, the Financial Accounting Standards Board, or FASB, the SEC and other bodies that have jurisdiction over the form and content of our accounts, our financial statements and other public disclosure are constantly discussing and interpreting proposals and existing pronouncements designed to ensure that companies best display relevant and transparent information relating to their respective businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our international operations are subject to compliance with the Foreign Corrupt Practices Act, or the FCPA, which prohibits corporations and individuals from paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. We also may be implicated under the FCPA for activities by our partners, collaborators, CROs, vendors or other agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our present and future business has been and will continue to be subject to various other laws and regulations. Various laws, regulations and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances used in connection with our research work are or may be applicable to our activities. Certain agreements entered into by us involving exclusive license rights or acquisitions may be subject to national or supranational antitrust regulatory control, the effect of which cannot be predicted. The extent of government regulation, which might result from future legislation or administrative action, cannot accurately be predicted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 27, 2023, we had 43 full-time employees, including 35 in research and development and eight in general and administrative functions. We also contract with a number of consultants to supplement the efforts and responsibilities of our employees. None of our employees are subject to a collective bargaining agreement or represented by a labor or trade union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are committed to fostering a diverse workforce and a culture of inclusion. We pursue fair employment practices in every aspect of our business and are dedicated to creating a productive work environment for all our employees. Both at work and in the clinic, we are committed to recruiting individuals that exemplify diversity in culture and life experience and are always striving to grow and improve. As an emerging company operating in a competitive industry, much of our success is rooted in investing in the development of each of our employees. It is our goal to empower all employees to take full advantage of their professional growth opportunities, to lead them to long-term job satisfaction and organizational success. Our people are our greatest competitive advantage and as we grow, we plan to continue to add to our human capital initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We were incorporated under the laws of the State of Delaware in July&#160;2018. Our principal corporate office is located at 930 Winter Street, Suite&#160;M-500, Waltham, MA 02451, and our telephone number is (617) 443-2400. Our website address is www.aerovatetx.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this Annual Report on Form&#160;10-K.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We own various U.S. federal trademark applications and unregistered trademarks, including our company name. All other trademarks or trade names referred to in this Annual Report on Form&#160;10-K are the property of their respective owners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July&#160;2, 2021, we closed our initial public offering, or IPO, in which we issued and sold 9,984,463 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,302,321 additional shares of common stock, at a public offering price of $14.00 per share. Including the option exercise, our aggregate net proceeds from the IPO were $126.9 million, net of underwriting discounts, commissions and estimated offering costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company until the earlier of: (i)&#160;the last day of the fiscal&#160;year (a)&#160;following the fifth anniversary of the completion of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235 billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June&#160;30th, and (ii)&#160;the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Solely for convenience, the trademarks and trade names in this Annual Report on Form&#160;10-K are referred to without the symbols &#174; and &#8482;, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our website address is https://www.aerovatetx.com. Our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d)&#160;of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available through the &#8220;Investors&#8221; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form&#160;10-K or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#8217;s Interactive Data Electronic Applications system at www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, we may use our website, LinkedIn or our Twitter account (@AerovateTx) to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.aerovatetx.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our Twitter or LinkedIn posts are not incorporated into, and does not form a part of, this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our code of conduct, corporate governance guidelines and the charters of our Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are available through the &#8220;Investors&#8221; portion of our website.</p><a id="_d4ed763c_06d3_4dae_bb49_ded2bfc6aa80"></a><a id="Item1ARiskFactors_707099"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">In evaluating the Company and our business, careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report on Form&#160;10-K and in other documents that we file with the SEC. Investing in our common stock involves a high degree of risk. If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition or results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing the Company. New risk factors can emerge from time to time, and it is not possible to predict the impact that any factor or combination of factors may have on our business, prospects, financial condition or results of operations.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Limited Operating History, Financial Position, and Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company with a limited operating history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company established in July&#160;2018 with a limited operating history. Since our inception, we have devoted substantially all of our efforts to organizing and staffing our company, research and development of AV-101, our initial product candidate, business planning, raising capital, and providing general and administrative support for these operations. We have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the pharmaceutical industry. We have completed our Phase 1 clinical trial of AV-101. We announced the initiation of our Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase 2b/Phase 3 clinical trial for AV-101 in adults with PAH in December&#160;2021. We may explore additional indications for AV-101, but do not intend to conduct research on additional product candidates at this time. We have no products approved for commercial sale and therefore have never generated any revenue from product sales, and we do not expect to in the foreseeable future. We have no other experience as a company conducting clinical trials, submitting applications for regulatory approvals, such as a New Drug Application, or NDA, or commercializing any products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses in each&#160;year since our incorporation in July&#160;2018, do not expect to become profitable in the near future, and may never achieve profitability. Our net losses were $51.5 million and $23.0 million for the years ended December 31, 2022 and December 31, 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $87.9 million. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We have no products approved for commercial sale, have not generated any revenue from product sales and have incurred losses in each&#160;year since our inception in July&#160;2018. Substantially all of our operating losses have resulted from costs incurred in connection with our research and development program of AV-101 and from general and administrative costs associated with our operations. AV-101 will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We also do not yet have a sales organization or commercial infrastructure and, accordingly, we will incur significant expenses to develop a sales organization or commercial infrastructure in advance of generating any commercial product sales. In addition, as a public company, we will continue to incur additional costs associated with operating that we did not incur as a private company. As a result, we expect to continue to incur significant expenses and operating losses for the foreseeable future, and we anticipate these losses will increase as we continue to develop AV-101 through clinical trials and regulatory submissions. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; deficit and working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The amount of our future losses is uncertain and our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and success or failure of the clinical development of AV-101, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully open clinical trial sites for AV-101 and recruit and retain subjects for clinical trials, and any delays caused by difficulties in such efforts;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain regulatory approval for AV-101, and the timing and scope of any such approvals we may receive;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and cost of, and level of investment in, research and development activities relating to AV-101, which may change from time to time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing AV-101, should it receive regulatory approval, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the experience of any delays or any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract, hire and retain qualified personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the establishment of a sales, marketing, access and distribution infrastructure and the scaling-up manufacturing capabilities, whether alone or with third parties, to commercialize any product candidates for which we may obtain regulatory approval, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenditures that we will or may incur to pursue additional indications for AV-101 or develop or acquire additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of demand for AV-101, should it receive regulatory approval, which may vary significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk/benefit profile, cost and reimbursement policies with respect to AV-101, if approved, and existing and potential future therapeutics that compete with AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the changing and volatile United States and global economic environments, including as a result of the ongoing coronavirus disease 2019, or COVID-19, pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future accounting pronouncements or changes in our accounting policies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes to government policies and/or regulation impacting the commercialization of pharmaceutical products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have no products approved for commercial sale and have not generated any revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated revenue, and we do not expect to generate any revenue in the near future. We do not expect to generate significant revenue unless and until we obtain regulatory approval of, and begin to sell AV-101. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully enroll subjects in, and complete, our ongoing and any future clinical trials for AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain sufficient safety data required to obtain United States and foreign regulatory approval for AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely file and receive U.S. Food and Drug Administration, or FDA, acceptance of our NDA for AV-101 for review;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receive regulatory approvals from the FDA and foreign regulatory authorities for AV-101 in order to commence marketing of AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish commercial manufacturing capabilities or make arrangements with third-party manufacturers for clinical supply and commercial manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain and maintain patent and trade secret protection or non-patent regulatory exclusivity for AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">execute a commercial launch of AV-101, if approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain and maintain acceptance of AV-101, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">position AV-101 to effectively compete with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain and maintain healthcare coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enforce and defend intellectual property rights and claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">implement measures to help minimize the risk of COVID-19 or any of its variants to our employees as well as patients and subjects enrolled in our clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain a continued acceptable safety profile of AV-101 following approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize AV-101, which would materially harm our business. If we do not receive regulatory approvals for AV-101, we may not be able to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will require additional capital to finance our operations, which may not be available on acceptable terms, or at all. If we are unable to raise capital when needed, we would be forced to delay, reduce or terminate our product development or commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since our inception, we have invested substantially all of our efforts and financial resources in the development of AV-101 to address the core disease processes of PAH. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the clinical development of AV-101, including in connection with our Phase 2b/Phase 3 clinical trial. These expenditures will include costs associated with clinical trials, obtaining regulatory approvals, manufacturing and supply, as well as commercializing AV-101, if approved for sale. Our overall costs have risen due to the delays in site activation and patient enrollment, and due to our increased headcount to mitigate the effects of staff shortages at clinical trial sites and CROs. In addition, other unanticipated costs may arise. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had cash and cash equivalents and short-term investments of $129.2 million. We expect our existing cash and cash equivalents and short-term investments will be sufficient to fund our planned operations into the second half of 2025 based upon our current operating plans. However, our operating plans may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our future capital requirements depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, timing, rate of progress, results and costs of our preclinical studies or clinical trials for AV-101 and any additional product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and scope of additional product candidates we decide to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we discover and develop additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and costs of manufacturing development and commercial manufacturing activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost, timing and outcome of regulatory review of AV-101 and any additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of building a medical affairs and commercial organization including a sales force in anticipation of commercialization of AV-101 and any additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing associated with commercializing AV-101 and any additional product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any product liability or other lawsuits related to AV-101 and any additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of AV-101 and any additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we pursue additional indications for AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or in-license other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain collaborations on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with being a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential additional expenses attributable to adjusting our development plans (including any supply related matters) to the ongoing COVID-19 pandemic; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales of AV-101 and any additional product candidates, if approved.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay, limit, reduce or terminate clinical studies or other medical and development activities for AV-101; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize AV-101, or reduce our flexibility in developing or maintaining our sales and marketing strategy.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies or AV-101 that we would otherwise pursue on our own. We do not expect to realize revenue from sales of AV-101 in the foreseeable future, if at all, and unless and until AV-101 is clinically tested, approved for commercialization and successfully marketed. To date, we have funded our operations through private placements of convertible preferred stock, convertible notes and proceeds from our initial public offering, or IPO. We will be required to seek additional funding in the future and currently intend to do so through public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets. Additionally, global economic instability, higher interest rates and diminished credit availability may limit our ability to obtain debt financing on favorable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize AV-101. Disruptions in the financial markets in general, and more recently due to the ongoing COVID-19 pandemic, geopolitical conflicts and economic instability, may make equity and debt financing more difficult to obtain, and may have a material adverse effect on our ability to meet our fundraising needs. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Future issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans or pursuant to our Sale Agreement, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">We registered shares of common stock that we have issued and may issue under our employee equity plans and will file additional registration statements on Form S-8 to register additional shares pursuant to the &#8220;evergreen&#8221; provisions under our equity compensation plans. Accordingly, these shares are available for sale in the open market, subject to Rule 144 volume limitations applicable to affiliates, and subject to any vesting restrictions and lock-up agreements applicable to these shares. Additionally, our sales agent may sell shares of our common stock pursuant to our Open Market Sale Agreement</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-size:10pt;">, or the Sale Agreement, we entered into with Jefferies LLC on August 15, 2022. If we sell, or the market perceives that we intend to sell, substantial amounts of our common stock under our Form S-3 shelf registration statement or otherwise, the market price of our common stock could decline significantly. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Development of AV-101</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business is entirely dependent on the successful development, regulatory approval and commercialization of AV-101, our only product candidate under development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have invested substantially all of our efforts and financial resources in the development of AV-101 for the treatment of PAH, which has not been approved for sale or commercial use. Currently, AV-101 is our only product candidate and we have not licensed, acquired, or invented any other product candidates for preclinical or clinical evaluation. This may make an investment in our company riskier than similar companies that have multiple product candidates in active development and that therefore may be able to better sustain a failure of a lead candidate. The success of our business, including our ability to finance our company and generate any revenue in the future, will, at this point, depend entirely on the successful development, regulatory approval and commercialization of AV-101, which may never occur. We may have inadequate financial or other resources to advance AV-101 through the clinical trial process, depending on the requirements of the FDA and similar foreign regulatory agencies. In addition, our clinical development program for AV-101 may not lead to regulatory approval from the FDA and similar foreign regulatory agencies if we fail to demonstrate that AV-101 is safe and effective in our ongoing Phase 2b/Phase 3 clinical trial, and we may therefore fail to commercialize AV-101. Further, interpretation of trial results by the FDA and similar foreign regulatory agencies may vary and AV-101 may not receive regulatory approval even if it is successful in planned and future clinical trials. Any failure to obtain regulatory approval of AV-101 would have a material and adverse impact on our business. Even if we successfully obtain regulatory approvals to market AV-101, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of AV-101, even if approved.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to seek regulatory approval to commercialize AV-101 in the United States and in selected foreign countries. The clinical and commercial success of AV-101 will depend on a number of factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise any additional required capital on acceptable terms, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely completion of clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors, as well as timely completion of any preclinical studies that may be required in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support approval of AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to consistently manufacture AV-101 on a timely basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability, and the ability of any third parties with whom we contract, to remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current Good Manufacturing Practices, or current GMPs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk-benefit profile of AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence, duration and severity of potential side effects or other safety issues experienced with AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the differentiation of AV-101 from other available approved, or investigational, drugs and treatments of PAH, and the willingness of physicians, operators of hospitals and clinics and patients to adopt and utilize AV-101 administered using a dry powder inhaler, or DPI;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully develop a commercial strategy and thereafter commercialize AV-101 in the United States and internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare and Medicaid and similar foreign authorities) and other third-party payors for AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients&#8217; ability and willingness to pay out-of-pocket for AV-101 in the absence of coverage and/or adequate reimbursement from third-party payor;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience of the administration of AV-101 using our DPI;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of AV-101, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient demand for AV-101, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and enforce intellectual property rights in and to AV-101; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize AV-101. Even if regulatory approvals are obtained, we may never be able to successfully commercialize AV-101. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of AV-101 to continue our business or achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the scope of regulatory approval generally is similar in other countries, in order to obtain separate regulatory approval in other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. For example, European regulatory authorities generally require a trial comparing the efficacy of the new drug to an existing drug prior to granting approval. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution of AV-101, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing regulations in these jurisdictions. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The COVID-19 pandemic and any future outbreak of other highly infectious or contagious diseases, could seriously harm our research, development, and commercialization efforts, increase our costs and expenses and have a material adverse effect on our business, financial condition, and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Public health crises such as pandemics or similar outbreaks could adversely impact our business. For example, in December 2019, an outbreak of a novel strain of coronavirus spread to the majority of countries around the world, including the U.S. The extent to which the COVID-19 pandemic, or the future outbreak of any other highly infectious or contagious diseases, impacts our operations will ultimately depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity, and duration of the pandemic, actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. Similar to other biopharmaceutical companies, we may experience protocol deviations or delays in enrolling patients and completing our ongoing global Phase 2b/Phase 3 clinical trial of AV-101. We have experienced delays in activating new trial sites as a result of staffing shortages and short-term interruptions at clinical trial sites due to COVID-19 related issues as well as general supply chain delays.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, as a result of medical complications associated with PAH, the patient populations that AV-101 targets may be particularly concerned with COVID-19, or the future outbreak of any other highly infectious or contagious diseases, which may make it more difficult for us to identify patients able to enroll in our current and future clinical trials and may impact the ability of enrolled patients to complete any such trials. Any negative impact the COVID-19 pandemic, or the future outbreak of any other highly infectious or contagious diseases, has on patient enrollment or treatment or the execution of our AV-101 clinical trials could cause costly delays, which could adversely affect our ability to obtain regulatory approval for and to commercialize AV-101, increase our operating expenses, and have a material adverse effect on our financial results. Timely enrollment in planned clinical trials, including our global Phase 2b/Phase 3 clinical trial for AV-101 is dependent upon clinical trial sites in geographies which could be and have been adversely affected by global health matters, such as pandemics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are conducting our first late-stage clinical trial of AV-101, a dry powder formulation of imatinib for the treatment of PAH administered using a DPI, to assess its safety and tolerability. Although we believe that AV-101 has therapeutic potential for PAH based on oral imatinib&#8217;s results in the Phase 3 IMPRES trial, we are utilizing a novel dry powder formulation which may not achieve better or similar levels of clinical activity or may have similar tolerability challenges as oral imatinib. The results of earlier studies and trials of oral imatinib in PAH patients and our Phase 1 clinical trial of AV-101 may not be predictive of future trial results for AV-101.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The results of our Phase 1 clinical trial, as well as clinical testing of oral imatinib in PAH patients by third-parties, may not be predictive of the results of our ongoing Phase 2b/Phase 3 clinical trial. In December&#160;2021, we announced the initiation of our Phase 2b/Phase 3 trial of AV-101 with a target enrollment of 200 patients in the Phase 2b portion. We are in the process of site activation and patient enrollment. At this time, we expect to complete patient enrollment of the Phase 2b portion of the trial in the middle of 2023 and report topline data from the Phase 2b portion of the trial in the fourth quarter of 2023 or first quarter of 2024. However, it is difficult to predict the timing of topline data availability with certainty due to the ongoing impacts of COVID-19 that continue to cause site activation and patient enrollment delays for </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Phase 2b portion of our trial. Our belief that AV-101 has a potential therapeutic benefit for PAH patients is based in part on the Phase 3 IMPRES trial conducted by Novartis AG, or Novartis, which showed oral administration of imatinib, marketed as Gleevec for multiple cancers, led to statistically significant improvements across both primary and secondary endpoints in PAH patients on top of PAH standard of care therapies. Despite the statistically significant improvements in six minute walk distance, or 6MWD, and hemodynamics, there was no difference between oral imatinib and placebo in time to clinical worsening (TTCW), a composite endpoint consisting of death, hospitalization due to worsening PAH, worsening functional class, and a 15% reduction in 6MWD. Oral imatinib was associated with significant adverse events that precluded its approval as a therapy for PAH. AV-101 is our proprietary inhaled dry powder formulation of imatinib that delivers the medicine directly to the lung tissues using a DPI. While we have completed a Phase 1 clinical trial in 82 healthy volunteers in which AV-101 demonstrated lower plasma levels of imatinib compared to 400 mg of oral imatinib and a favorable tolerability profile at a dose of up to 90 mg twice a day, AV-101 has not yet completed a trial in any patients with PAH to assess its efficacy and AV-101 may not have the same clinical activity as oral imatinib seen in the IMPRES trial. We also cannot be certain that AV-101 will continue to show similar tolerability when dosed in PAH patients as it did in healthy volunteers, and we may not be able to demonstrate to the satisfaction of the FDA the safety, efficacy and acceptable risk-benefit profile of AV-101 during our ongoing Phase 2b/Phase 3 clinical trial. As a result, even if AV-101 does achieve lower imatinib plasma concentrations in our Phase 2b/Phase 3 clinical trial, there can be no assurance that AV-101 will exhibit similar tolerability as compared to our Phase 1 clinical trial or improved tolerability as compared to the IMPRES trial of oral imatinib. Product candidates in later stages of clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical and biotechnology industries, including Novartis in the IMPRES trial of oral imatinib, have suffered significant setbacks in Phase 3 clinical trials, even after positive results in earlier clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Notwithstanding any promising results in our Phase 1 clinical trial, we cannot be certain that we will not face similar setbacks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, we may utilize &#8220;open-label&#8221; trial designs and plan to use an open-label extension trial in addition to our Phase 2b/Phase 3 clinical trial to collect additional data on AV-101 and may do so as appropriate in the future. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial or extension may not be predictive of future clinical trial results with AV-101 when studied in a controlled environment with a placebo or active control. Currently, we are collecting additional safety information for AV-101 in the long-term extension study eligible to patients who have completed participation in our current Phase 2b/Phase 3 clinical trial. Once an optimal dose has been identified in our Phase 2b/Phase 3 clinical trial, the long-term extension study would qualify as an &#8220;open-label&#8221; trial design.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result of the foregoing, even if we are able to complete any planed and future clinical trials of AV-101, the results may not be sufficient to obtain regulatory approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have experienced and may in the future encounter difficulties with site activation and patient enrollment in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We have experienced and may in the future experience difficulties in site activation delays and patient enrollment in our clinical trials for a variety of reasons as a result of staff shortages and short-term interruptions at clinical trial sites and CROs. We are activating new sites and enrolling patients in IMPAHCT, our ongoing Phase 2b/Phase 3 clinical trial to evaluate the safety and efficacy of different doses of AV-101 in adults with PAH with a target enrollment of 200 patients in the Phase 2b portion. At this time, we expect to complete patient enrollment of the Phase 2b portion of the trial in the middle of 2023 and report topline data from the Phase 2b portion of the trial in the fourth quarter of 2023 or first quarter of 2024. However, it is difficult to predict the timing of topline data availability with certainty due to the ongoing staff shortages and short-term interruptions at clinical trial sites and CROs that continue to cause site activation and patient enrollment delays for the Phase 2b portion of our trial. The Phase 2b portion of this trial is a dose-ranging trial in which pulmonary vascular resistance is the primary endpoint. The Phase 3 portion of the trial will be based on the optimal dose selected in the Phase 2b portion with 6MWD as the primary endpoint. The enrollment of patients depends on many additional factors, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">size and nature of the patient population and process for identifying patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability and efficacy of approved drugs for the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the general willingness of patients to enroll in the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience, and to obtain Investigational Review Board, or IRB, approval to conduct our trial at U.S. sites, and similar approvals at sites outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient referral practices of physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new therapies that may be approved for the indications we are investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition for patients from other investigational clinical trials in PAH being conducted at the same time as our Phase 2b/Phase 3 trial; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical site&#8217;s ability to obtain and maintain patient consents.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Enrollment risks are heightened with respect to indications that are rare or orphan diseases, which may limit the pool of patients that may be enrolled in our clinical trials. We are developing AV-101 for the treatment of PAH, which is an orphan </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">disease and does not have a large patient population. As a result, we may encounter difficulties enrolling subjects in our clinical trials evaluating AV-101 for the treatment of PAH due, in part, to the small size of this patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, our clinical trials may compete with other clinical trials for product candidates that seek to treat PAH, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our overall costs have risen due to the delays in site activation and patient enrollment, and due to our increased headcount to mitigate the effects of staff shortages at clinical trial sites and CROs. Any additional delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing or any future clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical development is expensive and can take many&#160;years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. We have completed our Phase 1 clinical trial of AV-101 in healthy volunteers and announced initiation of our Phase 2b/Phase 3 dose-ranging clinical trial in adults with PAH in December&#160;2021. The FDA has agreed in principle with the proposed study design of our Phase 2b/Phase 3 efficacy trial, dose strengths, statistical analysis and that a single efficacy study with strong results could be sufficient to support a 505(b)(2)&#160;NDA. However, changes in regulatory requirements and guidance may occur and we may need to amend our clinical trial protocol to reflect these changes with appropriate regulatory authorities. In addition, we may experience delays in completing our ongoing and planned studies and trials of AV-101. Furthermore, we cannot be certain that studies or trials for AV-101 will begin on time, not require redesign, enroll an adequate number of subjects on time or be completed on schedule, if at all. These factors may also impact our ability to release data within our anticipated timeframe. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in obtaining regulatory authorization to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining institutional review board, or IRB, approval at each trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting an adequate number of suitable patients to participate in a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">having subjects complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing subject safety concerns that arise during the course of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adding a sufficient number of clinical trial sites; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining sufficient quantities of AV-101 for use in clinical trials from third-party suppliers on a timely basis.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies, if additional studies are required, and clinical trials that could delay or prevent our ability to receive marketing approval or commercialize AV-101, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials or conduct additional studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of AV-101 may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon our development program for AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of AV-101 may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls, or be unable to produce sufficient product supply to conduct and complete clinical trials of AV-101 in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our investigators might have to suspend or terminate clinical trials of AV-101 for various reasons, including non-compliance with regulatory requirements, a finding that AV-101 has undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of AV-101 may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quality of our active pharmaceutical ingredient or other materials necessary to conduct clinical trials of AV-101 may be insufficient or inadequate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may determine that we cannot rely on the Section&#160;505(b)(2)&#160;approval pathway for AV-101, in which case we may be required to conduct additional clinical trials and provide additional data and information and meet additional standards for product approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may determine that we have identified the wrong listed drug(s), or LD, or that approval of a Section&#160;505(b)(2)&#160;application for AV-101 is blocked by patent or non-patent exclusivity of the LD or LDs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators may revise the requirements for approving AV-101, or such requirements may not be as we anticipate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future collaborators may conduct clinical trials in ways they view as advantageous to them but that are sub-optimal for us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are required to conduct additional clinical trials or other testing of AV-101 beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of AV-101 or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur unplanned costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be delayed in obtaining marketing approval for AV-101 or not obtain marketing approval at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval in some countries and not in others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be subject to additional post-marketing testing requirements, which could be expensive and time consuming; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have the treatment removed from the market after obtaining marketing approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or ethics committees of the institutions in which such trials are being conducted, by the Safety Monitoring Committee, if any, for such clinical trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site or a manufacturing, processing or storage site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, we are conducting our Phase 2b/Phase 3 clinical trial for AV-101 in adults with PAH globally. This presents additional risks that may delay completion of our clinical trial. These risks include a delay in obtaining or a failure to obtain, regulatory authorization to commence a trial in each country where we plan to conduct the trial, the failure of enrolled patients in foreign countries to adhere to the clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any of our clinical trials of AV-101 are unsuccessful, delayed or terminated, its commercial prospects may be harmed, and our ability to generate revenues from sales of AV-101 will be delayed or not realized at all. In addition, any delays in completing our clinical trials may increase our costs, slow down our AV-101 development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of AV-101. If AV-101 generally proves to be ineffective, unsafe or commercially unviable, it would have a material and adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">AV-101 may cause undesirable side effects or have other properties that could delay or prevent its regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The results of our preclinical studies or clinical trials may show that AV-101 may cause undesirable side effects, which could interrupt, delay or halt clinical trials, resulting in the denial of regulatory approval by the FDA and other regulatory authorities. In light of widely publicized events concerning the safety risk of certain drug products, regulatory authorities, members of Congress, the Government Accounting Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of drug products, revisions to drug labeling or boxed warnings that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials. Data from clinical trials may receive greater scrutiny with respect to safety, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or require longer or additional clinical trials that may result in substantial additional expense and a delay or failure in obtaining approval or approval for a more limited indication than originally sought.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While AV-101 was generally well-tolerated in our Phase 1 clinical trial, subjects treated with 90 mg of AV-101, the highest dose in this trial, reported a higher frequency of adverse events, including cough at the time of inhalation of the dry powder and headache. However, all adverse events were generally mild and transient with only one discontinuation due to vomiting. The only adverse events experienced by subjects treated at lower doses of AV-101 in the Phase 1 MAD portion of the trial were cough at dosing (1 of 9 patients in the medium dose and 1 of 9 patients at the low dose) and throat irritation (1 patient of 9 at the medium dose). In contrast, the Phase 3 IMPRES trial of oral imatinib in PAH patients demonstrated significant AEs, including nausea, edema, vomiting and diarrhea. Despite the clinical effects of oral imatinib on their disease, 26% of patients on oral imatinib and 7% of placebo patients discontinued due to AEs by 24 weeks of the trial. Further development of oral imatinib for the treatment of PAH was discontinued by Novartis. We believe that delivery of imatinib directly to the lungs through our proprietary dry powder formulation has the potential to maximize the amount of drug in the targeted tissues while minimizing systemic exposure and minimizing the potential for serious adverse events. Nevertheless, if unacceptable side effects arise in our Phase 2b/Phase 3 clinical trial or other trials we may conduct, we, the FDA, or the IRBs at the institutions in which our studies are conducted could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of AV-101 for PAH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If AV-101 receives marketing approval and we or others later identify undesirable side effects caused by such product or by other imatinib products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw, suspend or limit approvals of the product, or seek an injunction against its manufacture or distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to recall a product or change the way such product is administered to patients or conduct additional clinical trials or post-approval studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to add additional warnings or boxed warnings to our drug labeling or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, which may include distribution or use restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to fines, injunctions or the imposition of criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product may become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interim, topline and preliminary results from our preclinical studies and clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, we may publicly disclose preliminary, interim or topline data from our preclinical studies and clinical trials. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the information we choose to publicly disclose regarding a particular study or trial is typically selected from a more extensive amount of available information. Investors may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the preliminary or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, any of our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We intend to use the 505(b)(2)&#160;regulatory pathway to seek regulatory approval of AV-101, but if the FDA concludes that our marketing application no longer qualifies for the Section&#160;505(b)(2)&#160;regulatory pathway, then our application may not be accepted by the FDA for review and approval may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We intend to seek FDA approval for AV-101 for PAH through the Section&#160;505(b)(2)&#160;regulatory pathway. Section&#160;505(b)(2)&#160;of the Federal Food, Drug, and Cosmetic Act, or FDCA, was enacted as part of the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments, and permits the submission of an NDA where at least some of the information required for approval comes from preclinical studies or clinical trials not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The FDA interprets Section&#160;505(b)(2)&#160;of the FDCA to permit the applicant to rely upon the FDA&#8217;s previous findings of safety and efficacy for an approved product. The FDA requires submission of information needed to support any changes to a previously approved drug, such as published data or new studies conducted by the applicant or clinical trials demonstrating safety and efficacy. The FDA could require additional information to sufficiently demonstrate safety and efficacy to support approval. If the FDA later determines AV-101 does not meet the requirements of Section&#160;505(b)(2), or that additional information is needed to support a marketing application for AV-101, we could experience delays in submitting a marketing application or in obtaining marketing approval. Moreover, even if AV-101 is approved under the Section&#160;505(b)(2)&#160;regulatory pathway, the approval may be subject to limitations on the indicated uses for which it may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Commercialization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face, and will continue to face, significant competition and our failure to effectively compete may prevent us from achieving significant market penetration for AV-101, if approved. Most of our competitors have significantly greater resources than we do and we may not be able to successfully compete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The pharmaceutical industry is highly competitive, with a number of established, large pharmaceutical companies, as well as many smaller companies. Many of these companies have greater financial resources, marketing capabilities and experience in obtaining regulatory approvals for product candidates. There are several pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations actively engaged in research and development of products to target PAH. We expect AV-101 to compete on the basis of, among other things, efficacy, safety, convenience, price, and the availability of reimbursement from commercial, government and other third-party payors. One or more of our competitors may develop products based upon the principles underlying our proprietary technologies earlier than us, obtain approvals for such products from the FDA more rapidly than us or develop alternative products or therapies that are safer, more effective and/or more cost effective than AV-101. We also expect to face competition in our efforts to identify appropriate collaborators or partners to help commercialize AV-101 in our target commercial areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If approved, AV-101 is expected to face competition from drug products that are already on the market, as well as those in clinical development for PAH. In particular, we expect that AV-101 will face competition from branded and/or generic prostanoids available in oral form as Orenitram (United Therapeutics Corporation, or United Therapeutics) and Uptravi (Janssen Pharmaceuticals,&#160;Inc., or Janssen), by inhalation as Tyvaso and Tyvaso DPI (United Therapeutics), and Ventavis (Janssen) and by infusion as Remodulin (United Therapeutics) Flolan (GSK) and Veletri (Janssen), which are existing drug products indicated for the treatment of PAH. Potential new prostanoid entrants include Yutrepia (Liquidia Corporation) which has received tentative FDA approval pending resolution of ongoing litigation with United Therapeutics, treprostinil palmitil (Insmed) and ralinepag (Arena Pharmaceuticals in collaboration with United Therapeutics). Additional drugs in development for PAH outside of the prostanoid pathway include sotatercept (Acceleron Pharma,&#160;Inc., a wholly-owned subsidiary of Merck&#160;&amp; Co.,&#160;Inc., or Merck), rodatristat ethyl (Enzyvant, Inc.), MK-5475 (Merck &amp; Co., Inc.), and seralutinib (Gossamer Bio,&#160;Inc.). Finally, we are aware that Tenax Therapeutics,&#160;Inc. and Aerami Therapeutics,&#160;Inc. have announced they intend to develop imatinib for PAH and have completed Phase 1 studies with their respective formulations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that AV-101, if approved, could be used prior to or in combination with prostanoids, and in combination with existing front-line agents such as the oral PDE5 inhibitors, including Revatio (Pfizer&#160;Inc.) and Adcirca (United Therapeutics); the sGC stimulator Adempas (Bayer AG); and oral ERAs, including Tracleer (Janssen), Letairis (Gilead Sciences,&#160;Inc.) and Opsumit (Janssen). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources and experience than we do. If we successfully obtain approval for AV-101, we will face competition based on many different factors, including the safety and effectiveness of AV-101, the ease with which AV-101 can be administered and the extent to which patients accept the inhaled route of administration, the timing and scope of regulatory approvals for AV-101, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, by being more effective, safer, less expensive or marketed and sold more effectively than AV-101. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing AV-101. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the FDA or comparable regulatory authorities approve generic versions of AV-101, or do not grant AV-101 a sufficient period of market exclusivity before approving its generic version, our ability to generate revenue may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Once a NDA is approved, including under the 505(b)(2)&#160;pathway, the product covered thereby becomes a &#8220;reference listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; commonly known </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">as the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of Abbreviated New Drug Applications, or ANDAs, and may obtain therapeutical equivalence evaluations for 505(b)(2) pathway drugs under FDORA&#8217;s expanded authorities, in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials to assess safety and efficacy. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labelling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant&#160;percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Generic drug manufacturers may seek to launch generic products following the expiration of any applicable exclusivity period we obtain if AV-101 is approved, even if we still have patent protection. Competition that AV-101 could face from generic versions could materially and adversely affect our future revenue, profitability, and cash flows and substantially limit our ability to obtain a return on the investments we have made in AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the market opportunity for AV-101 is smaller than we estimate or if any regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The incidence and prevalence for target patient populations of AV-101 has not been established with precision. AV-101 is an inhaled dry powder formulation of antiproliferative imatinib for people who suffer from PAH. A DPI is used to deliver the medicine directly to lung tissues, enabling treatment of the diseased tissues directly while reducing the amount of drug delivered to other organs in the body which can cause unwanted adverse events. Our projections of both the number of people who have PAH, as well as the subset of people with PAH who have the potential to benefit from AV-101, are based on our estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The total addressable market opportunity will ultimately depend upon, among other things, the patient criteria included in the final label, the indications for which AV-101 is approved for sale, acceptance by the medical community and patient access, product pricing and reimbursement. The number of patients with PAH for which AV-101 may be approved as treatment may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. AV-101 is our only product candidate and therefore our business is dependent on the market opportunity for our product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The successful commercialization of AV-101 will depend in part on the extent to which governmental authorities, private health insurers, and other third-party payors provide coverage and adequate reimbursement levels. Failure to obtain or maintain coverage and adequate reimbursement for AV-101, if approved, could limit our ability to market our product and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States and markets in other countries, patients generally rely on third-party payors to be able to afford medical services and pharmaceutical products that receive FDA approval. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. A decision by a third-party payor not to cover or separately reimburse for AV-101, could reduce physician utilization if approved. Assuming there is coverage for AV-101 by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union, or EU, or elsewhere will be available for AV-101 and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. For more information, see &#8220;Business &#8211; Government Regulation &#8211; Pricing and Reimbursement.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Private third-party payors tend to follow Medicare coverage policies and payment limitations in setting their own reimbursement rates to a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">substantial degree, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that may require us to provide scientific and clinical support for the use of AV-101 to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules&#160;and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules&#160;and regulations are likely. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, increasing efforts by governmental and other third-party payors in the United States and abroad to cap or reduce healthcare costs have resulted in increasing challenges to prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and adequate reimbursement for particular drugs when an equivalent generic drug, biosimilar or a less expensive therapy is available. Even if we show improved efficacy or improved convenience of administration with AV-101, pricing of existing third-party therapeutics may limit the amount we will be able to charge for it. These third-party payors may deny or revoke the reimbursement status of AV-101, if approved, or establish prices for it at levels that are too low to enable us to realize an appropriate return on our investment. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Outside the United States, pharmaceutical products are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries will likely put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for AV-101. Accordingly, in markets outside the United States, the reimbursement for AV-101 may be reduced compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if AV-101 obtains regulatory approval, it may fail to achieve market acceptance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if AV-101 receives FDA or other regulatory approvals, its commercial success will depend significantly on its adoption and use by physicians and patients for approved indications. The degree of market acceptance of AV-101, if approved, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the safety and efficacy of AV-101 as compared to other available treatments for PAH;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient satisfaction with the results of AV-101 and overall treatment experience, including, the ease and convenience of administration of AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perceived advantages of AV-101 over alternative treatments, such as prostacylins;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which AV-101 is approved and patient demand for approved products that treat those indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manufacture and release adequate commercial supplies on a timely basis;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare and Medicaid) and other third-party payors for AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment with AV-101 in relation to alternative treatments and patients&#8217; ability and willingness to pay out-of-pocket for the product, if approved, in the absence of coverage and/or adequate reimbursement from third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by physicians, operators of hospitals and clinics and patients of the product as a safe, effective and easy to administer treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">physician and patient willingness to adopt a new therapy over other available therapies for treatment of PAH;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales, marketing and distribution efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse publicity about AV-101 or favorable publicity about competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product liability claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval of other new therapies for the same indication.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot assure you that AV-101, if approved, will achieve market acceptance among physicians and patients. Any failure by AV-101, if approved, to achieve market acceptance or commercial success would adversely affect our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell AV-101 effectively in the United States and foreign jurisdictions, if approved, or generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently employ a Chief Commercial Officer but do not have other employees in our commercial organization. In order to commercialize AV-101, if approved, in the United States and foreign jurisdictions, we must build our marketing, sales, commercial operations, access and distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If AV-101 receives regulatory approval, we expect to establish a full commercial organization in the United States with technical expertise and supporting marketing, sales, access and distribution capabilities to commercialize it, which will be expensive and time consuming. As a company, Aerovate has no prior experience in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing, commercial operations, access and distribution capabilities would adversely impact the commercialization of AV-101. We may choose to collaborate with third parties that have commercial capabilities, either to augment our own commercial capabilities or in lieu of Aerovate building certain capabilities such as those related to sales or distribution. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize AV-101. If we are not successful in commercializing AV-101, either on our own or through arrangements with one or more third parties, we may not be able to generate product revenue and we would incur significant additional losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We face an inherent risk of product liability as a result of the ongoing clinical testing of AV-101 and will face an even greater risk if we commercialize it. For example, we may be sued if AV-101 allegedly causes injury. Any such product </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of AV-101. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a diversion of management&#8217;s time and our resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize AV-101.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of AV-101. We currently carry product liability insurance covering our clinical trials, however, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any dose of AV-101, we intend to expand our insurance coverage to include its sale; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely, and intend to continue to rely, on qualified third parties to supply all components of AV-101. As a result, we are dependent on several third parties, some of which are sole source suppliers, for the manufacture of AV-101 and our supply chain, and if we experience problems with any of these suppliers, or they fail to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, it would materially and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not own or operate manufacturing facilities for clinical or commercial manufacture of either our proprietary dry-powder formulation of imatinib or the DPI, including the drug substance and packaging. We have limited personnel with experience in drug-device product manufacturing and we lack the capabilities to manufacture either the drug component of AV-101 or the DPI on a clinical or commercial scale. We outsource all manufacturing and packaging of AV-101 to third parties and obtain the DPI from a sole source supplier, and we do not plan to own or operate our own manufacturing and packaging facilities. There can be no assurance that our clinical development product supplies will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. In addition, any replacement of any of our third-party suppliers could require significant effort and expertise because there may be a limited number of qualified replacements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain of our suppliers are subject to regulatory requirements covering manufacturing, testing, quality control and record keeping relating to AV-101, and are subject to pre-approval and ongoing inspections by the regulatory agencies. Failure by any of our suppliers to comply with applicable regulations may result in long delays and interruptions to our manufacturing capacity while we seek to secure another supplier that meets all regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Reliance on third-party manufacturers entails risks that we would more directly manage and control, or to which we would not be subject, if we manufactured AV-101 ourselves, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on the third parties for regulatory compliance, quality assurance and hazardous materials handling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach of the manufacturing and quality agreements by the third parties because of factors beyond our control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility of termination or nonrenewal of the agreements by the third parties because of our breach of the manufacturing agreement or based on their own business priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with respect to any manufacturers with which we do not have a long-term agreement, the possibility that the manufacturer decides to stop supplying to us or changes the price or other terms of supply; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Changes in the products produced by our suppliers, such that they satisfy specifications but have an unanticipated negative impact on the performance of AV-101.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any of these factors could cause the delay of required approvals or commercialization of AV-101, could prevent us from commercializing it successfully, could cause the suspension of initiation or completion of clinical trials and regulatory submissions, and could lead to higher product costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the facilities used by our contract manufacturing organizations, or CMOs to manufacture AV-101 are subject to various regulatory requirements and may be subject to inspection by the FDA or other regulatory authorities. We do not directly control manufacturing at our CMOs, and are completely dependent on them for compliance with current regulatory requirements. If our CMOs for AV-101 cannot successfully manufacture components of finished product that conforms to our specifications and the regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on them for the manufacture of AV-101. If we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce AV-101 according to the specifications previously submitted to the FDA or another regulatory authority. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds our facilities or those of our CMOs inadequate for the manufacture of AV-101 or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or commercialize AV-101 and the timing of any such approval and commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, our CMOs may experience manufacturing difficulties or delays due to resource constraints or as a result of labor shortages, disputes or unstable political environments or on account of global pandemics or similar events, including the COVID-19 pandemic. If our CMOs were to encounter any of these difficulties, our ability to provide AV-101 to patients in clinical trials, or to provide product for the treatment of patients once approved, would be jeopardized.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely, and intend to continue to rely, on third parties in the conduct of all of our clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently do not have the ability to independently conduct any clinical trials. The FDA and comparable foreign regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as good clinical practice, or GCP, requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GCP-compliant clinical trials of AV-101 properly and on time. Our global Phase 2b/Phase 3 clinical trial is managed by one CRO and is anticipated to be carried out in over 20 countries and numerous clinical sites. While we have agreements with these third parties, we monitor and control only certain aspects of their activities and have limited influence over their actual performance and the amount or timing of resources that they devote to our programs. Third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. The third parties with whom we contract for execution of our clinical trials play a significant role in the conduct of these trials and the subsequent collection and analysis of data. Although we rely on these third parties to conduct our clinical trials, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on these third parties does not relieve us of our regulatory responsibilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the third parties conducting our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval in a timely fashion, or at all, for AV-101, our results our business and results of operations and the commercial prospects for AV-101 would be harmed, our costs could increase, and our ability to generate revenues could be delayed. We may also be required to register certain clinical trials and post the results of completed clinical trials on government-sponsored databases within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on third parties to supply the raw materials to produce AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will rely on independent third parties to supply the raw materials that we use to produce AV-101. As such, we will be dependent upon their services and will not be in a position to control their operations as we might if we directly produced these raw materials. We do not have supplier contracts with these third parties. Although we believe the raw materials used to manufacture our products are readily available and can be obtained from multiple reliable sources on a timely basis, circumstances outside our control may impair our ability to have an adequate supply of raw materials to produce AV-101 which could lead to production delays, interruptions or the need to identify and qualify new raw materials in the production of AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may seek to establish collaborations, and, if we are not able to establish them on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product development program and the potential commercialization of AV-101 will require substantial cash to fund expenses. We may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s own evaluation of a potential collaboration. Such factors a potential collaborator will use to evaluate a collaboration may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for AV-101, the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">costs and complexities of manufacturing and delivering AV-101 to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for AV-101. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may also be restricted under collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of AV-101 for which we are seeking to collaborate, reduce or delay its development program, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop AV-101 or bring it to market and generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation.</p><a id="_Hlk125042827"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have four issued U.S. patents, and many pending patent applications with respect to AV-101. We can provide no assurance that any of our other current or future patent applications will result in issued patents. If we cannot protect our patent rights or our other proprietary rights, others may develop products similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any product candidates we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our success depends to a significant degree upon whether we can continue to secure, enforce and defend intellectual property rights that protect our AV-101 product candidate and to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others. If we are unable to obtain and maintain sufficient intellectual property protection for AV-101 or other product candidates that we may identify, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors and other third parties could develop and commercialize product candidates similar or identical to ours, and our ability to successfully commercialize AV-101 and other product candidates that we may pursue may be impaired. We own four issued U.S. patents with respect to AV-101, and we can provide no assurance that any of our other current or future patent applications will result in issued patents or that any issued patents will provide us with any competitive advantage. Failure to obtain additional issued patents could have a material adverse effect on our ability to develop and commercialize our product candidates. Furthermore, other parties may successfully challenge, invalidate or circumvent our issued patents so that our patent rights do not create an effective competitive barrier or revenue source.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We seek to protect our proprietary position by, among other things, filing patent applications in the United States and abroad related to our proprietary technologies, development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or to maintain, defend and enforce any patents that may issue from such patent applications at a reasonable </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, any of our non-provisional patent applications may fail to result in issued patents with claims that cover our proprietary products and technology, including our AV-101 product candidate or any other product candidate in the United States or in other foreign countries, in whole or in part. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreement and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal, technological and factual questions and has, in recent&#160;years, been the subject of much debate and litigation throughout the world. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. The subject matter claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Therefore, our pending and future patent applications may not result in patents being issued in relevant jurisdictions that protect our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive product candidates, and even if our patent applications issue as patents in relevant jurisdictions, they may not issue in a form that will provide us with any meaningful protection for our product candidates or technology, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Additionally, our competitors may be able to circumvent our patents by developing similar or alternative product candidates or technologies in a non-infringing manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States, the natural expiration of a patent is generally 20&#160;years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or the USPTO, or become involved in opposition, derivation, revocation, reexamination, <i style="font-style:italic;">inter partes</i> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others, or other proceedings in the USPTO or applicable foreign offices that challenge priority of invention or other features of patentability. An adverse determination in any such submission, proceeding or litigation could result in loss of exclusivity or freedom to operate, patent claims being narrowed, invalidated or held unenforceable, in whole or in part, limit the scope or duration of the patent protection of AV-101, all of which could limit our ability to stop others from using or commercializing similar or identical product candidates or technology to compete directly with us, without payment to us, or result in our inability to manufacture or commercialize product candidates or approved products (if any) without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates, or could have a material adverse effect on our ability to raise funds necessary to continue our research programs or clinical trials. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We cannot be certain that the USPTO and courts in the United States or the patent offices and courts in foreign countries will consider the claims in our patents and applications covering our AV-101 product candidate and possible future product candidates as patentable. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products off-label. Although off-label prescriptions may infringe or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent, including through legal action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we lose or cannot obtain additional patent protection for our AV-101 product candidate or other future product candidates it could have a material adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intellectual property litigation could cause us to spend substantial resources and prevent us from pursuing our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time we may have to defend our intellectual property rights. If we are involved in an intellectual property dispute, we may need to litigate to defend our rights or assert them against others. Disputes can involve arbitration, litigation or proceedings declared by the USPTO or the International Trade Commission or foreign patent authorities. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we were to initiate legal proceedings against a third party to enforce a patent covering our product candidate, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Third parties might allege unenforceability of our patents because during prosecution of the patent an individual connected with such prosecution withheld relevant information or made a misleading statement. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution, but that an adverse third party may identify and submit in support of such assertions of invalidity. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidate. Our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Third parties may initiate or threaten legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our commercial success depends upon our ability and the ability of our strategic partners to develop, manufacture, market and sell our drugs and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. Extensive litigation regarding patents and other intellectual property rights is common in the biotechnology and pharmaceutical industries. We may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our drugs and technology, including interference, derivation, reexamination, post-grant review, opposition, cancellation or similar proceedings before the USPTO or its foreign </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">counterparts. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, resulting in payment of damages. These damages potentially include increased damages and attorneys&#8217; fees if we are found to have infringed such rights willfully. Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. We may not be aware of all such intellectual property rights potentially relating to our drugs and their uses. If a third party claims that our AV-101 product candidate or our technology infringe its patents or other intellectual property rights, we or our partners may have to discontinue an important product or product line, alter our products and processes, pay license fees or cease certain activities. We could be required to obtain a license from such third party in order to continue developing and commercializing AV-101 or other product candidates. However, we may not be able to obtain a license to needed intellectual property on commercially reasonable terms, if at all. Even if a license can be obtained on reasonable terms, the rights may be nonexclusive, which would give our competitors access to the same intellectual property rights. We might also be forced to redesign or modify our product candidates so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign or modification could be impossible or technically infeasible. There are many patents issued or applied for in the biotechnology industry, and we may not be aware of patents or patent applications held by others that relate to our business. This is especially true since patent applications in the United States are filed confidentially for the first 18&#160;months. Moreover, the validity and breadth of biotechnology patents involve complex legal and factual questions for which important legal issues remain. Thus, we do not know with certainty that our drugs or our intended commercialization thereof, does and will not infringe or otherwise violate any third party&#8217;s intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents on drugs in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those we could obtain in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection to develop their own products. In addition, competitors may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patent rights or other intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to biotechnology. This could make it difficult for us to stop competitors from infringing our patent rights or misappropriating our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit our right to enforce our patent rights against third parties, including government agencies, government contractors, or doctors. In these countries, patents may provide limited or no benefit. We must ultimately seek patent protection on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patent rights at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we do not obtain additional protection under the Hatch-Waxman Amendments and similar foreign legislation by extending the patent protection for AV-101, our business may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of the first FDA marketing authorization of AV-101, a United States patent that we own may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments allow the owner of an approved product to extend patent protection for up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. During this period of extension, the scope of protection is limited to the approved product and approved uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we plan on seeking patent term restoration for our products, we may not succeed if, for example, we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we cannot obtain patent term restoration or the term of any such patent restoration is less than we request, our competitors may enter the market and compete against us sooner than we anticipate, and our ability to generate revenue could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop, manufacture and market our product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, analysis of the scope of relevant patent claims or determination of the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of AV-101 in any jurisdiction. For example, in the United States, applications filed before November&#160;29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States, EU and elsewhere are published approximately 18&#160;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates could be filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover AV-101 or the use of AV-101. After issuance, the scope of patent claims remains subject to construction as determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that AV-101 is not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States, the EU or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market AV-101. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to correctly identify or interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing AV-101. We might, if possible, also be forced to redesign AV-101 in a manner that no longer infringes third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in United States patent law could diminish the value of patents in general, thereby impairing our ability to protect AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Recent court rulings, including rules&#160;from the United States Supreme Court, have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the America Invents Act, or the AIA, which was passed in September&#160;2011, resulted in significant changes to the U.S. patent system. An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application and diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may become involved in opposition, interference, derivation, inter partes review or other proceedings challenging our patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The USPTO and European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and European and other patent agencies over the lifetime of a patent. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by additional payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance with such provisions will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we fail to maintain the patents and patent applications covering AV-101 or if we otherwise allow our patents or patent applications to be abandoned or lapse, it can create opportunities for competitors to enter the market, which would hurt </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">our competitive position and could impair our ability to successfully commercialize our product candidates in any indication for which they are approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time consuming. If we were unsuccessful, we could lose valuable rights in intellectual property that we regard as our own. The issuance of a patent is not conclusive as to its inventorship.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information and to maintain our competitive position. Trade secrets and know-how can be difficult to protect. We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, collaborators consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our product candidates that we consider proprietary. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary information will be effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we and our partners do not adequately protect the trademarks and trade names for our products, then we and our partners may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our competitors or other third parties may challenge, infringe or circumvent the trademarks or trade names for our products. We and our partners may not be able to protect these trademarks and trade names. In addition, if the trademarks or trade names for one of our products infringe the rights of others, we or our partners may be forced to stop using the trademarks or trade names, which we need for name recognition in our markets of interest. If we cannot establish name recognition based on our trademarks and trade names, we and our partners may not be able to compete effectively and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may make drug products that are similar to AV-101 but that are not covered by the claims of our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or current or future strategic partners, might not have been the first to make the inventions covered by our issued patent or pending patent applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or current or future strategic partners, might not have been the first to file patent applications covering our inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our pending and future patent applications may not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be unable to obtain regulatory approval for AV-101 under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of AV-101 and adversely impact our potential to generate revenue, our business and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not previously submitted an NDA or any other marketing application to the FDA or similar filings to comparable foreign regulatory authorities. An NDA or other similar regulatory filing requesting approval to market a product candidate must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, effective, pure and potent for each desired indication. The NDA or other similar regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of pharmaceutical products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ from country to country. We are not permitted to market AV-101 in the United States or in any foreign countries until it receives the requisite approval from the applicable regulatory authorities of such jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of AV-101 for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that AV-101 is safe and effective for the requested indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s disagreement with our trial protocol or the interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to demonstrate that the clinical and other benefits of AV-101 outweigh any safety or other perceived risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s requirement for additional preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s non-approval of the formulation, labeling or specifications of AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s failure to approve our manufacturing processes and facilities or the facilities of third-party manufacturers upon which we rely; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Of the large number of pharmaceutical products in development, only a small&#160;percentage successfully complete the FDA or other regulatory bodies&#8217; approval processes and are commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we eventually complete clinical testing and receive approval from the FDA or applicable foreign agencies for AV-101, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. The FDA or the applicable foreign regulatory agency also may approve AV-101 for a more limited indication or a narrower patient population than we originally requested, and the FDA, or applicable foreign regulatory agency, may not approve it with the labeling that we believe is necessary or desirable for the successful commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of AV-101 and would materially adversely impact our business and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">AV-101 is a drug-device combination product, which may result in additional regulatory risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our finished drug product, a proprietary inhaled dry powder formulation and DPI, will be regulated as a drug-device combination product. The DPI we use to administer AV-101 is currently CE marked and used outside the United States but AV-101 would be the first drug to obtain approval with this DPI in the United States. We believe the delivery device we selected will work well with AV-101 and we have conducted human factor studies with this DPI; however, the Phase 2b trial will be the first time we use the device in a clinical trial setting, and the capsules we use with the DPI in Phase 2b will be filled with higher amounts of active pharmaceutical ingredient compared to the Phase 1 clinical trial. There may be additional regulatory risks for drug-device combination products. We may experience delays in obtaining regulatory approval of AV-101 given the increased complexity of the review process when approval of the product and a delivery device is sought under a single marketing application. In the United States, each component of a combination product is subject to the requirements established by the FDA for that type of component, whether a drug, biologic or device. The DPI will be subject to FDA design control device requirements which comprise among other things, design verification, design validation (including human factors testing), and testing to assess performance, cleaning, and robustness. Delays in or failure of the studies conducted by us, or failure of our company, our collaborators, if any, or our third-party providers or suppliers to maintain compliance with regulatory requirements could result in increased development costs, delays in or failure to obtain regulatory approval, and associated delays in AV-101 reaching the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are currently conducting, and may in the future conduct, clinical trials for AV-101 outside the United States, and the FDA, EMA and applicable foreign regulatory authorities may not accept data from such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have initiated a global Phase 2b/Phase 3 clinical trial of AV-101 in adults with PAH. The acceptance of trial data from clinical trials conducted outside the United States by the FDA, EMA, or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the United States population and United States medical practice; (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. Many foreign regulatory authorities have similar approval requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, such foreign trials will be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA, or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States. If the FDA, EMA, or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in AV-101 not receiving approval or clearance for commercialization in the applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for AV-101, we will be subject to ongoing regulatory requirements, which may result in significant additional expenses. Additionally, AV-101, if approved, could be subject to labeling and other restrictions, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If AV-101 is approved by the FDA or a comparable foreign regulatory authority, it will be subject to extensive and ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with current GMPs, and Good Manufacturing Practices, or GMPs, for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses, including the duration of use, for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. The FDA may also require a REMS in order to approve AV-101, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to current GMP regulations and implementing tracking and tracing requirements for certain prescription pharmaceutical products. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with current GMP and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will have to comply with requirements concerning advertising and promotion for AV-101. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote AV-101 for indications or uses for which they do not have approval. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. We also must submit new or supplemental applications and obtain approval for certain changes to AV-101, if approved, product labeling, or manufacturing process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we discover previously unknown problems with AV-101, such as adverse events of unanticipated severity or frequency, or problems with the facility where AV-101 is manufactured, or if the FDA disagrees with the promotion, marketing or labeling of AV-101, the FDA may impose restrictions on it or us, including requiring withdrawal of it from the market. If we fail to comply with applicable regulatory requirements, the FDA and other regulatory authorities may, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue warning letters or other regulatory enforcement action;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose injunctions, fines or civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend or withdraw regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any of our ongoing clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve pending applications or supplements to approved applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require revisions to the labeling, including limitations on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose a REMS which may include distribution or use restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the conduct of an additional post-market clinical trial or trials to assess the safety of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities where regulatory inspections identify observations of noncompliance requiring remediation; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrict the marketing of the product, require a product recall, seizure or detention, or refuse to permit the import or export of the product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any government action or investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from AV-101. If regulatory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of AV-101. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may seek priority review designation for AV-101, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six&#160;months, rather than the standard review period of ten&#160;months. We may request priority review for AV-101 for the treatment of PAH. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe AV-101 is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have received orphan drug designation from the FDA and EMA for AV-101 for treatment of PAH, but we may be unable to obtain additional designations or to maintain the benefits associated with orphan drug status, including the potential for non-patent market exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have obtained orphan drug designation for AV-101 in the United States from the FDA and in the European Union from the EMA. We may not be able to obtain orphan drug designation for additional indications for AV-101 or for future product candidates or maintain the benefits associated with orphan drug designation, including the potential for non-patent market exclusivity. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug or biologic as an orphan drug if it is a product intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population of 200,000 or more in the United States where there is no reasonable expectation that the cost of developing the product will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Similarly, in the European Union, the European Commission, upon the recommendation of the EMA&#8217;s Committee for Orphan Medicinal Products, grants orphan drug designation to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions and either (i)&#160;such condition affects not more than 5 in 10,000 persons in the European Union or (ii)&#160;without incentives, it is unlikely that the marketing of the drug in the European Union would be sufficient to justify the necessary investment in its development, and, in each case, for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Generally, if a product with an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product and indication for that time period, except in limited circumstances. Any competitor developing imatinib in the same indication with orphan drug designation may block our ability to obtain orphan drug exclusivity in the future if the competitor receives marketing approval before we do. The applicable exclusivity period is seven&#160;years in the United States and ten&#160;years in Europe. The European exclusivity period can be reduced to six&#160;years if, at the end of the fifth&#160;year, it is established that a product no </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">longer meets the criteria for orphan drug designation, including if the product is sufficiently profitable so that market exclusivity is no longer justified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we obtain orphan drug exclusivity for AV-101, that exclusivity may not effectively protect AV-101 from competition because different products can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition or if another product with the same active moiety is determined to be safer, more effective, or represents a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a product nor gives the product any advantage in the regulatory review or approval process. Although we have received orphan drug designation from the EMA, there is no guarantee that we will enjoy the benefits of such designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">A fast track designation by the FDA, even if granted for AV-101, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a product candidate is intended for the treatment of a serious or life-threatening condition and the product candidate demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for fast track designation by FDA for a particular indication. We may seek fast track designation for AV-101, but there is no assurance that the FDA will grant this status to AV-101. The FDA has broad discretion whether or not to grant fast track designation, so even if we believe AV-101 is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a fast track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw fast track designation at any time if it believes that the designation is no longer supported by data from our clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">A breakthrough therapy designation by the FDA, even if granted for AV-101, may not lead to a faster development, regulatory review or approval process, and each designation does not increase the likelihood that AV-101 will receive regulatory approval in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may seek a breakthrough therapy designation for AV-101 for treatment of PAH. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe AV-101 meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if AV-101 qualifies as a breakthrough therapy, the FDA may later decide that it no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we obtain FDA approval for AV-101 in the United States, we may never obtain approval for or successfully commercialize AV-101 outside of the United States, which would limit our ability to realize its full market potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to market AV-101 outside of the United States, we must obtain marketing authorizations and comply with numerous and varying regulatory requirements of other countries regarding quality, safety and efficacy. Clinical trials conducted in one country may not be accepted by foreign regulatory authorities, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional non-clinical studies or clinical trials, which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of AV-101 in those countries. We, as a company, do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market for AV-101 will be reduced and we would not be able to realize the full market potential of AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute AV-101, if approved. For more information, see <i style="font-style:italic;">&#8220;Business &#8211; Government Regulation &#8211; Healthcare Laws and Regulations.&#8221;</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental laws that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay regulatory approval of our current or future product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain regulatory approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements, (ii)&#160;additions or modifications to product labeling, (iii)&#160;the recall or discontinuation of our products or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. See the section entitled &#8220;<i style="font-style:italic;">Business&#160;&#8212; Government Regulation &#8212; Healthcare Reform and Legislation.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2022, the Inflation Reduction Act of 2022, or the IRA, was signed into law. The IRA includes several provisions that will impact our business to varying degrees, including provisions that create a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, impose new manufacturer financial liability on all drugs in Medicare Part D, allow the U.S. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries. The effect of IRA on our business and the healthcare industry in general is not yet known. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current or future product candidates or additional pricing pressures. In particular any policy changes through CMS as well as local state Medicaid programs could have a significant impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the demand for our current or future product candidates, if we obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to set a price that we believe is fair for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain coverage and reimbursement approval for a product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate revenue and achieve or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of taxes that we are required to pay; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of capital.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If AV-101 is approved and we are found to have improperly promoted off-label uses of this product, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, if approved. In particular, while the FDA permits the dissemination of truthful and non-misleading information about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The government has also imposed consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inadequate funding for the FDA, the SEC and other government agencies, including from government-shutdowns, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years the United States government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Separately, since March 2020 when foreign and domestic inspections were largely placed on hold due to the COVID-19 pandemic, the FDA has been working to resume pre-pandemic levels of inspection activities, including routine surveillance, bioresearch monitoring and pre-approval inspections. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue, depending on the circumstances, a Complete Response Letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Employee Matters and Managing Growth</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will need to continue to expand our managerial, operational, finance and other resources in order to manage our operations and clinical trials, continue our development activities and commercialize AV-101. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively manage our clinical trials and the development of AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify, recruit, retain, incentivize and integrate additional employees, including sales personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to improve our operational, financial and management controls, reports systems and procedures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be unable to successfully implement these tasks, which could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, our business may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, as well as other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of AV-101, completion of our ongoing and any future clinical trials or the commercialization of AV-101, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competition for qualified personnel in the pharmaceutical and biotechnology fields is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have limited director and officer insurance and product liability insurance policies. Any significant insurance claims would have a material adverse effect on our business, financial condition and results of operations. Insurance availability, coverage terms, including deductibles and pricing, continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage, and insurers may not respond as we intend to cover insurable events that may occur. We have observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate insurance. Such conditions have resulted in higher premium costs, higher policy deductibles and lower coverage limits. For some risks, we may not have or maintain insurance coverage because of cost or availability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage to our reputation, and subject us to significant financial and legal exposure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We rely on information technology systems that we or our third-party providers operate to process, transmit and store electronic information in our day-to-day operations. In connection with our product discovery efforts, we may collect and use a variety of personal data, such as names, mailing addresses, email addresses, phone numbers and clinical trial information. A successful cyberattack could result in the theft or destruction of this personal data, intellectual property, other data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication, level of persistence and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. We may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#8217; personal data could result in significant liability under state (e.g., state breach notification laws), federal, and international law and may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in the losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, other expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to prevent or mitigate the impact of such security breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business. By way of example, the California Consumer Privacy Act, or CCPA, which went into effect on January&#160;1, 2020, creates a private right of action for data breaches impacting California residents that is expected to increase data breach litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Ownership of Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</p><a id="_Hlk125099008"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50&#160;percentage point change (by value) in the ownership of its equity over a three&#160;year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future or subsequent shifts in our stock ownership, some of which are outside our control. As of December&#160;31, 2022, we had federal net operating loss (NOL) carryforwards of approximately $____ million and are accruing additional net operating losses in calendar&#160;year 2023, which will be added to the net operating loss carryover balance once the current&#160;year is completed. Our ability to utilize our net operating loss carryforwards could be limited by an &#8220;ownership change&#8221; as described above, which could result in increased tax liability to us. Furthermore, our ability to utilize our NOLs or credits is conditioned upon our attaining profitability and generating United States federal and state taxable income. As a result, the amount of the net operating loss and tax credit carryforwards presented in our financial statements could be limited and may expire unutilized. Federal net operating loss carryforwards generated since our incorporation in July&#160;2018 will not be subject to expiration. However, any such net operating loss carryforwards may only offset 80% of our annual taxable income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive tax reform legislation could adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The rules&#160;dealing with United States federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, or IRS, and the United States Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent&#160;years, many such changes have been made and changes are likely to continue to occur in the future. For example, the TCJA was enacted in 2017 and made significant changes to corporate taxation, including the reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for net operating losses from taxable&#160;years beginning after December&#160;31, 2017 to 80% of current&#160;year taxable income and the elimination of net operating loss carrybacks generated in taxable&#160;years ending after December&#160;31, 2017 (though any such net operating losses may be carried forward indefinitely), and the modification or repeal of many business deductions and credits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, on March&#160;27, 2020, former President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act, which, among other things, suspends the 80% limitation on the deduction for net operating losses in taxable&#160;years beginning before January&#160;1, 2021, permits a 5-year carryback of net operating losses arising in taxable&#160;years beginning after December&#160;31, 2017 and before January&#160;1, 2021, and generally caps the limitation on the deduction for net interest expense at 50% of adjusted taxable income for taxable&#160;years beginning in 2019 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The recent presidential and congressional elections in the United States could also result in significant changes in, and uncertainty with respect to, tax legislation, regulation and government policy directly affecting us and our business. For example, the United States government may enact significant changes to the taxation of business entities including, among others, a permanent increase in the corporate income tax rate, an increase in the tax rate applicable to the global intangible low-taxed income and elimination of certain exemptions, and the imposition of minimum taxes or surtaxes on certain types of income. The likelihood of these changes being enacted or implemented is unclear.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be promulgated or issued under existing or new tax laws, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our second amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board of directors will be elected at one time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that special meetings of the stockholders may be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office, and special meetings of stockholders may not be called by any other person or persons;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds (2/3) of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement of approval of not less than a majority of all outstanding shares of our voting stock to amend any bylaws by stockholder action and not less than two-thirds (2/3) of all outstanding shares of our voting stock to amend specific provisions of our second amended and restated certificate of incorporation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our second amended and restated </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our amended and restated bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claim for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers, and employees to us or our stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our second amended and restated certificate of incorporation or our amended and restated bylaws (including the interpretation, validity or enforceability thereof) or (iv)&#160;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the Federal Forum Provision. In addition, our bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules&#160;and regulations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We recognize that the Delaware Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March&#160;2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court were &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A global financial crisis or a global or regional political disruption could cause extreme volatility in the capital markets and lead to diminished liquidity and credit availability, higher interest rates, declines in consumer confidence and economic growth, increases in unemployment rates and uncertainty about economic stability. For instance, the ongoing COVID-19 pandemic has led to a period of considerable uncertainty and volatility and interest rates in the U.S. have recently increased to levels not seen in decades. In addition, the impact of geopolitical tension, such as a deterioration in the bilateral relationship between the United States and China or an escalation in conflict between Russia </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">and Ukraine, including any resulting sanctions, export controls or other restrictive actions, also could lead to disruption, instability, and volatility in the global markets. A severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including weakened demand for AV-101, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or resulting in the inability of any future customers to pay for AV-101, if approved. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect the Company&#8217;s current and projected business operations and its financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. We had no exposure to the SVB closure and did not experience any adverse impact to our liquidity or to our current and projected business operations, financial condition or results of operations. However, uncertainty remains over liquidity concerns in the broader financial services industry, and there may be additional impacts to our business and our industry that we cannot predict at this time. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the Company, the financial institutions with which the Company has credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which the Company has financial or business relationships, but could also include factors involving financial markets or the financial services industry generally. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These<span style="font-style:italic;font-weight:bold;"> </span>could include, but may not be limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Delayed or lost access to, or reductions in borrowings available under revolving existing credit facilities or other working capital sources and/or delays, inability or reductions in the company&#8217;s ability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Potential or actual breach of contractual obligations that require the Company to maintain letters of credit or other credit support arrangements; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by our suppliers, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. For example, a supplier may determine that it will no longer deal with us as a customer or a supplier could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on the Company, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution. Any supplier bankruptcy or insolvency, or the failure of any customer to make payments when due, or any breach or default by a supplier, or the loss of any significant supplier relationships, could result in material losses to the Company and may have a material adverse impact on our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business is affected by macroeconomic conditions, including rising inflation, interest rates and supply chain constraints. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates and overall economic conditions and uncertainties such as those resulting from the current and future conditions in the global financial markets. For instance, recent supply chain constraints have led to higher inflation, which if sustained could have a negative impact on our development of AV-101 and future product candidates, as well as our business and results of operations. If inflation or other factors were to significantly increase our business costs, our ability to develop our current pipeline and new therapeutic products may be negatively affected. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the operation of our business and our ability to raise capital on favorable terms, or at all, in order to fund our operations. Similarly, these macroeconomic factors could affect the ability of our third-party suppliers and manufacturers to manufacture clinical trial materials for our product candidates.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our employees and independent contractors, including principal investigators, consultants, commercial collaborators, service providers and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; United States federal and state fraud and abuse laws, data privacy and security laws and other similar non-United States laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third-parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other United States federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Actual or perceived failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and financial performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, retention, and security of personal information, such as information that we collect about patients and healthcare providers in connection with clinical trials in the United States and abroad. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, affect our or any service providers&#8217;, contractors&#8217; or future collaborators&#8217; ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us or our collaborators, service providers and contractors to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing processing of personal information could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the CCPA, which went into effect on January&#160;1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business. Further, on November&#160;3, 2020, the CPRA was voted into law by California residents. The CPRA significantly amends the CCPA, and imposes additional data protection obligations on companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to implement and enforce the CCPA and the CPRA, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The substantive requirements for businesses subject to the CPRA went into effect on January&#160;1, 2023, and become enforceable on July&#160;1, 2023. The effects of the CCPA, as modified by the CPRA are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply and increase our potential exposure to regulatory enforcement and/or litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain other state laws impose similar privacy obligations and we also anticipate that more states will increasingly enact legislation similar to the CCPA. The CCPA has prompted a number of proposals for new federal and state-level privacy legislation and in some states efforts to pass comprehensive privacy laws have been successful. For example, on March&#160;2, 2021, Virginia enacted the Consumer Data Protection Act, or the CDPA. The CDPA will became effective January&#160;1, 2023. The CDPA regulates how businesses (which the CDPA refers to as &#8220;controllers&#8221;) collect and share personal information. While the CDPA incorporates many similar concepts of the CCPA and CPRA, there are also several key differences in the scope, application, and enforcement of the law that will change the operational practices of controllers. The new law will impact how controllers collect and process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates and respond to consumer rights requests. In addition, similar laws will enter into force in Colorado, Connecticut and Utah later in 2023. Proposed and newly enacted legislation may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. Many countries in these regions have established or are in the process of establishing privacy and data security legal frameworks with which we, our collaborators, service providers, including our CROs, and contractors must comply. For example, the European Union General Data Protection Regulation, or the GDPR, went into effect in May&#160;2018 and imposes strict requirements for processing the personal information of individuals within the European Economic Area, or the EEA, including clinical trial data. The GDPR has and will continue to increase compliance burdens on us, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and process information about them. The processing of sensitive personal data, such as physical health condition, may impose heightened compliance burdens under the GDPR and is a topic of active interest among foreign regulators. The GDPR also increases the scrutiny of transfers of personal data from the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws; in July&#160;2020, the Court of Justice of the European Union limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the EU-U.S. Privacy Shield and imposing further restrictions on use of the standard contractual clauses, which could increase our costs and our ability to efficiently process personal data from the EEA. In addition, the GDPR provides for more robust regulatory enforcement and fines of up to &#8364;20 million or 4% of the annual global revenue of the noncompliant company, whichever is greater.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Relatedly, following the United Kingdom&#8217;s withdrawal from the EEA and the EU, the GDPR ceased to apply in the United Kingdom at the end of the transition period on December&#160;31, 2020. However, as of January&#160;1, 2021, the United Kingdom&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December&#160;31, 2020 but subject to certain United Kingdom specific amendments) into United Kingdom law, referred to as the UK GDPR. The UK GDPR and the United Kingdom Data Protection Act 2018 set out the United Kingdom&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to the greater of &#163;17.5 million or 4% of global turnover. Although the United Kingdom is regarded as a third country under the EU&#8217;s GDPR, the European Commission, or EC, has now issued a decision recognizing the United Kingdom as providing adequate protection under the GDPR and, therefore, transfers of personal data originating in the EU to the United Kingdom remain unrestricted. Like the GDPR, the UK GDPR restricts personal data transfers outside the United Kingdom to countries not regarded by the United Kingdom as providing adequate protection. The United Kingdom government has confirmed that personal data transfers from the United Kingdom to the EEA remain free flowing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, many jurisdictions outside of Europe are also considering and/or enacting comprehensive data protection legislation. For example, as of August&#160;2020, the Brazilian General Data Protection Law imposes stringent requirements similar to GDPR with respect to personal information collected from individuals in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In China, there have also been recent significant developments concerning privacy and data security. On June&#160;10, 2021, the Standing Committee of the PRC National People&#8217;s Congress published the Data Security Law of the People&#8217;s Republic of China, or the Data Security Law, which took effect on September&#160;1, 2021. The Data Security Law requires data processing (which includes the collection, storage, use, processing, transmission, provision and publication of data), to be conducted in a legitimate and proper manner. The Data Security Law imposes data security and privacy obligations on entities and individuals carrying out data processing activities and also introduces a data classification and hierarchical protection system based on the importance of data in economic and social development and the degree of harm it may cause to national security, public interests, or legitimate rights and interests of individuals or organizations if such data are tampered with, destroyed, leaked, illegally acquired or illegally used. The appropriate level of protection measures is required to be taken for each respective category of data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Also in China, on August&#160;20, 2021, the Standing Committee of the National People&#8217;s Congress of the PRC promulgated the Personal Information Protection Law, or PIPL, which took effect on November&#160;1, 2021. PIPL raises the protection requirements for processing personal information, and many specific requirements of the PIPL remain to be clarified. Fines for PIPL violations range from $7.7 million to up to 5% of the infringing company&#8217;s previous&#160;year&#8217;s revenues. We may be required to make further significant adjustments to our business practices to comply with the personal information protection laws and regulations in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, because the interpretation and application of many privacy and data protection laws (including the GDPR), </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">commercial frameworks, and standards are uncertain, it is possible that these laws, frameworks, and standards may be interpreted and applied in a manner that is inconsistent with our existing data management practices and policies. If so, in addition to the possibility of fines, lawsuits, breach of contract claims, and other claims and penalties, we could be required to fundamentally change our business activities and practices or modify our solutions, which could have an adverse effect on our business. Any inability to adequately address privacy and security concerns, even if unfounded, or comply with applicable privacy and security or data security laws, regulations, and policies, could result in additional cost and liability to us, damage our reputation, inhibit our ability to conduct trials, and adversely affect our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act and a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make our common stock less attractive to investors and adversely affect the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging growth company until the earlier of (i)&#160;the last day of the fiscal&#160;year in which we have total annual gross revenues of $1.235 billion or more; (ii)&#160;the last day of the fiscal&#160;year following the fifth anniversary of the date of the completion of our IPO; (iii)&#160;the date on which we have issued more than $1 billion in nonconvertible debt during the previous three&#160;years; or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules&#160;of the Securities and Exchange Commission, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of June&#160;30th. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing only two&#160;years of audited financial statements in addition to any required unaudited interim financial statements and a correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirement to provide detailed compensation discussion and analysis in proxy statements and reports filed under the Exchange Act and instead provide a reduced level of disclosure regarding executive compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved and some of the disclosure requirements of the Dodd-Frank Act relating to compensation of executive officers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we are still evaluating the JOBS Act, we currently intend to take advantage of some, but not all, of the available exemptions available to us so long as we qualify as an &#8220;emerging growth company.&#8221; We have taken advantage of reduced reporting burdens in this Annual Report on form 10-K. In particular, we have provided only two&#160;years of audited financial statements and have not included all of the executive compensation information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">application dates for public or private companies, we will adopt the new or revised standard at the time public companies adopt the new or revised standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result, changes in rules&#160;of United States generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. In addition, our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an &#8220;emerging growth company,&#8221; which may increase the risk that material weaknesses in our internal control over financial reporting go undetected. Likewise, so long as we qualify as an &#8220;emerging growth company,&#8221; we may elect not to provide you with certain information, including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile and may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a public company, and particularly after we are no longer an &#8220;emerging growth company,&#8221; we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules&#160;subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules&#160;and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to Section&#160;404, we are required to furnish a report by our management on our internal control over financial reporting. Management&#8217;s initial certification under Section 404 of the Sarbanes-Oxley Act was provided with this annual report on Form 10-K. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we have engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we have been and will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In connection with our IPO, we began the process of documenting, reviewing and improving our internal controls and procedures for compliance with Section&#160;404 of the Sarbanes-Oxley Act, which will require annual management assessment of the effectiveness of our internal control over financial reporting. We have also begun recruiting additional finance and accounting personnel with certain skill sets that we need as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our stock price and make it more difficult for us to effectively market and sell our service to new and existing customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to the periodic reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules&#160;and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We do not have control over these analysts. There can be no assurance that existing analysts will continue to provide research coverage or that new analysts will begin to provide research coverage. Although we have obtained analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to securities litigation, which is expensive and could divert management attention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The market price of our common stock may be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c3231dff_9877_47e1_bd40_fe193a3204be"></a><a id="Item1BUnresolvedStaffComments_255070"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B. Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_d4d6458b_88d8_45b9_9ce3_56f41973b087"></a><a id="Item2Properties_265850"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our headquarters is located in Waltham, Massachusetts, where we lease approximately 5,000 square feet of office space. Our Waltham lease expires in December 2024. We also lease approximately 3,500 square feet of office space located in Foster City, California which expires in October 2025. We believe that our existing facilities, as well as facilities available for rent, are sufficient for our current needs and our needs for the foreseeable future.</p><a id="_9618e3dd_09be_4a65_80e1_30c14c35bd9e"></a><a id="Item3LegalProceedings_561652"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time we may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. As of the date of this Annual Report on Form&#160;10-K, we are not currently a party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><a id="_f469f13c_5425_477d_8ed0_e713588f4923"></a><a id="Item4MineSafetyDisclosures_480642"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_0b896601_1b94_4840_9c76_9b37f1253d98"></a><a id="PARTII_103847"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock trades under the symbol &#8220;AVTE&#8221; on The Nasdaq Global Market and has been publicly traded since June&#160;30, 2021. Prior to this time, there was no public market for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Holders of Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March&#160;27, 2023, there were approximately 13 holders of record of shares of our common stock. This number does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to fund the growth and development of our business. We do not intend to pay cash dividends to our stockholders in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions, and other factors that our board of directors may deem relevant. Investors should not purchase our common stock with the expectation of receiving cash dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Securities Authorized for Issuance Under Equity Compensation Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Information about our equity compensation plans will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Proceeds from our Public Offering of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July&#160;2, 2021, we closed our IPO in which we issued and sold 9,984,463 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,302,321 additional shares of common stock, at a public offering price of $14.00 per share. All of the shares of common stock issued and sold in our IPO were registered under the Securities Act pursuant to a registration statement on Form&#160;S-1 (File No.&#160;333-256949), which was declared effective by the SEC on June&#160;29, 2021. Jefferies LLC, Cowen and Company, LLC and Evercore Group L.L.C. acted as joint book-running managers for the IPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The aggregate net proceeds to us from the IPO, inclusive of the over-allotment exercise, was approximately $126.9 million, after deducting underwriting discounts and commissions and other offering expenses of approximately $12.9 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There has been no material change in the planned use of IPO proceeds from that described in our final prospectus filed with the SEC pursuant to Rule&#160;424(b)(4)&#160;under the Securities Act on June&#160;30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form&#160;10-K.</p><a id="_c505f46a_3e48_4438_b1c2_770ac4c313ab"></a><a id="Item6Reserved_387707"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item&#160;6. Reserved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_152a38b8_5b7e_467d_a3e8_9048a8e039ae"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs, and involve risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those discussed in the section titled &#8220;Risk Factors&#8221; included under Part&#160;I, Item&#160;1A and elsewhere in this Annual Report. See &#8220;Special Note&#160;Regarding Forward-Looking Statements&#8221; in this Annual Report.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Our initial focus is on advancing AV-101, our dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, or PAH, a devastating disease impacting approximately 70,000 people in the United States and Europe. Imatinib, marketed as Gleevec tablets, was originally developed for the treatment of multiple cancers. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients in an international Phase 3 trial conducted by Novartis but was poorly tolerated due to adverse events, or AEs, and never approved for the treatment of PAH. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. We have completed a Phase 1 clinical trial in healthy volunteers and AV-101 was generally well-tolerated with no serious adverse events reported. We are enrolling patients in Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), our global Phase 2b/Phase 3 trial of AV-101 in adults with PAH, and we have assembled a team with deep expertise in developing innovative PAH and inhaled therapies and commercializing novel drugs. We do not have any products approved for sale and have incurred significant operating losses since our inception and expect to continue to incur significant operating losses for the foreseeable future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Developments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Initial Public Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In July&#160;2021, we completed our initial public offering, or IPO, of 9,984,463 shares of our common stock at a price to the public of $14.00 per share, including the exercise in full by the underwriters of their option to purchase 1,302,321 additional shares of our common stock. Including the option exercise, our aggregate net proceeds from the offering were $126.9 million after deducting underwriting discounts and commissions and other offering costs. Immediately prior to the closing of our IPO, all outstanding shares of our redeemable convertible preferred stock were converted into 14,182,854 shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">COVID-19 Pandemic and Future Infectious Disease Outbreaks</p><a id="_Hlk128048000"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We continue to closely monitor the impact of the COVID-19 pandemic on our business, operations and clinical development timelines. In addition, we are actively monitoring its impact on our clinical trial enrollment, trial sites, contract research organizations, or CROs, third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. The ultimate impact of the COVID-19 pandemic or any future infectious disease outbreaks is highly uncertain and subject to change. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We continue to actively monitor the impact of infectious disease outbreaks on our business operations and may take future actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. The COVID-19 pandemic or any future infectious disease outbreaks may affect our business, operations and clinical development timelines and plans, including the resulting impact on our expenditures and capital needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have no products approved for sale, and we have not generated any revenue to date. In the future, we may generate revenue from collaboration or license agreements we may enter into with respect to our drug candidate, as well as product sales from any approved product, which approval we do not expect to occur for at least the next several&#160;years, if ever. Our ability to generate product revenue will depend on the successful development and eventual commercialization of AV-101 and any other drug candidates we may pursue. If we fail to complete the development of AV-101 in a timely manner, or to obtain regulatory approval, our ability to generate future revenue and our results of operations and financial position would be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, our research and development expenses have related to the development of AV-101. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred under agreements with contract research organizations, or CROs, and consultants to conduct and support clinical trials of AV-101 and our preclinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to manufacturing AV-101 for use in clinical trials; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related costs, including salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in research and development efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our research and development expenses consist principally of direct costs, such as fees paid to CROs, investigative sites and consultants in connection with our clinical trials, preclinical and non-clinical studies, and costs related to manufacturing clinical trial materials. We deploy our personnel related resources across all of our research and development activities. We track direct expenses on a clinical and non-clinical basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of AV-101. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future clinical trials and nonclinical studies of AV-101 or any future product candidates due to the inherently unpredictable nature of clinical and preclinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We will need to raise substantial additional capital in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our future clinical development costs may vary significantly based on factors such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">per patient trial costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of trials required for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of sites included in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the countries in which the trials are conducted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the length of time required to enroll eligible patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients that participate in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of doses evaluated in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drop-out or discontinuation rates of patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential additional safety monitoring requested by regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of patient participation in the trials and follow-up; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety profile of the product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel-related costs, including salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals in executive, finance and other administrative functions. Other significant costs include legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services, and insurance costs. We anticipate that our general and administrative expenses will increase for the foreseeable future to support our continued research and development activities, pre-commercial preparation activities and commercialization activities for AV-101. We also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comparison of the&#160;Years Ended December&#160;31, 2022 and December&#160;31, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes our results of operations for the&#160;years ended December&#160;31, 2022 and December&#160;31, 2021 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 38,622</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,987</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,635</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,615</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,035</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,580</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 53,237</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 30,215</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (53,237)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (23,022)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (30,215)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,830</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,765</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (79)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (76)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,751</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 62</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,689</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (51,486)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (22,960)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (28,526)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (51,511)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (22,963)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (28,548)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the&#160;year ended December&#160;31, 2022 were $38.6 million compared to $15.0 million for the&#160;year ended December&#160;31, 2021. The increase of $23.6 million was primarily due to increases of $13.5 million in clinical trial costs, $6.8 million in headcount related costs, $3.0 million in manufacturing costs, and $0.9 million in professional fees, partially offset by lower pre-clinical and regulatory related costs of $0.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses for the&#160;year ended December&#160;31, 2022 were $14.6 million compared to $8.0 million for the&#160;year ended December&#160;31, 2021. The increase of $6.6 million was primarily due to increases of $2.5 million in headcount related costs, $1.7 million in professional services related to other consulting expenses, corporate legal fees and audit and accounting services, $1.2 million in insurance expense and $1.2 million in other operating expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Total Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other income for the&#160;year ended December&#160;31, 2022 was $1.8 million compared to $0.1 million of other income for the&#160;year ended December&#160;31, 2021. The change was primarily due to interest earned on the Company&#8217;s cash and cash equivalents and short-term investments for the&#160;year ended December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">From our inception through December&#160;31, 2022, we have received aggregate net proceeds of $79.8 million from the sale of shares of our convertible preferred stock and $5.0 million from convertible promissory notes to related parties. In July&#160;2021, we completed our IPO with aggregate net proceeds from the offering of $126.9 million, after deducting underwriting discounts and commissions and offering costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">At-the-Market Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">On August 15, 2022, we entered into an Open Market Sale Agreement</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-size:10pt;">, or the Sale Agreement, with Jefferies LLC, or the Agent, pursuant to which we can sell, from time to time, at our option, up to an aggregate of $75.0 million of shares of </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">our common stock, through the Agent, as our sales agent. As of December 31, 2022, no shares were sold under the Sale Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have prepared operating plans and cash flow forecasts which indicate that our existing cash and cash equivalents and short-term investments on-hand of $129.2 million will be sufficient to fund our planned operations into the second half of 2025. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of conducting clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the type, number, scope, results, costs and timing of preclinical studies and clinical trials of AV-101, including changes to our development plan based on feedback received from regulatory authorities, and preclinical studies or clinical trials of other potential drug candidates or indications we may choose to pursue in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of manufacturing for AV-101 or any other product candidates, including commercial scale manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review and approval of AV-101 or any other drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with hiring additional personnel and consultants as our business grows, including additional clinical development personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and amount of the milestone or other payments we must make to any future licensors, if we enter into any license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of establishing or securing sales and marketing capabilities if AV-101 or any other product candidate is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third- party payors and adequate market share and revenue for any approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients&#8217; ability and willingness to pay out-of-pocket costs for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with any products or technologies that we may in-license or acquire.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Until such time, if ever, as we can generate substantial product revenue to support our cost structure, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, potentially including collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. Our failure to raise capital or enter into such other arrangements when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our drug candidates even if we would otherwise prefer to develop and market such drug candidates ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Contractual Obligations and Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August&#160;2021, we entered into a lease agreement, or the Waltham Lease, for approximately 5,000 square feet of office space in Waltham, Massachusetts. The base rent under the Waltham Lease is $43.00 per rentable square foot, or approximately $18,000 per&#160;month and is subject to scheduled annual increases of $1.00 per rentable square foot during the lease term. The term of the Waltham Lease is thirty-nine&#160;months, unless extended or earlier terminated pursuant to the terms of the Waltham Lease. We have the option to extend the Waltham Lease for one additional period of three&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April 2022, we entered into a lease agreement, or the Foster City Lease, for approximately 3,500 square feet of office space in Foster City, California. The base rent under the Foster City Lease is $76.80 per rentable square foot, or approximately $22,600 per month and is subject to scheduled annual increases of 3% on each annual anniversary during the lease term. The term of the Foster City Lease is thirty-nine months, unless extended or earlier terminated pursuant to the terms of the Foster City Lease. We have the option to extend the Foster City Lease for one additional period of one year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we do not have any other operating lease obligations, long-term debt obligations, capital lease obligations, purchase obligations or long-term liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business for contract research services, contract manufacturing services, professional services and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comparison of the&#160;Years Ended December&#160;31, 2022 and December&#160;31, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth a summary of the net cash flow activity for the&#160;years ended December&#160;31, 2022 and December&#160;31, 2021 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (39,122)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,399)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,926</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (113,434)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 396</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 190,457</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (31,800)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 49,624</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net cash used in operating activities for the year ended December 31, 2022 was $39.1 million, consisting primarily of our net loss incurred during the period of $51.5 million adjusted for $4.6 million of noncash charges and $7.8 million for net changes in operating assets and liabilities. Noncash charges consisted primarily of $5.5 million in stock-based </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">compensation expense, partially offset by $0.9 million of amortization of our investments. The net change in operating assets and liabilities related to a $5.0 million increase in accounts payables and accrued liabilities, a $4.7 million increase in prepaid expenses and other current assets, partially offset by a $1.9 million decrease in other long-term assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2021 was $27.4 million, consisting primarily of our net loss incurred during the period of $23.0 million adjusted for $2.1 million of noncash charges and $6.5 million for net changes in operating assets and liabilities. Noncash charges consisted primarily of $2.0 million in stock-based compensation expense. The net change in operating assets and liabilities related to a $6.8 million increase in prepaid expenses and other current assets and a $0.3 million increase in other long-term assets, partially offset by a $0.6 million increase in accounts payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by investing activities for the&#160;year ended December&#160;31, 2022 of $6.9 million was comprised of sales and maturities of investments of $154.7 million, offset by purchase of short-term investments of $147.6 million and purchases of property and equipment of $0.2 million to support our research activities and leasehold improvements, furniture and fixtures for our office spaces in Waltham, Massachusetts and Foster City, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used by investing activities for the&#160;year ended December&#160;31, 2021 of $113.4 million was comprised of purchases of short-term investments of $113.2 million using the proceeds from our initial public offering in July&#160;2021 and purchases of property and equipment of $0.2 million for purchases of property and equipment to support our research activities and leasehold improvements, furniture and fixtures for our office space in Waltham, Massachusetts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities for the&#160;year ended December&#160;31, 2022 was $0.4 million due to $0.8 million in net proceeds received from stock option exercises and issuances of common stock under our employee stock purchase plan, which were partially offset by $0.4 million of payments made for offering costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities for the&#160;year ended December&#160;31, 2021 was $190.5 million due to $63.6 million in net proceeds received from the First Milestone Closing, Second Milestone Closing and Third Milestone Closing of Series&#160;A redeemable convertible preferred stock, net of issuance of costs, and $126.9 million in net proceeds from the issuance of common stock, net of issuance costs, in connection with the closing of the Company&#8217;s IPO on July&#160;2, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the related disclosures of contingent liabilities in our consolidated financial statements and accompanying notes. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and judgments on an ongoing basis. Actual results may differ significantly from these estimates under different assumptions, judgments or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note&#160;2 to our consolidated financial statements included in Part&#160;II, Item&#160;8 of this Annual Report on Form&#160;10-K for a summary of significant accounting policies and the effect on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are required to estimate our expenses resulting from obligations under contracts with vendors, consultants and CROs, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. We reflect research and development expenses in our consolidated financial statements by matching those expenses with the period in which services and efforts are expended. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We account for these expenses according to the progress of the preclinical or clinical study as measured by the timing of various aspects of the study or related activities. We determine clinical trial cost estimates through review of the underlying contracts along with preparation of financial models taking into account discussions with research and other key personnel and outsider service providers as to the progress of studies or other services being conducted. During the course of a study, we adjust our rate of expense recognition if actual results differ from our estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time public companies adopt the new or revised standard. The decision to opt out of the extended transition period under the JOBS Act is irrevocable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 2 to our consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10 K for a summary of recently issued accounting pronouncements.</p><a id="_c562f600_7a2a_4cf6_9e6e_220536493b54"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest Rate Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities related to our cash, cash equivalents and short-term investments. We invest our excess cash primarily in money market funds, commercial paper, corporate debt securities and U.S. Treasury bills. We mitigate credit risk by maintaining a well-diversified portfolio and limiting the amount of investment exposure as to institution, maturity and investment type.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the short-term maturities of our cash equivalents and short-term investments, along with the low risk profile of our investments, we do not believe that an increase in market rates would have any significant impact on the realized value of our investments. An immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and short-term investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inflation Fluctuation Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inflation generally affects us by increasing our cost of labor. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the&#160;years ended December&#160;31, 2022 and December&#160;31, 2021.</p><a id="_749a9f0b_0980_4052_90ff_0ede40e34736"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8. Financial Statements and Supplementary Data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements required to be filed pursuant to this Item&#160;8 are appended to this Annual Report on Form&#160;10-K. An index of those consolidated financial statements is found in Item&#160;15, Exhibits and Financial Statement Schedules, of this Annual Report on Form&#160;10-K.</p><a id="_6c5aba3e_e4ce_482a_88fe_9d35959ab956"></a><a id="Item9ChangesinandDisagreementsWithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5e6b37d0_8a92_4cab_bd86_3ceb2b740ef3"></a><a id="Item9AControlsandProcedures_752435"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (i)&#160;recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms and (ii)&#160;accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives. Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act) as of December&#160;31, 2022. Based upon such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, our principal executive officer and our principal financial officer, and effected by our board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP, and includes those policies and procedures that:</p><div style="margin-top:6pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:24.45pt;margin-top:0pt;padding-left:24.5pt;text-align:justify;text-indent:-24.5pt;"><span style="display:inline-block;min-width:24.5pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of assets;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:24.45pt;margin-top:6pt;padding-left:24.5pt;text-align:justify;text-indent:-24.5pt;"><span style="display:inline-block;min-width:24.5pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:24.5pt;margin-top:6pt;padding-left:24.5pt;text-align:justify;text-indent:-24.5pt;"><span style="display:inline-block;min-width:24.5pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the supervision of and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework provided in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in (2013 Framework). Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Attestation Report of the Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K does not include an attestation report of our registered public accounting firm due to an exemption established by the JOBS Act for &#8220;emerging growth companies.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There was no change in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) that occurred during the period covered by this Annual Report on Form&#160;10-K that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_69143ce5_da2d_4da6_8b1d_9085dad4b42c"></a><a id="Item9BOtherInformation_913298"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 27, 2023, we delivered written notice to Jefferies LLC, or Jefferies, that we were terminating the Open Market Sale Agreement dated August 15, 2022, or the Sales Agreement, by and between us and Jefferies, effective as of a date no later than 10 trading days from the date of delivery, the Termination Date. All of the continuing obligations under the Sales Agreement will be terminated as of the Termination Date, other than those provisions which expressly survive termination as provided in the Sales Agreement. We are not subject to any termination penalties related to the termination of the Sales Agreement. Prior to termination, no shares of our common stock, $0.0001 par value per share, were sold pursuant to the Sales Agreement. &#160;A copy of the Sales Agreement was filed as Exhibit 1.2 to our Registration Statement on Form S-3 (File No. 333-266883) filed with the SEC on August 15, 2022.</p><a id="_b5588a83_c6a0_4075_9261_60e5dcd37ddc"></a><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_85eabb61_9cb2_4ab6_929c_16fcfdb4063a"></a><a id="PARTIII_336999"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;10. Directors, Executive Officers and Corporate Governance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;10 will be included in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</p><a id="_1a9791b8_285e_40e2_b79e_1585ff855efd"></a><a id="Item11ExecutiveCompensation_18647"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11. Executive Compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;11 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</p><a id="_b8f9af6f_3d3c_491a_93e3_92a4e8d4eb67"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;12 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</p><a id="_970795f2_077e_4bf5_a45f_f2b4a4040621"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;13 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</p><a id="_930c81e0_77e4_4140_972b_e3a42787424d"></a><a id="Item14PrincipalAccountingFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14. Principal Accounting Fees and Services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our independent public accounting firm is KPMG LLP, San Diego, California (PCAOB Auditor ID: <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:AuditorFirmId" id="Narr_3LNoIRXLXUmArZQU-QTXGw">185</ix:nonNumeric>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;14 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b698b61b_2750_44d8_b1c4_4ea6b068f653"></a><a id="PARTIV_243698"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsFinancialStatementSchedule"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15. Exhibits, Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span>All financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The consolidated financial statements of Aerovate Therapeutics,&#160;Inc., together with the report thereon of KPMG LLP, an independent registered public accounting firm, are included in this annual report on Form&#160;10-K beginning on page&#160;F-1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span>Financial statement schedules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the consolidated financial statements or notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span>Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">A list of exhibits is set forth on the Exhibit&#160;Index immediately preceding the signature page&#160;of this annual report on Form&#160;10-K and is incorporated herein by reference.</p><a id="_da055c22_c0ac_400d_b237_322e72405f32"></a><a id="Item16Form10KSummary_747275"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16. Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has elected not to include summary information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dd359983_4230_4831_821e_598d79fba5a0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AEROVATE THERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:93.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (Auditor Firm ID: 185)</p></td><td style="vertical-align:bottom;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:93.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#BALANCESHEETS_90827"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:93.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#COMPREHENSIVELOSS_41676"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:93.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#STOCKHOLDERSEQUITY_810711"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></a></p></td><td style="vertical-align:bottom;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:93.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#CASHFLOWS_844977"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:93.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_7"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0f3fc1a5_f69c_4cfd_aa06_c10b3dd3d222"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics,&#160;Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Opinion on the Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Aerovate Therapeutics, Inc. and subsidiary (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:AuditorName" id="Narr_qY-xvUhKBkeJpt-XhKvQLw">KPMG LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="dei:AuditorLocation" id="Narr_1rkIWM0cqUaxTPR_Ktfusw">San Diego, California</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">March&#160;29, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_97ca082a_00c6_44ff_8f63_c69c77b9e043"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AEROVATE THERAPEUTICS,&#160;INC.</p><a id="BALANCESHEETS_90827"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)</p><a id="_dff33fd4_e673_4dd5_8c32_f9d70e0f242c"></a><a id="Tc_lg0nKqrDVUiyq4m0PrO90g_1_2"></a><a id="Tc_LiAcl4tmgEqb8gE01DbW6A_2_2"></a><a id="Tc_KTzYhSQEK0egBF2tja76vA_2_5"></a><a id="Tc_wM1wjLZLLkmEDJyZtu-nxw_3_0"></a><a id="Tc_TX9tMzrGXEC_Px0nM4eB0g_4_0"></a><a id="Tc_gqRt0B__zUSppXytTffpYw_5_0"></a><a id="Tc_3N6wL2xEZkSLQbq6c7V7Ag_5_2"></a><a id="Tc_ASZ3QZUtgE2wtTjNsdz1Pw_5_5"></a><a id="Tc_41_pQ0loDUipUcFJGNYMIA_6_0"></a><a id="Tc_J2d-uxuQeU-MBDXKsUs9tg_7_0"></a><a id="Tc_CiNaMn7igUSEYWmhKGsuZw_8_0"></a><a id="Tc_C-A4ZLisc0OlSsGKvhYvwQ_9_0"></a><a id="Tc_UYPMEEXkYk6_8m8fLaxiXQ_10_0"></a><a id="Tc_6HWyK6Y91k2ARwGZj4EZOQ_11_0"></a><a id="Tc_K1eBmdV77kO2nCjM-OXmDA_12_0"></a><a id="Tc_YQKhHWHkuk-yZGbTG1DJeQ_12_2"></a><a id="Tc_Kh8TGDmKoUSSg-ndl5EczQ_12_5"></a><a id="Tc_QPAZBDTJc0Kn5Dd5JMZM4g_14_0"></a><a id="Tc_y_oLO7c2N0KmQ3kVl_WAnQ_16_0"></a><a id="Tc_q9vNCfLtMUCbR-TivbwCyA_17_0"></a><a id="Tc_KgUOVn-I-0Sg8dBY4QDkDQ_17_2"></a><a id="Tc_bcN2mqF720yirPxswOkogw_17_5"></a><a id="Tc_33nQUo3ky0WGL8dHWTdLOw_18_0"></a><a id="Tc_BsisxBidUE6-P5D2Dj-UHw_19_0"></a><a id="Tc_q6iL9_ChaU2NZS6Y8wmwXQ_20_0"></a><a id="Tc_EGvvSuE3OEimKOCXNnVt-w_21_0"></a><a id="Tc_HnkUfe0VYE-QUEhwRft-WQ_22_0"></a><a id="Tc_WKyWH-Mgd0uJPtUxAKqR0g_23_0"></a><a id="Tc_OKDWzBklNkyn4qh4a-7eUQ_25_0"></a><a id="Tc_xDO0EqnMqka72BahLs-03A_26_0"></a><a id="Tc_6EKSrt-3Pk68j3TrXI5_lg_27_0"></a><a id="_30e3378f_8936_4eea_96d6_b7d2c3125aca"></a><a id="_30e3378f_8936_4eea_96d6_b7d2c3125aca_2"></a><a id="_30e3378f_8936_4eea_96d6_b7d2c3125aca_3"></a><a id="Tc_fSYQFq5feEK3e1pULnZNQg_28_0"></a><a id="Tc_pU5xKDm9dEW8i1NSpW230Q_29_0"></a><a id="Tc_S9DrDi_WS0GnywKu0crjvQ_30_0"></a><a id="Tc_gVEo2MMlu0yRgil54-ia7g_31_0"></a><a id="Tc_zpFkhC64TU-cU-QgHQvgug_32_0"></a><a id="Tc_-MgXcUmZfEih1p_IU8xCKQ_33_0"></a><a id="Tc_P2TDb7Sc9EWgC84W4qvrrg_33_2"></a><a id="Tc_G-49OPbD402cNg66vTSY-Q_33_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_BshbZgCJiUOdxfxuP7r9ZQ_5_3">22,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_ChFY0z1raEqsIFVHB_LD-Q_5_6">54,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_okIiEkUXY0GORgfA7iir7w_6_3">106,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_05Hg6z9yv0CDTGETdnoxfQ_6_6">113,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_AVvc6oyBp0azBpMCawlFOg_7_3">2,276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_zFVnZCqbWU24obq1HJCi_A_7_6">6,958</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_wLqm5x-N30Wg3ehCQwyVAA_8_3">131,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_XRZDD3NcZEuIF_Pjc0g08w_8_6">174,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_LPmDqLlbXkKOT-zEHyx-oQ_9_3">242</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_UjyvAkuUaEeSbGj2N4ChhQ_9_6">186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_run3zlxPZkekKM7LkDo2og_10_3">1,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_I3mfboFzA0ejbhS9goDA0g_10_6">542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other long-term assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_uIntJNeVYE-uL9Aczv6Dkw_11_3">2,560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_kuHUjRlKlUGAKobstrowVA_11_6">302</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_cU3HodLO0UOVq4ZrAPlSgw_12_3">135,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_i6wYejn0Lk2hvm3r7FcxdQ_12_6">175,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_3ZVfPhRpg0SyKgsCimxlwg_17_3">2,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_O00KUbI_00awYQtrqaK0Iw_17_6">1,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="Tc_RGPPqW6oXkCNErqIVOgIJw_18_3">4,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="Tc_R2yIg7oaakCB3X_aujwvMg_18_6">1,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_ayVFzMXhF0it1QUSMzFCtg_19_3">385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_yZJyFLen1Uiu9eurGMJzKg_19_6">192</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_lzrlKN4h6E2GuPZy_rKpTQ_20_3">7,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_QMDZxhU2OEaa49U7C3X1ug_20_6">2,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_BpWx3NBb6kqHHkIUXwrJKA_21_3">705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_yr1ULZSqYEa52UbWyE-LWg_21_6">382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilities" scale="3" id="Tc_2F1BUIGZnk2W5HJD0hIjRQ_22_3">71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilities" scale="3" id="Tc_0NPlu4vDI0qPAX_7qmk_Cg_22_6">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_dGuoYwWxWUemD1V6TgAEww_23_3">8,558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Q8bZF55s7EqNUcryUTjv1w_23_6">2,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_z9mMtPYsik2QH0LFW_1ZYw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_hWJ6CREPLkyiFeYsovcW-Q">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_aptyqB1vXUqTf0pesNV7rw"><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_66hlIIhzzEuM_6c-7O5sMQ">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31,&#160;2022 and December&#160;31,&#160;2021, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_EOOk-pEWvEi_dgoNw3Wryg"><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_lhayzOqt60O4Ai0Fm1EgBQ">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31,&#160;2022 and December&#160;31,&#160;2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_bJuePYP0z0enEK1t8naDBw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_nnISsMCKK0SB6DzIZRp3nQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_vBHuVQP2_UiRDy7vCXybfA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_4W05xFfv4UKnZDUwNxvdVA">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_0kEhaSrj7kKUWuXifymvnw"><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_KsWjhP-Gfky1DHcBrxq7LQ">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31,&#160;2022 and December&#160;31,&#160;2021, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_-d_S17wxDE2NI2WsAp-gvQ">24,722,974</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_D73Qm4-x4k2FS1u6leYWBw">24,410,393</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_yRE9VHYos06cYhHQPpwzYQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_GAre_n3AxkK4BhXuL_0rVg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December&#160;31,&#160;2022 and December&#160;31,&#160;2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_LetS7YtUfU2b1olNNNw1Yw_28_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_P932XJGjWkSns0gEAYolNw_28_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_ajkkpc0yFkeV_1MOmE0o2Q_29_3">215,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_bvz7c8kK_0GlHdXTA4CN6A_29_6">208,867</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_JazhZDDk9k-jwapNgnsMEg_30_3">466</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_FvSu11NOKUWT__kITML-Iw_30_6">59</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_RumJbTLZUUSXFS61mn0PUg_31_3">87,903</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_fKpL3-oU_kebo8ZfJh_bgg_31_6">36,392</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_FQ54tX2pfk2vLiVY-Tafmw_32_3">126,743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ien-EJ9nDkGLvzk-KJrqKg_32_6">172,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_xEQc8ubQu0KI9eG659UsHA_33_3">135,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_yzpzca7QXE-pSIKh3C7umw_33_6">175,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0e46e406_ec4e_41ee_80ff_e978fd34aeed"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AEROVATE THERAPEUTICS,&#160;INC.</p><a id="COMPREHENSIVELOSS_41676"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)</p><a id="_20f89532_1d2a_4180_a8bb_2d6957ed46e3"></a><a id="_89dbaea2_1b18_4846_954f_26b70e2a71f9"></a><a id="Tc_kYotc-iTAU2NmC26E3vOdw_1_2"></a><a id="Tc_HQ_CAdoFbUC2LgLraZxT2w_2_2"></a><a id="Tc_SXWhlv27dE6agquv2L4RyA_2_5"></a><a id="Tc_p4t5d3uU6kahCKfkgPFK5w_3_0"></a><a id="Tc_mkPE2JKvjEaTzTlhX_qxjw_4_0"></a><a id="Tc_BGPZDa-znkCZ5trv4DXB4g_4_2"></a><a id="Tc_GKkbEgEnwECczhBRZvpAYA_4_5"></a><a id="Tc_sD3GIhemPEC7Lh1tmzCkZw_5_0"></a><a id="Tc_7mFl_61auEy_gZeagMiryA_6_0"></a><a id="Tc_HcB6z3Stjkip_DF36WwKWg_7_0"></a><a id="Tc_-mDgRXADy0STDpyp9hGpNA_8_0"></a><a id="Tc_D-DClh8zVk6QwYZKQ4tH8A_9_0"></a><a id="Tc_CHWfdNc_k02gdaPEd5ZWpg_10_0"></a><a id="Tc_d5w-WN7skEqr9Wb0EGZtWA_11_0"></a><a id="Tc_pQJpk0E5TESNregXnrpdVw_12_0"></a><a id="Tc_BCJz_mLZIkqjzOCHuvQBYA_13_0"></a><a id="Tc_INdGTFjkYUu-Id1fndJevg_14_0"></a><a id="Tc_fgtbNxCBq0KVGPZlx_AGlw_14_2"></a><a id="Tc_9rgESLxq_k2DD-4ppGUb1A_14_5"></a><a id="Tc_QFANPNoR7UKCRFDK5fQ6zA_15_0"></a><a id="Tc_F1EBOoFKBEuAtQBgnhwKow_16_0"></a><a id="Tc_bCqnqHEFM0qOQCZxBk_I6w_16_2"></a><a id="Tc_F31wBokomk-4ptCdTue31g_16_5"></a><a id="Tc_SL2ddW2OIUyvKqwW1ELmXw_17_0"></a><a id="Tc_Nj1_dR2HC0ueO8-ZysVtJg_18_0"></a><a id="Tc_t2lorl8FJkmb8kylb4Jzhw_19_0"></a><a id="Tc_Fful03h4o0CXgOow_gccBw_19_2"></a><a id="Tc_rJffQRpuGEGm0h9CgRTtNA_19_5"></a><a id="Tc_b3FF357PFUauOV3hdl5lxw_20_0"></a><a id="Tc_uM3TxjKeyk-wzaR_VJ6l2w_20_2"></a><a id="Tc_MTWENhhgqkiFVGn76KK2ig_20_5"></a><a id="Tc_u8PdByJyQkKW1Vg7x6ownA_21_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_KwBfGLUn6kiFVFlmAqkJCA_4_3">38,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_uylLWOpFNUadHvYyEmx4Tw_4_6">14,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_66Ej4Gmlz0WBR5cN5VJ-mQ_5_3">14,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_1U84i6ssGkqFPCe86HN0yw_5_6">8,035</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_08DMHlxZnEKhQ__6s-8gAw_6_3">53,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_B4nhiudxFUyAa06DHS1zsQ_6_6">23,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_TeIkXXE-0E6g26FiciCOJg_7_3">53,237</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_mP6U2RXYCEqorH2eGYBPxA_7_6">23,022</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="Tc_z_HMzt_ax0qtziMuyCnMHQ_9_3">1,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="Tc_dd9cEUDHBUq-wyWulKXGXg_9_6">65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_YqZd81muhECgYELN80s-RA_10_3">79</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_syKfXKvjqUebSCM8K5RMMQ_10_6">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_9ZUW_qMgvUivUJwQBwmIBw_11_3">1,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_GVEhD58RoUmFzgMiAupaTA_11_6">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_ip-OyvmVdU2RmsJkAWQfLA_12_3">51,486</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_bgd9NcBpbkix3FwQCsVYgQ_12_6">22,960</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_OfwkpJUbd0Cawaet_Un-JQ_13_3">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_trrGS4dBRUKOqcA06TgldA_13_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_h1f91aT6WEOM5BhgWnSEJw_14_3">51,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_F1ypdjx3gEq0BQoOfXQB7Q_14_6">22,963</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1p1UPNwa2kmRH-lLfZcD-g_16_3">51,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_gx_K219p_0axJ7T8QMHBXA_16_6">22,963</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Unrealized loss on securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_opktWRnD4kCNCONE_wq-_Q_18_3">407</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_Xb6Zl-foYk-EplioTotUTg_18_6">59</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_H2wJdHyTYE-fIOL028U_ZA_19_3">51,918</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_2GQ_Qu26DUeb4me8GYjMxg_19_6">23,022</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_wez4CqpMuUONtiGhxqcQ9g_20_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_wez4CqpMuUONtiGhxqcQ9g_20_3_2">2.10</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_WyT2NP6Y7Eqx0L_uCOZuTA_20_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_WyT2NP6Y7Eqx0L_uCOZuTA_20_6_2">1.87</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average shares of common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_E28bZvFTwU2p1MPuwMJSlQ_21_3"><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_E28bZvFTwU2p1MPuwMJSlQ_21_3_2">24,472,104</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_zund3kD6H0axeTIvQdawvQ_21_6"><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_zund3kD6H0axeTIvQdawvQ_21_6_2">12,293,629</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_84409ae0_f368_4ea7_875f_f1b6d4eafe18"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AEROVATE THERAPEUTICS,&#160;INC.</p><a id="STOCKHOLDERSEQUITY_810711"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(IN THOUSANDS, EXCEPT SHARE AMOUNTS)</p><a id="_85613309_7d01_4a20_b9d8_f4d0a9c9007e"></a><a id="Tc_RDt-_8GNF0yJ0pyw3zHVAA_1_7"></a><a id="Tc_iVRbr5T-2UqQPQluYQOeZw_2_2"></a><a id="Tc_joOGJKoKpE6efpJeOoOFTg_2_7"></a><a id="Tc_WspxvgPPNEmifRiVs0F8zQ_2_21"></a><a id="Tc_wZVfoZzpn0Czmqwhe-Ms6w_2_27"></a><a id="Tc_eLY4F7PML0qY9d_c0sIgSQ_3_2"></a><a id="Tc_HrdJ4b_-VU2B00WoLMrjBQ_3_7"></a><a id="Tc_bMYZ1205U0aFQ2TxuFQOWw_3_18"></a><a id="Tc_KUmZsM1tuE-nWE1bsNPo4w_3_21"></a><a id="Tc_MJ6_RPvMEU22n4fwJ1djxg_3_27"></a><a id="Tc_zSgtZ3s-B0idVdtRPGM_zA_4_2"></a><a id="Tc_BRdT6cHbLU6PcK5-x_473A_4_7"></a><a id="Tc_ilix8NyQEUedBKehwiYw_Q_4_13"></a><a id="Tc_fllPVa0XCkC6uabn6tI8Sg_4_18"></a><a id="Tc_t9buHuUY6Uau0AK7VVN1-Q_4_21"></a><a id="Tc_1gMZGS8ApEGjHG_lo-RkqQ_4_24"></a><a id="Tc_jA3F3ofalkmePUtvW4Qpxw_4_27"></a><a id="Tc_LcWuGu0OfUi9YQTfu-K36Q_5_2"></a><a id="Tc_Aoy9D9oZIkukVNRWzIGyFg_5_4"></a><a id="Tc_SMq4MweCzEacK0kjUMEdQQ_5_7"></a><a id="Tc_QKs2lE5kBkqDrqpTu93hZQ_5_9"></a><a id="Tc_6hwO7A0bLkyn92X2vhuO6g_5_13"></a><a id="Tc_tnoAPNRZ8EqblFBCmQdb4g_5_15"></a><a id="Tc_qx6xaxnFbUKgOKd7ZL3mJw_5_18"></a><a id="Tc_x2h7wele60KYXCLTFa3TIg_5_21"></a><a id="Tc_NJJIrAZcgEed1ulXemrQRA_5_24"></a><a id="Tc__q1E5cmWSkO1c3w-t2Ftpw_5_27"></a><a id="Tc_M_-9rCyOjkCGJvBKJdTTBw_6_0"></a><a id="Tc_jebn5gKGGEm5vVJpJjCReQ_6_4"></a><a id="Tc_j3FS7UOQDEmdITEsY4VpRw_6_9"></a><a id="Tc_qdRmGoWy_Uix0hsvVFEOTg_6_15"></a><a id="Tc_8WKIbaSz70OHoSq6IlF66w_6_18"></a><a id="Tc_8qKvLh5pYkS8C0gFlQHxhQ_6_21"></a><a id="Tc_Z3AQOdWJVEKlfhaFq_YEkg_6_24"></a><a id="Tc_g3P6Qhy0oUCbxsYscugcqA_6_27"></a><a id="Tc_LeiHbLo_50KOy9KjCRXglA_7_0"></a><a id="Tc_WuziS1f36EmuV4GLVCxjRQ_7_7"></a><a id="Tc_EojJ9ZlPZ0-CUTUhOMyA_Q_7_13"></a><a id="Tc__jqLT5XssU2U2qZFOIk_jw_8_0"></a><a id="Tc_qwnQF-Ei_UaPzusGjUx5ZQ_8_2"></a><a id="Tc_QT-sgZdFeEe9ul2LOmePdQ_8_7"></a><a id="Tc_bdnxma2sAEeANAjSzMxJHQ_8_13"></a><a id="Tc_2IKY9xTVuESMiIVXX2bEiQ_9_0"></a><a id="Tc_0EfjuzR4I0Wp2_38mZtqEw_10_0"></a><a id="Tc__WSDiO60zkOwlOhRh1tSqA_10_2"></a><a id="Tc_RGL-uIr_HEiOFW-4fsWjtg_10_7"></a><a id="Tc_EX2IGB4rJEusVVc6g5wqOg_11_0"></a><a id="Tc_7GneAfjEpU6vuqg7j-HCeg_11_2"></a><a id="Tc_pYtvej62H0e5WBc4npsCVA_11_7"></a><a id="Tc_dfm6kF5Eb0eZvTQsnRRNdQ_11_13"></a><a id="Tc_cudtxD01j0a6O0yWAvG6zg_12_0"></a><a id="Tc_M-ZlNPwiwUqa8RSbb4nbFA_12_2"></a><a id="Tc_5QW2QrGVi0mleDMxdEi4Fw_12_7"></a><a id="Tc_vB12LQzE3Eahvl6WeUe1Kg_12_13"></a><a id="Tc_al-mTkP99UOYoI4KvGcgpA_13_0"></a><a id="Tc_zOoTDlh08UiwPggws7t7lQ_13_2"></a><a id="Tc__c7uXjant0ao2B1I9Hqe9w_13_7"></a><a id="Tc_iKSzar2C_0C-W2LCElbMZw_13_13"></a><a id="Tc_BR1gWUQuDkSIy66yBnyaJw_14_0"></a><a id="Tc_tb1EquPOy0ao3kj1EhsiKA_14_4"></a><a id="Tc_l2vJsCOthEChie8lKCs_Wg_14_9"></a><a id="Tc_-qVe-4DchkWgI013dR1Xyg_14_15"></a><a id="Tc_NZ1oLm2nwEKApdxhCx9KLQ_14_18"></a><a id="Tc_rDPosAEwH0-PSR7Od1ogfA_14_21"></a><a id="Tc_3nLLIjJ4OEud5vkqHOLbhg_14_24"></a><a id="Tc_nL13LsRvc0Wi-38OusBFHQ_14_27"></a><a id="Tc_EJc8xkC3g0eLA65GBmNj8A_15_0"></a><a id="Tc_iS4fBofXKEOC05awGo5khw_15_2"></a><a id="Tc_rUea3Thf106A4Me-jw8HqQ_15_7"></a><a id="Tc_1g-ul6v3G06X9TPHJyEQxg_15_13"></a><a id="Tc_AbBQDYkMokG4_JtJOQRTUg_16_0"></a><a id="Tc_UXZoKYSkyUW88pnkvl4muA_16_2"></a><a id="Tc_6ho-1x2VS02HbuuqW3_2nw_16_7"></a><a id="Tc_Xnp0c68lG0OLl9lUP3VSMg_16_13"></a><a id="Tc_9xLe_Mf54UOgt8Oll-lmeA_17_0"></a><a id="Tc_wvq4HDkD6EKui5iDgyS6Wg_17_2"></a><a id="Tc_vA-WtSDLJ0Gm6KCiRpqXfg_17_7"></a><a id="Tc_dXarozP8sEeixak7MdOnaw_18_0"></a><a id="Tc_vtOWalJ_TkqY78bZCwjG-g_18_2"></a><a id="Tc_gPKL-i7l-UWsTBijJN6UvQ_18_7"></a><a id="Tc_LGsQ9ajpGU2DSYoeeaztQQ_19_0"></a><a id="Tc_QsEmfdVjb0-WzWQFsB6DvA_19_2"></a><a id="Tc_4MufxuZIdEm2D1brVVan5A_19_7"></a><a id="Tc_17ZDxpyg6kC9a5TtuAPD2w_19_13"></a><a id="Tc_QIrrp8kamUyiJkzlDJ1O-g_20_0"></a><a id="Tc_2aJHkqxqeUCkArgE_O92zA_20_4"></a><a id="Tc_-SQKWSUOj0yyDWCUOfEe8w_20_9"></a><a id="Tc_0g_VPU3QIkOpM4bh9WYf6g_20_15"></a><a id="Tc_9Y1EKmBGS06CA_PcTrVtcg_20_18"></a><a id="Tc_JloIn7ZEWkyaYeBgEHLEMQ_20_21"></a><a id="Tc_s-Q_X8-E8k6GOUIjf3c_XQ_20_24"></a><a id="Tc_Xow25BrlsEWV_mgiFw_k4g_20_27"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series&#160;Seed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series&#160;A&#160;Redeemable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Redeemable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Deficit)</b></p></td></tr><tr><td style="vertical-align:top;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8aHpRkxHpkCDJdb7yykJBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_Y_wxFhLUSU2R7l-wRVus3g_6_2">6,489,534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8aHpRkxHpkCDJdb7yykJBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_ftGW_GngOkK6-8feG32WLA_6_5">12,285</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_9gGeJ_r-oESMCylkTiaQrA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_V6KOFF_HIkm26Vu-pWh9aQ_6_7">4,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_9gGeJ_r-oESMCylkTiaQrA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_Wd-9K-kSzUueA5FXPBa6xg_6_10">4,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i_IWKm7ZUkG0SD8gBMvkNg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_nCkaSyiHd0q6ALWdtr7A3g_6_13">243,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_z_7Smwx-xk6PNyccCkFacw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PcOQWpSW2EGd9KpeiSRIIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8mp6iyQs8EWVefjoefm6_w_6_19">63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_FgzULbdEkEmMgengviJ06w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FlYzV5V60kKR3Xb49ZQI6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jLHjYtNHAkeV-GYSxUldvw_6_25">13,407</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2020_lex_lE13Tka9RtZYzaRxrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_bYqmkR-_nkO6D42le_N7xg_6_28">13,344</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of Series A redeemable convertible preferred stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjitDg4W4EOE9Yf-R3ycdQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_mlS24KE9S0C-UQ1Xf2PA5A">1.893</ix:nonFraction> per share, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" sign="-" scale="3" id="Narr_mEY_Tc8F8EqcWgNhNVvtzw">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA" decimals="INF" format="ixt:numdotdecimal" name="avte:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_dCKSsU7Wp0qXpdlDgs7Qnw_7_2">33,562,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_EQxMtfnqs06K-0gH4PUYTg_7_5">63,512</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_vGST7hUNHUyjx-QRVKVB1A;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_PVPYhzV1KUSipoQZo14khg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_p1B0cgyja0eXXB8mJzHwhA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_zcK2QswtF0-XQisdNE1kTQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_8gXmbsc5V0WGwB8z3WrE4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_oWEmnNhdQEiWCw4bOf86UQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of Series A redeemable convertible preferred stock to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" sign="-" scale="3" id="Tc_qR2zlZPxJEyrOlEx81fHvA_8_5">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_0eG-SoEK5kuF1ShBTbmZBA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_vYbLbfdpEUebrPRsjQkIrg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_9TlgPwHWh0uwDbto1Gn0ag;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_CF5UUFhDtkuwemyNcYLVqg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="3" id="Tc_wYtjKxvNuku89KYt9AM2dQ_8_25">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="3" id="Tc_Wtio7Inx80asV1JaKa6WuQ_8_28">22</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA" decimals="INF" format="ixt:numdotdecimal" name="avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" sign="-" scale="0" id="Tc_0CNs3xPVm0OCfuahbk2rlw_9_2">40,052,154</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA" decimals="-3" format="ixt:numdotdecimal" name="avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" sign="-" scale="3" id="Tc_92iUMV4iu0eazeyUU1TANw_9_5">75,819</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg" decimals="INF" format="ixt:numdotdecimal" name="avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" sign="-" scale="0" id="Tc_e3aZox_bEUWd02tnrxlsPA_9_7">4,000,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg" decimals="-3" format="ixt:numdotdecimal" name="avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" sign="-" scale="3" id="Tc_owxXBVWGRkSDbAIRZJ4UUA_9_10">4,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw" decimals="INF" format="ixt:numdotdecimal" name="avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" scale="0" id="Tc_PILo7odZI0eqBJW7TmeDxg_9_13">14,182,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw" decimals="-3" format="ixt:numdotdecimal" name="avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" scale="3" id="Tc_uNJ9NQQBXUma4IQc25fsjQ_9_16">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g" decimals="-3" format="ixt:numdotdecimal" name="avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" scale="3" id="Tc_SLGOYs9isUGbUV_kY2IHWw_9_19">79,817</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_GU_-C10K_kufCNxbtEHvYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_xUSK3YkFk0WkQFu1WRz5ng;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" scale="3" id="Tc_-qRZGU4oQ0eI2Scf4IpZEQ_9_28">79,818</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common stock upon initial public offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_912yMiQA6EuoTS2GqOOWZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_SPYadEtbxUyiMyoMbj-zGw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_rJOBhH_4jUuJYBXIyixO8w_10_13">9,984,463</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_L85-JD5aTUKfLVLEJZdA9A_10_16">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_OosdAaM9NkmhMhvvPNzVfg_10_19">126,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_kME_VnS40Ey8bN1ipvIIgg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_O4BKDDh0GkaxTRKHLBJZgQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_j9NnASA830ClH0TrLw4byg_10_28">126,945</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Unrealized loss on investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_cd88Enej1kGdiFZxGBTS-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_3AeL89uIOUWv41QC_R_viQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1_lGy5tgq0Cu3RjgvjBrwA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_jf-F9WUfIkyExXtG1HLbpA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_e317zEghQ02cEtFAKXumKw_11_22">59</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_q6gqT2ZUikaTPHXP0K2tnw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_UDxagcqzRU-k3mLUdWd4pA_11_28">59</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_nj82nS1K_EyhUa226xKdDw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_shlVgBLiW06hH9N0n9n3nA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_4BYXfP_Jb0SBZ-QiJJauxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_KpodL4ETDEakj5UypzaC8g_12_19">2,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-htaxShuM0mu9hvSRX9XlA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_WdzbLmCHVkKzYMBb7IboLQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_wrCqS1OqNke9cnq9XaTsXw_12_28">2,043</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_xugVTio6i0afQ8eJushCTw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Tfghgj6ncUaJhMrK7Zddcg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_bUCrvbpg-UOAq0-Dzxstgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Zab77IL0sEuX-g4J7QAoxw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_g0jXDBz0lEqllR8Gr6oWSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_bZjqszrTWU6DpxBdXqxZ1g_13_25">22,963</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jdnK_vFchUiP2ItLpOw9kg_13_28">22,963</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_V7_LcdS0EE6yymFDgcmfhA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_V0VRYutPckKpqgmFqtDXwA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_89y_KHQk9EymnrvTUUnZ4g;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__cF4v94lHEyR31ih6-E_WQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ok3TV3BnH0eWo3UW7uDQug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_zN7FT4Wom0y1VnZ9Pyw3KQ_14_13">24,410,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ok3TV3BnH0eWo3UW7uDQug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pacFyYFx_0eJ4dkODkiPzA_14_16">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3CjGTVHCT0eUwawBJaweUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_iZR8GgEBKkSNmaIbEcsdhw_14_19">208,867</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6B2XB2kFVUWrsHm32rtreg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_7ru3he7ZGkealUXnEjYrwQ_14_22">59</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HN0Xoks5e0ezwLw29ZL8OQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Rq6WMuKmP0WiDo2Rq4qkjQ_14_25">36,392</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__lu_XDYvsk6kt-873g2LJA_14_28">172,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Unrealized loss on investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_OmhxfVgQCESxlgDb4_pJpA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_q7BbjAy1H0GnnYjlqlNn1Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ze7UL0SREU-ymT6vUXcLKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_cemoZSwJvUGon3ssmaX5Sw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yReDKtcgo0KOffS55fF_QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_vK32pcROw0eWVqh-YWXizw_15_22">407</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_QGA3oU86m0uadUBtG201gA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_j-_q65jCSEOqxB3aK3F4rg_15_28">407</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_pfuZVQLFS0iQYSds25WBYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_BAqDeljnCUWK-LcCFz5e8g;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_DW-qWgX6KUGWwHIIOUBVYQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxaL35pKjEOanh6iG7wiBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_2uebchd-506ooZ-sVToxDg_16_19">5,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_YZqCbmXx5EO_3uRH4nk_Uw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_DraQ_PjnZ06wPW8F-PJ8Fw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_FJjZoS2Mlk-zdS_SEa4DnQ_16_28">5,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_SkywTp5LwEarI0V2Akphrg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Rve_yEtVik-IvzJJRRL0XA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_omk-CWuOBEuUDXV1Eh_GyA_17_13">298,712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_WWFZwnrdM0ySldpeT4dC9A;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxaL35pKjEOanh6iG7wiBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_dyvOEsmcyE-3SLaFhUowzg_17_19">617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_voeCO464H0uFQ8dGV2vLbg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ttimKTVVBE-5HnXVZ5mGvw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_f-DCb56KEEac8L6rW6arCw_17_28">617</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common stock under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_9Z36iEtH-U6auxzWMeR0kA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_JRtInkjAkUuk9CReiPXp-Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_StockCompensationPlanMember_gpUHdU7SI0iF5rb9E2h1XA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_80NsiNVHCkOPFbTprbd_0g_18_13">13,869</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_5WQjntt1FkWeCko6wgN7qA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxaL35pKjEOanh6iG7wiBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_9YA8IDfmJU6tGz_WRVKijA_18_19">150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ji1TW4Zr2kqi-qIrB_6mwg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_d3SsXOCB50K_JnEqsVSgLg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_oZTNLBXJNEG3mjYWtM6psg_18_28">150</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_A62rI6HNkUCVIRjAlLZg0Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_CVAmf7WadUq49f3TtsN3IQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_CGyXEL1XvUqkgQurGsmk1A;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_JxIe_etIgESVo40crkG05w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_UFXC1_PXnEOl3UAe3rfe4Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KD9Fb9Ua2k--d7ATP52t5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_2HFxuVj0TEOlhkZtBvebdg_19_25">51,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rV0kD94PqkaVaUZ1wwT1aA_19_28">51,511</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_b1yO5jQyE0u1XcHo2dnzDQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_vgAee7eWOkaa4ZB8w02AzA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_7aPy-MGM50yJ2UV_65neTQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ao9WX4t1XEmuc3Xz8JS1ow;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YwXIEvLewkaQioMwjwbsbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_vkSNk_C4rkOjkewe1UhcPA_20_13">24,722,974</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YwXIEvLewkaQioMwjwbsbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Z8KlXCx_rUShhSQUQoE33w_20_16">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KBAJsq8X1UePf0wtOE4-gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fZWLFSzlWUyXn2sAKpJ8rw_20_19">215,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ONawfJkraU2j7s81xUzW8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_lwcZFbdUs0GZEwhk4R_0Gg_20_22">466</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wX9u88nSX0ugu2QhP2n3ww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_tqiKHIGzuEiLmyy26Vn6xw_20_25">87,903</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_I5jAuKFxhUiMaUb4NesHuQ_20_28">126,743</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f5b314a4_c592_4e99_a2ac_b7578503c757"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AEROVATE THERAPEUTICS,&#160;INC.</p><a id="CASHFLOWS_844977"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(IN THOUSANDS)</p><a id="_31f85d5e_0e15_4433_ae1a_730793fad939"></a><a id="Tc_OPPDe5YUpUu8qxIG9OoDOQ_1_2"></a><a id="Tc_4jmYCOP5U0OWFBGRTV9Zcw_2_2"></a><a id="Tc_tnQqVPeUQ0mfHKuvM37AHw_2_5"></a><a id="Tc_CnMoFf-iPk6bIRnejlzUXQ_3_0"></a><a id="Tc_ZtujyG6Eek2fu7V_Gd5Nlw_4_0"></a><a id="Tc_KkeIm4FZyUm5aYAeyhfi4g_4_2"></a><a id="Tc_4t4wL-gXf0qJsO-6glszUw_4_5"></a><a id="Tc_bJnFxUdDFkiHiMJ6zWcVPA_5_0"></a><a id="Tc_WjpXMdQgsEKPPTlGySU0gA_6_0"></a><a id="Tc_Or0JpOy_gUO4q9mOXJWmOQ_7_0"></a><a id="Tc_VmW49HAQO0i04fnsg1aG7A_8_0"></a><a id="Tc_nWTfMvV3tkSlfTJE-_Mrkw_9_0"></a><a id="Tc_6wVK82v7Hkeyf3KFHbNpXQ_10_0"></a><a id="Tc_w2mJVBbLg0aEIxBIDQZu-A_11_0"></a><a id="Tc_H2iALfUbY0CyRkiEHJB7jA_12_0"></a><a id="Tc_p3FoGZVu80unLE8xK9o3Ig_13_0"></a><a id="Tc_AYXMbvEhTUS_ZOPyTqU10w_14_0"></a><a id="Tc_89SjI3CBiUCyUS3AlD41Bg_15_0"></a><a id="Tc_UXt_94Drh0GgtONIQ_sbfw_16_0"></a><a id="Tc_xnPdYcyVdUeQZfBy0sCbRg_16_2"></a><a id="Tc_8_sQIKCd2kqPbL9xTL_6jw_16_5"></a><a id="Tc_hlSUqKB2iUy_JsQ6Fg0hoQ_18_0"></a><a id="Tc_D5CRDKzHekaUiJt3pQUe7g_19_0"></a><a id="Tc_KMsdUu6y40OzjX23HQTM9Q_20_0"></a><a id="Tc_EtYybwx7GUycZyakKEJ9xg_20_6"></a><a id="Tc_b4d3cGRpOkCXFpSG9c6anw_21_0"></a><a id="Tc_jamziXmWB0an6Jow_XSvaw_22_0"></a><a id="Tc_7fGPUthgrEuyI0_m3JMx8Q_22_2"></a><a id="Tc_1DHt5uQ2WEiCfDjxzFTmdA_22_5"></a><a id="Tc_6EX7RetKm0uqjSowyN4L0Q_24_0"></a><a id="Tc_uEDdmAtYHE2YzAnsthfJRw_25_0"></a><a id="Tc_I2VqUKgRYUGTXvi_KRK0TQ_25_3"></a><a id="Tc_Rl2W8bRRgkOi447FrvdTRQ_26_0"></a><a id="Tc_zXn3ZQ1iWUezoz1Nn8lTkw_26_6"></a><a id="Tc_HJ17d8V54kOwGdKzaV-oww_27_0"></a><a id="Tc_P4kGbMqNR0C1bQ5vTVjScA_27_6"></a><a id="Tc_hyHPoBm34EevGOwoJtSYjg_28_0"></a><a id="Tc_jY1woSNR0E6YcP6l8T0AJQ_28_6"></a><a id="Tc_jHPhV6eJrkKZQQ-h51910w_29_0"></a><a id="Tc_jLGLzbJUrEW5k-4C1ktPbw_29_3"></a><a id="Tc_5rRWLpUdIEuEICmJHCIM4g_30_0"></a><a id="Tc_sN4u0l7lFUKPhTBI-4Klbw_30_2"></a><a id="Tc_w2z3v79x1UmHBww-N_QApw_30_5"></a><a id="Tc_nsDpdJN_Gk2_pEUpf3dS-w_32_0"></a><a id="Tc_Gg_1jKVFnEyvuqJBSFEAyA_33_0"></a><a id="Tc_wVNF4Au-Gk6dps17WxEvzg_34_0"></a><a id="Tc_kzevGDEQdUmfc0PSj7MXBQ_34_2"></a><a id="Tc_6Uic0uw_fESl7ypoB8vdSA_34_5"></a><a id="Tc_jhP9qx-nuEexGaupvk55OQ_36_0"></a><a id="Tc_xn3KHWL4cUWpZvj8n2p6UA_37_0"></a><a id="Tc_u7OEdL-MhkaNvy3ylfL5_A_37_2"></a><a id="Tc_TG3fdkpwxkegWJbuGh74Ag_37_5"></a><a id="Tc_H1gXrbcEMUePy9DxsguvNQ_38_0"></a><a id="Tc_ovm_yjkjYEOpI5qlhCh6YA_38_2"></a><a id="Tc_T_SGkG-Jp06fkypwddrxyA_38_5"></a><a id="Tc_KxQTyb_ymky-ABjqDLEYkw_38_6"></a><a id="Tc_9JdFo1JeD0mnTVFPfbxxZQ_39_0"></a><a id="Tc_7WsJrfa2sUqJKNd2F7gJUA_39_2"></a><a id="Tc_ktv1ZlZdA0-4VQSTjX6jRw_39_3"></a><a id="Tc_7EibaZv7PU2x-9hFLp1uhg_39_5"></a><a id="Tc_EgPwnhGuVU2df5haPW7qqA_40_0"></a><a id="Tc_VUhC1i6VZUG3r18y7eDvWw_40_2"></a><a id="Tc_5yZ3kSgO6kWq16-GiHd40Q_40_3"></a><a id="Tc_5IJ8QLM-lE-3dH8oCyAqGA_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XDMssgcfrkGM2a0DjHBf7w_4_3">51,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_FuOMvrQLxEKLULzKfeOLMw_4_6">22,963</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_qgK9mOzu_06IGZmIU5kP2Q_6_3">5,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_oPzpNGU6HUKgLxBeN5_FMg_6_6">2,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_vlTnoMypyE648_G5TviXgw_7_3">68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_SsFP2cbYoUixr62JSQWp7w_7_6">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of discounts and amortization of premiums on investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" sign="-" scale="3" id="Tc_LJ4PG__ZpEuxiOvjPnz3Ow_8_3">910</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" scale="3" id="Tc_D9k35xpgvEm2FQWllmzcwQ_8_6">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_4ouDAqC6oU6TlRUD2Ye1Qw_10_3">4,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_yA0GuiUWLk-EUm4nuC4Iuw_10_6">6,855</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other long-term assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="Tc_9KUS41BWC0iaZ0aID4QiMg_11_3">1,872</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="Tc_cQCF6x-_8Umcu5DC7PAclA_11_6">302</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_WQgaYohXB0iSkTYqpAxHdQ_12_3">1,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_t0lZJB7iL02PBdbPKFClfw_12_6">609</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_KP3p31tgdkCPcRYkqHdPeQ_13_3">3,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" sign="-" scale="3" id="Tc_pCm25ZsNNEm6tBjKV-rP8g_13_6">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease assets and liabilities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability" scale="3" id="Tc_u4GVKEwLBUaXVUfa7Pil2Q_14_3">43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability" scale="3" id="Tc_kCbrTiXPsUyjeF8ZfwuYxQ_14_6">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="avte:IncreaseDecreaseInOtherLiabilities" sign="-" scale="3" id="Tc_n4NoGC1wdkuRDQpe_lgPHQ_15_3">133</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="avte:IncreaseDecreaseInOtherLiabilities" scale="3" id="Tc_9qprgrLhp06D7NRWJvpoVw_15_6">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_FVcmCFz_T0OKt6-JGEqCBQ_16_3">39,122</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_59lSWkmbK0OCurgHKW5ihg_16_6">27,399</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="Tc_c0IPjqiMqUioF77A_erp7w_19_3">147,623</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="Tc_ql_1PhYGb0CSNPQs58duCQ_19_6">113,253</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Sales and maturities of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="3" id="Tc_IQbw-T9b20CQZOoXXLYkYw_20_3">154,744</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_ZCOXPUdu4U-_ENEu7Hy7Aw_21_3">195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_5nQaVPdTpUKLwGsKcMNixg_21_6">181</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_8EeQhJSdZ02kCu4u7DXS9g_22_3">6,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_s2F94ZpMJkKwIqA9c8OQmA_22_6">113,434</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from sale of Series A redeemable convertible preferred stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Tc_Twt4gvRCG0ufFOAJyImDZA_25_6">63,512</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments for deferred offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_9wb6DFDvUUKnLQoqVxBmYQ_26_3">371</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="Tc_tETd_oH1d0udP6F1nY7AkA_27_3">150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc__TzXI_5wh0qAlxvYzWSISg_28_3">617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_sDch3dHMLES1r_WR0rPx7w_29_6">126,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_bfivy069Wk6uIL89A6mUUg_30_3">396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_ay96aziW60ydnCQs3x78xQ_30_6">190,457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_WocDWsXpL06TeTOKS_ozHg_32_3">31,800</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_aNtd09qiYUW5cWI_KvSrLw_32_6">49,624</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at the beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_EDzdcNznAkK1QW9607HIFw_33_3">54,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2020_lex_lE13Tka9RtZYzaRxrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_g9jhHjv8skCFgDXZOfzP6A_33_6">4,573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_AEU1hKe3C0Cfo-zwjksxoA_34_3">22,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc__Gt-OFO0ZU-rt-GekjFl8g_34_6">54,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of noncash investing and financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use asset obtained in exchange for operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_ibW4SAjL0kK0OEbob-BiHQ_37_3">765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_qOehJyjJxE-PDafVxojRkw_37_6">542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred offering costs included in accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="avte:DeferredOfferingCostsIncludedInAccountsPayable" scale="3" id="Tc_c_0aJdAkwEqw4ZuAuRGOug_38_3">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of property and equipment in accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_5ot6m5Rmik--mr5LDUPMzA_39_6">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="Tc_1R0s5dk9VUaP9DrllgegkA_40_6">79,818</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AEROVATE THERAPEUTICS,&#160;INC.</p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p><a id="_Hlk129215296"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_wbiBJY_VfkOIejeqWUaLGA" continuedAt="Tb_wbiBJY_VfkOIejeqWUaLGA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Organization and Nature of Operations</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Aerovate Therapeutics&#160;Inc. (&#8220;Aerovate&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in July&#160;2018, and is headquartered in Waltham, Massachusetts. The Company has a wholly owned subsidiary, Aerovate Securities Corporation. The Company is a clinical-stage biopharmaceutical company that is focused on the development of drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. The Company&#8217;s initial focus is on advancing AV-101, the Company&#8217;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;). The Company initiated a global Phase 2b/Phase 3 trial of AV-101 in adults with PAH in December&#160;2021.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Initial Public Offering</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">On July&#160;2, 2021, the Company completed its initial public offering (&#8220;IPO&#8221;). The Company&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-256949) relating to the IPO was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on June&#160;29, 2021. The shares began trading on The Nasdaq Global Market on June&#160;30, 2021. The Company issued <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_f35-tn37YkSEpT0jtT5KhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_B4XvHSu4t0SzB69rDZ3sbQ">9,984,463</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_45gK5TQqjU22PAv52bixOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_0yMrmHeeh02GaSuu4OI6zQ">1,302,321</ix:nonFraction> shares associated with the full exercise of the underwriters&#8217; option to purchase additional shares, at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_GUwnxPWZUk-8QC102OTn9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_iOL-_7gQ90uwADLbQPAd2g">14.00</ix:nonFraction> per share. Immediately prior to the closing of the Company&#8217;s IPO on July&#160;2, 2021, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock were converted into <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_f35-tn37YkSEpT0jtT5KhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_yX6RLZhAPE2UFgmr4XFEOg">14,182,854</ix:nonFraction> shares of the Company&#8217;s common stock. In aggregate, the shares issued in the IPO generated approximately $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_f35-tn37YkSEpT0jtT5KhQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_58oNNM_k40S1tyHXNPpbOQ">126.9</ix:nonFraction> million in net proceeds after deducting underwriting discounts and commissions and other offering costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"><span style="font-style:italic;font-weight:bold;">At-the-Market Offering </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"><span style="font-size:10pt;">On August 15, 2022, we entered into an </span><span style="font-size:10pt;">Open Market Sale Agreement</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-size:10pt;">, or</span><span style="font-size:10pt;"> the Sale Agreement, with Jefferies LLC, or the Agent, pursuant to which we can sell, from time to time, at our option, up to an aggregate of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_8_15_2022_To_8_15_2022_srt_CounterpartyNameAxis_avte_JefferiesMember_FWTe7abbGk2o3kC0iODEaQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_yq5dI0NH_kieEf_pfaA_0Q">75.0</ix:nonFraction></span><span style="font-size:10pt;"> million of shares of our common stock, through the Agent, as our sales agent. As of December 31, 2022, </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_avte_JefferiesMember_XuFYdSUixkyetwSnndM8uw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_SuQTLTm_80ylWPd-d77hnQ">no</ix:nonFraction></span><span style="font-size:10pt;"> shares were sold under the Sale Agreement.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Liquidity and Management Plans</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Since inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations and has not realized revenues from its planned principal operations. The Company has incurred losses and negative cash flows from operations since inception. In addition, the Company expects to incur substantial operating losses for the next several&#160;years as it continues its research and development activities. As of December&#160;31, 2022, the Company had cash and cash equivalents and short-term investments of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_RBKHVXAyKEqXFKp1NuKomA">129.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through debt or equity financings or other arrangements to fund operations. Management believes that the Company&#8217;s current cash and cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve&#160;months from the filing date of this report.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_wbiBJY_VfkOIejeqWUaLGA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_OGZpl4gwkkOlyoNan_ustg" continuedAt="Tb_OGZpl4gwkkOlyoNan_ustg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_VuCsMdt5PE6igXO4YLSQEA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the Company&#8217;s wholly owned subsidiary, Aerovate Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="avte:ReverseStockSplitPolicyTextBlock" id="Tb_BWq9MrAaC0qyl12MJOnM6A" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Reverse Stock Split</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">On June&#160;22, 2021, the Company effected a <span style="-sec-ix-hidden:Hidden_AH0m-scr1ESIQqpsOnDeyg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-3</span></span>.1060103 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of its issued and outstanding common stock. Accordingly, the conversion ratio for the Company&#8217;s outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. The par value of the common stock was not adjusted as a result of the Reverse Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:UseOfEstimates" id="Tb_ixM6fPljRk6Zhjo_qTYDZA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_4tA4norhmUKl0OvAX_T3kg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Cash and Cash Equivalents</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Cash and cash equivalents include cash in readily available checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three&#160;months or less from the date of purchase to be cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="avte:ShortTermInvestmentPolicyTextBlock" id="Tb_8crYH2Zq60atYHk6hHUKaA" continuedAt="Tb_8crYH2Zq60atYHk6hHUKaA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(e)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Short-term Investments</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;">Short-term investments consist of corporate debt securities, commercial paper and U.S. Treasury bills, classified as available-for-sale securities and have maturities of greater than three&#160;months. The Company has classified all of its available-for-sale investment securities as current assets on the consolidated balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company carries these securities at fair value and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the consolidated statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OGZpl4gwkkOlyoNan_ustg_cont1" continuedAt="Tb_OGZpl4gwkkOlyoNan_ustg_cont2"><ix:continuation id="Tb_8crYH2Zq60atYHk6hHUKaA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">using the specific identification method and recorded in other income (expense), net in the consolidated statement of operations and comprehensive loss.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_Yig97Oxa1k2g5pMIXeiuRg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(f)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Concentration of Credit Risk</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_8N3gxwRXq0-pOdIWfI39QA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(g)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Comprehensive Loss</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_UYqW3FA00UuTJOf94VClew" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(h)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Fair Value Measurements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Level 1: Observable inputs such as quoted prices in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="avte:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" id="Tb_zZD2SFPZBUeH7_LchiItag" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(i)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Prepaid Expenses and Other Current Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Any expenses paid prior to the related services rendered are recorded as prepaid expenses. Such prepaid expenses are expensed in the period the expense is incurred. If the expense is for a service covering multiple periods, it is expensed from the date the services begin and over the period of the service rendered (or contract service period if services rendered dates are not defined).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_68bQ0dJ72U2YPiZHDWSC7w" continuedAt="Tb_68bQ0dJ72U2YPiZHDWSC7w_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(j)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Property and Equipment, Net</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and construction-in-progress are stated at cost less accumulated depreciation or accumulated amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from <span style="-sec-ix-hidden:Hidden_bBazvaq5mUO3D78wc3eoZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <span style="-sec-ix-hidden:Hidden_Ha-ILLgVZUue-n7HxT3H2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;years</span></span>. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OGZpl4gwkkOlyoNan_ustg_cont2" continuedAt="Tb_OGZpl4gwkkOlyoNan_ustg_cont3"><ix:continuation id="Tb_68bQ0dJ72U2YPiZHDWSC7w_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_UC0guKgHWEy8BIoHOFc8Ug" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(k)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Impairment of Long-lived Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December&#160;31, 2022, there has been <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="Narr_dHlaxzn7pESUrLf1E3lbaA">no</ix:nonFraction> such impairment losses recorded by the Company.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_tdfsWcmVnU244eR6nTbQUg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(l)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Leases</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets (&#8220;ROU assets&#8221;) which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to separate lease and non-lease components and not recognize lease liabilities and ROU assets for short-term leases with terms of twelve&#160;months or less.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="avte:ConvertiblePreferredStockPolicyTextBlock" id="Tb_uQoalqdxqkeI0W0AWkAWiQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(m)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Convertible Preferred Stock</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company records convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#8217;s control, including a deemed liquidation event, holders of the convertible preferred stock can cause redemption for cash. Therefore, convertible preferred stock is classified outside of stockholders&#8217; deficit on the balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_SSpFQzMW4kyChQefpOOLJA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(n)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Research and Development Expenses</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_hJ3uD38dRkGnm0U89176Pg" continuedAt="Tb_hJ3uD38dRkGnm0U89176Pg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(o)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock-Based Compensation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;">Stock-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option grants and restricted stock units, estimated in accordance with the applicable </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OGZpl4gwkkOlyoNan_ustg_cont3" continuedAt="Tb_OGZpl4gwkkOlyoNan_ustg_cont4"><ix:continuation id="Tb_hJ3uD38dRkGnm0U89176Pg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">accounting guidance, recognized using the straight-line method over the vesting period for service-based options and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">The fair value of stock options is estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, expected dividend yield, and a risk-free interest rate. Options and awards granted during the&#160;year have a maximum contractual term of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_L6Aulrv6skCjIRhGAQFN1w" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_QpXkLOqLsUSOk3cq4YaIsg">ten&#160;years</ix:nonNumeric>. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected volatility of stock options is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury (&#8220;U.S. Treasury&#8221;) yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_9A8pPY0sZkKAAfp8PB2l_A" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">(p)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">Income Taxes</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss (&#8220;NOL&#8221;) and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company records uncertain tax positions on the basis of a two-step process whereby (1)&#160;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_6SG937B5Vki5UoHZXIUn_g" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">(q)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">Segment Reporting</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as <ix:nonFraction unitRef="Unit_Standard_segment_4id_vXrVjkay3ChrkF2qUA" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_zqquROffpEiU4uEjT94qgg">one</ix:nonFraction> operating segment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_vLrC1klqqkeiGfJ4Ok21-g" continuedAt="Tb_vLrC1klqqkeiGfJ4Ok21-g_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">(r)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities, which include convertible preferred stock prior to the conversion of such shares to common stock and outstanding stock options under the Company&#8217;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_52c8d707_1030_4d90_81cb_8ca7d4581404"></a><a id="_35379541_9ada_4baf_afb8_2a655507e385"></a><a id="Tc_8cc6-H1Pxk-SWxafYDPmKA_1_2"></a><a id="Tc_R11GLTO5O0qePswr1f4hsA_2_2"></a><a id="Tc_jM6fqqn4_U2wOn-HnsXD_Q_2_5"></a><a id="Tc_5lEbKnhKhEGahQsglJK0Mw_3_0"></a><a id="Tc_MsBH9afyf0qf99i6Pu4M_A_4_0"></a><a id="Tc_vFYjmqjxck-238ay0PLMdA_4_2"></a><a id="Tc_8ntvNLCW0UWA8pwyHQRlXQ_4_5"></a><a id="Tc_iLXHujACTkWgn0kz1iFpZw_5_0"></a><a id="Tc_igu_RVQZgkCONeZt1EQY7Q_5_3"></a><a id="Tc_W0KPHNIVkEWq6y8wh-toqQ_6_0"></a><a id="Tc_j_0eDiV1vkWaD4Z4cju_3A_6_2"></a><a id="Tc_Pp7-DwFBhEGPTZ1zkYd_HQ_6_5"></a><a id="Tc_ZIy9beJbZEyKo-nrAf9Wxg_8_0"></a><a id="Tc_ctlzTmCK50GcR9uyfr7ozA_9_0"></a><a id="Tc_9KboUgVfIkaK8daOgARokg_10_0"></a><a id="Tc_5lDhJwXRikKmztYQM1leLA_10_2"></a><a id="Tc_EYv7C47ypU-SxD_dh8L7-A_10_5"></a><a id="_48dfdb1b_9ef8_4ba8_b4fa_a34e5b5e95f9"></a><a id="Tc_EiJ-ttDtB0W7lLITK6z9Xw_1_2"></a><a id="Tc_-bCymsVDVUm2sELKh9OaxQ_2_2"></a><a id="Tc_ozZA3VXxkUWrsiD2813Pcw_2_4"></a><a id="Tc_gas8voOu2UaU5aPZ6et7MA_3_0"></a><a id="Tc_Ph6c2wwxtUKtdZspbayyGg_4_0"></a><a id="Tc_8G1YKbkj1UCaJeU4TIYsYA_4_4"></a><ix:continuation id="Tb_OGZpl4gwkkOlyoNan_ustg_cont4"><ix:continuation id="Tb_vLrC1klqqkeiGfJ4Ok21-g_cont1"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_JYNSM2sqv0-5gb3WLyBbgA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;">The following table summarizes the Company&#8217;s net loss per share:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_s3NXbCEMeEKfOdTYiT9KSg_4_3">51,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_lmuhCG_pkU-V-weAh1ExHg_4_6">22,963</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of Series A redeemable convertible preferred stock to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_qthA2_MWG0-O-o6csyodmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="3" id="Tc_WESrCxMEr0yjUVURVCcJOw_5_6">22</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_q-V-3FlhFkSgR6uUxsl2zw_6_3">51,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_PhkL6HYgZEWCoCvU-7VE2A_6_6">22,985</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_6Re2y1MiAU-N3uQjyLn97w_9_3"><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_6Re2y1MiAU-N3uQjyLn97w_9_3_2">24,472,104</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_KTNpkwlx1UaADcensl1RtA_9_6"><ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_KTNpkwlx1UaADcensl1RtA_9_6_2">12,293,629</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_wfT3I8Fpck2BJWjZArHi5g_10_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_wfT3I8Fpck2BJWjZArHi5g_10_3_2">2.10</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_en7aWYAIQki8saHDe8rAhQ_10_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_en7aWYAIQki8saHDe8rAhQ_10_6_2">1.87</ix:nonFraction></ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_wof_PKN-ZEyZC46_H7EYBg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2u36RAc4eEiBYcmpsvX8AA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_-C_40fK05kKV5MweZSwMmQ_3_2">4,110,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_rJ1OBbHLXUyHKgkaKxW57Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_I4ocL8XFekK0TRisz-alSQ_3_4">3,454,374</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_o4StUCQIc0a31cjpbHrNkg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ZCJBpVCU_0COyIvwqDpftQ_4_2">28,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_FJlWEHxa8k-CAW_Ot0UnkQ_5_2">4,139,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_L-nW507IGESA2cP9Ow0Kzg_5_4">3,454,374</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33.1pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_0dLiFzCxKE2HjXWwp4WWJA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(p)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Recently Issued Accounting Pronouncements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard will be effective for the Company on January 1, 2024, and is not expected to have an impact on the Company&#8217;s financial position or results of operations upon adoption.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2b58cb24_8f33_4c77_863e_6aca81a88fa7"></a><a id="Tc_sU3gZ1CTZkKVAZOnj-bbIA_1_5"></a><a id="Tc_79fh1sKw40Sgm00VD_zrzw_2_5"></a><a id="Tc_SxTrGuZ8_UuTlPyT8ETrWg_3_5"></a><a id="Tc_qs0bfdAavUGpmMgyKNSRzA_3_8"></a><a id="Tc_fzM0up1MUUyplcSE_eFaKw_3_11"></a><a id="Tc_w3UXZRCyS0Cx4y2uuouCMw_4_5"></a><a id="Tc_QUpF7fjem0GGE5tPB8i5CQ_4_8"></a><a id="Tc_S-wQA-R0pUa3i3ZtjWp0vg_4_11"></a><a id="Tc_MicWy8-cSEiVHTSuAnVgkg_5_2"></a><a id="Tc_umVJrvybS06hI0JrLTZXdA_5_5"></a><a id="Tc_IDGq5IeUf0GCWRHUeABjiQ_5_8"></a><a id="Tc_bcYxcKrO9kyS6ylQwXBbsg_5_11"></a><a id="Tc_8tdd3U0Z80qTxRXkfbkJoQ_6_2"></a><a id="Tc_iMWriZfjoUeTHt6ZYFEpFg_6_5"></a><a id="Tc_42mZPQDOck6uxaHwVs_O7g_6_8"></a><a id="Tc_ajDRBvgDBkqD-ZQPlyU9IQ_6_11"></a><a id="Tc_Gk2dvzIBP0u2LZUiZSu5cg_7_0"></a><a id="Tc_ZooR8V-qUEOKrdkI15olAQ_8_0"></a><a id="Tc_t4GPm9jglkCA2-JW1ehisw_9_0"></a><a id="Tc_t4z3LSl6RkmAdhX8TnWLWQ_9_2"></a><a id="Tc_WmDAhwlOrE6k3cmjYaXHlw_9_5"></a><a id="Tc_89iC-pqS8EugWuHAAqFaiA_9_8"></a><a id="Tc_vswBTK3o5E6RAFQipDDw0A_9_9"></a><a id="Tc_qYGeg928eUiMVzC6Ywvi4Q_9_11"></a><a id="Tc_afLX0YvNQ0agTIiQIxwotA_9_12"></a><a id="Tc_TqMCONkuFkKBfiUv79DiFQ_10_0"></a><a id="Tc_SXOBtvZkX0uX7zXJDLgJaQ_10_9"></a><a id="Tc_cnYAbukE_UaMhVAEOkGTfQ_10_12"></a><a id="Tc_xT7Nw50280axlWpc7kNi8A_12_0"></a><a id="Tc_wM_0QQrQ3UmJ1SNvNh3VHw_13_0"></a><a id="Tc_oOBxodDP10umlzpMDirZdg_13_6"></a><a id="Tc_9orcTrMzN02MTbi-u5XD7w_13_12"></a><a id="Tc_vlxkMiuW1kuniJOdzanzyg_14_0"></a><a id="Tc_1ihSUp7ro0GLtk41W3rZ-g_14_9"></a><a id="Tc_TWLwgg5TgECPmkgDpfXmfA_14_12"></a><a id="Tc__ZQRPTmcX0CDk7Sjs-SWWw_15_0"></a><a id="Tc_AxRTGxKMBk66knH15jWaXA_15_6"></a><a id="Tc_78F7DhINK0mYOJKLeBUMAw_15_12"></a><a id="Tc_6xkVxSQCW0Sbt417h_ng8g_16_0"></a><a id="Tc_6BMRv1_MDEikk2BwUGs6Fg_16_12"></a><a id="Tc_ODZW4xT1WECTEc6-IZJoOA_18_0"></a><a id="Tc_f5LCj-GZ3E2AQPqhGwpEHg_18_2"></a><a id="Tc_oAVDPQWZkEOfgo4vWsYYng_18_5"></a><a id="Tc_t2Z-qp5sB0asiPz5Xmzutg_18_8"></a><a id="Tc_5EHg-wiq8Eev0mOYy9OfJA_18_11"></a><a id="Tc_VzLA95NQek6UGVPB6Pm3qw_18_12"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_39-M3jGLWUWUnU5xreYtvg" continuedAt="Tb_39-M3jGLWUWUnU5xreYtvg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">(3)&#160;FAIR VALUE OF FINANCIAL INSTRUMENTS</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_aAqCtuZOTUaBTLQCwWuL8Q" continuedAt="Tb_aAqCtuZOTUaBTLQCwWuL8Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__I6MyJ-3P0WLSD1L0CQLMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_TJyPB8IFYk2h0LGcdh63gQ_9_3">18,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BZC2smINzEqMpJkFZy61dA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_pc_hpmf0XkubShY_YUFKLA_9_6">18,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CkuAokZFEE6-3rAKVgGLlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_1KC6mySGWUS6sZ8lCAQpuA_10_3">18,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ydsgvjwLrUe_yWrw82jE-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_wsGOo6UTOkChc-haWx4y3w_10_6">18,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_USRDgmPtwkOyBzlosVP3AQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_7-phMTskKEi9G4dB3l7MfQ_13_3">55,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VJ2CIL3_20mu--166dWxVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_u48Q47sL4Eu9IP68tueJzA_13_9">55,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_zqKb8DAZgESt_eax0wleGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_0pDbo9EeCEe5RB9XH3SN2w_14_3">26,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_zemR5DkqREKFgJjFkN8qqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_bxducuXdiEq7y_JSfb7zFw_14_6">26,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_aQq0ijr06kSW_SZprlK7sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_MxaUQaa9V0CG6H9ml8pyqg_15_3">24,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_rPrkP4ujk0W_7H8LCrqXLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_rUyTQ0pXbEifm867jcq5aw_15_9">24,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CkuAokZFEE6-3rAKVgGLlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_feQ1ov9kkEKIq-HNJ6taTA_16_3">106,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ydsgvjwLrUe_yWrw82jE-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_8rkGlTruoEGags2fvWZVlQ_16_6">26,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6Vn0yOonI0i5051pthm-IQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_qc_yjBk3I0mRgal0cjFt5A_16_9">79,982</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CkuAokZFEE6-3rAKVgGLlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_OQ75s_2mCUmt7GVAtUuQPg_18_3">125,259</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ydsgvjwLrUe_yWrw82jE-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_-HWzGNrNqk2eatujt028iw_18_6">45,277</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6Vn0yOonI0i5051pthm-IQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_jJgRdjTlpkmnyitewxDSLg_18_9">79,982</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3803d005_f48f_41e6_9a8e_5938637562e8"></a><a id="Tc_4ZDT3jfIXk-qmcu4irH0LA_1_5"></a><a id="Tc_b6WIHXBEYE-i662sgL4juA_2_5"></a><a id="Tc_JgpwRezb10eYzRLxqCOBtg_3_5"></a><a id="Tc_AF9fASXJ50iotq86oM_8qQ_3_8"></a><a id="Tc_SLEKKtJGE0SoGDqk8d6CgA_3_11"></a><a id="Tc_S5Rd7rS3JkyG6rCDDsQF2A_4_5"></a><a id="Tc_tvcmKTFM30m1ySau4UFOzA_4_8"></a><a id="Tc_46l3FZzX_0GRos98hm5lKA_4_11"></a><a id="Tc_WV2fSHruOEubzErLi8Ja4Q_5_2"></a><a id="Tc_aEtjH3QQL06h4u9AuRZp9g_5_5"></a><a id="Tc_G0SmWHmvsku9YzvuaFI56g_5_8"></a><a id="Tc_lxtfRLrKDESZH2jfxZ1aNQ_5_11"></a><a id="Tc_BHizNc8f2EWuQ2hD3bKOSw_6_2"></a><a id="Tc_1mbOYZ5lrECBlR0TJBilTQ_6_5"></a><a id="Tc_hP7_uViBEEiG0NuHAcBMDQ_6_8"></a><a id="Tc_49JxCROnQU2hThI4EWgEYw_6_11"></a><a id="Tc_9uhlO2mJ9EqAMoGllPIzUQ_7_0"></a><a id="Tc_TzM5FGS6Qkit_34ovT8-9g_8_0"></a><a id="Tc_GFQhsGuI4kOMTcj4nqzK-g_9_0"></a><a id="Tc_cH4yL5eup0iYqajKde0Awg_9_2"></a><a id="Tc_DggymIeyQUqrbcJnUY8UeQ_9_5"></a><a id="Tc_5LnfK-1cQUOj7BxClGHZRw_9_8"></a><a id="Tc_PLeZ2O06g0-l5hzi5isZ7Q_9_9"></a><a id="Tc_fDbMFIKbG0-AeVwh7j4zdw_9_11"></a><a id="Tc_ghjr2FG2cEysCKuF3xjy3A_9_12"></a><a id="Tc_i70y886RA0OU3rlkrWlJIg_10_0"></a><a id="Tc_bolRCFeLp0qXCxv_j-mPhw_10_6"></a><a id="Tc_90gojd1RpEqyk5b-dn0itw_10_12"></a><a id="Tc_HKnmZHkGD0CAV9OI3Rlqwg_11_0"></a><a id="Tc_lTKY0Sn1vU-ppLWQ9AxvcQ_11_12"></a><a id="Tc_PJwbnsVbV0eeOi31oQW6OQ_13_0"></a><a id="Tc_0rpYYr76tU25OC5lHR5Upw_14_0"></a><a id="Tc_zxPvxMm3ckuWXIsoRqSzrQ_14_9"></a><a id="Tc_Atbnww-5BEmqyeA9raCxdA_14_12"></a><a id="Tc_O56FGkpIsUy8PImhbq7hfg_15_0"></a><a id="Tc_eFFvHNqipEakUo8uWPqJjQ_15_6"></a><a id="Tc_7bQhcaaPCkOQa0Yqnnt01g_15_12"></a><a id="Tc_SWUSTReifEStCi77cz6CrQ_16_0"></a><a id="Tc_-J6AdqliKkekxE5neIiU7g_16_6"></a><a id="Tc_kGyDe_txNEeC2jQSee2caA_16_12"></a><a id="Tc_IsR5ytCVREaYBdWrlWXMhA_17_0"></a><a id="Tc_LdBkXYsi7U21SML-gfKeZA_17_12"></a><a id="Tc_65gsLk26c0m9cpl10Mum8w_19_0"></a><a id="Tc_VHYmDHedf0KI1Q_bnG9-FQ_19_2"></a><a id="Tc_i123WaNKpUSGpHrv8Rj5pw_19_5"></a><a id="Tc__ASqTfpUpky-QOe6aTJLZg_19_8"></a><a id="Tc_xYr-WtutQUy1YI6JdRsM0g_19_11"></a><a id="Tc_OB5lKumzskaGTI1r6zDJ2w_19_12"></a><a id="_80dc96d6_438b_4c4f_b10e_eb03ab42ee7b"></a><a id="Tc_7HAqKk9AUE-fjFFNd1XllQ_1_4"></a><a id="Tc_NOq-4D5zxEuXDBei2x_wcA_2_7"></a><a id="Tc_aPu_P-Xs4E-jt0BivAotMQ_2_10"></a><a id="Tc_Iakgkh_jZkCBaiIiarFeBA_3_4"></a><a id="Tc_BY7NqzYsn0SSvBmpZEaBJg_3_7"></a><a id="Tc_ekXf5PsCy0e64j3hplzfPA_3_10"></a><a id="Tc_TPisR95XsEqRQSKT5m-ewQ_3_13"></a><a id="Tc_bmUo8JTVxEOPlYPZcEk1-Q_4_2"></a><a id="Tc_Z5dazY6bmkq0atXiNVaDCA_4_4"></a><a id="Tc_kKiRw_ZaAUS5q-g-KpbGAA_4_7"></a><a id="Tc_8oOnazvLlEu4vp-_gMdTPA_4_10"></a><a id="Tc_X6CELIlYwEyEQSehKHzJtg_4_13"></a><a id="Tc__r6H1q7zw0GDN0oOcXBB3g_5_0"></a><a id="Tc_2YIF9zuogUCZN17a_FxE1Q_5_2"></a><a id="Tc__FqMJ15Di0a7xTZQi1t2GA_6_0"></a><a id="Tc_UHitvQypxkq4zSCz1PI__A_6_2"></a><a id="Tc_V1OnU_-2qkuWUuwsOilXxg_7_0"></a><a id="Tc_G9cNufLEZkK5BGOcMSgU8g_7_2"></a><a id="Tc_BukKHY1bfU2p_d8coUJLkg_8_4"></a><a id="Tc_ItwGjeF28UmfB1tqVZ9fmQ_8_7"></a><a id="Tc_utE5u17eO0WhFpbwsPVVKQ_8_10"></a><a id="Tc_XAYp4tju0U-VzBKEv2MXPw_8_13"></a><a id="_142b5cf7_8e5b_404b_b984_f575aebc3726"></a><a id="Tc_JGcuCL4hA0mbJWK22IuF7A_1_4"></a><a id="Tc_YfaN_lKBxEy9m_jcDXeyYQ_2_7"></a><a id="Tc__9zley-gVEm5MLpbuUJ_6g_2_10"></a><a id="Tc_Z_w1XZtZREWqWaOZOHra0A_3_4"></a><a id="Tc_HiZ0zLLRj0uIfxUZ-7kJWA_3_7"></a><a id="Tc_KEawENuCaUSob1lXRF-tgw_3_10"></a><a id="Tc_zke5tAdQHEK9MhBaOQNg4Q_3_13"></a><a id="Tc_xAQYa4koSkS1VCCasHG3rg_4_2"></a><a id="Tc_LmeVTrgqwE-Bd0aSIYRu6g_4_4"></a><a id="Tc_G1iX-rSWZ0qz83icpK-Mjw_4_7"></a><a id="Tc_og3bVHLL2kmk8m4A8rISqQ_4_10"></a><a id="Tc_6RMOfSnTb0CB4LgVpRfMyw_4_13"></a><a id="Tc_HQEX_6xtwEG6C2xI2JlR1w_5_0"></a><a id="Tc_WQHkUME_Dk-kt2-3iqx9qw_5_2"></a><a id="Tc_4afYTIelVkW4CG_qgAGgqA_5_4"></a><a id="Tc_vk3TA26BkkqfVpOd4lriAg_5_7"></a><a id="Tc_kuC7oz8IDUi2MvdeZqmu6g_5_8"></a><a id="Tc_opSzK_mvN0GstB1cZrf0Gg_5_10"></a><a id="Tc_R0vQtHVHw0Gby6w5Dz8O4A_5_13"></a><a id="Tc_MhLcg4USo0Wyk1_s08KE8w_6_0"></a><a id="Tc_rYKByNsTMU2VDis2BjlI4A_6_2"></a><a id="Tc_aAJK2tXKt0Cso6n_uSZmMA_7_0"></a><a id="Tc_yfa3w4Pa_0Sxd4BDj_EvTg_7_2"></a><a id="Tc_YK4KZkNgH0y9uhDEfSWEvw_7_8"></a><a id="Tc_-pOnlEYrK0ChEe9r9oiMGg_8_4"></a><a id="Tc_UbuLAoprl02vHDSebYAjMQ_8_7"></a><a id="Tc_fIGWk8pN1E2CDRV80NmMyQ_8_10"></a><a id="Tc_674azj1YXkOeMTYGk4rvMA_8_13"></a><ix:continuation id="Tb_39-M3jGLWUWUnU5xreYtvg_cont1" continuedAt="Tb_39-M3jGLWUWUnU5xreYtvg_cont2"><ix:continuation id="Tb_aAqCtuZOTUaBTLQCwWuL8Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1EYoksMxjEatDkF4HraTtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_dIFQbTEhAU-tpJAiGoDaQQ_9_3">39,653</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_btTJ7hB3m0msnUE_XEjudA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_7lQJa94slk-QNQW3j_bz7Q_9_6">39,653</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_X-cBBwKLukqd96ZZFzoANQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_GICQ4trp302cz5f0WbG7Xw_10_3">14,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XKXReW8Iv0iqNoVsfOn3wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_NQguJQM4LUylZg62AHl72Q_10_9">14,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_h7PXcaYot0um0bjFUh0YmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_FS1WjlQ2OkevDqWQUUEVsA_11_3">54,101</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fkQ2x2flakWcJsOn3HTX-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_uPARljEulE2JFBNPPcJsHg_11_6">39,653</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tuJ-pg1BnECbTpf6Uk40Bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_XzhsHS3NGUePoNPzUjR-sg_11_9">14,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_RR9WWKOeMEOQdAup8Pv4AA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_U-TytD5Mc0e8hlsT3YSGAQ_14_3">25,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8VmyKaoxLEOzzbfyzwCJ2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_UV5Lf5UYbEuEpn94oOkVcQ_14_6">25,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_y6dmyknKUU-SGERHF0Dc_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_6uoFrjiAc0GiyEvphSVjLw_15_3">10,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_tGjRsdl680qEsQ3mUldJJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_9dpjWf3d_kuzvw1hpbBuJw_15_9">10,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_X-cBBwKLukqd96ZZFzoANQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_BIjYibUTwUCSbtN_aOL3cQ_16_3">77,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XKXReW8Iv0iqNoVsfOn3wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_aqxw7-ClQkuIC1A9_XE1xA_16_9">77,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_h7PXcaYot0um0bjFUh0YmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_jY3RpkHHeEOjHM5jImpgrw_17_3">113,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fkQ2x2flakWcJsOn3HTX-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_Pcl1Lh-vPkSeRyfKtAJkxA_17_6">25,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tuJ-pg1BnECbTpf6Uk40Bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_3ZqdXuaopU-NB3Z_nZfQ4Q_17_9">88,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_h7PXcaYot0um0bjFUh0YmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_0JMD-pFQ6UOvFZTYNVU29Q_19_3">167,279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fkQ2x2flakWcJsOn3HTX-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_LRKgdGCy50CyrJyII_pf-A_19_6">64,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tuJ-pg1BnECbTpf6Uk40Bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_-ce0_HQpIEyMMMnlnGgwWg_19_9">102,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 33pt;">Cash Equivalents and Short-Term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Financial assets measured at fair value on a recurring basis consist of the Company&#8217;s cash equivalents and short-term investments. Cash equivalents consisted of cash, money market funds and commercial paper, and short-term investments consisted of U.S. Treasury bills, agency bonds, corporate debt securities and commercial paper. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="Tb_-BMOIaXxm0qqmhA6tg0NVQ" continuedAt="Tb_-BMOIaXxm0qqmhA6tg0NVQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:36.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xiCQZvKWqESmhAB-Ehu1tg" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_6G0dg6TpAkimUZ6qzVbGnA">1&#160;year</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_JKsxK7pW_Eq8ZnF4oNKiWg_5_5">55,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_ltXTQ_tTSkmt0uFZqLpkOQ_5_8">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_10NcrVwO2Ui8ardk4D_UNA_5_11">84</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_lJiznXRccEiRP_RwE2xwGw_5_14">55,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_PvqmJS3bP0uIcfv-_n2kqg" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_lrVUMVBPW0aO5odqIDT2nw">2&#160;years</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_nn22DjA1U0u9nR850fLlWg_6_5">27,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_P4znHQF3GUSWjTutnltemQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_kjUogDnZwUeLi5hasW2msw_6_11">267</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_ln1Udo6HckqxuQgY1y3A3A_6_14">26,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:36.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7ZoMrQXRJk2hJ6cbQPFKvQ" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_fKErKTfLTUu8071JUTzE8A">2&#160;years</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_NXTnp3AaZ0mq71EW-m3UVQ_7_5">24,536</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_SddZsyORh06nlYc0js2CuQ_7_8">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_ej9epzaNuUiDkBnEs7VQdQ_7_11">133</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_tBm6ksEo5UStbaq9t201qw_7_14">24,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_jWtpH0CJDkyY-j8rzSBehw_8_5">107,289</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_lxI5XrSt_0C0tDJ6b5I0WQ_8_8">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_-Oei1cmotkuNy3LpMXcOgg_8_11">484</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_czWur5KjfUOI3uBE_qj7Gw_8_14">106,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_j8WxaSALUESwMgXMefh0UQ" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_IowvwOG6fU65Jeg7_oqMOQ">1&#160;year</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_wU7MM6fx1k6kRWXTgrWRYg_5_5">10,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_4zmgcDZlQk6o4nx4rgTn7A_5_11">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_FaQty5sF0kWDvUoWhFwC_w_5_14">10,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_mt2q9GoKi0-AvNO-EXkZnw" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_EoyjfYxWZ0aqO9YxOFEjNA">1&#160;year</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_w0Ss-t_Va0WMkXXitlcukA_6_5">77,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_K8MzSbhAdE2FVDfd2zTOhA_6_8">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_CIQBoEs5xUmcNbFwvRtO3Q_6_11">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_XaDOvs_0PU-byA8Z-wS62w_6_14">77,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_7nzerVxUhkyRb7q9DTrxjA" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_x-n9lXX2rEC8lYKKqAf_1w">2&#160;years</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_fbouYxiNUk-LuMHAd5Ss0w_7_5">25,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_x3mFjHO3VUO4NhKB8PSX5g_7_11">48</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_GGv8bGda1EyWnHKoKi15Rw_7_14">25,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_hdiKwDnru0aVmtgAOUGzqQ_8_5">113,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_R8e2-rWLj0mQvDBQCCs9PA_8_8">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_E0agcq1oBUK63DDNppdhVA_8_11">68</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_PRTSf6647EeYcChZJuvv8w_8_14">113,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_104f8999_db84_4f52_a270_4ada19573448"></a><a id="Tc_I9pb_-cn00K-zTDy5u6pEQ_1_2"></a><a id="Tc_XAzGl--XNE6-RB_Yr7tqsw_2_2"></a><a id="Tc_3R8p5c0I2ECtzmGp37UUhw_2_7"></a><a id="Tc_g5m3KTyx8UiCwrOpXurQGQ_3_4"></a><a id="Tc_kDgovjtfh0m_sXcotCjuOQ_3_10"></a><a id="Tc_HFfVvopqxUS2ZO9bc2jEsA_3_13"></a><a id="Tc_E9lE_fxkSEC6zlf_XVzScA_3_16"></a><a id="Tc_dD6Msiez40Kcj6yXtRBfDg_4_2"></a><a id="Tc_n-Wc6Q8jCkyyE20-49QGtA_4_4"></a><a id="Tc_hOxyzoMEUEa_uXSWOHMuGw_4_7"></a><a id="Tc_nxAxFo_cVE-aql6nEG3jvg_4_10"></a><a id="Tc_a9KyY13pG02BKjEVU6vTew_4_13"></a><a id="Tc_PpoEfIxEHEep5skVo9UV3g_4_16"></a><a id="Tc_7DSDGBxB5EOzVgWQ5IaTFA_5_0"></a><a id="Tc_VJtIESYyyE6w7aRmtM-Z1Q_5_1"></a><a id="Tc_rTBjHTXXK0qfOBmejNN07w_5_4"></a><a id="Tc_La5YmpvjFUyOPGSnFf_EQQ_5_7"></a><a id="Tc_v9s8zUUtUUylrFc_A_KtHw_5_8"></a><a id="Tc_NzEUYYEoRE6W4TcpaBc8kg_5_10"></a><a id="Tc_eM-pH9-6Dk6scC9arHG2Qg_5_11"></a><a id="Tc_8rJJFagmgkmnv5DGFSbE0Q_5_13"></a><a id="Tc_v3DtcjIVpkmT5KnD-leKtg_5_16"></a><a id="Tc_6yeLpTYB4U2oTYKCNirJeg_6_0"></a><a id="Tc_1zWACrL9aE6OkJnKqX8vlg_7_0"></a><a id="Tc_Is4rkBymRkOuucGL3XVhUw_7_8"></a><a id="Tc_K9UtCUZeBUCKknwkQMfVCg_7_11"></a><a id="Tc_EfVjEU6OnU2rA-Tj0cWmiA_8_1"></a><a id="Tc_RDHAisIS4Ueq2Cjl0H09gQ_8_4"></a><a id="Tc_6SABoPaCfUCi1KMub3wnTA_8_7"></a><a id="Tc_sd09Ustqu0q8jmV5xKTqGQ_8_10"></a><a id="Tc_KStSJvk77U-7XvxzylO1pQ_8_13"></a><a id="Tc_2xwe-Mvvlk6Aqd0w941IDw_8_16"></a><a id="_6d31ede3_c53c_45f5_802f_fd44a99f9db6"></a><a id="Tc_Z7jDz-XMpEyTJfqSpqrcxg_1_2"></a><a id="Tc_-LZBeIUGPUSyYVcAu6IBlw_2_2"></a><a id="Tc_-8NHgWQEqEq_4pCvWVNQyA_2_7"></a><a id="Tc_2rsiyXlKjk6KYZ3R9GbeRg_3_4"></a><a id="Tc_4jnhAjod2UeScZ0cf6o78w_3_10"></a><a id="Tc_MtSA_8zJukqxTRiyfFI2rA_3_13"></a><a id="Tc_JoAtdut__EWL2evUDr56Kw_3_16"></a><a id="Tc_I5E7JqvB8kCvy-at-8si4A_4_2"></a><a id="Tc_ceh1coV_W0q1tysNcGRbQw_4_4"></a><a id="Tc_XC6V0Kt5j0OY-2VZ7vnYvw_4_7"></a><a id="Tc_4G_9RgehKEex8cKbQiLX2w_4_10"></a><a id="Tc_RWTaH4ilNUCAWsuUitMjVQ_4_13"></a><a id="Tc_EWtJTnqkQk-32tWXu2aVyw_4_16"></a><a id="Tc_J8pYqdu6HEamiwVgP6BA2A_5_0"></a><a id="Tc_NyYgdhcFg06MBmJGyRsv2Q_5_1"></a><a id="Tc_AXZuUpzLLE27NtiFTZuaAg_5_4"></a><a id="Tc_gmozY-Ect0WMTlDmIC_ZKQ_5_7"></a><a id="Tc_WCbf9OTxyEGUgeRu6aUaBg_5_8"></a><a id="Tc_pgeCqYvsKkaOEKqg2kyQ9A_5_10"></a><a id="Tc_yWllH7i980u9IxUMXNOifA_5_11"></a><a id="Tc_szrMxDd5YEu-mG0fQoH1RQ_5_13"></a><a id="Tc_EVjsASheFEmPZOr0-aH4PA_5_16"></a><a id="Tc_Sp_D8tmBn0aNTxtnwMBtkw_6_0"></a><a id="Tc_ezCq-mYdOkyKFtlG2YQ6ew_6_8"></a><a id="Tc_AbjvRZPSdEqyVMTiuc3uLQ_6_11"></a><a id="Tc_dxc7R_CtjEGsGA_TTm2Vlg_7_0"></a><a id="Tc_vVmrMQVHPkKt-SjAPzIOBg_7_8"></a><a id="Tc__PNCT_aDykOMm2CvXmCOuw_7_11"></a><a id="Tc_4faJKOU-8E-vRZPO3QmirA_8_1"></a><a id="Tc_q-3EqEJ0CUa_TH3tnAth5w_8_4"></a><a id="Tc_ceYoYoLIDkayA6f0JbbLFw_8_7"></a><a id="Tc_hNR_ZyvRVkaRZNDzkRFiwQ_8_8"></a><a id="Tc_xzEm_qvpXEai7LoLkg2-nw_8_10"></a><a id="Tc_0j8BHbpgR0mkc7K72haJVw_8_11"></a><a id="Tc_O1Cx4QB2pkO17JSkXli4LQ_8_13"></a><a id="Tc_-DtOO53P2UCho029IudP-w_8_16"></a><ix:continuation id="Tb_39-M3jGLWUWUnU5xreYtvg_cont2"><ix:continuation id="Tb_-BMOIaXxm0qqmhA6tg0NVQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The following tables summarize the Company&#8217;s short-term investments with unrealized losses for less than 12 months and 12 months or greater:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="Tb_6DQQM50ii0qRv5uKBoNWhA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:71.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_CF8p4hsQH0aWfsZRzC--rg_5_2">34,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_v_NysTEh00GEzCuHtix8cg_5_5">84</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_D1r68Zfdc0G4JvfqFl_Spg_5_14">34,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_JPj9Moy8J0yoZgnG260izw_5_17">84</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_-OZXp1fnykGizYTCVV2g6Q_6_2">1,971</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_sMCbT3Yow0y4iHUTpQhwfg_6_5">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="Tc_SydZw-KmPEKJo0fO50W6QQ_6_8">24,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="Tc_4JuNoM2VcUqgL0o27LFqxQ_6_11">261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_rSs8AXLrN0u9Y9nuHHptVw_6_14">26,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_Nk38dYpOGkK3aRembqR9AQ_6_17">267</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_QAYnKIavkUGtlNQhEPvjdg_7_2">22,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_4lW6BZWjbU-d8DoRUYQsZA_7_5">133</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_DRt52gzza0W4GloDgkVoZg_7_14">22,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_JUQaN2lpiE6A5bNPH-Okyg_7_17">133</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_lJu18a54CECkTOtxBOAj9g_8_2">59,863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_uoaPPZrs40-_yFaXIiCIog_8_5">223</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="Tc_gaWITSgFk0K4TTZ52MMFLw_8_8">24,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="Tc_g5GsXBPRSkGf07EE28nF7A_8_11">261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_uHruFW88PUmup6gd6tg1pw_8_14">84,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_54Lf7VS170KXv3Id1mAxAg_8_17">484</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:71.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_PuOzqx_C8EOKSOEVuo6G_g_5_2">10,757</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_oIw3IzRX0Ueqj1HrmC42AA_5_5">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_9ZFgDk7RdEm26yLhvegIcw_5_14">10,757</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_TxvIgd89UE-qx0OEyYS7zA_5_17">11</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_xtmVPEUh1UiCOJP-xg4AQA_6_2">33,204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_FIIebe9ZCkKf0NzNPVivFw_6_5">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_E4s0zLdzg0yoKdc_kHnynw_6_14">33,204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_suFmpe2qdUKoNQntycKbWw_6_17">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_R9LVoDzqK0uNdLAwTzKduQ_7_2">25,194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_0uJyun5YYECWSUJA-rmnSQ_7_5">48</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_g2Wj5-D6vUaIho9rdoHBVQ_7_14">25,194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_AMPpsOaM4EyS07hCNnqSDQ_7_17">48</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_oE_Sg_u_sEqxgNPiCtcHQA_8_2">69,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_5V1G4XGHDU2qFNyZ4rwNNw_8_5">68</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_xy8QuW5dE0C-8JwVRiB8vA_8_14">69,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_F3sHH8fddUmGmrB2qypy3g_8_17">68</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#8217;s available-for-sale securities as of December&#160;31, 2022 were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. The Company concluded that an allowance for credit losses was unnecessary as of December&#160;31, 2022. It is neither management&#8217;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. <span style="-sec-ix-hidden:Hidden_NQg-uPEboUy3bkc7fClBSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued interest receivable</span></span> related to short-term investments was $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_3BpSFz349EKBC1pez2vW1g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" scale="6" id="Narr_0GX9frt0cEOWsS0SmMOQuQ">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_uqnI7J_-ykeUEvSi8eqaBQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" scale="6" id="Narr_2jV6GHeil0ayp0AxSxTvxw">0.1</ix:nonFraction> million as of December&#160;31, 2022 and December 31, 2021, respectively.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_4b502ce2_2c98_4d6f_8319_8c327bfcd50d"></a><a id="Tc_VW5y8cPAtEiOzCEFJoGptQ_1_2"></a><a id="Tc_-QnlAdPBTk6r4pVRvAli0A_2_2"></a><a id="Tc_walnLpFx00SUF-4cUhw1Yw_2_5"></a><a id="Tc_fN3uUCOlEk28mrl1S8IrgQ_3_0"></a><a id="Tc_lAl5z6KtL0yc5IR1wfZHBw_3_2"></a><a id="Tc_n6KEzxput0qg3qlLFdFTFQ_3_5"></a><a id="Tc_exKGyoh1XEKk6bv1xzqxaQ_4_0"></a><a id="Tc_wJ2AKZB-H0SeR13O2ZsdXQ_5_0"></a><a id="Tc_iEiaEolfWUufNG7iAY_CNg_6_0"></a><a id="Tc_XKteLIJ070Gbk7BpXDYZWQ_6_2"></a><a id="Tc_DjzEPptnYUm1Zo-VGhAW2w_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_o-7r-PrNy0edP38Dbkf5lA" continuedAt="Tb_o-7r-PrNy0edP38Dbkf5lA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4)&#160;BALANCE SHEET COMPONENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prepaid Expenses and Other Current Assets</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="avte:ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="Tb_LACHwZUuOkSercxES6DpWg" continuedAt="Tb_LACHwZUuOkSercxES6DpWg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_ieEHNRVF00S343Qq9U7Ejg_3_3">1,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_EYesuGUMhUCgbcDSogbxoA_3_6">1,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="avte:PrepaidResearchAndDevelopment" scale="3" id="Tc_fZrKITdblUKr2Tbjj4yM8w_4_3">478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="avte:PrepaidResearchAndDevelopment" scale="3" id="Tc_qMhPVWTU0kGdUTXcQ1-qIg_4_6">5,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_g2F5HWz07Ei5Xf_eqfLU4g_5_3">295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_KSrwUMAv3Uuphy8xIkXicg_5_6">240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_yBuJ1A2aXUGf770wb7jkxA_6_3">2,276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_x2KXQ7V67k2pVp6moR7H1Q_6_6">6,958</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8a0c3d9c_721f_4be2_aa79_9fa2188951d5"></a><a id="Tc_QDAJvrMzRkiJxwooLoXx0Q_1_2"></a><a id="Tc_h6z9sW5wSEmgGKoR6YUIYg_2_2"></a><a id="Tc_Vwlz77g1Gkuf3GJ8DVxk8g_2_5"></a><a id="Tc_9U3FFSrJ9U-T44NolcSovA_3_0"></a><a id="Tc__TPGZSSMNUmqFCGR71Bv6g_3_2"></a><a id="Tc_Mu7DazXuw0a5uG8Mz1LAGg_3_5"></a><a id="Tc_YIoclUacAE2HuF9sCZWuuw_4_0"></a><a id="Tc_l141Xz7cn0Ko8OWN9oaBEg_5_0"></a><a id="Tc_4Ew4Qh_6rUmO44SA9seCDw_6_0"></a><a id="Tc_PHfVb2vbpEykn362vPOu1A_6_2"></a><a id="Tc__XuXUgC-_0yeKlhGQNVVtg_6_5"></a><ix:continuation id="Tb_o-7r-PrNy0edP38Dbkf5lA_cont1"><ix:continuation id="Tb_LACHwZUuOkSercxES6DpWg_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accrued and Other Current Liabilities</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_v0r-wjIUB0ueBpeRrztr5Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Accrued and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedResearchAndDevelopmentCurrent" scale="3" id="Tc_ulmhDh9BDkyImhQ__7x-Kg_3_3">2,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedResearchAndDevelopmentCurrent" scale="3" id="Tc_VJHM2VfKnU-s7qh8gf74Lg_3_6">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_7m0BC00rREm8_tYvdNbI8A_4_3">1,691</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_53P_4LpJ8kyRy3LYd6UzgA_4_6">790</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_g8JK6iafs0y9DlZNQgtN2A_5_3">380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_CXIv_wDCUEmF120cGqQqeg_5_6">143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="Tc_9CIuU6sK60SAXJ_YLmRITg_6_3">4,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="Tc_L8GpetrY7UqrlTq1pahRag_6_6">1,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_30e0e9ff_edc7_42ff_b734_f93e205b2879"></a><a id="Tc_B6xEcTaY-06RKneX5SeIVQ_1_1"></a><a id="Tc_4YR1DDbdTU-meatDnxsFkQ_2_1"></a><a id="Tc_X3Kw77ZmZk-d-2wHCPe-dw_3_0"></a><a id="Tc_CisPjO5SG0WaaleKY1z8Uw_3_2"></a><a id="Tc_zvJYxwepwEeTpaJbIF9DCQ_4_0"></a><a id="Tc_WhDGmQqN_UOx-EdBSHeo1w_5_0"></a><a id="Tc_VBlKVrh4H0myZ6YiXIMN8w_6_0"></a><a id="Tc_iCi_BO4ZBkahrLk3okm2QQ_7_0"></a><a id="Tc_GrwTBVPhdk2n1Y9JFhuvnw_8_0"></a><a id="Tc_tI3ZFONUuE2vsZeaj3zm3g_8_2"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_hBDakIE1rEy4UrV2oWCwuw" continuedAt="Tb_hBDakIE1rEy4UrV2oWCwuw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5)&#160;COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In August&#160;2021, the Company entered into a lease agreement (the &#8220;Waltham Lease&#8221;) for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_UveSBE_izUeNb4VPRsSftw" contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_I5wcShJpG0OhjXjvlcq-_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_uODXJHW3UUaURzFrAIIPNA">5,000</ix:nonFraction> square feet of office space in Waltham, Massachusetts for the Company&#8217;s corporate headquarters. The Waltham Lease has a term of <ix:nonNumeric contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_I5wcShJpG0OhjXjvlcq-_g" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_ouN4A2OFa0Os1BgkSH8dvQ">thirty-nine months</ix:nonNumeric> (&#8220;Lease Term&#8221;), unless extended or earlier terminated. The Company has the option to extend the Waltham Lease for <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_h_ieJm0F5UauCwtcprOqhQ">one</ix:nonNumeric> additional period of <ix:nonNumeric contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_I5wcShJpG0OhjXjvlcq-_g" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_pYAh2kpEsU-9IEqe6W09JA">three&#160;years</ix:nonNumeric>. The Lease Term had an initial abatement period, and the initial base rent payable is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_YaLLcUjHZki458JcBBF_AA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRent" scale="0" id="Narr_zwcHSTLKPUudtycbDDdumw">18,000</ix:nonFraction> per&#160;month following the abatement period. The initial base rent payable will increase by approximately <ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_YaLLcUjHZki458JcBBF_AA" decimals="INF" format="ixt:numdotdecimal" name="avte:LeaseIncreaseInRentPercentage" scale="-2" id="Narr_qLwAz2I8e0KZ1qZgdMZ-dA">2</ix:nonFraction>% per&#160;year over the Lease Term. The Waltham Lease commencement date was September&#160;1, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In April 2022, the Company entered into a lease agreement (the &#8220;Foster City Lease&#8221;) for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_UveSBE_izUeNb4VPRsSftw" contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_nM5HHKPZJk6bkcFB2fyHpw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_kDEYIaU3lkaB6qAfzJ1mpA">3,500</ix:nonFraction> square feet of office space in Foster City, California. The Foster City Lease has a term of <ix:nonNumeric contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_nM5HHKPZJk6bkcFB2fyHpw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_oeas0g0lnk-pTw11PQTUdA">thirty-nine months</ix:nonNumeric>, unless extended or earlier terminated. The Company has the option to extend the Foster City Lease for on additional period of <ix:nonNumeric contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_nM5HHKPZJk6bkcFB2fyHpw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_F_HYHfJ5YUmgem7rHwYQcg">one year</ix:nonNumeric>. The base rent payable under the Lease Term will be $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_mp5ueIyU6EupPXatRN7igQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRent" scale="0" id="Narr_Sqg7s0QjYEKnBswRln8_Xg">22,600</ix:nonFraction> per month and will be subject to annual increase of <ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_mp5ueIyU6EupPXatRN7igQ" decimals="INF" format="ixt:numdotdecimal" name="avte:LeaseIncreaseInRentPercentage" scale="-2" id="Narr_WQGN4uMhgEesc1NUMtmdAA">3</ix:nonFraction>% on each anniversary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022, the consolidated balance sheet includes an operating lease right-of-use asset of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_YRfEgYfYBkqJai4VTgszeA">1.0</ix:nonFraction> million and operating lease liability of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_XKDrkZO-4Um8sWfJxogbDQ">1.1</ix:nonFraction> million. The total operating lease expense was $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_4NPmbh5Z_0a_toFe-OSKeQ">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_vS7WInFbykW01fOHLF58xg">0.1</ix:nonFraction> million, for the years ended December 31, 2022 and 2021, respectively. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb__NIO-hqCDEiClYrxVFsUVg" continuedAt="Tb__NIO-hqCDEiClYrxVFsUVg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc__puXVc-y_Eiw_k8LYo158Q_3_3">426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_EJh22mERDk2DiHVZY3jOyA_4_3">508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_7AKKb0MTf0mtfQxe0i9IVw_5_3">242</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_SWGcXjFvrkiX8MUbDESXBg_6_3">1,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_XHQ7wMeJ-0KgtlK-2CSKDw_7_3">86</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_xGBYlqLsTUGy79sFIoStAw_8_3">1,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b557be19_1216_432e_b78b_2054a880d4d9"></a><a id="Tc_dtNq6w0JYUSq8A4UWD_iRw_1_2"></a><a id="Tc_lQj-u9lOj0aZz5W-3rlbWA_2_0"></a><a id="Tc_GBgeCKWx8k-IlNZoFBBrdw_2_2"></a><a id="Tc_n2RG15-_10qLENwVi7L8DA_2_5"></a><a id="Tc_230cy6EijUmC8d8kF0CeGQ_3_0"></a><a id="Tc_KM9yOEFpSk-48zEVVTYuXA_4_0"></a><a id="Tc_qNDbjCDiWEKKD14CcsyB-A_5_0"></a><a id="Tc_cnYRXDlWdkGe3RrSVKSZpw_5_2"></a><a id="Tc_OiROJ14K2kqq0GhDfIUV4Q_5_5"></a><a id="Tc_N8P3B9EFTEG9m0h6MopHFw_6_0"></a><a id="Tc_nXan4owWmEaIS8GcP5DFdw_7_0"></a><a id="Tc_6iMlHzgN9UyNLjsfb_nLkg_7_4"></a><a id="Tc_sQx7NIGfyU67azCdY8QvZw_7_7"></a><ix:continuation id="Tb_hBDakIE1rEy4UrV2oWCwuw_cont1"><ix:continuation id="Tb__NIO-hqCDEiClYrxVFsUVg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The components of operating leases for the years ended December 31, 2022 and December 31, 2021 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_gXyaHqOC20C_UrVoS54WDA_3_3">385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_4XUA4peJOU-MIVqbXcmitQ_3_6">192</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_aevpghVU-EKUrOhXQmB-jw_4_3">705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_FFim2YocF0iAUW5J863_UA_4_6">382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_ryC-19E4XUyejWdTBFlvdA_5_3">1,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_K1IMuG68D062xkaqa0THwg_5_6">574</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_iBAP1fQJ0EyDC2TEyPPi6g_6_3"> 2.4</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_YezS8xTEw0uAfil1on7Lvg_6_6"> 3.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_FLPX6Jc7p0WvdNET1MBifg_7_3">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_M1HMlDWJ_EendVGIRSYu1w_7_6">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company may from time to time be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December 31, 2022 and 2021, and no material legal proceedings are currently pending or, to the best of its knowledge, threatened.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_bK4MJQqeW0G-Lpi5nFVDIg" continuedAt="Tb_bK4MJQqeW0G-Lpi5nFVDIg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6)&#160;STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33.1pt;">Under the Company&#8217;s Amended and Restated Certificates of Incorporation dated August&#160;3, 2020, the Company had a total of <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA" decimals="INF" format="ixt:numdotdecimal" name="avte:CapitalStockSharesAuthorized" scale="0" id="Narr_rxpxBh7co0CQegOi3RfLGw">94,052,154</ix:nonFraction> shares of capital stock authorized for issuance, consisting of <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_EWYEIKTgeUeffA3gXvlsqg">50,000,000</ix:nonFraction> shares of common stock, par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Niri3TMFD0ewGSvuKwDfeQ">0.0001</ix:nonFraction> per share, and <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_9OVwWoggX0WsmWitNKCteQ">44,052,154</ix:nonFraction> shares of convertible preferred stock, par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_MnhPi1CPNEqwa4dRoLGE5A">0.0001</ix:nonFraction> per share. Shares of authorized convertible preferred stock were designated as <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_crMw-EmKcUeuKdVO9DDyyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_864Jr6_IS0-VSDfwBZ3FJg">4,000,000</ix:nonFraction> shares of Series&#160;Seed redeemable convertible preferred stock and <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_No7St9Lvr0y96G_5EWC44g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_2xDZHN8Y0E-BMADuN3gWfw">40,052,154</ix:nonFraction> shares of Series&#160;A redeemable convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Following the Reverse Stock Split, the Company filed a Second Amended and Restated Certificate of Incorporation, which provided for <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_6_22_2021_zuE5gWkeyk2gMuDMHkgnlQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_DOJIEB9coEWFivY_YLzK5Q">150,000,000</ix:nonFraction> authorized shares of common stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_6_22_2021_zuE5gWkeyk2gMuDMHkgnlQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_57GSPKpXD0qwWwsvFV2Jew">0.0001</ix:nonFraction> per share and <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_6_22_2021_zuE5gWkeyk2gMuDMHkgnlQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_w5whNIyxRkG3oVpecyBWjg">10,000,000</ix:nonFraction> authorized shares of undesignated preferred stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_6_22_2021_zuE5gWkeyk2gMuDMHkgnlQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_I3WXKhPtZUGAN72tK3MnCA">0.0001</ix:nonFraction> per share, effective upon completion of the Company&#8217;s IPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Redeemable Convertible Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In August&#160;2018, the Company sold to RA Capital Health Care Fund,&#160;L.P. an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_W0a55wDra0WelJUBZUsesw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_Jm3gkYeG3kqzGBxCeYOjTA">4,000,000</ix:nonFraction> shares of Series&#160;Seed redeemable preferred stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_W0a55wDra0WelJUBZUsesw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr__uwuIOYqn0-tU4Erf9hPCw">1.00</ix:nonFraction> per share, for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_vnUkVXoGN0-57YWUs8EYpA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_jYF-EFI2Z0OM27TYOEoKcQ">4.0</ix:nonFraction> million. On August&#160;5, 2020, the Company entered into the Stock Purchase Agreement. The Company&#8217;s initial closing of its Series&#160;A redeemable convertible preferred stock occurred on this date. The Company issued <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_8_5_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_pNNDYw-rNUWvdmmuAHZlsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_Zg8-cSKMNU2QWoLXsOq9Kg">3,468,536</ix:nonFraction> shares of Series&#160;A redeemable convertible preferred shares for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_8_4_2020_To_8_5_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_KQ7-UIfWqUG1_y4Ju1lXmw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_9ZuVLI8nl0aPYIdie0DmOA">6.6</ix:nonFraction> million at a price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_8_5_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_pNNDYw-rNUWvdmmuAHZlsg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_cjo5xRMBmUiYzYWBbGitxw">1.893</ix:nonFraction>. In addition to the cash proceeds, <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_8_5_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_pNNDYw-rNUWvdmmuAHZlsg" decimals="INF" format="ixt:numdotdecimal" name="avte:TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes" scale="0" id="Narr_PILz7vMtA0CHfdUWx1Ck6g">3,020,998</ix:nonFraction> shares of Series&#160;A redeemable convertible preferred stock were issued in connection with the conversion of the 2019 Notes&#160;and the 2020 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Stock Purchase Agreement contained provisions that potentially obligate the Company to sell, outside of its control, an additional <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_8_5_2020_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_oObJ-Nmc4UqeH2X0G6kfiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_NKA8QoUV1k29Xq5Pc6gXUA">33,562,620</ix:nonFraction> shares of Series&#160;A redeemable convertible preferred stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_8_5_2020_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_oObJ-Nmc4UqeH2X0G6kfiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_HrX71w2AvEeevbAOV_c1MQ">1.893</ix:nonFraction> per share for expected gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_8_4_2020_To_8_5_2020_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_Dv12U9pPlk25gS6TpZJscg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_3zbhSUZ3BkazM4fuhiu8vg">63.5</ix:nonFraction> million, upon the occurrence of three subsequent Milestone Closings or earlier, at the option of any holder of the Series&#160;A redeemable convertible preferred stock. If the defined milestones were not achieved prior to the Company&#8217;s initial public offering, the holders had the right to purchase these shares prior to the completion of the initial public offering. If the shares were not purchased prior to the completion of the initial public offering, then this right to purchase these shares would have automatically expired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;">On February&#160;1, 2021, upon the completion of the First Milestone Closing, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_2_1_2021_avte_MilestoneAxis_avte_FirstMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_wwresvhtM0-V7mH5Vgo-hA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_8xeRmuC7rE6qpsj281x0nA">4,224,274</ix:nonFraction> shares of Series&#160;A redeemable convertible preferred stock at the Series&#160;A Original Issue Price for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_30_2021_To_2_1_2021_avte_MilestoneAxis_avte_FirstMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_hfGGAslhNEeVOwN6WrF5gQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_577DBj8KKUujeGgbuoPrhg">8.0</ix:nonFraction> million. On June&#160;4, 2021, upon the completion of the Second Milestone Closing and the Third Milestone </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_efe76d0a_9f15_4e8c_8be7_41e9879dad0e"></a><a id="Tc_Cih3wWL0002KTVSIS4Ydjg_1_2"></a><a id="Tc_8kg9NZqwfEiIzCGmVi4M7w_2_0"></a><a id="Tc_WUy-qdivx0e9L_kRCI20xg_3_0"></a><a id="Tc_1VnVU0YJKEGZrYt6o_11fQ_4_0"></a><a id="Tc_1FSuQzFzEU-nNTLN2v6AZw_5_0"></a><a id="Tc_WqNOoVDxAkGp01utyDlFgA_6_0"></a><ix:continuation id="Tb_bK4MJQqeW0G-Lpi5nFVDIg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Closing, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_6_4_2021_avte_MilestoneAxis_avte_SecondAndThirdMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_GDEihDdvTUyXLABx1mfHnw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_esGDggMWE0-3vWjC7SNzgQ">29,338,346</ix:nonFraction> shares of Series&#160;A redeemable convertible preferred stock at the Series&#160;A Original Issue Price for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_6_3_2021_To_6_4_2021_avte_MilestoneAxis_avte_SecondAndThirdMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_rGO8UuK3d0mu99ddFv5hjA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_c9aUsGHJUE2S_aXGPvZcCA">55.5</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Immediately prior to the closing of the Company&#8217;s IPO on July&#160;2, 2021, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock converted into <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_xbOuftPGHkeAHGLhw_3HrQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_Y3Vvrgtd7k2G2g3qKUx0ow">14,182,854</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In August&#160;2018, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_djafJWnh40CLwBS3AvdTBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr__0vlyfl860iQMSTNNPYLUw">241,467</ix:nonFraction> shares of common stock to RA Capital Healthcare Fund,&#160;L.P. at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_djafJWnh40CLwBS3AvdTBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_pU3jULeTZkmCLy4GT90PPQ">0.0012</ix:nonFraction> per share. On July&#160;2, 2021, in conjunction with the Company&#8217;s IPO, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_f35-tn37YkSEpT0jtT5KhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Wc1gyIeRwk2stIJb9_XsuA">9,984,463</ix:nonFraction> shares of its common stock and all outstanding shares of the Company&#8217;s redeemable convertible preferred stock were converted into <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_xbOuftPGHkeAHGLhw_3HrQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_P10QE8LVnkeABuTk2TpCKA">14,182,854</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The holders of the common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_U58quFcv5ki9AFPMBo9uqw" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_PvcTYb2K9UG6ACE8durCkQ" decimals="INF" format="ixt-sec:numwordsen" name="avte:NumberOfVotesForEachShareOfCommonStock" scale="0" id="Narr_XRP-d64lQkivNpFzT_dTIA">one</ix:nonFraction> vote for each share of common stock held at all meetings of stockholders.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" id="Tb_Z0L6wBHZsk2KX8wx4klaDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022, the Company had reserved the following shares of common stock for future issuance:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_CommonStockMember_aFm9TwWFNkWt1zWekbZnjQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_-K-reKipTEiWpmQM0FOcNQ_2_2">4,110,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_TXk4moIa40GbN1BvRlu_JA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_c213H-BezUWja3zvJJCLtw_3_2">1,077,557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for vesting of outstanding restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_7kFZeYf8XkSj3t3wwiM5lA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_TDKTxnhXyECyedYS8DmfRA_4_2">28,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BFKtiMbYKEWGiX8enBMhZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_9Qg7lCV1W0q4K-aS4G0Kbw_5_2">216,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_bpYtMVH2wkeVbsfWhztHEQ_6_2">5,432,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_zVLzJvvhjk2npb8bfYnvKw" continuedAt="Tb_zVLzJvvhjk2npb8bfYnvKw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7)&#160;SHARE-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Stock Option Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company&#8217;s 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;) was adopted by the Company&#8217;s board of directors and approved by the Company&#8217;s stockholders in June&#160;2021 and became effective as of June&#160;29, 2021. Upon the effectiveness of the 2021 Plan, the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) was terminated and no further grants may be made thereunder. The Company&#8217;s 2021 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022, a total of <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_TXk4moIa40GbN1BvRlu_JA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_WcMJ2vsasEGr3vqKwzlWzA">3,576,415</ix:nonFraction> shares of the Company&#8217;s common stock were authorized for issuance with respect to awards granted under the 2021 Plan. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_U-Vimp94EE-Vhg_ROQBzFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_3ZL93hmtjU2gLh2Ya3v_lw">4</ix:nonFraction>% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. The number of shares available under the 2021 Plan increased by <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_1_1_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_hoI7V65KHEG5GkLS5GdTEw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_e6BYtqJI30CI_TATXNdWMQ">976,415</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_1_1_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_KW9jG2TQGUqptBykLu-x_Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_Qbz1VJUFxk6u1pb1XNbRCw">988,918</ix:nonFraction> shares, effective January 1, 2022 and January 1, 2023, respectively, as determined by the Company&#8217;s board of directors. Any shares subject to awards granted under the 2021 Plan or the 2018 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_U-Vimp94EE-Vhg_ROQBzFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_E_-9Eb2i5EGmdfgsvhed-A">2,467,977</ix:nonFraction> options had been granted and <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_StqYaHLjzEKZmEQ6yLvUGA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_n_UbqMtTTE6m2-CT2D6wQw">28,881</ix:nonFraction> restricted stock units awarded under the 2021 Plan, with <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_8KFv4vg0cUCOT78XuWQJLw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_K6QK-pZGPkmGEg_16VKPtQ">1,077,557</ix:nonFraction> shares authorized for future issuance. As of December 31, 2022, a total of <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyEighteenStockOptionAndIncentivePlanMember_xoITfiC24kGgUX1H39EHoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_VF9UXMT-HEyZw9u7f29ZyQ">1,642,242</ix:nonFraction> options had been granted and were outstanding under the 2018 Plan.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ccffe4a5_a6a4_4834_b99c_87e9f92cb846"></a><a id="Tc_fbhtMTKCq02Aef2ni9v0uQ_1_7"></a><a id="Tc_n1cAcx86L0KcIMCx33P42g_2_7"></a><a id="Tc_Bau-7Aq7DE-x5vq62yXWzQ_3_7"></a><a id="Tc_wnPfB4gYF066YndWETAuyw_3_9"></a><a id="Tc_C7JevbNXuEmCU22LvCbx4g_4_4"></a><a id="Tc_9DroYUgWw0KYxj4fpDax-g_4_7"></a><a id="Tc_8BK8KZhmcUO2Dj4IQl5jdQ_4_9"></a><a id="Tc_4WSNJEB6lUO_vragFh844g_5_2"></a><a id="Tc_DuEXi-HOVUGI5WHMvrsfRQ_5_4"></a><a id="Tc_cV7JQIN4E0u1P_tHV2PX5Q_5_7"></a><a id="Tc_-Hj0m0KvPE21x6vesZcjhw_5_9"></a><a id="Tc_yBJp2hFoa0OZKKRZbaBGyQ_6_0"></a><a id="Tc_B0xX5yKhUUqA828owIKLRg_6_4"></a><a id="Tc_0BQgrycsrkST1W1-i4JsbQ_6_9"></a><a id="Tc_-XoqujvuykepqkIbiC56xg_7_0"></a><a id="Tc_ZNWvkWPPDUq4rDDE59N0vA_8_0"></a><a id="Tc_SvRwsHmCa0q_j78WPtRxog_9_0"></a><a id="Tc_zBhNke4xd0mnuN1rlk8yAw_9_2"></a><a id="Tc_ZNGzejEDOU6RiFl5W1EL7g_9_5"></a><a id="Tc_7IPpjkXyE0a_Hvcx8whICw_10_0"></a><a id="Tc_0LXvlJj-1kyv4N8JZHvyVg_10_4"></a><a id="Tc_jzjiF8JZe0CZX1jo_e2HWQ_11_0"></a><a id="Tc_RjcbUQKi2kixllayinSmSQ_12_0"></a><ix:continuation id="Tb_zVLzJvvhjk2npb8bfYnvKw_cont1" continuedAt="Tb_zVLzJvvhjk2npb8bfYnvKw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The options that are granted under the 2021 Plan and the 2018 Plan are exercisable at various dates as determined upon grant and terminate within <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_Cyq09hAZqUesspxvNiCeCg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_080p8yaVNEWyVH-R1cyctw">10&#160;years</ix:nonNumeric> of the date of grant. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_uKh2d8qoz0GftAIlA0yOkQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_9FuVdbUhV0uvrx8hBa_1RA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Ijxpoj-1Hk6x8fZ0AX37ug">four&#160;years</ix:nonNumeric>.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_P1XVjdUuhkmKOliY9Ef2VA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the&#160;year ended December&#160;31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_dmRXkRp_AEWcYbtGi-XkNw_6_2">3,454,374</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_k49KRWwUa0ecnq3NbsAkPw_6_5">6.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_USTuOt2UDkOdgVwksejHZw_6_7"> 9.42</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_VgwWDAnCvEqwEOUGtcU7og_6_10">19,378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_AQZD2vvSf0CQH-LDLZcUKw_7_2">954,557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_bT8V-0WIZk2O8U7Se-lQRA_7_5">15.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Os09JbQB2EKbOLcSNpAAEg_8_2">298,712</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_fk-MJ_579E2w7BAJtRwthg_8_5">2.09</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_vtIQ3bjhw0O4WyEcmsh3Sg_10_2">4,110,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_LY9yN_w2Dkqi0J9ku63Ucw_10_5">9.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_q5lyUXQ890CoL95V0NruqA_10_7"> 9.23</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_LPGlAK18MEmdVIESFe72IA_10_10">82,490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="Tc_Zwa4Dm8Cp0SPF5Mq3IFAlw_11_2">1,044,465</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="Tc_6nopaVCNhk-k0hX7cCCuZQ_11_5">7.58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_kFLeHgo67kajMjiaaaTZyQ_11_7"> 8.11</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="Tc_8XwAkSeot0qaTGmaXW0ILA_11_10">22,682</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_vc_6x68X70OehbSUrt3tIA_12_2">4,110,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ElkSg1Ul5kiVznC69-mc1w_12_5">9.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_qTQ8xI1uu0a-JAb2_DH4Rg_12_7"> 8.46</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="Tc_HySWU0C12Uma4I01yUvQKg_12_10">82,490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The weighted-average grant date fair value of stock option grants was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_RV-MksCrdUugMi8XAfYAwg">10.48</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_WT8G21KiQkapldm-vkAlmA">4.46</ix:nonFraction> per share for the years ended December 31,&#160;2022 and December 31, 2021, respectively. All exercisable options are vested and all outstanding options are vested or expected to vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022 there was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_Nl1y9JTY90epD7TQaHKPyA">17.2</ix:nonFraction> million of unrecognized stock-based compensation expense related to nonvested stock-based compensation arrangements granted under the 2021 Plan and 2018 Plan, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_kxJ0LQuBz06c50_exIJ7qg">2.7</ix:nonNumeric>&#160;years</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company&#8217;s Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was adopted by the Company&#8217;s board of directors and stockholders in June&#160;2021 and became effective upon the consummation of the IPO. A total of <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_VdsnaK6Ohkqmx-_Z9SCPxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_wc7lZb9YiEKUNINcZML1UQ">230,000</ix:nonFraction> shares of the Company&#8217;s common stock is initially available for issuance under the ESPP. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_vrB-dEU-EE2kBgR4L-Vkig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_qNk_70orKkyjEJb7tg1G6A">1</ix:nonFraction>% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. The number of shares available under the 2021 Plan increased by <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ZEq1R1quB0CHCsbXWqAwWw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_bRjAWz8ymU22Y37lGueNmw">247,229</ix:nonFraction> shares effective January 1, 2023 as determined by the Company&#8217;s board of directors. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_iezkj5eDqUCfolKO8YRv0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_n2m17Ht5TEeMK7475xcJ2g">15</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The ESPP provides for <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_0fmPIdzRUE-bEqICdqsXyg" format="ixt-sec:durwordsen" name="avte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="Narr_fy2yRw72E0e82RmpHgJnMw">six-month</ix:nonNumeric> offering periods, and at the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_iezkj5eDqUCfolKO8YRv0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" scale="-2" id="Narr_7p2r_Tjc5kicQh2qnobdnQ">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of December&#160;31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_0fmPIdzRUE-bEqICdqsXyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Narr_CIlL0daiXUutCy-MKFeW2Q">13,869</ix:nonFraction> shares had been issued under the ESPP, and <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BFKtiMbYKEWGiX8enBMhZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_9zh9UnwSkkGFh9hNvuZbMg">216,131</ix:nonFraction> shares authorized under the ESPP Plan were available for issuance.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_A3tQ6Pc-MUWW0lWzsdm_8A_1_4"></a><a id="Tc_j5Si140MM0muJeIKoL1tVQ_2_4"></a><a id="Tc_nFhxlaT0vEeXdNMIvrH4ew_3_4"></a><a id="Tc_64UiCG5f0USIpYSQaFo0Ig_4_2"></a><a id="Tc_fslJy13CIkmxmwJI3OLz5g_4_4"></a><a id="Tc_92AzeiKQPUGmVT8fihzEUw_5_0"></a><a id="Tc_I_8bZjQpL0SiPq_h8w607Q_5_2"></a><a id="Tc_gMkbPj84Uk6xbIndkyKTZg_5_5"></a><a id="Tc_YYa872yBPk-T-p9I3OlDVA_6_0"></a><a id="Tc_kd5l3e4g5UiiRncX1WLIBg_6_4"></a><a id="Tc_PXf1GTrcKE2yk1zuIbwv6Q_7_0"></a><a id="Tc_9bdaw2u1pUuNqwbr61wVfA_7_2"></a><a id="Tc_1BAIVSPJUkasdJ-nfm4n9A_7_5"></a><a id="Tc_tAJUCldx0EykxLvwrREjIQ_8_0"></a><a id="Tc_X0IVASWoZUW1YJIscCTXSw_8_2"></a><a id="Tc_Gn5Vq_LpyUe_KJeyi3E3tQ_8_5"></a><a id="Tc_IRf7ufiwiUeHNvPzUWyEAQ_9_0"></a><a id="Tc_pVVd9k5ftE-FPu79g293hg_9_4"></a><a id="Tc_bN7Mi7hcgESCj-Rf3GiVEw_1_2"></a><a id="Tc_f5aCu04gAkGngoHeJkhziA_2_2"></a><a id="Tc_QhIrXtNOkE6FE0eohm8wUw_2_4"></a><a id="Tc_dQL19dWBIUSIt8QzGc_RnQ_3_0"></a><a id="Tc_edWcXloQcE6wKxsupiHrtg_3_2"></a><a id="Tc_QsGx_jDPIk6L3C8ufqRgGw_3_4"></a><a id="Tc_LNrJXND-zkK5jdYpFTF0Hg_4_0"></a><a id="Tc_9NxuWLUrQU6V_DLTS0ZaYw_4_2"></a><a id="Tc_-9BnqQoyC0qRZW5_2fqXcg_4_3"></a><a id="Tc_iijkJCfGjk2VrA8KkGx_cw_4_4"></a><a id="Tc_AF-T8OHUxUGiWeZo1_DoxQ_4_5"></a><a id="Tc_rM9C7qsKWkK5C-e8haqdbw_5_0"></a><a id="Tc_kQnguN9jdEqESlYciWi4Hw_5_2"></a><a id="Tc_Np1EHoMzcEiH6g6Vp4P7yA_5_3"></a><a id="Tc_4_I7KSVOR0yF4rDMcF3Pqg_5_4"></a><a id="Tc_arvxV4y0ok2PVE5Qv7Dfow_5_5"></a><a id="Tc_tA3dX19PyEidmp8vV3_5og_6_0"></a><a id="Tc_34XSV-UIUEiTnnR8pCb7pQ_6_2"></a><a id="Tc_ZoXyXaPHvEy9PBIAJqKQyQ_6_4"></a><a id="_8689229c_b254_4a74_a046_8b5f72b935bf"></a><a id="Tc_CVOghahLhEOfLurfIJnTgQ_1_2"></a><a id="Tc_Nm5-cQXSPESkmF_gG543Dw_2_2"></a><a id="Tc_YE2lrFaCXEKMWOPsQcYhyA_2_5"></a><a id="Tc_9yBiyTr0N0OjkE3N6IhgZw_3_0"></a><a id="Tc_MvLUk_w0b0eLzq88LgF3ng_3_2"></a><a id="Tc_AHyizpctOkWE-Nx4-3Gv3g_3_5"></a><a id="Tc_FBB8HyRPu02YoAlCOTtwLw_4_0"></a><a id="Tc_kgRe1OWbV0GpjGOoXaLZag_5_0"></a><a id="Tc_9vHqQoGFPkeGraTVe_Z1Vw_5_2"></a><a id="Tc_HD3rVkWCgEORfpUe1Kqt2A_5_5"></a><ix:continuation id="Tb_zVLzJvvhjk2npb8bfYnvKw_cont2" continuedAt="Tb_zVLzJvvhjk2npb8bfYnvKw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_StqYaHLjzEKZmEQ6yLvUGA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_x33hDuesrkGSibGHpb6n8Q">28,881</ix:nonFraction> restricted stock units had been awarded under the 2021 Plan. A summary of the status of and changes in unvested restricted stock unit activity under the Company&#8217;s equity award plans for the nine months ended December 31, 2022 was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="Tb_0mVZv9y3tkyYJ9QaLZyoLQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_fgJFPg2M10KBUnon7q7Qww_6_2">28,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_w1BuKzWMjE2s9AJIq3-fQA_6_5">21.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_GmhQi37eeUGF1JQNFm9Fkw_9_2">28,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_z5cp_w3VF0KMQWWcDCnrfQ_9_5">21.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Stock-based compensation of restricted stock units is based on the fair value of the Company&#8217;s common stock on the date of grant and recognized over the vesting period. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_gWG-e8KNUkuG8sHbxrnFJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fJh_ywGZikyIQAcBTW536A" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Ehw5nsHqYEy5pa-VhnPWOQ">four years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December 31,&#160;2022, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock units of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_7kFZeYf8XkSj3t3wwiM5lA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_UpNqqWcuZEm6XHfLxy_-vg">0.6</ix:nonFraction>&#160;million, which is expected to be recognized over the remaining weighted-average vesting period of&#160;<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ffQ1QIahIk-nBDBoGTbC3Q" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_LoznO9AfOkK603M_VLagNg">3.3</ix:nonNumeric>&#160;years. The Company did not incur or have any unrecognized stock-based compensation related to restricted stock units as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Stock-Based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company estimated the fair value of stock options using the Black-Scholes valuation model. The Company accounts for any forfeitures of options when they occur. Previously recognized compensation expense for an award is reversed in the period that the award is forfeited. The fair value of stock options was estimated using the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_e3CQPQAO7kGieDZpznXiZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:51.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_aiS3g6rqK0C4IYQ7jBBLcw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_x8V36iuU7EC5jfEG1KAMxg">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_L6Aulrv6skCjIRhGAQFN1w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_xmNYUKkCgEG3rSmNWOctIg">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_jKuzK2N-lk6r-oAi8Vk34Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_lAMLghS35Ea8dFmNrR6hNA">5.2</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_tvsHVVkheEq71hXbwUCgSQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_t6FUGrRL_kuVgRQ6lWoRIg">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_Y2ZssEejsEugYANpqYOolQ">73.5</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_09fp_NcMtUuh7GBYXozBCw">76.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_bHuS3TAlDEW8omesUaP5Iw">68.7</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_M_jgJDDjTECgeQBEK6LKMg">69.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_a2g6VJAmbEKu45gZ0WPp9w">1.6</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_8XiNi1iHZkK1DhDZXNQw0Q">4.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_HnbWlc-plUWnI9IklIsKbQ">0.9</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_uh-MlFdtr0ClB70P9FbpvA">1.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_txAc4B8X7k-_wku7oUoX4Q" continuedAt="Tb_txAc4B8X7k-_wku7oUoX4Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Stock-based compensation expense recognized for stock option grants has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_fPutlC_Wlkew2sr7ZE8ROQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_TNLfqhLqYEi1wllRcKqAQw_3_3">3,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_PUAKc7nXUEaEH4mxzoylkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_-rk1N-bKNUKIHgMyoGKeUw_3_6">1,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2skYMq1PvUmc9GZXaVoMzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_U6z2ddyAOUulYyPbsJoa0g_4_3">2,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_BRUvW3FPrk2wFPzvj1avag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_lSxUWjeL9kil7JycBTd4SQ_4_6">370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_qa8X49mTNUu9p2D21Jfk9g_5_3">5,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_cXTG5xkTTEOhOvS0oEC11g_5_6">2,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a80dd96e_e517_4b97_8cda_e62e30d7dcab"></a><a id="Tc_q5j3jgBS40-ow9e-9hMJwg_1_2"></a><a id="Tc_fIBf0hlEbk2u3aRtgRQylg_2_2"></a><a id="Tc_Sk3zwRqx60Org8v341R64A_2_5"></a><a id="Tc_Po1ZlOezWUuEW5sGl_Phtw_3_0"></a><a id="Tc_A322kLAPy0yUMkY4_5c-_A_3_2"></a><a id="Tc_DGuwQmGkFEW5aavCnmX4Jg_3_5"></a><a id="Tc_14hULVZDlEixQOlAa1MRVg_4_0"></a><a id="Tc_863aSgmVnUiSwyOUHGRg2A_4_6"></a><a id="Tc_7YaxD1Mv902mTNs5aAb1Zw_5_0"></a><a id="Tc_9iLUcPPn-UOFeuors-iiTw_5_6"></a><a id="Tc_HCFL8LSNcEmXx1bOj5c2hg_6_0"></a><a id="Tc_QNEBp6B9fESGJ3JWhOHzLw_6_2"></a><a id="Tc_7e9uyds73k2qexjbOg9Vdg_6_5"></a><ix:continuation id="Tb_zVLzJvvhjk2npb8bfYnvKw_cont3"><ix:continuation id="Tb_txAc4B8X7k-_wku7oUoX4Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive (loss) income was as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8pxhy8PI8Ei91_HCoX_sIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_wt9P60nKy0OV9efk1EapLA_3_3">5,316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_38m67FS0GEuKtolLvc65gQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_jm0LYUCQbU-ZFiqiwBTWPg_3_6">2,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_0fmPIdzRUE-bEqICdqsXyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_7puJD3IJsEaoNMQBhlkPgw_4_3">98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ffQ1QIahIk-nBDBoGTbC3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_BgaAz3xyokG3_QuoOgZ8Xg_5_3">63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_DQ2mR4db2E2AZtwDqUTzYg_6_3">5,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_tsHYz1rER0WLhoZ2mnsFyQ_6_6">2,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33.1pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_ZdNH_3r4lUqvJLchQSuI_Q" continuedAt="Tb_ZdNH_3r4lUqvJLchQSuI_Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8)&#160;RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Services Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In August&#160;2018, the Company entered into a services agreement (&#8220;Services Agreement&#8221;) with Carnot, LLC (&#8220;Carnot&#8221;), an entity owned and controlled by RA Capital Management,&#160;L.P. under which Carnot provides research and other services to the Company. RA Capital Management,&#160;L.P. is a related party due to its equity ownership of the Company. The Company pays Carnot for services performed and costs incurred. The Services Agreement is for a term of <ix:nonNumeric contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_efAf7fiBWUqdDgHCEPGdfA" format="ixt-sec:durwordsen" name="avte:RelatedPartyTransactionTerm" id="Narr_QsHWsupPTkeRlF4AvFuFgw">two years</ix:nonNumeric>. The Company may terminate the Services Agreement by giving <ix:nonNumeric contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_efAf7fiBWUqdDgHCEPGdfA" format="ixt-sec:durwordsen" name="avte:NoticeToTerminateAgreementPeriod" id="Narr_VJso7Su_cUG_kL4L_y5iRw">30&#160;days</ix:nonNumeric>&#8217; prior notice and either party can terminate the services agreement for a material breach, if not cured within <ix:nonNumeric contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_efAf7fiBWUqdDgHCEPGdfA" format="ixt-sec:durwordsen" name="avte:MaterialBreachCorrectionPeriod" id="Narr_1UpBbpjRkEeZE8-pAk8R_g">30&#160;days</ix:nonNumeric> following notice by the nonbreaching party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In July&#160;2019, the Services Agreement with Carnot was amended whereby research and other services are now performed by Carnot Pharma, LLC (&#8220;Carnot Pharma&#8221;), an entity owned and controlled by RA Capital Management,&#160;L.P., and the term was updated to the later of (i)&#160;<ix:nonNumeric contextRef="Duration_7_1_2019_To_7_31_2019_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_524LLIpT_U62C9wdu6QZ1w" format="ixt-sec:durwordsen" name="avte:RelatedPartyTransactionTerm" id="Narr_8R71rxe3TEKXEEKQu4zYrw">two&#160;years</ix:nonNumeric> from July&#160;15, 2019 and (ii)&#160;completion of services under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Expenses incurred by the Company under the Services Agreement with Carnot Pharma totaled less than $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeStatementLocationAxis_avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_6iVtOxWY10m-DhjKq-psJw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="Narr_i-FD3-X4pUCJw2K28N3cWg">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_qimOehD_5ke94_ayOtSdCg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="Narr_DELGy-CuD0WyvpNzHCWrKg">0.1</ix:nonFraction> million for the&#160;years ended December&#160;31, 2022 and December&#160;31, 2021, respectively, and are presented in the statement of operations and comprehensive loss as research and development and general and administrative expenses. As of December&#160;31, 2021, $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_VCaJi4v2YU2yhYi2bTbHgA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" scale="0" id="Narr_HjtdPuqen0Cf25yr_1MfEA">2,000</ix:nonFraction> was due to Carnot Pharma, LLC by the Company for services rendered under the agreement, and <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_KRknw7U1FU-LFYLG7DaGWg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" scale="0" id="Narr_kqiz5VK2BkSeKoGyg5xTEQ">no</ix:nonFraction> amount was due to Carnot Pharma, LLC as of December 31, 2022.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ZdNH_3r4lUqvJLchQSuI_Q_cont1"></ix:continuation><a id="_63f8240f_6d6f_4768_930b_d09a31d23b16"></a><a id="Tc_4AYtn5DH00yRfVkCeT160w_1_2"></a><a id="Tc_JVGnd6WtT02JWlNFOBG1-A_2_2"></a><a id="Tc_movbyoBlzUiKeLty-MW60A_2_5"></a><a id="Tc_TF1odaGdBEmzqlHkBaE8Kw_3_0"></a><a id="Tc_OJfZiPAe7UOaJOYxfGNa2g_4_0"></a><a id="Tc_kHu3v0OKgU-hmmqZbQG6TA_4_2"></a><a id="Tc_J2IMg1cdZU63hbq-55r6JQ_4_5"></a><a id="Tc_uvQiV780h0OZ22crtYSpiA_5_0"></a><a id="Tc_KkNuJaFglU-qW_wMJnfV3w_6_0"></a><a id="Tc_pyEg2IWTKkyf0NEQEGTgNQ_7_0"></a><a id="Tc_3sD6_TGatkaiiCbNdb0QWA_8_0"></a><a id="Tc_FkEaZmSbJUuEWO84Zc_pQw_9_0"></a><a id="Tc_ZW0fcyISIUONWEdnRZgG5w_10_0"></a><a id="Tc_XV9Zuh9ha0izkVsHEbRm0w_11_0"></a><a id="Tc_WARzSOxWkUWO9QP_f-n2yw_12_0"></a><a id="Tc_872nMmGEykeY_4mj5S-FYQ_13_0"></a><a id="Tc_8trnp7umVkCz3CJcOALbjQ_14_0"></a><a id="Tc_RtwH-oq6hUma-h26m-GKBQ_14_2"></a><a id="Tc_ajeHz6Z7O0iWEboz2G2CFQ_14_3"></a><a id="Tc_DxC8u8awx0-k4qGOs2Gjgw_14_5"></a><a id="_f7080a3b_e5dc_4fb9_a3f4_5eba55621427"></a><a id="Tc_C1CrnlD_IEG8S-YXiH-7HA_1_2"></a><a id="Tc_7lxL9de6n0aagWEgZQW5eQ_2_2"></a><a id="Tc_03xaesFWFU-Aq86mdFRXAg_2_5"></a><a id="Tc_apJK0vT-20eqbW1Vj7aQ7Q_3_0"></a><a id="Tc_qU2V_7gw00Wx0wjnRdcgLw_3_2"></a><a id="Tc_IiB5xFM0XkC0CtmOTYoCAg_3_5"></a><a id="Tc_Hw-Qs0iRKUuwffTAvTrK_A_4_0"></a><a id="Tc_uKV2ExW0IkWNlCijF7XiUQ_5_0"></a><a id="Tc_hA9VM-6Pa0267-Wf3PW8Rg_6_0"></a><a id="Tc_5BIyk3Oa70-GK0mcqt7-NA_7_0"></a><a id="Tc_VE0JbnNtmE64Vu00AwjIBw_8_0"></a><a id="Tc_xuOR2Cqho0eWZEeqDDlt9g_9_0"></a><a id="Tc_qezGNUPPbEuEHGYPOnx21A_9_2"></a><a id="Tc_lhrP3DdEQUqzNfZCsRAH6w_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_JYRFgSrC5kKNm5obA7qisw" continuedAt="Tb_JYRFgSrC5kKNm5obA7qisw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9)&#160;INCOME TAXES</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_XDo211gxuEKnYDaj25DLTw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred income tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">NOL carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_6v6x1gFlsECwS7ky0yDyOg_4_3">11,781</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_dp-LLsIXrkqUzldfrda_Fg_4_6">7,498</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_yOxDnP-2jUmstFf9-53tEA_5_3">1,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_6NwV0V0yyUmshm_vINkPdw_5_6">530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="avte:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" scale="3" id="Tc_UT0nnhlLsUGa_VgfHJVGww_6_3">8,490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_E0ae-PWvkE-yL5o9JZGx5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_ULB74I1QAUWM1PjbXh3MQQ_7_3">1,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_Er4qVao84EmpmbOHl3GgKw_7_6">615</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_LNqVjhi7r02rWwYmRIp_ag_8_3">23,585</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_I763L93SEUKEAKssXU4HRg_8_6">8,643</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_kcfsrp8d5kyY_N3oZJMiZw_9_3">23,283</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_dVU-2wYGJUObvgX9BGWs6g_9_6">8,517</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_8QyZ_DHAukq6qN_aZ-cVVw_10_3">302</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_05acbkki-E6BCHokjMHp3g_10_6">126</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred income tax liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="Tc_GQs38gtDN0KlV3e0kuNZWQ_12_3">302</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="Tc_KWKLgPzrwkiT5tcCcC2PyA_12_6">126</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="Tc_Utck1ThWmku7UUjijZkB5Q_13_3">302</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="Tc_yOMDFeQRgUGy6DV0F-z2Rg_13_6">126</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax assets (liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_nezSGvSzDU6xkqS5dwZsuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_grA669EFjkGNr9NoCceaaA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_ewdtZ242JkitGzEQ4eDklg_3_3">10,829</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_ZingQ7-Z_UOig35Mfatc3w_3_6">4,821</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" sign="-" scale="3" id="Tc_aR4ItJQ1mkGBmMGBSNWYqw_4_3">2,828</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" sign="-" scale="3" id="Tc_zuYpbR8azUuiI56CtlSMIw_4_6">520</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent and other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="Tc_jCwthPTy20iNBtGuRsCI1Q_5_3">563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="Tc_AjTI0p1rLk2J3-1UgdcD6A_5_6">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" sign="-" scale="3" id="Tc_hUk0QS6Vq0yjqExa7mCmJg_6_3">787</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="Tc_qU4n7ToO8UaHtHzBRGs_Ng_6_6">115</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="avte:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" sign="-" scale="3" id="Tc_7ALV_3iZ6Uyc8pNsFWhL0g_7_3">757</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="avte:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" sign="-" scale="3" id="Tc_UlYXiOzmVUS1ed9rSp44Pw_7_6">392</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="Tc_qtbkMVwyA0euG0NgpmtEZQ_8_3">14,663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="Tc_YxjK3b6bF0WBjqOD4Hcpxg_8_6">5,618</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_GF7XabABfEa7GLqSLW1azA_9_3">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_JKzf0oDUC0qC7LhzmLhNiw_9_6">3</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company had federal NOL carryforwards available of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bX05x-nRLk2IigYinMKBjw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_nsRwifj8C0mzMUBNAz9Hbw">46.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_gjNW4nJ7gUG3lYvOm_OCOQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_xTeS6qGCm0-XlhYaeObEgQ">32.6</ix:nonFraction> million as of December&#160;31, 2022 and December&#160;31, 2021, respectively, before consideration of limitations under Section&#160;382 of the Internal Revenue Code or Section&#160;382, as further described below. The NOL generated from 2018 onwards of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bX05x-nRLk2IigYinMKBjw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_3Q45e_qgoEeaWxX_PZnW6w">46.6</ix:nonFraction> million will carryforward indefinitely and be available to offset up to 80% of future taxable income each&#160;year. Additionally, the Company had state NOL carryforwards available of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember__U571LHq90ebMUCnu-8gKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_hQLYCZH8hkysqe2A-jJ-cA">34.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_c5GfZjqasEeR4_aZW3f6NQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_zMlwPQJGIEOxXkz-C0k2ag">20.3</ix:nonFraction> million as of December&#160;31, 2022 and December&#160;31, 2021, respectively. The state NOLs may be used to offset future taxable income and will begin to expire in 2038. At December 31, 2022 the Company had federal and state research and development credit carryforwards available of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_rRDeb8AKE02Eu6qsh0BInw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_CEf9f15k70qbuqBBt81FwA">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_Gyry4bLRNEOzHxfxq7X4iw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_km5G4IPY3EylVZnQwJojvg">0.6</ix:nonFraction> million, respectively. The federal credit carryforwards will begin to expire in 2038, unless previously utilized. The Massachusetts credit carryforwards will begin expiring in 2036, unless previously utilized. The California credits carry forward indefinitely. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;">The Company has established a full valuation allowance for its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred since inception. Such objective evidence limits the ability to consider other subjective evidence such as the Company&#8217;s projections for future growth. Based on this evaluation, as of December&#160;31, 2022 and December&#160;31, 2021, a valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_bUvxS6H-kECPr7hJrUxKqQ">23.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_VP13bagYQkSC8nhW3S3Qmw">8.5</ix:nonFraction> million, respectively, has been recorded against all of the Company&#8217;s net deferred tax assets, as the Company has determined that none of the Company&#8217;s balance of net deferred tax assets is more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted in the future if objective negative evidence in the form of cumulative losses is no longer present and </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0e4b565f_9ef7_47a6_8586_465eaadc8021"></a><a id="Tc_8qakOiwVA0-V3AZ257xdEA_1_2"></a><a id="Tc_N2ug7ibybEW2uazvmaN2Tw_2_2"></a><a id="Tc_0I7-QS_JFkyJig8UmmdwEw_2_5"></a><a id="Tc_ClbbMSsezUKX5xN8olpHYw_3_0"></a><a id="Tc_504Z8Q7YqUalHZJxH9YnUw_3_2"></a><a id="Tc_Se3nVmTsA0-VVMQbxOEWEA_3_5"></a><a id="Tc__cXyC5EEKUusm9z-5gpGkA_4_0"></a><a id="Tc__Otw93hNlEyiCJNA7QLSKQ_5_0"></a><a id="Tc_r1hWVNaPKk6t9NTXLJyj9w_6_0"></a><a id="Tc_x6ZEIRZphkyITJ8R1MXJag_6_2"></a><a id="Tc_4Dgsm2YMDEKEpeVqrkX_OA_6_5"></a><ix:continuation id="Tb_JYRFgSrC5kKNm5obA7qisw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">additional weight may be given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company&#8217;s projections for growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The future utilization of the Company&#8217;s NOL and tax credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold 5% or more of the Company&#8217;s common stock. An assessment of such ownership changes under Section&#160;382 and 383 was not completed through December&#160;31, 2022. Utilization of our net operating loss and income tax credit carryforwards may be subject to a substantial annual limitation due to ownership changes that may have occurred or that could occur in the future. These ownership changes may limit the amount of the net operating loss and income tax credit carryover that can be utilized annually to offset future taxable income. The Company will examine the impact of any potential ownership changes in the future.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_sHnfWcDim0CRreeNVbNKvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The following table summarizes the activity related to the Company&#8217;s gross unrecognized tax benefits at the beginning and end of the&#160;years ended December&#160;31, 2022 and December&#160;31, 2021 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance of unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_QLxocEOyOUCGelnNbeSz7Q_3_3">529</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2020_lex_lE13Tka9RtZYzaRxrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_cH8nRBBfxEOW_Qtdo2Fuig_3_6">276</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions based on tax positions related to the current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_NAN2yHYIakWKJSBPf_FZng_4_3">461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_plowHCivrU23GDJgPo0MrQ_4_6">253</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions based on tax positions related to the prior year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_Ay9yuC_dskSEUDJPcOWYvw_5_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_8vjjWyCvikyedSLToWmJjA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance of unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_5T5dTIgkXkGtx_Twmzv_-Q_6_3">993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ" contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_j8Tw9mEX_UuXsHf7n2sjAQ_6_6">529</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The unrecognized tax benefit amounts are reflected in the determination of the Company&#8217;s deferred tax assets. If recognized, none of these amounts would affect the Company&#8217;s effective tax rate, since it would be offset by an equal corresponding adjustment in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company is subject to taxation in the United States and various states. The Company&#8217;s Federal and state returns are subject to examination, as 2018 was the first&#160;year of operations for the Company.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9cb71922_32e4_44e4_bb65_6f0e2f457fa8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="5" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT INDEX</b></p></td></tr><tr><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:88.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:8.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3.1</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:88.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921088918/tm2121331d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-40544) filed with the SEC on July 2, 2021).</span></a>&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3.2</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921088918/tm2121331d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-40544) filed with the SEC on July 2, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.1</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1A (File No. 333-256949) filed with the SEC on June 17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.2</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921078871/tm2114556d4_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Investors&#8217; Rights Agreement among the Registrant and certain of its stockholders, dated August 5, 2020 (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-256949) filed with the SEC on June 9, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.3</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000149315222008189/ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-40544) filed with the SEC on March 30, 2022)</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.1#</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921078871/tm2114556d4_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2018 Equity Incentive Plan, and form of award agreements thereunder (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-256949) filed with the SEC on June 9, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.2#</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 Stock Option and Incentive Plan, and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form S-1A (File No. 333-256949) filed with the SEC on June 17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.3#</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form S-1A (File No. 333-256949) filed with the SEC on June 17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.4#</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form S-1A (File No. 333-256949) filed with the SEC on June 17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.5#</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Registration Statement on Form S-1A (File No. 333-256949) filed with the SEC on June 17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.6#</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Employment Agreement (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form S-1A (File No. 333-256949) filed with the SEC on June 17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.7#</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form S-1A (File No. 333-256949) filed with the SEC on June 17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.8</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921104289/tm2125007d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease, dated August 6, 2021, by and between the Registrant and PDM 930 Unit, LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-40544) filed with the SEC on August 12, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.9</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000149315222011470/ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease, dated April 26, 2022, by and between the Registrant and Hudson Metro Center, LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-40544) filed with the SEC on April 29, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">21.1*</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries of Registrant (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-40544) filed with the SEC on March 30, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">23.1*</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of KPMG LLP, Independent Registered Public Accounting Firm.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">24.1*</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#SIGNATURES_810279"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on signature page).</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">31.1*</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:88.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">31.2*</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">32.1**</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">32.2**</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.INS*</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Instance Document</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.SCH*</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.CAL*</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.DEF*</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.LAB*</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.PRE*</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">104</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Cover Page&#160;Interactive Data File</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>Filed herewith.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Indicates a management contract or compensatory plan, contract or arrangement.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The certifications furnished in Exhibit&#160;32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form&#160;10-K and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f6f9bb5e_e1a6_4c9f_9280_13da0bc97d81"></a><a id="SIGNATURES_810279"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form&#160;10-K to be signed on its behalf by the undersigned, thereunto duly authorized<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:44.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:47.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">AEROVATE THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:47.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Date: March 29, 2023</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">By: </p></td><td style="vertical-align:top;width:44.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><i style="font-style:italic;">/s/ Timothy P. Noyes</i></p></td></tr><tr><td style="vertical-align:bottom;width:50.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Timothy P. Noyes</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Chief Executive Officer</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each person whose individual signature appears below hereby authorizes and appoints Timothy P. Noyes and George A. Eldridge, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form&#160;10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form&#160;10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on March&#160;29, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:36.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:26.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:26.24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><i style="font-style:italic;">/s/ Timothy P. Noyes</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Chief Executive Officer and Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.24%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">March&#160;29, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Timothy P. Noyes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">(Principal Executive Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><i style="font-style:italic;">/s/ George A. Eldridge</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.24%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">March&#160;29, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">George A. Eldridge</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">(Principal Financial Officer and Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Accounting Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">/s/ Mark Iwicki</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.24%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">March&#160;29, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Mark Iwicki</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">/s/ Allison Dorval</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.24%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">March&#160;29, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Allison Dorval</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">/s/ David Grayzel, M.D.</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.24%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">March&#160;29, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">David Grayzel, M.D.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">/s/ Maha Katabi, Ph.D.</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.24%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">March&#160;29, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Maha Katabi, Ph. D.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">/s/ Joshua Resnick, M.D.</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.5%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.24%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">March&#160;29, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Joshua Resnick, M.D.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">/s/ Donald J. Santel</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.5%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">March&#160;29, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Donald J. Santel</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>tmb-20221231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 08:26:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LIST OF SUBSIDIARIES</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Subsidiary</b></p></td><td style="vertical-align:bottom;width:1.99%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Jurisdiction of Incorporation</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Aerovate Securities Corporation</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Massachusetts</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tmb-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 08:26:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We consent to the incorporation by reference in the registration statements (No. 333-257579 and No. 333-263990) on Form S-8 and in the registration statement (No. 333-266883) on Form S-3 of our report dated March 29, 2023, with respect to the consolidated financial statements of Aerovate Therapeutics, Inc.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">/s/ KPMG LLP</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">San Diego, California</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">March 29, 2023</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>tmb-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 08:26:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) / RULE&#160;15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I, Timothy P. Noyes, certify that:</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">1.&#160;</font><font style="font-family:'Times New Roman','Times','serif';">I have reviewed this Annual Report on Form 10-K of Aerovate Therapeutics, Inc.;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">2.&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">3.&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">4.&#160;</font><font style="font-family:'Times New Roman','Times','serif';">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">a)&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">b)&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">c)&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">d)&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="margin-top:12pt;"></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">5.&#160;</font><font style="font-family:'Times New Roman','Times','serif';">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">a)&#160;</font><font style="font-family:'Times New Roman','Times','serif';">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">b)&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;"></div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">/s/ Timothy P. Noyes</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Timothy P. Noyes</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dated: March 29, 2023</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Chief Executive Officer</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(Principal Executive Officer)</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>tmb-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 08:26:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) / RULE&#160;15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I, George A. Eldridge, certify that:</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">1.&#160;</font><font style="font-family:'Times New Roman','Times','serif';">I have reviewed this Annual Report on Form 10-K of Aerovate Therapeutics, Inc.;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">2.&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">3.&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">4.&#160;</font><font style="font-family:'Times New Roman','Times','serif';">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">a)&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">b)&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">c)&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">d)&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="margin-top:12pt;"></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">5.&#160;</font><font style="font-family:'Times New Roman','Times','serif';">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">a)&#160;</font><font style="font-family:'Times New Roman','Times','serif';">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:nowrap;">b)&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;"></div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">/s/ George A. Eldridge</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">George A. Eldridge</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dated: March 29, 2023</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Chief Financial Officer</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(Principal Financial and Accounting Officer)</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>tmb-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 08:26:34 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In connection with the Annual Report on Form 10-K of Aerovate Therapeutics, Inc. (the &#8220;Company&#8221;) for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><div style="margin-top:12pt;"></div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">/s/ Timothy P. Noyes</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Timothy P. Noyes</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dated: March 29, 2023</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Chief Executive Officer </b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(Principal Executive Officer)</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>tmb-20221231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 08:26:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In connection with the Annual Report on Form 10-K of Aerovate Therapeutics, Inc. (the &#8220;Company&#8221;) for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><div style="margin-top:12pt;"></div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">/s/ George A. Eldridge</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">George A. Eldridge</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dated: March 29, 2023</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Chief Financial Officer</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(Principal Financial and Accounting Officer)</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tmb-20221231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &F XD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHI,CUH$+13<^U*#0,6BDS2T %%%% !1110
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MYZB#[4M9VF:W::O&)+6=)5QS@\C\*O[L]*@Z8M25T.HI!TI:"@HHHH ****
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M6WE6:,C[RFK.[/2D="=]AU%(*6@84444 %%%% !1110 4444 %%%% !1110
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M87C;Q);^$/"FK:U=,%AL;9YSD]<+D#\34I\7:/\ :$MQJ5I]H=BBQ&==S-Z
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M5EN1RR^>S2.S/GHO\<G^ KR_XIWLM_XCT_3V;]U#%YS1KPH))_\ K5ZI%!%
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M:J(, #L *DQFEI#L%%%% Q*Y/XH?#S3?BGX#U?PMJP)L=2@,3,GWD;JKCW#
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M5(P1^%<E\4/"D7B7P[<PN.73 ([. =IKS*#QCK/PHOX=/USS-2TY^(-0C&)
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MUS*9[RUA-A.['YB\1V9/N5VFO;@,5^BMM[GXEZ#8U*YS3Z**D84444 %%%%
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M!96]_JMQ<V\8[QX1,CV+(QKZ9'2LWP]H5CX;TBUTS3+2*QT^TC$,-O @1(T
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MQYU/1I1%JL0N$5MIGM_D?\5Z&O2+/X^Z#/"6>\2,@<B6)E8?EP:BMP_5C/\
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M ?&>J6C%+E;%H8V'\)D(3/Y,:_,;]FQS%XSNE9"K26RLFX8R-W;\Z_6;XH>
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M(1Z4M% "48I:* $VCTHQCI2T4 )BC:/2EHH 2C /6EHH 3%&T#M2T4 %%%%
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MM?R/V3.\J_MC"O#1J<KNFGZ'!_#?X:6?A73TV@/*WS23.,-*?Z#VKT G: ,
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M3@,5D>I""@K"T444&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4QE![4^B@35S(UKPY8Z['MN(07'W7 P17FVN_#2]T]FEM5^TQ
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MHSF]BUHXHQ2-Y!GVE/[J':OYT[[7 #MC@=\=HVX_7%:8\":ON#26$TI'3?\
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MK%TXT:\J4?LZ?-;CZ***W.4**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@""<X#8^]CBO-O!GC:^^U^*K
M'6Y5DGTJ4R*P7;F(Y*FO2I%W-@]*\4^*O@C7+KQ1]LT* 20ZG;?8[P[@ HW#
MG\@:X<4ZD4IPZ'IX"G2JRE1JV7,M&^EG^JN;WA;XA75MX1BUC6DGN)+^X?[+
M#:6Y=@F?EX'L.M:UO\7M#ET&YU1WN($MI1!+#+"1*LAZ+M]36/XVT76K'1="
MLM%CG:RMF6.[CM'"2E ,?*U<II/@Z^M]&\4KJ6@W5[#>WD4D4+3@R[1GYMV?
MO#BN9U:T9**6ECO5##5Z<JTG;71)ZVO;\M3TG_A9FE1:)-JEW%>6$,;B,I<0
ME'+'H%'<GVI?#GQ0TCQ!<W%L@N;*ZAC\UH;V(Q,4QG< >HKS@>#?%-[X4C$L
M$MP]EJ*W5G:7<H,AB7^%F]:U5\.ZUXT\47FL7=@=(@339+**.20%W9L\G'8&
MCZQ7EHEJOQ']4P?*_?[ZWVU5M//\#K]#^*^C^(=0:VM4N_+"LRW4ELRPL%ZX
M?I5.T^-.@7=_' %NT@ED,,5Z\!$#L.P:L'P;9^((/#R^%[W1S:Q1VLL!O_-&
MTY!"E0.>:P;;PMXEU+PQI'A.XT?[(EI<1F2_,@*%%;.1CN::Q%5I6_+KV"&"
MPSE)2EL_YNFNJ[]-/,[[6?C)H6BZA?64B7DUS9D"18;=GX(!W9'& #5O4?BG
MH]EI^FW47GWO]HKNMXK:(N[CN<>U<WIWA2_AUWQS,UH&@O+=4MR<'>=F#^M<
M]+X.OH? 7AVRGT:\EU*UB?RKBRF"/;OV!YY!H]O746W^0EAL%>,>;MU[J_X,
MZ3Q)\9/['\0:);16%R]E=Q>;,&MF$H!' 4=SGJ.U:[_%W1EUHZ1Y-W+?"2-&
MCCA)V[E# GT SS7):GH?BBTC\':M+9?VKJ&G"1;F*-QN;</EY]JZ'P;X?O[/
MQ]XIU2\LS!#="'R7;!SA1D4H5:[D[]UT[H4\/@U2YFTVEWW?-;_@B:%X^M=*
MT+6-3U75)KR""_:$%X-K*<@+&H'WNM4O%'QG6S\,_;].L;M;GSUB,=Y;L@4'
MG)[\CI7.W/@'79O#5V8;4-=VVN_VC%;NX_>Q@Y ST&:Z'Q7'KGC?P'>Q'16L
M+I)HWBMVD4O*%.3R.E+VU>497T^1T?5\&JT)734I6>MK+2W]>1:C\<#5?%GA
MGR[V\L8+R&9FL)[0J)=H/))^[C'XU=?XU>'X;WR,W;VXE$!O1"?(WDXQOZ=:
MPKC1-9UWQ3X5U.;3)+&&*SGAG#L#Y9*D#ZYR*YZ/POXF/A!_!G]CJP:YS_:1
ME4)LW[MV.N:B5:ORM);=?/33YD+"X67+S26VJOMJU?Y6/2=?^+.B^'M2EL)Q
M<RW,<:2[+>(R;E89!&.O'6ND\,>(K+Q3I,.HV#E[>4<%A@\'N*X'3/"=_;?$
MK4KN2V#V/]DI;1SM@AG&.,5O?"'1[S0O"2VE]"8)UGD;82#\I8D5UTJM657E
MDM-?E;_,\_$4</"C>F[RTZ[W_P CMZ***] \D**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BF/)L[$TP7 )QC!H FHJ,2$]!D?6G,=JDT *1G%-$8'89HCD$@R""/4&G
MT ,\L8Z"D\K/I4E)0*PP0C/04@A ]*&F"C)( ]_2G(^_/''KFDM-AC3"#Z$4
M@MQG)QFIJ*8K(9LXQ2&($YP*>>!437 09;@9QUI60QQA'M]<4OECV^M",6)R
M,4^F]06FQ'Y0]!CTQ2[*=1D^E K#/*^GY4&+G(P#0LH9L$8STR>M24!8C\KZ
M4>2/09J2HVD"+EL#G'7&32L%B.2W5E*D J>V*HZ+X?L="MC;6%K':PEBY5!P
M2>IK3B<2#((/N.E*QQR.?:ERK<+M)Q6P@C &, #VH\L>@IHF!) *EASC/.*%
MF#D@=O>J"R';!Z TT0@?6I&8*.:1&WKF@+#1".I S5+5](M]9LYK2[B6>VE&
MUXF'##WK1HHZ6&4K*PBL88X((UA@C&U(T& H]!5P#%#':I-,24,Q&1D=0#T^
MM*UAMW=V245&9E#[<C)Z#/)H\T4Q$E%(#D4M !1110 4444 %%%% !1110 4
M444 %%%% !1110 444AH 6BHVDVM@#-/!R* %HHHH **** "BBB@ HHHH 0@
M&HFA+ C(P?:IJ9)*(UR3@=,T":ON-$./2CR02<@>OXTC3@ D\<XY-2JVX9IW
M"PP18YXSZXH\E<YP,_2I**0[$?E YR :00 =<&I:*!63T(_)7!P,9YI!#@Y&
M*D)P*:L@8D"@+#?)QTP/PI1"!Z&GT$XH"R&+"%/0?E1Y?(/'Y4\$^E,:8+DG
M@#CDXIW"R!H\^E)Y"XQ@?E2-<*"!D GH#WJ1&WKFIL%D((Q2JNVAGV@FF";)
MXIA8EHI <BEH&%%%1M+M)&,T 245#]HQ)L. <9QGFI0<C- "T45&\H3&?YT
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MTL:7$$L*N,Q.VY,$D'GG ((KV:'X1^%;?3A81Z)9I9B*6'R0AQLE8-(.O\1
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M&JVMM:W=K'<06TT4\,<@X22,[HV&/[I (^E)RCV+M+N>)WGQQ\36FG:E8/\
MV2OB>PU*>S(CMKB:.Z6. 3!HXE^8<, Q8X7&<&K'ASXW>*?%VH&6RLM-M=+M
M_#5KKMR)M[RL\HG'E)@@8!B!W$>V.<CTC5_A/X5UB6::]T6VEEGN&NI),LK-
M(R!&.00>5 !]A5O2? /AW289H[#2K>UCFLTT]_+4@&W0-LCZ]!O;_OHU5XOH
M2E+N>8V/Q.\>ZJ/"VFQKH5GKNM:7)K+2S12O;6\*K'B+[P9V+/RV0 !T-8NJ
M_M,:SIOAV*Z&D6\M_?V5G>Z=9J[?O5+N+L%LY.Q8G8''(*YKV/7/AAX;\2V&
MGV.I:1;W5K8(([5&W*85 VA592"!@ 8[XYJ6X^&?ARZNM,N9M'M'GTRWDM;)
MRG^HBD4*Z*.F"H HO'L#4NYY/J?Q[UV_U!;;0;*&XBNY+N2QN8[26Z$L$'EJ
M"5C8'YY&8%NBJ,X/2L'XB_$;QAXO\)ZJ8[2ST.PT^;2H[VVN3(+LRS&&5PC
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MP"00Q9<Q+(J.2S-@M]W:".]>XZUX0T37]7L=1U#3K>\U"P22.":5<M"DB[7
M]F'%4M(^&_AK2=/L;"RTBT@L[&&6T@@13MCCD_UB@>C=Z?-%;DM2>QX?>>(/
M'>F>)?#^HPW6EWVIQ>#KB_NI+A)5AD598V4",,<N5PI8MP23BO5?$?Q)OK'X
M,GQCIMG%->O90W,-M<.5C9Y"@VDCH/GZUN:7\,/#>C6RP6>DP0QK:R62KN9L
M0R-N>/))X) -:-QX8TJ7P\NAR649TA$2%;7G;M4C8/PP/RHE*+V&DT>.^(OC
M!XYT#Q#<^'X=,@U?5-,L(M0N_L5C.\=T9)' BC()\L!4^^V<D]!G-9USX_\
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M<VL$L,\WEX;S1N8#@B10 <_=%:;?&SQ>FJ/X4>RT4>*SK']FI>D3"P6/[/\
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MZT8/K3J* $YI:** "BBB@ HHHH **** "FXIU% " 8I:** "BBB@ II%.HH
M0#%+110 W%*!BEHH **** "D(S2T4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tmb-20221231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'H R<# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<MX_\,7'
MBW3+"QCECCMEU&VN;M) 3YL,<@D9!CN2J]>*ZFB@35U8X;QKX7UF^U?2-=\/
M7-G;ZKIZ36YBU%':":&7;N!*'<I!16!'H0:O_#_PO-X3T(6UY=)>:C<7,U[=
MW$:;$DFE<LY523@9. /05U/>N6^(#,ND0$,P/VR#E3@_?Z5:;E:)BXQBW/\
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M1N/]YOS-'('M/([/-&:XS<?[S?F:-Q_O-^9HY ]IY'9YHS7&;C_>;\S1N/\
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M<4[FHW:LGQ5_R*^L_P#7G-_Z+-;ALKD_\N\GY5D^*[*X7PMK),+@?8ISR/\
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M@K7O^O&;_P! :M?3O^/"V_ZY+_(5D>/_ /D2M?\ ^O&;_P!%M6OIO_'C;?\
M7)?Y"GT,_MOT+.*,4M%(T$Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!
M,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q01FEH
MH YSQYX%T[XB>')M%U.2\BM)65V:PNWMI<J<C#H01[^M?,'A[]GSPYJ'Q_\
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M4 %%%% !1110 5X7X/\ ^3N?B)_V+FE?^ARU[I7A?@__ ).Y^(G_ &+FE?\
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M?\G+?%#_ +!>C?\ H,]>Q+6M7XEZ+\D<>%^&?^*7YCZ***R.P**** "BBB@
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M/[;]"U1112- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\+\'_\G<_$3_L7-*_]#EKW2O"O!W_)W/Q$_P"Q
M<TK_ -#EKHH[3]/\CAQ6]+_%^C/<UZTZFKUIU<RV.U!112,<4QBTF:HZIK-E
MHUL;B^N8K6$=7E?:/_KUY]J/QB;4[AK'PMI,^LW/3SBI6(>_J?QQ5QISGLM#
M&56$-&STR29(D+NP1%Y+,< 5P?B+XPZ+I4YM;$OK%^>%@LQN!/\ O?X9K'B^
M'7B/QE()?%FM216W7[!9$*N/0XX_0FNZ\/\ @W2/#%N$TVRCMV[R 9=OJQYK
M2T*>[NS+FJ5=O=7<X4:=X\\=\W4Z>%]-?_EE'GSF'OW_ #(^E='X9^$^A>&V
M$HMOMUV#N^TW9WMGU'8?E^-=H!@"EI.K)JRT7D6J$$[O5^8P+@  8Q3)<^6^
M.I%2GI4;_=/TK!FS6C1Y+^RD,_ KP]_UTN__ $IEKUTBO(_V4/\ DA7A_P#Z
MZ7?_ *4RUZ]71B/XT_5G+@_]WIOR0QDW#!K"UCP+H>N@_;-*M9F/\>P*WYC!
MKH**Q3<?A=CJ<8O='F-U\#K*WD:?1-4O]'GZ@1R;US^A_6H?[-^)/AK_ (][
M^SU^ =$G&V0_R/ZFO5*:2#6WMI/XM?4P>'A>\=/0\N3XOWVC/L\1>&;W31WF
MB&]/UQ_.NDT;XJ>&-:"B'588I#U2XS&1^?'ZUU3PI*I5E#*>H/(KF]8^&OAO
M7=QNM*@\P_\ +2)?+;\UQ2YJ4MU;T)Y:T?A=_4Z5+B.6,2(ZNAZ,IR/TI?-4
M]Z\PF^"[Z6WF>'_$-_I3=1&6WJ3^&/Y4S?\ $KPX,M'9>(H5[IA9/Z']#3]G
M%_#(/;2C\4'\M3U,R!>M <'D'BO#O'/QUU;0_"]\R>&KFRUI%Q$MP&,;$\9!
MQU!Z9!'K@9KE-;_:BU'P1\#+7Q3J&GV-]XA6YBLYM,%PT3C.59W^0?-N0GY1
MM((P<5:PU26R,)X^C3OS.UE<[GP.<_M+?%#WTO1O_09Z]B2OSAT;]N74=&^(
MGB3Q8OA*VEDUNUL[9K8WK!8A ' 8-LYSYGZ5]Q? OXDS?%OX8Z-XJGL4TZ6_
M$I-M'(9%39(R?>(&<[<UKBL+5HJ,YJRLD<>79CAL2Y4Z4KN\G\K_ /!.^S1G
M-4=8UO3]"MQ/J-Y!8P%@HEN) BY],FL@?$?PL0/^*BTS_P "D_QKAM)[(]MS
MBM&SI:6LC2/%FBZ]/)#INJV=_*@W,EM.KD#U(!^E:P.:6JW*33U0M%%% PHH
MHH **** "BBB@ IIZ_A3J0]: ,/Q7X5T7Q;IOV77+"WO[:,^8GGC!B8?Q(XP
M4(]00:\^\-?#;X9ZQ=QR6=Q'XD(=FB@O-:FU&$%" Q6)Y&4[20#P<'%=A\4?
M#MQXK\!Z[I-K/'!-=6S(K3,5C/0E7(Y"L 5)[ FO#_AII]QJ_CZQ!T71O#<-
MGK-SJL3VVK6D\OER6RQ?9H8X&SL8C<Q8#A%X)Y'1!7@W>QYM>2C5BN2_R/IF
M!41=J!54< *, 5+44 PI&<_C4M<YZ*V"BBB@84W8OI3J* &>6N[..?6N9\>G
MRM*MF7@B^MS_ ./UU'>N6^(7_(&@_P"OV#_T.G#XS.?PLE.NW7H@_"LGQ=K=
MQ+X3UI&"X:RG4D#_ *9M4YZ"LGQ5_P BOK/_ %YS?^BS6R2N<TI/E.\T7_D%
M67_7%/\ T$5>JAHO_(*L_P#KBG_H(J_6+W.N/PH****104444 %%%% !1110
M 4444 %%%% !1110 4444 <_X]_Y$S7N_P#H,W'_  !JJ66N72V5N!LQY:]O
M85;\>_\ (EZ__P!>$W_H#5B6G_'I;_\ 7-?Y"M8ZHYIM^TT[&M_;]W_L?]\T
M?V_=_P"Q_P!\UG446'<T?[?N_P#8_P"^:/[?N_\ 8_[YK.HHL%S1_M^[_P!C
M_OFC^W[O_8_[YK.HHL%S1_M^[_V/^^:/[?N_]C_OFLZBBP7-'^W[O_8_[YH_
MM^[_ -C_ +YK.HHL%S1_M^[_ -C_ +YH_M^[_P!C_OFLZBBP7-'^W[O_ &/^
M^:/[?N_]C_OFLZBBP7-'^WKO_8_*C^W[H=2GY5G5S'C7PQKGB068T;Q==^%O
M*W>:;6TBG\[.,9WCC&.WK51BF]3.<Y13<=3N/^$@NC_SS_*E_M^Z_P!C\J^=
M/AKH_CSQFFN3W'Q/U.$:7K=SI@1--MB)4A9<$G&1G=T%>]'MU...:TJ4U3?+
M>YCA\1*O'F<6E\OT-#^W[O\ V/\ OFC^W[O_ &/^^:SJ*QL=5S1_M^[_ -C_
M +YH_M^[_P!C_OFLZBBP7-'^W[O_ &/^^:/[?N_]C_OFLZBBP7-'^W[O_8_[
MYH_M^[_V/^^:SJ*+!<T?[?N_]C_OF@Z]=_['_?-9U<K\3]7\0:-X/O)_#%BF
MH:NQ$,,# [MS_*I7Y2"0S*?FPN <X JXP4FD9SJ."<NQWG]O7>?X,_[M>-^%
MM2EC_:K\?2C8&;PWI9;CC[\G^-2:Y\7KGP#\'8_&?B;19//5D673K1BDB[GV
M -Y@&&R"3VZ8XQ7SAI/[8^A:?\8/$/C!O#NJ/::GI=I81VZS1>;&T+,2Y)XP
M=PQCWKNH8:I)2<8Z;'BXS,*%.=)3G9WO9^C/N[^WKK_8_*@:_=?['Y5Y%X0^
M/V@^,O!NGZ];VMW#+>!_+T\D22H0Y7#$<<D$\5=\WQ?XO_U:KX=T]N=SG]ZP
M_GG\JYGAY1^+0]*.+C.*E3?-<[W6OB+:^'XRU]=PQ.!Q"!N=OHHY_.N5D^)?
MBCQ46B\/Z:+:VZ?;;H?J,\?H:=HOPXTC2F$TR-J5WU,UT=PS[+TKJ@ JJH&%
M48 ' 'X4_P!U'97'^]GK)V1QMG\.A?78OO$=_-K5V.=C,1$I^G7'Y5W5A=#2
MK=;>SMK:VA7HD,>U:KT5G.3GN;0A&&QH?VY<^D?_ 'S2_P!O77_3/_OFLZBL
MN5=C;F?<T?[?N_\ 8_[YH_M^[_V/^^:SJ*+"N:/]O7?^Q_WS0-<N6.&V8]A6
M=2@<BAK0F3=CSS]F'5[BV^"6@(FW'F79Y'_3S+7J?]OW?^Q_WS7C_P"S1_R1
M;0/]^Z_]*9:]/K>NOWL_5G-A'_L]/T1H_P!OW?\ L?\ ?-']OW?^Q_WS6=16
M%CKN:/\ ;]W_ +'_ 'S1_;UU_P!,_P#OFLZBBP7-'^WKK_8_*C^WKK_8_P"^
M:SJ*+!<T3KUT>OEG_@-(=<N3U$?_ 'S6?118+EZ75I;E"DT<,J'JLB;@?PKY
M]_:S^&,_C'X8O#X7\-B[ULW\#^7IZ!7,8W;C@D @<5[I01FMJ525*2E'H<N)
MHQQ--TY]3\M+'X _$34=;OM(MO"&I3:E81Q2W-LJ*6A63)0G)[A6Q]*_2']E
M+POJ_@WX&>&-(URPGTS4[99Q-:W ^=,S.PS]0<_C6=\,T!_:'^)G _Y!.B_^
M@SU[<@QCBNO'8R>(2IR2Z,\C)\JHX-NK!MO5?*Z_R*VI:39ZQ"(;ZT@O(0=P
MCN(PZY]<&LP^ _#8'_( TS_P#C_PK?IK=*\KF:V9],X1D]4>=)HUAHWQ@TE+
M"RM[)'TBY++;Q+&&(ECQG &:]%6N%U#_ )+)HW_8'NO_ $;'7<KWJYN]O0QH
MI+F2[CA2T@Z4M9G2%%%% !1110 4444 %)2TAH \_P#C4]MJ7P_\0:,U]9VU
MY=6$CQQ75VEN'1<%BS-TCZ*S=@U>>?"[Q-H=]XKTVUMO!G@32;LAL76B:Q9S
MSQD(<^6B1ASZ<8XKT#XMZ7>2:<VK1^([3P[I]A;RM>276D17P>,X)'SD$#C[
MHSN)%>:_"W5C-XPTIKO6'B>:YN;5;2Z\'P:?(TT488QF56)C8HX< X+!6Z<B
MNNG%.FW_ )GE5I-5XK_(^BH>AJ2F1YYR.]/KDW/5"BBB@ HHHH 3O7+?$+_D
M#0?]?L'_ *'74]ZY;XA?\@:#_K]@_P#0Z</C,ZGPLJMVK*\4J6\,:N%!9C9S
M8 Y_Y9D?SQ6JW:FUT7LSE:NK#]+^(WAB+3K1'UVQ5EB0%3*/[H']#5O_ (65
MX5_Z#UC_ -_15' ]*,#T%3RQ-%.:5M"]_P +*\*_]!ZQ_P"_HH_X65X5_P"@
M]8_]_15' ]!1@>@HY8CYY^1>_P"%E>%?^@]8_P#?T4?\+*\*_P#0>L?^_HJC
M@>@HP/04<L0YY^1>_P"%E>%?^@]8_P#?T4?\+*\*_P#0>L?^_HJC@>@HP/04
M<L0YY^1>_P"%E>%?^@]8_P#?T4?\+*\*_P#0>L?^_HJC@>@HP/04<L0YY^1>
M_P"%E>%?^@]8_P#?T4?\+*\*_P#0>L?^_HJC@>@HP/04<L0YY^1>_P"%E>%?
M^@]8_P#?T4?\+*\*_P#0>L?^_HJC@>@HP/04<L0YY^1>_P"%E>%?^@]8_P#?
MT4?\+*\*_P#0>L?^_HJC@>@HP/04<L0YY^1>_P"%E>%?^@]8_P#?T4?\+*\*
M_P#0>L?^_HJC@>@HP/04<L0YY^13\9?$#PY>^$]9M[?6;.>:6SEC2-),LS%#
M@ 5/:#;:P ]1&H/Y"I<8I:>B5D9N\I<TA****"@HHHH **** "BBB@ HHHH
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M<X>S?<Y;%&*ZG^R;/_GW2C^R;/\ Y]UHYP]F^YRV*,5U/]DV?_/NE']DV?\
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MSX-6A)?WI?FR2FMT-.IK=#6)WG"ZA_R631O^P/=?^C8Z[E>]<-J'_)9-&_[
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M_P#,(@_+>*ZJ%N6IIT_5'EXV_/07][]&>I(,-Q4E1(P9^/2I:Y$K'J!1113
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M@!:*3FCF@!:*3FCF@!:X?PU_R4SQC_USLO\ T!Z[?FN(\-\?$OQB?^F5E_Z
M]=%+X9^GZH\_$_Q*/^+_ -M9VJ=:?3%ZT[FN9;'>A:*3FCFF,6BDYHYH 6BD
MYHYH 6BDYHYH #TJ/M4F#4?:DQ'"^"?^1\\=?]?5M_Z*KO5Z5P?@G_D?/'?_
M %]6W_HJN\%=>)_B?*/Y(\W+U^X?^*?_ *4QU%)S1S7*>F+12<T<T +12<T<
MT +12<T<T +12<CK03B@!:*;NH!)-&X#J:W0TZFMT- '"ZA_R631O^P/=?\
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M)_?8^@%)_:]Y_P ]C_WR*K-VIM;-*Y@F]"W_ &O>?\]C_P!\BC^U[S_GL?\
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MU#_DLFC?]@>Z_P#1L==RO>KELO0YZ6\O4<.E+2#I2U!T!1110 4444 %%%%
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MY:2^9FL-*LU+$N_ET0@4*H50% Z < ?04M%%<VYZ 5S6A_\ ([^)_P#<M/\
MT!ZZ6N:T/_D=_$_^Y:?^@/712^&?I^J.#$_Q*7^+_P!M9TM%%%<YZ 4444""
M@JK+M90RG^$]***:=@:3T9GW?A[3KS)>U16/\4?RG]*SSX4>V;=8ZA-;G^ZW
M(KH**UC6G'2^AQSP="IJX_H<Z)/$-B>8X+^,=UX8TY/%Z0,$OK.XM'[DC*BN
M@^O/UH=1(I5E#*>H(R*MU8S_ (D;_@9_5ZL?X=1_/7_@E*TUNQO3^YNHR?1C
MM/ZT:UK5GX?T][Z_F$%LG\1Y+'L .Y-077AC3;ODVXC;UC^6O-_B[X7N++1;
M6YM99Y[.&4F2-CN"9& W'T(KHP]&A7JQ@Y63?]:G%C,3C,'AYU8TU)I=/7L/
M\+_$[1X?%&M37 GMH-1FB:.21.$"IM^?G@'UKUA65U#*0RD9!'0BODF-#*WE
MHOF,QVK&!DDGL,#O7T5X-UVWL_#^FV-[,\5W#"(W\U<<CMD_E7J9I@HT[3I:
M_P# /GN'<WG7YZ5=VBKM/S;.MHIL<J3H'C=74]U.1^=.KYNS6C/O4TU=!111
M2'>X4444 %%%% !2]O\ /I24O;_/I1U0/_,K?"__ %WBC_L+R?\ HM*[M>HK
MA/A?_KO%'_87D_\ 1:5W:]12Q/\ %E\OR1C@/]WCZO\ -CZ:W0TZFMT-8'HG
M"ZA_R631O^P/=?\ HV.NY7O7#:A_R631O^P/=?\ HV.NY7O5RV7H<]+>7J.'
M2EI!TI:@Z HHHH **** "BBB@ I&Z4M(>E F<9\7=-_MGX<>(K+[?;Z:);5E
M-Q=OLA4<$B1NR'!4GL&->!_#W7--OO&UC)<?\(QX:L[/6KC4XI8M<LY7*R6Z
MP_9H5B;A6(RV[&<+QFOH'XI^'Y/$_@+7M+BN8;1[JV91+<_ZH=R)/]@@8;V)
MKPP7=A\1];TJVM/#_@>UN=-AN5BL+?6;2Y>_+0-&+=1&F5AR=S,PR-@PN:ZZ
M-G%W/'QM_:Q:>O8^G8&W+D'(]JEKG_ &B7/AOP;HVE7EP+NZLK.&WEF7H[*@
M!(SVR*Z"N5JSL>O%MI-JP4444BAKG"DUYM\6OB9:^!6TZT18DU;4"Z075W$[
M06T8QODD*J21T 0?>.!P,D>E'H:C\L9S5)V=S.:<E9,\(TS4]!\(7_A/Q#%J
M-QJ7A_R=1MKS6#;2,3>3212,\BA<J'*,!Q@<"M;P[%*_@":^DAFMHM3\137]
MO'.A1_)DN"4+*>5R.<'UKV#R@Q/Z8KGO&RXTZS'7_3[<<_[XK7VEV<SHM7;?
M]:%%F''--W#U%=BL,>.$7_OFE\E/^>:_]\U'/J;*F[(XW</44;AZUV7DI_SS
M7_OFCR4_YYK^5'.'(^YQNX>HHW#U%=EY*?\ /-?^^:/)3_GFO_?-'./D?<XW
M</6C</45V7DI_P \U_[YH\E/^>:_]\T<XN1]SC=P]11N'K79>2G_ #S7_OFC
MR4_YYK_WS1SCY'W.-W#U%&X>HKLO)3_GFO\ WS1Y*?\ /-?^^:.<.1]SC=P]
M:-P]179>2G_/-?RH\E/^>:_]\T<X<C[G&[AZBC</6NR\E/\ GFO_ 'S1Y*?\
M\U_[YHYQ<C[G&[AZBC</45V7DI_SS7_OFCR4_P">:_\ ?-'./D?<XW</6C</
M45V7DI_SS7_OFCR4_P">:_\ ?-'.'(^YQNX>HHW#UKLO)3_GFO\ WS1Y*?\
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M17FI7.=BLV4C4=6;'/T'K6U*C.O-0IJ[9QXG%4<)2E5K2LD7_AP?],\6\?\
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M YQS2UB=J5E8****!A1110 4444 %%%% "'I4?:I#TJ/M28'"^"?^1\\=?\
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MFZI'G@?CU_$44_W?[Q_+U.BK[[5)?/T_X)W>FZ?#I=C!:6T8B@A0(B#L *M
M8% &*6L#J2ML%%%% PHHHH **** "F2_=-/IDGW30!Q7PY_X_/%W_8<G_P#0
M(Z[<=37$?#G_ (_/%W_8<G_] CKMQU-;XC^*_E^2.# _P%ZO\Q:***P.\***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/2H?, '<_
M2ICTK"\0V&JZE9I'I.I+IDX8%I9+<2@K@Y !]\4TDW9NQ$Y<BNE?R6_Z'.^"
M7!\=^.C@_P#'U;?^BJ[Y>1GUKS"S^'?BG3=0O[RW\61+=7SH\[G3D;<57:#@
MGC'M7H]A#/#90I<2B:=4 DD"[0S8Y..W-=6)Y7+FC)/1?@DCR\N]I&FX5(.+
MNWK;JV^C?<M4445R'KA1110 4444 %%%% #6Z4C=1]:5NE(W4?6@#BOA[_R$
M_%__ &&9/_1<==JO:N*^'O\ R$_%_P#V&9/_ $7'7:KVKHQ'\5_+\D>?@OX"
M]7^;'T445SGH!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@NR;[9<?\]Y/^^C1]LN/^>\G_?1J&BBP79-]LN/^>\G_ 'T:/MEQ_P ]Y/\
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MF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2QQH$1>BJ.*=117*]7=GHI)*RV"C%%%.XPHHHI %%%% [@:\QT<?\9*>(_\
ML5['_P!*)*].->9:/_R<IXC_ .Q8L?\ THDK:GM+T?Z''7^*G_B1Z;11163.
MM!1112 **** "BBB@ HHHH *4,0."1].*2B@&D]QV]O[Q_.F_B3]3113NWN&
MVP4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ IKQK(,,H8<\, :=11=]&#2>C-O1
M[&"6R#>3%RQZH/6M=(]AX/'I5#0O^0>O^^?YUIUBVV]6;PA&*M%6"BBBI- H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#4;6Z,Z.45G3[
MK$<CZ5+10!$_RJ<?E7R-XH^('B>ZU?5[6XU^>YLEU&9[9%C2(11K(WEJ-H!.
MT <DY)YKZ[=-QZXQS7S)K?P*\7W&LZM=K#I\L,]]-);I;SE6\EG)3<&4 ,!@
M'GM7N91/#0K2^L6\KGQO$M+&U*,%@[[N_*8WA+XD>(X_%=@]]JMQ?:2D$RSV
M A1FE?9F-@^ W!SGGD&NZG^(&N:M*4T^P@TY,X\Z]D!./7GC/X&J/@7X'>)-
M)\::7?:JNG'1$AF%S"L[-,9&7$8 "XP#DDYKVJ+P)H*J"-.B/^\6/]:VQM;!
M^U_=J_IL99/A\T^JVKNSN][WL>.OHS:L=VN^*VG7K]GM 0OTZ8_2M73=/\':
M,08;=9I /];/&TC?J,?I7J@\&Z*HP--M_P 4S1_PANB_] RV/_ *\]XFF]+/
M\$>XL)B%K>-_1O\ 4X8^--,10JB; X 6/ %,/C>S)PD%Q(?91_C7=GP9HA/_
M ""[7_OW2_\ "&:)_P! NU_[]U'M:'\K+^KXO_GXON_X)P?_  EY;_5Z==-^
M&/Z4G_"2WC_<T>=O]XG_  KO?^$,T3_H&6W_ 'Q2?\(9HG_0,M?^_8I*M27V
M ^J8E[UON2.#_MO6&^[I QVW,:/[0U]^$L($/^TX_P :[P>"]#'_ ##+;_OB
MC_A"]#_Z!=M_WQ3^L0_D7]?,/J59[UG^'^1\S_&%;V/7;&?4I+:*6>#9%"DJ
M[B%)R0N<XYZXQ7%V,7VG4;2V$T4$MQ*L4;32",;B>.20,^@[U]8ZW\&O!7B6
MY@N-2\,Z;>7%N"L,TL +Q@G)"MU'-5I/@3X!N+J">;PIIDTUNZR1/+#O*,#D
M$9)P00*]VAG4*=!4G#6W3;[CX[%\*U<1BW7516;3U;N8K:'JUV@@N]45H.CB
M,8)_E6W8:?;:9;"*W144=3GD^Y/>NB'@O10/^0;;$_\ 7.E_X0O0_P#H%VW_
M 'Q7S\\0ZFCV^X^UI8*-)J2U?F[LQ,@]Q^=''J/SK;_X0O0_^@7;?]^Z/^$+
MT/\ Z!=K_P!^ZQYX]CK]G/R,3CU'YT<>H_.MO_A"]#_Z!=K_ -^Z/^$+T/\
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M (0O0_\ H%VO_?NC_A"]#_Z!=K_W[HYUV#DGY&)QZC\Z./4?G6W_ ,(7H?\
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M$+T/_H%VO_?NC_A"]#_Z!=K_ -^Z.==@Y)^1B<>H_.CCU'YUM_\ "%Z'_P!
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MGKS_ !G^=:=5;+3K?38!!:Q);P@D[$&!D]:LUBWJ="V%HHHH&%%%% !1110
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M.GA[PUK^O>*=+-[I5W!IGC6:/Q#JR7"-_HAM96=+>0$<%D-JNT]?+:N4\,^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "DQFBB@ P*,"BB@ P*,444 &!05!HHH -HHP***
M#%&*** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tmb-20221231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (P V8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>U?6T/A?2+='2+2[.-'?S&5(% +?WB,=?>G:MX<TO7HEBU+3K6_C4Y5;F%9
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MDR4O_#>/@$?\P?Q1_P""EZ / -(\$>'-5TG0?#EK\%-<G\8+-%#>IJLTPL8
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M/K7O-% 'RZG['^O06W_"-P?$[68/A^)O,71E11(J9SY0E^]MK0\<?L@?V_\
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M]']O_M1?]"UX._\  IZ /IBBOF?^W_VHO^A:\'?^!3T?V_\ M1?]"UX._P#
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MP^";#3=+@,<1D/\ RT<GJ?:OI%1@44M !1110 4444 %%%% !37'RTZD89%
M&!+X9T&7Q3!K,EI:MKL<1BCN#CS0AZ@=\5OXKYUUK3=6;]LG0[Q(+O\ LI='
M=7E7/D[\]^V:^BZ $Q1BEHH 3%&*6B@!,48I:* $Q6-XL\':-XYTB32]=TVW
MU33Y#EK>Y3<A_"MJB@#S#2OV:/AAHFI6VH6'@C2+2\MF#PS16X#(PZ$'UKTU
M4"# '%.HH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48%+10!YI\?O@U#\;O
M DFB'49](U"&9+NQU"W)#6]PARC8'4>HKR*Z_9Z^*'Q2OO#MA\2_%FF7/A?0
M[J.[-KI5J8Y;^2/[AD8GL><5]44F* /G+Q?\!/&WACXIZMXW^%NNV&F3:[$D
M6JZ9JD!D@D=1M65"#PP _&NP^ 'P.G^%%OKFIZUJS:_XM\077VS4]1*;%9OX
M41>R@5Z[BEH ^;?VA='E\'_&;X:?$E%;^S[*:32-1(&=D<^ KGV!'ZU]"P6M
MI<1K(D,3HXW!@H^8'O2ZII%GK=G):7]M'=VTF-\4J[E..G%6(84@C2.-0B(
MJJ.@% 'A_P =?@%JWC?Q3X<\;>"]:B\/>,] #QP2W$7F07$+<M%(H[$BL;P+
M\!/&&I?%2W^)'Q*UZSU'5]+M'MM+T_2X3';6H8'=)R<EC7T92%01B@#QG]F/
M4/&^J>%]<D\:WQU&;^U[@6%RT/E%[7=A!CT'3-4OCA\!M<\5^./#WC_P-KL>
M@>,M&BDM@;J/S+>Z@?&8W4?SKW*.)8E"J JCH ,"G8H ^<_ W[._BC7?B1<>
M/OBEK=IK.JC3I-*L=-TZ$QV]K#)PYYZL17#I^RI\4M'\'WWPRT;QS80_#:\E
M<!Y;5C?6]L[9>W5LX(P2,U]B 8H(SUYH ^2_%7@*SU?XV_"3X=:#$QT3P)!_
M:-ZX&0H";(E)]2>:^LU!'6J5IH=A8W]U?6]I%%>76//G5 'DQTR?:K] !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !2'H:6D;@&@#E+CXB^'[7QY;>$I;L+X@G@-Q';E.3&.IS765XIJ?
MPIUB[_::TKQRC0_V/;Z8]HX)^?>3Q7M= !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%96G^$=(TK6;W5K33X(-1O0HN+E%P\H'3)K8HH **** "BBB@ HHHH ****
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M$--;46E\YG\KY&D_O%>F?>O3Z* /%[GX4:GXG_:"L?%FKQ10Z!X=LC#H]NK
M[IGX>0CM@<"O9P,4M% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !2$9%+10!S$_@CP_/XTM_$DMI VOP
MPF".Y)_>",]173U\ZZW'J[?MDZ(ZB]_L@:/)N*[O(+Y[]LU]%4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4C#(I:1C@4 <[-XST*'QA!X>DO
M85UV6(S1VQ^^4'4BNCKPO5?AEK]W^U-I'C2.UB.@V^EO;23^8-XD)X&VO=*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0XQS2TC#(H \ZOOC
M'8V7QDL?A\;.9KVZLVO%N01L"CL:]&KS6]^#MO>_&FP^(!U&1;BULFLULPHV
ML#WS7I5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0*OTY[UF^!/BOX3^)=M+-X9UVSU=83B1;>4,R?4=10!UU%%% !1110 4444
M%%%)TH 6BL7Q+XPT;P?;0W&LZC;Z;#-((8WN'VAW/11[TOB'Q;HWA31Y-5UC
M4;;3=.0 M<W,@1!GIR: -FBN.\"?%SPA\2C./#6OV6K/!_K8[>0%T^HZUV .
M: %HI,T9H 6BDS1F@!:*3-&: %IK' I<TC<B@#Q75/BGK=K^TYI7@B-H1HMQ
MICW3J5^?>#V/I7ME<Q-X T&Y\:V_BJ2Q5M>@@-NEUN.0AZC%=-F@!:*3-&:
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MF3>'KG/I7UWX;\/VGA?0K'2;)6%I91+!$'.3M48&30!\[_\ #;(_Z)5X\_\
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MD)D^N,5]"5\X?L,^'+K3OA1>Z[>0&";Q'JEQJ2J1C,;.=IQ[CFOH^@ HHHH
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M9;6%G"EO:6T:Q11(,!5 P *N444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4AZ4M(W(- 'E^H?!QK[XZ:?\
M$$:CL6UL6L_L6W[V?XLUZC7BVJ?%C6K3]I;2? J+;_V+<Z8]VY*_O-X/8^E>
MTT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AZ&EI#0!RT_P]
MT&Y\<VWBR2R4Z[;P&WCN2>0AZC%=57SOK>K:PG[8VB6"7%VNCMH[N\*Y\@OG
MJ>V:^B* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI+- .37S+HO[07C_ $#XBZ5X&^(GABPT74/$5M*VBZGIMP9H3.JDB*3(X/\
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M]4_\%\=?3%% 'S+)^SI\7%21C\=M58!3\O\ 9T?/%?C5\:?@]XZC^*OBA9]
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M)OX?_P"@U8?^!"?XT?\ ";^'_P#H-6'_ ($)_C0!N45A_P#";:!C/]M6&/\
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M%Q_\71_PP?\ !?\ Z%63_P &%Q_\77T%10!\^G]A'X+J,_\ "*R<?]1"X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***:9 HR2!0 ZD+!>IQ3?-7U!^E?)'[9WQ4
MU_4M UKPAX%U"73KRPMA>:MJL)Q]FC!XC4_WCZ4 ?7'F+MSGCUI$F2091@X]
M5YKXY^*OCGQ!=?"[X0>#M*UJXTR\\5B"&ZU*-_\ 2/*"@OM/8GUHU'P_>?LO
M_'#P%;Z)XBU;4/#GB5FLKW3]5NVN/WP'$BEN0<T ?9-%-#80%N*0R#MCZ9H
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MFOA_QM\4O%/Q$_:#^&VM:7J-QIG@ :M)86]O&Q3^T7 .Z1@.JCM73>)["_\
MVA/VH]<\%W^O:CI?A+PO8QO)8Z9<- UU._.69>< =J /KL.IZ'(Z\4ZOES]F
M+6=<\'_%CX@?"_4M:N==T[19$N=-GOG+SI"_\!8]<5]1#I0 $@=:8\T<8RSA
M1TR32R'"U\!^*_B=X6^*7Q0\97'C_P <:OHV@:-='3-,T30Y9%D5E^_<2>7R
M<'UXH ^_1(K' -(DR2DA'#$'!QVKX=\2>-?$W@S]G'0=&T3XAIXHE\2:W'I.
MG>(X.9H+:1\$,>OF*..:O^._!%_^ROXQ^'&O^'O%&LWUCJFH1Z5K5GJ=XT\=
MR9,#S0&^ZV?2@#[5!S2TR%M\2,.01FGT (6 ZG%-25)!E6##V.:^9OVX]?UO
M1/#/A:.+6+CP[X1N]42#Q!JMG)Y<L,!/R@-_"">"17F?PK\7:=X1^/FI6'PX
M\7W?BGP%:Z!+?ZM#=WC74=K.JDH59N06(Y% 'W(9XU8*74,>V:>#FO@_P%\*
MM<^-OP2UKXJ:GXVURV\8WAN+_3)+6]>.WLTC)*1^4."/EYS7TW^S%\1[SXH_
M!'POX@U)EDU*XML7+KT:13M)_'&: /5J*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCXH?#,?$W2(K!M<
MU/0Q&^_S=,F\MV]C7;T4 ?/UO^R<;"=+B#XB>*WGBY037FY-W;<.XKPKXG_L
M\_%GX=?"7QT;;Q?INJVNHL]S=;K)FNIP3PN[VK[VJ.6!)T9)$5T;JK#(- 'P
M;XE\+^,/"WPH^#7C76XVUYO#4\<EVMC;GS(+9AC)3J2O>NH\5^.-/_:<^//P
MXA\'0W5_I/A^1M0O]3>!XXHFQ\L>X@9;VK[(-M&T/E&-?*QMV8&W'ICTJOI^
MBV.D*RV5E;V@8Y801*@)_ 4 /O[/[?836WF-%YJ%/,0X9<C&1[UX+/\ LC))
M+))_PL7Q<N]BVU;W@9[5]"#@4&@#XB^-_C[4/A)JFA?"/3_%FK:58W<37.I^
M++V%KB:.$_\ +.-@,!CZ]JZ;P)H'PR\2?!SQEX$^&TTVH:K>6,C7-W>1/]HN
MY2,[G=ADDFOJF]T.PU&3?=6-M<-C&Z6%7/ZBEL]$L-/<O:V5M;,1@F&%4)_$
M 4 ?":_'K3[?]EX_#5M,U%?B"(/[&&B&T?>7SMW_ .YCG=7U[\#/"5QX%^$W
MA?0[M!'=6EE&DJ YVMCD5UQT+3S?"]^PVWVP?\O'DKYG_?6,U> Q0 M>7?M*
M^"KSX@?!;Q5HNGQ&>]GM&,,8ZLR\@#ZXKU&D(S0!\$>,/CQI_C_]FJP^&NE:
M5J3^/+Z.'2I-&:T=7@96 =V)& N 3FOM'X:^'7\)^!=#TB3_ %MG9QQ/_O!1
MFM>/0=/BO6O$L;9+MOO7"PJ)#_P+&:OJH7I0 M(>E+2$9% 'R;^UQ\=M2T'Q
MCHWP[TW59_"=MJ<1FU+Q&MLTGDP_W(R!PYZ9J;X1:7\+=5^'/BKP5\.[J>_U
M?4+&0WE]?1OY]S*RGYG=ASSVKZ?O-$L-1?==V-O<MTW31*Y_44EGH6G:?(7M
M;"UMG/!:&%4)'X"@#X6\)_'W3_!/[,^H?#;4M,U&'Q[;02Z-#HJVCL\SME5=
M3C!7G.:^JOV;/!-U\/?@MX6T.^C,-];V:&>,G.UR,D?K7?R:'I\MZ+Q["V>[
M'2=HE+C_ (%C-75&!TQ0 M>??'3P%K/Q,^'.J^'=#UG^P;V\4)]LVDX7N./7
MI7H5% 'Y]_$[X2_%[PCXL^$&D1>(])FBL[_R[5K2P98[?"\M)]:[JZ\0C]G7
M]J76_$'C&.>+0?%&F0[=9@@9X%N(QAE;&=N>U?8DMM',Z,\:.R'*EE!(/MZ5
M!?Z3::K"8;VU@NXLY\N>,2+GZ$4 ?,'[,"7'Q"^-?Q'^)\-C<V>@:F\=EITE
MU&8WN$0<N%(Z>AKZK'09J*UM(K.%888DAB7A4C4*H'L!P*FH 9+]TCFOACX9
MW'A']FCXS_%&V\?Z2;2?7;UM1L-6>R,T5U"R_P"K5L'D=-M?=/6J5_HECJFS
M[996]V$.4$\2OM/MD<4 ?G-;_#OQ _P@U7QSI7AR\AT2T\9Q^(=.T7R2LWV1
M6^=A'U&>N/>O3?BG\4-+_:A\7?#'PSX*M[S4%M]3BU;5)Y+=DCLHX^2KDC[_
M &Q7VJ+=%B$:HH0# 4#@#TQ5:QT6PTUY'M+*VM7D.7,,*H6^N!S0!:@010H@
MX"C IYZ4 8%+0!\C?MJV,D?CKX::MXET^\U?X8V5XYUBTM8VE42$'RWE0?>0
M'KGBN&EL?"_Q-_:*T4_!W1VL-.&DW,&OW]C:&VLI8WC*QQD !6<'\:^[;BVC
MNXVCFC66-A@HX!!^H-5['1K'2XREG9V]HAZI!$J _D!0!\,_#3X\:=\'/V?=
M<^'>N:;J-MXVTK[5IUMI"6KNUYO+"-HR.&7##)SQ7TE^RAX!OOAQ\!_"NC:E
M$8-02V$EQ"W5'8EB#^=>I3Z%I]S>I>36-M+=)]V=X5+K]&(S5X #IQ0 M%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUV9X]*W/VP-"N_$'QA^%]_X=U*:^O-$T,ZK;72MEKE8R"2<=<J#79+KGCT_
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M4XQW.16Y\0O@)K.B>+O"'CGQQX0N_B(DNAQ:;KD6GR-]H@G4#]ZJH07!Y!H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tmb-20221231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )T L4# 2(  A$! Q$!_\0
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MH@:OIZOF?]J?]D6Y_:>\>> +G4]<AM_!WAZY-U>Z-)"S->L2,C<#@ J,?B:
M/SV^!'BGP5^S+^T!\#M8\+^)M.U:U\0:0FE^)HK*??Y-S*<$R>F&9?\ ODU^
MSL+[UX.1C@U\?_'S_@FS\.OB'X*BLO >C:7X!\1VUU%<0:K;6Y)PIY5@#R"/
MU%?5/@K2]1T3PGI&GZO=I?ZE:VL4-Q=1J565U4 L >F<4 ;=%%% !1110 44
M44 87C+QA8>!M%DU74VD6T22*(F-=QW2.J+Q]6'YU9E\2:;#(R/J%K&ZJ796
MF4%0.I(SP!7(_'7PWJ'BSX?3Z;I<!N+M[RTD$8(&52XC=N3Z!2?PKR&+]GK[
M9J7AZ]OO#<$]R?%-_>:C+*RLSVC^:8PQS\R9,?R]/:@#Z-F\0Z;;6T$\NH6T
M<,^!#(TRA9">F"3S^%81^*6@R:QJNE6MT;_4=,E@ANK:V7<T1F&4)YZ8Y)KY
M1\0_!;QF/#J:"?![W=JEIJ<5A+;B*5H'DN)&B7,C 1+L*$,H)&<9&,5T&A?!
MOQ):2:O.OA9K;4]2&A7+WVZ,,Y@V"X1V!SD%2WO0!]3S^);"(7*I=Q7%Q;Q&
M9K>%U:4J!V7.>:R= ^)FAZ]J5WIZ7?V6^MC"LEO=;8VW21B10!GDX/..AS7@
M5M\ ]9TK0] N;'1U@UPRZS_:5RD@$KI/%/Y09LY(+&,X[9Z5SEY\'?$%O%XA
MM;CX>RZGK>IV&G6VFZZD\6+.>*W5'9B6#1[7&=RY)Q0!]8>)_%UEX5BL7O';
M?>W*6EO%&N6DD;/;T !)/8 U>LM:LM0N9(+>\@N)HP"Z12*S*#TR <BO%OC3
MH6J(WPYDF<W1M9IK2XE!^4SRVC1QN2?]OC/O7->"O@7K/A2P\&'2-)CTO5%\
M-SV6JW*7'E,]P?+*;Y%RQ.0V&&<?C0!]#^(]>'AW2YKYK2ZOQ&!_H]E$996Y
M_A4=:\^A_:/\-SZ;=W8L=:22WOUTS[&]@PFDN"N[:BYYP.O/%4/#/A3Q]X0T
MK7[NX9=3OOL+BQM_[4EN-T^#M_UB@+SWK USX8-I7PS\%6.H^$9_%[6,IN]2
M@MKKR[D7#HQ>4?,HD.YV!!/0\4 >K^'_ (CV6OZM!IGV._TV]FM?MD<&H0>4
M[1[BIXR>00,CW%==7SC\,=!US3?&?@?3]26>&ZL;?5+R2WN)_.EMK.5T6WAD
M?)R1@]S]VOHV@!:*** "BBB@!DT@BC9R<!1DUY!H?[3OAS6IK*0Z7KEEI-[>
MG3[;6+JRVVDD^\H%W!B1E@0"1VKUR[4O;R!>6*D#ZU\[?![]G*2S\$Z<GBN[
MU>6ZM+^XOTT:6[!M(Y?.=XF"*.<9! )Z]>E 'M/A_P"(6B>(M$T[5+>^CBMM
M0+"W%RPB=R&*D!2>N0:V/[9LQ?BQ-W"+PKN^SF1?,QZ[<YKXN\7_  B\=W/A
M:#1SX2EN;N#1VCLKJU$,C+,+B1RK22-^ZP"I!09/K7=^'_ .NC7I4U#P)-=>
M([C46OH?%5Q<H@M8&3"J65M^Y.5\L#:<YH ]]\5_$/1?"&@:QK%Y>++;:3$9
MKN.V(>1 /]D'@_7WK3L?$6GZE:O<VU]!-!'R[)(I"<9PW/%?$'_#/7CVX\.:
M]8_V3J,FL#1KNSGE?[/!#J,LA&T;U)>7)&[<^-OXUW%]\*_$&KQ74VA>!Y_#
M&E6ME:0:CH;31QG67CF5G12K$'Y 1O;!;.#0!]766J6VI6BW%G<17,+#B2%P
MRG\1Q6'HGQ'T/7;*YO8;V.&TAN9+437#K&LK(VUBN3R-P(S[&O._@QX1U/3]
M2\9ZG%H<OA'0-4\H:?H,Q4-%(L;"2?:A*IOR@V@_P9[UY/X&^#DOC&W#:GH2
M:A;Z?X;OM)\NX8$)J'VESG:>C$'(;'\76@#[#1@R@@Y!Y!KS34?C[X;TKQ<^
MA7 OE$5TEA-J7V8_9([IP"L+2=F(*^W(R:X:R^%_Q$ETW0]EY]G$-A;13Q/K
M,\1$BH ^512O4'D'FN*\1_"3Q9=?$:]O8]%U.XU5O$%OJ=OJ"7B#2?LD84$/
M"3EI=H=<E<DE3GC- 'KT7[3/A26XE3RM42W,<TMK>R63+!>+"?WIA8_>VCGM
MD D=*]5T^^AU.R@N[:02V\\:RQNO1E(R#^5?,6C-K%S?:MXC\>^%=4TL:;97
MJ:?;A(5T^PA8$84*Y9Y'  +$#D]!7N/P:TR[T?X5^%K.^+&ZATZ%7W=0=HX/
MTZ4 =I1110 4444 %%%% 'YZ_P#!6U[RV3X(2Z;:1WVH)XE+6UI*<)-*/+*(
M?8G /UKQK]K'5_B9JVM_#'4_C#\-M+\ >"M.UV%IM7\/.EQ/DD84L#\HXZ?X
M5]K?MJ?LH:S^U#IW@U-#\2P^%[_PYJ#:A%<RP&7+87;@ \8*YKRRY_X)_P#Q
M)^*&K:+#\8/C/=>,?"^FW2W?]CP6HA65UZ9.?PSSUH ^X=*N(+O3+6>V?S+>
M6)7C?^\I&0?RJW5;3[./3[*&VA01PPH(T1>BJ!@#\JLT %%%% !1110 4444
M %%%% !139/N'Z5\N>(/C7XEU;Q*(8->M_"?AN[O[^UAUF>U\T1M:X01G/&9
M&WMD]EP* /J6BOD2?X^^-O$>A>&-8M7U#2]%.EM>:GJ>G:1]IC\Q;AHB2'8%
M5VH6P,D UVOB?XTZWX8\<P3RR^=X7"PF-8[8_P"EPO"S"9)/[QD"($[[J /H
M:BO-/@QX]_X3/2KN2\U.WNM6,IGDL[="!:1,2$C!_CQMP6&03FN0LM4\<_%/
M5O&%]H?BB/PU8Z'J,NF6-FMJDJSR1 ;WG9N=I8XPN. #0![U17C/@GXD>)]0
M\7Z]IE_8Q:H+-].B8::Z^7!YT):67+$;D!&1WYJ3XG^(/%FI_$+2_!_A;6(-
M 9],N-5N+V2W$[ML942, ] 68DGZ4 >Q5R?C?1-3UM=._LYK0I;W(FFAO"VV
M0*#M'R^_->?3?%#Q+JG[.$'BS2K-[CQ+=6Z(L=G 9@)?-$;NJ9Y P3C/XU@Z
M?XYUW4/A?K]]<^-;O1M6\/SM)J37VCQQSQ)LW+%Y>X@[LY# G.<4 +HW[/OB
M?P[J\6M:5K&E07UEJEW?:?92Q2-;117*CSHB1\V-X+J1ZXKHD^#&MR?#6]\'
MRZW:^1J-O<27MTENP<WDLWFEE&<>7R5*GD@]:ZWX.-XH?P'IUSXPOH[[6;D&
MX9HH!%L1N40J">0",^]:6I_$SPGI&H2:?>^(-.M;Y&"M;RW"K(">@(SF@#Q2
M?]F'5=0EO-2GN]"L[]I+-X])LK1ETR40%B/.3JQ;=C@<8'6O3_@O\.;GX>:=
MK7VR6S%SJE^U\]IIL1BM+;("[(U/(^[D].2:R?"/CCQ3J/QW\3^&=6CL(=#M
M-,@O+#[*S/(X>1@6<D#!..@X%2_%;QEXJ\*>+/ ]OI,&G_V#JFK165_<3,QG
M 96.V-,8Q\H.XF@#U:BOE;Q#\>O$6@^/$EN-8M8XU\31Z"?"IM3YIMG(5;C?
MUR2P;/W<#%>^2>+9[7P=JNMZEITFD&QCN)&@N'5CLC#'=E3C! R* .MHKY(^
M'/QH\4:G-X,U67Q;_;<.I,9]<L)=+\BWTRU,;/YGGD #9\@YSG)]*]/\>?'-
ME\&ZI?\ A2TGG \F"UUBY@*V;2RRI&I7.#(!OSD#''6@#VBBO(_ACXD\0V7C
M#Q/X0\2:I'KUSI=O;7T&HB 0LT<H<%&4<95D.".H(KR^^^-_C7PKX=L/B'?Z
MA9W_ (>U:>\@BT)+;8;98UE,)$F<L3Y/S9_O<4 ?5E%>"^!O%/C^PUNUTO5M
M3L?$-WK6A'5[-#!]GCMY@4#1%ER2GS]>N15;P3\7O$USX(\'^(?$+6BS7>N3
MZ1J5O9K^Z_ULD490GGY2J_6@#Z#HIJ'(IU !1110 4444 %%%% !1110 444
M4 %%%% !1110 445E>)O$5GX5T2[U6_G6"TMHS([-U/L/<G 'N: -6BO,_@M
MX_UOQU!XD?7(K:UGLM2,$%O;\F.$QHZ!SGEOFY]\CM6];_%3PO=^)4\/PZU;
M-K+LZ+9Y(=F098 $<X% '74444 -*[NO(I GX_A3Z* &% 3GC\12[/\ .*=1
M0 W8*3RP!P /PI]% $$]I%=(4F1)4R#M=01D'(J4( <TZB@!&&:0H#UYIU%
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MY<3;L99B3R#P?2J<WP TW4?#VKZ;JVK:AJD^L7L%[?WTS*LDYA92D>%& F$
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MX.?%.CY]M*/_ ,=H K^'O@U_8%U>7_\ PD>IW>L7T]O)=ZA*4$DT4((2' 7
M0@G..N:Q(/V9M$-TL-YJFI7^@0R7,MKH<SK]G@><.LA! W'B1\ GC-=&=!^(
MP!QXJTC/;_B4M_\ ':S[77O&'A_XC>']$UC5-/U2PU2"Y<F"S,#QM&%(P=YR
M,$T 6? 7P9M_!&L+J4NMZCKES!8KIMF;YEQ;6P;<$ 4#)Z98\G K-N?@TEK9
M^&=!T]F?0[36)-9O)+B3,ADWM*JJ,=#(YY[!:]83.T9ZTN* $0$9S3J3%+0
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ML^@6(LO[7N!<3(O12$"A5]AC]:ROB+ J?$[X:L% )OKK) _Z=GKT^O-?B/\
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M[QYE58YG5=H/3C'3TKU>0?*?H:\_^!,83P"HSG_3[W_THDH ]#HHHH ****
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MVC\*>$/!VO76LR0O.L<[PQJ509/S%OI0!]F4G2O/SX\\4@X_X5_J'_@=;_\
MQ5,G\=>*Y(71/ &HJ[# /VZWX/\ WU0!Z&"#2UX[\/O$OCWP_P"#M-L-:\%:
MC?:G"C":X_M"!MY+$CDMZ$#\*Z'_ (3WQ3_T3_4?_ ZW_P#BJ (/AI_R/_Q)
M_P"PE!_Z31UZ17A_A'4_&F@>*?%VH3?#^^DAU:[BN(1'?6^5"PHA!RWJIKK?
M^$_\6?\ 1.M3_P# ZV_^+H ]#HKSS_A/_%G_ $3K4_\ P.MO_BZ/^$_\6?\
M1.M3_P# ZV_^+H ]#HKSS_A/_%G_ $3K4_\ P.MO_BZ/^$_\6?\ 1.M3_P#
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M16WDP0L0>-QA4;OH30!ZP.E1W*-)"ZH_EN5(5\9VGL<4]!A1_6E(R,4 >+_
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M*** "BBB@!&Z5YKXN_Y+-X"_Z]M0_P#0$KTINE>:^+O^2S> O^O;4/\ T!*
M/2A2T@I: "BBB@ HHHH **** "BBB@ HHHH **** &2<@9S^%?%4E[<:#XWA
MUC4/#7C&]\0+XGN?[2GCLIY[:;3")%1 GW&3'ED #C&:^V*\R\??$?6]%\8V
MOASP]H=IJ=]+9M>O-J%^+6)4#A-J\$LV3G'8?6@#JO 5UIE]X9LKC1],ET:P
MD!,=E/:FV>/DYS'_  G-='6+X5O=1U'1;6XU:TM[&_=29;>UG\Z-#D]'P,_E
M6U0 54U72K36]/N+&_MX[NSG0QRP2KN5U/4$=Q5NB@#G_"7@/0/ ]K-;Z'I<
M&FQ3.'D$627(& 6)))P.!GI7)_$9!_PLOX:<=+ZZ_P#29Z],KS7XC_\ )2_A
MI_U_77_I,] 'I"@$"O(_VN$!_9F^)7'_ # KH?\ CAKUU?NBO)/VN/\ DV;X
ME?\ 8#N?_0#0!_-HYRQI*5OO&DH **** "BBB@ HHHH **** "OL_P#X))#/
M[7^F?]@RZ_\ 017QA7VA_P $D?\ D[_3/^P9=?\ H(H _=95 '2EVCTH'2EH
M 3:!VHP/04M% "!0.@HQ2T4 )BC%+10 F*,4M% '+> _$\_BF#6);B-(_L>J
M7-C'LS\R1MA2<]R*ZC%<!\'/^0?XF_[&"^_]&5Z!0 F*,4M% "8HVCTI:* &
M[!GI2X'I2T4 -*@GD4ZBB@ HHHH \-^/9T>+Q3X3D\9J[^!%\_[4&#&W%UA?
M),X7^#&\#/&:R/A;)X;N_C,]Q\-!'_PBATQQJ[6"E;!KG>/)V?P^8!OSM[8S
MVKK/BMK:V'CWP9::OJYT7PO.UQ+/,7$<5S.@7RH96(P%(+-S][&.U9/A'Q%:
MP_'N?2?"^LG6-!N],>\O[2"59K;3YPZK'Y97A-X+93/5<T >Y+TI:1>E17<O
MDV\D@5GV*6VI]YL<X'UH FHKSOX4?%1_B8_B59-#O="DT;4#8&'4 %ED 0,'
M*C. =PP,FN7NOCUJ4.OSSQ^'5?PA;ZT-!FU,W(\X3DA3((\?ZL.RJ><]^F<
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M!EU_Z"*^+Z^T/^"2/_)W^F?]@RZ_]!% '[KCI2T@Z4M !1110 4444 %%%%
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MHI: /QO'_!%3XCL,_P#"9^'O^^9?_B:7_ARG\1?^AU\/_P#?,O\ \37['T4
M?CA_PY3^(O\ T.OA_P#[YE_^)H_X<I_$7_H=?#__ 'S+_P#$U^Q]% 'XX#_@
MBG\1<_\ (Z^'_P#OF7_XFL3Q7_P1]\?>$K>REG\7:%,+N]ALD"++D-(VT'D5
M^U5>>?&C_D%>&_\ L/V/_HT4 ?EG_P .5/B*?^9T\/CZ++_\31_PY3^(O_0Z
M^'_^^9?_ (FOV.'2EH _'#_ARG\1?^AU\/\ _?,O_P 31_PY3^(O_0Z^'_\
MOF7_ .)K]CZ* /QP_P"'*?Q%_P"AU\/_ /?,O_Q->\_L5?\ !-?QA^S-\;K7
MQKK/B32=2LXK.:W\BS$F_<X !Y&*_1:B@!%Z=<TM%% !1110 4444 %%%% !
M1110!Y_\'/\ D'^)O^Q@OO\ T97H%>?_  <_Y!_B;_L8+[_T97H% !1110 4
M444 %%%% !1110 4444 <#\=M.FU7X2>)K>"[CLY#:EO-FN/(CP""5:3^%6
M*GV)KR#]FKQAX7U;Q?<6.E>'_#.E:@MCODN-"U$W;,H;!4_(,#/OS7KOQXM]
M(O/A+XCCUN\>QTXVX+SQ1>:RL&4H G\1+;1M[YQ7CW[/F@7TGQ3O=4DM-8TS
M38;.46T-[I'V-':617DW-N.[#!BJXX#&@#Z?0 +@=*4J&ZT+]T4%@* (4LK>
M-65((U5CE@% !/O0;* S"7RD\T#:'Q\V/3-3;AZ^])O .,\T 9?BM1_PBVL?
M]><W_H!K+^%/_)-/"_;_ (EL'3_<%:OBO_D5M8_Z\YO_ $ UD_"DY^&GA?\
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M[3ZXKP7XT?"SXB>*?AUK%@/%PU9F\J5+.UTY+>60)*KE5?<>2JG'')H ]4\
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MH1GI6EXA^)NB>&?%^@>&;R9AJ^MLXM(44MPBEB6/\(X/XT :_BO_ )%;6/\
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MC_KSF_\ 0#65\*O^2:>%_P#L&P?^@"@#JJ_ +_@IY_R>9XW^EM_Z)6OW]K\
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M_*MNO,OV>;&YT[X96$-S$UJ//G,%I)('>UA,C>7"QR?F5>".QR*]-H ****
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M_P#Q- '\R_V=_P"XWY&C[._]QOR-?TT_\*+^'(_YD;P[_P""N'_XF@_ OX=
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M!B2[L...@)KBM$^./BU] U:YU6[ELM=ATZ;5;71KW1C;"6*)\N(Y2QWX3@\
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M@#+T?]J/1]?B:RTW1-2OO$@O)++^QK=HG?<B*[-Y@?9M 8<Y[T[Q1^U+X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F,4M%% !1110 4444
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MD^H7:6=O$A +,0222>@558D^U3:-X\\/>(K^>RTO6K#4+N !I8;:X5V0'H2
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M%(.:6@ HHHH **** "BBB@!CQJ_WAD>AI]%% !1110 P1JK%@ ">I]:?110
M4444 %%%% !1110 4444 (>E>?\ C3XR:%X&\;>&/"U\MW)JNOW'D6PAMV:)
M3M9LO)]T<(>,YKT&O._BKX+U'Q7K/@>YT](F32=;2^N3*V"(A%(IV^IRPXH
MS+CXZV=GXI@TZ;1-2BTN;5#HZ:RRJ(&N\9V!<[L9XW8QD5ZG$@4$@ ;N21WK
MP>P\/>-M;^+BZIXH\-?;-&L[V0Z48]006UK'C"SM%C+RGU)..W<U[TAXH =1
M110 UT6088!AZ$4H&!BEHH **** "BBB@ HHHH @FLH+K'G0I*!T#J"!206$
M%K_J8(X0>OEJ!G\JL44 %(6 Q[TM9OB$WHT6^_LTQ+J @<V[3_ZL2;3M+>P.
M* -#<#WI=P]:\/\ @UXE\1:CXYU*PD\1-XOT&WLT^UZFT2)##J&[YX8&4#>@
M&<CG&!SS7.:KX_\ %_VG5_%L.O>7IFF>*$T1="$*&*2VWI&[,V-WF%GW ^G%
M 'TF#D9I:YGQAX_TKP):PSZH+KRI-V&MK62;&!DYV X_&M?0M;M?$>CV>IV,
MGFV=W$L\,F"-R,,J<$ C@]* +]%%% !1110 4444 %(1D8I:* &HBQC"C IU
M%% !3'C63 8 CWI]% " 8&*6BB@ HHHH **** "BBB@ HHHH *3&*-WIS2;^
MGO0 C1J[!BH)'0D=*?2;N,]*6@ HHHH 8D:IDJ N3DXI]%% !1110 4444 %
M%%% !1110 UAFO&=9G\#_"KQ_')JMW;Z5'<Q->V\+N\CFXSL=P@R0-I Z8R3
M7LYKYF_: UN;PW\9=!NE\2OX0BETB:+[=%I#7_GD2J?+; (0#J#U- 'T-X?U
M^P\4:9;ZEIEPMW93@M',JE0W;H0#^E:9&:Y/X8:C_:O@O3+HZO\ V\TB$G4/
MLOV;S>3_ ,L^-N*ZV@#FK_P'I6I>);C6KF)IKFXTXZ7*C-\C0%MQ!'N37#:9
M^S/X7L;6]M;FZU+5+6:R.G6L5[=%A8VVX,(X< %<,JD$Y/RCGBO7J* .*^'G
MPMT_X?2:C<I?7VL:IJ!3[3J.I2B29U0$(F0  %!. !65\1E'_"R_AI_U_77_
M *3/7I5>:_$?_DI?PT_Z_KK_ -)GH ])7H*6D7[HI: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAK-Y/I^GW%Q;6CW]Q&A9+6
M)@K2'T!8@#ZFK]% 'G?P\^)^H^.M0NXI_".HZ);6LLD$ES=S0LOFH0&7".3^
M->AKC'%<%\(V5K?Q1M&,:_> ^_*UWU !1110 4444 %%%% !1110 4444 %%
M)N%&X>HH 6L[Q%HL7B+0K_2YI98(KR!X'D@?:ZJPP2I['!K1HH \N\*? Z'P
MAX?N-$M?%.OM8R6XMXE:Y13;*"#E"JC!..2<]3ZTV;]GWP[<>*VUEKO4O(DO
M$U&?2A<D6D]T@ 69DQ][Y0<9 )YQ7J=% &7XC4+X<U0#_GUE_P#0#6)\(!CX
M6^%/^P9;_P#HM:W?$O\ R+NJ?]>LO_H!K"^$/_)+?"?_ &#+?_T6M '7T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A_P 5
MX)O%GQ9T#PM=ZI>:;HQT>\U K97+0-+.C(J$N"#A0Q;&?KG%:'PWU+_A-/@%
MI\_B/4;D%K)VNKV*<Q3LD;,/,W+SDJH.1US79^./ACX>^(:6@UW3UNWM&8P3
M*[1O&&&& 92#@@ $=#1'\-?#,-O-;QZ7!';2Z>NE/"IPGV89Q'C. .3^= '%
M_LXZ-<+X6N?$<E_J$]IKLWVNSM+ZZ>;[+;=(P"Q)RP 8^[5[#5/1]+M=$TNT
MT^QA6WL[6)888DZ(BC  _ 5<H **** "BBB@ HHHH **** "BBB@ HHHH *\
M7^+/]IZ1\0M-UBXTK5]<\-#39K,6VD3A6BNI& #.A9=V5X4Y^4\XKV?O7CGQ
M6\<VFG>.=/T#7KK2M)\/R6,E\E[JL9*RW2,/+123M!3&_!Y..* .F^"6E:WH
MWP[TNUU]9TU!?,Q%=2^;-%$78Q)(_=@I )]:[ZN'^#GC"^\<^!+#5]0CC6>5
MI$\V!&2.=5<JLJ*W(5E 89]:[B@ HHK/U_7;+PSHUWJFI7*6=A:1F6:>3HBC
MJ: -"O-?B/\ \E+^&G_7]=?^DSUT/@CXD:%\0H;I]&NGE:U=4GAGA>&6,D94
ME& (!'(/>N<^)# ?$KX:_P#7[=?^DST >EK]T4M-0\4Z@ HHHH **** "BBB
M@ HHHH **** "BBDSB@!:**;(XC1F8A0!DD]J '454TO5+76;*.[LKB.ZMI1
MN26)MRL.G!^H-6Z "BO,-:^.,.E>)=3T6T\,>(==GTXHMS-IMFLD2,RA@NXL
M,G'\Z@_X7O<?]$\\9?\ @O3_ .+H ]6HKRG_ (7O<?\ 1//&7_@O3_XNC_A>
M]Q_T3SQE_P""]/\ XN@#U:BO*?\ A>]Q_P!$\\9?^"]/_BZ3_A>]Q_T3SQC_
M ."]/_CE &U\)%VVOB?WU^\)_-?\*[VO ? ?Q5U/P]#K:W?P\\7AKO5)[R/;
M8H<QN1MS\_7CFNH_X7O<?]$\\8_^"]/_ (Y0!ZM17E/_  O>X_Z)YXR_\%Z?
M_%T?\+WN/^B>>,O_  7I_P#%T >K45Y3_P +WN/^B>>,O_!>G_Q='_"]KC_H
MGGC'_P  $_\ BZ /5J*YSP%XVL_B!X:M-:LHYX(+@NODW2;)$9&*LK#L0017
M1T %%5%U*VEOIK-+F-KJ%5>2$,-R!L[21V!P:MT %%%% '"?%;Q)KGA3P_/J
M6EMIMI96T33WNH:B7=;>-1G*Q(,N3Z9%>-^&_P!I*Z_X2;3]/F\6:3K:WCQY
M@N=)N-,94<X5DD8LI]LXR>,UZ;^T!K$=KX$O-,GT37-8@U&)U>30X%E>WV@,
M'8%@,9'3OTKQ3X::+JOQ[U2VU#Q ^N0VZ6"1V-Y/HT=G;R6WFH[ D.Q9VV)Z
M8'(H ^NHVW+G!'UI],C4*@ &*?0 4444 9OB7_D7=4_Z]9?_ $ UA?"'_DEO
MA/\ [!EO_P"BUK=\2_\ (NZI_P!>LO\ Z :POA#_ ,DM\)_]@RW_ /1:T =?
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (W
M0UX/\3OA]9:A\9/!NZ_U>"+57NC=PP:E-'&YCB!3Y0P P?2O>#T->8_$#_DK
M_P -/]^__P#1(H ]+MXE@@CC7.U%"C<23CZGK4E-3[HIU !1110 4444 %%%
M% !1110 4444 %%%% !7S5^U>=9AU30[IK35-0\-V[PR/;Z4@?$HF7>TR]2O
ME;L'H#UKZ5KP#]H7X=7WB/Q-I&JR7UG%H+K'IUY%>-)D!IE?$:J"&,A54.1P
MI)H ]!^"1U8_#O2VUEI#=-YCQB9PTH@+DQ!RO!8)M!KOJX;X.>"[WP%X&L=)
MU"6%[F-Y9#';9,,(=V81IG^%0V!]*[F@ KSKX^^'-0\3_"[5K33+=[N\1X+D
M6T9&Z98IDD9!GN54C\:]%I* /&?A$;[Q1\2?%?C :5?Z/I%Y965E!'J4!@EE
MDCWEV\MN0!OV@GKVXK&^*7@WQ)/\4? CQ>,[NW2?4+HP1K:1$6X^SN<#(Y].
M:]_ Q_A7FWQ'_P"2E_#3_K^NO_29Z )?^%?>+C_S4/4/_ *#_P")KA_C?;>.
M/AI\)/%OBJQ\?7<][I&G37<,<UC"49D4D X'2O?%^Z*\D_:WX_9G^)7_ & [
MG_T T ?C^?\ @K+^T IQ_;.E<>FG)1_P]H_: _Z#&E?^"]:^-&^\:2@#[,_X
M>T?M ?\ 08TK_P %ZT?\/:/V@/\ H,:5_P""]:^,Z* /LS_A[1^T!_T&-*_\
M%ZT?\/:/V@/^@QI7_@O6OC.B@#[,_P"'M'[0'_08TK_P7K1_P]H_: _Z#&E?
M^"Y*^,Z* /LS_A[/^T!_T&-*_P#!<E'_  ]H_: _Z#&E?^"]:^,Z* /LS_A[
M/^T!_P!!C2O_  7)7OO[$G[<OQF_:8^.%KX+U[Q+;6%C+9S7'G65A&)-R $#
MGBORVK[0_P""2/\ R=_IG_8,NO\ T$4 ?LG_ ,*^\7=OB)?@?]>,'_Q-))\.
M_%LL;(WQ"U JP((^Q0?X5Z*.E+0!Y-X7^#/B#PAH-II&G>/]1BLK52L:M9P,
M>6+'G;ZDUJ?\*^\7?]%$U#_P!@_^)KT6B@#R#3?@MXDT?5=5O[/XAZC%-J<B
MS7.ZRMV!95"C'R\< ?E6I_PKGQG_ -%(O_\ P7V__P 37I=% 'FG_"N?&?\
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MG_7K+_Z :POA!_R2WPG_ -@RW_\ 1:T =?1110 4444 %%%% !1110 4444
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M2_Z&?2?_  ,C_P :/^%8>$?^A9TK_P  X_\ "C_A6'A'_H6=*_\  ./_  H
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MU^='L;J?28RD$JQ2LHV9/*<9!/K7I%QH>G7<QEFL;>:4]7>(%C^)% 'CE_\
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M2:I?:[J^H^4MQJ&HLID*1@B-!M  4 GMR2369\18E7XF?#7"@?Z==?\ I,]
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MQ)_X"I_\51_P^0^"_P#T#/$G_@*G_P 57XF9-&30!^V?_#Y#X+_] SQ)_P"
MJ?\ Q5'_  ^0^"__ $#/$G_@*G_Q5?B9DT9- '[9_P##Y#X+_P#0,\2?^ J?
M_%4?\/D/@O\ ] SQ)_X"I_\ %5^)F31DT ?MG_P^0^"__0,\2?\ @*G_ ,51
M_P /D/@O_P! SQ)_X"I_\57XF9-&30!^V?\ P^0^"_\ T#/$G_@*G_Q5'_#Y
M#X+_ /0,\2?^ J?_ !5?B9DT9- '[:+_ ,%CO@N[!1I?B0DG 'V9/_BJ^IM$
M^+^I^(-(LM3L_ >N26EW"EQ"Y: $HPR#R_I7\U=KS<1_[P_F*_IN^#?_ "2C
MP=_V"+7_ -%"@"G_ ,+)UO\ Z$#7/^_D'_Q=8/\ PG/C(^-FO/\ A"M;&B&P
M\H6_FP9$^_._&_\ N\5Z[BC% ' ?\+)UO_H0=<_[^0?_ !=<=\1/$?BKQ#/X
M9N+'X>ZS+_9>JQWLR-/ I:,(ZD+\_7YJ]PQ1B@#R]?BUXEVC/PP\0 ^T]M_\
M<I5^+7B4]?ACKX_[;V__ ,77I^/>C;0!YBOQ8\2DG/PR\0#ZS6__ ,73_P#A
M:WB3_HFFO_\ ?^W_ /BZ]*V^AQ2X/J: /,&^+/B4'CX8>(&^D]M_\73E^*_B
M4CGX9:^/^VUO_P#%UZ9@^N:YO6O&"Z/XOT#0VMS(VK+.PER (_+4-TQSG- '
M,?\ "UO$AZ?#/7O^_P#;_P#Q=,;XL^)0>/ACX@(]?/MO_CE>G+R.M&#ZT >8
MCXM>)3_S3'Q!_P!_[;_XNE/Q8\2@@#X8Z^?^V]MQ_P"/UZ=CWQ28/]XT >8-
M\6/$I)7_ (5CXAYXW":VX_\ 'ZYD>)_%E[\5++Q"WPZUJWL;?2Y;,[I[<N7:
M1&& 'Z8!KW7;[T8/KF@#@!\2-;''_" ZY^$D'_Q=8?BCQ7XRU]=&M-'\*:KI
M$AU>P>ZNYIH51;1;F-K@'#$G,0<8QS7KF*,4 -0;<\44^B@ HHHH **** &2
M#./QKY5\<W8LO&6HK\+;WQ5J7B0W+?;+"&V%SI8ESR)&N %0?]<V_"OJJ49'
MX&OBA/&3^$?B''KUW8^-)/$B>)KB+43#97<MH^F?O BJH!C(&(B-HSG)]: /
MK/X=R>(9?"&E/XJM;*S\0&+_ $N'3V+0J_\ LD_YSFNE8X'7%8OA/Q-;>,="
MM-6LHKF"VN5W(EY;M!(!GNC $?C7,>*;+XDRZW*^AZAH$.C94I#>V\KS8'WL
ME6 ^E &E8_%SPCJ?B*70K77[2;5(BZM &(RR??4-C!*]P#D=ZKZ5\:O!6M#4
M6L_$=E*FGPFXN6+%52(''F D#<N01D9%?.=HL'Q1U.;28-.N/#$6E#4%T;28
MM.FB,]VRR(]Q-,RA0I+,5&>=P)K,UJQO/''AO0+71?#>I6\OACPXEOJT$]BT
M.]DF@+6ZY #MB*0X7(_,4 ?6W@[Q_H/CRWN)M"U.+44MW\N78&5D8C(!5@",
MCD>M<O\ $?\ Y*7\-/\ K^NO_29ZYWX/W/\ PEGQ1\8^+-.LKNST*[L[*SB:
M[MVMVGEC#ER$8 X4,HR1]*;XLT?Q%9_&CP#<:CKL5_IDM]=^19)9B-HO]'?&
M7W'/Y4 >VK]T5Y)^UQ_R;-\2O^P'<_\ H!KUM?NBO)/VN/\ DV;XE?\ 8#N?
M_0#0!_-HWWC24K?>-)0 4444 %%%% !1110 4444 %?:'_!)'_D[_3/^P9=?
M^@BOB^OM#_@DC_R=_IG_ &#+K_T$4 ?NN.E+2#I2T %%%% !1110 4444 %%
M%% 'G_P<_P"0?XF_[&"^_P#1E>@5Y_\ !S_D'^)O^Q@OO_1E>@4 %%%% !11
M10 4444 %%%% !1110!R'Q&T2_\ $_AJ_P!'M[6WN[:]M9HITGG>$Y(^0*R@
MD9.<GJ.*X#X+?#KQ5X.UZ276P4LEMO)B7^W+F\ .1QLD7 ^H.:]%^*%SK5I\
M/]<F\.@G64MR;; !(/<@'J0,D#UQ7@G[,OC;Q;XG\3&VN;S7;_1;5;Q+N;7K
M8Q-O$_\ HY0NH).S<#C(&%H ^HD^Z.<^].IJ\J,4Z@ HHHH S?$O_(NZI_UZ
MR_\ H!K"^$/_ "2WPG_V#+?_ -%K6[XD_P"1=U3_ *]9?_0#6%\(/^26>$_^
MP9;_ /HM: .OK\ O^"GG_)YGC?Z6W_HE:_?VOP"_X*>?\GF>-_I;?^B5H ^5
M**** "BBB@ HHHH **** "BBB@":T_X^(_\ >'\Q7]-WP:_Y)3X._P"P1:_^
MBA7\R-I_Q\1_[P_F*_IN^#7_ "2GP=_V"+7_ -%"@#M**** "BBB@ HHHH *
M*** $/2O,_&PS\8?A[_N7W_HI:],/2O-/&O_ "6'X>_[E]_Z*6@#TRBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!",UYE\0?B-X@T3Q99>'?#/AJ#6KZ:
MT:]EEO;X6D2('"84[3O;)''&!7IC$]J\4^*?P5U7XCZE87MS+X=GN+3S422^
ML9F98V8%5!25>PY]: /4O"5[JFI:'9W&LV,&G:DZDS6UM<>?&AR<8? R/P%;
M1&<<UR_PX\,3>#O".G:1.UJ\ELA4FS1TB.23\JNS$?B:ZF@"/R5]!]<4"!5S
M@  \5)10 Q(A']W@>@Z5YQ\1_P#DIGPT_P"OZZ_])GKTJO-?B/\ \E+^&G_7
M]=?^DST >DK]T5Y)^UQ_R;-\2O\ L!W/_H!KUM?NBO)/VN/^39OB5_V [G_T
M T ?S:-]XTE*WWC24 %%%% !1110 4444 %%%% !7VA_P21_Y._TS_L&77_H
M(KXOK[0_X)(_\G?Z9_V#+K_T$4 ?NN.E+2#I2T %%%% !1110 4444 %%%%
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M]TRW:*2*QL-12VD699U+NR,R^8#'N4<\&OIFOF;]IF_T3PGX]T/Q!J]CX?\
M$)?3Y;*+2-9E".F7!,R95@1CY3D?0T >J? J:[/P^L(K^\2[NE>4[5NEN6@C
M+EHXW=2<LJ$ ^XKT0G%?/?[+?PX?PQ!_;MI+IJZ/?V*JD6E%_*>0RNYX8#A
MP0'&2!S7K>L_$[PKH5^^GZAXBTVQOD*AK>>Z1) 3T&">] '4[A2;AG&>:^;?
M$OQJ\7^ O&5C#K4]A<P7T-[<_P!E0VY1;>")&>)EN>DCL%&4]SZ53U/XU^._
M!>BZ5>ZM<Z9J<WB/1UO;"*.V,:V=RTD2+&3D[T F4Y.#E#0!]/@@]#FO-OB/
M_P E+^&G_7]=?^DSU!\,_%OB'_A-_$GA'Q)>6^JW>G6]M>PW]O (-Z2[@49
M<95D.#Z&L?QAX[T+7/C-\/M(L=1AN-1M;V[,UNA.Y,6[YSQ0![0OW17DG[7'
M_)LWQ*_[ =S_ .@&O6U^Z*\D_:X_Y-F^)7_8#N?_ $ T ?S:-]XTE*WWC24
M%%%% !1110 4444 %%%% !7VA_P21_Y._P!,_P"P9=?^@BOB^OM#_@DC_P G
M?Z9_V#+K_P!!% '[KCI2T@Z4M !1110 4444 %%%% !1110!Y_\ !S_D'^)O
M^Q@OO_1E>@5Y_P#!S_D'^)O^Q@OO_1E>@4 %%%% !1110 4444 %%%% !111
M0!POQK.EM\+/$0UC[2-/^S$N;,9FSN&W8#QG=MZ\>O%>6_!;P/K<?Q)DU_4]
M*UC3+-+646T=Z]MY8>5E,A)B.YLE=P!P!D^M=G^TAX8TK5_AAJM[JL-_=P:?
M \@M;*^EM5EW87]X4.2HX)] ":XOX16FE^$/BKI^B:;=W&JP7N@BZ$PUN>^C
MMV4J&5D<E0K$_*W4@&@#Z*VAT..AKAK#X.Z)INO)J\5SJS722F8+)J<[QEB?
M[A?'Z5W8Z4M 'FVF^#?$'AB^\=ZGIDEE<W^LWD=U8QW181IB)$(D(Y_A/3VK
MA;SX,>,+G4K_ $=;C3/^$3U'Q!'KLTY9A=1 %':%1C!S(G#9Z&OH+&:6@#B?
MB;\/]#\:^'+D:WIT5^+:WE>+S"WR$H<D8(J3X.1"'X5^$T480:7; #T'EKQ7
M0>)/^1=U3_KUE_\ 0#6%\(/^26^$_P#L&6__ *+6@#KZ^>_B=^P?\&OC%XTO
MO%7BOPL=1UN]V^?<?:I4W;1@<*V.@%?0E% 'RC_PZ_\ V=O^A(/_ ('3?_%4
M?\.O_P!G;_H2#_X'3?\ Q5?5U% 'RC_PZ_\ V=O^A(/_ ('3?_%4?\.O_P!G
M;_H2#_X'3?\ Q5?5U% 'R@W_  3!_9W53CP0>G_/[-_\57'?"C_@G'\!/%/A
M(7U_X.::<WEU%G[;*,*LS*HX;T K[=D^Z?H:\_\ @2H'@%<=K^]_]*)* /%/
M^'7_ .SM_P!"0?\ P.F_^*H_X=?_ +.W_0D'_P #IO\ XJOJZB@#Y1_X=?\
M[.W_ $)!_P# Z;_XJC_AU_\ L[?]"0?_  .F_P#BJ^KJ* /E-/\ @F%^SPC!
ME\$D%2"/]-F_^*KZ>T31[7P_I-GIMC%Y-G:1+!#&/X448 _(5>HH **** "B
MBB@ HHHH **** $/2O-/&O\ R6'X>_[E]_Z*6O2STKS3QK_R6'X>_P"Y??\
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MN8TCVQ1@A(U5!@ 9)/<DUG_$*S@A^)_PVDCA1':^NLLJ@$_Z,]>H5YK\1_\
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M'R]37].GV:+_ )Y)_P!\BO/OC-#&FE^'-J*/^)_8]!_TTH _G/\ ^%->//\
MH2]?/N--F_\ B:/^%->/?^A*\0?^"V;_ .)K^G+[/$W)C4GU(I/LT7_/)/\
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M6UK>E1,XBC8,[*I(&6<@<]%KU,4BKMIU !1110 4444 %%%% !1110 4444
M%%%% "'I7FGC7_DL/P]_W+[_ -%+7I9Z5YIXU_Y+#\/?]R^_]%+0!Z91110
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M3Q)<>)O!4,]Y?RZE>6]Q-:SRW-N()D='*[)$!P'  !(X/44 >@4444 %%%%
M!1110 4444 %%%% !1110 4444 >?_!S_D'^)O\ L8+[_P!&5Z!7G_P<_P"0
M?XF_[&"^_P#1E>@4 %%%% !1110 4444 %%%% !1110!R'CRV\:306@\'7>C
MVLRN?M!U>&2567'&W8PP<YZUQGA3X?>.Y_B?8>*O%^JZ'<QV-A+9P0:3;2QL
MQD9268NQX^4<"O8J* $48%+12$@4 +12;AZT;AZT 9WB7_D7=4_Z]9?_ $ U
MA?"'_DEOA/\ [!EO_P"BUK=\2?\ (NZI_P!>LO\ Z :POA!_R2SPG_V#+?\
M]%K0!U]%%% !1110 4444 %>=? P@>"I^1QJVH_^E4E>BUYHW[/WA)KNZN$A
MU&V-U.]Q(EOJ<\:;W.YB%#X&2<T >D[P.X_.C>/4?G7FW_#/GA/.1_:Q^NKW
M/_Q='_#/OA3_ *BO_@VN?_BZ /2=X]1^=&\>H_.O-O\ AGWPI_U%?_!M<_\
MQ='_  S[X4_ZBO\ X-KG_P"+H ])WCU'YT;QZC\Z\V_X9]\*?]17_P &US_\
M71_PS[X4_P"HK_X-KG_XN@#TG>/4?G1O'J/SKS;_ (9]\*?]17_P;7/_ ,71
M_P ,^^%/^HK_ .#:Y_\ BZ /2=X]1^=&\>H_.O-O^&??"G_45_\ !M<__%T?
M\,^^%/\ J*_^#:Y_^+H ])WCU'YT;QZC\Z\V_P"&??"G_45_\&US_P#%T?\
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M$NF6$D\ZF5YYKBY??+/*YR\CMW)-=$O08.?>EH **** "BBB@ HHHH ****
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MNHV=_!?1"\+"-C&V=I*\\T =D#D4M>:FZ^*V/ETWPOGU-W/_ /$4GVKXL_\
M0.\+?^!<_P#\10!Z717FGVKXL_\ 0.\+?^!<_P#\11]J^+/_ $#O"W_@7/\
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MRX73[K,D$23,/^!J?QS0!ZW1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1129H 6DP#1N&<4;AB@ P!1BC<,XS1D4
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M,KGH<9KT'X;_ !;3Q+H2WNHW&FRRRWZ6$:Z,\UPJ2,N0)-R!D/N1CIS7)?\
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7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tmb-20221231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )K I8# 2(  A$! Q$!_\0
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8_>GTQ^]
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MW[GN*]:=3 <4NZO//H1U%-W4A?':F ^BF;SZ4^@5PHHHH&%12L5QM//-2T4
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M^T?$IO\ EP\*_P#@=<__ !FO0:*.;R#V-_M/^OD>>_:/B3G'V#PK]/M]S_\
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MU0DN\]/UI^:\@\.^)M"^%-]X6\+)JFK^((?$L\XL]9OKI;M!*BC,;2C&,X.
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M$Y]3M++_ ,"]A7N*'^M92ARV:V9UTJOM'.+5G%V_R)****S.D**** "BBB@
MI&Z4M(W2@#B_B'_R$/!W_8<C_P#2>>NT'05Q?Q#_ .0AX._[#D?_ *3SUV@Z
M"K>R.>'\2?R_(;(^P=,TPW ':HM3G:ULY9E4N8T9]BCEL#I7RK\//">I_&WX
M7WOC^^\:Z[9>)+Q[F>TCT^_,5M8%&;RXA"/E8#:,[LD@U5.GSIMNRV,J^(=*
M2A&-V[]4MO4^LO,QCIBD,N#C%>,_#WXVPW'[.^G>/M?DPT-FXN?+',TT3M$0
M@]7=#@?[5<=\$K_Q<OQTU*/Q1JEW+-JGAQ-9?2I)"8;!I+EE6)%[%410?<FK
M]@_>OT,OKT/W:BKN=OE<^F0W&>E4K36K34)+F.UN(;A[:3RIEBD#&-_[K8Z'
MV/-4?%NO)X:\+:QJ\G^KL+.:Z;Z(A8_R-?-K:OJWPJ_8_7Q'87/V?Q%KI34+
MC4' +12WDH)D.>Z*X'/]VIA2<UH_)%U\4J#LU>R;?HM#ZI-RN<<9]S2F;!P1
MS7RY\0_"5_\  :P\,^,]&\7:YJ4BZC;6NJPZE?M<0WT,K;&8(W"L"01MQ6M\
M4/&*^,/BW<>$=0\6OX.\*:'8QWFI7-O=K:RWD\I^2'S#RJ!03\O)R>>!6GL&
M]8O3_(P>/Y?=G&ST6ZUOMZ;=3Z$O]8M=+LYKN\GBMK6%=TLTSA$0>I)X JQ;
MW272*\;!T8;E93D,.Q%>7>"/ /A6\\%ZQIFF:]=^*= U=3#(+S43>K&I38RH
MQR1D'."3S4'[+NO7&K_"BRLKV8S:AHD\^C7+L<DM!(4!_%0A_&LW3LF^QTPQ
M#E.$9*W,F]-=O/YGKU%%%8G:%%%% !1110 4444 %%%% !1110 444AY% '@
M_P"U=/>^)]&\._#O1YA'JGBN^$;,V=L=M%B25VQS@?(/?-><_&'P9\3/#&D:
M'XWUK6M#U>W\&7,=['::78-;RF'*I(@8L1MV]B.U?6TNGP37$<[PQ--&"%D9
M 64'J >HI)[".YC:.5$DC;AD=<JP]".]=4,0Z?*DMOUW/+K8)5Y3E*6^B\K;
M>NNI\U6?CG1/"'[3.J^(M<U&#3M \3^'K272=4NW\NW8*/F0R-@*3][!([>M
M7?@UXBTGXC?';XK:A81R3Z3>6&G01RS1%%N4 F1G4$<J2#AN]>^7?AC3-0MH
M[>ZL+2YMXL>7%+ K(F.F 1@59MM)MK-R\$$4+E0I9(P"5'09]!GI3=>+C9)W
MM8B.#J*:YI)QYG)[]5:V^Q\:>#(-4UOQ?H?P2N(9#9>$M=GU*ZD(XDT^(K):
MJ3W!>4#'^ROH:W]7ALO"_P"TEXT/B7QCJ/@6RUNUM;C3M1@GBM[>Y6-"KQM)
M*C*&4]!D<5]6KI5M'=O=)!$MU(H5Y@@WL!V)ZD<5!JGAW3]:C$>H6=M>Q@Y"
M7,*R*#]&!JOK*<OALK6^?5F/]FM1^+6Z:]$K)?TSYB\::/X3C^ GQ?U3POXH
MN?&,VHQI_:&H7$R3AY$5%4*R(JM\A&2N17JVN0>%X_@#;6_BLBW\-3:7:P73
M*&'EJZHJME<E<$@Y[=:](CT"PAL'LH[.WCM&X,"1*L9'^Z.*GETZ&>V^SR11
MO;D;3$R J1Z8Z8K*57F279W.J&#Y-4EM;RUN?,7@3Q1J)\=:IX$\/>-T^(7A
MB;0IYH;\LL\VG2_<CBDN(_E?.>_/'3N>.^$TWA!?A&OA[Q7\3]6\)7UE'/I^
MH^'[F\M[?9\SJP2)XM[*RG.5SG=7V-IGAS3=&1DL+"UL48Y9;:!8P?K@"HKS
MPEH^H7GVNXTNQGNQTGEMD9Q_P(C/I6OMUKI^7^1RK+Y63<KM76M[6=M%K?H9
M_P .=)TW1? >@V.BS2W.E6]G&EI+/G>T6T;2V0.<8["OF77A\./^&HO'@^(_
M]C_9#861LQK 4C?M ;;GO@#\J^OHXA$@1>%'0 5G77AG3+^0RW6GVEQ,>LDL
M"LWYD5C"KR2D^Z.NOA/:PA%6]W575UM;]3P7XE:9X:\0_ 234/AC-I\L?A.[
M75]-&E8:**:!C(ZJ!W*L^0.N<5F?"R6_^-]I\2_'\,+P'6+ Z'HB2C:4A2+Y
ML'T:9V_$5]*6NC6=E;M!!;0P0L<M'%&$4_4#BGV>FPV$"PV\4<$2](XD"J.<
MG@57MK1<4M>Y'U&]2,Y/2VR5M=4G]S/C3X5W?@V7X.6VB^)OBEJ_ABYMK5].
MU#P[<WEO;O$0"K1K"\/F$$'C&<YXYKT'Q;I5EHWQ5_9[L-,>6;3;2WNX;>28
M'>8EMH0A;@8) '8<U[[<>$=&O+T7D^E6,UV.D\ELC2#_ ($1FKLNFV\TD,DD
M$3R0Y\IR@W)D8.#V_"M)8F\N9)ZW[=5;L94\ X4^1M:6L];Z.^NMCQWQ$N/V
MLO"++T_X1B]R?^V\?^(K*^ ?BS1M(\<?$GPQ?:E;6GB"Z\77MU!ITTH6::)X
MHV#HAY9<(QR.F#7N[Z="\ZSM'&9U!59-HW 'MGKBJZ^'=.745U'[#;'4 -HN
MO)7S0,8^]C-8JHG'E:Z6.B6%E[3VD7]J_P!\;&A&<Y[T^F(FTGGK3ZP/2"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ IC]Z?3'[T >:^+?\ DNO@'_L&
MZM_.UKTE>E>;>+?^2Z^ ?^P;JW\[6O25Z5I/:/I^IR4/BJ?XOTB$CK'&78@*
MHR3Z"OE3QI\:/ ]U^TSX"U>/Q1IKZ78:??P75V)QLA=EPJL>Q)KZL=-Z%<CG
MVK(_X0W1"23I%@2>23:IS^E52G&#;DNY.)HU*RBJ;2LT]?+4\+^(WBG3?"'Q
MW\ >/[NZC'A/4](FTE]5!_<0EB)8F=N@5LXR:HZS?6'QO^/VGGPW<1ZKHN@:
M%>PW6IVKB2W\^Y 58UD'#' R<'BOHV?0[&[L_LD]K!/:;0OD21*8\#H-N,4F
MFZ%9:/"(;"TM[*'.?+MXEC7\ABM(UE&SMJE8YG@YRDTY>ZVI/O=6VOTT/F?X
M0_'3PU\/?@*NB:]J,&G^*/#D$VGRZ+,VVZEE1F6,1Q'YG#C;@@'J:]._9E\)
MWW@[X'^%].U&%K:\$+330N,%"[L^T@]" PKT.?PII%U?K?3:99RWBG(N'MT,
M@/\ O$9K4"87&1^53.HI)I+=W+P^%G3<7-_"K*W;3_(\+\#2KI7[4WQ*L9N)
M=3TO3;VWSP62(/&V/7EQ7-_$?3_@4FN^(=8U'7XM.UR-VCU+3],U22WN+N1>
M-C6Z,&D8]. <UZ[KWPR.H_%'PYXULKP6=WI]O-8WD1CW"[MW&57.1@J_S \]
M372S>$-&N;\7TVEV4MZ#G[0]NAD_[ZQFK]JE*,KO8S^K3<90Y5\3:OYZGD?[
M+WAD> /A+=7][9#0[;4+RZU<64F1]D@;'EH<\C$:+UJM^S?#+XVU3Q3\4M0A
M*3^(+HV^FAN3%I\+%(P/]X@L<=< U[N]JDD;(ZJZ,-I5AD$4V"QCM(%B@1(8
MT&%2-=H ]@*SE6<W)M?$;4\(J?LXW]V.OS_X!X7\8U;5?V@?@WI\&3-!<7M]
M(0/NQK$.3[$BO>%Z8'&*XBR^'$K?%J_\:WUXEPW]G1Z986JQ8^SQ[M\C$YY9
MFQS@8  KN0F .:522:C%=$:8>G.,ZDI?:?X)6'#I2T45B=H4444 %%%% !2-
MTI:1NE '%_$/_D(>#O\ L.1_^D\]=H.@KB_B'_R$/!W_ &'(_P#TGGKM!T%6
M]D<\/XD_E^1%<X* 'H>M?(_CRQ^ ]GINLZGIFI?;]0OW?'AO1=3E'VRY.0JM
M:(V1\W7*@"OKJ2/S,=./6LN'PCHUO?F]CTJQCNR<FX2V02?]] 9K2G4Y'<QQ
M6'>(22M\U?[CYPL?@%XYM?A=\,-%T2^TFS.ANVI7]CJRR-%)=.QD083J(VD?
M )QD+Z56\-67Q17]J0?VG>>&7OAX?@:[>U@G$+67VEP5CW'(ESGD_+C'%?5I
MB7& !5?^S8!<&=8HUG(VF4*-Q7.<9ZXSVK7ZS+WFUO?\3E_LV"<.5M6MU[')
M?&#39M:^$OC+3X.9[O1KR% !U9H6 _G7&^#]1\)ZU^S+X=D\4FT'AB?1;6&[
M-U_JE^15(;TP_&>Q'M7LDMLLT;1L 488*D=17!?"OX5_\*Y\-:AX=GNH]4T=
M[V>>R@EAX@AD<OY3 DAL$MSQUZ5E&2]FXONF=-2C*5922NFFG?\ #Y'S1XS^
M'WPZ\1ZOX6\*_#N_G\5:J^H03R3Q:I)?VVEV<;[G(.]D0D  #J03Q76:YI_@
M[PI^U/K]Y\0+/2X]/UC2K:72M0UM(_LR21_+*@>3Y5<C;UYXXKZ;TOPYIFAA
MAIVGVM@K?>%M"L>[ZX%+J?A^PUJ,1ZA96U[&#D)<1+( ?8$&M_K5_==[6?KK
M;_(XEEUES:*5T[6TTO\ Y[G@?[-D&DS_ !!^)VJ^$[9;;P/<W-I'9&W0I;2S
MI&PN'B7&-I)'(X-;7[)4#S>"O$NJJ,VNK>)M1O;9O6,R! ??E#7J7B/PU<7?
M@[4M(T.>#1[F>V>"VG$.4MV8$!@JD=,YQD5'\-_!%K\.?!.C^'+-C)#I]NL/
MF$8+D#YF(]2<G\:B=93C)]79?)&M+"2IU*=]H\SOYR>WH=-1117(>N%%%% !
M1110 4444 %%%% !114<H)'!P: )**\ZUG4_'=MJES'97'A\6@<^4+BVG:0*
M>1N(D S]!5'^V?B)_P _'AG_ ,!+C_X[6JIMJYS2Q$8NUF>IT5Y9_;/Q$_Y^
M/#/_ ("7'_QVC^V?B)_S\>&?_ 2X_P#CM/V3)^LQ[,]3HKRS^V?B)_S\>&?_
M  $N/_CM']L_$3_GX\,_^ EQ_P#':/9,/K,>S/4Z*\L_MGXB?\_'AG_P$N/_
M ([1_;/Q$_Y^/#/_ ("7'_QVCV3#ZS'LSU.BO+/[9^(G_/QX9_\  2X_^.T?
MVS\1/^?CPS_X"7'_ ,=H]DP^LQ[,]3HKRS^V?B)_S\>&?_ 2X_\ CM']L_$3
M_GX\,_\ @)<?_':/9,/K,>S/4Z*\L_MGXB?\_'AG_P !+C_X[1_;/Q$_Y^/#
M/_@)<?\ QVCV3#ZS'LSU.BO+/[9^(G_/QX9_\!+C_P".T?VS\1/^?CPS_P"
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MKG2E:/I^IRT<1%2GZ_I$]3HKRS^V?B)_S\>&?_ 2X_\ CM*-9^(G_/QX9_\
M 2X_^.U'LF=/UF/9GJ5%>6_VU\1?^?GPS_X"7'_QVD_MGXB?\_'AG_P$N/\
MX[1[)C^LQ[,]3HKRT:S\1/\ GX\,_P#@)<?_ !VC^VOB+_S\^&?_  $N/_CM
M'LF+ZS'LSU' %+7EO]M?$7_GY\,_^ EQ_P#':/[:^(O_ #\^&?\ P$N/_CM'
MLF'UJ/9_<>I4G6O+O[:^(O\ S\^&?_ .X_\ CM)_;/Q$_P"?CPS_ . EQ_\
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MX_LI/BSX-N!IVMJL=AJ*%&TBY#L6\C&U3'E@,<X!QQGK7<'XDZ<?^89XA_\
M!%=__&ZTE%VCZ,YJ-:FG-WZ_I$Z#51>'3+O^SC"+_P IOLYN,^7YF#MW8YQG
M'2O&O%VD?%3XH>'YO"VI:-H7AS3KW$5]JD-^UR[1?Q"./:,$_P"T37HG_"R-
M/_Z!?B'_ ,$5W_\ &Z/^%D:?_P! SQ#_ ."*[_\ C=$&X;)!5E2JZ.;2\BA\
M0/"FL2?"JX\,^$6B@O'M8]/AENI,"&' 1FS@Y(0' '?%=%X.\,6?@KPMI>A6
M";+6Q@6!/4X'+'W)R3[DUF?\+(T__H&>(?\ P17?_P ;H_X61I__ $"_$/\
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M.4IR3<MWU"G"C2E#D?NQ327K_P  Z^BN4_X61I__ $#/$/\ X(KO_P"-T?\
M"R-/_P"@9XA_\$5W_P#&ZY^5G=]8I]SJZ*Y3_A9&G_\ 0,\0_P#@BN__ (W1
M_P +(T__ *!GB'_P17?_ ,;HY6'UBGW.KHKE/^%D:?\ ] SQ#_X(KO\ ^-T?
M\+)T[_H&>(?_  17G_QNA18_K%/N=WH?_'\/]UOY"NFKS7PGX\L=2UN&UCL=
M9A>4,%>ZTFYAC'&>7= HZ=S7I(.0#ZUSS5F=5&<9QO%BT445!T!2%0>M+10
MP1J  !@"DVCT/YU)28H6@K=B/:OI^M&%]/UKQ#]KV69?AYHEO#=W-F+O7[&U
ME>TF:)VC>3:PW*0>AKC=<T(_!'XL?#VR\)^(-7NH-?O7M;_1;^_>[1X0N?-4
M.24*GN/\:ZX4N>-[ZN]OEYGF5L;[&HX<MTK7U_FT6GR/J+:OI^M)M7T_6O(;
M_P".%W<ZCK*>&/"&H>)=/T:=[:_U"&XCA3S4&9$B#G,A7@'&!GBIM?\ VB?#
M.B?#70_'"BYNM#U.YBME,2?O(B[$$LO7Y2K9 R21Q67LJETK:LV^N45>\MO4
M]8VJ.WZTNU?3]:\ \=^/X?%_PEU/4O&/A+Q!X=TF&_L_)B2Z2.XN5>9!'("K
M?*,L,J>:ZOQW\<['P1XXM/",>AZIK6N7E@+VTM[!5(D^=EVDD@)C:26;C'Y5
M7LI[=2?KM+5MV6G>^OE\CU&0A.>@[YJ*QO+;4+5+BUFCN87SMDB<,K8..".#
MR*\V\ _&&/QSJ>N^'=2T6Z\,^)=-A6:?3;MUDW1./ED1UX9>Q]#7BOP+^.%U
MX+^ ^D-:>#=7UO2='%P=3U* I'' #/(Y\L.092%89V\#D9R*%AYR3?56_&_^
M1,L=2C):W33?W6/KO:OI^M&U?3]:\[\2_&C1M#\)^']:M(;G6'\0&--*L;-1
MYUTTB[E'S$!0!R23Q@U5\+_&&2_\8Q^$_$7A^Z\+Z]<6[75G#+,D\=S&OWRC
MI_$N1E2.]2J<[-V_I&SQ5)244]_6VOGL>G;5]#^=&U?3]:\1TG]H\^*_%5[H
M6@>$-6U=].U)K#4KB-XUBM55POF%B?FSR=H^; S5KQ9\=-8\+KJ-^/AWKUUX
M;TUW%UJC/%$1&A^>5(6;>R#!.>.!FG[*:=F1]<H\KDF[+R9ZW=WUM926\<T\
M<+SOLB5W ,C8SA0>IQDX'/%3@#:.]>%_%K5[?Q!XG^!^IV;^9:7FNK<0OTW(
M]I(RG\C7M6J:G:Z)IEUJ%[*+>TMHFFFE;HJJ,DG\!42@XQ3ZLUIUU*<UTC;\
M5<N;5]/UHVCTKQ!OVD'MM'M_%%QX-U:V\#3LFS6VECW!'8*LK09W",EEYR3[
M5T/Q"^-%OX0U?1=#TK2+OQ1XCU:)KBUTZR94_<CK*[MPB^YJW2J;&?URC9OF
MVM^.W_#GHGVZV-XUH)XOM2IYAAWC>%S@,5ZXSQFK6T>E?.7PV\:'QG^T_KEQ
M-I5[H=[:>%8;:[L+]0'AE6Z9N"#M=2K@AAQS723?M"S7UC?ZUH/@[4]?\)6+
MR)/K%O/$F\1\2/#$QW2*N#SQG!QFFZ$XO0B&-IRBY2TLVON/:=J^GZTFU?3]
M:\G\8_M":!X3LO!MS'9ZAJUOXJ1FL#I\>]FPB,J[<YW-O4>W.2,5BQ?M*-:Z
M[/X<U7P1K>F^*Y(UFL-'4QS&]C8L-PE4[$ VMN+$ 8ZDD92I5&KV*EC:$79R
M_/Y?>>Y;5]/UI=J^GZUYI\-/C!%XZFU_3KO1;W0->T%E%_I5P5E=0P)1D9>'
M#!3C'>N:UC]HF^\,B'5=<^'^NZ/X4DF2'^UKEX@T>YL*[P!MRJ3W/(]*2ISO
MRC>+I*"G?1^OS]/F>X;5]#^=&U?0_G38762-6'0C(J7 K*[V9V[ZH9M7T/YT
M;5]#^=/Q1BBX#-J^A_.C:OH?SI^*,47 9M7T/YT;5]#^=/Q1BBX#-J^A_.C:
MOH?SI^*,47 9M7T/YT;5]#^=/Q1BBX#-J^A_.D*@#H0:DQ37[T7"QYKXL'_%
M\_ (Z@Z9JW'KS:UZ,J@^OUKSGQ;_ ,EU\ _]@W5OYVM>DKTJYO2/I^IRT=93
M]?TB&U?3]:3"^GZTV1AM<]/?..U?(?Q7\5ZOX_\ $6E>*=.U"\L/"FD^)K'1
M]/6VE:-=0D:8"YF8 C*@C8O7HQ[U=*FZLK7LB<3B?J\;\MWV/K[:H[?K1A?3
M]:^=_P!J&\TJ/Q)\.+;Q#K5UHWANXO;M;Z>VNWML@6[&/+(0?O[?SKKO@7H7
M@.RBOM0\$^(KCQ!#.%CF:;57O FW)488G8>3]:IT[4U.[^XA8IRK.C9??^AZ
MQ*RQ(6)"JH))8\ 53T;6+#7["*^TZ[AOK.7)CGMW#H^#C@CKR*\Z_:<\37/A
MCX*^([BQ8I?7426$# X(>9Q&,?\ ?7Z5HW]_I'P+^$EON)%AHME';Q1J,O/(
M $1%'=G; ^IS67(Y14EU9HZZ]JX=(J[_ $_)GH6%]/UH*CW'XU\M? ^'Q3IO
M[1NHQ^*=6N;G4=3\.?VI<V1F)@MG>X4)%&N< (F%R.^:Z+]HCQ-JGBLW_@KP
MU>RV2:?ILNK:[J%O(4DMXE1FAA5@<AI'4'_=!]:V="\U34MUOT.:..4J$JO+
MJFU;J['N>LZ[I_A^U%SJ5[!86YD2(2W$@12S'"KD]R3@"M!=I4'DCUS7@7AC
M13X__9 L;"_D>[N;KP_O6:5RTGG*I9'R<G(95.?:O0O@=XN;QY\)_"VNRY\^
MZL4$^>/WJ_))_P"/*U9RI\B>NSL;4L3SSBFK*4>9?Y'>84]C1M7T/YTX=:7%
M9)G<,VKZ'\Z-J^A_.GXHQ1<!FU?0_G1M7T/YT_%&*+@,VKZ'\Z-J^A_.GXHQ
M1<!FU?0_G057'2GXH/2BX'$_$!1_:/@[_L.1\^O^CSUV05?2N/\ B'_R$/!W
M_8<C_P#2>>NT X%6WHC"'\27R_(9M7T/YTF%]/UHF7('&:^9_CK\%]%\-^ _
M%'C6Y\2:ZOB>SBEO;759=2=2DV<QQ)&"$"EMJA0.X]:JG%3DHMVO^9&(JRHP
M<XQNEJ];'TQM7T_6C"^GZU\Y^/\ Q9K^M^"?A)X6EOKG2M9\9&W34[RV/ERI
M"D DN I'*LQ*KGL&-9WB'P=%^SQ\3/A]=>&+[4(M'\0:B=)U.PN[R2X24LA*
M2C>3M<')R/2M51TLWJ[V^1R2QS7O*/NJUW?:]NGYGT]M7T_6L[3-=T[6)+M+
M&]@NVM9C;SB&0-Y4@ZHV.C#/2JGC'7$\,>#M;UI_N:?93W9R,\)&6/\ *O,/
M@EX#EN?V>]-LVU*[TR_UZ$ZG>:A9OMN/,N&\UBK=FPVW/;'%<ZC>+DWU.JI6
M<:JI):V;^ZWYGM0"_7\:,*.WZU\J>-O EM\$_BK\-/\ A"=1U5;[7-2-KJ-E
M<W\MR+RW !>1PY/(_O>N*W[W0!\>_C;XQT/7;^]7POX4@M88M-M+EX$GN)E9
MS+)L(+;0N ">*Z/8V7,I:6O^-CE^NR4G3</?NE:_=7W]#Z!U34[/1=-GOKZY
MALK2!2\L\[A411U))Z"I;2XBO8$GA=989%#HZ'*LI&00>XKP'X2Z5)8>*/B7
M\*M2O+G6- L(H)+'[=*99$M;F)MT18\D*<@9KI_V5];EU#X4VVF74AEO- NK
MC19G;^(P2%5/_?&RHE1Y$Y)[6_$VI8KVDE&2M>Z^:W1Z]M7T/YT;5]#^=/Q1
MBL+G>,VKZ'\Z-J^A_.GXHQ1<!FU?0_G1M'88_&GXHQ1<",QDGKUJ04M%($K!
M1110,**** "BDW#UHR/44 >"_MCZ='JWP]T&SFB>:&;Q!8I(D;,I*F3!Y4@C
MKU[5W'@GX(>"_ =^=3T/18X-09-OVR>:2XF"D<A7D9B!]#7?R*CE=P!P<C-*
M& 7 -;>UDH>S6QQ/"PE5=66K=OP/B/P/9>$O!4OB#0/'?CCQ)X,UFVU2ZD2&
M+49;>VNX9)&>.:(;2&W G.#G.?6NS\:^&O#NB_!SX<6'A7[9<Z"_BZPEC>^5
MS(ZM<DLS!U!QDGJ ,<U]/SV-O=LC2QQN4.5+H#CZ9Z5(8DQ@X(SFMG7?,I'#
M'+E&,J=UJK)VUU[Z_D>._M6KN^"U\%4'-]I^-O/_ "]Q5R'Q#\>:9\/OVK]'
MU/64F33I/"?DRW4<1D2VW73X=\<A21C..,BOI(JF.>3TKSVX^',UU\;+;QLU
MW"+2/0VTE[-E)=F,QDWYZ;<'%*E527++S_&W^1IB</.4E4IO6\?P;?ZGFO@+
M5;;XG?M$>(O&V@,;GPO8: NDKJ(4K%<SM('(0G&X*%P3[TGPCMV_X8NDB\HA
MSI.IY3:<Y,D_:OHJ&&*!0D:+&BC "C  ]!3B(L%2 0<C![U,JSMRKR_ JG@U
M&7/*6KO?_M[_ (8^-?$.C/'\)/@-XAO6U:TT+2+<QZE=Z2[)<6B2P!5FRH)
M!'S'T)KO_AE9?##7?B3I.H:%XVUKQCKVGP3/;_;+Z6ZBMT8 /DE JD\#!.3^
M%?1)B5UQA0N.!CMZ4RULH+<,(HD@4DL0B@ D]3QZU4J_,FMM_P =S*G@%2J1
M:::TW6ONV7H>(_LN0&&W^)#M$4=O%]Z02I&1MCQ_6O(]=\:W'CSP5XPE\3^.
M]=TGQ5F]M(O!6DJB"-5WA$9!&SR*1@LY.,9.1BOM!8(TSM 4GD^Y]3^51"QM
MO/,XCC\TKM,FT;B/3/6DJZYW-K73\!SP-Z*HJ6FOXO?Y'S7=*W_"._LT_(WR
M3VC-Z*/L#5[-\9M O?%GPH\5:5IP+7MYITT4"KU9RIP/QZ?C79^5&>N*>=N"
M"1BHE5YFG;;_ #N=%/"JG&<6_B27W*Q\2^$S\+=9^'FFZ+XI\=^++#43:1VE
M]X8FU";>DBJ%:%8 A.T$8 '8>U>A>,-3T_X2_M#^&_$VLF2T\*7/AIM'@U*9
M6,5O,LBNJR'!VEE7@D>M?2#65MYWG&*,S8QYNT;L>F:6>S@N(FCE1)8VZI(,
M@_@:U=?6]MSEA@'&GRIK2UG9]-NI\X^$?%%M\2?VB/$U]I"7,6F7'A%;*TU"
M>$QQW/[]LRQYY*Y; )'.TD<8KR_X76_@CPSX''AKQUXX\3^#_$.G/+;7NBC4
MI88F&]L&) K!E8'/RGDDU]P+#&HR, X[5'+8V\\B2O'&TB9VLR E<]<>E5]8
MTY4M-/P$\!)^\Y*]VW=.WO6NM_(^;_$/A_2M!\7_ +.UAH27)T6W>[-J;D-Y
MHC:W1EW;@"&Y[@<UV&J1?\99:&Y3Y!X2N1OQQG[5'WZ9QG\Z]F$:*#C&!S2A
M4+9XSCK63K/3T:^\ZEA$KZ]4_NM_D?//AZ>]TW]H3XSWEE;?:;R'1+&6"  X
MED6*0JOXD ?C7A?Q.\2KXX^!5UJ>H_$/7=:\53Q1S7GARV5([:T;>ID22%8\
MJJ<@,S#)"\\U]]8CZ9J..SMHY'D2*-'?!9E4 MCID]ZJ.)2U:UT_#0YZF <T
MX\VCYKK_ !/]-A-/CQ9PGMM'\JN5&NU5"@\"GY'J*Y&[ML]>*44D+129'J*,
MCU%!5Q:*3(]11D>HH"XM%)D>HHR/44!<6BDR/449'J* N+129'J*,CU% 7%I
MK#@TN1ZBD8C:>>U 7/-?%O\ R73P#_V#=6_G:UZ0O2O-O%A'_"\_ //_ ##-
M5_G:UZ2"*TGM'T_4Y*#]ZI_B_2)SWQ#\-ZCXL\$ZSHVE:G_8U_?6S6\5\$+F
M'=P6P".<9[CK7R_\7OASX_\ !'@+P=I#>)M%GTJTUS3X+.WM-&:-HI _R2,3
M*VX Y+# SGJ*^Q-P'<?G4<H5AS@UI1K2I;*Y&)PE/$:MM.UMW^AY?XC\>>%_
M 6G:+9?$G5M.DU&6)F%[/9,EO(X(#%<A@A^9>"<UYM\*ETWQ5^TIJOBCP1:?
M9_!Z:.MI>7EO#Y-M>7?F978,#>0HY;''KS7TE+:03JRR(CJWWE900?K4L4,4
M*JD:JBJ,!5& *(UN1.W4SEAI3E'F:M&WKH>-?M>6LC_!/4+M%+_V;>6E^RCN
ML<Z%OTR?PJ]\5_AIJ_Q4?PEJ6A:_9Z=!I<QOE@O;,W4-Q(5'E.5#KRG)'N:]
M&\6^'K+Q=X;U+1=00265_;O;RKZJPP?YYK,^'/A:Y\%^"-&T*\U(ZI+IT"VX
MNV389%7A<C)YQ@=>U*%3D@K/5,*N']K6ES+W915_5/\ X)\\^&] \?6_[6#K
M?^(M,N;I-!B:[N8=,>..:V\]<Q*OFG:^0?FY^E:>O?!SQ_X*\,>/;RS\9Z3<
M0ZNMW?7GVC1W:YF!C.(_,$W&%&U<#BOI<(F\/P6Q]ZG,RD8SQBM'B9<R:2T7
M9&2RVERR3;=VVM7I<^?O@.^K^'/V9(;[7-1MKBP31FGM8H[<Q-;PB(Y1R6.]
MN#SQ73_LJZ3/HWP#\'P7,;1RR6S7.UNNV61I%_1A73_%7P/-\1O!-]X;@U+^
MRX+TQQW$JQ[R8 ZF2,<C&X KGL#TKK-.L;?3+*VM+=%C@@C6*-!P%51@#\JB
M=3GC)O>3O8THX;V52&ND8V^;_P"&+*'/-/IH('>ER/45SGIH6BDR/449'J*
MN+129'J*,CU% 7%HI,CU%&1ZB@+BTC=*,CU%(Q&.M)@<9\0_^0AX._[#D?\
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MLJ7*%$D/ 0D'&XD@8Z\TN>IW9HZ>&CNEWV[?,YW_ (4;X) _Y!4X'J=2NO\
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M (4;X*_Z!5Q_X,KK_P".56\>/XOA^$5]?+=6VG^*["W^VM_9;,\#F([S&I<
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M*[G7/@:EWXAUW7M)\8>(_#NH:K(LTHL)T$'F)&$4E6C.[@>M:/@KX)Z-X/\
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MHZ5E/1F\-$+1114&@4R12V".U/HH \YUGP]X[N]4NIK+4O#T=HSGR4N;*=I
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M+?$7_H*>&/\ P N/_CU>I44>VEY?<@^KQ[O[V>6_\(M\1?\ H*>&/_ "X_\
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M4J*/;2\ON0?5X]W][/+?^$6^(O\ T%/#'_@!<?\ QZC_ (1;XB_]!3PQ_P"
M%Q_\>KU*D;I1[:3[?<A/#Q[O[V>#>-O#OCV&]\+"?4O#C%M718O+LIUVOY,W
M)_>\C&>*ZC_A%OB*?^8KX8_\%]Q_\>K=^(?_ "$/!W_8<C_])YZ[0=!5.M*R
MV^Y&$,/'VD]7TZOL>7?\(M\1/^@KX8_\%]Q_\>I/^$6^(H&?[4\,?^ %Q_\
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MO_C5'_#0'AW_ *!'BG_PFK[_ .-5N[3G&,GTI,"IY86O85ZVW.ON_P""8?\
MPT!X> P-)\5#_N6[[_XU2?\ "_\ PZ>ND^*CWY\-WW_QJMVC%'+#M^(_WW\R
M^[_@F$/V@/#N[/\ 9'BG/K_PC=]_\:I)/C_X=;&=)\58[C_A&[[G_P A5LVU
MU!>1^9;S1SQY*[HV##(ZC(J8#/09^@JN6">J_$$ZRL^=6]/^">-^(A\(?$^M
M76K7O@OQ0M_='-S+:Z#J4'GGN7$: ,?<\UV7AGXN^"?"&DVVE:+X<\2Z=IUN
MNV*V@\,7RHH_[]?KWKL@#V'O24VXRT=S&-*47S1LGZ?\$Q/^&@_#X_YA/BK_
M ,)J^_\ C5'_  T'X?\ ^@3XI_\ ":OO_C5:]U=0V-N\]S-';PH,M)*P55'N
M34@(8 @@@\@CO4\L;7L:_OME-?=_P3$_X:#\/_\ 0)\4_P#A-7W_ ,:H_P"&
M@_#_ /T"?%/_ (35]_\ &JW.E)1:'8/W_P#,ON_X)B?\-!^'_P#H$^*?_":O
MO_C5'_#0?A__ *!/BG_PFK[_ .-5JSWEO:M&LT\<+2ML0.X7>WH,]3[5-3Y8
M;V%>M_.ON_X)B?\ #0?A_P#Z!/BG_P )J^_^-4?\-!^'_P#H$^*?_":OO_C5
M;=+2M#L/]_\ S+[O^"8?_#0?A_\ Z!/BG_PFK[_XU1_PT'X?_P"@3XI_\)J^
M_P#C5;E)1:'8/W_\R^[_ ()B?\-!^'_^@3XI_P#":OO_ (U1_P -!^'_ /H$
M^*?_  FK[_XU6W11:'8/W_\ ,ON_X)B?\-!^'O\ H$^*?_":OO\ XU1_PT'X
M?_Z!/BG_ ,)J^_\ C5;=%%H=@_?_ ,R^[_@F)_PT'X>_Z!/BG_PFK[_XU1_P
MT'X>_P"@3XI_\)J^_P#C5;=%%H=@_?\ \R^[_@F)_P -!^'_ /H$^*?_  FK
M[_XU1_PT'X>_Z!/BG_PFK[_XU6W11:'8/W_\R^[_ ()B?\-!^'O^@3XI_P#"
M:OO_ (U1_P -!^'_ /H$^*?_  FK[_XU6W11:'8/W_\ ,ON_X)B?\-!^'O\
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M3$_X:#\/_P#0)\4_^$U??_&J/^&@_#__ $"?%/\ X35]_P#&JVZ*+0[!^_\
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MNI%R AC3&_)  /?UKHUYVK.]NQYR2=+G4E9MZ7Z-:7\^I9\&?:_B5^S]XO\
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M/N_2HGLK:2Y6Y:WB:X48$Q0%P/3/6HO^%$^$?^?.[_\ !E<__'*/^%$^$?\
MGSN__!E<_P#QRCFAW8<E9[P7WO\ R+:*L:A5 51T &!2YJG_ ,*)\(_\^=W_
M .#*Y_\ CE'_  HGPC_SYW?_ (,KG_XY2YH=V/EK?RK_ ,"?^1<S1FJ?_"B?
M"/\ SYW?_@RN?_CE'_"B?"/_ #YW?_@RN?\ XY1S4^[#EK?RK_P)_P"1<S1F
MJ?\ PHGPC_SYW?\ X,KG_P".4?\ "B?"/_/G=_\ @RN?_CE'-3[L.6M_*O\
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M!KS/Q1\'?"\'QA\$V"6=Q]FGT_4GD5KZ<DE#;;<$OD?>/0\UW_\ PHSPB?\
MESN__!E<_P#QRM)2IVCJ]CFHJMS3]U;_ ,S[+R+N:K1:9907!GCM((YSUE6-
M0Q_'&:C_ .%%>$/^?.[_ /!E<_\ QRD_X47X0_Y\KS_P97/_ ,<J%."T39NX
M57O!?>_\BW/!%<Q-'-&DL;#!1P"#^!IMM:P640BMX8X(AT2)0H'X"JW_  HS
MPA_SYW?_ (,KG_XY0/@7X1/_ "Y7@_[B5S_\<I<\-KL.2LW?D7WO_(9XBT*S
M\4Z!J.CWZ^99WT#P2J#@[6&#CWYK/\%^%6\,^#M)T._NUUA]/@6 7,L6-X7A
M202><8'6M)O@;X07_ERO#_W$KG_XY0/@=X0_Y\KO/3_D)7/_ ,<JE4BE9/\
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MM;.#Q)XPN(8_M<^H2B"&!V7<[OM&2JGY0%&3Q6/^U_D?!><,?]&;4K 7)/\
MSR^TQ[OZ5Z?XD\3:9X/T&ZU?5KN.RT^TB\V661L!5_Q)X [FHBK4XR2O=_Y?
MYFTIN5><6^5**_&_^1Y7X(^+?C&Q^*\'@#QYIFEI?WMDU_9:CHKR>2ZKPR,L
MG(/#<^W3FN@^.OQ@E^%N@0#2K*/5_$M\'-EI\A(5DC7?+*Y'(15!R?4@5RWP
MIT'5/B!\0KSXL:[92Z8CVQT_0=-F&)([3=DS2#LSGD#L#W[>;ZOX\N)K[XC^
M(/$_A/Q,VIW-G<Z3I8BTAW@LK-59=V\X&78EV8=L#M6\:4955=;+5>=S@>(J
M4L._>>K=F][6W/6-2\;^(_&G[-<7C/19ETKQ VG)JJI;#,;E,.\7S G:ZJR^
MO->G>"_%%OXS\*Z/K=H=UMJ%I'=(?0,H./J,X_"O'_V=O$UOKW[.%G:R6-[:
M)8:0;>22^MS$DW[LDM&3]Y>>M:W[(C2O^SYX0,N3^ZF"$_W/.DV_IBLZL%%3
M5K-/\_\ AC?#5W.=-IW4HW^ZWYW/:%.12TU>E.KD/:"BBB@ HHHH **** "D
M;I2TC=* .+^(?_(0\'?]AR/_ -)YZ[0=!7%_$/\ Y"'@[_L.1_\ I//7:#H*
MM[(YX?Q)_+\ALK%1Q7@7C_XB_&#PKINK>)XO#/A\>&]-,DLFG37,KWSVZ'YI
M-R_(#M!;';'.:]\E.,$]*\%^->OW7Q2U2;X5>$I@9KD*OB'4T!,>FVF06C)[
MR2#*A!T&<XSFM*.L]5IU.?&-J%XR:?2W<[C4O'&OZ_\ #[1-<\%Z3;ZC>:M'
M!-%'?S^3%;QR)O\ ,D(Y(' PO))KE?!'Q8\9V'Q3B\!^/M-TF*_O;%[^PU'1
M&D,$JH<.C+)\P(YY[UZ%<7NA_"_P.K7=Q%IVB:/:)$)I#PD:*%7ZG   [DBO
M,_A#HFJ_$'X@7?Q4UZT?3K:2U.G^']-E7$D5F6W&:0=F<DG!Y ]L5I#EY92<
M=.C,*CJQG3BI/G=K]K+1O[SVS4K^+3=.NKN=MD-O&TLC$XVJHR3^0)KR3X4^
M+O&&M_"*[\726YUS5M6N)KW2]+DD6%(K=I,01[\?="8<DY)S76_&TRCX->.C
M;_Z\:%>[".N?(>H?@_<VEC\%_"$K2)%:1:):N9'.U540J<D]ABLHQ_=-I:W1
MT3DWB%"]DHM_DCSV7XN_$7X?^,_#&G>/M'T)]*\1W7V*WN-#EE+VDQ^ZL@?[
MP]QZUV?CO5_BA+KCV7@O2-"2PAA61M1UR>0B=SSY:)'RN/[S<<UPFE1R?M"?
M%'2O$HADB\!>%9FDTR9\YU6\P5,H'_/),<'^(@&N_P#B]\4E\ Z5;66FVIUC
MQ9JF8=*TF(Y:5_[[?W8UZECQQBNB44I12C[UM3D@WR5'.;Y$]'U??7UV,+X<
M?$K6OC5\,O$J01CPSXML9+G2Y6@82)!=H,!T+#E<XX(KJO@5XWG^(?PPT/6[
MP :A+"8KQ1VGC8I)QV^93Q5'X&?#(_"WP2ME=7 O=6OKB2_U*ZQ@27$AW/C_
M &1T'L*YK]E M_PC7C15S]F3Q;J0@]-N\9Q[;LU,U&2FX]+%4)U5*C[1ZR3O
M\MCW.BBBN,]@**** "BBB@ HHHH **** "D)QVI:CESQC\Z ';A2YKR[7=0^
M),&KW::?=^%UL1(?(%S:7+2A.VXK( 3CT&*H?VK\5O\ G]\(?^ 5U_\ ':V5
M)O6Z.26)47;E?W';_$#X>:7\2=-LK'5_.\BTO8;Z/R)-A\R-MRY.#QGJ*G\;
M^";#Q_X4U'P]J9E&GW\7DS>0^Q]N0>#VZ5P/]J_%;_G]\(?^ 5U_\=H_M7XK
M?\_OA#_P"NO_ ([3]G+17V,76@[WIO71Z?\ !.A\;?!?0/'>CZ/8WK7EG-I!
M!T_4+"X,-U;$+MRCX/4<'((-)X,^#UKX0OI[N;Q!K_B2XF@-N7UR^\]50D$A
M4550$X'.,US_ /:OQ6_Y_?"'_@%=?_':/[5^*W_/[X0_\ KK_P".U=JG+R\V
MAE>CS^T]D[^G_!*[_LK^&I="N] EUGQ#)X:F#^5HAOP+6W+$G*#9N."20&9E
M]JZ/QE\$-%\:Z9H=M/=ZAIEWH8 TW5-,N!#=6XV!" Y!!! &00<UB?VK\5O^
M?WPA_P" 5U_\=H_M7XK?\_OA#_P"NO\ X[3?M&T^82]@K_NGKIM\^YH^$?V?
M?#G@_P 61>)X;G4]0U\6SVLU_J-UYTERK$$F0D=1M  7  X K,?]F'PXUEJ.
MF+K&OQ^';YI)&T&._"V<;N269!MW#YB6VEBN>U._M7XK?\_OA#_P"NO_ ([1
M_:OQ6_Y_?"'_ (!77_QVG^]WYA6P]DO9/[NZL^IL>(?@1X=\2^#?#_AVXDO;
M>/0$B73=0M+CR[NV*($#+)@\D#G((-5;/]G[1D\,^(M'U#6-;UTZ];"TO;_4
M[WS;@Q@, JD*%4#>W11UYS5'^U?BM_S^^$/_  "NO_CM']J_%;_G]\(?^ 5U
M_P#':5JG\W];E7H7YO9._I_P3K_$?PNTCQ3\/U\'7S3_ -CB*"$>5)MDVQ,K
M)\WKE!VJE\0O@WHWQ%O-/O[FZU#2=8T\,MIJVD7'D742M]Y=V""I]""*YW^U
M?BM_S^^$/_ *Z_\ CM']J_%;_G]\(?\ @%=?_':E1FG=2*E.E--2IO[NWS.N
M\ ?#6'P$;V0:YK>OW-WL$ESK=[Y[ +NP% 554?,<[0,\9Z"NR!P*\?\ [5^*
MW_/[X0_\ KK_ ..T?VK\5O\ G]\(?^ 5U_\ ':4J<I.[:+A6A3CRPIM+T_X)
M[!FC->/_ -J_%;_G]\(?^ 5U_P#':/[5^*W_ #^^$/\ P"NO_CM3[)]T:?6E
M_)+[O^">P9HS7C_]J_%;_G]\(?\ @%=?_':/[5^*W_/[X0_\ KK_ ..T>R?=
M!]:7\DON_P"">P9HS7C_ /:OQ6_Y_?"'_@%=?_':/[5^*W_/[X0_\ KK_P".
MT>R?=!]:7\DON_X)[!FC->/_ -J_%;_G]\(?^ 5U_P#':/[5^*W_ #^^$/\
MP"NO_CM'LGW0?6E_)+[O^">P9HS7C_\ :OQ6_P"?WPA_X!77_P =H_M7XK?\
M_OA#_P  KK_X[1[)]T'UI?R2^[_@GL&:,UX__:OQ6_Y_?"'_ (!77_QVC^U?
MBM_S^^$/_ *Z_P#CM'LGW0?6E_)+[O\ @GL&:,UX_P#VK\5O^?WPA_X!77_Q
MVC^U?BM_S^^$/_ *Z_\ CM'LGW0?6E_)+[O^">P9HS7C_P#:OQ6_Y_?"'_@%
M=?\ QVC^U?BM_P _OA#_ , KK_X[1[)]T'UI?R2^[_@GL&:,UX__ &K\5O\
MG]\(?^ 5U_\ ':/[5^*W_/[X0_\  *Z_^.T>R?=!]:7\DON_X)[!FC->/_VK
M\5O^?WPA_P" 5U_\=H_M7XK?\_OA#_P"NO\ X[1[)]T'UI?R2^[_ ()[!FFM
M@YYKR'^U?BM_S^^$/_ *Z_\ CM*-5^*QZWOA#'M977_QVCV3[H/K2_D?W?\
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M*N #Y@965R=H.XKG)/-.^'WP:T;X=:A>ZE:SWVJZS?!5NM5U:X,]S*HZ+NP
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M7O\ \9H_X6EHG_/+6/\ P17O_P 9HY6'UBE_,=917)_\+2T3_GEK'_@BO?\
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M@-$RDXR"PYSC%8<W[45K:VMAK%UX2UVU\&W;I$OB*:%%@4O@*Y3=O$9)QO(
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MCP[7OA#X8@^*OA&T2VOA!/8ZA)(#JMV22GD;<,9<C[QX!&>^<"NU/P/\(?\
M/IJ'_@YO?_CU)XF_Y+'X(_[!VJ?^V]=Z:UE.5HN_1G-1H4KS]U;_ *(X+_A1
M_A#_ )]-0_\ !S>__'J/^%'^$/\ GTU#_P '-[_\>KO&8*I+9"@9)'4"O'M#
M^.VHZ]\5](\-KX8N--T;4H;B:WU#4<QS3B,9W+%_"I(_BY-3!U)[,JJL+1<5
M..K\CI?^%'^$/^?34/\ P<WO_P >H_X4?X0_Y]-0_P#!S>__ !ZIOB;\1Y/
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M_A1_A#_GTU'_ ,'-[_\ 'J[RBCVD^[#ZO1_E1P?_  H_PA_SZ:C_ .#F]_\
MCU'_  H_PA_SZ:C_ .#F]_\ CU=Y12=2?<7L*/2*/(/&'P;\*VEYX;$5M?@3
M:HD3AM6O&RIBE)',IQR!R,'CK71_\*/\(?\ /IJ'_@YO?_CU:7CG_C\\*?\
M89C_ /1,U=56CJ2Y5J81H4G.7NKI^1P?_"C_  A_SZ:A_P"#F]_^/4?\*/\
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M*=''PN_X0(277]C?8_L6\./.V?7&,_A25=)_-,:P,G!:*_*_OW.+\47DE_\
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M9@#]J#X=XQSI>H<YS_#Z_AW->R.,H1DC(QD=17C=U^S#I5[K4.KR^,O&+:C
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M0X?J]6=.'/#X7M>W?_,R/A1XHU;7_ OC73O$-\-5N-!O[S23J)0(;J-(P0S
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M (JO5-M+MK15&M+?@<KPZ;OS/[SRG_A'_B/_ ,_?A;_OQ<__ !5'_"/?$?\
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M^$?^(_\ S]^%O^_%S_\ %5ZMMHVT>V?9?<'U9?S/[V>4_P#"/_$?_G[\+?\
M?BY_^*H_X1_XC_\ /WX6_P"_%S_\57JVVC;1[9]E]P?5E_,_O9Y3_P (_P#$
M?_G[\+?]^+G_ .*H_P"$?^(__/WX6_[\7/\ \57JVVC;1[9]E]P?5E_,_O9Y
M3_PC_P 1_P#G[\+?]^+G_P"*H_X1_P"(_P#S]^%O^_%S_P#%5ZMMHVT>V?9?
M<'U9?S/[V>5?\(_\2/\ G[\+?]^+G_XJC_A'_B1_S]^%O^_%S_\ %5ZKMHVT
M>V?9?<'U9?S/[V>5?\(_\2/^?OPM_P!^+G_XJC_A'_B1_P _?A;_ +\7/_Q5
M>J[:-M'MGV7W!]67\S^]GE7_  C_ ,2/^?OPM_WXN?\ XJC_ (1_XC@Y^U^%
MO^_-S_\ %5ZKMIK#@T>V?9?<'U:/\S^]GSEXDT;QZOQ;\&127/AUKUK#4O),
M<5QY>W-OO#?-G/*XQ[Y[5W*^'OB21_Q]>%A[>3<__%5;\6\?'3P#_P!@S5OY
MVM>C*I'?/O6LJKM'1;?J<U+#Q;FN9[]_)'E__"/_ !(_Y^_"W_?FY_\ BJ/^
M$?\ B1_S]^%O^_%S_P#%5ZF2 ">N*Y-OBIX57QS!X.&L02>)9HFF73XCO<*H
MR2V,A>.<$BLU4D]DON-I480M>;5_-G,?\(_\2/\ G[\+?]^+G_XJC_A'_B1_
MS]^%O^_%S_\ %5Z@TZ*I)X SDD]*Y/P-\6?"OQ*FU2/PUJB:J=,E$-TT:.JH
MQW8P6 # [3RN11[633?*M/('1IIJ+F]=M6<U_P (]\2/^?OPL?\ MC<__%4O
M_"/?$G_GZ\+?]^;G_P"*KT+Q%K=IX;T*^U:^D\JSLH'N)G/9%4D_RK'\%>-X
M?%?@?3?$MQ:OI%M>VPN_+NW4&.,C(+'.!\N#[4_:2:O9?<3[*DI<KF[VON]C
ME?\ A'_B1_S]^%O^_-S_ /%4?\(]\2#_ ,O?A8_]L;G_ .*KK/!7Q+\-_$6T
MO;KPYJ<>K6MG<-:S3P [!( "0&(PPP1R,BK7C+QMHO@#P_<:UK]ZFFZ9;X\R
M>0$@9.  !DDDGH!3YYWY>57]!^RIN//SNW>[.(_X1[XD8_X^O"W_ 'YN?_BJ
M/^$>^(__ #]^%O\ OQ<__%5J>)_B]I>C?#-?'6GPS:UH9CBN=]L-K?9W8 R@
M-@X4')'H#7=6=W%?6T-Q"V^*5 Z,.A!&0:'.:5VE]PHTZ<GRJ;VON]CS+_A'
MOB1_S]^%O^_-S_\ %4?\(_\ $C_G[\+?]^+G_P"*KU-<-3MM3[5]E]QK]67\
MS^]GE7_"/_$C_G[\+?\ ?BY_^*H_X1_XD?\ /WX6_P"_%S_\57JNVC;2]L^R
M^X/JR_F?WL\J_P"$?^)'_/WX6_[\7/\ \51_PC_Q(_Y^_"W_ 'XN?_BJ]5VT
M;:/;/LON#ZLOYG][/*O^$?\ B1_S]^%O^_%S_P#%4?\ "/\ Q(_Y^_"W_?BY
M_P#BJ]5VT;:/;/LON#ZLOYG][/*O^$?^)'_/WX6_[\7/_P 51_PCWQ(/2[\+
M?]^;G_XJO5=M-9?0T>U;Z+[@^K1_F?WG@GC70_B!'>>%_M%SX<+G5D$7E17&
M-_DS8W9;E>O3GI74'P_\1_\ G[\+#_MC<_\ Q5=!\005U#P=_P!AR/\ ]$3U
MV@&0*MU6DM%]QA##KGE[SZ=?(\K_ .$?^)'_ #]^%O\ OQ<__%4?\(_\2#_R
M]^%O^_%S_P#%5ZE(XCQGG->4ZS^U)\-=!UN73+OQ!MDAF^SS7$=K*]O%)NVE
M6E"[!@\$YP.YHC.<](QO\BYTZ=+XYM?-DG_"/_$C_G[\+?\ ?BY_^*I#X>^(
MY/\ Q]^%O^_-S_\ %5Z=!=PW5O'/"XEAD4.DB'(92,@@]QBN4\5_$:V\.^+_
M  QX:2SFOM2UR60(L1 $$4:[GE<GL.![DTE4DWRI+[@E2IP7,YM+3J^ISO\
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M 'XN?_BJ]5VT;:/;/LON#ZLOYG][/*O^$?\ B1_S]^%O^_%S_P#%4?\ "/\
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M_P#SZ^(?_">O?_C5'_#0'A?_ )]?$/\ X3U[_P#&JU<FC)HM#L%\1_,ON_\
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M?_C5'_#0'A?_ )]?$/\ X3U[_P#&JU<FC)HM#L%\1_,ON_\ MC*_X: \+_\
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M#L%\1_,ON_\ MC*_X: \+_\ /KXA_P#">O?_ (U0?C_X7/\ RZ^(?_">O?\
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MU\O^"4+;X\^%K:)(DL]?2-%"JJ^'KW  Z#_55+_PT!X7_P"?7Q#_ .$]>_\
MQJM7)HR:5H=B_P!^MI+[O_MC*_X: \+_ //KXA_\)^]_^-4?\- >%_\ GU\0
M_P#A/WO_ ,:J[J&HVVE64UW>W$=K:PKNDFF8*B#U)/ %2PS+/$LD;K)&ZAD=
M3D$$9!ST-/DCV"]:]N=?=_\ ;&;_ ,- >%_^?7Q#_P"$]>__ !JC_AH#PO\
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M\Z-OT_.L[_A1GA?_ *B__@ZN_P#X[1_PHSPO_P!1?_P=7?\ \=HO3[L.6O\
MRK[W_D:.WZ?G1M^GYUG?\*,\+_\ 47_\'5W_ /':/^%&>%_^HO\ ^#J[_P#C
MM%Z?=ARU_P"5?>_\C1V_3\Z-OT_.L[_A1GA?_J+_ /@ZN_\ X[1_PHSPO_U%
M_P#P=7?_ ,=HO3[L.6O_ "K[W_D:.WZ?G1M^GYUG?\*,\+_]1?\ \'5W_P#'
M:/\ A1GA?_J+_P#@ZN__ ([1>GW8<M?^5?>_\C1V_3\Z-OT_.L[_ (49X7_Z
MB_\ X.KO_P".T?\ "C/"_P#U%_\ P=7?_P =HO3[L.6O_*OO?^1H[?I^=&-O
M/]:SO^%&>%_^HO\ ^#J[_P#CM'_"C/# Y_XG'_@YO/\ X[34J:ZARU^R^]_Y
M'(^)6'_"Y/!'(_Y!VIC_ -)Z[\C\/QKS#Q-\(M MOC#X*LHSJ?DW&GZD[[M6
MNBV5^SXPQDR!\QR 1GC/2N\'P.\+D=-8_P#!S=__ !VM9RI\L=>AS4574IZ+
M?OY+R-/;D?\ UZH_V#IN<_V?:Y]?)7_"F?\ "B_"_P#U%_\ P=7?_P =I#\#
M?"X[ZO\ ^#J[_P#CM9J<(ZILW<*SWBOO?^1:ETZVN(UCEMX940 *KHI"_08I
MMOI5G9R>9!:6\+XQNCC"G\P,U6/P.\+C_H+G_N-7?_QV@? WPN?^@O\ ^#J[
M_P#CM-SAMS,7LZE[\BOZO_(3Q/X>M?%7A[4='OD+VE] ]O(%P2 RD9&>X[5G
M^#/"DGASP5I&@ZE<1ZO)86Z6YN)(\;U3A<J<\@8K2'P.\+@Y/]L ]/\ D-7?
M_P =H_X4=X5//_$X/_<:N_\ X[3]I&UKD.E4E/GE%7VW>WW=RQ#I%E;2+)%9
MV\4BG(=(U!!]B!1-I%C<RM)/96\TC8RTD8).!@<X] !5?_A1OA?_ *B__@ZN
M_P#X[1_PHWPOZZN/^XU=_P#QVCVD7]IE^SJVM[-?>_\ Y$Q/B%X&?QEX)O\
MP[872:/!>E8[B6*(']SN!D08(P64%=Q]3736%G%I]E;VD"+'!!&L4:#C:J@
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M?I^=!7_.:SO^%&>%_P#J+_\ @ZN__CM(?@;X7';6#]-:N_\ X[2YJ:ZA:O\
MRK[W_D8WCGB]\*_]AB/_ -$S5U>W_.:X/QQ\'/#MG?>%%B.JA9M8CC</JUTW
MR^3,>,R<'W']:ZO_ (49X8_ZB_\ X.;O_P".UK*=.R,8JNZD]%TZ^7H:./I^
M=4Y=%T^>5Y);*VDD<[BS1J223R>E1?\ "C/"PZG5_P#P=7?_ ,=IK? [PL/^
M@N/^XU=__'*E2AT;-90K25G%/Y_\ M2:7:36OV:2U@>VQ@0M&I0?\!QBBPTN
MTTJ#R;*VAM(LYV0($7\@,56_X4;X6QUU;_P=7?\ \=H_X4=X7_ZB_P#X.KO_
M ..T_:1VYF+DJK5P7]?]NFB\:LKJ0-K J5SQC!']:XWX:?#W_A7F@7NA_:1?
M:7)>W$]I"\8_T>&1B_E')Y )/([&N@'P.\+$9SJ__@[N_P#X[2_\*-\+ G_D
M+Y/_ %&KO_X[24X)<J;^X4J5:4E)P5UY_P# )1H>G*P9;"U5@<AA$N1^E)?:
M%IVINCW=A:W3I]UIHE<K],CBH_\ A1OA<]/[7_\ !U=__':7_A1GA?\ ZB__
M (.KO_X[3]JK_$Q*E42LH1^__P"U(O$^CW.K^&-2TS3;M=+NKFV>WAN@I?R"
MRE=P7VSFH?!'A2V\$>$]+T&SR;;3X%A5B "Q Y8XSU.3CWJU_P *+\+G_H+_
M /@YN_\ X[2GX&>%S_T%_3_D,W?_ ,=I>TA;EN[ J592YU%7M;?[^AH[?\YH
MV_3\ZSO^%&>%_P#J+_\ @ZN__CM'_"C/"_\ U%__  =7?_QVIO3[LTMB.L5]
M[_R-';]/SHV_3\ZSO^%&>%_^HO\ ^#J[_P#CM'_"C/"__47_ /!U=_\ QVE>
MGW8<M?\ E7WO_(T=OT_.C;_G-9W_  HSPO\ ]1?_ ,'5W_\ ':/^%&>%Q_T%
M_P#P=7?_ ,=IWI]QVK_RK[W_ )&_HO%^!D [6_I735P^B_"O0O#FI0WUC_:@
MN(L[?/U.YF3D8.49RIZ]Q7;KT%93:;NCHI<W+[PM%%%0;A2$9I:* &,N3TI=
MM.HH%9'F7Q[^)>I_"SPC8ZEI%A;:C?W>HV^GQ07;LD>96V@DJ"1BF>!-6^*-
MWKFSQ=HGA[3]),1;SM-O9)9M_&T890,=>:Y+]LR.>;X<Z#':S"WN7\1:>L4Q
M4.$;S.&VGKCTK>TS1_%/A+3]8U/QYXWM]=\.PV$IN(8=,%JR#;RV]#GA=PX]
M:ZU&/LD[:MO]#R)3J?6Y+7EBD]+6Z[]3T*'QMX?NM6DTJ'6M/FU6/[]C'=(T
MZ_5 =P_*N8UOXT>']%^)-AX,NIA'>7-G)=M<M*BQ0[3C8Y+9#'J!CICUKY8^
M))L)_A[H7B+PQ\*3X3TF+4;*?3O$C74*7&UIE )C4F0APW\1/7)KTKQI\./#
M&N_M7^%X-0T*PO(=1T"XN;M)H%83RJV%=@>I   /M6T:$%K*^S[;HYGCJL[J
M"5TXZZ[-^:/;8]9UN;XB/8"/37\,G3%N(YTF+7;7!D QY?\ SSV\[O7C-:E[
MX]\-Z;J7]G7FO:;::@%WFUFO(TEQZ[2<X_"O*K6""P_:LE@A188(/ ZHB@8"
M*+P8 ]@ *\%TNPT_QM\#;_08_"%]XB\<ZM?2M#KBZ:S1W+&?Y;O[2PP(PHZ$
M@X&-O-1&A&24F]-/QZEU,9.E=))N\M^ZMIIW/M^'6]/N&MA%>02&Z4M %E4^
M:!U*\\@>U2G4+9;Q;0S1BZ9/,$&\;RN<%MO7&>]?/OB70[;PK\=?@=IEO;Q6
M<%O8ZG$L<*!(@?*B)  Z<DG%;6H3*?VN]-4.&=?!MQE1S@_:DZ^G!K+V5]GI
M9O[KG4L6]>:.JDE]Z3_"YZKJ?C;0-%U"WL=0UK3[&]N/]5;7-U''))_NJQ!/
MX5LQN).5.1ZU\7_"32O$/Q(\":SJUU\.M'\3WFMW5U]IU34=01+@-YC+L 9"
M8Q'P  >,<5]+_ O0/$/A;X7Z%I/BF5)]:LX3#*Z2^:-H9A&-W<A-HS[4ZM)4
M[J^HL+BY8AKW+)W=^UK:;6UWT9WFVC;3J*Y3U+#=M&VG44!8;MHVTZB@+#=M
M&VG44!8;MHVTZB@+#=M&VG44!8;MHVTZB@+#=M&VG44!8;MHVTZB@+#=M&VG
M44!8;MHVTZB@+#=M&VG44!8;MI&& :?3'[T!8\U\6C_B^G@$?]0S5OYVM>DK
M7FWBW_DNO@'_ +!NK?SM:])7I6DWI'T_4Y:+O*IZ_I$;*XCB9SDA03@5X=HW
M[0>H>)?C)H7A6#PS<Z;H6J6]Q/!J6H@Q33^4I)9(NH0G&"V"?2O<V&0>>#7A
M'CI%7]K7X8XQG^RM1S_WQ5T4I-J79_D8XR4X1C*#M[R3^;2/1OB-\0'\"Z=$
MUKHM_K^J7;-':6-A'G<P&<NYXC0=V/ZUE? +XDWGQ:^&]EXDO[*+3[B>::)K
M>%RRKLD*#D_2N]ND4VTV?[C?RKQ;]C#'_"AM,P<_Z;>?^CWI*SI2=M4_\PE.
MHL5"-_=:?X6_S/0_BWXT7X=_#K7O$957;3[5Y(U8\,^,(/Q8J/QK$TWQ7J?@
M'X4:+J7BE=0U_P 0RP1+-%86@:::YD&?+"( % .1DX QR:Y[]KYC_P *9G5L
M_9VU.P6X]/+^TQYS[=*]E$0\E1GMTIV4::?=O]"FYRQ$DG:T5][N>8_ OXK:
MG\4;'Q'-J^BIH-WI.JRZ:UFDWFLGE@?>; &<D] !6+\9?V@M0\ 736VB^&+G
M5$M+NVMM0U&Y!AM+?SF0*JMUD?#@X7@=SVJ+]FH*NK_%CL/^$ROCC_OFIOVM
MXPGPC7G=_P 3C3>N/^?F.MU&#Q"@UII^AQ.I6>!=13U7-KZ-G7_&6[U_3/AK
MK>I^&KO['J^GP_;4_=JXE6,AWC(93PZJPSU&:Z7P=XEMO&'A;1];M&W6^H6L
M=S&?9U#?UH\4*A\+:J)<>4;.4/GIC8<UYI^R+++)^S[X1\XG*Q3*F?[@GD"?
M^.[:Y[7I-]G^9V<\EB8KHX_DU_F>S 9HVT+S3JQ.^PW;1MIU% 6&[:-M.HH"
MPW;1MIU% 6&[:"O'-.I&Z4 <5\0EQJ/@[WUR/_T1/7:!>!7&?$/_ )"'@[_L
M.1_^D\]=H.@JWLC&&M2?R_(@N@WEG8,OVKPS7/&WQM\/:5?ZG>>&_!L.GV4,
MEQ-(VI3G;&BEF;[OH#7O$@!'7%>#?M(3S>,]1\*_"W39B+CQ'="XU)D/,6GP
M$/(3[.0% [X(Z&M**O.S7_#'-C&XTW)2::VMW>WXG??!KQAK'C[X<:+X@US3
M8]*O]1B-P+2)F950LWEGGGYDVM^-8WC'Q;K-U\:/"?A#1[P6EM':S:QJ[*BL
M7@&8XHN0<;I#DD8/R]:]*L+*#3+6&UMXQ'!!&L<:+T55   _ 5XIX/>1_P!K
M/X@"<G?'H.GK;;N\9)+8]MQ-5!*<Y.VB3?Z$57.G3IP<M6U=_*_XV-GQ+K?Q
MAM=;O5T/P[X7N-'20_9[B\U"9)63U<!< _2N;\$?$SQS\7/@[XSU.SM[/1=<
ML9;FVTRXL#Y\5Q+$,Y7S%.06!7IZUT?[2GC>\\)?#IK'1_F\1>(94T?3E&2P
MDEX9Q[JI8_7%=I\//!=K\// VC>';%0D-A;K%G^^^,LY]RQ)/N337*J5W%:L
MSY)2Q+C&;LEKZO;_ #(?A)XR7XA_#S0O$*X#7UJDD@'02=''X,#78;:\4_9
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M%+_J3_\ OW=?_%42@Y-RNM2J=:-.*@HO3R/6\FC)KR3^V_BE_P!2?_W[NO\
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MZO'R\TA9&.TL<G:,X"\ 55*$9RY&9XJI.E3YX).S5_0^@ .<5RWB7QY!X?\
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MKA?,\KRRV=N> <YKT'_A;/AS^]J?U_L6]_\ C-'_  MGPYS\^I\C&?[$O?\
MXS4P]I!6MI\_\S2M&C6FJCEJE:]UM]QQOB[PKXM\(_%F;QMX1TBV\10ZI8I8
MW^F372VSHT9^2568$$8ZCMCCKD1^"_AKXGOO$OC[4?&T5E%%XHTNWLS!8.66
M% DB-%DX+%49<O@9.<=,UVW_  MGPYSE]4(/4?V)>\_^0:!\6?#@Z/J8]QHM
M\,?^0:KFJ]$OZ^9E['#N?.Y.U[VNK7^X\S\*Z;\2_ >@VOA>/P%HGB)+%/L]
MMKC:@D,<D0.%:2/RRQ.,9QZ5W/B+P=JVJ_$?X;:XD-N+71TO1?&.3 1I;=54
M(#RPSGTP*TO^%K^&_P"_J?K_ ,@2]_\ C-+_ ,+9\.#.'U0 ]O[&OO\ XS1*
MI.]V@C3H027/HK;VZ>B1DKX(U7_AH)/%0CC.D#0#I^[S!YGG><KXV]<8!YK
MNOA3K]YXA^+\\,\=C'XFMX(M/NDEY#+;",E@.5&X=?>NT_X6QX<QC?J?O_Q)
M;WG_ ,@TO_"VO#I 'F:IQ_U!;W_XS4*<ULNEMAN.&EO/JW\VK?D>):E\*_&>
MO^ O#WAR#P-H_AYM'N;.2XOUNXV:[\IP&:/:HV@\N=S9). *^G1T'^>]<?\
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M:I:YX\\&^)M*GTW58-0O["< 2V\VB7Q1P#D _N>E:*3Y5%H3C2C4E5A4U?\
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MLSHIU855>#%V#THV#TIU%0:C=@]*-@]*=10 W8/2C8/2G44 -V#THV#TIU%
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M,Q("@9)/85\H>-/CAX&N?VF/ FL1>*=-DTK3M/OH+J[68;('9<*K'L2:^LL
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M TZ/7K%[W6?%5[<Z?;B4%KF(@$.@[C"G\J=\'O'^A_!77_B/X6\7ZC!H4_\
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C* $&<^U+110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tmb-20221231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &V GH# 2(  A$! Q$!_\0
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M9=R>BF1.77/'X4^@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN(H#;.Y.2?+8IG\@*R<+1;['73KN<XQ=M5?3;3_ASU&BBBL3N"BBB@ HHHH
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M_?ZY_P#B:=@]I_=?W';45Q/G?$#_ )X>'/\ O]<__$T>=\0/^>'AS_O]<_\
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M5/4-(2Y'_CU+J^C>,->LFM-1TOPK?6K,&:&=[EU)!R"05]:O(?'R !;;PVH
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M6M6U6^L[&.:^6,3,2ZDJ0BJ,* 1P.U?0EE (+2*(-D1J%S] !7%47N)7ZO\
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M'9B[5YR._6F^6.X!'O2^:OJ*/-7U%"T!7W (O&>:=M4#ITIOFK_>%'FK_>%
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M"L23R:A;V2W\TBJ/*C1GVJK-UW$@G'M6_G//K65VCHC"E+X>FG4Y'_A7;?\
M0X>,?_!V_P#\31_PKMO^AP\8_P#@[?\ ^)KKJ*7,RO8P[?BSD?\ A7;?]#AX
MQ_\ !V__ ,31_P *[;_H</&/_@[?_P")KKJ*.9A[&';\6<C_ ,*[;_H</&/_
M (.W_P#B:/\ A7;?]#AXQ_\ !V__ ,37744<S#V,.WXLY'_A7;?]#AXQ_P#!
MV_\ \31_PKMO^AP\8_\ @[?_ .)KKJ*.9A[&';\6<C_PKMO^AP\8_P#@[?\
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MQC_X.W_^)KKJ*SYF='LH::?F<C_PKMO^AP\8_P#@[?\ ^)H_X5VW_0X>,?\
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MKZA80ZK875C<*'@N8FAD4]"K @Y]L&OG;]GC1=4U#Q7)9:]8W$-OX)TF7P[
M]S&0LYDN&)="?O#R4C&?]JOI'WI=S'&6)QTR<X^E=-.KR*4;;GGU<,JM2$V[
M6_%;_GJ?-'P+T#5I/B':Z%JEE<PZ?\/8;^SM)YHRJ3-<3XB9">&VP@C(]/>M
M_1O&5C\&/B5\08?%B7=E;:]J$>J:?J,=E-/%<1^2JM"&C5OG4J?E/8U[P6)
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MD=+TN>+339Q6&ES/,B1 [F>65U7<>.!@8KTZUM(+*!(+>&.WA082*) JJ/0
M<"G301W$31RQI+&X*LCJ&##T(/6FJMO=MI^)'U2"?-UW\KGE_P"SQ8R-X3U3
M7IE*MK^J3ZBF[J8RVV,_B!FO4Z9!;Q6T4<4,20Q1J%2.-0JJ!T  X%/K.<N>
M39O1I^R@HIW"BBBH-PHHHH ZG2_^/&'Z5<'2J>E_\>,/^[5P=*P>YU"T444A
MA1110 4444 8'B$YGBQS\IZ=N:RMC?W3^56O$_PN\+>,M02^UO1+74KM$$:R
MSJ2P4'..#TS60?@%\/0/^14T_P#[Y;_&M4X6UN<DHU6W9+[W_D5?%OA*P\<>
M'+_0M7@>;3;Z/RIT1RC%<@\,.1R!TJ/Q!X+TSQ.-'_M"WDE&DWL5_:!7*[)D
M#!2<'D ,>#5X_ /X?8S_ ,(II_\ WRW^--'P#^'W_0J:?_WRW^-:JI%*VI@Z
M-26LHI_-_P#R)YK\2_A]/XZ^+WP\FFT=Y=*T(W&HW6ILH"[@%$5OUY)<!^F.
M*C^*OPRD^(/Q4\#27NFW-UHEK:ZA]IN[>0Q-;2E8_*974AE;(."*]-'P"^'I
M;_D4]/'_  %O\:7_ (4%\/<<^$]/'_ 6_P :T^L)6M?3]3EE@YSYKI:M-ZOI
MM]DP?!7PKT/P(FI-80W5W=ZD0;V^U.X>ZN+G ("N[G)4 D;<8YK L?V=_"FF
M7,;6;ZY:Z>DWVA-(AU>=+)'W;N(@W SSMSCVKOQ\ _A\/^94T_\ [X;_ !II
M^ GP^SC_ (133_\ OEO\:E5]6^9FWU5V2Y(Z;?U8JP^#M.M_%MWXE2!QJ]U:
M1V,LI<E3"C,R@)G&<L>1S6+XN^$VB^,=?T_6[LZC::K9QF%;G3;Q[=GB+;C%
M)M^^N1G!KI/^%"?#[./^$4T_/^ZW^-*/@)\/N/\ BD]/_P"^6_QI*JHNZ;+>
M'DU9PC;?1M?H<CXH^"7A_P 4>(9]<+ZKHVK7"+'<W6BZA):-<J.@D"\-CH#C
M-:3?"[0CI.@:<;:YDMM#NTOK(R7,CR+,I)#.[$E^6;KGM6X/@)\/<_\ (J:?
M_P!\M_C0?@'\/BW_ "*FG_\ ?#?XT_;II)R9"PS3YE"-_7_@%._\&:;J7B?3
M_$%Q;.^J6%O-:P2>8P41R[=^5'!SM'/;%<KHGP%\+Z%KEGJ<2ZM=FQD,UC:7
M^HRW%O9N01NCC8X!P2.2<=J[?_A07P^_Z%33_P#OAO\ &C_A07P^_P"A4T__
M +Y;_&A5DMFRGAI2UE!?>_\ (QK;X;:!#8>(;)M.\^TU^=[G4H+ABZ3.ZA6Z
M]!A1TZ5@>'O@#X6\.:M87Z#5=2;3CNL(-5U*6ZALCC ,4;G (' )R1VKN!\
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MC?W35+_A0/P^_P"A4T__ +Y;_&C_ (4%\/O^A4T__OEO\:.:'F'+7[+[W_\
M(EN16"-E3T-<W\. 3X+T[ )'[[G_ +;25JW/P#^'ZP2$>%=/!"D_=;T^M<U\
M-_@CX%U+P98W-SX8L99G:7<S*V3B9P._H!5<T.5[F7+6]HM%][\O([;8W]TT
M;&_NFJ0^ 7P^_P"A4T__ +Y;_&D/P"^'P_YE33_^^6_QJ>:'F:6KVV7WO_Y$
MO;&_NFC8W]TU1/P$^'H//A33_P#OEO\ &D?X"_#U?^94T_\ [Y;_ !HYX>8[
M5^R^]_\ R)?V-_=-&QO[IK/_ .%#_#W'_(J:?_WRW^-'_"A_A\#SX3T_'J%;
M_&CGAYA:OV7WO_Y$T-C?W31L;^Z:H#X"?#UNGA33\?[K?XT[_A07P^_Z%33_
M /OEO\:.>'F'+7[+[W_\B7=C?W31L;^Z:I?\*"^'W_0J:?\ ]\M_C1_PH+X?
M?]"II_\ WRW^-'-#S#EK]E][_P#D2[L;^Z:-C?W35+_A07P^_P"A4T__ +Y;
M_&C_ (4#\/O^A4T__OEO\:.:'F/EK]E][_\ D2YM;^Z:XOP,I/BWQSP<_P!H
M0_\ HFNH/P!^'N#_ ,4I8?\ ?+?XUPO@7X+^"+WQAXWMY_#=C+#;7T20JRGY
M 8@2!SZU:G#E>YA.-;GA[JZ]7V?D>C[&_NFC8W]TU17X!?#X_P#,J:?_ -\M
M_C2GX!?#X#/_  BFG_\ ?+?XU'/3\S91KVV7WO\ R+NQO[IHV-_=-4?^%"?#
MW'_(J:?_ -\M_C1_PH3X?8_Y%33_ /OEO\:.>'F'+7[+[W_\B7MC?W31L;^Z
M:S_^%#?#WMX4T_\ [Y;_ !I#\!_A[C/_  BFG_\ ?+?XT<\/,.6OV7WO_P"1
M-'8W]TT;&_NFJ ^ OP]/_,J:?_WRW^-.'P"^'Q'_ "*FG_\ ?+?XT<]/S'RU
M^R^]_P#R)=V-_=-&QO[IJE_PH+X??]"II_\ WRW^-'_"@?A]_P!"II__ 'RW
M^-'-#S%RU^R^]_\ R)=V-_=-(4;'W3^54_\ A07P^_Z%33_^^6_QH/P!^'Q'
M_(J:?_WRW^-'-#S'RU^R^]_Y'9Z6?]!B Z[>15U>E9GA[PUIWA73(]/TJTCL
MK*/.R&($*N>O4FM.L#KC>VNXM%%%(H**** "BBB@ I#TI:1NGK0!'(Y1"<@8
M]:^>OAQ\=?$/B7XOFTU(6T?@O7WOH/#DB0[9&>T=5?>^>=X\QAQ_".:[K]H?
MQI<>"/A7J]SI[;=8O@FF:<@.&:YG81ICW&XM^%>%>._ 7Q.\!_"OPU=/9^%O
ML'P_>#4[=M+DN3>,D0Q*/G&T[U+[L^]=E&$91]ZVNAXF-KSC-*%_=U=O7;[K
M_@?1/BWXR>$_ 6I-IVMZNEKJ7V9;I;18I))949]B[%527);C:N3QG&.:N>$/
MBAX<\=^&YM>TC58IM,MBZ7,LJF$V[(,NLJN 4*CDA@*\JT2]T[Q9^U)IVM6H
MCG@F\#I>VDV 2JO<KAE/;Y6P2/4BN#\::9?ZCX=_:<L=&C=[A]0MI##;KEG7
M[-"TH"CJ60-QWIJA!VC>SLOQ=A/&5$W-*\;R5O173/=_#WQ^\&>*M8M-,T_4
MY?/OMWV&6XLYH(;S )/DR.H63@9X/3D4>*/V@/ _A#4-0T_4M:(U"Q=8KBSM
M[6:>=24WYV(I)4+R6' [FO(=.30OB%;^!A=_&NQU.W@O[.[TW2[:RM8)FGC^
MY$ IWKW4C XKL/A3:6\GQW^-5T8HVG$^GP^;M&\(;<DKGKM. <=.*)4J:N]=
M/7O;L$<57FHI6U>^CZ-]'T-^^_:9^'5@; MXF@E@O$CD2YMHI)88UD^X99%4
MK%N[;R*UM3\0W,7Q7\/Z9'XDM[>VNM.N9SH9LR\EV5*XE6;HH3/*]\UX%X7T
MRQ@_8A\:B*"&-7&L,Y50-Q6ZD"DGN0%4#TP,5V5E(S_''X1,Q+D^#[HDYY8[
M(:<J4$WR]+_D3'%5I**J6UY7I_BLSN+[]I7X?:9K7]F3ZX5D6X^R/=+9S-:I
M-NVA&G">6#NX^]UKU)) X5@001D8KXE^*?Q/U7X@_ WQ;?7?BG0=!L6GN+6/
MP?!8B2]/ES$8=S(&5SMWDJF .?>OLCPX2=$TPD[B;6+//^P*RJTE"*?7_ACI
MPN*E7J2B]5:Z^;:Z-]NMC6HHHKF/5"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (;O_CWD_P!T
M_P JY/X4_P#(A:=_O3?^CY*ZR[_X]Y/]T_RKD_A3_P B%IW^]-_Z/DJEL9/^
M(O1_H=>?:N$\>>'O'6KZC#+X9\9V'ARS6/;);W6B"]9GS]X.94P,=L5WJ_=%
M><?'[QZ_P_\ AW>W=K\^K79%CI\ /,EQ(=J #O@G/'I3@FY)(BLXQI.4FTEV
MT.8^ OB_QGXGU[Q=%KVN6?B#1M+NA8VE]:Z:+/SIE&92 ';(4X'7K6A\8-<O
MKWQCX$\(6%Y/9-JM^;F[DMG*/]F@7>R[AR-QVK^-=/\ "+P%'\.?A[H^AKA[
MB"+?<R'K).QW2,?4EB?RKA_'7^@_M,_#JYE!\FXT^^M(SV\S:&Q]< UO[LJK
M:71_@CSW&I3PL>=N[:OK>UVORV-SQGX?^(4NI7NHZ1\0=,T#153S$M;KP\MR
MT05?F)D,RY]>@KSWPYKOC?XA?L_>(]:U'6BVHI+-<Z1?:?;?8VEBA;*,4#'A
MRIXSTKJ_VD_$-S+H&E^"=)D*ZUXKNEL$VGYHX.LTGT"YY]Z[35K#3O _POO+
M.%%@TW3=+:)$[!%C('\J(OW%=+5A./-7ERR:45KJ[:[?=O\ <:'PX\5IXW\#
MZ)KJ8 O[2.<CT8K\P_ YKIZ\J_9GLI;/X&^$(YLB1K$2;6[!F)'Z$5ZFG"UA
M424VD=^&DY482ENTAU%%%0=(4444 (>AKSKX=_\ (]?$#_L(0_\ HH5Z*>AK
MSKX=_P#(]?$#_L(0_P#HH52^&7]=3&?QP^?Y,]$7O7/>-]5US2M#DD\/:0FL
MZJS!(;>6<0QJ3_&['G:.IP"?2M\=ZS/$OBG2/"6EO?ZUJ=KI-BI"FYO)5BC!
M/ &2<9-);ERMR:NVAY[^SQXY\1^._#&L7'B>2SEU*SU6XL3]AB*0@(1PN221
MSU/-:/QY\9W/@GX9ZM?6+F/4)0MI:L.HED8(I'TS7G?[*WCSPW?6WBC2K?7=
M/GU*YU^]N8;2*Y4RR1$@AU7.2OO6_P#M5J5^'>G784M!9ZS93S<<;!*,DUU.
M'[^S5EH>1"M+ZBYQ=VD^MS=UN7Q=X+^'NE6'ANP37M7CMECFOM5NML4.U,M+
M*?OOSG"CD\=*@^#GB35OB?\ !NQU#6KA!JM[%/%+-9J8 &#LF5 .5QCUKJ/'
M7C70/"GAN6?6=8LM)@N8GCADO9UB61BI("DGDUYC^R3XST+4_A5I6DV6KV5Y
MJMMY\DUI!.K2QJ9F(+*#D#D4DKTI2Y>IHY*.)A#GNG%Z7TZ'4?L[>*;W7_ C
M6>J7#7.J:+>3:7<2R$EI#&V%8D]25QS7J:G->(?LUGSIOB%?H#]ENO$MP8CV
M.U54D?B*]O7D9K*JDJCL=.#DY4(M^?YCJ***R.T**** "BBB@ HHHH ****
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M /VI[+YOL?R-'F^Q_(UXU_PJ#PE_T"Y__!C=?_':/^%0>$O^@7/_ .#&Z_\
MCM'LX]P]K6_D7W__ &I[+YOL?R-'F^Q_(UXU_P *@\)?] N?_P &-U_\=H_X
M5!X2_P"@7/\ ^#&Z_P#CM'LX]P]K6_D7W_\ VI[+YOL?R-'F^Q_(UXU_PJ#P
ME_T"Y_\ P8W7_P =H_X5!X2_Z!<__@QNO_CM'LX]P]K6_D7W_P#VI[+YOL?R
M-'F^Q_(UXU_PJ#PE_P! N?\ \&-U_P#':/\ A4'A+_H%S_\ @QNO_CM'LX]P
M]K6_D7W_ /VI[+YOL?R-'F^Q_(UXU_PJ#PE_T"Y__!C=?_':/^%0>$O^@7/_
M .#&Z_\ CM'LX]P]K6_D7W__ &I[+YOL?R-'F^Q_(UXU_P *@\)?] N?_P &
M-U_\=H_X5!X2_P"@7/\ ^#&Z_P#CM'LX]P]K6_D7W_\ VI[+YOL?R-'F^Q_(
MUXU_PJ#PE_T"Y_\ P8W7_P =H_X5!X2_Z!<__@QNO_CM'LX]P]K6_D7W_P#V
MI[+YOL?R-'F^Q_(UXU_PJ#PE_P! N?\ \&-U_P#':/\ A4'A+_H%S_\ @QNO
M_CM'LX]P]K6_D7W_ /VI[+YOL?R-'F^Q_(UXU_PJ#PE_T"Y__!C=?_':/^%0
M>$O^@7/_ .#&Z_\ CM'LX]P]K6_D7W__ &I[+YOL?R-'F^Q_(UXU_P *@\)?
M] N?_P &-U_\=H_X5!X2_P"@7/\ ^#&Z_P#CM'LX]P]K5_D7W_\ VI[+YOL?
MR-'F^Q_(UXU_PJ#PE_T"Y_\ P8W7_P =H_X5!X2_Z!<__@QNO_CM'LX]P]K6
M_D7W_P#VI[+YOL?R-'F^Q_(UXU_PJ#PE_P! N?\ \&-U_P#':/\ A4'A+_H%
MS_\ @QNO_CM'LX]P]K6_D7W_ /VI[+YOL?R-'F^Q_(UXU_PJ#PE_T"Y__!C=
M?_':/^%0>$O^@7/_ .#&Z_\ CM'LX]P]K6_D7W__ &I[+YOL?R-'F^Q_(UXU
M_P *@\)?] N?_P &-U_\=H_X5!X2_P"@7/\ ^#&Z_P#CM'LX]P]K6_D7W_\
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M/6QXB_U\/^X?YUCUJC"6[.0^+WBN]\#?#'Q+X@TY8FO]-LGN(5G4M&6! &X
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M2YH1?=!1114EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (!I^6_]QO\ ODT>6_\ <;_ODUF?\*&\*?W-7_\ !Y>__':/^%#>%/[FK_\
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M^^369_PH;PI_<U?_ ,'E[_\ ':/^%#>%/[FK_P#@\O?_ ([1S0[A:M_(OO\
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MMK:)(8D"_=51@#\A5CRW_N-_WR:S/^%#>%/[FK_^#R]_^.T?\*&\*?W-7_\
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MV_DC[4US!!=G/F)$[$\8P2 2 :V?B9NM?VAOA7=2_P#'NZWUNI)X\UHLC\<
MU:BO:Z]K[6Z=CF]K?#==TM[];;FEXV\>>*M4\?Q^!?!,EC97T5H+W4=6U&%I
MTM(R=J*D8(W.QSU. !2^+],\=6/PAUTWWB."Y\162F[M;_2K9K3>J88(Z%FS
MG!!QP0:\S\2^$_"NH?M*^(K;QS=-;6.I:3;SV44^HR6<%P4)#@[74.RYS@YQ
MUK4^#.IQV/@SXH16=]/J/@FPN9H](N+B<SKY8B/F*DC9+(&X!R:V<8QBN7I9
M[?J8*K*524:G5M+7:WE^I[GX!\41>-?!>BZY#\JW]I'<;1_"2.1^!R*Z)>E>
M6?LS6TUK\#?!RR@AFL@X![*68K^A%>J+R*X9JTFCU\/)SHPE+=I?D+1114G0
M%%%% "'H:\Z^'?\ R//Q _["$/\ Z*%>BGH:\Z^'?_(]?$#_ +"$/_HH52^&
M7]=3"?QP^?Y,]"[<<8KS;XS?$+5?!MIHVG^'X8)_$>NWJV%B+O)AC)Y:1P.2
M% )P",UZ1GK7A?[15Q'X>\6_#/Q-?/Y.CZ;K.R\N&^Y"LB%0S'L,GJ:NE%2F
ME+S,<7*4*#<=-OQ:+/ASQMXW\'?$[2/"7C34=,UNUUNWEEL=2L+0VK)+&,M&
MZ;F!!'0]:]NC.5!KP#Q1K6G>/OVA/A_:Z#?0:K_8L-S?7LUI*)4A1DVH&920
M"Q/ KWZ,80557[+M9M$X5M\ZO=)Z-N_1?J/HHHK [PHHHH **** "BBB@!,8
MI:** "BBB@ HHHH **** &E@#UQ2D@BN+\9^&+;5-2BN);O5+=_+V[;+5+BV
M3&?[L;J,^_6N?_X0BR_Z"6O9_P"P[>?_ !VM%%/J<TJDT[*/Y_Y'I6H:=9ZO
M9S6E];17EK,I22"= Z.I[%3P1[&I88HK:%(HD$<: *J(,!0.  .U>8?\(39?
M]!+7O_!]>?\ QVC_ (0FR_Z"6O\ _@]O/_CM/D7<GGG>_)^?^1V'B;X=^%O&
M,T,VN>'M,UB6'(C>]M$E91Z L#Q[5=7PQI,=K96ZZ;:+;V3K):Q"!=D##H4&
M,*1ZC%<%_P (39?]!+7_ /P>WG_QVC_A"++_ *"6O_\ @]O/_CM/ENK<Q%VG
M?V>OS_R/1;W2+'4)+:6ZM(;F6UD\V!YD#&)^FY2>AQW%>8>'_@?ILGBKQWJ/
MBC3M+UVQUS5(=0LX+FW$I@"0K&<[APQ(/3M5K_A"++_H):__ .#V\_\ CM'_
M  A%E_T$M?\ _![>?_':J%X)I2W_ .'(G^\E&4H;>O:W;L=_+H&F7-I;6DVG
M6TMK;.CPPO"I2-D^X57& 5[$=*GN-*L[F]MKR:VBENK;=Y,SH"\6X8;:>HR.
M#CK7G/\ PA%E_P!!+7__  >WG_QVC_A"++_H):]_X/;S_P".U'+WD:^TEMR?
MG_D=5K_PU\)>)]1BO]8\-:5JE[&!LN;NRCED&/\ :(S6K_8NFO<64S6-N9+$
M$6DAB7,&1M.SCY>...W%<!_PA%E_T$M?_P#![>?_ !VC_A"++_H):_\ ^#V\
M_P#CM5;^\0G9MJ&_]=CMO$O@O0/&4<,>N:-8:O' V^-;VW67RV]5W XJ6/PI
MHL5E<V2:79I9W7^OMUMT"3< ?.N,-P .>PKA/^$(LO\ H):__P"#V\_^.T?\
M(19?]!+7_P#P>WG_ ,=I<NEN8?,[\WL]?G_D>FQVT,$4<4<:QQ( J(HP% '
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M49%>5_\ "$67_01U[_P>WG_QVC_A"+'_ *"6O?\ @]O/_CM'(NX>UG_+^?\
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M9SC)Y/T%<GX CU^[\4?$^U3Q)X=TJ[DUZX^VVFM6'G3R0%0(FW&5<Q%" !C
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MH_ TZZ\$>'KWPZN@3Z%I\NAJH4:<UJGD*!TPF,#G/(YYJQ_PHK0O^@MXG_\
M"AO/_CE'_"BM"_Z"_B?_ ,*&\_\ CE#J1?VF-T9-W]FK^O\ P"MX:\$Z!X,L
MI;3P_HMGH\4K;W2RA"&0XQECU;\<UP?PP^!&D:%X3T>#Q1X?T?4_$&GRSNEX
M8!-L#3,Z89@,X!'4<&O1?^%%Z%S_ ,3;Q.0>W_"0WG_QRE_X47H7_06\3_\
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M]!;Q/_X4-Y_\<HYJ?=_<@_?]OQ_X!H.#L;CL:YSX<@_\(7IWUFZ?]=I*OS_
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M%O$^?^QAN_\ XNE'P+T+_H+>)_\ PH;S_P".5/-!N[;^XVC&M'W8Q_\ )O\
M@&ESZ&CGT-9W_"B]"_Z"WB?_ ,*&\_\ CE'_  HO0O\ H+>)_P#PH;S_ ..4
M<U/N_N*_?]OQ_P" ://H:,'T-9W_  HO0O\ H+>)_P#PH;S_ ..4?\*+T+_H
M+>)__"AO/_CE'-3[O[@_?]OQ_P" :6#Z5Q7@?_D;?'7MJ$/'_;&NB/P+T+_H
M+>)__"AO/_CE</X&^$&D7GB[QM;R:GXA5+>^B5#'KETC',0/S$/EC[FJ4J?*
M]7]QC+V_/"Z[]?)^1Z5SZ&JNJZ19:[I\UCJ-G#?V4R[9+>XC#QN/0@\&JP^!
M>A$?\A;Q/_X4-Y_\<H_X47H6/^0OXG_\*&[_ /CE3SP6TG]QJU6E'E<4UZ_\
M K>%_ OAWP3#+%X?T*QT9)3F06<"H7]-QZG\ZW3]#67_ ,*+T,?\Q;Q1_P"%
M#>?_ !RD_P"%&:'G_D+>)_\ PHKS_P".4W.$M6V9PA4@K0@E\_\ @&I@^AHY
M]#67_P *,T/_ *"WB?\ \**[_P#BZ7_A1>A#KJWB?_PHKS_XNES4_P"9_<C3
M_:.WX_\  -/GT-'/H:S/^%%Z$<8U?Q/_ .%%>?\ QRE_X47H7_06\3_^%#>?
M_'*.:GW?W(/W_;\?^ :7/H:,'T-9W_"B]"_Z"WB?_P *&\_^.4?\*+T+_H+>
M)_\ PH;S_P".4<U/N_N'^_[?C_P#1Y]#1CV-9W_"B]"_Z"WB?_PH;S_XY1_P
MHO0O^@MXG_\ "AO/_CE'-3[O[@_?]OQ_X!W6E\64/^[5P5F>'/#]OX:TN*PM
MIKJXBCSA[VY>XE/U=R2?QK4KE>^AUQO97"BBB@H**** "BBB@ I#TI:1NE '
M%?&/QK=?#GX9^(_$UG;175SI=F]S%#,Q5'88X)'..>U>:WWQ5^*/@OPS!XL\
M0^&/#^L>&A EU=_\(_=S"\MH64,9/+E7#A0<D @X!KI_VIS_ ,8]^//^P5+_
M $K,\<?$+0/"/P#E:_O[:2:;1%M;>SCE5YKF=X JQ(@.6)) P!773BG!.U]3
MR,3-JM)*?+:-_G=G63^-KK4->\&/HU]HK:#K,4L\GVJ5EN[A/+#1FV4<-URV
M>@JY??&'P1I6OIH=[XLT>VUAG\O[%)>() QZ*1G@GT->'>'_  [>^$-=_9LT
M?4EVZA8:=>PSQMR8W^RIE<^W3\*Y3XG^(9/'/P3^(&KZ+X8\(Z+X42:\A,]\
MQ&HSW$;E6E4(FU93)]T,22<$]:U]C&4U%/3_ (-CF^O5(TY2?Q=G?^52>WJ?
M66O^._#WA12=8UFRTP"![D_:IUC_ '28W/R>@W+D^XK.N?BOX.M])@U.7Q-I
M4.GSVAOHKF2Z14> $ R@D\KD@9]2!7BGB/PWI_C+XV?!:#6;:/4H%\.7=UY<
MXW(TBK;E2PZ-@G.",9 /:K_C/P1H6L_M.^ =.N]+MI=.L_#]]<0VGE*(5=9X
MMIV ;3C<3@C&><<5G[*&BOT;^Z_^1O\ 6ZK3E%*UXI?.W^9T%_\ &JVLOC!I
MD$FOZ=#X'N?#,NKF\D=%B=Q/&B.)3VPQ&.^17J/AGQGH?C+24U/0M5M=6TYR
M0MS9RB1"1U&1W'I7B>M^#=%U/]JWPQ:W>EVD]KI_A6XGM;=H5\J)Q<HJL$QM
MX#'''!.>M<1XEM[KP]I_[3%IX<A:T$:6MQ'!:+M"E[53,R@="5W'BG[*,TN7
M>R_.QG'$UJ,I<R4ES-:7Z1N?1^B_%KP9XBUQ]&TSQ-IE_JB9!M(+E6D..N #
M\V.^,XIGB/XO^"O!^IQ:=K?BC2=*OI,%;:ZNT20 ]"5)RH/8G&:\*TWX>:WX
MR\(> FAU_P #Z9HVG7-E>Z;<Z7:2).NS&(T8R8W/RI'?)XJ7QCX@E\8-\4(]
M \+^$+72]*>2SUC4]?9EN+J40@D@(O "E0I=N<<4G1CS<J?]7L4L=4Y+R23>
MV^NEWI^K/INVNXKR%)87$D;@,KJ<@@\@@]ZEZUYC^S1-)/\  ?P.TK.[?V7"
M,R'+8 (&?P KTX=*Y9QY9N/9L]6C/VM.,WU28M%%%2;!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0W
M7_'O)_NG^5<G\*?^1"TW_>F_]'O767?_ ![R?[I_E7)_"G_D0M._WIO_ $?)
M3Z&3_B+T?Z'8?P5POQ O/'HN[6U\'V6BK&R,]QJ&M32%4/&$2*/YF)]20!7=
M X'M7!_$CP_8^-T@T=O%VI^&[R/]\4T745MIW0@K\P()*?AU[U4;<VI%:_L[
M)V?K;\3+^"7Q.U/X@V.N6VN6%M8:WHFH-IUW]AD+V\C@ AHR><$'H>E-^,WB
MW5-+NO"OAW1+LV6JZ_J<=N+A0"T4"_/*P!!'W01^-<A^R_</HM[XW\'0RV^J
MZ;H&H*L&LQ1A7NVD7<_FLIP\BG@MWK3^)P,7[17PIEE/^CE+^-,]/,,>1^.
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M !%:*+CHIV,9-SUE2O\ <>E7WAO2M1U73M3N+&";4-.W_9+EU!>#>-K[3VR
M :Y:\^!?@*_U>^U.Y\*:9/=WN_[0SQ960L,,Q0G;N(."V,^]<]_PKUO^AO\
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M'_@[;_XBC_A7A_Z&[QA_X.V_^(H]DOYOP#VU3^3\4>O[O>C=[UY!_P *\/\
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M[2,(N3U/'4^YKE?BU\/KWQG!H-[I$\%OK6BZC%?6LD^0A .)$; )P5)%8?\
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MS?@/VU3^3\4>O[O>C=[UY!_PKP_]#=XP_P#!VW_Q%'_"O#_T-WC#_P ';?\
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M^-Y=^$?#.EZ-J,T)C\RVB\O?W4,1VSBN:_X5ZW_0W^,/_!VW_P 11_PKUO\
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M[$,LCX[#;6!XDN9[7X0?%\PN\$$OC-H;R5,@K;N]N)N1R!L)R?2G["WNO?\
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M@MX1$N0QL\@'^[N;'Z5Z)7+-<LVCTL/)SI1D]VD%%%%0;A1110 'I7%^!_\
MD;/'/_80A_\ 1-=H>E<7X'_Y&WQU_P!A"'_T35I>ZS"?\2'S_([2N-^)OQ D
M\":;8+8V']K:UJ=TME86+2>6LDK=W?!PH')(%=E7D/QKE33O'?PMU*X(CL8-
M9,<LK<*C.A"DGZU=**E-)D8JHZ=%M.VWZ+\#0\-_$;Q-9>.K/PIXTTC3;.[U
M&!Y["]TBX>2"0I]^-@ZA@P'<<&O3J\A\?,NH_'GX<V-N0US9+=W<ZJ<E(MF
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M A9CL4, =HXXZ5V]]:0:E9SVMRBS6\Z-'+&QX=2,$'Z@U0_X4S<_]#WXN_\
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M]?8Y%3>(_A7X2\6:1INF:GHEO-9:;C['%$S0_9P!C"%""HQQ@=JUO^%,W/\
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M_P#0]^+O_ V#_P",4KP_F*O6_D_+_,ULCU%&1ZBLG_A3-S_T/?B[_P #8/\
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MQ=_X&P?_ !FI<HR=^8UBJD$HQAMINGL:V1ZBC(]163_PIFY_Z'OQ=_X&P?\
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M@^H(/<$&N<\$_!3P=\.;^>^T'18K2^F01/=O(\TVS.=@>1B0OL,5G?V'K/\
MT.FO?E:__&:/[#UG_H=->_*U_P#C--*25E(PE*,I*;IZK;5&?I_PWO[[]HO4
M_'&I:=!!8V&CQ:9I4RNADG9F+32, <C:"$&?4UZ#;^$=*M/$]YK\-C%'J]W;
MQVL]Z"=\D2$E%/., DGBN._L/6?^ATU[\K7_ .,T?V'K/_0Z:]_Y*_\ QFG)
M2G:\MB8.-.]H;N^ZW[G3V_P]T"VL]<LTTJV^R:Y.]SJ4+#<MU(ZA69P2>2%
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M=_*U_P#C-']B:S_T.FN_E:__ !FI]D^YT>W?\OXH]/WKZBC>OJ*\P_L36?\
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MG_OE5'Z5JBL7H['3%W5Q:***"@HHHH **** ,'Q$,SP_[A_G6/6QXB_U\/\
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M +?_ 'U1_8-K_M_]]57MY?S,E86FDURK7_A_S/,?!/PL\-?#Z2\FT:Q>.[O
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?C%%% !BC%%% !BC%%% !B@"BB@8M%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tmb-20221231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '< 9L# 2(  A$! Q$!_\0
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MOI^I"(2Q&38%=&4\%6 Q[5L?#?X1_%C6=3U:\^(WB/3;;3[BPDT^'1M%M$1
M74 SM*!NSU.WIS7TM10!^?=S^Q9\8)_AW<_#:W\2:!I_A>WCD$>HQ:>AO-0!
MD,BQRL1E>>"P.>*^@-(^".O1?&KP%XSN#!%:Z-X5.CW5N');SCUP>XKZ$HH
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M\0='UJ77[74C:@VR/(/GM1$3M$1X[<8Z5]L @]*6@#YQ^%OPR^+<NI:SJOQ
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MQ._9J^*=_P"+_%%I#X>\*?$#0-=G>:UUC7PL-[I <\JK( 6"]1DYXZUZ_P#
M+X#^(_A[XD(\2W:ZQ9:/HL&D:5?RS%Y9027G<@_=R6"@<\(* /!O$_[9OC'Q
M)XF\47OA;QUX#\+:'HM]/8V^C:_N:\OO);#,2/N!B"%^E=9XO_:R\;^,_!WP
M8U/X9PV%O?\ CBYGM)XM30M'')'N5B#UP'0GW%9NJ_LS?$KX:>)_$\'@+PIX
M-\4^'?$-_-J4%SXAMT%SI,DSEF5<@F15)X!->C7/[.WBNWU7X'R+/9:C_P (
MC?376JW,<:6RDNIR$C0 8!;' [9H PO#/QP^)_P@^)FM>&?BY>Z-KUJGAR;7
M;2[T2W,)01L0R,&ZYP>?>O#OV@?&/QQ\;? *T\7>(/[#;P+K^H6<L&D6D3"[
ML(3.#&[/T;@#/UKZI^)7P"U'XA?'R+6[N&)O"D_A6YT2Y<28D$DC$@A?0#O7
MA7BG]G7]H#6OA/;_  FWZ+/X7T*Z@:SUJ2?_ $K4H(Y0R1NG1"%[^U 'W'IL
M\=EX.L;B4E8HK-)&([ )DU\=P?&WX_?$'PMK_P 3O!X\/6?@33IIVM=%OK9G
MO+Z"%B';S!P"VTXK[+M--QX:M]/NHQ)BV6&5,\'Y<$5\A0? KXU^ ?#VL_"[
MPA-I%QX U>2?R=>O9BMYID$S$O&L8X8C) )/>@#SS]J+6/%/[0UW^SCK?AF\
MTBVT#Q)=,]O8:K;&54NS$2YD'1DV@@#U&:^S/B)XBN_@U\"=7UBRTM=2O="T
MII4L;)-J.Z)R%49PN><>E>4^(OV:-2T@_ #2O"Z1RZ/X"U)IKQYWV.8C 4W
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MFZDSN.FP?)$!GD L&./QH ^RXSE!3J0 *,#BEH **** "BBB@ HHHH ****
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MBHXY ^>,5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?A7X=\&V\IG72[78\I.=\C,7D;H.KLQZ=Z[B]TJUU';]IMHK@+RHE0-CZ9H
M;I.N6&O6YGT^[AO(0<%X6W 'TJ]7E7P9A%OXC\=PH D2:F B+PJ_+V':O5:
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MO^1F\>?]A,?^@UZC7EWP>'_%3>/?^PF/_0:]1H **** "BBB@ HHHH ****
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M5:\C^!>FVNCZUXXLK*".VM(=2"QQ1C 4;>U>N4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 TM@<BE
MW<>E17(8Q_(<,*\-\'_'CQ3XH^,6L^!I/ <UE%I$D9NM3:_C95BDW&-PHY.0
MO3J* />**:AR,XQ[&G4 %%%% !1110 4444 %%%% !39#A#U_"G5#<']W^.*
M /S?_;)^#?C>T^)OBW7-.\%'Q?:^(9],FL;ZU=6N+(6T@:2,JQ& V#@C^E>W
M_L9>#O&%WX]^(7Q%\6:';>&&\1BVAMM)BF#RHD*X\R0 G:S?6OG#]JG5/AE:
M?M8>*+?XM>,/%2V#V-M)IEGX;N90MH<8=9%C(P2<?D:]_P#V!9O@Y/=>*F^%
M6K>*=3?RXOMO_"123,%&3M\OS"?TH ^QZ0CO2T4 1) %<MZTYXP]/HH 0#%+
M110!Y=\'O^1F\>?]A,?^@UZC7EWP>_Y&;QY_V$Q_Z#7J- !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M (:\&^&(Q^U1\6O^O'2__0)*]ZKP;X9?\G4?%K_KRTO_ - DH ]X]:6D]:6@
M HHHH **** "BBB@ HHHH *ANCMBSTYJ:L;Q=X?B\5>'-0TB:>>VBO8FA::V
M?;+'G^)3V(H ^#?C/X'^,WA[]IWQ1XO\"_"72/%NB:I;0PR7.H;'\YU7AUR<
MIC)X& :]W_9-U'XE7$_B!OB%\.-)^'\:I']F;3P@^T')SNVGM[UYYJO[.?[1
M'@>YEM_ 7QJEU;39& CA\30"66%0.SAN>I[#I6KX0_9@^,_C#4[2\^*/QFU)
M[.%E9](\.Q_9H9=K9P[;CD$9!X[T ?8*G<,BEJ*WA%O!'&.B*%J0L!UH 6BJ
MXU"V+ "XC)/ &X4][J&-@KRHK'HK'!H EHI P)X-+0!Y=\'O^1F\>?\ 83'_
M *#7J->7_"'9_P )/X[VEB?[2&<CI\E>H4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X-\,O^3J/
MBU_UY:7_ .@25[P>E>$?#+9_PU)\6,%BPLM,R".!\LG3F@#W?UI:3UI: "BB
MB@ HHHH **** "BBB@ K$\:>([+P?X5U37-2E$%AIUN]S/(<<(HR>I [5MUY
MI^TEH-]XI^!/C?2-,A%QJ%[IDT$$1=4#.1P,L0!^- 'S3X6_:'_:)^.VES>+
M?AEX)T#3_!KEA8?\)!=.EU>(,_.H5&&#CCGN.:]F_9;_ &D_^%[V^O:9JVC3
M^&_&7AN?[%J^E3-D*_\ ?0]2A]2!7S;\"OBE^T;\)/A-X<\&6?P .LQZ-:BV
M6Z37;8"0 GG 8@=>U=[^Q)X'^(^G_&+XM>-O'W@F3P=_PD\D,]O;M<Q3#(/(
MRC=J /M"N0^+'B&Z\*?#[Q!K%C;W5W>V5A-/!!9PF:5Y AVA4'+'.,"NOKGO
M'FEWVN>%M3T_3-0;2=0N;=XK>_10S6[D?*X!X.#@_A0!^:GP:TSX?^$=0\#7
MWQ$\(_%/0?$-Q=0EO$.I>=#I4EXS%E!+R !>V"N*].@^#\G[4&I?&3Q[KGB/
M5=/U#P_KM_HF@P6%[)%#9_8U!20JI 8LS9P1VKH-:^&WQY^-&G>'_A[X]TBQ
MT[P[IMW%<ZAXM2XAFDU-8FW*%A7!B+$ $X['UI_B#X<?'#X5^(OB-HGPXT"Q
MUSPIXUO)M2BOYKR.%M*N9QMG8HQW2= >.* /=_V2?']]\4?@%X.\2ZBQ:^N+
M5X9W8Y,CQ2/$7/IGR\_C7KEQ?06@!FE2('@%V"@_G7 ?L^_#"/X-?";PWX.C
MD\[^R[;;)+_?E=F>1OQ=F-=GK7AG3/$*QKJ-G'=B,[D$F>#0!Y]\&I4F\3>/
M'1@R'4QA@<@_+7JM>3_!&R@T_7/'%M;QB*"/4@$1>@&VO6* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DL
MJ0H7=@B 9+,< 5377M-89%];8_Z[+_C7/_%]VC^%WBIT8JZZ=.0P."#L-?DQ
M_P )#JG_ $$+KH/^6K>GUH _8<Z[IV#_ *=;?]_E_P :\)^&>K6*?M1_%B4W
MD 1K/3 &,@P<))TYK\[O^$AU0_\ ,1NO^_S?XU#'J=Y%=37*74R7$V!)*'(9
M\=,GVH _8[^W-/'6^MO^_P O^- US3W8*E[;LQX $J\_K7X[_P#"0ZH!_P A
M&Z_[^M_C72_#/Q!J;_$CPNC:A<LK:C I!E8@C>..M 'ZWHX<9'3UIU1Q)M%2
M4 %%%% !1110 4444 %<A\76\/+\,_$9\6.8_#?V-_[0<9RL./F/'-=?7'_%
MRX\/VOPV\12^*H/M7AQ+1S?P9;]Y%CYE^4@\].#0!^8VEP_#J>4VOP \7?%^
M\U!0&@@TRX=;%6+<,X8*-I (_"OMK]DC_A=T46M6_P 6(HO[.C"_V5-*4-V_
M/S"7:Q&>!7P])IGAK68Q<_L^?"SXD>&=2Y6#4;*=_LI8-\NY9G8%<$G&._M7
MVM^QSHOQXTVRU>;XT:['J<<RJ--MS%"L\."=WF&-%R2,>M 'TU1110 4F*6B
M@! ,4M%% 'EWP>_Y&;QY_P!A,?\ H->HUY=\'O\ D9O'G_83'_H->HT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C_C#_R2OQ7_ -@V?_T
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MZ01N_O\ -R:Z7P5J?AF>!K/PU>:7-;0#YH-+DC98_J$/':@#J:CEE6(;F(
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''_&'_DE?BO\
M[!L__H!K\B?3Z#^5?KM\8?\ DE?BO_L&S_\ H!K\B?3Z#^5 !1110 5TWPQ_
MY*3X4_["=O\ ^AUS-=-\,?\ DI/A3_L)V_\ Z'0!^OL?W1]*?3(_NCZ4^@ H
MHHH **** "BBB@ J.;&SD9'I4E1S_<_'M0!\O_M!_MLZ/\%O&,/AFP\/ZEXB
MU%)K=-1FM4VVU@LSA4,DG0,<\"O3_A=\<--^(OCGQ?X5@M+JSU/PXT(G%PF!
M(DB;E=3GD$\9KXO_ &W?".BOXZU]_#?QC\)>%-5UB6SEUK0-?NXD=I+<AX9
M6;*^A7'/X5Z9^QMKW@3PQX@UC4-9^,_A?QM\2?%31)<BPU"%5"QKA(8T#<X]
MN: /MFBF(<J*5I%3[S 'K0 ZBHS,@(&X<].:<6 '6@!U%-#@_P Z7K0!Y?\
M![_D9O'G_83'_H->HUY=\'O^1F\>_P#83'_H->HT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''_&'_ ))7
MXK_[!L__ * :_(GT^@_E7Z[?&'_DE?BO_L&S_P#H!K\B?3Z#^5 !1110 5TW
MPQ_Y*3X4_P"PG;_^AUS-=-\,?^2D^%/^PG;_ /H= 'Z^Q_='TI],C^Z/I3Z
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M!'0_)7J=>1_ O2[;1=8\;65G'Y5M#J(5$R3@;?4UZY0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <?\8?\
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M*** "BBB@ HHHH X_P",/_)*_%?_ &#9_P#T U^1/I]!_*OUV^,/_)*_%?\
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M]A,?^@UZC7EOP>/_ !4WCS_L)C_T&O4J "BBB@ HHHH **** "BBB@ HHHH
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M  A=G\3>.\G@:D /^^:]0H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#S'X]_$74_A#\.-6\7V6FQ:I!I437%S!).8CY8')4X.36[\)O%FI>.O
M FE:_J5A!IKZA"MS%;P3F4+&P!7)('.#7"_MG2M#^RY\29$.&7292,_A77?
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ME/H \N^#W_(S>//^PF/_ $&O4:\N^#W_ ",WCS_L)C_T&O4: "BBB@ HHHH
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MD8/->W?LP>!_&?A&;6CXL^+Z?%)94C$"K!%']DZY/[L<Y]Z^.OVWV^ FF_M
M:C)XFT3QCK?BEH(3>RZ)=F.&#< (T'R\$\<9[U['_P $XQX"DO/&D_@7P_XF
MT6W410W3>([LRN9 2=JJ57;QS0!]QU#=2F&/<%+$=AUJ:FL 1S0!\A^ _C%\
M4?$G[6]AH'BG3%\*^&;KP_/?6NB*ZRR/ME"++*V,ACSP/6N2U*;XS_'?7?BK
MXI\(?$JZ\&Z!X0U6YT?3-&BLX)5NY[4 RF1G7(WD@>W:O8M?\)ZK<_MJ^'O$
M,-C,VBP^$YK22["_(LIN,A<^N,&O(+W5OB1^SUKGQ2\(:%\/+SQ1IOBW6;O6
M=&U."4%!+=JJR+-_="E>#[T ?3/[-_Q*;XO?!CPKXKE_X^;ZTQ<'&,S(QCD_
M\?5J],,JJ<%@#[FO*OV7OAC=?!WX(>%?"=[)YE[96S/<8'"R22-*ZCZ%R/PK
MOO$'AFV\2)&EU)<(L9ROV>X>(_CM(H X?X/G'BCQZ/\ J)#G_@->I5Y+\#K&
M'2]9\;6D!8QQ:B%7<2Q^[W)Y->M4 %%%% !1110!Q[_%CPF-?71/^$@TX:P2
M5%@UPOG9!P?EZ]:ZN!_,4GISBOGW6-%T\?MH>'W%C;"1O"\[EQ$N2WG]<XZ\
M]:^A54+T&* '4444 %%%% !1110 4444 %%%% 'B/[:?_)J_Q+_[ \O\A78?
M /\ Y(IX(_[!%M_Z+6N/_;3_ .35_B7_ -@>7^0KL/@'_P D4\$?]@BV_P#1
M:T =]1110 4444 %%%% !1110!Q_QA_Y)7XK_P"P;/\ ^@&OR)]/H/Y5^NWQ
MA_Y)7XK_ .P;/_Z :_(GT^@_E0 4444 %=-\,?\ DI/A3_L)V_\ Z'7,UTWP
MQ_Y*3X4_["=O_P"AT ?K[']T?2GTR/[H^E/H **** "BBB@ HHHH *9+@K@G
M'-/JO=,$B))  /4T ?&?[17P]\">'/&WC&^UCXC67A?4?&<%FEI973Y>*_@D
M!MYE(Y R%&/0FND_8V\ ^)_#?C?XB:OXS\>:+XN\2WSVT-U;Z,NQ;<)&-C.N
MT89EP:\ _;(^%'C"+XG>*]?TOP._C6+79M-GT[4;&1))[ 6SAI(BI(VAL#D5
M[Q^QIX3\87GQ ^(7Q%\5>'(_"*^(A;06FD&4/,JPKCS) /NLV30!];T444 1
M&$$YI#;(6!Q4U% #4C5.@IU%% 'EGP='_%3^//\ L)C_ -!KU.O+O@]_R,WC
MS_L)C_T&O4: "BBB@ HHHH \%UG_ )/-\._]BI<?^CQ7O5>"ZS_R>;X=_P"Q
M4N/_ $>*]ZH **** "BBB@ HHHH *0]*6D/(- '+^)_B7X8\%7D=MKVO66E3
MRKO2.YD"EE]16/\ \+^^'?\ T..E?]_Q7R-_P4)7_BX?AW_KP;_T,U\J9QQQ
M0!^@W[6_QB\%>)/V;OB#I>F>)M/OM0NM+DC@MH90SR,0. /6NI^"GQN\!Z5\
M(_!]E=^*]-MKJ#2K=)(GF 9&$8!!%?F><D=O;K3MW7@=: /UC_X7[\._^AQT
MK_O^*Z+PMXWT/QK%+/H>K6VJP1-L=K9]P4^AK\>=WL/UK[K_ .">./\ A#O$
M^/\ G^7_ -!H ^NJ*** "BBB@ HHHH X_P",/_)*_%?_ &#9_P#T U^1/I]!
M_*OUV^,/_)*_%?\ V#9__0#7Y$^GT'\J "BBB@ KIOAC_P E)\*?]A.W_P#0
MZYFNF^&/_)2?"G_83M__ $.@#]?8_NCZ4^F1_='TI] !1110 4444 %%%% !
M7%?&;PE?^/?A;XF\.Z7=K8:AJ=E);07+D@1.PP&)'/Y5VM<;\8M*UW7/AAXC
ML/#%T]EX@N+-TL;B-]C1RG[K ]L4 ?F5)^R%/\%]&GG^)5QJOB!8(P?MVB^,
M#:N^, D0R,#G)''UKZ9_X)\S?#*X;Q6_P_E\6M<H(X[^'Q)/).B$'@12$E6Y
MSDK7S58?L<?M'R7'VO7M%\+>-+XG<UUXD?[<S-ZX<XY[_05]G_L?^%OBOX/M
M-5TWXB:/X:T73HDC73H/#ULD*C'WMP7KQCKZ4 ?2E%%% !12$X&31N% "T4@
M(/>EH \N^#W_ ",WCS_L)C_T&O4:\N^#W'B;QY_V$Q_Z#7J- !2$X%+6/XQF
MDMO"NKS1.T<L=I*Z.IP5(4D$4 :V\>H_.C>/4?G7Y+M\=/B&&;_BM=<ZD?\
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M&OR)]/H/Y5^NWQA_Y)7XK_[!L_\ Z :_(GT^@_E0 4444 %=-\,?^2D^%/\
ML)V__H=<S73?#'_DI/A3_L)V_P#Z'0!^OL?W1]*?3(_NCZ4^@ HHHH ****
M"BBB@ I"H88/2EHH :$ X  %* !VI:* "BBB@".XSY1P<5\.ZC/\6?CYK_Q0
M\5^$_B!=^#M#\&:I<Z-I>D0(ICO)[4 RF;()PQ*@8K[BG!,9Q7PS+XL\9?LW
MZU\5/!=G\/-:\40>+M:O-;T/4]-0/#ONPH9)C_ %('X4 ?3?[./Q.;XP_!KP
MKXLD4+<7]K_I  P/.1C')@>F]&KTMYEC(#,!GU->2?LI?#+4/@]\"?"OA759
M%DU&S@D>XVC 2225Y63WVER,^U=YXN\#:9XS@A34A.5A.Y/)E9,'\"* ..^$
M4T:>)O'A,BX.ICOC^&O3OM<7_/1/^^Q7B7@GX"Z8NK>(O[3M[M+8W8-DRW3@
MM'MZG!KK?^%$>%?[E[_X&R?_ !5 'H'VN+_GHG_?8K%\:W,;^$-:4.I)LY1@
M,/[A]ZYG_A1'A7^Y>_\ @;)_\52-\!?"4BE7BO'0C!5KR0@C\Z /RB?F1QT(
M8_SI,>_Z&OU)'[*WPS '_%/1'W+DT?\ #*_PS_Z%V'_OHT ?EMCW_0T8]_T-
M?J3_ ,,K_#/_ *%V'_OHT?\ #*_PS_Z%V'_OHT ?EU:L%NXAU.]<?G7[!^$+
MF+_A%='/F*,6D7!8?W17 C]ECX: Y'A^($=,.1BM5?@-X310JQWJJ!@*+V3
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MX5QPEZ3_ -?LG^-8WA3X&Z/-83MJL=Z)Q<RA/]-D_P!7O.SOZ8H ]:^UQ?\
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MHH **** "BBB@ HHHH :RA@0>0:SM%\/:?X>MOLVG6L5G;EVD\J%0J[F)8G
M[DDG\:TZ0]* .>U;P1HNL3:B]YIUK<-J, M[LR1 F:,9PK>HY-4O#GPK\+^$
M8[6/1=$L=.6V5TC%O"J[5?&Y>!T.*\$\;_$CQ/X#_::\1:B;Z2[\$V6FZ='J
M6FMDK;+*S@W*=\@@9 [9/:F6OQ6\:Z7XY^+=SX6T^+QG]FOM-2QL+W4UM8(X
MI("S,CL,<]<=\T >_>%?A9X7\"O>MH.B66EF];?<?9X0HD/N!]34/AKX2^$?
M!^H7^H:+H-AI][?9^TS6\"HTF3SGCW/YUX5>_'7XJ7?@;QA<:[X6TCP,;/3)
M)K74HM;BO2)>P\M1D'T/KBN0_9Z\3ZK-\0+CP[H_BWQ &U30_MTB^,(VD(O"
M<;K<'&8P.2HXZ4 ?5&B?"CPEH&KQ:IIFA6-GJ44'V=+F*%1(J>@/]:CD^$'A
M*?QA_P )4^@V#>(/^@@8%,O3'WL>G%?-OP]CO_AK\>=+T2+QEXJU<:AYZZK+
MXFR+.YDP"@M > <EC@'IQ7V%;L7B!- #HX_+&,YI]%% "=:H:SH=CK]E]DU"
MWCNK8NDGE2J&7<K!E.#Z$ _A6A10!QGBGX0>$?&NJ6FHZWH%AJ=[:$&">Y@5
MWCP<C!(]>:M>+?AKX;\>Z='8^(M'L]7M8F#QQ740<*0,9&1Z 5U-% '/0^!=
M$M/[),.G6\7]DJ4L0B "W&W:0HZ#@XI+GP1HEQI^IVDFGP&WU)S+=)L&)7./
MF8=SP/RKA?VK-3U/1_@5XDN='U";2M2"Q+#>P'YH29%&[WX)X[UXYX[^,'B!
MOA++I&HWSZ;XWT+6].M+Y[5RAGADF79*N.TB]0#@'(H T[K]DOQ'X@\927>K
M>*M,NM'DO%GE=-)1+Z>"-@T4#2@] 0.>O%?4Z*J#;C ':OFCQ-\</C%HVNWM
MGIGPOT;4;&W<K#=S^)X(7D4=&9",J3Z&I_VB/C!XDTSPA:^&O#@CL/&VK:9+
M>W;)-O72[9(RTDH;H6R,+Z]10!]&SQ).,$\=P>A^M<OX>^%/ACPGJNH:EHNB
MV.F7U^=UQ<VT*H\AZ\D#UYKP/QCXA^(4O[+&CZKX?U>*T8>'A=:CK$Y:6Z)"
M9'E@$#<V?O$\5]$?#FZFO? /ANXN)&FGFT^!WD<Y+$Q@DDT 4+;X0^$[+Q5-
MXF@T+3XO$$N2^HK;KYI)&"<XZD=ZV?\ A%K$:JVI^1&=0,0@-R4!?RP<[<^G
MM6U10!S7AGX>:!X.DOGT72K733?3&XN3;1A#*_\ >;'6NDP,4M% &1J'AC3M
M2U.UU"XM8Y;VT5UMYW7<T8< . >V<#\JPH?A%X4M_%<OB>/0["/Q!)][45@4
M2DXQG<!U]Z[2B@#C+[X1>$M3\50>);O0+"?78,>7?M"/,7'0Y]:U9/!NCR?V
MH'L(&_M-0MY\@_?@#'S>O%;<N=AQU[9KY+^'OQ2\3>&?BYXP_MW47OO!5]XG
MDT>&6=B3IESY<;0C/_/-\D<\ X]: /=/B)\,HO$OA7['HEQ#H.L6MN;?3M2$
M"R?90?E90I_A9?E(]*\V^"/[-VI?#_QQ)XBUS5M+NYHK1[.SLM(TY;6&+>0T
MCG^\S$?A7(>#?BU\2=%\+ZW<>'_#\'CF<^)K^W==5UA+/[/&K?*J%QAA[#I7
MH7@_XX>)8O"'B7Q%\1O#&G^#;32(_-0V>JI?><,9P=G1NP7O0![@T0/&XYQC
M'45S-O\ "[PM#XN?Q.FAV*Z^Z['OT@42D<]2._/6OGGX)>)/B'X[\:_$0:QK
M(T:_U#3[*[TZS(\V+2XI P4;<C+E0"<\Y^E7/!G@O6OA#\<_#^BZ'XTU[QBN
MK0S3:[:Z[<F=+:(<K-&>B$O\H7TH ]UUOX0>$?$7B:U\0:EX?T^]UFUQY-[-
M K2ICI@XKH=4\/6.L+:"\MX[C[+*)X?-&[8X! 89[\FM(4M '-0_#SP_#XM/
MB9=)L_[?,?E'4?*7SBF,8W8STXKI*6B@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "D;H:6B@#S*U^%TB?%CQ?XFO7M[O3-<TRVT\V3+D@1AMV
MX=""&Q^=<%\*/V3M)\'7_CNVU_[+XH\.ZU?07.GV&H1^8;2.-"%C.>"!GCCH
M*^B-H(Q2[1Q[4 >-^+OV6O >I^$]1TW1-!L/#MU/LECNM/MTC(EC<21[L#E=
MX&1W%<AIGP'\?>.-4AU#XH>)-+>YTNVFMM'N?"D,EK+"95"N[LQ8YP!C'3FO
MI,C(H*@C!Y^M 'SAX<^!_P 1/$/B/P^WQ(\5:;JFB>&KL7NEQ:3 \5Q/,JE4
M>Y=LAL*3G &2>U?1D *Q@'M3A&H)( !/<4Z@ HHHH **** "BBB@#A?C9X"N
M?B9\.-3\.V=Q':3W1C*S2C*KM=6_I7G?QZ_9P'Q<'AJ[L+]=(UC2KJWDEN /
MDN;=&5FB?N1D9'H0*]](!ZTA0$8- 'G-[^SO\.=7NY+V_P#!FBWE[,2TL\MF
MA9V/4DXKG/B3^RGX+\=)JM[':SZ=K-UIITZ.XM+J2!50(5C!5" 5&>AKVND(
MS0!XII?P+ET3]FT_#6SO0+DZ7]A-W,S2*'(Y;GG'M7J?@[2)-!\*:-IDKB22
MRLXK9G7HQ1 I(_*MC:** %HHHH **** "BBB@".7.WCKFO)?"OP.MX-*^(&G
M:ZT&HV/B?5);X(@Y16C10/\ >!0'\J]=(SUHQ0!\_?!_]E;1/"O@>7PWXRM[
M/QJR:C<7L%WJ, E<"1LC=N'WL<&NQUG]FKX<ZOX6N_#W_"+V5CI-U*DTT-BG
MD;W0Y4DKCD'I7J&** /F>U_9:U#P)XC\;>(? >KBSUC5=,BLM,;5[B>Y2W=<
MAF<%OF&#QZ4[X!_"7XR?#76X8_$&K^#-0T:=S)J%U9V=Q_:5V^.&:5V(//J,
< <"OI8J#VH"X_P#KT +1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tmb-20221231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (0 TL# 2(  A$! Q$!_\0
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M_P#ORM &EN%&X5F_V=?_ /04?_ORM']G7_\ T%'_ ._*T :6X4;A6;_9U_\
M]!1_^_*T?V=?_P#04?\ [\K0!I;A1N%9O]G7_P#T%'_[\K1_9U__ -!1_P#O
MRM &EN%&X5F_V=?_ /04?_ORM']G7_\ T%'_ ._*T :6X4;A6;_9U_\ ]!1_
M^_*T?V=?_P#04?\ [\K0!I;A1N%9O]G7_P#T%'_[\K1_9U__ -!1_P#ORM &
MEN%&X5F_V=?_ /04?_ORM']G7_\ T%'_ ._*T :6X4;A6;_9U_\ ]!1_^_*T
M?V=?_P#04?\ [\K0!I;A1N%9O]G7_P#T%'_[\K1_9U__ -!1_P#ORM &EN%&
MX5F_V=?_ /04?_ORM']G7_\ T%'_ ._*T :6X4;A6;_9U_\ ]!1_^_*T?V=?
M_P#04?\ [\K0!I;A1N%9O]G7_P#T%'_[\K1_9U__ -!1_P#ORM &EN%&X5F_
MV=?_ /04?_ORM']G7_\ T%'_ ._*T :6X4;A6;_9U_\ ]!1_^_*T?V=?_P#0
M4?\ [\K0!I;A1N%9O]G7_P#T%'_[\K1_9U__ -!1_P#ORM &EN%&X5F_V=?_
M /04?_ORM']G7_\ T%'_ ._*T :6X4;A6;_9U_\ ]!1_^_*T?V=?_P#04?\
M[\K0!I;A1N%9O]G7_P#T%'_[\K1_9U__ -!1_P#ORM &EN%&X5F_V=?_ /04
M?_ORM']G7_\ T%'_ ._*T :6X4;A6;_9U_\ ]!1_^_*T?V=?_P#04?\ [\K0
M!I;A1N%9O]G7_P#T%'_[\K1_9U__ -!1_P#ORM &EN%&X5F_V=?_ /04?_OR
MM']G7_\ T%'_ ._*T :6X4;A6;_9U_\ ]!1_^_*T?V=?_P#04?\ [\K0!I;A
M1N%9O]G7_P#T%'_[\K1_9U__ -!1_P#ORM &EN%&X5F_V=?_ /04?_ORM']G
M7_\ T%'_ ._*T :6X4;A6;_9U_\ ]!1_^_*T?V=?_P#04?\ [\K0!I;A1N%9
MO]G7_P#T%'_[\K1_9U__ -!1_P#ORM &EN%&X5F_V=?_ /04?_ORM']G7_\
MT%'_ ._*T :6X4;A6;_9U_\ ]!1_^_*T?V=?_P#04?\ [\K0!I;A1N%9O]G7
M_P#T%'_[\K1_9U__ -!1_P#ORM &EN%&X5F_V=?_ /04?_ORM']G7_\ T%'_
M ._*T :6X4;A6;_9U_\ ]!1_^_*T?V=?_P#04?\ [\K0!I;A1N%9O]G7_P#T
M%'_[\K1_9U__ -!1_P#ORM &EN%&X5F_V=?_ /04?_ORM']G7_\ T%'_ ._*
MT :6X4;A6;_9U_\ ]!1_^_*T?V=?_P#04?\ [\K0!I;A1N%9O]G7_P#T%'_[
M\K1_9U__ -!1_P#ORM &EN%&X5F_V=?_ /04?_ORM']G7_\ T%'_ ._*T :6
MX4;A6;_9U_\ ]!1_^_*T?V=?_P#04?\ [\K0!I;A1N%9O]G7_P#T%'_[\K1_
M9U__ -!1_P#ORM &EN%&X5F_V=?_ /04?_ORM']G7_\ T%'_ ._*T :6X4;A
M6;_9U_\ ]!1_^_*T?V=?_P#04?\ [\K0!I;A1N%9O]G7_P#T%'_[\K1_9U__
M -!1_P#ORM &EN%&X5F_V=?_ /04?_ORM']G7_\ T%'_ ._*T :6X4;A6;_9
MU_\ ]!1_^_*T?V=?_P#04?\ [\K0!I;A1N%9O]G7_P#T%'_[\K1_9U__ -!1
M_P#ORM &EN%&X5F_V=?_ /04?_ORM']G7_\ T%'_ ._*T :6X4;A6;_9U_\
M]!1_^_*T?V=?_P#04?\ [\K0!I;A1N%9O]G7_P#T%'_[\K1_9U__ -!1_P#O
MRM &EN%&X5F_V=?_ /04?_ORM']G7_\ T%'_ ._*T :0.:6L:)[NTUBVMY;L
MW$<J.3E O(^E;- !1110 AK*U#_D/:9_USF_DM:IK*U#_D/:9_USF_DM &J.
ME+2#I2T %%%% !114<PR!SCW'6@"2BOB[X[?##2OAK\2OA;)X%U36Q\2]9\2
M1-,SZG-</=Z>JN;IID9B@C V\A1@D 5%\=/#6D-^TWKNL>// _C'Q+X//A^S
MCL[[0[6\FMK:57E,Q?R&'(4J3P3Q0!]K45\::KJOA;XY_$OX4?#;PWJD]Q\*
M)O#-UKC1V-W-%]M$4R0112/D2 (V[*D@Y&#R*Y/Q-XCUWX&6'QL^'OAO6K^'
M3;6XT-="FGF>:72TU*X6VE5)'RWRDLRY)P30!][T5\CZW\-],_9E^,OPFN?!
MUSJ<-IXFU&71=:M+K4)KE+O=$7CE(D8X=64G(QG/2OK9<G- #J**HOKFGQNR
M->P*ZDJP,@X/H: +U%9_]OZ;_P _UO\ ]_!1_;^F_P#/];_]_!0!H45G_P!O
MZ;_S_6__ '\%']OZ;_S_ %O_ -_!0!H45G_V_IO_ #_6_P#W\%']OZ;_ ,_U
MO_W\% &A16?_ &_IO_/];_\ ?P4?V_IO_/\ 6_\ W\% &A16?_;^F_\ /];_
M /?P4?V_IO\ S_6__?P4 :%%9_\ ;^F_\_UO_P!_!1_;^F_\_P!;_P#?P4 :
M%%9_]OZ;_P _UO\ ]_!1_;^F_P#/];_]_!0!H45G_P!OZ;_S_6__ '\%']OZ
M;_S_ %O_ -_!0!H45G_V_IO_ #_6_P#W\%']OZ;_ ,_UO_W\% &A16?_ &_I
MO_/]!_W\%']OZ;_S_6__ '\% &A16?\ V_IO_/\ 6_\ W\%']OZ;_P _UO\
M]_!0!H45G_V_IO\ S_6__?P4?V_IO_/];_\ ?P4 :%%9_P#;^F_\_P!;_P#?
MP4?V_IO_ #_6_P#W\% &A16?_;^F_P#/];_]_!1_;^F_\_UO_P!_!0!H45G_
M -OZ;_S_ %O_ -_!1_;^F_\ /];_ /?P4 :%%9_]OZ;_ ,_UO_W\%']OZ;_S
M_6__ '\% &A16?\ V_IO_/\ 6_\ W\%']OZ;_P _UO\ ]_!0!H45G_V_IO\
MS_6__?P4?V_IO_/];_\ ?P4 :%%9_P#;^F_\_P!;_P#?P4?V_IO_ #_6_P#W
M\% &A16>?$&FC_E^M_\ OX*/[?TT$C[=!D?]-!0!H45G_P!OZ;_S_6__ '\%
M']OZ;_S_ %O_ -_!0!H45G_V_IO_ #_6_P#W\%']OZ;_ ,_UO_W\% &A16?_
M &_IO_/];_\ ?P4?V_IO_/\ 6_\ W\% &A16?_;^F_\ /];_ /?P4?V_IO\
MS_6__?P4 :%%9_\ ;^FY'^G0<_\ 305<@N([J)98762-NC*<@T 24444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!DW?_ ",6G_\ 7.7^E:U9-W_R,6G_ /7.
M7^E:U !1110 AK*U#_D/:9_USF_DM:IK*U#_ )#VF?\ 7.;^2T :HZ4M(.E+
M0 4444 %17 8Q-LP7P=N[IFI:0@'K0!\>_#OX7_'_P )?$CQ!XPU?1O WB/7
M-8N1&VJW>J7/FVE@&^2VMT$>(U5<G ^\V2<YS7K/Q*7XZIK5S#X'B\&7.BW4
M2JD^LFXCN+-CPY 3(E]0#M]Z]IVB@*!0!\C:;^R+XH^#VD?#G6/AQJVFZCXS
M\+V]Y:7JZZ'BM-2CNYO/G&8P6BQ*25QGC&<XS6HG[*WB/QOX$^),_C/6K*V\
M>>-9;6X\[2HV-IIC6C(]K''N^:15D0.2<9)/2OJ7:,]*-HH ^<?"?PJ^*?CS
MXC^$O$'Q7?PS:6/A'S9M.M/#C32&ZNG39YTK2 ; JYPH'4]:^C54KGG.:7'.
M:6@ KG/!\*&ROLHISJ%UU'_35JZ.N?\ !O\ QY7O_80NO_1K4 ;GD1_W%_[Y
M%'D1_P!Q?^^14E% $?D1_P!Q?^^11Y$?]Q?^^14E% $?D1_W%_[Y%'D1_P!Q
M?^^14E% $?D1_P!Q?^^11Y$?]Q?^^14E% $?D1_W%_[Y%'D1_P!Q?^^14E%
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MY$?]Q?\ OD5)10!'Y$?]Q?\ OD4>1'_<7_OD5)10!'Y$?]Q?^^11Y$?]Q?\
MOD5)10!'Y$?]Q?\ OD4>1'_<7_OD5)10!']GC_YYK_WR*RO#T*&WN,JI_P!(
MDZCWK9K*\/?\>]Q_U\2?SH T?(C_ +B_]\BCR(_[B_\ ?(J2B@"/R(_[B_\
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M1110 4444 %<_P"#?^/*]_["%U_Z-:N@KG_!O_'E>_\ 80NO_1K4 =!1110
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M@D<Y7G&,T =?\++?XLPZE=GXB7GA*ZLC&#;#P[;7$4@DSSO\UV!&!V[UZ66
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M^"C^W]._Y_;?_OX*D9H45G_V_IW_ #^V_P#W\%']OZ=_S^V__?P4 :%%9_\
M;^G?\_MO_P!_!1_;^G?\_MO_ -_!0!H45G_V_IW_ #^V_P#W\%']OZ=_S^V_
M_?P4 7V[5F^'?^08O_723_T,T_\ M[3CC_38/PD%9^@ZU90Z:JR74*-O<[6<
M \L30!T%%9_]OZ=_S^V__?P4?V_IW_/[;_\ ?P4 :%%9_P#;^G?\_MO_ -_!
M1_;^G?\ /[;_ /?P4 :%%9_]OZ=_S^V__?P4?V_IW_/[;_\ ?P4 :%%9_P#;
M^G?\_MO_ -_!1_;^G?\ /[;_ /?P4 :%%9_]OZ=_S^V__?P4?V_IW_/[;_\
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M.FP2RM(B; JY(49Y8Y)KZ)7O3J* "N;\(6T4EG?%HD8G4+KDJ"?]:U=)7/\
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M^(/A+X?V\4OBOQ%I'A^WG;;"VJWD< E('(7>1G'MTH ^<_A3\3_A?I.MR_\
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M7P[=/%INK:Y<3BXLGVVQ9IO+9^/ESD$$XSG- 'U5:_$+PO>S:?%;^(M+GEU
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MP<<UT=% $%G;1V=O%!"@CAB4(B 8 4< "IZ** ,F[_Y&+3_^N<O]*UJR;O\
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M^$DL&(_?'_OVW^%4-$UZSMM/5))2K[W)&P]V)]* .DHK*_X26P_Y['_OAO\
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M7.=!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5E>'O\
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M1*=X 8X;).Z@#[;\Q?6L_P 0>)-+\)Z/=:MK.H6^EZ9:IYD]W=R".*)?5F/
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M(;J#L&:Z6HJW]I*[N[LJE_#CI;0****R-0HHHH **** "BBB@ HHHH ****
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M#<_B#1TT&UEM?.:%E2:V>-Y)B2&DC8.I^8;AM!% 'T-N'K2@@U\V-^T^VB_
MK4/&DNJZ-XGO4NX+"#^S+.YMO(N)I%C$5Q:L99HV1F.1DLRC(4=*[#X%_%?7
M/'7B/Q-HNLVCW0TM();?7H=#O-*M;M9-^8UBN2S!T*')#L"&4\=* /9****
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M_P"?C_R&W^%9VB:Y96\$X>;!,\C#Y&/&?I0!TE%9G_"1Z=_S\?\ D-O\*/\
MA(]._P"?C_R&W^% &G169_PD>G?\_'_D-O\ "C_A(]._Y^/_ "&W^% &G169
M_P )'IW_ #\?^0V_PH_X2/3O^?C_ ,AM_A0!IT5F?\)'IW_/Q_Y#;_"C_A(]
M._Y^/_(;?X4 :=%9G_"1Z=_S\?\ D-O\*O6US'=PK+$V^-N0<8_G0!+1110
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M?R)5=TXKZQHSW3RQ1Y8J.TNXKRWCGAD$L,BAD=3D,#W%3UQG:,\L4>6*?10
MSRQ1Y8I]% #/+%9?AY<VUP#S_I$G\ZUZRO#W_'O<?]?$G\Z -+RQ1Y8I]% #
M/+%'EBGT4 ,\L4>6*?10 SRQ1Y8I]% #/+%. VC%+10 4444 %%%% !1110
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M<44+@HUG]E8K*,=?WA<9SV%?3_QX\.ZKXI^%FOZ9HY8ZA/#^[1#@N 02H/N
M17YLPRZEX5UH/&9],U2RE(R"4DBD&0?H?\:XZV-GA9)1V>Y]3E&14<WHSG.=
MI1V1]7>*/%FCZ)K7BF"]U*WMIU^(^FWAB>0!A#&;9I),==J@')KZ3UOQYH^E
M^%9]=34;66T6!IHI%F7;+@$@ YP<U^8&J:GJ7BS7IKVZ:6]U2^F#,P&7E<X
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M][C_ *^)/YUJ9]JR_#W_ ![W'_7Q)_.@9JT444 %%%% !1110 4444 %%%%
M!1110 445GZSK^G^'=/FOM3NX;"RA_UEQ<.$1><#)-&^@&A17!#X\_#P]?&>
MBC_M]3_&H[GX_?#VWMI9AXOTB7RU+;([M"S8'0<]36GLI_RO[BN5]CT#(H!&
M:^,F_;GU4>*LC1+8Z!YNW9N)FV?WL]/PQ7T9:?'_ .'EQ;Q2GQ?I$.]0VR6[
M167(S@C/!K:KA*U*SE'<J4)1W1Z%29Q7!_\ "^?AW_T.FB?^!J?XUMWFM_\
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M &F-9LM?^ -[?:?<1W=G/>:<\<T3 JP-Y#TKV34M,MM7LIK2\A2XM9E*212
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M&#C/ _R:F4:/LU*$M>JL.$JO.XS6G<[NBBBN<Z0HHHH **** "BBB@ HHHH
M**** "J&KZ)I_B&PDL=2LX+^SDY>"YC#HWU!J_10!Q/_  I?P&/^9/T7_P
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MWPE^,$'Q:A\0/;:+?:3_ &+J<FE3&\DA=99H\"3RVC=@RJV5)SU!':O0!R*
M%HHHH **** "BBB@ HHHH R;O_D8M/\ ^N<O]*UJR;O_ )&+3_\ KG+_ $K6
MH **** $-96H?\A[3/\ KG-_):U365J'_(>TS_KG-_): -4=*6D'2EH 9(,@
M8..:^&OC-\._ WP@^*][XD\9_'GQ5X9EUJQ"V]I!>L;@*LKN0-B'$*[^ 0,'
M/)K[HKQ3XF_#2VU'X@:QKE_J>F6.FZYX8?P_.][($EB;S&9&CSP0?,8,/84
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M=5!=7/Q2\5?!U+/1-7T\>&F;4-5DO]/EMDMF%L8A#EU7>Q9OX<C STKZ3HK
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M+#Y4AA*>9M+0LN=O\2U] T4 ?*%Y;74'PX^.>OW.CZM"WC26[31[+^SIGN9
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M,RDMT !/:MB+P)I*>.I?%WV=VUN2Q73?/>5B%@61I JIG:OS.22!DX&371T
M<+\%/AQ;_"SX8Z%X<B&^:V@#W<Y^]/<N=\TK'N6D9F/UKN0,#%+10 4444 %
M%%% !1110 4444 9-W_R,6G_ /7.7^E:U9-W_P C%I__ %SE_I6M0 4444 (
M:RM0_P"0]IG_ %SF_DM:IK*U#_D/:9_USF_DM &J.E+2#I2T %?%_P"U1+X+
MB_:7\-)XU\%ZO\4+*7P\_D>']%T^;49M/D$Q_P!*:WCZAP=F[J-OY?9LL@B4
MNQ"J 22>@'K7S!\5VUNZ^,6G>-OA[\0_ 6DLFEG2M0@UN8R_:D\PNH.R08"L
M<@@Y^9LY'% &U^S1_P *Y_X2'5?^$)^$'B+X;W)MP9[O6?#<VEI<KNX16D&&
M(.#@5]$5Y!\%O$?C?7-7OT\4^)? ^N6T<(,,7A02^;&V<$R;Y&&W''0<UZ_0
M 4444 %%%% !1110 5Y;\'_ ^J>%M2\173^(FOM'O-5O[B/2VLU3R9)+AG+>
M;N+-U(P0!S7J5<_X-_X\KW_L(77_ *-:@#H**** "BBB@ HHHH **** "BBB
M@ HHHH *Y_QKXZT;X>Z*^K:[=-9V".L;2B)Y,,W3A 3V]*Z"FLBMU&: /GK]
MEGXI^&]6L]2\.VU](^KW&L:EJ$=N;:50T#SLZON*[1E2#USS7T/31&H.0!FG
M4 %%%% "'I7EW[-?_)*K?_L(ZC_Z635ZB>E>7?LU_P#)*K?_ +".H_\ I9-0
M!Z@03WHQQ3J* &&//6C9BGT4"LANVFF+/7'Y5)11N%BA?:'8:FFR\L[>Z3^[
M-$K#]:X?7OV>?A]XB+M=>&K-)&_Y:0+Y;?FM>CT5FZ<'NCIIXBM1_AS:]&SP
M^7]E+1;)_,T'Q%K^@2#[HM[PL@_X":@D^&?Q9\/$?V+\18=4C7I'J]IR?;(S
M7N]0\$__ %ZCV$.FAU_VEB+6FU)>:3_2YX6GBOXW>'B1?>$](\11J>NGW?DL
M1ZX;-3']IF;0UV^)_ /B71 OWI_LIDA]\,.M>WE,]A^-#1@]0#1R36TQ_7*$
M_P"+07R;C_FOP/*M'_:D^'.KNL9UY;"4]5OHVA ^K$;?UKT#2/&6A^((O-TS
M5['4(CT>VN$D4_B":KZKX$\.ZZ&&HZ)87N[J9K=6)_'%<%K7[+GPZU.3SH=$
M_LRX_AET^>2#;[@*0/TJ?WT>S'_L%3;FA]TO\CUD3AAD8/XT\/GZ5X0/V;=3
MT?YO#GQ%\1Z9@Y6.:?SD^F..*E'A_P".'AH9M/$>B>)XUX5-0MO);'NR#.::
MJ36\&'U.C/\ A5X_.Z_2WXGN8;.?6@OCM7A!^+7Q2T!L:S\-6OHUZRZ1<A]W
MT4\U:M?VJO#]NXAU_1M;\/3=Q>63%5^I%/V\.N@GEF)6L$I>DD_R=SVPOV[U
MY7^SH?\ BF/$GK_PDNI_^CS3Y/VE?AXFD3WZ>)+:584W&%<B5O0!3@YKS[]E
M_P",_A[57UCP\LTD&I7>JWFHP).NT21R2%P ?4 \BJ]K"_*GJ9?V?BU"51TV
ME'=V9]*9I:C5@5SG@T\=*U. 6BDS2T %%%% !1129H 6BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#)N_^1BT_P#ZYR_TK6K)N_\ D8M/_P"N<O\
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MYHW1TI:**U.(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)N_\ D8M/_P"N<O\
M2M:LF[_Y&+3_ /KG+_2M:@ HHHH 0UE:A_R'M,_ZYS?R6M4UE:A_R'M,_P"N
M<W\EH U1TI:0=*6@ HHHH **** "BBB@ HHHH *0TM(: ///CUJ&L:7\*/$5
MSH)D744M_E>'[ZKD;BN.X7-?FF+R<7'V@32"?S/-\S>=V_\ OY_O>_6OT(_:
MPOM;T_X17[Z(95+2(ET\/WA"<[OP]:^%/ 7A#4_%OB>S&EZMIVA2V#&[?4=9
MA\VQMU *_OD+*&4YP 2.<5]%EUJ>'E4DKG92:C!MF,C7.M:U"C.]SJ.HW4<*
MEVR\TTCJB#)ZLS%0,^HK[!^'OPQ^*_P=\ K>:7K6G$*CW5SH-["71#R2%D'.
M[ Z<#)/UKYV/[/?Q)E\=:.WASXF?";Q4$U^QU]+17-I,9K:9)5MXA&9&6-O+
M&<'/S'VK]"/A_-XGO_"EN?&UII%MKS%Q/!HLLDMJ%W$+M:0!CE<9R.I-<^)S
M#VB4(1]WS1G.LI:1/S^L?COXHB^+LGC]9(6UN:U33956(;'M%D+K;X[*&9B#
MUR>IZ5]:6WQV\>W4"2P?"34S&PW O>*,CU^Y7PKJ7[8'P=\-_M;ZU%<^$-9D
M\,V0_LZ.R2"/*ZNEVZ/-@R8\HH$QWR.E?JY:.KPH5&%*C QT%8XC$8>;BJ=/
MU"<X-KE1XE_PN#XH2<Q_"F8 ]-]^O'UXKYG_ &FO%?CGQ!K]E#XKTF70;01!
MK?3UE#PL<\L6!^8Y ^G:OT,KY6_;3T/XI?$7PK<^#O GPY76XI6L[I/$1UJU
MM?)9+E9)8A'(P?E(]I8<'?WP:SHXJG1FINFK?/\ 4F-11=[&-^SS\4?B-HO@
M010>#[_Q;I@F;[/=FX",HSRHR#N .>:]07]H'Q9;D_;?A-KT*CO#*)/_ &45
MW?PCUGQ#K7A<R>)?!2^ [V*4Q1Z6M_#>#R@!M??%\HSDC'48KML5%6O3J2<O
M9K[V*4U)WL?,_P 2?VJM3TKPE>/8^$-;T;4F 1+G4K4>1%DXR3GD^@KPS]F_
MXZWGPT\57=K>DS:%K-]/J.H)%!OD-U*=TDXP,Y8\D=,=ABON?QY'X<N/#%[#
MXJFLH=%E41S/?RK'%R<#+,0!STKY@_8:@\&:_=>/KR.XTR]UW3_%.JZ=8".=
M9)%TV*55B<+DY4A@-_0\5O3KX:--QE#4M3ARVL>QP_M6?#@A4FUF6U<_PSV<
MJ_\ LM:-O^TK\.+G;M\46J9YQ(&3^8KT"70=.G4B2PMI >#NB4Y_2LNY^'/A
MB\SY^@:=+DY.ZV0_TKCO0[/[_P#@&5X]C'MOCEX"O"!#XKTQR3C_ (^ .:Y_
MXJ^-OA7KW@B[7Q=)HGBG15*S'3;A8[L2NI^7$9R"<]#VKH;GX'^ ;G_6>$]*
MYR"5ME4_I7GWQ3_93\,^(_"]Q#X9TRTT765*O#,N0K8_A/H#ZU5-8=S7,VD-
M<C=F>/\ ["6E_#/P[J6J65KX;TNP\:2:EJ-Y9:C%81I+]BFG9T@20#< D>U2
MO P!CBOML'-?!?[,WP ;XD27VNW>IR6>F:?>W>E@V4A2<W4$ABDP>RAE;GO7
MT&WP'\6Z/SH/Q.UF ?PQWZK.J^W-;XBEAE4_=3LO,J487]UGN5%>'+HOQQT'
M_4:WH'B&(?PW,1AD;\1P*&^*GQ2T'_D,?#0WR#J^D78D)]\<US^P;^&2?S_S
M(Y>Q[%K6M6'A_3Y+_4[^UTVQB_UES>3+%&F3@99B /SKF? OQ#\,>)(EL='\
M2:1JMZ#)*UM97T4TH3><L51B<<CG&.:\$^-O[15CK?P_U#1-8^'UX7O"L;6G
MB&S#V;88'+ \-@@8&.N*\;_8^\5^ _@SXBDBN_#FC:-YT4R)KEO9!;E0[^88
MW<#)0G&!VVKV%:K!5W!U+;%>RDU<_1.EKRZ+]I7X;ROM'BBT7W8, /Q(JW#^
MT'\.9R<>+]+3']^;:/UKF]C57V']Q'++L>C45P</QP\ 3KNC\7Z2PSC/VE:N
M)\7O!4BAE\4Z40>_VI/\:GV=3^5ARR['845S*_$KPH^W'B/2SNZ8ND_QJRGC
M?P](VU=<TYF]!=(3_.ER3["L^QNT5E1^)M(E.$U2S<]<+.A_K5B+6+&928[R
M!P.NV1?\:FS6Z"Q=HJ%+F*1=R2JP]0P-.WIC.X?G2N*S)*2FAE/0@_C02 ,G
M^=*XQ]%,R/:E#"G<0ZBF[A2[A1<0M%-)!I,BBXQ]>4_LZ?\ (L>)/^QEU/\
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MPOXV^&&H:9IUQH>KW,TL+"RUS2EO[:0+("VZ&3"DX!PQZ'!YQ7EO[/6O^&_
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M "BBB@ HHHH \@_:/^*VK_#C1?#FF^&UA_X2CQ5K$.B:9-=)OA@D<,SRNO\
M$$1'8#N0*YCX>^-_B)X&^.]K\-O'^O6?B^TUK1Y-5TG7(-/2QE$D+A9X'C0E
M2 "C!AS\^#4_[6_@[6]3T_P+XPT'2YM<N_!/B*#6Y=,M0#/<P!'CE$8/5@LA
M8#(SC%87P]U75_CM^T?I7CZ+PIKGACPGX8T2XT^WE\16?V.XN[NY<&0+$3NV
M(L:?,< EN* /IRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:QP
MOI3J9+_JVYQQ0!\V?$#XM?$_P]^T9\/-",&FZ1X$US5;G3PAVSWE\L=L9/,8
MXQ$N[H!R0.>N*]0^*&A?$/7Y;=/!OC'3_"%I'$S33SZ6M[-))_" '(54[D\G
MBOGG]I'XM8^/?POEM?!/CC4K7P=K%W-J5U8>'YYH61[9D4Q.HQ)\Q'(K>_:L
M^,WB-=.\->%?#F@>+K/2?$\'G:OXAT?1)KNXT^S_ (H$C4?)/)RF6^X"3R<8
M /1OV2OBYKOQG^$%MKOB2*V35X;RZT^::S7;#<F&5H_-0=@VW.!Q7M%>7_L\
MZIX;O/ASI]AX3\.:SX7T/2O]"M['6]/>RF 4?>V/RP/=NYS7J% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?-/[3?B;XM_"KPCXK^(NC^,-&M
M]#T%!=0^'9=*5_MD2[=R23LVY78EL;!C@>M=I\2?C7>>%OA+HNK6-HC>,?$<
M<-MH^DN<F2\F3(!!YV)RS'LJDUX-\</BG<>-OC;+X9\6^#O&Y^&/AB>.X-GI
M/AV>[3Q#>+AE:211@01GD(/OL.> !7I_CWX.^+?BWXO\*_$7P?X[?P.;/27M
M[73-7\.)=O 93N>38\B^5(5 0\$@9'>@#IOV4/'?BCX@?"B2^\8:A#JFO6FL
M:CIDUW!;+;I(+>Y>($(O X2O9J^9/V%_ 7CGP/X&\21^,=;FU!9]?U%[:SN-
M+6S>,_:YB\^0<L)B0X!& #@<5]-T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &3=_\ (Q:?_P!<Y?Z5K5DW?_(Q:?\ ]<Y?
MZ5K4 %%%% "&LK4/^0]IG_7.;^2UJFLK4/\ D/:9_P!<YOY+0!JCI2T@Z4M
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MBA\I3'+NP%*[<A@<XK?^+?P1TGXE?#?5O"UIY7A^6\,<L-]8P*C0SQL'BDP
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %(0#U%+10 FT4FP>E.HH ;M'I0$ [4ZB@!I0'M2[1Z4M% #?+
M4G..:7:*6B@!,"C:.>.M+10 @ %!&:6B@!-H]*-H]*6B@!-HSTH*@]12T4 )
MM [4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[X'^-:F*,4 9?]MR?] R]_[X'^-']MR?] R]_P"^!_C6IBC% &7_ &W)_P!
MR]_[X'^-']MR?] R]_[X'^-:F*,4 9?]MR?] R]_[X'^-']MR?\ 0,O?^^!_
MC6IBC% &7_;<G_0,O?\ O@?XT?VW)_T#+W_O@?XUJ8HQ0!E_VW)_T#+W_O@?
MXT?VW)_T#+W_ +X'^-:F*,4 9?\ ;<G_ $#+W_O@?XT?VW)_T#+W_O@?XUJ8
MHQ0!E_VW)_T#+W_O@?XT?VW)_P! R]_[X'^-:F*,4 9?]MR?] R]_P"^!_C1
M_;<G_0,O?^^!_C6IBC% &7_;<G_0,O?^^!_C1_;<G_0,O?\ O@?XUJ8HQ0!E
M_P!MR?\ 0,O?^^!_C1_;<G_0,O?^^!_C6IBC% &7_;<G_0,O?^^!_C1_;<G_
M $#+W_O@?XUJ8HQ0!E_VW)_T#+W_ +X'^-']MR?] R]_[X'^-:F*,4 9?]MR
M?] R]_[X'^-']MR?] R]_P"^!_C6IBC% &7_ &W)_P! R]_[X'^-']MR?] R
M]_[X'^-:F*,4 9?]MR?] R]_[X'^-']MR?\ 0,O?^^!_C6IBC% &7_;<G_0,
MO?\ O@?XT?VW)_T#+W_O@?XUJ8HQ0!E_VW)_T#+W_O@?XT?VW)_T#+W_ +X'
M^-:F*,4 9?\ ;<G_ $#+W_O@?XT?VW)_T#+W_O@?XUJ8HQ0!E_VW)_T#+W_O
M@?XT?VW)_P! R]_[X'^-:F*,4 9?]MR?] R]_P"^!_C1_;<G_0,O?^^!_C6I
MBC% &7_;<G_0,O?^^!_C1_;<G_0,O?\ O@?XUJ8HQ0!E_P!MR?\ 0,O?^^!_
MC1_;<G_0,O?^^!_C6IBC% &7_;<G_0,O?^^!_C1_;<G_ $#+W_O@?XUJ8HQ0
M!E_VW)_T#+W_ +X'^-']MR?] R]_[X'^-:F*,4 9?]MR?] R]_[X'^-']MR?
M] R]_P"^!_C6IBC% &7_ &W)_P! R]_[X'^-']MR?] R]_[X'^-:F*,4 9?]
MMR?] R]_[X'^-']MR?\ 0,O?^^!_C6IBC% &7_;<G_0,O?\ O@?XT?VW)_T#
M+W_O@?XUJ8HQ0!E_VW)_T#+W_O@?XT?VW)_T#+W_ +X'^-:F*,4 9?\ ;<G_
M $#+W_O@?XT?VW)_T#+W_O@?XUJ8HQ0!E_VW)_T#+W_O@?XT?VW)_P! R]_[
MX'^-:F*,4 9?]MR?] R]_P"^!_C1_;<G_0,O?^^!_C6IBC% &7_;<G_0,O?^
M^!_C1_;<G_0,O?\ O@?XUJ8HQ0!E_P!MR?\ 0,O?^^!_C1_;<G_0,O?^^!_C
M6IBC% &7_;<G_0,O?^^!_C1_;<G_ $#+W_O@?XUJ8HQ0!E_VW)_T#+W_ +X'
M^-']MR?] R]_[X'^-:F*,4 9?]MR?] R]_[X'^-']MR?] R]_P"^!_C6IBC%
M &7_ &W)_P! R]_[X'^-']MR?] R]_[X'^-:F*,4 9?]MR?] R]_[X'^-']M
MR?\ 0,O?^^!_C6IBC% &7_;<G_0,O?\ O@?XT?VW)_T#+W_O@?XUJ8HQ0!B1
=RS7VMVDOV2>".-'#-*H Y'UK<I,4M !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tmb-20221231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (# R4# 2(  A$! Q$!_\0
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M?] Q/_ D?X4?VCJ7_0,3_P "1_A0!JT5E?VCJ7_0,3_P)'^%']HZE_T#$_\
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M*;YT?]]?SIP.: #%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH
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M&=-_Y]$_6C_A&=-_Y]$_6M2B@#+_ .$9TW_GT3]:/^$9TW_GT3]:U** ,O\
MX1G3?^?1/UH_X1G3?^?1/UK4HH R_P#A&=-_Y]$_6C_A&=-_Y]$_6M2B@#+_
M .$9TW_GT3]:/^$9TW_GT3]:U** ,O\ X1G3?^?1/UH_X1G3?^?1/UK4HH R
M_P#A&=-_Y]$_6C_A&=-_Y]$_6M2B@#+_ .$9TW_GT3]:/^$9TW_GT3]:U**
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MXCX1ZY?>)O!=AJ6I:_H'BB[D:16U3PVI6SDPQ'R NY&, 'YCR.U=O0 4444
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MI:'^W#JN!]K_ +0^T[@WF_>SN^7[W3CVKU'X':-I_P 3?BM\;+SQAI]MJU[
MVGZ7&E_&LODVIL4D*IN' +R.>V3]* /IGQ!XZ\-^$]!&MZWK^F:/HQVD:A?W
MD<-N=WW?WC$+SVYYJ;PQXMT/QMH\6K>'M8L-=TN4D1WNFW*7$+XZX="0?SKX
M7_9XM8?%7B'X$^'=;1=5T#2=.\2SZ=!>$2QR/;WBV\!(;.XK"YP3ZY'2O=?@
M'IT'AO\ :'^.FAZ3#'::$LVDWZ6MN-L45S-;/YNU1PNX1QL<=2<]Z /HFN<\
M3_\ (5\/?]?I_P#1;5T0KFO%TODZAH#A'DQ>GY8QDG]VU '2CJ:6LP:R_P#T
M#KW_ +]C_&E_MEO^@=>_]^Q_C0!I45F_VRW_ $#KW_OV/\:3^VF_Z!U[_P!^
MQ_C0!IT5EC6V/_,.O/\ O@?XT?VT_;3KO_OA?\: 6IJ45E_VV_.=/N_IM7_&
MC^VW_P"@=>?]\+_C3LP-2BLQ=:=A_P @^\_[X7_&D_MMLC_B7W9^B+_C2%<U
M**RQK;$9.G7G_?"_XTO]M-_T#KW_ +]C_&@9IT5F#6F/_,.O?^_8_P :7^V6
M_P"@=>_]^Q_C0!I45F_VRW_0.O?^_8_QH_MEO^@=>_\ ?L?XT :5%9O]LM_T
M#KW_ +]C_&C^V6_Z!U[_ -^Q_C0!I45F_P!LM_T#KW_OV/\ &C^V6_Z!U[_W
M['^- &E16;_;+?\ 0.O?^_8_QH_MEO\ H'7O_?L?XT :5%9O]LM_T#KW_OV/
M\:/[9;_H'7O_ '['^- &E16;_;+?] Z]_P"_8_QH_MEO^@=>_P#?L?XT :5%
M9O\ ;+?] Z]_[]C_ !H_MEO^@=>_]^Q_C0!'I?\ R&=7_P!^/_T 5K5S6GZH
MR:KJ3BQNG+M'\H097Y._-:?]LM_T#KW_ +]C_&@#2HK-_MEO^@=>_P#?L?XT
M?VRW_0.O?^_8_P : -*BLLZV^?\ D'W?XH/\:#K3C_F'W8'N@_QH#R1J45EM
MKI7K878]?E7C_P >K'U#XG:!I,HBOKZWLI#_  7%U"C?D7J7**W948REI%-G
M645QD'Q;\,W4JQP:K9SR-P$CO(68_0!ZW4\0K(H*6=RX/=0I_P#9J%.+T3'*
MG.'Q)FM169_;;9(_L^\S[(O^-']MM_T#KS_OA?\ &J(\S3HK+_MMO^@?>8_W
M!_C3O[9;_H'7O_?L?XT :5%9O]LM_P! Z]_[]C_&C^V6_P"@=>_]^Q_C0!I4
M5F_VRW_0.O?^_8_QH_MEO^@=>_\ ?L?XT :5%9O]LM_T#KW_ +]C_&C^V6_Z
M!U[_ -^Q_C0!I45F_P!LM_T#KW_OV/\ &C^V6_Z!U[_W['^- &E16;_;+?\
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MRI=E&/\ D?-:_L[_ !*TY?\ B7?%6\..GGJY_P :AD\-_M >!F$UGKUAXOA
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M>'XK'R7CB\/^'+21HD<[?GDN9CO<KM.-J(/G.0<#'J= !1110 4444 %%%%
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M=]I+Y_HQGA_Q3I/BO3X[_1]0@U"SD&5E@?</Q]#[&M2/[S?X5\V>(_V:M:\
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M3^)L &FWXM[]?OV%U^[F4^P/WOPKT3>,]>*Z8R4U>+/'K4:M"?)5BT_,9?\
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MO>&-:_9R\4:;?:]916;ZOX@%Z\5T@>"WDOK@>8<GY1M;()&.E<>D[?!SQ/\
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MY;/O@GN(+=O.*,.&V^8BDCNN.U 'T/UKP/\ ;)O)+'X3.(R=T]TD/'!^;/\
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M*4\-.Z?1[KUZ/Y&U1116YYX4444 %%%% !1110 4444 %%%% !1110 4444
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M'_"P/#'_ $,6E?\ @;%_\54\\>YI[*I_*_N-^BN?_P"%@>&/^ABTK_P-B_\
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MQ+X,N+^PU39&L?F30LQB(0  ;U,9 ]Z /HH$,,@Y%('!Q@Y^E<9\&;SQ'?\
MPM\,WGBV99_$=W9)<WK)&L:J[C=M"J !M! _"O,/B%X^^)/AO]H#X>Z<9M+T
M[P+K6L3:<+6*,S7=XJV,TWF.Y&(P'C "KDGJ3VH ^@BP7J:-P/>OGC6?$WQ
M^+'Q>\<>%?!GB^+P/IO@V*TBEN?[,AO9+V\GA\[#>;PL:(8_N\DL>1BJ?ASX
MO?$GXA_LWV7B/0+71K#Q=&UY:ZO<W>\V]I);&5)9(XA_K"7C&%) &[KQB@#Z
M4# ]Z6O,_P!FOQCJWQ"^ O@/Q+KUPEUK.J:1;W5W,D8C5Y&0%B%' Z]!7IE
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M_KFW\JCTC_D%VG_7)/\ T$5)?_\ 'C<?]<V_E4>D?\@NT_ZY)_Z"* +E%%%
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M: '44TMB@-DD8QB@!U<YXG_Y"OA[_K]/_HMJZ.N<\3_\A7P]_P!?I_\ 1;4
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M.?\ GWU#_P ##_A1_P ,8_#G_GWU#_P,/^%>[8]Z,>];_6J_\[+]I+N>$_\
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MWU;P'I&@ZC-X'^)5U9:OJNJ6T+-!9- P%TKN!M4RJL>,GDYK[0*9[_I1Y?\
MD"@#AM<^'^MZEXALK_3/'.KZ#I=LD:_V+96]JUO(%/0L\3. 1@<,.G%>%?M&
M_%F&Q^,_PQBB\)^--3A\+:]-=ZE=:9X9O+JW$3V$T8*2)&5D^:5!\O3\*^L
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M[9> K"'4/#.D^$+I6DW:1H<ZS6L(W'&UE51D]3QUKNJ "BBB@ HHHH ****
M"N/\=Z-9:W=^'+>^MTN85U%9 CC(W*C%3^!&:["N9\3L!J?AXG@?;2?_ "&U
M"T=PO;8K_$ZRUG4? NKV?A[;_:TT!CAW/M'/!Y[<9K+^"GPZ7X8^ ;#2'P;\
MYFNY!SNE;D\^W3\*Z'PIXXT3QG)J2:/?1WWV";R+C8#A']/?IVKH,5O*<XTW
M0>BO<YU"$ZGMEVL+1116!T!1110 4444 %%%% !1110 4444 %%%% !1110
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MG1ESP>OW_F95*<:JY9'B7@?X+^-O#/B:SU'4_B/?:O8Q,3)92*^V0'H.6/\
M*O8YE9XF1&*,RD!QU'O5K%&!Z5=6M.O+FJ:OT2_(5.E"DN6"T]6?/5Y\ /B'
M=7D\T?Q6U"))'+! KC )Z<.!7HOPD\">(/ MA?6^O>*)O$S3R!X7F0J80,Y
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MX@:RZ[T*[@95((SU!KZ#IJ1I'G8JKD[CM&,GUIU !1110!DZE_R'-)_WI/\
MT UK5DZE_P AS2?]Z3_T UK4 %%%% "'I62W_(T)_P!>G_L]:QZ5DM_R-"?]
M>G_L] &O1110 QSC'&:^"K<_#'_A:'Q)'Q6\,^+/$^M?VW*;+5$TW5)[9[/
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M!R3GK73_  A^#NF?!_1[ZVM+_4-;U+4KC[9J6LZO-YUW?3;0N^1@ .%55 4
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MPRU8C]YC?>D^FMEY'ENE?LU>"M/P9;2?4&];J<G_ -!Q73V?PG\(6( B\/6
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MW]BU31-3"">TE*AER4)5E92"&!P: /1JYSQ-SJGA[KG[:?\ T6U='7.>)_\
MD*^'O^OT_P#HMJ .B%+2"EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** ,G3/^0SJW^]'_Z *UJR=,.-9U?_
M 'X__0!6M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 5[__ (\;C_KFW\JCTG_D&6O_ %R3_P!!%27_ /QX
MW'_7-OY5'I'_ "#+4=_*3^0H N4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!DZB/\ B=Z3_O2?^@&M:LG4O^0YI/\
MO2?^@&M:@ HHHH 0]*R6_P"1H3_KT_\ 9ZUCTK);_D:$_P"O3_V>@#7HHHH
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M'=9_Z&:X_P# :/\ PKI** .;_P"$=UG_ *&:X_\  :/_  H_X1W6?^AFN/\
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M@5[_ $ %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 (3@5Y5\3?VD?!WPN\8:#X8U*6]O-<U>]M;)+33K<RFW-Q*(HI
M)F)"QH6/<Y.#@'!KU1^5]/>OGC]KG4-+L/#_ (+$MQ:6]XWC?P\\BO(BR%%O
M8^3ST S["@#U'XB_$L?#Z"TV>'/$'BB]N=QCL?#UD+B3"X#%BS(B@;A]YAGM
M3/A!\7-%^,WAF36M%2\MA;74MA>66H0^3<VES$=LD,J9(#*?0D>AK'^-?QWT
M7X1>$[:_W1:KK.K2+9Z'I4,R[M0N6Z*&Z!!]YG/ 4'G. :7[,G@27P'X%NEU
M'5++6/$VLZC<:WKESI\@:#[;<-O=(\=%7@#/) S0![!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/4KU-.L[BZD5
MVBAC,CB)2[8 R< <D\=!5RJUY<Q6<,MQ<2)#!$I=Y'. J@$DDGH .<T >1>'
M/VGM"UCQ[I/A34O#7BKPK>ZR)#I5SX@TY;>"^*+N98R)&8-MYPZJ:O\ QQ_:
M0\)? 9M#BU\:A>7>KW @@M-+A665%+!3+(&=0L89E!.>I& :\P\+^);+]I7X
MWZ)XOM[VSB\">#9KA-$9IE$VL7SCRWF5201$HR%X^8DFO!/VB==\?1Z1\0=?
M\5_"77Q>WNKV=EI^K)<6C6MKIL-U&8HT'F%P96&]OEY9ESP* /T?3E1FG5F>
M&=4NM;\/V%_>Z7/HMW<1+)+I]TR-+;L>J,4)4D>Q(K3H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)U+_ )#FD_[TG_H!
MK6K)U+_D.:3_ +TG_H!K6H **** $/2LEO\ D:$_Z]/_ &>M8]*R6_Y&A/\
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M.IQ0 M%)N'J*,T +12!@3UHR <9YH 6BBDR* %HI,TM !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ_O2_P#?IO\ "C_A*;'^]+_WZ;_"MBB@#'_X2FQ_O2_]^F_PH_X2FQ_O2_\
M?IO\*V** ,?_ (2FQ_O2_P#?IO\ "C_A*;'^]+_WZ;_"MBB@#'_X2FQ_O2_]
M^F_PH_X2FQ_O2_\ ?IO\*V** ,?_ (2FQ_O2_P#?IO\ "C_A*;'^]+_WZ;_"
MMBB@#'_X2FQ_O2_]^F_PH_X2FQ_O2_\ ?IO\*V** ,?_ (2FQ_O2_P#?IO\
M"C_A*;'^]+_WZ;_"MBB@#'_X2FQ_O2_]^F_PH_X2FQ_O2_\ ?IO\*V** ,?_
M (2FQ_O2_P#?IO\ "C_A*;'^]+_WZ;_"MBB@#'_X2FQ_O2_]^F_PH_X2FQ_O
M2_\ ?IO\*V** ,?_ (2FQ_O2_P#?IO\ "C_A*;'^]+_WZ;_"MBB@#'_X2FQ_
MO2_]^F_PH_X2FQ_O2_\ ?IO\*V** ,?_ (2FQ_O2_P#?IO\ "C_A*;'^]+_W
MZ;_"MBB@#'_X2FQ_O2_]^F_PH_X2FQ_O2_\ ?IO\*V** ,?_ (2FQ_O2_P#?
MIO\ "C_A*;'^]+_WZ;_"MBB@#'_X2FQ_O2_]^F_PH_X2FQ_O2_\ ?IO\*V**
M ,?_ (2FQ_O2_P#?IO\ "C_A*;'^]+_WZ;_"MBB@#'_X2FQ_O2_]^F_PH_X2
MFQ_O2_\ ?IO\*V** ,?_ (2FQ_O2_P#?IO\ "C_A*;'^]+_WZ;_"MBB@#'_X
M2FQ_O2_]^F_PH_X2FQ_O2_\ ?IO\*V** ,?_ (2FQ_O2_P#?IO\ "C_A*;'^
M]+_WZ;_"MBB@#'_X2FQ_O2_]^F_PH_X2FQ_O2_\ ?IO\*V** ,?_ (2FQ_O2
M_P#?IO\ "C_A*;'^]+_WZ;_"MBB@#'_X2FQ_O2_]^F_PH_X2FQ_O2_\ ?IO\
M*V** ,?_ (2FQ_O2_P#?IO\ "C_A*;'^]+_WZ;_"MBB@#'_X2FQ_O2_]^F_P
MH_X2FQ_O2_\ ?IO\*V** ,?_ (2FQ_O2_P#?IO\ "C_A*;'^]+_WZ;_"MBB@
M#'_X2FQ_O2_]^F_PH_X2FQ_O2_\ ?IO\*V** ,?_ (2FQ_O2_P#?IO\ "C_A
M*;'^]+_WZ;_"MBB@#'_X2FQ_O2_]^F_PH_X2FQ_O2_\ ?IO\*V** ,?_ (2F
MQ_O2_P#?IO\ "C_A*;'^]+_WZ;_"MBB@#'_X2FQ_O2_]^F_PH_X2FQ_O2_\
M?IO\*V** .>.I0ZGK6FF 2,(S(6+1D  H1WKH:3%+0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tmb-20221231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (  G,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH ***8\@CQDCDX&3[4 /HI <BJ\U_!;O&LLB1
MM(P1 [ %F/0#U- KEFBD#9]J6@8444A.* %HI,^U!.!0 M%1-<1HP5G56/0%
MJ;]K0D %2?\ >H GHHHH ***3- "T4@.:6@ HHHH **** "F2C*'Z&GTR3[I
M^AH$SRS]FWQ'J7BWX0Z5JNK7DE_?RW%XCSRXW$)=2HH. .BJ!T[5ZHM>,_LC
MC_BQ.C?]?FH?^EL]>S+6U96J22[G)A&W0@WV0ZBBBL3L"BF.^SMFDCF$B@KT
M- $E%0)=(\IC!!<=5SR*FH 6BBB@ HHHH *\N^*/B+4=)^)'POL;.[DM[/4M
M2NHKR),8F1;61U4\=F /&.E>HUX[\8O^2L_!O_L+7G_I')6M)7D<>*;5*Z[Q
M_-'KD? '&.G%2TQ>E/'2L4=:%HHHIC"BJ[7:HP5MJLQP 6Z_Y_QIS7*J.>GK
MGC_/!H FHJ))UD4,A# ],&I <B@!:*0G%&?:@!:**3- "UYK9:Y?R?'W5]&-
MS(=,B\-VMVEMQL$K74ZL_P!2%4?A7I5>4:>/^,FM<_[%.R_]++FM8)6E?L<F
M(;3A;O\ HSU5:=35IU9'6%%%-=]@'&<T .HJ#[6GF;-RA^NW<,D>H%)+>) ,
MR$("<98X'Y]J5P+%%1QRB3D# ZU)3 **** "BD)I: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 0]*^8OVH_&'B71[Z'Q7H-S*=(^'-U:ZGJEA
M"/\ C_$N1+&2/^><#[\=_-!/W17T7XCU0Z-HEY>K:W%[)#&62VM(S)+*W95
M[DX&>@ZG@5Y+X,^$&C^)? ,MQXHL]7FU+7$DNM:M+FZNH=TTRYDA,(8*RH"(
MEPI&V->O6KC;=F<[[6/1KWQ]HVF^!7\73Z@BZ EF+\W8Y!AV[@P]<CM7S[\3
MO%M[XJ^)WP2N[[PA?Z")O$'FV=U>-$S-$;6<[)%1BT3\@[#D>^00,#PG\/\
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MQV\L^)_A[6?$_P (+-](^&TGAN>\\0:9>)HMC9QBYC@AG5Y)IQ'\JM@'"Y)
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M)X &<TQC#'QC^E(R 8[?2O.M7_:(^'^AVM_<7OB>T@BL;MK&Y^5V,$RA2P<
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M&GZGX^\/_#I](TK7O$*07U\LGDM?/B2X9$+R-P-HP 6(& ,<4^5V1/,KM';
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MX+_\&UU_\8KOJ*.>/\B_'_,/J\O^?DOP_P C@?\ A*OC+_T+O@O_ ,&UU_\
M&*/^$J^,O_0N^"__  ;77_QBN^HHYX_R+\?\P^KR_P"?DOP_R.!_X2KXR_\
M0N^"_P#P;77_ ,8H_P"$J^,O_0N^"_\ P;77_P 8KOJ*.>/\B_'_ ##ZO+_G
MY+\/\C@?^$J^,O\ T+O@O_P;77_QBC_A*OC+_P!"[X+_ /!M=?\ QBN^HHYX
M_P B_'_,/J\O^?DOP_R. _X2GXR?]"[X,_\ !M=?_&*7_A*OC+_T+O@O_P &
MUU_\8KOJ*.>/\B_'_,/J\O\ GY+\/\C@?^$J^,O_ $+O@O\ \&UU_P#&*/\
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M_D7X_P"9U_5Y?\_)?A_D<#_PE7QE_P"A=\%_^#:Z_P#C%!\4_&0_\R[X+_\
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MXT;Q*;<V\5UJEOX1:T@;3Y;"&:1?+E<Q^?YK1IDNLH 8X"$ FCR ^L\YI:\
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M6X&,_C7;T4TVM41."J+EEL>(C]G35#_S5GQM_P"!,'_QJE_X9SU/_HK7C?\
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MXW_\"8/_ (U7M>Y32T?6*G?\%_D'U*AV_%_YGB?_  SGJ?\ T5KQO_X$P?\
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M?6*G?\%_D'U*AV_%GB?_  SGJ?\ T5KQO_X$P?\ QJC_ (9SU/\ Z*UXW_\
M F#_ .-5[91BCZQ4[_@O\@^I4.WXL\3_ .&<]3_Z*UXW_P# F#_XU1_PSGJ?
M_16O&_\ X$P?_&J]LHH^L5._X+_(/J5#M^+/$_\ AG/4_P#HK7C?_P "8/\
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M7Q9X[UO0/$?[)OBF32-!O?"=W8^(88K_ $2Z;#6-T;F'S8U*G!0YR.WS'@#
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M,Q^;W%1_%+X/^$_C)HD.E>+=&AU>U@E\Z$N2DD+_ -Y'4AE/T-7?^%H>#_\
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M)->?3_LP?#6?XC-XX?PK9'Q"9A<FX.[89?\ GH8\["^>=V.OOS78#XH>#O\
MH:]$_P#!C#_\51_PM#P?_P!#7HG_ (,8?_BJ%&HM4F#J46K.2^\I>(OA)X=\
M1^)8/$$MI+::W% ;7^T=/N9+6=X2<^6[QLI9<\X.<=L4GB'X0^%O$O@<>#[W
M1H7\/+L,=I&QC\ME;<KJP.X.&YW YSG.<\WO^%G^#_\ H;-$_P#!C#_\51_P
ML_P?_P!#7HG_ (,8?_BJ.6IV8>TH]U]Z.6?X):+X7%YK7AG2(G\51Z5)I]K<
M7EW*RS<NZB8LQ+Y=LEFR3Z\5\_\ A']G'3S;06L'PG\1>$O$T<8WZK!XB6*S
M2XQS,K13DD;LMA8\\XP*^J?^%G^#_P#H:]$_\&,/_P 52#XG>#@<_P#"5Z)G
M_L(P_P#Q56O:+HR)2HR^TOO*.F?"[2['Q')XC?[3+XBN+*.PN=1%U(IFB3)
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M[_D<>+JTW2TDMX]?[R/>UJ0=*Y<?$OPBAPWBG15/OJ,/_P 53O\ A:'@X?\
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M%H>#O^AKT3_P8P__ !5')+L+VU/^9?>=/17,?\+0\'?]#7HG_@QA_P#BJ/\
MA:'@[_H:]$_\&,/_ ,51R2[![:G_ #+[SIZ*YC_A:'@[_H:]$_\ !C#_ /%4
M?\+0\'?]#7HG_@QA_P#BJ.2?8/;4_P"9?>=/17,?\+0\'?\ 0UZ)_P"#&'_X
MJC_A:'@[_H:]$_\ !C#_ /%4<DNP>VI_S+[SIZ*YC_A:'@[_ *&O1/\ P8P_
M_%4?\+0\'?\ 0UZ)_P"#&'_XJCDEV#VU/^9?>=/17,?\+0\'X./%.BMCTU&'
M_P"*K?LKZ'4+6.YMY(YX)5#QRQN&5U/0@C@BI:<=T7&<9?"[EBBBBD6%%%%
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M_0GZ-_X!I_A7:44>TJ?S,/84OY5]R_R.+_X4MX"_Z$_1O_ -/\*/^%+> O\
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M^%'_  I;P%_T)^C?^ :?X5VE%'M*G\S#V%+^5?<O\CB_^%+> O\ H3]&_P#
M-/\ "O-?B9\*_!UA\1OAA;6WAG2X+>\U*ZCN(H[5 LJBUD8!ACD @'\*]^KR
MKXK_ /)4/A)_V%;O_P!(Y*WHU*G/\3Z_D<N*HTE2^!;KHNZ\CH!\%? 2\#P?
MHH'H+)/\*7_A2W@+_H3]&_\  -/\*[2BL/:3WYF=/U>BGI!?<O\ (XO_ (4M
MX"_Z$_1O_ -/\*/^%+> O^A/T;_P#3_"NTHH]I4_F8_84OY5]R_R.+_X4MX"
M_P"A/T;_ , T_P */^%+> O^A/T;_P  T_PKM**/:5/YF'L*7\J^Y?Y'%_\
M"EO 7_0GZ-_X!I_A1_PI;P%_T)^C?^ :?X5VE%'M*G\S#V%+^5?<O\CB_P#A
M2W@+_H3]&_\  -/\*/\ A2W@+_H3]&_\ T_PKM**/:5/YF'L*7\J^Y?Y'%_\
M*6\!?]"?HW_@&G^%'_"EO 7_ $*&C?\ @&G^%=I11[2I_,P]A2_E7W+_ ".+
M_P"%+^ Q_P RAHW_ (!I_A7GUI\*/!K?'S4[!O#&E&Q3PU:SK;_94V+(UU<
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M ((I/\:/^%VP_P#0E>-?_!%)_C1[&IV#ZW0_F/2*\J^*_P#R5#X2?]A6[_\
M2.2KO_"[8?\ H2O&O_@BD_QKSGXD?%>&_P#B%\-+G_A%O%5N+/4;F3RKC2'2
M2;-JZXC!/S$9R1Z"MZ%&?.M._P"1R8K%473LI=5^:/HZBO-Q\;(3_P R3XV_
M\$4G^-'_  NV'_H2O&O_ ((I/\:P5&=MCK^MT/YCTBBO-_\ A=L/_0E>-?\
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M*-I]!4FX"C<*+ 1[3Z"C:?05(&!I:+ 1;3Z"C:?05+118"+:?04;3Z"I:*+
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MC^UOC3_SQ\#?]_[S_P"(I>Q?=!]:7\DON/:LT9]Z\5_M;XT_\\? W_?^\_\
MB*/[6^-/_/'P-_W_ +S_ .(H]B^Z#ZVOY)?<>U9HS[UXK_:WQI_YX^!O^_\
M>?\ Q%']K?&G_GCX'_[_ -Y_\11[%]T'UI?R2^X]JS1FO%?[6^-/_/'P/_W_
M +S_ .(H_M;XT_\ /'P/_P!_[S_XBCV+[H/K2_DE]Q[5GWHS7BO]K?&G_GCX
M&_[_ -Y_\11_:WQI_P">/@;_ +_WG_Q%'L7W0?6E_++[CVK-)FO%O[6^-/\
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M;7\DON/:L^]>4V!'_#36N9Z?\(G9Y_\  RYK+_M;XT_\\? __?\ O/\ XBN
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M$/VD:BNG@;H<9\P6^\3;2.?N9QGBF2_M"Z"GB_X<Z%%8WTQ\=V,VHZ7>A$$
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M,6J:SJ-YKFH6L',-M-=3/*T*8X*H&"<<';Z&L#XD_ +QIXT\3:/JFB_%J_\
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MJ/SKS'_ADG3/^B@^/O\ P=+_ /&J/^&2=,_Z*#X^_P#!TO\ \:HY*7\_X?\
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MGV8*#9D#'!)]:VIQII2M/IV_X)QXBI7;IWI?:_F79GT9D>H_.C(]1^=>8_\
M#)>F$_\ )0?'W_@Z7_XU1_PR3IG_ $4'Q]_X.E_^-5CRTOY_P_X)VNKB+_PO
M_)D>G9'J/SHR/4?G7F/_  R3IG_10?'W_@Y7_P"-4?\ #).F?]%!\??^#E?_
M (U1RTOY_P /^"+VN(_Y]?\ DR/3LCU'YT9'J/SKS'_ADG3/^B@^/O\ P<K_
M /&J/^&2=,_Z*#X^_P#!RO\ \:HY*7\_X?\ !#VN(_Y]?^3(].(4]<&C(]1^
M=>8_\,DZ9_T4'Q]_X.5_^-4?\,DZ9_T4'Q]_X.5_^-4<M+^?\/\ @A[7$?\
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M *'[P_\ ^#"+_&C_ (:,^&'_ $/WA_\ \&$7^-0?\*T\(?\ 0K:-_P" ,?\
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MW_@#'_A1_P *T\(?]"MHW_@#'_A1:AVE^ 7QG>/XD_\ PT9\,/\ H?\ P_\
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M'_P__P"#"/\ QH_X:,^&'_0_>'__  81_P"-0?\ "M/"'_0K:-_X Q_X4?\
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MM4^#NE7-[X?TR[N'NKT-+-:([$"[F !)&3@ "O4?^%9^$/\ H5M&_P# &/\
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M-_X Q_X46H=I?@%\9WC^)/\ \-&?##_H?_#_ /X,(_\ &C_AHSX8?]#]X?\
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M Q_X46H=I?@%\9WC^)/_ ,-&?##_ *'[P_\ ^#"+_&C_ (:+^&'_ $/WA_\
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MG:@ HHHH **** "O+/BK_P E0^$G_85N_P#TCDKU.O+/BK_R5#X2?]A6[_\
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MC,****8!7F7CFZL)OBWX*L+L>9%+::E#*C1.R8>.(!6(&!NY !/->FTFT=@
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M^8!OKS_GI1YBW/F*_LETK]K;X.QP:-)INGV7@^_LS#'&SPV;$P^7 9.5!PA
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ML_\ Y)KVO9]*0+FCVD?Y%^/^8?5ZO_/U_<O\CQ7_ (6AX@_Z)9XQ_P"^+/\
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M*XRN#D>U>B-X=C\ _M%_!RXTB\U 2^);+4(M7:>[EE6^$=IYJ%E9B 58 C:
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MZ;5_(4:J=O,^AJ*8KC@=S2CK61T#J*** "BBB@ HHHH **** "BBB@ HHHH
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M.696DX4YXYS[5KV_PG\2?$+XSZ'X]\;+::=IWAN&5-#T&UF\]DFE $EQ/)@
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MA>)=5\/R_P!I7>MZ;;QW4UA9Z?+-*\;E@K1A5^<?(V2.!CGJ*^4=>\5S>*_
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M,&ODE-!UM_A'X@U&QT._U7^POB=<Z]<Z/ KQ3WMA\P8Q8P3_ *S<,==E>X_
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M C>9C^(#&>:K^$-8M+G]I3X=Z[;/X@U6PN_"]Y:/J]_IT\<;W!DA)14V*(E
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M444 )BEHHH *2EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tmb-20221231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #Y LD# 2(  A$! Q$!_\0
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MW_[77C=%'M)=P_M3%_S_ (+_ "/9/^&B/^I?_P#)W_[71_PT1_U+_P#Y._\
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M (:S_P"I5_\ *C_]JKY[HH^J4?Y?Q8?VCBOY_P %_D?0G_#6?_4J_P#E1_\
MM5'_  UG_P!2K_Y4?_M5?/=%'U2C_+^+#^T<5_/^"_R/H3_AK/\ ZE7_ ,J/
M_P!JH_X:S_ZE7_RH_P#VJOGNBCZI1_E_%A_:.*_G_!?Y'T)_PUG_ -2K_P"5
M'_[51_PUG_U*O_E1_P#M5?/=%'U2C_+^+#^T<5_/^"_R/H3_ (:S_P"I5_\
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M+H_X4_XN_P"@1_Y,P_\ Q=1RR['%]4Q'_/N7W,XVBNR_X4_XN_Z!'_DS#_\
M%T?\*?\ %W_0(_\ )F'_ .+HY9=@^J8C_GW+[F<;179?\*?\7?\ 0(_\F8?_
M (NC_A3_ (N_Z!'_ ),P_P#Q='++L'U3$?\ /N7W,XVBNR_X4_XN_P"@1_Y,
MP_\ Q='_  I_Q=_T"/\ R9A_^+HY9=@^J8C_ )]R^YG&T5V7_"G_ !=_T"/_
M "9A_P#BZ/\ A3_B[_H$?^3,/_Q='++L'U3$?\^Y?<SC:*[+_A3_ (N_Z!'_
M ),P_P#Q='_"G_%W_0(_\F8?_BZ.678/JF(_Y]R^YG&T5V7_  I_Q=_T"/\
MR9A_^+H_X4_XN_Z!'_DS#_\ %T<LNP?5,1_S[E]S.-HKLO\ A3_B[_H$?^3,
M/_Q='_"G_%W_ $"/_)F'_P"+HY9=@^J8C_GW+[F<;179?\*?\7?] C_R9A_^
M+H_X4_XN_P"@1_Y,P_\ Q='++L'U3$?\^Y?<SC:*[+_A3_B[_H$?^3,/_P 7
M1_PI_P 7?] C_P F8?\ XNCEEV#ZIB/^?<ON9QM%=E_PI_Q=_P! C_R9A_\
MBZ/^%/\ B[_H$?\ DS#_ /%T<LNP?5,1_P ^Y?<SC:*[+_A3_B[_ *!'_DS#
M_P#%T?\ "G_%W_0(_P#)F'_XNCEEV#ZIB/\ GW+[F<;179?\*?\ %W_0(_\
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M $ ?_)RW_P#CE'MJ?\R^\/JU?^1_<SSVBO0O^% >/?\ H _^3EO_ /'*/^%
M>/?^@#_Y.6__ ,<H]M3_ )E]X?5J_P#(_N9Y[17H7_"@/'O_ $ ?_)RW_P#C
ME'_"@/'O_0!_\G+?_P".4>VI_P R^\/JU?\ D?W,\]HKT+_A0'CW_H _^3EO
M_P#'*/\ A0'CW_H _P#DY;__ !RCVU/^9?>'U:O_ "/[F>>T5Z%_PH#Q[_T
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MEZ7_ ,\+O_OA?_BJ.9!]9H_S&#%^S;\,[:V2"U\(V5A&+1;)_L+26[31!XY
M)6C93*=\,;;G+-D'GDYWHOA5X6@$0CTH1K#K)U^-$GE"I?$$&4+NP,[F)0?+
MEB=N3FC_ (67I?\ SPN_^^%_^*H_X67I?_/"[_[X7_XJCF0?6:/\P_Q;\,M
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MSJZ*Y3_A9&F?\\+O_OA?_BJ/^%D:9_SPN_\ OA?_ (JCV<^P>UAW.KHKE/\
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MD:9_SPN_^^%_^*H_X61IG_/"[_[X7_XJCV<^P>UAW.KHKE/^%D:9_P \+O\
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M^^%_^*H]G/L'M8=SJZ*Y3_A9&F?\\+O_ +X7_P"*H_X61IG_ #PN_P#OA?\
MXJCV<^P>UAW.KHKE/^%D:9_SPN_^^%_^*H_X61IG_/"[_P"^%_\ BJ/9S[![
M6'<ZNBLG0O$EMXA\_P"SQRIY.W=YH SG.,8)]*UJS::=F:IJ2NC@_BE_S#/^
MVO\ [)7!UWGQ2_YAG_;7_P!DK@ZYI_$?.8S^/+Y?D%%%%0<84444 %%%% !1
M110!1UO6[#PYID^HZG=1V=E#C?+(>,DA54#J69B%"C))( !) K D^*GAE/#V
MC:TE]-=66LJ&TY;2RGGN+H;2^4@1#*<*"3\O ZXK>UO6K?P_ITE]=1W<L,9
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M:Y_S_?\ D)/_ (FC_A.M<_Y_O_(2?_$T:!:E_,_N_P""8-%;W_"=:Y_S_?\
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M:VEST'.*A[.^O+?Y?TSD:***] \P**** "BBB@ HHHH **** "BBB@ HHHH
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M$3_ZC.D?^!7_ -:L&BBZ#FA_+^)O?\(G_P!1G2/_  *_^M1_PB?_ %&=(_\
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MX%?_ %J/^$3_ .HSI'_@5_\ 6K!HHN@YH?R_B;W_  B?_49TC_P*_P#K4?\
M")_]1G2/_ K_ .M6#11=!S0_E_$W6\)_*?\ B<Z1_P"!7_UJ^?/'GA[ROVH?
MAK%_:6G-YFEZP?,6?*+C[+P3CC.>/H:]E;[IKP3QYQ^TK\-3ZZ?JX_2VKZ#(
MM<7)+_GW5_\ 34RHRAS*T?Q/IJ#PK^Z7_B<:5T_Y^?\ ZU2?\(K_ -1C2?\
MP*_^M7/0?ZI?I4E3:7<[[Q[&[_PBO_48TG_P*_\ K4?\(K_U&-)_\"O_ *U8
M5%%I=Q7CV-W_ (17_J,:3_X%?_6H_P"$5_ZC&D_^!7_UJPJ*+2[A>/8W?^$5
M_P"HQI/_ (%?_6H_X17_ *C&D_\ @5_]:L*BBTNX7CV-W_A%?^HQI/\ X%?_
M %J/^$5_ZC&D_P#@5_\ 6K"HHM+N%X]C=_X17_J,:3_X%?\ UJ/^$5_ZC&D_
M^!7_ -:L*BBTNX7CV-W_ (17_J,:3_X%?_6H_P"$5_ZC&D_^!7_UJPJ*+2[A
M>/8W?^$5_P"HQI/_ (%?_6H_X17_ *C&D_\ @5_]:L*BBTNX7CV-W_A%?^HQ
MI/\ X%?_ %J/^$5_ZC&D_P#@5_\ 6K"HHM+N%X]C=_X17_J,:3_X%?\ UJ/^
M$5_ZC&D_^!7_ -:L*BBTNX7CV-W_ (17_J,:3_X%?_6H_P"$5_ZC&D_^!7_U
MJPJ*+2[A>/8W?^$5_P"HQI/_ (%?_6H_X17_ *C&D_\ @5_]:L*BBTNX7CV-
MW_A%?^HQI/\ X%?_ %J/^$5_ZC&D_P#@5_\ 6K"HHM+N%X]C=_X17_J,:3_X
M%?\ UJ/^$5_ZC&D_^!7_ -:L*BBTNX7CV/4_!GA^ST73GE@2V>ZNFW7%U;'=
MYQ7*KEN^ ,8[<^IJ'XB:;:ZEX6G%U!'/Y$L,\6]<E)%D4JP]"/ZD=ZL^"/\
MD5[+_@?_ *&U'C?_ )%>]_X!_P"AK7!=^U^9Z5E[&UM+'E-%%%>D>4%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% '<_#'_F)?]LO_ &>NZKA?AC_S$O\ ME_[/7=5YM;XV>M0_AHX/XI?\PS_
M +:_^R5P==Y\4O\ F&?]M?\ V2N#KAG\1X6,_CR^7Y!1114'&%%%% !1110
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M$9?)YL.?R1ZEI7C;2-(L(K2&*]:./."ZH3R2>S#UJW_PLC3/^>%W_P!\+_\
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M/^_"_P"%']@:7_T#;3_OPO\ A5^BBR#DCV*']@:7_P! VT_[\+_A1_8&E_\
M0-M/^_"_X5?HHL@Y(]BA_8&E_P#0-M/^_"_X4?V!I?\ T#;3_OPO^%7ZXOXP
M^,AX%^'FKZDMPL%X8C!:$L QF?A=H[D<MCT4GM4R:A%R?0UI4%5J1IQ2NVE]
MYTO]@:7_ - VT_[\+_A1_8&E_P#0-M/^_"_X5'X9UN+Q+X=TS5H<>7>VT=P
M.VY0<?AG%:=-6:NB)4E%N,HZHH?V!I?_ $#;3_OPO^%1-X8TEGW?V9:9_P"N
M"_X5YIK7QVU#1]?\1 ^&8)O#&@:Q::/?:DNID72O.D!$JVWD[617N$4_O=V
M2!VJS\*?COIGC>.TTW4[A+;Q)<W^HVD=O!9SI;O]GN)E"+,P,9E\F-9&3?NP
M2VT BJ)Y(]CT<:!I@'_(.M/^_"_X4?V#IG_0.M/^_"_X5R4'QQ\%SVFH7(U2
M>.&R@BNF,^GW,1GAD?RXY+<-&#<([X56AW@ED ^\N9=4^,WA71+*SN;V?4K<
MW4$UTEJVBWINHX(FVR32VXA\V*,$CYY%5>1SR*KF?<?*NQU']@Z9_P! ZT_[
M\+_A1_8.F?\ 0.M/^_"_X53UW6=170H;SPUI]MXAN;EHS KWPM[8QL03*TP5
MSL"Y(V(Y)P ,$D97P]^(2>,_!]QKE_:1Z)]DN;NUNLW(EMU-O*\<DB3E5#QY
M0G?A>AR!@T<S[ARKL=#_ &#IG_0.M/\ OPO^%']@Z9_T#K3_ +\+_A7&I\>_
M QT:^U6;69+&PLH8+F:6_L+FU/D32".*95DC4O$SG'F*"GJ0*?<?'7P59Z/<
MZE=:I<6<-M>II\T%UIMU#=1W#Q^9'&;=HA*"ZD%?D^;("Y) HYGW#E78Z_\
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MG[J[RXW=\<>H\W&TY5(I4V[O3?3YGT>2XFEAZLI5TN5*]VDW?I9[W_X<\^^
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M7>-L[.0"<C)\,?">^@^%'B?PEJEW!9#7/MZ16VGN\UMI,%PK(EO 6"$I&#D
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M\AM[^7"RNNV3C!7@'<0"*[CP!X2O/!GA'4X;72;/3M9NIIKOR7UR[U2.:X9
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M"/Q18P>#-(U271TTCP;;W$%A>6<TC3ZANMWM83+$8E6'$4A9@KR9?'3% #M
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>tmb-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/29/2023 8:26:30 PM-->
<!--Modified on: 3/29/2023 8:26:30 PM-->
<xsd:schema targetNamespace="http://aerovatetx.com/20221231" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:avte="http://aerovatetx.com/20221231">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentWithUnrealizedLossesDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentWithUnrealizedLossesDetails">
        <link:definition>40303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENT WITH UNREALIZED LOSSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" id="DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
        <link:definition>40402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails">
        <link:definition>40502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2Imported" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2Imported">
        <link:definition>40502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details) (Calc 2) (Imported)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>40902 - Disclosure - INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" id="DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails">
        <link:definition>40903 - Disclosure - INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>00305 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails">
        <link:definition>40202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>40203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails">
        <link:definition>40303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>40501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>40601 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" id="DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails">
        <link:definition>40602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails" id="DisclosureShareBasedCompensationDetails">
        <link:definition>40701 - Disclosure - SHARE-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" id="DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails">
        <link:definition>40703 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" id="DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails">
        <link:definition>40704 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" id="DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails">
        <link:definition>40705 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" id="DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails">
        <link:definition>40706 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>40901 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DocumentCover" id="DocumentCover">
        <link:definition>00090 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstruments" id="DisclosureFairValueOfFinancialInstruments">
        <link:definition>10301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>10401 - Disclosure - BALANCE SHEET COMPONENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10501 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10601 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>10701 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>10801 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10901 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsTables" id="DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>30303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>30403 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30503 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30603 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>30703 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30903 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" id="DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails">
        <link:definition>40702 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>40904 - Disclosure - INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20221231_pre.xml" xlink:title="Presentation Links" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20221231_cal.xml" xlink:title="Calculation Links" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20221231_def.xml" xlink:title="Definition Links" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20221231_lab.xml" xlink:title="Label Links" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://aerovatetx.com/20230215/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:element name="SeriesARedeemableConvertiblePreferredStockMember" id="avte_SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesSeedRedeemableConvertiblePreferredStockMember" id="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WalthamLeaseMember" id="avte_WalthamLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RaCapitalHealthcareFundL.pMember" id="avte_RaCapitalHealthcareFundL.pMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockPurchaseAgreementMember" id="avte_StockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FirstMilestoneMember" id="avte_FirstMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SecondAndThirdMilestoneMember" id="avte_SecondAndThirdMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwentyTwentyOneStockOptionAndIncentivePlanMember" id="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" id="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ServicesAgreementWithCarnotLlcMember" id="avte_ServicesAgreementWithCarnotLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember" id="avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" id="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" id="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" id="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" id="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInOtherLiabilities" id="avte_IncreaseDecreaseInOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ReverseStockSplitPolicyTextBlock" id="avte_ReverseStockSplitPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShortTermInvestmentPolicyTextBlock" id="avte_ShortTermInvestmentPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" id="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertiblePreferredStockPolicyTextBlock" id="avte_ConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" id="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaidResearchAndDevelopment" id="avte_PrepaidResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="LeaseIncreaseInRentPercentage" id="avte_LeaseIncreaseInRentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestoneAxis" id="avte_MilestoneAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestoneDomain" id="avte_MilestoneDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CapitalStockSharesAuthorized" id="avte_CapitalStockSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes" id="avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="RelatedPartyTransactionTerm" id="avte_RelatedPartyTransactionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" id="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" id="avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredOfferingCostsIncludedInAccountsPayable" id="avte_DeferredOfferingCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DebtSecuritiesAvailableForSaleMaturityTerm" id="avte_DebtSecuritiesAvailableForSaleMaturityTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentCurrent" id="avte_AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="FosterCityLeaseMember" id="avte_FosterCityLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwentyEighteenStockOptionAndIncentivePlanMember" id="avte_TwentyEighteenStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfVotesForEachShareOfCommonStock" id="avte_NumberOfVotesForEachShareOfCommonStock" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="IncreaseDecreaseInOperatingLeaseAssetAndLiability" id="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" id="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NoticeToTerminateAgreementPeriod" id="avte_NoticeToTerminateAgreementPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaterialBreachCorrectionPeriod" id="avte_MaterialBreachCorrectionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="JefferiesMember" id="avte_JefferiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>tmb-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/29/2023 8:26:30 PM-->
<!--Modified on: 3/29/2023 8:26:30 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentWithUnrealizedLossesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentWithUnrealizedLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2Imported" roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2Imported" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DocumentCover" xlink:type="simple" xlink:href="tmb-20221231.xsd#DocumentCover" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstruments" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingencies" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingencies" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquity" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquity" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensation" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensation" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactions" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureRelatedPartyTransactions" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxes" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxes" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityTables" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesTables" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureRelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesDetails" />
  <calculationLink xlink:role="http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638157183889285123" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638157183889285123" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638157183889285123" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638157183889285123" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638157183889285123" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638157183889285123" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638157183889285123" xlink:to="us-gaap_ShortTermInvestments_638157183889285123" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638157183889285123" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638157183889285123" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638157183889285123" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638157183889285123" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638157183889285123" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638157183889295116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638157183889295116" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638157183889295116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638157183889295116" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638157183889295116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638157183889295116" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638157183889295116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638157183889295116" xlink:to="us-gaap_LiabilitiesCurrent_638157183889295116" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638157183889295116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638157183889295116" xlink:to="us-gaap_AccountsPayableCurrent_638157183889295116" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638157183889295116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638157183889295116" xlink:to="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638157183889295116" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638157183889295116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638157183889295116" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638157183889295116" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638157183889305113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638157183889295116" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638157183889305113" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities_638157183889305113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638157183889295116" xlink:to="us-gaap_OtherLiabilities_638157183889305113" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638157183889305113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638157183889305113" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638157183889305113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638157183889305113" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638157183889305113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638157183889305113" xlink:to="us-gaap_PreferredStockValue_638157183889305113" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638157183889305113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638157183889305113" xlink:to="us-gaap_CommonStockValue_638157183889305113" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638157183889305113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638157183889305113" xlink:to="us-gaap_AdditionalPaidInCapital_638157183889305113" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638157183889315113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638157183889305113" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638157183889315113" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638157183889315113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638157183889305113" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638157183889315113" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638157183889315113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638157183889315113" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesTradingUnrealizedLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss_638157183889315113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedLoss_638157183889315113" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638157183889465111" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638157183889465111" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638157183889465111" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638157183889465111" xlink:to="us-gaap_OperatingIncomeLoss_638157183889465111" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638157183889465111" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638157183889465111" xlink:to="us-gaap_OperatingExpenses_638157183889465111" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638157183889475110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638157183889465111" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638157183889475110" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638157183889475110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638157183889465111" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638157183889475110" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638157183889475110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638157183889465111" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638157183889475110" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638157183889475110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638157183889475110" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638157183889475110" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638157183889475110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638157183889475110" xlink:to="us-gaap_OtherNonoperatingExpense_638157183889475110" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638157183889475110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638157183889475110" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183889475110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183889475110" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638157183889485113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183889475110" xlink:to="us-gaap_NetIncomeLoss_638157183889485113" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638157183889485113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183889475110" xlink:to="us-gaap_ShareBasedCompensation_638157183889485113" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638157183889485113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183889475110" xlink:to="us-gaap_Depreciation_638157183889485113" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" xlink:label="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_638157183889485113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183889475110" xlink:to="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_638157183889485113" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638157183889485113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183889475110" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638157183889485113" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638157183889485113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183889475110" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638157183889485113" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638157183889485113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183889475110" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638157183889485113" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_638157183889485113" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183889475110" xlink:to="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_638157183889485113" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638157183889495120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183889475110" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638157183889495120" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_IncreaseDecreaseInOtherLiabilities" xlink:label="avte_IncreaseDecreaseInOtherLiabilities_638157183889495120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183889475110" xlink:to="avte_IncreaseDecreaseInOtherLiabilities_638157183889495120" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157183889495120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157183889495120" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_638157183889495120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157183889495120" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_638157183889495120" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638157183889495120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157183889495120" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638157183889495120" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638157183889495120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157183889495120" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638157183889495120" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157183889495120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157183889495120" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638157183889495120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157183889495120" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638157183889495120" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638157183889505115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157183889495120" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638157183889505115" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638157183889505115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157183889495120" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638157183889505115" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638157183889505115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157183889495120" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638157183889505115" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638157183889505115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157183889495120" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638157183889505115" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638157183889505115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638157183889505115" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638157183889515118" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_ShortTermInvestments_638157183889515118" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentWithUnrealizedLossesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENT WITH UNREALIZED LOSSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_638157183889515118" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_638157183889515118" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638157183889515118" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638157183889515118" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638157183889515118" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638157183889515118" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_638157183889515118" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_638157183889515118" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638157183889515118" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_638157183889515118" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638157183889525116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638157183889525116" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_PrepaidResearchAndDevelopment" xlink:label="avte_PrepaidResearchAndDevelopment_638157183889525116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="avte_PrepaidResearchAndDevelopment_638157183889525116" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_AccruedResearchAndDevelopmentCurrent" xlink:label="avte_AccruedResearchAndDevelopmentCurrent_638157183889525116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="avte_AccruedResearchAndDevelopmentCurrent_638157183889525116" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638157183889525116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638157183889525116" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638157183889525116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638157183889525116" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails" xlink:type="extended" xlink:title="40502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638157183889525116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638157183889525116" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638157183889525116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638157183889525116" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638157183889535116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638157183889535116" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2Imported" xlink:type="extended" xlink:title="40502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details) (Calc 2) (Imported)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638157183889535116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638157183889535116" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638157183889535116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638157183889535116" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638157183889535116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_638157183889535116" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638157183889535116" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638157183889535116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_638157183889535116" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638157183889535116" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638157183889535116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638157183889535116" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638157183889535116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638157183889535116" xlink:to="us-gaap_DeferredTaxAssetsGross_638157183889535116" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638157183889545116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157183889535116" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638157183889545116" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638157183889545116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157183889535116" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638157183889545116" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638157183889545116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157183889535116" xlink:to="us-gaap_DeferredTaxAssetsOther_638157183889545116" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_638157183889545116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157183889535116" xlink:to="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_638157183889545116" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638157183889545116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638157183889535116" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638157183889545116" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638157183889545116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities_638157183889545116" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_638157183889545116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities_638157183889545116" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_638157183889545116" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" xlink:type="extended" xlink:title="40903 - Disclosure - INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638157183889555117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638157183889555117" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638157183889555117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638157183889555117" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_638157183889555117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_638157183889555117" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_638157183889555117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_638157183889555117" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xlink:label="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_638157183889555117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_638157183889555117" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638157183889555117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638157183889555117" order="6" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>tmb-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/29/2023 8:26:30 PM-->
<!--Modified on: 3/29/2023 8:26:30 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DocumentCover" xlink:type="simple" xlink:href="tmb-20221231.xsd#DocumentCover" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstruments" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingencies" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingencies" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquity" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquity" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensation" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensation" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactions" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureRelatedPartyTransactions" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxes" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxes" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityTables" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesTables" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aerovatetx.com/20230215/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="definition: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="LeaseContractualTermAxis" xlink:title="LeaseContractualTermAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="LeaseContractualTermDomain" xlink:title="LeaseContractualTermDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LeaseContractualTermAxis" xlink:to="LeaseContractualTermDomain" xlink:title="definition: LeaseContractualTermAxis to LeaseContractualTermDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_MilestoneAxis" xlink:label="MilestoneAxis" xlink:title="MilestoneAxis" />
    <link:loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_MilestoneDomain" xlink:label="MilestoneDomain" xlink:title="MilestoneDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MilestoneAxis" xlink:to="MilestoneDomain" xlink:title="definition: MilestoneAxis to MilestoneDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="definition: AssetsAbstract to PrepaidExpenseAndOtherAssetsCurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="ShortTermInvestments" xlink:title="ShortTermInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="ShortTermInvestments" xlink:title="definition: AssetsCurrentAbstract to ShortTermInvestments" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:title="us-gaap_OtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:AssetsAbstract To us-gaap_OtherAssetsNoncurrent" order="2" priority="0" />
  </link:definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:label="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" xlink:label="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesTradingUnrealizedLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_JefferiesMember" xlink:label="avte_JefferiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avte_JefferiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" xlink:type="extended" xlink:title="40202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_InvestmentTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_DebtSecuritiesAvailableForSaleMaturityTerm" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="avte_DebtSecuritiesAvailableForSaleMaturityTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_WalthamLeaseMember" xlink:label="avte_WalthamLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="avte_WalthamLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_FosterCityLeaseMember" xlink:label="avte_FosterCityLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="avte_FosterCityLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_LeaseIncreaseInRentPercentage" xlink:label="avte_LeaseIncreaseInRentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="avte_LeaseIncreaseInRentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40601 - Disclosure - STOCKHOLDERS' EQUITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_RaCapitalHealthcareFundL.pMember" xlink:label="avte_RaCapitalHealthcareFundL.pMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avte_RaCapitalHealthcareFundL.pMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_StockPurchaseAgreementMember" xlink:label="avte_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="avte_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_MilestoneAxis" xlink:label="avte_MilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="avte_MilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_MilestoneDomain" xlink:label="avte_MilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="avte_MilestoneAxis" xlink:to="avte_MilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_FirstMilestoneMember" xlink:label="avte_FirstMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="avte_MilestoneDomain" xlink:to="avte_FirstMilestoneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SecondAndThirdMilestoneMember" xlink:label="avte_SecondAndThirdMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="avte_MilestoneDomain" xlink:to="avte_SecondAndThirdMilestoneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_CapitalStockSharesAuthorized" xlink:label="avte_CapitalStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="avte_CapitalStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes" xlink:label="avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_NumberOfVotesForEachShareOfCommonStock" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="avte_NumberOfVotesForEachShareOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" xlink:type="extended" xlink:title="40602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SHARE-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="avte_TwentyEighteenStockOptionAndIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xlink:type="extended" xlink:title="40703 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" xlink:type="extended" xlink:title="40705 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xlink:type="extended" xlink:title="40706 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ServicesAgreementWithCarnotLlcMember" xlink:label="avte_ServicesAgreementWithCarnotLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="avte_ServicesAgreementWithCarnotLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember" xlink:label="avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_RelatedPartyTransactionTerm" xlink:label="avte_RelatedPartyTransactionTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avte_RelatedPartyTransactionTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_NoticeToTerminateAgreementPeriod" xlink:label="avte_NoticeToTerminateAgreementPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avte_NoticeToTerminateAgreementPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_MaterialBreachCorrectionPeriod" xlink:label="avte_MaterialBreachCorrectionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avte_MaterialBreachCorrectionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - INCOME TAXES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>tmb-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/29/2023 8:26:30 PM-->
<!--Modified on: 3/29/2023 8:26:30 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Elected Not To Use the Extended Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated By Reference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities and other liabilities current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 6)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 5)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2022 and December 31, 2021, respectively; no shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2022 and December 31, 2021, respectively; no shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 24,506,390 and 24,410,393 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 24,722,974 and 24,410,393 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesTradingUnrealizedLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesTradingUnrealizedLoss" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Trading, Unrealized Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss on securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss on investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares of common stock outstanding, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common stock outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares of common stock outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common stock outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:to="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Seed Redeemable Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Seed Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Seed Redeemable Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Redeemable Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Redeemable Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock purchase plan awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity shares issued .value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity shares issued .value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series A redeemable convertible preferred stock per share, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of new shares classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series A redeemable convertible preferred stock per share, net of issuance costs, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series A redeemable convertible preferred stock per share, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series A redeemable convertible preferred stock per share, net of issuance costs, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares conversion securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of Series A redeemable convertible preferred stock to redemption value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of Series A redeemable convertible preferred stock to redemption value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of Series A redeemable convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:label="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:to="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock upon initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" xlink:label="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" xlink:to="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock upon initial public offering, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock upon initial public offering, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon initial public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon initial public offering, net of issuance costs, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under ESPP, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" xlink:label="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" xlink:to="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of discounts and amortization of premiums on investments net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of discounts and amortization of premiums on investments, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" xlink:to="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease asset and liability, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Lease Asset And Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease assets and liabilities, net</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_IncreaseDecreaseInOtherLiabilities" xlink:label="avte_IncreaseDecreaseInOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_IncreaseDecreaseInOtherLiabilities" xlink:to="avte_IncreaseDecreaseInOtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_IncreaseDecreaseInOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase decrease in other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_IncreaseDecreaseInOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase decrease in other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avte_IncreaseDecreaseInOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Short-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale, Maturity and Collection of Short-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and maturities of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of Series A redeemable convertible preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (decrease) increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the beginning of the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of noncash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset obtained in exchange for operating lease liability</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="avte_DeferredOfferingCostsIncludedInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_DeferredOfferingCostsIncludedInAccountsPayable" xlink:to="avte_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs included in accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs included in accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs included in accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment in accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE OF FINANCIAL INSTRUMENTS.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE OF FINANCIAL INSTRUMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE SHEET COMPONENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE SHEET COMPONENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ReverseStockSplitPolicyTextBlock" xlink:label="avte_ReverseStockSplitPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ReverseStockSplitPolicyTextBlock" xlink:to="avte_ReverseStockSplitPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Stock Split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ShortTermInvestmentPolicyTextBlock" xlink:label="avte_ShortTermInvestmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ShortTermInvestmentPolicyTextBlock" xlink:to="avte_ShortTermInvestmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ShortTermInvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investment [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ShortTermInvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_ShortTermInvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ConvertiblePreferredStockPolicyTextBlock" xlink:label="avte_ConvertiblePreferredStockPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ConvertiblePreferredStockPolicyTextBlock" xlink:to="avte_ConvertiblePreferredStockPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ConvertiblePreferredStockPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ConvertiblePreferredStockPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF FAIR VALUE INSTRUMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SHORT TERM INVESTMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Unrealized Loss on Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of prepaid expenses and other current assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" xlink:label="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" xlink:to="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of common stock shares reserved on and as converted basis for future issuance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF UNVESTED STOCK UNIT ACTIVITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED AND EXPENSE BY AWARD TYPE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_JefferiesMember" xlink:label="avte_JefferiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_JefferiesMember" xlink:to="avte_JefferiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Jefferies, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jefferies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents and short term investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity, reverse stock split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements are amortized over the remaining life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Long-Lived Asset, Held-for-Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss available to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock awards and units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Treasury Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Treasury bills</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Debt Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agency bond</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agency bond</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Paper [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial paper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total fair value of assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Off-balance Sheet Risks [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Investments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_DebtSecuritiesAvailableForSaleMaturityTerm" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_DebtSecuritiesAvailableForSaleMaturityTerm" xlink:to="avte_DebtSecuritiesAvailableForSaleMaturityTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity term for debt securities classified as available for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities Available For Sale Maturity Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross unrealized gains</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross unrealized loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, Less than 12 months, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, Less than 12 months, Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, 12 months or Greater, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, 12 months or Greater, Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, Total Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, Total Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_PrepaidResearchAndDevelopment" xlink:label="avte_PrepaidResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_PrepaidResearchAndDevelopment" xlink:to="avte_PrepaidResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_PrepaidResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_PrepaidResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_PrepaidResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_AccruedResearchAndDevelopmentCurrent" xlink:label="avte_AccruedResearchAndDevelopmentCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_AccruedResearchAndDevelopmentCurrent" xlink:to="avte_AccruedResearchAndDevelopmentCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued payroll and other employee benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Contractual Term [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Contractual Term [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_WalthamLeaseMember" xlink:label="avte_WalthamLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_WalthamLeaseMember" xlink:to="avte_WalthamLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_WalthamLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Waltham Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_WalthamLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Waltham Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_WalthamLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Waltham Lease</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_FosterCityLeaseMember" xlink:label="avte_FosterCityLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_FosterCityLeaseMember" xlink:to="avte_FosterCityLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_FosterCityLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foster City Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_FosterCityLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foster City Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_FosterCityLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foster City Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of land</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, option to extend</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for rent</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_LeaseIncreaseInRentPercentage" xlink:label="avte_LeaseIncreaseInRentPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_LeaseIncreaseInRentPercentage" xlink:to="avte_LeaseIncreaseInRentPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_LeaseIncreaseInRentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease increase in rent percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_LeaseIncreaseInRentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease rent percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_LeaseIncreaseInRentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease rent percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of net minimum lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Amount representing interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average incremental borrowing rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average incremental borrowing rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss) [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_RaCapitalHealthcareFundL.pMember" xlink:label="avte_RaCapitalHealthcareFundL.pMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_RaCapitalHealthcareFundL.pMember" xlink:to="avte_RaCapitalHealthcareFundL.pMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_RaCapitalHealthcareFundL.pMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RA Capital Healthcare Fund, L.P [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_RaCapitalHealthcareFundL.pMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RA Capital Healthcare Fund, L.P [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_RaCapitalHealthcareFundL.pMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RA Capital Healthcare Fund, L.P</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_StockPurchaseAgreementMember" xlink:label="avte_StockPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_StockPurchaseAgreementMember" xlink:to="avte_StockPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_MilestoneAxis" xlink:label="avte_MilestoneAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_MilestoneAxis" xlink:to="avte_MilestoneAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_MilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_MilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone [Axis]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_FirstMilestoneMember" xlink:label="avte_FirstMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_FirstMilestoneMember" xlink:to="avte_FirstMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_FirstMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_FirstMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_FirstMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Milestone</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SecondAndThirdMilestoneMember" xlink:label="avte_SecondAndThirdMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_SecondAndThirdMilestoneMember" xlink:to="avte_SecondAndThirdMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_SecondAndThirdMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second and Third Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_SecondAndThirdMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second and Third Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_SecondAndThirdMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second and Third Milestone</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss) [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_CapitalStockSharesAuthorized" xlink:label="avte_CapitalStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_CapitalStockSharesAuthorized" xlink:to="avte_CapitalStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_CapitalStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital stock shares authorized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_CapitalStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital stock shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_CapitalStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital stock shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity shares, value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued, price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued, price per share</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes" xlink:label="avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes" xlink:to="avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of temporary equity shares issued in connection with conversion of notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of temporary equity shares issued in connection with conversion of notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of stock shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of stock shares issued</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_NumberOfVotesForEachShareOfCommonStock" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_NumberOfVotesForEachShareOfCommonStock" xlink:to="avte_NumberOfVotesForEachShareOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes for each share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Votes for Each Share of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes for each share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xlink:to="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Stock Option and Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Stock Option and Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_TwentyEighteenStockOptionAndIncentivePlanMember" xlink:to="avte_TwentyEighteenStockOptionAndIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Plan</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" xlink:to="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Plan and 2018 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Plan and 2018 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Plan and 2018 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of outstanding common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock available for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock available for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional common stock available for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock available for issuance, awards granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock available for issuance, awards granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of common stock purchase price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of common stock purchase price</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Duration of offering period for share-based compensation arrangement by share-based payment award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount percentage on marker price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount percentage on marker price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock-based compensation weighted-average period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock-based compensation weighted-average period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock options granted and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding, beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price Outstanding, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price Outstanding, beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted- Average Remaining Contractual Term, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted- Average Remaining Contractual Term, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value Outstanding, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value Outstanding, beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price, Vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted- Average Remaining Contractual Term, Vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted- Average Remaining Contractual Term, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">weighted-average grant date fair value of stock option grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units, beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant date fair value, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant date fair value, beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant date fair value, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant date fair value, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ServicesAgreementWithCarnotLlcMember" xlink:label="avte_ServicesAgreementWithCarnotLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ServicesAgreementWithCarnotLlcMember" xlink:to="avte_ServicesAgreementWithCarnotLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ServicesAgreementWithCarnotLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to service agreement with Carnot LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ServicesAgreementWithCarnotLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service agreement with carnot LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_ServicesAgreementWithCarnotLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service agreement with carnot LLC</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember" xlink:label="avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember" xlink:to="avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to research and development and general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development and general and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development and general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_RelatedPartyTransactionTerm" xlink:label="avte_RelatedPartyTransactionTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_RelatedPartyTransactionTerm" xlink:to="avte_RelatedPartyTransactionTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_RelatedPartyTransactionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of related party transaction for service agreement , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_RelatedPartyTransactionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of service agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_RelatedPartyTransactionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of service agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_NoticeToTerminateAgreementPeriod" xlink:label="avte_NoticeToTerminateAgreementPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_NoticeToTerminateAgreementPeriod" xlink:to="avte_NoticeToTerminateAgreementPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_NoticeToTerminateAgreementPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of days in which notice to terminate an agreement must be given.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_NoticeToTerminateAgreementPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice To Terminate Agreement Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_NoticeToTerminateAgreementPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination notice period</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_MaterialBreachCorrectionPeriod" xlink:label="avte_MaterialBreachCorrectionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_MaterialBreachCorrectionPeriod" xlink:to="avte_MaterialBreachCorrectionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_MaterialBreachCorrectionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of days in which material breach must be corrected or agreement will be terminated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_MaterialBreachCorrectionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material Breach Correction Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_MaterialBreachCorrectionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material breach correction period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses from transactions with related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount payable to related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Authority</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research credit carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Capitalized Research and Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized R&amp;D</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets (liabilities)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Federal statutory income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Federal statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent and other differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent and other differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xlink:label="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xlink:to="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Research and Development Credits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance of unrecognized tax benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance of unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions based on tax positions related to the current year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions based on tax positions related to the current year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions based on tax positions related to the prior year</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>tmb-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/29/2023 8:26:30 PM-->
<!--Modified on: 3/29/2023 8:26:30 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DocumentCover" roleURI="http://aerovatetx.com/20230215/role/DocumentCover" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstruments" roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBalanceSheetComponents" roleURI="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquity" roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensation" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsTables" roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBalanceSheetComponentsTables" roleURI="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityTables" roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationTables" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails" roleURI="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DocumentCover" xlink:type="extended" xlink:title="00090 - Document - Cover" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638157183890105101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638157183890105101" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638157183890105101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638157183890105101" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638157183890105101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638157183890105101" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638157183890105101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638157183890105101" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638157183890105101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638157183890105101" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638157183890105101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638157183890105101" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638157183890105101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638157183890105101" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638157183890115101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638157183890115101" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638157183890115101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638157183890115101" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638157183890115101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638157183890115101" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638157183890115101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638157183890115101" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638157183890115101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638157183890115101" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638157183890115101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638157183890115101" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638157183890115101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638157183890115101" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638157183890115101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638157183890115101" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638157183890115101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638157183890115101" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638157183890115101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638157183890115101" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638157183890115101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638157183890115101" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638157183890125109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638157183890125109" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638157183890125109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638157183890125109" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638157183890125109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638157183890125109" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638157183890125109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638157183890125109" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638157183890125109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638157183890125109" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638157183890125109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638157183890125109" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638157183890125109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638157183890125109" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638157183890125109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638157183890125109" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638157183890125109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638157183890125109" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638157183890135101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638157183890135101" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638157183890135101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638157183890135101" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638157183890135101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638157183890135101" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638157183890135101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638157183890135101" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638157183890135101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638157183890135101" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638157183890135101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638157183890135101" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638157183890135101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638157183890135101" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_638157183890145100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_638157183890145100" order="35" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638157183890145100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638157183890145100" order="36" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638157183890145100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638157183890145100" order="37" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638157183890145100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638157183890145100" order="38" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638157183890145100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638157183890145100" order="39" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638157183890155100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638157183890155100" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638157183890155100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638157183890155100" xlink:to="us-gaap_AssetsCurrentAbstract_638157183890155100" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638157183890155100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638157183890155100" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638157183890155100" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638157183890155100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638157183890155100" xlink:to="us-gaap_ShortTermInvestments_638157183890155100" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638157183890155100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638157183890155100" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638157183890155100" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638157183890155100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638157183890155100" xlink:to="us-gaap_AssetsCurrent_638157183890155100" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638157183890155100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638157183890155100" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638157183890155100" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638157183890155100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638157183890155100" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638157183890155100" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638157183890155100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638157183890155100" xlink:to="us-gaap_OtherAssetsNoncurrent_638157183890155100" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638157183890155100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638157183890155100" xlink:to="us-gaap_Assets_638157183890155100" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157183890155100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157183890155100" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638157183890165111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157183890155100" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638157183890165111" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638157183890165111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638157183890165111" xlink:to="us-gaap_AccountsPayableCurrent_638157183890165111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638157183890165111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638157183890165111" xlink:to="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638157183890165111" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638157183890165111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638157183890165111" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638157183890165111" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638157183890165111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638157183890165111" xlink:to="us-gaap_LiabilitiesCurrent_638157183890165111" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638157183890165111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157183890155100" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638157183890165111" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities_638157183890165111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157183890155100" xlink:to="us-gaap_OtherLiabilities_638157183890165111" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638157183890165111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157183890155100" xlink:to="us-gaap_Liabilities_638157183890165111" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638157183890165111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157183890155100" xlink:to="us-gaap_CommitmentsAndContingencies_638157183890165111" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638157183890165111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157183890155100" xlink:to="us-gaap_StockholdersEquityAbstract_638157183890165111" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638157183890165111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157183890165111" xlink:to="us-gaap_PreferredStockValue_638157183890165111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638157183890175097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157183890165111" xlink:to="us-gaap_CommonStockValue_638157183890175097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638157183890175097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157183890165111" xlink:to="us-gaap_AdditionalPaidInCapital_638157183890175097" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638157183890175097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157183890165111" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638157183890175097" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638157183890175097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157183890165111" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638157183890175097" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638157183890175097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157183890165111" xlink:to="us-gaap_StockholdersEquity_638157183890175097" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638157183890175097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157183890155100" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638157183890175097" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638157183890185108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638157183890185108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638157183890185108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638157183890185108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638157183890185108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638157183890185108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638157183890185108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638157183890185108" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638157183890185108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638157183890185108" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638157183890185108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638157183890185108" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638157183890185108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638157183890185108" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638157183890185108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638157183890185108" order="8" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638157183890185108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638157183890185108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638157183890185108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638157183890185108" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638157183890185108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638157183890185108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638157183890185108" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638157183890185108" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638157183890195097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638157183890185108" xlink:to="us-gaap_OperatingExpenses_638157183890195097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638157183890195097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638157183890195097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638157183890195097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638157183890195097" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638157183890195097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638157183890195097" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638157183890195097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638157183890195097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638157183890195097" xlink:to="us-gaap_OtherNonoperatingExpense_638157183890195097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638157183890195097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638157183890195097" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638157183890195097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638157183890195097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638157183890195097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638157183890195097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638157183890195097" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638157183890195097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss_638157183890195097" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638157183890195097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638157183890195097" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638157183890195097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638157183890195097" xlink:to="us-gaap_NetIncomeLoss_638157183890195097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_638157183890195097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638157183890195097" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_638157183890195097" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesTradingUnrealizedLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss_638157183890205096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_638157183890195097" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedLoss_638157183890205096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638157183890205096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638157183890195097" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638157183890205096" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638157183890205096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638157183890205096" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638157183890205096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638157183890205096" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638157183890205096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638157183890205096" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638157183890205096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638157183890205096" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638157183890205096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638157183890205096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638157183890205096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157183890205096" xlink:to="us-gaap_StatementEquityComponentsAxis_638157183890205096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638157183890205096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157183890205096" xlink:to="us-gaap_PreferredStockMember_638157183890205096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638157183890215095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157183890205096" xlink:to="us-gaap_CommonStockMember_638157183890215095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638157183890215095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157183890205096" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638157183890215095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638157183890215095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157183890205096" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638157183890215095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638157183890215095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157183890205096" xlink:to="us-gaap_RetainedEarningsMember_638157183890215095" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638157183890215095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157183890205096" xlink:to="us-gaap_EquityComponentDomain_638157183890215095" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638157183890215095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157183890205096" xlink:to="us-gaap_StatementClassOfStockAxis_638157183890215095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_638157183890215095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157183890215095" xlink:to="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_638157183890215095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember_638157183890215095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157183890215095" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember_638157183890215095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638157183890215095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157183890215095" xlink:to="us-gaap_ClassOfStockDomain_638157183890215095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638157183890215095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157183890205096" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638157183890215095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638157183890215095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638157183890215095" xlink:to="us-gaap_StockCompensationPlanMember_638157183890215095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638157183890215095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638157183890215095" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638157183890215095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638157183890225096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157183890205096" xlink:to="us-gaap_StatementLineItems_638157183890225096" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638157183890225096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638157183890225096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638157183890225096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638157183890225096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638157183890225096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_SharesOutstanding_638157183890225096" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638157183890225096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_StockholdersEquity_638157183890225096" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_638157183890225096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_638157183890225096" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638157183890225096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_638157183890225096" xlink:to="avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638157183890225096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638157183890225096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638157183890225096" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638157183890225096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638157183890225096" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638157183890225096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638157183890225096" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:label="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering_638157183890235100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering_638157183890235100" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" xlink:label="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares_638157183890235100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares_638157183890235100" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638157183890235100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638157183890235100" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638157183890235100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638157183890235100" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesTradingUnrealizedLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss_638157183890235100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedLoss_638157183890235100" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638157183890235100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638157183890235100" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638157183890235100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638157183890235100" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638157183890235100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638157183890235100" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638157183890245095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638157183890245095" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638157183890245095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638157183890245095" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638157183890245095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_NetIncomeLoss_638157183890245095" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638157183890245095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638157183890245095" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638157183890245095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638157183890245095" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638157183890245095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_SharesOutstanding_638157183890245095" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638157183890245095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890225096" xlink:to="us-gaap_StockholdersEquity_638157183890245095" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638157183890255095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638157183890255095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638157183890255095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157183890255095" xlink:to="us-gaap_StatementEquityComponentsAxis_638157183890255095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638157183890255095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157183890255095" xlink:to="us-gaap_EquityComponentDomain_638157183890255095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638157183890255095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638157183890255095" xlink:to="us-gaap_PreferredStockMember_638157183890255095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638157183890255095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157183890255095" xlink:to="us-gaap_StatementClassOfStockAxis_638157183890255095" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638157183890255095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157183890255095" xlink:to="us-gaap_ClassOfStockDomain_638157183890255095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember_638157183890255095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157183890255095" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember_638157183890255095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638157183890255095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157183890255095" xlink:to="us-gaap_StatementLineItems_638157183890255095" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638157183890255095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890255095" xlink:to="us-gaap_SharePrice_638157183890255095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638157183890265094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890255095" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638157183890265094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638157183890265094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638157183890265094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638157183890265094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638157183890265094" xlink:to="us-gaap_NetIncomeLoss_638157183890265094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157183890265094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638157183890265094" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157183890265094" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638157183890265094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157183890265094" xlink:to="us-gaap_ShareBasedCompensation_638157183890265094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638157183890265094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157183890265094" xlink:to="us-gaap_Depreciation_638157183890265094" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" xlink:label="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_638157183890265094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157183890265094" xlink:to="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_638157183890265094" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157183890265094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157183890265094" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157183890265094" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638157183890265094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157183890265094" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638157183890265094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638157183890265094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157183890265094" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638157183890265094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638157183890265094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157183890265094" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638157183890265094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638157183890275093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157183890265094" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638157183890275093" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_638157183890275093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157183890265094" xlink:to="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_638157183890275093" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_IncreaseDecreaseInOtherLiabilities" xlink:label="avte_IncreaseDecreaseInOtherLiabilities_638157183890275093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157183890265094" xlink:to="avte_IncreaseDecreaseInOtherLiabilities_638157183890275093" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183890275093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157183890265094" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157183890275093" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638157183890275093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638157183890275093" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_638157183890275093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638157183890275093" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_638157183890275093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638157183890275093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638157183890275093" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638157183890275093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638157183890275093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638157183890275093" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638157183890275093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157183890275093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638157183890275093" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157183890275093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157183890275093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157183890275093" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638157183890275093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157183890275093" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638157183890275093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638157183890285094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157183890275093" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638157183890285094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638157183890285094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157183890275093" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638157183890285094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638157183890285094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157183890275093" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638157183890285094" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638157183890285094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157183890275093" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638157183890285094" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157183890285094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157183890275093" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157183890285094" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638157183890285094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638157183890285094" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638157183890285094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638157183890285094" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6381571838902850941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6381571838902850941" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157183890295100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157183890295100" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638157183890295100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157183890295100" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638157183890295100" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="avte_DeferredOfferingCostsIncludedInAccountsPayable_638157183890295100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157183890295100" xlink:to="avte_DeferredOfferingCostsIncludedInAccountsPayable_638157183890295100" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638157183890295100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157183890295100" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638157183890295100" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_638157183890295100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157183890295100" xlink:to="us-gaap_ConversionOfStockAmountConverted1_638157183890295100" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638157183890295100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638157183890295100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638157183890305097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638157183890305097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstruments" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638157183890305097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638157183890305097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponents" xlink:type="extended" xlink:title="10401 - Disclosure - BALANCE SHEET COMPONENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638157183890305097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638157183890305097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10501 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638157183890305097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638157183890305097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10601 - Disclosure - STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638157183890315097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638157183890315097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="10701 - Disclosure - SHARE-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638157183890315097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638157183890315097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="10801 - Disclosure - RELATED PARTY TRANSACTIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638157183890315097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638157183890315097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10901 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638157183890315097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638157183890315097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638157183890325095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638157183890325095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ReverseStockSplitPolicyTextBlock" xlink:label="avte_ReverseStockSplitPolicyTextBlock_638157183890325095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="avte_ReverseStockSplitPolicyTextBlock_638157183890325095" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638157183890325095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638157183890325095" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638157183890325095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638157183890325095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ShortTermInvestmentPolicyTextBlock" xlink:label="avte_ShortTermInvestmentPolicyTextBlock_638157183890325095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="avte_ShortTermInvestmentPolicyTextBlock_638157183890325095" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638157183890325095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638157183890325095" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638157183890325095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638157183890325095" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638157183890325095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638157183890325095" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_638157183890325095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_638157183890325095" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638157183890325095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638157183890325095" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638157183890325095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638157183890325095" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638157183890325095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638157183890325095" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ConvertiblePreferredStockPolicyTextBlock" xlink:label="avte_ConvertiblePreferredStockPolicyTextBlock_638157183890335094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="avte_ConvertiblePreferredStockPolicyTextBlock_638157183890335094" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638157183890335094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638157183890335094" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638157183890335094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638157183890335094" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638157183890335094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638157183890335094" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638157183890335094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638157183890335094" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638157183890335094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638157183890335094" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638157183890335094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638157183890335094" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638157183890335094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638157183890335094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638157183890335094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638157183890335094" order="2" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638157183890345123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638157183890345123" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_638157183890345123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_638157183890345123" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_638157183890345123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_638157183890345123" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsTables" xlink:type="extended" xlink:title="30403 - Disclosure - BALANCE SHEET COMPONENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_638157183890345123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_638157183890345123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638157183890345123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638157183890345123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30503 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638157183890345123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638157183890345123" order="1" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30603 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" xlink:label="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock_638157183890355116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock_638157183890355116" order="1" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="30703 - Disclosure - SHARE-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638157183890355116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638157183890355116" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638157183890355116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638157183890355116" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638157183890355116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638157183890355116" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638157183890355116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638157183890355116" order="4" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30903 - Disclosure - INCOME TAXES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638157183890355116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638157183890355116" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638157183890365112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638157183890365112" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638157183890365112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638157183890365112" order="3" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638157183890365112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638157183890365112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638157183890365112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638157183890365112" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638157183890365112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638157183890365112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638157183890365112" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638157183890365112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638157183890365112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638157183890365112" xlink:to="us-gaap_IPOMember_638157183890365112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638157183890365112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638157183890365112" xlink:to="us-gaap_OverAllotmentOptionMember_638157183890365112" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638157183890365112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638157183890365112" xlink:to="srt_CounterpartyNameAxis_638157183890365112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638157183890365112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638157183890365112" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638157183890365112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_JefferiesMember" xlink:label="avte_JefferiesMember_638157183890365112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157183890365112" xlink:to="avte_JefferiesMember_638157183890365112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638157183890365112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638157183890365112" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638157183890365112" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638157183890375115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638157183890365112" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638157183890375115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_638157183890375115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638157183890365112" xlink:to="us-gaap_SaleOfStockPricePerShare_638157183890375115" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638157183890375115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638157183890365112" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638157183890375115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638157183890375115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638157183890365112" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638157183890375115" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638157183890375115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638157183890365112" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638157183890375115" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638157183890375115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638157183890365112" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638157183890375115" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638157183890375115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638157183890365112" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638157183890375115" order="7" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638157183890375115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638157183890375115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638157183890375115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157183890375115" xlink:to="srt_RangeAxis_638157183890375115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638157183890375115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638157183890375115" xlink:to="srt_RangeMember_638157183890375115" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638157183890385114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638157183890375115" xlink:to="srt_MinimumMember_638157183890385114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638157183890385114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638157183890375115" xlink:to="srt_MaximumMember_638157183890385114" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638157183890385114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157183890375115" xlink:to="us-gaap_StatementLineItems_638157183890385114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638157183890385114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890385114" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638157183890385114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638157183890385114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890385114" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638157183890385114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638157183890385114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890385114" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638157183890385114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638157183890385114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890385114" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638157183890385114" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638157183890385114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890385114" xlink:to="us-gaap_NumberOfOperatingSegments_638157183890385114" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" xlink:type="extended" xlink:title="40202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638157183890385114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638157183890385114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638157183890385114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157183890385114" xlink:to="us-gaap_StatementEquityComponentsAxis_638157183890385114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638157183890385114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157183890385114" xlink:to="us-gaap_EquityComponentDomain_638157183890385114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember_638157183890395161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638157183890385114" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember_638157183890395161" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638157183890395161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157183890385114" xlink:to="us-gaap_StatementLineItems_638157183890395161" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638157183890395161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890395161" xlink:to="us-gaap_NetIncomeLoss_638157183890395161" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638157183890395161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890395161" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638157183890395161" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638157183890395161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890395161" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638157183890395161" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638157183890395161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890395161" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638157183890395161" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638157183890395161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890395161" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638157183890395161" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638157183890395161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890395161" xlink:to="us-gaap_EarningsPerShareBasic_638157183890395161" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638157183890395161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157183890395161" xlink:to="us-gaap_EarningsPerShareDiluted_638157183890395161" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638157183890395161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638157183890395161" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638157183890395161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638157183890395161" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638157183890395161" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638157183890405114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638157183890395161" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638157183890405114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638157183890405114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638157183890405114" xlink:to="us-gaap_EmployeeStockOptionMember_638157183890405114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638157183890405114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638157183890405114" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638157183890405114" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638157183890405114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638157183890395161" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638157183890405114" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638157183890405114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638157183890405114" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638157183890405114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638157183890405114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638157183890405114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638157183890405114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638157183890405114" xlink:to="us-gaap_FinancialInstrumentAxis_638157183890405114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890405114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638157183890405114" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890405114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638157183890405114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890405114" xlink:to="us-gaap_USTreasurySecuritiesMember_638157183890405114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638157183890405114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890405114" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638157183890405114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638157183890405114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890405114" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638157183890405114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638157183890415114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638157183890405114" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638157183890415114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638157183890415114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638157183890415114" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638157183890415114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638157183890415114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638157183890415114" xlink:to="us-gaap_MoneyMarketFundsMember_638157183890415114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638157183890415114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638157183890415114" xlink:to="us-gaap_CommercialPaperMember_638157183890415114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638157183890415114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638157183890405114" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638157183890415114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638157183890415114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638157183890415114" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638157183890415114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638157183890415114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638157183890415114" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638157183890415114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638157183890415114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638157183890405114" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638157183890415114" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638157183890415114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638157183890415114" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638157183890415114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638157183890415114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638157183890415114" xlink:to="us-gaap_FairValueInputsLevel1Member_638157183890415114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638157183890415114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638157183890415114" xlink:to="us-gaap_FairValueInputsLevel2Member_638157183890415114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638157183890425117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638157183890405114" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638157183890425117" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638157183890425117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638157183890425117" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638157183890425117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638157183890425117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638157183890425117" xlink:to="us-gaap_ShortTermInvestments_638157183890425117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638157183890425117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638157183890425117" xlink:to="us-gaap_AssetsFairValueDisclosure_638157183890425117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638157183890425117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638157183890425117" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638157183890425117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638157183890425117" xlink:to="srt_RangeAxis_638157183890425117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638157183890425117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638157183890425117" xlink:to="srt_RangeMember_638157183890425117" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638157183890425117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638157183890425117" xlink:to="srt_MaximumMember_638157183890425117" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638157183890425117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638157183890425117" xlink:to="us-gaap_FinancialInstrumentAxis_638157183890425117" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890425117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638157183890425117" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890425117" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638157183890435118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890425117" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638157183890435118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638157183890435118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890425117" xlink:to="us-gaap_CommercialPaperMember_638157183890435118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638157183890435118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890425117" xlink:to="us-gaap_USTreasurySecuritiesMember_638157183890435118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638157183890435118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890425117" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638157183890435118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_638157183890435118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638157183890425117" xlink:to="us-gaap_InvestmentTypeAxis_638157183890435118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_638157183890435118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_638157183890435118" xlink:to="us-gaap_InvestmentTypeCategorizationMember_638157183890435118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember_638157183890435118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638157183890435118" xlink:to="us-gaap_ShortTermInvestmentsMember_638157183890435118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638157183890435118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638157183890425117" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638157183890435118" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_DebtSecuritiesAvailableForSaleMaturityTerm" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm_638157183890435118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638157183890435118" xlink:to="avte_DebtSecuritiesAvailableForSaleMaturityTerm_638157183890435118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_638157183890435118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638157183890435118" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_638157183890435118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638157183890435118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638157183890435118" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638157183890435118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638157183890445116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638157183890435118" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638157183890445116" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638157183890445116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638157183890435118" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638157183890445116" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent_638157183890445116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638157183890435118" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent_638157183890445116" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList_638157183890445116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638157183890435118" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList_638157183890445116" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_638157183890445116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_638157183890445116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638157183890445116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_638157183890445116" xlink:to="us-gaap_FinancialInstrumentAxis_638157183890445116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890445116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638157183890445116" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890445116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638157183890445116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890445116" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638157183890445116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638157183890445116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890445116" xlink:to="us-gaap_CommercialPaperMember_638157183890445116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638157183890455117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890445116" xlink:to="us-gaap_USTreasurySecuritiesMember_638157183890455117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638157183890455117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638157183890445116" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638157183890455117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638157183890455117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_638157183890445116" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638157183890455117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638157183890455117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638157183890455117" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638157183890455117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638157183890455117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638157183890455117" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638157183890455117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_638157183890455117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638157183890455117" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_638157183890455117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_638157183890455117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638157183890455117" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_638157183890455117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_638157183890455117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638157183890455117" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_638157183890455117" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_638157183890455117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638157183890455117" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_638157183890455117" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638157183890515113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent_638157183890515113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_PrepaidResearchAndDevelopment" xlink:label="avte_PrepaidResearchAndDevelopment_638157183890515113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="avte_PrepaidResearchAndDevelopment_638157183890515113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638157183890515113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638157183890515113" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638157183890515113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638157183890515113" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_AccruedResearchAndDevelopmentCurrent" xlink:label="avte_AccruedResearchAndDevelopmentCurrent_638157183890515113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="avte_AccruedResearchAndDevelopmentCurrent_638157183890515113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638157183890515113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638157183890515113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638157183890515113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638157183890515113" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638157183890515113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638157183890515113" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638157183890525113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638157183890525113" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638157183890525113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638157183890525113" xlink:to="us-gaap_LeaseContractualTermAxis_638157183890525113" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638157183890525113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638157183890525113" xlink:to="us-gaap_LeaseContractualTermDomain_638157183890525113" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_WalthamLeaseMember" xlink:label="avte_WalthamLeaseMember_638157183890525113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638157183890525113" xlink:to="avte_WalthamLeaseMember_638157183890525113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_FosterCityLeaseMember" xlink:label="avte_FosterCityLeaseMember_638157183890525113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638157183890525113" xlink:to="avte_FosterCityLeaseMember_638157183890525113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638157183890525113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638157183890525113" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638157183890525113" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand_638157183890525113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157183890525113" xlink:to="us-gaap_AreaOfLand_638157183890525113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638157183890525113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157183890525113" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638157183890525113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638157183890525113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157183890525113" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638157183890525113" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638157183890525113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157183890525113" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638157183890525113" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent_638157183890525113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157183890525113" xlink:to="us-gaap_PaymentsForRent_638157183890525113" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_LeaseIncreaseInRentPercentage" xlink:label="avte_LeaseIncreaseInRentPercentage_638157183890525113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157183890525113" xlink:to="avte_LeaseIncreaseInRentPercentage_638157183890525113" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638157183890535113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157183890525113" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638157183890535113" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638157183890535113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157183890525113" xlink:to="us-gaap_OperatingLeaseLiability_638157183890535113" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638157183890535113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157183890525113" xlink:to="us-gaap_OperatingLeaseExpense_638157183890535113" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails" xlink:type="extended" xlink:title="40502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638157183890535113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638157183890535113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638157183890535113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638157183890535113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638157183890535113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638157183890535113" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638157183890535113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638157183890535113" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638157183890535113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638157183890535113" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638157183890535113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638157183890535113" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_638157183890535113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_638157183890535113" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638157183890545112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638157183890535113" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638157183890545112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638157183890545112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638157183890535113" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638157183890545112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638157183890545112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638157183890545112" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638157183890545112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638157183890545112" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40601 - Disclosure - STOCKHOLDERS' EQUITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_638157183890545112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_638157183890545112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638157183890545112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_638157183890545112" xlink:to="us-gaap_StatementEquityComponentsAxis_638157183890545112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638157183890545112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157183890545112" xlink:to="us-gaap_EquityComponentDomain_638157183890545112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_638157183890545112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638157183890545112" xlink:to="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_638157183890545112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember_638157183890555118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638157183890545112" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember_638157183890555118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638157183890555118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_638157183890545112" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638157183890555118" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638157183890555118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638157183890555118" xlink:to="us-gaap_RelatedPartyDomain_638157183890555118" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_RaCapitalHealthcareFundL.pMember" xlink:label="avte_RaCapitalHealthcareFundL.pMember_638157183890555118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638157183890555118" xlink:to="avte_RaCapitalHealthcareFundL.pMember_638157183890555118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638157183890555118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_638157183890545112" xlink:to="us-gaap_PlanNameAxis_638157183890555118" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638157183890555118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638157183890555118" xlink:to="us-gaap_PlanNameDomain_638157183890555118" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_StockPurchaseAgreementMember" xlink:label="avte_StockPurchaseAgreementMember_638157183890555118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638157183890555118" xlink:to="avte_StockPurchaseAgreementMember_638157183890555118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_MilestoneAxis" xlink:label="avte_MilestoneAxis_638157183890555118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_638157183890545112" xlink:to="avte_MilestoneAxis_638157183890555118" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_MilestoneDomain" xlink:label="avte_MilestoneDomain_638157183890555118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avte_MilestoneAxis_638157183890555118" xlink:to="avte_MilestoneDomain_638157183890555118" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_FirstMilestoneMember" xlink:label="avte_FirstMilestoneMember_638157183890555118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avte_MilestoneDomain_638157183890555118" xlink:to="avte_FirstMilestoneMember_638157183890555118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_SecondAndThirdMilestoneMember" xlink:label="avte_SecondAndThirdMilestoneMember_638157183890555118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avte_MilestoneDomain_638157183890555118" xlink:to="avte_SecondAndThirdMilestoneMember_638157183890555118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638157183890555118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_638157183890545112" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638157183890555118" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638157183890565115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638157183890555118" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638157183890565115" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638157183890565115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638157183890565115" xlink:to="us-gaap_IPOMember_638157183890565115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_638157183890545112" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_CapitalStockSharesAuthorized" xlink:label="avte_CapitalStockSharesAuthorized_638157183890565115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="avte_CapitalStockSharesAuthorized_638157183890565115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638157183890565115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_CommonStockSharesAuthorized_638157183890565115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638157183890565115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638157183890565115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638157183890565115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_PreferredStockSharesAuthorized_638157183890565115" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638157183890565115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638157183890565115" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_638157183890565115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_638157183890565115" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_638157183890565115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_638157183890565115" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_638157183890575118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_638157183890575118" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_638157183890575118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_TemporaryEquitySharesIssued_638157183890575118" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638157183890575118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_SharesIssuedPricePerShare_638157183890575118" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes" xlink:label="avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes_638157183890575118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes_638157183890575118" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638157183890575118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_SharePrice_638157183890575118" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_638157183890575118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_ConversionOfStockSharesIssued1_638157183890575118" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638157183890575118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_CommonStockSharesIssued_638157183890575118" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638157183890575118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638157183890575118" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_NumberOfVotesForEachShareOfCommonStock" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock_638157183890585115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_638157183890565115" xlink:to="avte_NumberOfVotesForEachShareOfCommonStock_638157183890585115" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" xlink:type="extended" xlink:title="40602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638157183890585115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638157183890585115" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638157183890585115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638157183890585115" xlink:to="us-gaap_AwardTypeAxis_638157183890585115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890585115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638157183890585115" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890585115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638157183890585115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890585115" xlink:to="us-gaap_CommonStockMember_638157183890585115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638157183890585115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890585115" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638157183890585115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638157183890585115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890585115" xlink:to="us-gaap_StockCompensationPlanMember_638157183890585115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638157183890585115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638157183890585115" xlink:to="us-gaap_PlanNameAxis_638157183890585115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638157183890595116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638157183890585115" xlink:to="us-gaap_PlanNameDomain_638157183890595116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_638157183890595116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638157183890595116" xlink:to="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_638157183890595116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638157183890595116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638157183890585115" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638157183890595116" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638157183890595116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638157183890595116" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638157183890595116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SHARE-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890595116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890595116" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638157183890595116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890595116" xlink:to="us-gaap_AwardTypeAxis_638157183890595116" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890595116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638157183890595116" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890595116" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638157183890595116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890595116" xlink:to="us-gaap_EmployeeStockOptionMember_638157183890595116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638157183890595116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890595116" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638157183890595116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638157183890595116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890595116" xlink:to="us-gaap_StockCompensationPlanMember_638157183890595116" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638157183890605122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890595116" xlink:to="srt_RangeAxis_638157183890605122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638157183890605122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638157183890605122" xlink:to="srt_RangeMember_638157183890605122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638157183890605122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638157183890605122" xlink:to="srt_MinimumMember_638157183890605122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638157183890605122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638157183890605122" xlink:to="srt_MaximumMember_638157183890605122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638157183890605122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890595116" xlink:to="us-gaap_PlanNameAxis_638157183890605122" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638157183890605122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638157183890605122" xlink:to="us-gaap_PlanNameDomain_638157183890605122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_638157183890605122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638157183890605122" xlink:to="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_638157183890605122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember_638157183890605122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638157183890605122" xlink:to="avte_TwentyEighteenStockOptionAndIncentivePlanMember_638157183890605122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_638157183890605122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638157183890605122" xlink:to="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_638157183890605122" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890595116" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638157183890605122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638157183890605122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638157183890605122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638157183890605122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638157183890615122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638157183890615122" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638157183890615122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638157183890615122" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638157183890615122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638157183890615122" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638157183890615122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638157183890615122" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638157183890615122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638157183890615122" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_638157183890615122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_638157183890615122" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_638157183890615122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_638157183890615122" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638157183890615122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638157183890615122" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638157183890615122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638157183890615122" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638157183890625121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638157183890625121" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638157183890625121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890605122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638157183890625121" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" xlink:type="extended" xlink:title="40702 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638157183890625121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638157183890625121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638157183890625121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638157183890625121" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638157183890625121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638157183890625121" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638157183890625121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638157183890625121" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638157183890625121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638157183890625121" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638157183890635122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638157183890635122" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638157183890635122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638157183890635122" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638157183890635122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638157183890635122" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638157183890635122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638157183890635122" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638157183890635122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638157183890635122" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638157183890635122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638157183890635122" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_638157183890635122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_638157183890635122" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_638157183890635122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_638157183890635122" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638157183890635122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638157183890635122" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_638157183890635122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_638157183890635122" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638157183890635122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638157183890635122" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638157183890645120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638157183890645120" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638157183890645120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638157183890645120" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638157183890645120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638157183890645120" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638157183890645120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638157183890645120" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638157183890645120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638157183890645120" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638157183890645120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638157183890645120" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xlink:type="extended" xlink:title="40703 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890655120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890655120" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638157183890655120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890655120" xlink:to="us-gaap_AwardTypeAxis_638157183890655120" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890655120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638157183890655120" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890655120" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638157183890655120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890655120" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638157183890655120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890655120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890655120" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890655120" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638157183890655120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890655120" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638157183890655120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638157183890655120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890655120" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638157183890655120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638157183890655120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890655120" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638157183890655120" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638157183890655120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890655120" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638157183890655120" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6381571838906551201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890655120" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6381571838906551201" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6381571838906551201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890655120" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6381571838906551201" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890665122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890665122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638157183890665122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890665122" xlink:to="srt_RangeAxis_638157183890665122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638157183890665122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638157183890665122" xlink:to="srt_RangeMember_638157183890665122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638157183890665122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638157183890665122" xlink:to="srt_MinimumMember_638157183890665122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638157183890665122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638157183890665122" xlink:to="srt_MaximumMember_638157183890665122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890665122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157183890665122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890665122" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638157183890665122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890665122" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638157183890665122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638157183890665122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890665122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638157183890665122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638157183890665122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890665122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638157183890665122" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638157183890665122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890665122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638157183890665122" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638157183890665122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157183890665122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638157183890665122" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" xlink:type="extended" xlink:title="40705 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638157183890675118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638157183890675118" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638157183890675118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638157183890675118" xlink:to="us-gaap_IncomeStatementLocationAxis_638157183890675118" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638157183890675118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638157183890675118" xlink:to="us-gaap_IncomeStatementLocationDomain_638157183890675118" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638157183890675118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638157183890675118" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638157183890675118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638157183890675118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638157183890675118" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638157183890675118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638157183890675118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638157183890675118" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638157183890675118" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638157183890675118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638157183890675118" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638157183890675118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xlink:type="extended" xlink:title="40706 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638157183890675118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638157183890675118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638157183890675118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638157183890675118" xlink:to="us-gaap_AwardTypeAxis_638157183890675118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890685119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638157183890675118" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890685119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638157183890685119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890685119" xlink:to="us-gaap_EmployeeStockOptionMember_638157183890685119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638157183890685119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890685119" xlink:to="us-gaap_StockCompensationPlanMember_638157183890685119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638157183890685119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157183890685119" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638157183890685119" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638157183890685119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638157183890675118" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638157183890685119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638157183890685119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638157183890685119" xlink:to="us-gaap_ShareBasedCompensation_638157183890685119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157183890685119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157183890685119" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638157183890685119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157183890685119" xlink:to="us-gaap_RelatedPartyTransactionAxis_638157183890685119" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638157183890685119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638157183890685119" xlink:to="us-gaap_RelatedPartyTransactionDomain_638157183890685119" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ServicesAgreementWithCarnotLlcMember" xlink:label="avte_ServicesAgreementWithCarnotLlcMember_638157183890685119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638157183890685119" xlink:to="avte_ServicesAgreementWithCarnotLlcMember_638157183890685119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638157183890685119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157183890685119" xlink:to="us-gaap_IncomeStatementLocationAxis_638157183890685119" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638157183890695118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638157183890685119" xlink:to="us-gaap_IncomeStatementLocationDomain_638157183890695118" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember" xlink:label="avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_638157183890695118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638157183890695118" xlink:to="avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_638157183890695118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638157183890695118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157183890685119" xlink:to="srt_RangeAxis_638157183890695118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638157183890695118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638157183890695118" xlink:to="srt_RangeMember_638157183890695118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638157183890695118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638157183890695118" xlink:to="srt_MaximumMember_638157183890695118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638157183890695118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157183890685119" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638157183890695118" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_RelatedPartyTransactionTerm" xlink:label="avte_RelatedPartyTransactionTerm_638157183890695118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157183890695118" xlink:to="avte_RelatedPartyTransactionTerm_638157183890695118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_NoticeToTerminateAgreementPeriod" xlink:label="avte_NoticeToTerminateAgreementPeriod_638157183890695118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157183890695118" xlink:to="avte_NoticeToTerminateAgreementPeriod_638157183890695118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_MaterialBreachCorrectionPeriod" xlink:label="avte_MaterialBreachCorrectionPeriod_638157183890695118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157183890695118" xlink:to="avte_MaterialBreachCorrectionPeriod_638157183890695118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638157183890695118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157183890695118" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638157183890695118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_638157183890695118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157183890695118" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_638157183890695118" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - INCOME TAXES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638157183890705122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638157183890705122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638157183890705122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638157183890705122" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638157183890705122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638157183890705122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638157183890705122" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638157183890705122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638157183890705122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638157183890705122" xlink:to="us-gaap_DomesticCountryMember_638157183890705122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638157183890705122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638157183890705122" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638157183890705122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638157183890705122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638157183890705122" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638157183890705122" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638157183890705122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638157183890705122" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638157183890705122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638157183890705122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638157183890705122" xlink:to="us-gaap_ResearchMember_638157183890705122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638157183890705122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638157183890705122" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638157183890705122" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638157183890705122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638157183890705122" xlink:to="us-gaap_OperatingLossCarryforwards_638157183890705122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638157183890705122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638157183890705122" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638157183890705122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638157183890715133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638157183890715133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638157183890715133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638157183890715133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_638157183890715133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_638157183890715133" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638157183890715133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther_638157183890715133" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638157183890715133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross_638157183890715133" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638157183890715133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638157183890715133" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638157183890715133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet_638157183890715133" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_638157183890715133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_638157183890715133" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638157183890715133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities_638157183890715133" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638157183890715133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638157183890715133" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" xlink:type="extended" xlink:title="40903 - Disclosure - INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638157183890725121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638157183890725121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638157183890725121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638157183890725121" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_638157183890725121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_638157183890725121" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_638157183890725121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_638157183890725121" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xlink:label="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_638157183890725121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_638157183890725121" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638157183890725121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638157183890725121" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638157183890725121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638157183890725121" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638157183890725121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_638157183890725121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638157183890735117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638157183890735117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_638157183890735117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_638157183890735117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638157183890735117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_638157183890735117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054663935696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 27, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aerovate Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001798749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1377888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">930 Winter Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;M-500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">443-2400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVTE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,812,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated By Reference</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 4pt 0pt;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2023 Annual Meeting of Stockholders within 120&#160;days of the end of the registrant&#8217;s fiscal&#160;year ended December&#160;31, 2022. Portions of such definitive proxy statement are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K to the extent stated herein.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054662683808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,397<span></span>
</td>
<td class="nump">$ 54,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">106,823<span></span>
</td>
<td class="nump">113,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,276<span></span>
</td>
<td class="nump">6,958<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">131,496<span></span>
</td>
<td class="nump">174,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">2,560<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">135,301<span></span>
</td>
<td class="nump">175,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,575<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">4,822<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,782<span></span>
</td>
<td class="nump">2,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">8,558<span></span>
</td>
<td class="nump">2,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2022 and December 31, 2021, respectively; no shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 24,722,974 and 24,410,393 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">215,110<span></span>
</td>
<td class="nump">208,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(466)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(87,903)<span></span>
</td>
<td class="num">(36,392)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">126,743<span></span>
</td>
<td class="nump">172,418<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 135,301<span></span>
</td>
<td class="nump">$ 175,363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054664602448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">24,722,974<span></span>
</td>
<td class="nump">24,410,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">24,722,974<span></span>
</td>
<td class="nump">24,410,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054665850288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 38,622<span></span>
</td>
<td class="nump">$ 14,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,615<span></span>
</td>
<td class="nump">8,035<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">53,237<span></span>
</td>
<td class="nump">23,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(53,237)<span></span>
</td>
<td class="num">(23,022)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">1,830<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">1,751<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(51,486)<span></span>
</td>
<td class="num">(22,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(51,511)<span></span>
</td>
<td class="num">(22,963)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(51,511)<span></span>
</td>
<td class="num">(22,963)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss', window );">Unrealized loss on securities</a></td>
<td class="num">(407)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (51,918)<span></span>
</td>
<td class="num">$ (23,022)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.10)<span></span>
</td>
<td class="num">$ (1.87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.10)<span></span>
</td>
<td class="num">$ (1.87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding, basic</a></td>
<td class="nump">24,472,104<span></span>
</td>
<td class="nump">12,293,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding, diluted</a></td>
<td class="nump">24,472,104<span></span>
</td>
<td class="nump">12,293,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054663443232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series Seed Redeemable Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Redeemable Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>ESPP</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">6,489,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 12,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (13,407)<span></span>
</td>
<td class="num">$ (13,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A redeemable convertible preferred stock per share, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A redeemable convertible preferred stock per share, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,562,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of Series A redeemable convertible preferred stock per share, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of Series A redeemable convertible preferred stock to redemption value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</a></td>
<td class="num">$ (4,000)<span></span>
</td>
<td class="num">$ (75,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">79,817<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">79,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering, shares</a></td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="num">(40,052,154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,182,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">126,944<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">126,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,984,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss', window );">Unrealized loss on investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,043<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(22,963)<span></span>
</td>
<td class="num">(22,963)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,410,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">208,867<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(36,392)<span></span>
</td>
<td class="nump">172,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss', window );">Unrealized loss on investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(407)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,476<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(51,511)<span></span>
</td>
<td class="num">(51,511)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,722,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 215,110<span></span>
</td>
<td class="num">$ (466)<span></span>
</td>
<td class="num">$ (87,903)<span></span>
</td>
<td class="nump">$ 126,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of redeemable convertible preferred stock to common stock upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of redeemable convertible preferred stock to common stock upon initial public offering, shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of new shares classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054663816736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of Series A redeemable convertible preferred stock</a></td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 1.893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of Series A redeemable convertible preferred stock</a></td>
<td class="num">$ (22)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avte_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avte_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054662552544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (51,511)<span></span>
</td>
<td class="num">$ (22,963)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,476<span></span>
</td>
<td class="nump">2,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet', window );">Accretion of discounts and amortization of premiums on investments, net</a></td>
<td class="num">(910)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,677<span></span>
</td>
<td class="num">(6,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(1,872)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">3,672<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability', window );">Operating lease assets and liabilities, net</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_IncreaseDecreaseInOtherLiabilities', window );">Other liabilities</a></td>
<td class="num">(133)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(39,122)<span></span>
</td>
<td class="num">(27,399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(147,623)<span></span>
</td>
<td class="num">(113,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Sales and maturities of short-term investments</a></td>
<td class="nump">154,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">6,926<span></span>
</td>
<td class="num">(113,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from sale of Series A redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for deferred offering costs</a></td>
<td class="num">(371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from issuance of common stock under ESPP</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,945<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">190,457<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(31,800)<span></span>
</td>
<td class="nump">49,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at the beginning of the year</a></td>
<td class="nump">54,197<span></span>
</td>
<td class="nump">4,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">22,397<span></span>
</td>
<td class="nump">54,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">765<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DeferredOfferingCostsIncludedInAccountsPayable', window );">Deferred offering costs included in accounts payable</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,818<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of discounts and amortization of premiums on investments net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_DeferredOfferingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_DeferredOfferingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease asset and liability, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_IncreaseDecreaseInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_IncreaseDecreaseInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054669057872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Organization and Nature of Operations</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Aerovate Therapeutics&#160;Inc. (&#8220;Aerovate&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in July&#160;2018, and is headquartered in Waltham, Massachusetts. The Company has a wholly owned subsidiary, Aerovate Securities Corporation. The Company is a clinical-stage biopharmaceutical company that is focused on the development of drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. The Company&#8217;s initial focus is on advancing AV-101, the Company&#8217;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;). The Company initiated a global Phase 2b/Phase 3 trial of AV-101 in adults with PAH in December&#160;2021.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Initial Public Offering</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">On July&#160;2, 2021, the Company completed its initial public offering (&#8220;IPO&#8221;). The Company&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-256949) relating to the IPO was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on June&#160;29, 2021. The shares began trading on The Nasdaq Global Market on June&#160;30, 2021. The Company issued 9,984,463 shares of its common stock, including 1,302,321 shares associated with the full exercise of the underwriters&#8217; option to purchase additional shares, at an offering price of $14.00 per share. Immediately prior to the closing of the Company&#8217;s IPO on July&#160;2, 2021, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock were converted into 14,182,854 shares of the Company&#8217;s common stock. In aggregate, the shares issued in the IPO generated approximately $126.9 million in net proceeds after deducting underwriting discounts and commissions and other offering costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"><span style="font-style:italic;font-weight:bold;">At-the-Market Offering </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"><span style="font-size:10pt;">On August 15, 2022, we entered into an </span><span style="font-size:10pt;">Open Market Sale Agreement</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-size:10pt;">, or</span><span style="font-size:10pt;"> the Sale Agreement, with Jefferies LLC, or the Agent, pursuant to which we can sell, from time to time, at our option, up to an aggregate of </span><span style="font-size:10pt;">$75.0</span><span style="font-size:10pt;"> million of shares of our common stock, through the Agent, as our sales agent. As of December 31, 2022, </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;"> shares were sold under the Sale Agreement.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Liquidity and Management Plans</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Since inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations and has not realized revenues from its planned principal operations. The Company has incurred losses and negative cash flows from operations since inception. In addition, the Company expects to incur substantial operating losses for the next several&#160;years as it continues its research and development activities. As of December&#160;31, 2022, the Company had cash and cash equivalents and short-term investments of $129.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through debt or equity financings or other arrangements to fund operations. Management believes that the Company&#8217;s current cash and cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve&#160;months from the filing date of this report.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054668751360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES.</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the Company&#8217;s wholly owned subsidiary, Aerovate Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Reverse Stock Split</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">On June&#160;22, 2021, the Company effected a <span style="-sec-ix-hidden:Hidden_AH0m-scr1ESIQqpsOnDeyg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-3</span></span>.1060103 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of its issued and outstanding common stock. Accordingly, the conversion ratio for the Company&#8217;s outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. The par value of the common stock was not adjusted as a result of the Reverse Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Cash and Cash Equivalents</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Cash and cash equivalents include cash in readily available checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three&#160;months or less from the date of purchase to be cash equivalents.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(e)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Short-term Investments</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;">Short-term investments consist of corporate debt securities, commercial paper and U.S. Treasury bills, classified as available-for-sale securities and have maturities of greater than three&#160;months. The Company has classified all of its available-for-sale investment securities as current assets on the consolidated balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company carries these securities at fair value and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the consolidated statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">using the specific identification method and recorded in other income (expense), net in the consolidated statement of operations and comprehensive loss.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(f)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Concentration of Credit Risk</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(g)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Comprehensive Loss</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(h)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Fair Value Measurements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Level 1: Observable inputs such as quoted prices in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(i)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Prepaid Expenses and Other Current Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Any expenses paid prior to the related services rendered are recorded as prepaid expenses. Such prepaid expenses are expensed in the period the expense is incurred. If the expense is for a service covering multiple periods, it is expensed from the date the services begin and over the period of the service rendered (or contract service period if services rendered dates are not defined).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(j)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Property and Equipment, Net</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and construction-in-progress are stated at cost less accumulated depreciation or accumulated amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from <span style="-sec-ix-hidden:Hidden_bBazvaq5mUO3D78wc3eoZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <span style="-sec-ix-hidden:Hidden_Ha-ILLgVZUue-n7HxT3H2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;years</span></span>. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(k)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Impairment of Long-lived Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December&#160;31, 2022, there has been no such impairment losses recorded by the Company.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(l)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Leases</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets (&#8220;ROU assets&#8221;) which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to separate lease and non-lease components and not recognize lease liabilities and ROU assets for short-term leases with terms of twelve&#160;months or less.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(m)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Convertible Preferred Stock</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company records convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#8217;s control, including a deemed liquidation event, holders of the convertible preferred stock can cause redemption for cash. Therefore, convertible preferred stock is classified outside of stockholders&#8217; deficit on the balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(n)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Research and Development Expenses</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(o)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock-Based Compensation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;">Stock-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option grants and restricted stock units, estimated in accordance with the applicable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">accounting guidance, recognized using the straight-line method over the vesting period for service-based options and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">The fair value of stock options is estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, expected dividend yield, and a risk-free interest rate. Options and awards granted during the&#160;year have a maximum contractual term of ten&#160;years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected volatility of stock options is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury (&#8220;U.S. Treasury&#8221;) yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">(p)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">Income Taxes</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss (&#8220;NOL&#8221;) and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company records uncertain tax positions on the basis of a two-step process whereby (1)&#160;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">(q)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">Segment Reporting</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">(r)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities, which include convertible preferred stock prior to the conversion of such shares to common stock and outstanding stock options under the Company&#8217;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;">The following table summarizes the Company&#8217;s net loss per share:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,963)</p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of Series A redeemable convertible preferred stock to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,985)</p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,472,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,293,629</p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.87)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,454,374</p></td></tr><tr><td style="vertical-align:top;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,139,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,454,374</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33.1pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(p)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Recently Issued Accounting Pronouncements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard will be effective for the Company on January 1, 2024, and is not expected to have an impact on the Company&#8217;s financial position or results of operations upon adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054670745104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">(3)&#160;FAIR VALUE OF FINANCIAL INSTRUMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 125,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 167,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 33pt;">Cash Equivalents and Short-Term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Financial assets measured at fair value on a recurring basis consist of the Company&#8217;s cash equivalents and short-term investments. Cash equivalents consisted of cash, money market funds and commercial paper, and short-term investments consisted of U.S. Treasury bills, agency bonds, corporate debt securities and commercial paper. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:36.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_P4znHQF3GUSWjTutnltemQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (267)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:36.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (484)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (68)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The following tables summarize the Company&#8217;s short-term investments with unrealized losses for less than 12 months and 12 months or greater:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:71.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (267)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (223)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (484)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:71.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td></tr><tr><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td></tr><tr><td style="vertical-align:top;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (68)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (68)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#8217;s available-for-sale securities as of December&#160;31, 2022 were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. The Company concluded that an allowance for credit losses was unnecessary as of December&#160;31, 2022. It is neither management&#8217;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. <span style="-sec-ix-hidden:Hidden_NQg-uPEboUy3bkc7fClBSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued interest receivable</span></span> related to short-term investments was $0.3 million and $0.1 million as of December&#160;31, 2022 and December 31, 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054663798192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4)&#160;BALANCE SHEET COMPONENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accrued and Other Current Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Accrued and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,691</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054668802080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5)&#160;COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In August&#160;2021, the Company entered into a lease agreement (the &#8220;Waltham Lease&#8221;) for approximately 5,000 square feet of office space in Waltham, Massachusetts for the Company&#8217;s corporate headquarters. The Waltham Lease has a term of thirty-nine months (&#8220;Lease Term&#8221;), unless extended or earlier terminated. The Company has the option to extend the Waltham Lease for one additional period of three&#160;years. The Lease Term had an initial abatement period, and the initial base rent payable is approximately $18,000 per&#160;month following the abatement period. The initial base rent payable will increase by approximately 2% per&#160;year over the Lease Term. The Waltham Lease commencement date was September&#160;1, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In April 2022, the Company entered into a lease agreement (the &#8220;Foster City Lease&#8221;) for approximately 3,500 square feet of office space in Foster City, California. The Foster City Lease has a term of thirty-nine months, unless extended or earlier terminated. The Company has the option to extend the Foster City Lease for on additional period of one year. The base rent payable under the Lease Term will be $22,600 per month and will be subject to annual increase of 3% on each anniversary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022, the consolidated balance sheet includes an operating lease right-of-use asset of $1.0 million and operating lease liability of $1.1 million. The total operating lease expense was $0.4 million and $0.1 million, for the years ended December 31, 2022 and 2021, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The components of operating leases for the years ended December 31, 2022 and December 31, 2021 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company may from time to time be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December 31, 2022 and 2021, and no material legal proceedings are currently pending or, to the best of its knowledge, threatened.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054668809440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6)&#160;STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33.1pt;">Under the Company&#8217;s Amended and Restated Certificates of Incorporation dated August&#160;3, 2020, the Company had a total of 94,052,154 shares of capital stock authorized for issuance, consisting of 50,000,000 shares of common stock, par value of $0.0001 per share, and 44,052,154 shares of convertible preferred stock, par value of $0.0001 per share. Shares of authorized convertible preferred stock were designated as 4,000,000 shares of Series&#160;Seed redeemable convertible preferred stock and 40,052,154 shares of Series&#160;A redeemable convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Following the Reverse Stock Split, the Company filed a Second Amended and Restated Certificate of Incorporation, which provided for 150,000,000 authorized shares of common stock with a par value of $0.0001 per share and 10,000,000 authorized shares of undesignated preferred stock with a par value of $0.0001 per share, effective upon completion of the Company&#8217;s IPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Redeemable Convertible Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In August&#160;2018, the Company sold to RA Capital Health Care Fund,&#160;L.P. an aggregate of 4,000,000 shares of Series&#160;Seed redeemable preferred stock at a purchase price of $1.00 per share, for net proceeds of $4.0 million. On August&#160;5, 2020, the Company entered into the Stock Purchase Agreement. The Company&#8217;s initial closing of its Series&#160;A redeemable convertible preferred stock occurred on this date. The Company issued 3,468,536 shares of Series&#160;A redeemable convertible preferred shares for gross proceeds of $6.6 million at a price per share of $1.893. In addition to the cash proceeds, 3,020,998 shares of Series&#160;A redeemable convertible preferred stock were issued in connection with the conversion of the 2019 Notes&#160;and the 2020 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Stock Purchase Agreement contained provisions that potentially obligate the Company to sell, outside of its control, an additional 33,562,620 shares of Series&#160;A redeemable convertible preferred stock at $1.893 per share for expected gross proceeds of $63.5 million, upon the occurrence of three subsequent Milestone Closings or earlier, at the option of any holder of the Series&#160;A redeemable convertible preferred stock. If the defined milestones were not achieved prior to the Company&#8217;s initial public offering, the holders had the right to purchase these shares prior to the completion of the initial public offering. If the shares were not purchased prior to the completion of the initial public offering, then this right to purchase these shares would have automatically expired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;">On February&#160;1, 2021, upon the completion of the First Milestone Closing, the Company sold 4,224,274 shares of Series&#160;A redeemable convertible preferred stock at the Series&#160;A Original Issue Price for aggregate gross proceeds of $8.0 million. On June&#160;4, 2021, upon the completion of the Second Milestone Closing and the Third Milestone </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Closing, the Company sold 29,338,346 shares of Series&#160;A redeemable convertible preferred stock at the Series&#160;A Original Issue Price for aggregate gross proceeds of $55.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Immediately prior to the closing of the Company&#8217;s IPO on July&#160;2, 2021, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock converted into 14,182,854 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In August&#160;2018, the Company issued 241,467 shares of common stock to RA Capital Healthcare Fund,&#160;L.P. at a price of $0.0012 per share. On July&#160;2, 2021, in conjunction with the Company&#8217;s IPO, the Company issued 9,984,463 shares of its common stock and all outstanding shares of the Company&#8217;s redeemable convertible preferred stock were converted into 14,182,854 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022, the Company had reserved the following shares of common stock for future issuance:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,077,557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for vesting of outstanding restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 216,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,432,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054668791888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7)&#160;SHARE-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Stock Option Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company&#8217;s 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;) was adopted by the Company&#8217;s board of directors and approved by the Company&#8217;s stockholders in June&#160;2021 and became effective as of June&#160;29, 2021. Upon the effectiveness of the 2021 Plan, the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) was terminated and no further grants may be made thereunder. The Company&#8217;s 2021 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022, a total of 3,576,415 shares of the Company&#8217;s common stock were authorized for issuance with respect to awards granted under the 2021 Plan. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;4% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. The number of shares available under the 2021 Plan increased by 976,415 and 988,918 shares, effective January 1, 2022 and January 1, 2023, respectively, as determined by the Company&#8217;s board of directors. Any shares subject to awards granted under the 2021 Plan or the 2018 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022, 2,467,977 options had been granted and 28,881 restricted stock units awarded under the 2021 Plan, with 1,077,557 shares authorized for future issuance. As of December 31, 2022, a total of 1,642,242 options had been granted and were outstanding under the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The options that are granted under the 2021 Plan and the 2018 Plan are exercisable at various dates as determined upon grant and terminate within 10&#160;years of the date of grant. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_uKh2d8qoz0GftAIlA0yOkQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to four&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the&#160;year ended December&#160;31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,454,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 954,557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (298,712)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,044,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,682</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The weighted-average grant date fair value of stock option grants was $10.48&#160;and $4.46 per share for the years ended December 31,&#160;2022 and December 31, 2021, respectively. All exercisable options are vested and all outstanding options are vested or expected to vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022 there was approximately $17.2 million of unrecognized stock-based compensation expense related to nonvested stock-based compensation arrangements granted under the 2021 Plan and 2018 Plan, which is expected to be recognized over a weighted-average period of 2.7&#160;years</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company&#8217;s Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was adopted by the Company&#8217;s board of directors and stockholders in June&#160;2021 and became effective upon the consummation of the IPO. A total of 230,000 shares of the Company&#8217;s common stock is initially available for issuance under the ESPP. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;1% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. The number of shares available under the 2021 Plan increased by 247,229 shares effective January 1, 2023 as determined by the Company&#8217;s board of directors. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of December&#160;31, 2022, 13,869 shares had been issued under the ESPP, and 216,131 shares authorized under the ESPP Plan were available for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December 31, 2022, 28,881 restricted stock units had been awarded under the 2021 Plan. A summary of the status of and changes in unvested restricted stock unit activity under the Company&#8217;s equity award plans for the nine months ended December 31, 2022 was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Stock-based compensation of restricted stock units is based on the fair value of the Company&#8217;s common stock on the date of grant and recognized over the vesting period. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_gWG-e8KNUkuG8sHbxrnFJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to four years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December 31,&#160;2022, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock units of $0.6&#160;million, which is expected to be recognized over the remaining weighted-average vesting period of&#160;3.3&#160;years. The Company did not incur or have any unrecognized stock-based compensation related to restricted stock units as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Stock-Based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company estimated the fair value of stock options using the Black-Scholes valuation model. The Company accounts for any forfeitures of options when they occur. Previously recognized compensation expense for an award is reversed in the period that the award is forfeited. The fair value of stock options was estimated using the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:51.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.2 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">73.5 - 76.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">68.7 - 69.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.6 - 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.9 - 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Stock-based compensation expense recognized for stock option grants has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive (loss) income was as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33.1pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054668791888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8)&#160;RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Services Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In August&#160;2018, the Company entered into a services agreement (&#8220;Services Agreement&#8221;) with Carnot, LLC (&#8220;Carnot&#8221;), an entity owned and controlled by RA Capital Management,&#160;L.P. under which Carnot provides research and other services to the Company. RA Capital Management,&#160;L.P. is a related party due to its equity ownership of the Company. The Company pays Carnot for services performed and costs incurred. The Services Agreement is for a term of two years. The Company may terminate the Services Agreement by giving 30&#160;days&#8217; prior notice and either party can terminate the services agreement for a material breach, if not cured within 30&#160;days following notice by the nonbreaching party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In July&#160;2019, the Services Agreement with Carnot was amended whereby research and other services are now performed by Carnot Pharma, LLC (&#8220;Carnot Pharma&#8221;), an entity owned and controlled by RA Capital Management,&#160;L.P., and the term was updated to the later of (i)&#160;two&#160;years from July&#160;15, 2019 and (ii)&#160;completion of services under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Expenses incurred by the Company under the Services Agreement with Carnot Pharma totaled less than $0.1 million and $0.1 million for the&#160;years ended December&#160;31, 2022 and December&#160;31, 2021, respectively, and are presented in the statement of operations and comprehensive loss as research and development and general and administrative expenses. As of December&#160;31, 2021, $2,000 was due to Carnot Pharma, LLC by the Company for services rendered under the agreement, and no amount was due to Carnot Pharma, LLC as of December 31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054668802080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9)&#160;INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred income tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">NOL carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,781</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,498</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_E0ae-PWvkE-yL5o9JZGx5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 615</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,643</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,283)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,517)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred income tax liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (302)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (126)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (302)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (126)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax assets (liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_nezSGvSzDU6xkqS5dwZsuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,829)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,821)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,828)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (520)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent and other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (787)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (757)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (392)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,618</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company had federal NOL carryforwards available of $46.6 million and $32.6 million as of December&#160;31, 2022 and December&#160;31, 2021, respectively, before consideration of limitations under Section&#160;382 of the Internal Revenue Code or Section&#160;382, as further described below. The NOL generated from 2018 onwards of $46.6 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each&#160;year. Additionally, the Company had state NOL carryforwards available of $34.4 million and $20.3 million as of December&#160;31, 2022 and December&#160;31, 2021, respectively. The state NOLs may be used to offset future taxable income and will begin to expire in 2038. At December 31, 2022 the Company had federal and state research and development credit carryforwards available of $1.8 million and $0.6 million, respectively. The federal credit carryforwards will begin to expire in 2038, unless previously utilized. The Massachusetts credit carryforwards will begin expiring in 2036, unless previously utilized. The California credits carry forward indefinitely. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;">The Company has established a full valuation allowance for its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred since inception. Such objective evidence limits the ability to consider other subjective evidence such as the Company&#8217;s projections for future growth. Based on this evaluation, as of December&#160;31, 2022 and December&#160;31, 2021, a valuation allowance of $23.3 million and $8.5 million, respectively, has been recorded against all of the Company&#8217;s net deferred tax assets, as the Company has determined that none of the Company&#8217;s balance of net deferred tax assets is more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted in the future if objective negative evidence in the form of cumulative losses is no longer present and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">additional weight may be given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company&#8217;s projections for growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The future utilization of the Company&#8217;s NOL and tax credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold 5% or more of the Company&#8217;s common stock. An assessment of such ownership changes under Section&#160;382 and 383 was not completed through December&#160;31, 2022. Utilization of our net operating loss and income tax credit carryforwards may be subject to a substantial annual limitation due to ownership changes that may have occurred or that could occur in the future. These ownership changes may limit the amount of the net operating loss and income tax credit carryover that can be utilized annually to offset future taxable income. The Company will examine the impact of any potential ownership changes in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The following table summarizes the activity related to the Company&#8217;s gross unrecognized tax benefits at the beginning and end of the&#160;years ended December&#160;31, 2022 and December&#160;31, 2021 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance of unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions based on tax positions related to the current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 253</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions based on tax positions related to the prior year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_8vjjWyCvikyedSLToWmJjA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance of unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 529</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The unrecognized tax benefit amounts are reflected in the determination of the Company&#8217;s deferred tax assets. If recognized, none of these amounts would affect the Company&#8217;s effective tax rate, since it would be offset by an equal corresponding adjustment in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company is subject to taxation in the United States and various states. The Company&#8217;s Federal and state returns are subject to examination, as 2018 was the first&#160;year of operations for the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054666806992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the Company&#8217;s wholly owned subsidiary, Aerovate Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Reverse Stock Split</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">On June&#160;22, 2021, the Company effected a <span style="-sec-ix-hidden:Hidden_AH0m-scr1ESIQqpsOnDeyg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-3</span></span>.1060103 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of its issued and outstanding common stock. Accordingly, the conversion ratio for the Company&#8217;s outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. The par value of the common stock was not adjusted as a result of the Reverse Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Cash and Cash Equivalents</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Cash and cash equivalents include cash in readily available checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three&#160;months or less from the date of purchase to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ShortTermInvestmentPolicyTextBlock', window );">Short-term Investments</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(e)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Short-term Investments</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;">Short-term investments consist of corporate debt securities, commercial paper and U.S. Treasury bills, classified as available-for-sale securities and have maturities of greater than three&#160;months. The Company has classified all of its available-for-sale investment securities as current assets on the consolidated balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company carries these securities at fair value and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the consolidated statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">using the specific identification method and recorded in other income (expense), net in the consolidated statement of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(f)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Concentration of Credit Risk</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(g)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Comprehensive Loss</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(h)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Fair Value Measurements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Level 1: Observable inputs such as quoted prices in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(i)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Prepaid Expenses and Other Current Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Any expenses paid prior to the related services rendered are recorded as prepaid expenses. Such prepaid expenses are expensed in the period the expense is incurred. If the expense is for a service covering multiple periods, it is expensed from the date the services begin and over the period of the service rendered (or contract service period if services rendered dates are not defined).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(j)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Property and Equipment, Net</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and construction-in-progress are stated at cost less accumulated depreciation or accumulated amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from <span style="-sec-ix-hidden:Hidden_bBazvaq5mUO3D78wc3eoZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <span style="-sec-ix-hidden:Hidden_Ha-ILLgVZUue-n7HxT3H2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;years</span></span>. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(k)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Impairment of Long-lived Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December&#160;31, 2022, there has been no such impairment losses recorded by the Company.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(l)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Leases</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets (&#8220;ROU assets&#8221;) which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to separate lease and non-lease components and not recognize lease liabilities and ROU assets for short-term leases with terms of twelve&#160;months or less.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ConvertiblePreferredStockPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(m)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Convertible Preferred Stock</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The Company records convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#8217;s control, including a deemed liquidation event, holders of the convertible preferred stock can cause redemption for cash. Therefore, convertible preferred stock is classified outside of stockholders&#8217; deficit on the balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(n)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Research and Development Expenses</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(o)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock-Based Compensation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;">Stock-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option grants and restricted stock units, estimated in accordance with the applicable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">accounting guidance, recognized using the straight-line method over the vesting period for service-based options and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">The fair value of stock options is estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, expected dividend yield, and a risk-free interest rate. Options and awards granted during the&#160;year have a maximum contractual term of ten&#160;years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected volatility of stock options is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury (&#8220;U.S. Treasury&#8221;) yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">(p)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">Income Taxes</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss (&#8220;NOL&#8221;) and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company records uncertain tax positions on the basis of a two-step process whereby (1)&#160;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">(q)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">Segment Reporting</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">(r)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"><span style="font-style:italic;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities, which include convertible preferred stock prior to the conversion of such shares to common stock and outstanding stock options under the Company&#8217;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;">The following table summarizes the Company&#8217;s net loss per share:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,963)</p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of Series A redeemable convertible preferred stock to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,985)</p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,472,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,293,629</p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.87)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,454,374</p></td></tr><tr><td style="vertical-align:top;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,139,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,454,374</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.55pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(p)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Recently Issued Accounting Pronouncements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard will be effective for the Company on January 1, 2024, and is not expected to have an impact on the Company&#8217;s financial position or results of operations upon adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse stock split [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ShortTermInvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investment [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ShortTermInvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054663807024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">SCHEDULE OF NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;">The following table summarizes the Company&#8217;s net loss per share:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,963)</p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of Series A redeemable convertible preferred stock to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,985)</p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,472,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,293,629</p></td></tr><tr><td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.87)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,454,374</p></td></tr><tr><td style="vertical-align:top;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,139,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,454,374</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054664642288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE INSTRUMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 125,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 167,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">SUMMARY OF SHORT TERM INVESTMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:36.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_P4znHQF3GUSWjTutnltemQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (267)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:36.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (484)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (68)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:71.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (267)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (223)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (484)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:71.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td></tr><tr><td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td></tr><tr><td style="vertical-align:top;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (68)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (68)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054668804304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Accrued and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,691</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of prepaid expenses and other current assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054668901664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The components of operating leases for the years ended December 31, 2022 and December 31, 2021 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054668862480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock', window );">SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">As of December&#160;31, 2022, the Company had reserved the following shares of common stock for future issuance:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,077,557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for vesting of outstanding restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 216,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,432,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock shares reserved on and as converted basis for future issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054666805120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SUMMARY OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the&#160;year ended December&#160;31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,454,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 954,557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (298,712)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,044,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,682</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">SCHEDULE OF UNVESTED STOCK UNIT ACTIVITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SUMMARY OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:51.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.2 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">73.5 - 76.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">68.7 - 69.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.6 - 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.9 - 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED AND EXPENSE BY AWARD TYPE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Stock-based compensation expense recognized for stock option grants has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive (loss) income was as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054662582464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred income tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">NOL carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,781</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,498</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_E0ae-PWvkE-yL5o9JZGx5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 615</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,643</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,283)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,517)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred income tax liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (302)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (126)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (302)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (126)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax assets (liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_nezSGvSzDU6xkqS5dwZsuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,829)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,821)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,828)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (520)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent and other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (787)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (757)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (392)</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,618</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;">The following table summarizes the activity related to the Company&#8217;s gross unrecognized tax benefits at the beginning and end of the&#160;years ended December&#160;31, 2022 and December&#160;31, 2021 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance of unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276</p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions based on tax positions related to the current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 253</p></td></tr><tr><td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions based on tax positions related to the prior year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_8vjjWyCvikyedSLToWmJjA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance of unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 529</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054663988400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 15, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and short term investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avte_JefferiesMember', window );">Jefferies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate amount of shares</a></td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,984,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares conversion securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,182,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avte_JefferiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avte_JefferiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054666894928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2021</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' equity, reverse stock split</a></td>
<td class="nump">0.321956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Leasehold improvements are amortized over the remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Leasehold improvements are amortized over the remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054663438992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (51,511)<span></span>
</td>
<td class="num">$ (22,963)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of Series A redeemable convertible preferred stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (51,511)<span></span>
</td>
<td class="num">$ (22,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding, basic</a></td>
<td class="nump">24,472,104<span></span>
</td>
<td class="nump">12,293,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding, diluted</a></td>
<td class="nump">24,472,104<span></span>
</td>
<td class="nump">12,293,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.10)<span></span>
</td>
<td class="num">$ (1.87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.10)<span></span>
</td>
<td class="num">$ (1.87)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of Series A redeemable convertible preferred stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054667156080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">4,139,100<span></span>
</td>
<td class="nump">3,454,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">4,110,219<span></span>
</td>
<td class="nump">3,454,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">28,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054659635936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">$ 106,823<span></span>
</td>
<td class="nump">$ 113,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">18,436<span></span>
</td>
<td class="nump">54,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">106,823<span></span>
</td>
<td class="nump">113,178<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">125,259<span></span>
</td>
<td class="nump">167,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">18,436<span></span>
</td>
<td class="nump">39,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">26,841<span></span>
</td>
<td class="nump">25,135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">45,277<span></span>
</td>
<td class="nump">64,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">79,982<span></span>
</td>
<td class="nump">88,043<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">79,982<span></span>
</td>
<td class="nump">102,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">18,436<span></span>
</td>
<td class="nump">39,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">18,436<span></span>
</td>
<td class="nump">39,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">55,577<span></span>
</td>
<td class="nump">77,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">55,577<span></span>
</td>
<td class="nump">77,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">26,841<span></span>
</td>
<td class="nump">25,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills | Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">26,841<span></span>
</td>
<td class="nump">25,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bond | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">24,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bond | Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">$ 24,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054665879504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">$ 107,289<span></span>
</td>
<td class="nump">$ 113,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss</a></td>
<td class="num">(484)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 106,823<span></span>
</td>
<td class="nump">113,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList', window );">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent', window );">Accrued interest receivable</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">55,645<span></span>
</td>
<td class="nump">77,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">55,577<span></span>
</td>
<td class="nump">77,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">27,108<span></span>
</td>
<td class="nump">25,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss</a></td>
<td class="num">(267)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">26,841<span></span>
</td>
<td class="nump">$ 25,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">24,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss</a></td>
<td class="num">(133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 24,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm', window );">Maturity term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm', window );">Maturity term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm', window );">Maturity term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Agency bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm', window );">Maturity term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity term for debt securities classified as available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_DebtSecuritiesAvailableForSaleMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL121698322-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054659568416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">$ 59,863<span></span>
</td>
<td class="nump">$ 69,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(223)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Short-term investments, 12 months or Greater, Fair Value</a></td>
<td class="nump">24,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Short-term investments, 12 months or Greater, Unrealized Losses</a></td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">84,696<span></span>
</td>
<td class="nump">69,155<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">(484)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">34,928<span></span>
</td>
<td class="nump">33,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">34,928<span></span>
</td>
<td class="nump">33,204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">1,971<span></span>
</td>
<td class="nump">25,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Short-term investments, 12 months or Greater, Fair Value</a></td>
<td class="nump">24,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Short-term investments, 12 months or Greater, Unrealized Losses</a></td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">26,804<span></span>
</td>
<td class="nump">25,194<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">(267)<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">22,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">22,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">$ (133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054666891264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 1,503<span></span>
</td>
<td class="nump">$ 1,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_PrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">5,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other current assets</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 2,276<span></span>
</td>
<td class="nump">$ 6,958<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054666799920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 2,751<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and other employee benefits</a></td>
<td class="nump">1,691<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 4,822<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054665791472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,003,000<span></span>
</td>
<td class="nump">$ 542,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,090,000<span></span>
</td>
<td class="nump">574,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Total operating lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=avte_WalthamLeaseMember', window );">Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payment for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_LeaseIncreaseInRentPercentage', window );">Lease rent percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=avte_FosterCityLeaseMember', window );">Foster City Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">39 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payment for rent</a></td>
<td class="nump">$ 22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_LeaseIncreaseInRentPercentage', window );">Lease rent percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_LeaseIncreaseInRentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease increase in rent percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_LeaseIncreaseInRentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=avte_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=avte_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=avte_FosterCityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=avte_FosterCityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054666892992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amount representing interest</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of net minimum lease payments</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">$ 574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">$ 382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054661813296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 04, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 01, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 05, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 22, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_CapitalStockSharesAuthorized', window );">Capital stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,052,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary Equity, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">44,052,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary Equity, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,722,974<span></span>
</td>
<td class="nump">24,410,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">9,984,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avte_RaCapitalHealthcareFundL.pMember', window );">RA Capital Healthcare Fund, L.P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock shares issued</a></td>
<td class="nump">14,182,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_NumberOfVotesForEachShareOfCommonStock', window );">Number of votes for each share of common stock | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesSeedRedeemableConvertiblePreferredStockMember', window );">Series Seed Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary Equity, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesSeedRedeemableConvertiblePreferredStockMember', window );">Series Seed Redeemable Convertible Preferred Stock | RA Capital Healthcare Fund, L.P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary Equity, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary Equity, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity shares issued .value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary Equity, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,052,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity shares issued .value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,468,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes', window );">Temporary equity shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,020,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity shares issued .value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,562,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock | Stock Purchase Agreement | First Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity shares issued .value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,224,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock | Stock Purchase Agreement | Second and Third Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity shares issued .value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,338,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_CapitalStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital stock shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_CapitalStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_NumberOfVotesForEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes for each share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_NumberOfVotesForEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of temporary equity shares issued in connection with conversion of notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avte_RaCapitalHealthcareFundL.pMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avte_RaCapitalHealthcareFundL.pMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesSeedRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avte_SeriesSeedRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avte_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avte_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_MilestoneAxis=avte_FirstMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_MilestoneAxis=avte_FirstMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_MilestoneAxis=avte_SecondAndThirdMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_MilestoneAxis=avte_SecondAndThirdMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054665676944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">5,432,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avte_TwentyTwentyOneStockOptionAndIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">1,077,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">4,110,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">28,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">216,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avte_TwentyTwentyOneStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avte_TwentyTwentyOneStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054662798784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avte_TwentyTwentyOneStockOptionAndIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock available for issuance</a></td>
<td class="nump">988,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,576,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">976,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock available for issuance, awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,467,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,077,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock available for issuance, awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2021 Plan and 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum | 2021 Plan and 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum | 2021 Plan and 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="nump">216,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional common stock available for issuance</a></td>
<td class="nump">247,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of common stock purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Discount percentage on marker price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Duration of offering period for share-based compensation arrangement by share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avte_TwentyTwentyOneStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avte_TwentyTwentyOneStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avte_TwentyEighteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avte_TwentyEighteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054664602448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, beginning balance</a></td>
<td class="nump">3,454,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Outstanding, beginning balance</a></td>
<td class="nump">$ 6.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">9 years 2 months 23 days<span></span>
</td>
<td class="text">9 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, beginning balance</a></td>
<td class="nump">$ 19,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">954,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted</a></td>
<td class="nump">$ 15.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(298,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercised</a></td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, ending balance</a></td>
<td class="nump">4,110,219<span></span>
</td>
<td class="nump">3,454,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Outstanding, ending balance</a></td>
<td class="nump">$ 9.23<span></span>
</td>
<td class="nump">$ 6.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, ending balance</a></td>
<td class="nump">$ 82,490<span></span>
</td>
<td class="nump">$ 19,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options, Vested and exercisable</a></td>
<td class="nump">1,044,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and exercisable</a></td>
<td class="nump">$ 7.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and exercisable</a></td>
<td class="text">8 years 1 month 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="nump">$ 22,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and expected to vest</a></td>
<td class="nump">4,110,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and expected to vest</a></td>
<td class="nump">$ 9.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">8 years 5 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 82,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">weighted-average grant date fair value of stock option grants</a></td>
<td class="nump">$ 10.48<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="nump">$ 17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation weighted-average period</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054669315472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of units, Granted | shares</a></td>
<td class="nump">28,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date fair value, Granted | $ / shares</a></td>
<td class="nump">$ 21.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of units, Ending | shares</a></td>
<td class="nump">28,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date fair value, Ending | $ / shares</a></td>
<td class="nump">$ 21.62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054662652576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">73.50%<span></span>
</td>
<td class="nump">68.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">76.50%<span></span>
</td>
<td class="nump">69.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054669275184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 5,476<span></span>
</td>
<td class="nump">$ 2,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 3,347<span></span>
</td>
<td class="nump">$ 1,673<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054667183760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,476<span></span>
</td>
<td class="nump">$ 2,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,316<span></span>
</td>
<td class="nump">$ 2,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee stock purchase plan awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock awards and units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054666848976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - Service agreement with carnot LLC - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_RelatedPartyTransactionTerm', window );">Term of service agreement</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_NoticeToTerminateAgreementPeriod', window );">Termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_MaterialBreachCorrectionPeriod', window );">Material breach correction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Amount payable to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avte_ServicesAgreementWithCarnotLlcMember', window );">Research and development and general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avte_ServicesAgreementWithCarnotLlcMember', window );">Research and development and general and administrative expenses | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_MaterialBreachCorrectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of days in which material breach must be corrected or agreement will be terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_MaterialBreachCorrectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_NoticeToTerminateAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of days in which notice to terminate an agreement must be given.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_NoticeToTerminateAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_RelatedPartyTransactionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of related party transaction for service agreement , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_RelatedPartyTransactionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=avte_ServicesAgreementWithCarnotLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=avte_ServicesAgreementWithCarnotLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054659591568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets valuation allowance</a></td>
<td class="nump">$ 23,283<span></span>
</td>
<td class="nump">$ 8,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">46,600<span></span>
</td>
<td class="nump">32,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 34,400<span></span>
</td>
<td class="nump">20,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054663985120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 11,781<span></span>
</td>
<td class="nump">$ 7,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research credit carryforwards</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized R&amp;D</a></td>
<td class="nump">8,490<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,713<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">23,585<span></span>
</td>
<td class="nump">8,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(23,283)<span></span>
</td>
<td class="num">(8,517)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(302)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (302)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054662680976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory income tax rate</a></td>
<td class="num">$ (10,829)<span></span>
</td>
<td class="num">$ (4,821)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="num">(2,828)<span></span>
</td>
<td class="num">(520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Permanent and other differences</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock-based compensation</a></td>
<td class="num">(787)<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits', window );">Research and development credits</a></td>
<td class="num">(757)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">14,663<span></span>
</td>
<td class="nump">5,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax provision</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Research and Development Credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140054666790624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance of unrecognized tax benefits</a></td>
<td class="nump">$ 529<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions related to the prior year</a></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance of unrecognized tax benefits</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>tmb-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avte="http://aerovatetx.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tmb-20221231.xsd" xlink:type="simple"/>
    <context id="Duration_6_3_2021_To_6_4_2021_avte_MilestoneAxis_avte_SecondAndThirdMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_rGO8UuK3d0mu99ddFv5hjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="avte:MilestoneAxis">avte:SecondAndThirdMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-03</startDate>
            <endDate>2021-06-04</endDate>
        </period>
    </context>
    <context id="Duration_1_30_2021_To_2_1_2021_avte_MilestoneAxis_avte_FirstMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_hfGGAslhNEeVOwN6WrF5gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="avte:MilestoneAxis">avte:FirstMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-30</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="Duration_8_4_2020_To_8_5_2020_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_Dv12U9pPlk25gS6TpZJscg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="Duration_8_4_2020_To_8_5_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_KQ7-UIfWqUG1_y4Ju1lXmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_vnUkVXoGN0-57YWUs8EYpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_4_2021_avte_MilestoneAxis_avte_SecondAndThirdMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_GDEihDdvTUyXLABx1mfHnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="avte:MilestoneAxis">avte:SecondAndThirdMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="As_Of_2_1_2021_avte_MilestoneAxis_avte_FirstMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_wwresvhtM0-V7mH5Vgo-hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="avte:MilestoneAxis">avte:FirstMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_crMw-EmKcUeuKdVO9DDyyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_No7St9Lvr0y96G_5EWC44g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_W0a55wDra0WelJUBZUsesw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_k2O0Ht8ZSEm2brOMJb52XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ox5viBwu-U-6f6s2IgjvBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Qt-J82d3_02alNEkJwIh1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_9gGeJ_r-oESMCylkTiaQrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8aHpRkxHpkCDJdb7yykJBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_qthA2_MWG0-O-o6csyodmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_45gK5TQqjU22PAv52bixOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_StockCompensationPlanMember_gpUHdU7SI0iF5rb9E2h1XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2021_To_6_22_2021_bf3_5zAtv0aORHhCRdPPag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2021-06-22</startDate>
            <endDate>2021-06-22</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wX9u88nSX0ugu2QhP2n3ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KBAJsq8X1UePf0wtOE4-gA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ONawfJkraU2j7s81xUzW8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HN0Xoks5e0ezwLw29ZL8OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3CjGTVHCT0eUwawBJaweUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6B2XB2kFVUWrsHm32rtreg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FlYzV5V60kKR3Xb49ZQI6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PcOQWpSW2EGd9KpeiSRIIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IdoElH_PsUqt48Em-48oBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_rPrkP4ujk0W_7H8LCrqXLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_zemR5DkqREKFgJjFkN8qqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VJ2CIL3_20mu--166dWxVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_zqKb8DAZgESt_eax0wleGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_aQq0ijr06kSW_SZprlK7sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_USRDgmPtwkOyBzlosVP3AQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_tGjRsdl680qEsQ3mUldJJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8VmyKaoxLEOzzbfyzwCJ2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_RR9WWKOeMEOQdAup8Pv4AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_y6dmyknKUU-SGERHF0Dc_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YwXIEvLewkaQioMwjwbsbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ok3TV3BnH0eWo3UW7uDQug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i_IWKm7ZUkG0SD8gBMvkNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjitDg4W4EOE9Yf-R3ycdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_5_2020_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_oObJ-Nmc4UqeH2X0G6kfiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyEighteenStockOptionAndIncentivePlanMember_xoITfiC24kGgUX1H39EHoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_vrB-dEU-EE2kBgR4L-Vkig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_U-Vimp94EE-Vhg_ROQBzFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_1_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_KW9jG2TQGUqptBykLu-x_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_8KFv4vg0cUCOT78XuWQJLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_hoI7V65KHEG5GkLS5GdTEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_VdsnaK6Ohkqmx-_Z9SCPxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ZEq1R1quB0CHCsbXWqAwWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_jKuzK2N-lk6r-oAi8Vk34Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_tvsHVVkheEq71hXbwUCgSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_Cyq09hAZqUesspxvNiCeCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_StqYaHLjzEKZmEQ6yLvUGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_iezkj5eDqUCfolKO8YRv0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_KeaWaOuYKEmKgtUe5KHG_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_9FuVdbUhV0uvrx8hBa_1RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_32nsRXZZeE2LhzKjEdHwoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fJh_ywGZikyIQAcBTW536A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8pxhy8PI8Ei91_HCoX_sIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_38m67FS0GEuKtolLvc65gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_GUwnxPWZUk-8QC102OTn9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_avte_JefferiesMember_XuFYdSUixkyetwSnndM8uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_15_2022_To_8_15_2022_srt_CounterpartyNameAxis_avte_JefferiesMember_FWTe7abbGk2o3kC0iODEaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeStatementLocationAxis_avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_6iVtOxWY10m-DhjKq-psJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">avte:ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_qimOehD_5ke94_ayOtSdCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">avte:ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_aiS3g6rqK0C4IYQ7jBBLcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_L6Aulrv6skCjIRhGAQFN1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_f35-tn37YkSEpT0jtT5KhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_rRDeb8AKE02Eu6qsh0BInw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember__U571LHq90ebMUCnu-8gKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bX05x-nRLk2IigYinMKBjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_Gyry4bLRNEOzHxfxq7X4iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_c5GfZjqasEeR4_aZW3f6NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_gjNW4nJ7gUG3lYvOm_OCOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ffQ1QIahIk-nBDBoGTbC3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_3BpSFz349EKBC1pez2vW1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_uqnI7J_-ykeUEvSi8eqaBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_2_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_xbOuftPGHkeAHGLhw_3HrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_djafJWnh40CLwBS3AvdTBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="As_Of_6_22_2021_zuE5gWkeyk2gMuDMHkgnlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2021-06-22</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BFKtiMbYKEWGiX8enBMhZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_7kFZeYf8XkSj3t3wwiM5lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_CommonStockMember_aFm9TwWFNkWt1zWekbZnjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_TXk4moIa40GbN1BvRlu_JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BZC2smINzEqMpJkFZy61dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__I6MyJ-3P0WLSD1L0CQLMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_btTJ7hB3m0msnUE_XEjudA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XKXReW8Iv0iqNoVsfOn3wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1EYoksMxjEatDkF4HraTtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_X-cBBwKLukqd96ZZFzoANQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_lex_lE13Tka9RtZYzaRxrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6Vn0yOonI0i5051pthm-IQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ydsgvjwLrUe_yWrw82jE-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CkuAokZFEE6-3rAKVgGLlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tuJ-pg1BnECbTpf6Uk40Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fkQ2x2flakWcJsOn3HTX-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_h7PXcaYot0um0bjFUh0YmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_nM5HHKPZJk6bkcFB2fyHpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:FosterCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_I5wcShJpG0OhjXjvlcq-_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_o4StUCQIc0a31cjpbHrNkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2u36RAc4eEiBYcmpsvX8AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_rJ1OBbHLXUyHKgkaKxW57Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2skYMq1PvUmc9GZXaVoMzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_fPutlC_Wlkew2sr7ZE8ROQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_BRUvW3FPrk2wFPzvj1avag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_PUAKc7nXUEaEH4mxzoylkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8bQICbmQLU2n6JGchvzzOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_hkNcRgCMlEqt8tgDQQSL_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KD9Fb9Ua2k--d7ATP52t5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxaL35pKjEOanh6iG7wiBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yReDKtcgo0KOffS55fF_QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_KRknw7U1FU-LFYLG7DaGWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_VCaJi4v2YU2yhYi2bTbHgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_IosAfoWctk-rd00ZZE-fvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_27_2023_ZaOeJvmGG0W1uFVcFuGpRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="As_Of_8_5_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_pNNDYw-rNUWvdmmuAHZlsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_0fmPIdzRUE-bEqICdqsXyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_7_31_2019_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_524LLIpT_U62C9wdu6QZ1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_PvcTYb2K9UG6ACE8durCkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_efAf7fiBWUqdDgHCEPGdfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_mp5ueIyU6EupPXatRN7igQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:FosterCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_YaLLcUjHZki458JcBBF_AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_PvqmJS3bP0uIcfv-_n2kqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7ZoMrQXRJk2hJ6cbQPFKvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xiCQZvKWqESmhAB-Ehu1tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_7nzerVxUhkyRb7q9DTrxjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_j8WxaSALUESwMgXMefh0UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_mt2q9GoKi0-AvNO-EXkZnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Vote_U58quFcv5ki9AFPMBo9uqw">
        <measure>avte:Vote</measure>
    </unit>
    <unit id="Unit_Standard_sqft_UveSBE_izUeNb4VPRsSftw">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_4id_vXrVjkay3ChrkF2qUA">
        <measure>avte:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      id="Hidden_RaXIuauWqku0Xun2qBu32g"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      id="Hidden_-DTqJjWD8U-hAZ9Yia9iSQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      id="Hidden_bJuePYP0z0enEK1t8naDBw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      id="Hidden_nnISsMCKK0SB6DzIZRp3nQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i_IWKm7ZUkG0SD8gBMvkNg"
      id="Hidden_z_7Smwx-xk6PNyccCkFacw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IdoElH_PsUqt48Em-48oBQ"
      id="Hidden_FgzULbdEkEmMgengviJ06w"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg"
      id="Hidden_vGST7hUNHUyjx-QRVKVB1A"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw"
      id="Hidden_PVPYhzV1KUSipoQZo14khg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g"
      id="Hidden_p1B0cgyja0eXXB8mJzHwhA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA"
      id="Hidden_zcK2QswtF0-XQisdNE1kTQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g"
      id="Hidden_8gXmbsc5V0WGwB8z3WrE4w"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      id="Hidden_oWEmnNhdQEiWCw4bOf86UQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg"
      id="Hidden_0eG-SoEK5kuF1ShBTbmZBA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw"
      id="Hidden_vYbLbfdpEUebrPRsjQkIrg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g"
      id="Hidden_9TlgPwHWh0uwDbto1Gn0ag"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA"
      id="Hidden_CF5UUFhDtkuwemyNcYLVqg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA"
      id="Hidden_GU_-C10K_kufCNxbtEHvYw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g"
      id="Hidden_xUSK3YkFk0WkQFu1WRz5ng"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA"
      id="Hidden_912yMiQA6EuoTS2GqOOWZg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg"
      id="Hidden_SPYadEtbxUyiMyoMbj-zGw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA"
      id="Hidden_kME_VnS40Ey8bN1ipvIIgg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g"
      id="Hidden_O4BKDDh0GkaxTRKHLBJZgQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA"
      id="Hidden_cd88Enej1kGdiFZxGBTS-w"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg"
      id="Hidden_3AeL89uIOUWv41QC_R_viQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw"
      id="Hidden_1_lGy5tgq0Cu3RjgvjBrwA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g"
      id="Hidden_jf-F9WUfIkyExXtG1HLbpA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g"
      id="Hidden_q6gqT2ZUikaTPHXP0K2tnw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA"
      id="Hidden_nj82nS1K_EyhUa226xKdDw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg"
      id="Hidden_shlVgBLiW06hH9N0n9n3nA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw"
      id="Hidden_4BYXfP_Jb0SBZ-QiJJauxA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA"
      id="Hidden_-htaxShuM0mu9hvSRX9XlA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g"
      id="Hidden_WdzbLmCHVkKzYMBb7IboLQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA"
      id="Hidden_xugVTio6i0afQ8eJushCTw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg"
      id="Hidden_Tfghgj6ncUaJhMrK7Zddcg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw"
      id="Hidden_bUCrvbpg-UOAq0-Dzxstgw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g"
      id="Hidden_Zab77IL0sEuX-g4J7QAoxw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA"
      id="Hidden_g0jXDBz0lEqllR8Gr6oWSA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjitDg4W4EOE9Yf-R3ycdQ"
      id="Hidden_V7_LcdS0EE6yymFDgcmfhA"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjitDg4W4EOE9Yf-R3ycdQ"
      id="Hidden_V0VRYutPckKpqgmFqtDXwA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Qt-J82d3_02alNEkJwIh1g"
      id="Hidden_89y_KHQk9EymnrvTUUnZ4g"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Qt-J82d3_02alNEkJwIh1g"
      id="Hidden__cF4v94lHEyR31ih6-E_WQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_hkNcRgCMlEqt8tgDQQSL_A"
      id="Hidden_OmhxfVgQCESxlgDb4_pJpA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8bQICbmQLU2n6JGchvzzOQ"
      id="Hidden_q7BbjAy1H0GnnYjlqlNn1Q"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ"
      id="Hidden_Ze7UL0SREU-ymT6vUXcLKw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxaL35pKjEOanh6iG7wiBQ"
      id="Hidden_cemoZSwJvUGon3ssmaX5Sw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KD9Fb9Ua2k--d7ATP52t5w"
      id="Hidden_QGA3oU86m0uadUBtG201gA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_hkNcRgCMlEqt8tgDQQSL_A"
      id="Hidden_pfuZVQLFS0iQYSds25WBYg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8bQICbmQLU2n6JGchvzzOQ"
      id="Hidden_BAqDeljnCUWK-LcCFz5e8g"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ"
      id="Hidden_DW-qWgX6KUGWwHIIOUBVYQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yReDKtcgo0KOffS55fF_QQ"
      id="Hidden_YZqCbmXx5EO_3uRH4nk_Uw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KD9Fb9Ua2k--d7ATP52t5w"
      id="Hidden_DraQ_PjnZ06wPW8F-PJ8Fw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_hkNcRgCMlEqt8tgDQQSL_A"
      id="Hidden_SkywTp5LwEarI0V2Akphrg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8bQICbmQLU2n6JGchvzzOQ"
      id="Hidden_Rve_yEtVik-IvzJJRRL0XA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ"
      id="Hidden_WWFZwnrdM0ySldpeT4dC9A"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yReDKtcgo0KOffS55fF_QQ"
      id="Hidden_voeCO464H0uFQ8dGV2vLbg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KD9Fb9Ua2k--d7ATP52t5w"
      id="Hidden_ttimKTVVBE-5HnXVZ5mGvw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_hkNcRgCMlEqt8tgDQQSL_A"
      id="Hidden_9Z36iEtH-U6auxzWMeR0kA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8bQICbmQLU2n6JGchvzzOQ"
      id="Hidden_JRtInkjAkUuk9CReiPXp-Q"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ"
      id="Hidden_5WQjntt1FkWeCko6wgN7qA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yReDKtcgo0KOffS55fF_QQ"
      id="Hidden_ji1TW4Zr2kqi-qIrB_6mwg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KD9Fb9Ua2k--d7ATP52t5w"
      id="Hidden_d3SsXOCB50K_JnEqsVSgLg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_hkNcRgCMlEqt8tgDQQSL_A"
      id="Hidden_A62rI6HNkUCVIRjAlLZg0Q"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8bQICbmQLU2n6JGchvzzOQ"
      id="Hidden_CVAmf7WadUq49f3TtsN3IQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ"
      id="Hidden_CGyXEL1XvUqkgQurGsmk1A"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxaL35pKjEOanh6iG7wiBQ"
      id="Hidden_JxIe_etIgESVo40crkG05w"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yReDKtcgo0KOffS55fF_QQ"
      id="Hidden_UFXC1_PXnEOl3UAe3rfe4Q"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ox5viBwu-U-6f6s2IgjvBg"
      id="Hidden_b1yO5jQyE0u1XcHo2dnzDQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ox5viBwu-U-6f6s2IgjvBg"
      id="Hidden_vgAee7eWOkaa4ZB8w02AzA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_k2O0Ht8ZSEm2brOMJb52XA"
      id="Hidden_7aPy-MGM50yJ2UV_65neTQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_k2O0Ht8ZSEm2brOMJb52XA"
      id="Hidden_ao9WX4t1XEmuc3Xz8JS1ow"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ"
      id="Hidden_P4znHQF3GUSWjTutnltemQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <avte:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      id="Hidden_E0ae-PWvkE-yL5o9JZGx5w"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      id="Hidden_nezSGvSzDU6xkqS5dwZsuQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      id="Hidden_8vjjWyCvikyedSLToWmJjA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ"
      xsi:nil="true"/>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Hidden_ItY5_fvRF0q33fgyjXsiMQ">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Hidden_951k_fTdP0-aD5ub2vV5Ww">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Hidden_4PoK6XCve0q_m0oUzP4FUg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Hidden_G02T1cY-L02zTAI_qfAWFw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_z0txTyMl102jua1CHGpErw_2_1">0001798749</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_Xw4qNEvuHUSOT6cIiMx_SQ_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_HDKCuFaf3U6Ijvfa7Z3--A_5_1">false</dei:AmendmentFlag>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="INF"
      id="Hidden_GAre_n3AxkK4BhXuL_0rVg"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">24410393</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="INF"
      id="Hidden_dQ_Cvl9mWESujqCYmrqZLQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Hidden_H-3bEaFh4E-Fr641fpNCcQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_6_22_2021_To_6_22_2021_bf3_5zAtv0aORHhCRdPPag"
      decimals="6"
      id="Hidden_AH0m-scr1ESIQqpsOnDeyg"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.321956</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_KeaWaOuYKEmKgtUe5KHG_A"
      id="Hidden_uKh2d8qoz0GftAIlA0yOkQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_aiS3g6rqK0C4IYQ7jBBLcw"
      id="Hidden_bBazvaq5mUO3D78wc3eoZQ">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_L6Aulrv6skCjIRhGAQFN1w"
      id="Hidden_Ha-ILLgVZUue-n7HxT3H2Q">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      id="Hidden_NQg-uPEboUy3bkc7fClBSQ">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Hidden_yRE9VHYos06cYhHQPpwzYQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">24722974</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_32nsRXZZeE2LhzKjEdHwoQ"
      id="Hidden_gWG-e8KNUkuG8sHbxrnFJA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_bxJu0DrASEKavvqHUGDwPA">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_fmRJmnKK5EuazSWj_qcHrA">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_Gk3GxdSUiU-5DEPfIn6LzA">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_Zcc_EcwdN0GpE5ry0pgC6Q">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_QJgK4defjUiYfnmb5wvxgQ">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_DcXGMCXJokWebZOTZfwTzg">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_rPxpwea9IUaU6ZLJQa9JzA">001-40544</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_b0_GqEKlqEWepekGg5s7pw">Aerovate Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_aesgckgwxU6XQNPwkwnaRA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_hzXkZKkGek2BvcENovEgjg_1_1">83-1377888</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_YPngDXHlZEKrYu711HJTng">930 Winter Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_f3vZT0ztKECSK0ez7tJV0A">Suite&#160;M-500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_A3XL1gLaQ0i1Nj1gJNVhjw">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_HdvTLLpr20u3271TWWhIxg">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_cg6I6awGjUygzsLZ45J16g">02451</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_xnefd11PlEWAeyw0S-WftA_6_1">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_GedMZUOVCk2ZrYJViqlmxw">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_NfYxuY1eTU2yuAXU8Ef5tA">443-2400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_8M8mjX31602kHlXRLwyUZA_1_0">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_sRvzthd8nEChtJMeX8dgGQ_1_2">AVTE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_T1u6SVLldEGn9nipcxDdSg">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_NYzZEOQvdUuM2rtHDqloSw_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_rBwI0A5xMUmmWBDVrJQ3qw_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_IcTEKYC2W0uGJkCW6sX9Xw_3_3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_ruT7_OtHMkeUwZTRUWP62w">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_K0bKagzOWEmq_PyRQKDHLA">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_j516FwJUTUeVLj7Arlixfg">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_IosAfoWctk-rd00ZZE-fvg"
      decimals="-5"
      id="Narr_PAkVaPg2KUaA6S_1PFH8fw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">157300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_27_2023_ZaOeJvmGG0W1uFVcFuGpRQ"
      decimals="INF"
      id="Narr_ciwI8IpWXEaonpr_wX2Z4w"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">24812418</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_Bm2H4YMdY0u_6YZqU9zoDw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"&gt;The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2023 Annual Meeting of Stockholders within 120&#160;days of the end of the registrant&#x2019;s fiscal&#160;year ended December&#160;31, 2022. Portions of such definitive proxy statement are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K to the extent stated herein.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_3LNoIRXLXUmArZQU-QTXGw">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_qY-xvUhKBkeJpt-XhKvQLw">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_1rkIWM0cqUaxTPR_Ktfusw">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_BshbZgCJiUOdxfxuP7r9ZQ_5_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">22397000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_ChFY0z1raEqsIFVHB_LD-Q_5_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">54197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_okIiEkUXY0GORgfA7iir7w_6_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">106823000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_05Hg6z9yv0CDTGETdnoxfQ_6_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">113178000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_AVvc6oyBp0azBpMCawlFOg_7_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2276000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_zFVnZCqbWU24obq1HJCi_A_7_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">6958000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_wLqm5x-N30Wg3ehCQwyVAA_8_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">131496000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_XRZDD3NcZEuIF_Pjc0g08w_8_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">174333000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_LPmDqLlbXkKOT-zEHyx-oQ_9_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">242000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_UjyvAkuUaEeSbGj2N4ChhQ_9_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">186000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_run3zlxPZkekKM7LkDo2og_10_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1003000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_I3mfboFzA0ejbhS9goDA0g_10_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">542000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_uIntJNeVYE-uL9Aczv6Dkw_11_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2560000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_kuHUjRlKlUGAKobstrowVA_11_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">302000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_cU3HodLO0UOVq4ZrAPlSgw_12_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">135301000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_i6wYejn0Lk2hvm3r7FcxdQ_12_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">175363000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_3ZVfPhRpg0SyKgsCimxlwg_17_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2575000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_O00KUbI_00awYQtrqaK0Iw_17_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1208000</us-gaap:AccountsPayableCurrent>
    <avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_RGPPqW6oXkCNErqIVOgIJw_18_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">4822000</avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_R2yIg7oaakCB3X_aujwvMg_18_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1150000</avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_ayVFzMXhF0it1QUSMzFCtg_19_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">385000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_yZJyFLen1Uiu9eurGMJzKg_19_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">192000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_lzrlKN4h6E2GuPZy_rKpTQ_20_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">7782000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_QMDZxhU2OEaa49U7C3X1ug_20_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2550000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_BpWx3NBb6kqHHkIUXwrJKA_21_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">705000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_yr1ULZSqYEa52UbWyE-LWg_21_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">382000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilities
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_2F1BUIGZnk2W5HJD0hIjRQ_22_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">71000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_0NPlu4vDI0qPAX_7qmk_Cg_22_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">13000</us-gaap:OtherLiabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_dGuoYwWxWUemD1V6TgAEww_23_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">8558000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_Q8bZF55s7EqNUcryUTjv1w_23_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2945000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="4"
      id="Narr_z9mMtPYsik2QH0LFW_1ZYw"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="4"
      id="Narr_hWJ6CREPLkyiFeYsovcW-Q"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="INF"
      id="Narr_aptyqB1vXUqTf0pesNV7rw"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Narr_66hlIIhzzEuM_6c-7O5sMQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="INF"
      id="Narr_EOOk-pEWvEi_dgoNw3Wryg"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Narr_lhayzOqt60O4Ai0Fm1EgBQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="4"
      id="Narr_vBHuVQP2_UiRDy7vCXybfA"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="4"
      id="Narr_4W05xFfv4UKnZDUwNxvdVA"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="INF"
      id="Narr_0kEhaSrj7kKUWuXifymvnw"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Narr_KsWjhP-Gfky1DHcBrxq7LQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Narr_-d_S17wxDE2NI2WsAp-gvQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">24722974</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="INF"
      id="Narr_D73Qm4-x4k2FS1u6leYWBw"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">24410393</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_LetS7YtUfU2b1olNNNw1Yw_28_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_P932XJGjWkSns0gEAYolNw_28_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_ajkkpc0yFkeV_1MOmE0o2Q_29_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">215110000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_bvz7c8kK_0GlHdXTA4CN6A_29_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">208867000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_JazhZDDk9k-jwapNgnsMEg_30_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-466000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_FvSu11NOKUWT__kITML-Iw_30_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-59000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_RumJbTLZUUSXFS61mn0PUg_31_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-87903000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_fKpL3-oU_kebo8ZfJh_bgg_31_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-36392000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_FQ54tX2pfk2vLiVY-Tafmw_32_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">126743000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_ien-EJ9nDkGLvzk-KJrqKg_32_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">172418000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_xEQc8ubQu0KI9eG659UsHA_33_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">135301000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_yzpzca7QXE-pSIKh3C7umw_33_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">175363000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_KwBfGLUn6kiFVFlmAqkJCA_4_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">38622000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_uylLWOpFNUadHvYyEmx4Tw_4_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">14987000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_66Ej4Gmlz0WBR5cN5VJ-mQ_5_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">14615000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_1U84i6ssGkqFPCe86HN0yw_5_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">8035000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_08DMHlxZnEKhQ__6s-8gAw_6_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">53237000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_B4nhiudxFUyAa06DHS1zsQ_6_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">23022000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_TeIkXXE-0E6g26FiciCOJg_7_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-53237000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_mP6U2RXYCEqorH2eGYBPxA_7_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-23022000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_z_HMzt_ax0qtziMuyCnMHQ_9_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1830000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_dd9cEUDHBUq-wyWulKXGXg_9_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">65000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_YqZd81muhECgYELN80s-RA_10_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">79000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_syKfXKvjqUebSCM8K5RMMQ_10_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">3000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_9ZUW_qMgvUivUJwQBwmIBw_11_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1751000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_GVEhD58RoUmFzgMiAupaTA_11_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">62000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_ip-OyvmVdU2RmsJkAWQfLA_12_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-51486000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_bgd9NcBpbkix3FwQCsVYgQ_12_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-22960000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_OfwkpJUbd0Cawaet_Un-JQ_13_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">25000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_trrGS4dBRUKOqcA06TgldA_13_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_h1f91aT6WEOM5BhgWnSEJw_14_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-51511000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_F1ypdjx3gEq0BQoOfXQB7Q_14_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-22963000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_1p1UPNwa2kmRH-lLfZcD-g_16_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-51511000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_gx_K219p_0axJ7T8QMHBXA_16_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-22963000</us-gaap:NetIncomeLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_opktWRnD4kCNCONE_wq-_Q_18_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">407000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_Xb6Zl-foYk-EplioTotUTg_18_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">59000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_H2wJdHyTYE-fIOL028U_ZA_19_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-51918000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_2GQ_Qu26DUeb4me8GYjMxg_19_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-23022000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="2"
      id="Tc_wez4CqpMuUONtiGhxqcQ9g_20_3"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">-2.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="2"
      id="Tc_wez4CqpMuUONtiGhxqcQ9g_20_3_2"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">-2.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="2"
      id="Tc_WyT2NP6Y7Eqx0L_uCOZuTA_20_6"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">-1.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="2"
      id="Tc_WyT2NP6Y7Eqx0L_uCOZuTA_20_6_2"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">-1.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="0"
      id="Tc_E28bZvFTwU2p1MPuwMJSlQ_21_3"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">24472104</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="0"
      id="Tc_E28bZvFTwU2p1MPuwMJSlQ_21_3_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">24472104</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="0"
      id="Tc_zund3kD6H0axeTIvQdawvQ_21_6"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">12293629</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="0"
      id="Tc_zund3kD6H0axeTIvQdawvQ_21_6_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">12293629</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8aHpRkxHpkCDJdb7yykJBg"
      decimals="INF"
      id="Tc_Y_wxFhLUSU2R7l-wRVus3g_6_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">6489534</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8aHpRkxHpkCDJdb7yykJBg"
      decimals="-3"
      id="Tc_ftGW_GngOkK6-8feG32WLA_6_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">12285000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_9gGeJ_r-oESMCylkTiaQrA"
      decimals="INF"
      id="Tc_V6KOFF_HIkm26Vu-pWh9aQ_6_7"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">4000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_9gGeJ_r-oESMCylkTiaQrA"
      decimals="-3"
      id="Tc_Wd-9K-kSzUueA5FXPBa6xg_6_10"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">4000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i_IWKm7ZUkG0SD8gBMvkNg"
      decimals="INF"
      id="Tc_nCkaSyiHd0q6ALWdtr7A3g_6_13"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">243076</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PcOQWpSW2EGd9KpeiSRIIA"
      decimals="-3"
      id="Tc_8mp6iyQs8EWVefjoefm6_w_6_19"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">63000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FlYzV5V60kKR3Xb49ZQI6A"
      decimals="-3"
      id="Tc_jLHjYtNHAkeV-GYSxUldvw_6_25"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-13407000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_lex_lE13Tka9RtZYzaRxrQ"
      decimals="-3"
      id="Tc_bYqmkR-_nkO6D42le_N7xg_6_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-13344000</us-gaap:StockholdersEquity>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjitDg4W4EOE9Yf-R3ycdQ"
      decimals="3"
      id="Narr_mlS24KE9S0C-UQ1Xf2PA5A"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">1.893</us-gaap:SharePrice>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA"
      decimals="-3"
      id="Narr_mEY_Tc8F8EqcWgNhNVvtzw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-22000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <avte:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA"
      decimals="INF"
      id="Tc_dCKSsU7Wp0qXpdlDgs7Qnw_7_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">33562620</avte:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA"
      decimals="-3"
      id="Tc_EQxMtfnqs06K-0gH4PUYTg_7_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">63512000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA"
      decimals="-3"
      id="Tc_qR2zlZPxJEyrOlEx81fHvA_8_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-22000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g"
      decimals="-3"
      id="Tc_wYtjKxvNuku89KYt9AM2dQ_8_25"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">22000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_Wtio7Inx80asV1JaKa6WuQ_8_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">22000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA"
      decimals="INF"
      id="Tc_0CNs3xPVm0OCfuahbk2rlw_9_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">-40052154</avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares>
    <avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LbWNEp8NYki7AlwKYgZAeA"
      decimals="-3"
      id="Tc_92iUMV4iu0eazeyUU1TANw_9_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-75819000</avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering>
    <avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg"
      decimals="INF"
      id="Tc_e3aZox_bEUWd02tnrxlsPA_9_7"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">-4000000</avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares>
    <avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_lbGc8HVn00WuPu4HIc6Amg"
      decimals="-3"
      id="Tc_owxXBVWGRkSDbAIRZJ4UUA_9_10"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-4000000</avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering>
    <avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw"
      decimals="INF"
      id="Tc_PILo7odZI0eqBJW7TmeDxg_9_13"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">14182854</avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares>
    <avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw"
      decimals="-3"
      id="Tc_uNJ9NQQBXUma4IQc25fsjQ_9_16"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1000</avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering>
    <avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g"
      decimals="-3"
      id="Tc_SLGOYs9isUGbUV_kY2IHWw_9_19"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">79817000</avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering>
    <avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_-qRZGU4oQ0eI2Scf4IpZEQ_9_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">79818000</avte:ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw"
      decimals="INF"
      id="Tc_rJOBhH_4jUuJYBXIyixO8w_10_13"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">9984463</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eSBA37NOskS1RUPwnhuIBw"
      decimals="-3"
      id="Tc_L85-JD5aTUKfLVLEJZdA9A_10_16"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g"
      decimals="-3"
      id="Tc_OosdAaM9NkmhMhvvPNzVfg_10_19"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">126944000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_j9NnASA830ClH0TrLw4byg_10_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">126945000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sacVBs-ZekqHX0aqWQzdyA"
      decimals="-3"
      id="Tc_e317zEghQ02cEtFAKXumKw_11_22"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">59000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_UDxagcqzRU-k3mLUdWd4pA_11_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">59000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dAzwzmq0ZEWwnRqvi8Nz4g"
      decimals="-3"
      id="Tc_KpodL4ETDEakj5UypzaC8g_12_19"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2043000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_wrCqS1OqNke9cnq9XaTsXw_12_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2043000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__NzvoiUXKEiKMY1xD3Qx6g"
      decimals="-3"
      id="Tc_bZjqszrTWU6DpxBdXqxZ1g_13_25"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-22963000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_jdnK_vFchUiP2ItLpOw9kg_13_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-22963000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ok3TV3BnH0eWo3UW7uDQug"
      decimals="INF"
      id="Tc_zN7FT4Wom0y1VnZ9Pyw3KQ_14_13"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">24410393</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ok3TV3BnH0eWo3UW7uDQug"
      decimals="-3"
      id="Tc_pacFyYFx_0eJ4dkODkiPzA_14_16"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3CjGTVHCT0eUwawBJaweUg"
      decimals="-3"
      id="Tc_iZR8GgEBKkSNmaIbEcsdhw_14_19"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">208867000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6B2XB2kFVUWrsHm32rtreg"
      decimals="-3"
      id="Tc_7ru3he7ZGkealUXnEjYrwQ_14_22"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HN0Xoks5e0ezwLw29ZL8OQ"
      decimals="-3"
      id="Tc_Rq6WMuKmP0WiDo2Rq4qkjQ_14_25"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-36392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc__lu_XDYvsk6kt-873g2LJA_14_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">172418000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yReDKtcgo0KOffS55fF_QQ"
      decimals="-3"
      id="Tc_vK32pcROw0eWVqh-YWXizw_15_22"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">407000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_j-_q65jCSEOqxB3aK3F4rg_15_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">407000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxaL35pKjEOanh6iG7wiBQ"
      decimals="-3"
      id="Tc_2uebchd-506ooZ-sVToxDg_16_19"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">5476000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_FJjZoS2Mlk-zdS_SEa4DnQ_16_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">5476000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbD9PWCGfEa0ZCQkflEVJQ"
      decimals="INF"
      id="Tc_omk-CWuOBEuUDXV1Eh_GyA_17_13"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">298712</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxaL35pKjEOanh6iG7wiBQ"
      decimals="-3"
      id="Tc_dyvOEsmcyE-3SLaFhUowzg_17_19"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">617000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_f-DCb56KEEac8L6rW6arCw_17_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">617000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_StockCompensationPlanMember_gpUHdU7SI0iF5rb9E2h1XA"
      decimals="INF"
      id="Tc_80NsiNVHCkOPFbTprbd_0g_18_13"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">13869</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxaL35pKjEOanh6iG7wiBQ"
      decimals="-3"
      id="Tc_9YA8IDfmJU6tGz_WRVKijA_18_19"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">150000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_oZTNLBXJNEG3mjYWtM6psg_18_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">150000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KD9Fb9Ua2k--d7ATP52t5w"
      decimals="-3"
      id="Tc_2HFxuVj0TEOlhkZtBvebdg_19_25"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-51511000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_rV0kD94PqkaVaUZ1wwT1aA_19_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-51511000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YwXIEvLewkaQioMwjwbsbw"
      decimals="INF"
      id="Tc_vkSNk_C4rkOjkewe1UhcPA_20_13"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">24722974</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YwXIEvLewkaQioMwjwbsbw"
      decimals="-3"
      id="Tc_Z8KlXCx_rUShhSQUQoE33w_20_16"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KBAJsq8X1UePf0wtOE4-gA"
      decimals="-3"
      id="Tc_fZWLFSzlWUyXn2sAKpJ8rw_20_19"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">215110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ONawfJkraU2j7s81xUzW8Q"
      decimals="-3"
      id="Tc_lwcZFbdUs0GZEwhk4R_0Gg_20_22"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-466000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wX9u88nSX0ugu2QhP2n3ww"
      decimals="-3"
      id="Tc_tqiKHIGzuEiLmyy26Vn6xw_20_25"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-87903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_I5jAuKFxhUiMaUb4NesHuQ_20_28"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">126743000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_XDMssgcfrkGM2a0DjHBf7w_4_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-51511000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_FuOMvrQLxEKLULzKfeOLMw_4_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-22963000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_qgK9mOzu_06IGZmIU5kP2Q_6_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">5476000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_oPzpNGU6HUKgLxBeN5_FMg_6_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2043000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_vlTnoMypyE648_G5TviXgw_7_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">68000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_SsFP2cbYoUixr62JSQWp7w_7_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">15000</us-gaap:Depreciation>
    <avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_LJ4PG__ZpEuxiOvjPnz3Ow_8_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-910000</avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet>
    <avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_D9k35xpgvEm2FQWllmzcwQ_8_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">16000</avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_4ouDAqC6oU6TlRUD2Ye1Qw_10_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-4677000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_yA0GuiUWLk-EUm4nuC4Iuw_10_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">6855000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_9KUS41BWC0iaZ0aID4QiMg_11_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1872000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_cQCF6x-_8Umcu5DC7PAclA_11_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">302000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_WQgaYohXB0iSkTYqpAxHdQ_12_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1368000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_t0lZJB7iL02PBdbPKFClfw_12_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">609000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_KP3p31tgdkCPcRYkqHdPeQ_13_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">3672000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_pCm25ZsNNEm6tBjKV-rP8g_13_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-6000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_u4GVKEwLBUaXVUfa7Pil2Q_14_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">43000</avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability>
    <avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_kCbrTiXPsUyjeF8ZfwuYxQ_14_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">32000</avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability>
    <avte:IncreaseDecreaseInOtherLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_n4NoGC1wdkuRDQpe_lgPHQ_15_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-133000</avte:IncreaseDecreaseInOtherLiabilities>
    <avte:IncreaseDecreaseInOtherLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_9qprgrLhp06D7NRWJvpoVw_15_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">12000</avte:IncreaseDecreaseInOtherLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_FVcmCFz_T0OKt6-JGEqCBQ_16_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-39122000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_59lSWkmbK0OCurgHKW5ihg_16_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-27399000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_c0IPjqiMqUioF77A_erp7w_19_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">147623000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_ql_1PhYGb0CSNPQs58duCQ_19_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">113253000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_IQbw-T9b20CQZOoXXLYkYw_20_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">154744000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_ZCOXPUdu4U-_ENEu7Hy7Aw_21_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">195000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_5nQaVPdTpUKLwGsKcMNixg_21_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">181000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_8EeQhJSdZ02kCu4u7DXS9g_22_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">6926000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_s2F94ZpMJkKwIqA9c8OQmA_22_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-113434000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_Twt4gvRCG0ufFOAJyImDZA_25_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">63512000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_9wb6DFDvUUKnLQoqVxBmYQ_26_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">371000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_tETd_oH1d0udP6F1nY7AkA_27_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">150000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc__TzXI_5wh0qAlxvYzWSISg_28_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">617000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_sDch3dHMLES1r_WR0rPx7w_29_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">126945000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_bfivy069Wk6uIL89A6mUUg_30_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">396000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_ay96aziW60ydnCQs3x78xQ_30_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">190457000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_WocDWsXpL06TeTOKS_ozHg_32_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-31800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_aNtd09qiYUW5cWI_KvSrLw_32_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">49624000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_EDzdcNznAkK1QW9607HIFw_33_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">54197000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2020_lex_lE13Tka9RtZYzaRxrQ"
      decimals="-3"
      id="Tc_g9jhHjv8skCFgDXZOfzP6A_33_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">4573000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_AEU1hKe3C0Cfo-zwjksxoA_34_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">22397000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc__Gt-OFO0ZU-rt-GekjFl8g_34_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">54197000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_ibW4SAjL0kK0OEbob-BiHQ_37_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">765000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_qOehJyjJxE-PDafVxojRkw_37_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">542000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <avte:DeferredOfferingCostsIncludedInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_c_0aJdAkwEqw4ZuAuRGOug_38_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">15000</avte:DeferredOfferingCostsIncludedInAccountsPayable>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_5ot6m5Rmik--mr5LDUPMzA_39_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">21000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_1R0s5dk9VUaP9DrllgegkA_40_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">79818000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_wbiBJY_VfkOIejeqWUaLGA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(1)&lt;/b&gt;&lt;/span&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Organization and Nature of Operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Aerovate Therapeutics&#160;Inc. (&#x201c;Aerovate&#x201d; or the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in July&#160;2018, and is headquartered in Waltham, Massachusetts. The Company has a wholly owned subsidiary, Aerovate Securities Corporation. The Company is a clinical-stage biopharmaceutical company that is focused on the development of drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. The Company&#x2019;s initial focus is on advancing AV-101, the Company&#x2019;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#x201c;PAH&#x201d;). The Company initiated a global Phase 2b/Phase 3 trial of AV-101 in adults with PAH in December&#160;2021.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;On July&#160;2, 2021, the Company completed its initial public offering (&#x201c;IPO&#x201d;). The Company&#x2019;s Registration Statement on Form&#160;S-1 (File No.&#160;333-256949) relating to the IPO was declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on June&#160;29, 2021. The shares began trading on The Nasdaq Global Market on June&#160;30, 2021. The Company issued 9,984,463 shares of its common stock, including 1,302,321 shares associated with the full exercise of the underwriters&#x2019; option to purchase additional shares, at an offering price of $14.00 per share. Immediately prior to the closing of the Company&#x2019;s IPO on July&#160;2, 2021, all outstanding shares of the Company&#x2019;s redeemable convertible preferred stock were converted into 14,182,854 shares of the Company&#x2019;s common stock. In aggregate, the shares issued in the IPO generated approximately $126.9 million in net proceeds after deducting underwriting discounts and commissions and other offering costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;At-the-Market Offering &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;&lt;span style="font-size:10pt;"&gt;On August 15, 2022, we entered into an &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Open Market Sale Agreement&lt;/span&gt;&lt;sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt;&lt;span style="font-size:10pt;"&gt;, or&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; the Sale Agreement, with Jefferies LLC, or the Agent, pursuant to which we can sell, from time to time, at our option, up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$75.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million of shares of our common stock, through the Agent, as our sales agent. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares were sold under the Sale Agreement.&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Liquidity and Management Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Since inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations and has not realized revenues from its planned principal operations. The Company has incurred losses and negative cash flows from operations since inception. In addition, the Company expects to incur substantial operating losses for the next several&#160;years as it continues its research and development activities. As of December&#160;31, 2022, the Company had cash and cash equivalents and short-term investments of $129.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through debt or equity financings or other arrangements to fund operations. Management believes that the Company&#x2019;s current cash and cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve&#160;months from the filing date of this report.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_f35-tn37YkSEpT0jtT5KhQ"
      decimals="INF"
      id="Narr_B4XvHSu4t0SzB69rDZ3sbQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">9984463</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_45gK5TQqjU22PAv52bixOQ"
      decimals="INF"
      id="Narr_0yMrmHeeh02GaSuu4OI6zQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">1302321</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_GUwnxPWZUk-8QC102OTn9w"
      decimals="2"
      id="Narr_iOL-_7gQ90uwADLbQPAd2g"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">14.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_f35-tn37YkSEpT0jtT5KhQ"
      decimals="INF"
      id="Narr_yX6RLZhAPE2UFgmr4XFEOg"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">14182854</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_f35-tn37YkSEpT0jtT5KhQ"
      decimals="-5"
      id="Narr_58oNNM_k40S1tyHXNPpbOQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">126900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_8_15_2022_To_8_15_2022_srt_CounterpartyNameAxis_avte_JefferiesMember_FWTe7abbGk2o3kC0iODEaQ"
      decimals="-5"
      id="Narr_yq5dI0NH_kieEf_pfaA_0Q"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">75000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_avte_JefferiesMember_XuFYdSUixkyetwSnndM8uw"
      decimals="INF"
      id="Narr_SuQTLTm_80ylWPd-d77hnQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="5"
      id="Narr_RBKHVXAyKEqXFKp1NuKomA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">129200000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_OGZpl4gwkkOlyoNan_ustg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(2)&lt;/b&gt;&lt;/span&gt;BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the Company&#x2019;s wholly owned subsidiary, Aerovate Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;On June&#160;22, 2021, the Company effected a &lt;span style="-sec-ix-hidden:Hidden_AH0m-scr1ESIQqpsOnDeyg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1-for-3&lt;/span&gt;&lt;/span&gt;.1060103 reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of its issued and outstanding common stock. Accordingly, the conversion ratio for the Company&#x2019;s outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. The par value of the common stock was not adjusted as a result of the Reverse Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Cash and cash equivalents include cash in readily available checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three&#160;months or less from the date of purchase to be cash equivalents.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(e)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Short-term Investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"&gt;Short-term investments consist of corporate debt securities, commercial paper and U.S. Treasury bills, classified as available-for-sale securities and have maturities of greater than three&#160;months. The Company has classified all of its available-for-sale investment securities as current assets on the consolidated balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company carries these securities at fair value and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the consolidated statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;using the specific identification method and recorded in other income (expense), net in the consolidated statement of operations and comprehensive loss.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(f)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(g)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(h)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(i)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Any expenses paid prior to the related services rendered are recorded as prepaid expenses. Such prepaid expenses are expensed in the period the expense is incurred. If the expense is for a service covering multiple periods, it is expensed from the date the services begin and over the period of the service rendered (or contract service period if services rendered dates are not defined).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(j)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and construction-in-progress are stated at cost less accumulated depreciation or accumulated amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from &lt;span style="-sec-ix-hidden:Hidden_bBazvaq5mUO3D78wc3eoZQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span style="-sec-ix-hidden:Hidden_Ha-ILLgVZUue-n7HxT3H2Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&#160;years&lt;/span&gt;&lt;/span&gt;. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(k)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December&#160;31, 2022, there has been no such impairment losses recorded by the Company.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(l)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets (&#x201c;ROU assets&#x201d;) which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to separate lease and non-lease components and not recognize lease liabilities and ROU assets for short-term leases with terms of twelve&#160;months or less.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(m)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The Company records convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#x2019;s control, including a deemed liquidation event, holders of the convertible preferred stock can cause redemption for cash. Therefore, convertible preferred stock is classified outside of stockholders&#x2019; deficit on the balance sheets as events triggering the liquidation preferences are not solely within the Company&#x2019;s control. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(n)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(o)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"&gt;Stock-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option grants and restricted stock units, estimated in accordance with the applicable &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;"&gt;accounting guidance, recognized using the straight-line method over the vesting period for service-based options and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;"&gt;The fair value of stock options is estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, expected dividend yield, and a risk-free interest rate. Options and awards granted during the&#160;year have a maximum contractual term of ten&#160;years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected volatility of stock options is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury (&#x201c;U.S. Treasury&#x201d;) yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(p)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;"&gt;Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss (&#x201c;NOL&#x201d;) and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company records uncertain tax positions on the basis of a two-step process whereby (1)&#160;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(q)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(r)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#x2019;s potentially dilutive securities, which include convertible preferred stock prior to the conversion of such shares to common stock and outstanding stock options under the Company&#x2019;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;"&gt;The following table summarizes the Company&#x2019;s net loss per share:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,511)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22,963)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion of Series A redeemable convertible preferred stock to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,511)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22,985)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Weighted-average common stock outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,472,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,293,629&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.87)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,454,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,139,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,454,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33.1pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(p)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard will be effective for the Company on January 1, 2024, and is not expected to have an impact on the Company&#x2019;s financial position or results of operations upon adoption.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_VuCsMdt5PE6igXO4YLSQEA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the Company&#x2019;s wholly owned subsidiary, Aerovate Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <avte:ReverseStockSplitPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_BWq9MrAaC0qyl12MJOnM6A">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;On June&#160;22, 2021, the Company effected a &lt;span style="-sec-ix-hidden:Hidden_AH0m-scr1ESIQqpsOnDeyg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1-for-3&lt;/span&gt;&lt;/span&gt;.1060103 reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of its issued and outstanding common stock. Accordingly, the conversion ratio for the Company&#x2019;s outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. The par value of the common stock was not adjusted as a result of the Reverse Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.&lt;/p&gt;</avte:ReverseStockSplitPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_ixM6fPljRk6Zhjo_qTYDZA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_4tA4norhmUKl0OvAX_T3kg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Cash and cash equivalents include cash in readily available checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three&#160;months or less from the date of purchase to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <avte:ShortTermInvestmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_8crYH2Zq60atYHk6hHUKaA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(e)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Short-term Investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"&gt;Short-term investments consist of corporate debt securities, commercial paper and U.S. Treasury bills, classified as available-for-sale securities and have maturities of greater than three&#160;months. The Company has classified all of its available-for-sale investment securities as current assets on the consolidated balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company carries these securities at fair value and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the consolidated statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;using the specific identification method and recorded in other income (expense), net in the consolidated statement of operations and comprehensive loss.&lt;/p&gt;</avte:ShortTermInvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_Yig97Oxa1k2g5pMIXeiuRg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(f)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_8N3gxwRXq0-pOdIWfI39QA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(g)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_UYqW3FA00UuTJOf94VClew">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(h)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <avte:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_zZD2SFPZBUeH7_LchiItag">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(i)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Any expenses paid prior to the related services rendered are recorded as prepaid expenses. Such prepaid expenses are expensed in the period the expense is incurred. If the expense is for a service covering multiple periods, it is expensed from the date the services begin and over the period of the service rendered (or contract service period if services rendered dates are not defined).&lt;/p&gt;</avte:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_68bQ0dJ72U2YPiZHDWSC7w">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(j)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and construction-in-progress are stated at cost less accumulated depreciation or accumulated amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from &lt;span style="-sec-ix-hidden:Hidden_bBazvaq5mUO3D78wc3eoZQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span style="-sec-ix-hidden:Hidden_Ha-ILLgVZUue-n7HxT3H2Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&#160;years&lt;/span&gt;&lt;/span&gt;. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_UC0guKgHWEy8BIoHOFc8Ug">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(k)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December&#160;31, 2022, there has been no such impairment losses recorded by the Company.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="0"
      id="Narr_dHlaxzn7pESUrLf1E3lbaA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_tdfsWcmVnU244eR6nTbQUg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(l)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets (&#x201c;ROU assets&#x201d;) which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to separate lease and non-lease components and not recognize lease liabilities and ROU assets for short-term leases with terms of twelve&#160;months or less.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <avte:ConvertiblePreferredStockPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_uQoalqdxqkeI0W0AWkAWiQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(m)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The Company records convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#x2019;s control, including a deemed liquidation event, holders of the convertible preferred stock can cause redemption for cash. Therefore, convertible preferred stock is classified outside of stockholders&#x2019; deficit on the balance sheets as events triggering the liquidation preferences are not solely within the Company&#x2019;s control. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur.&lt;/p&gt;</avte:ConvertiblePreferredStockPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_SSpFQzMW4kyChQefpOOLJA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(n)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_hJ3uD38dRkGnm0U89176Pg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(o)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"&gt;Stock-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option grants and restricted stock units, estimated in accordance with the applicable &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;"&gt;accounting guidance, recognized using the straight-line method over the vesting period for service-based options and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;"&gt;The fair value of stock options is estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, expected dividend yield, and a risk-free interest rate. Options and awards granted during the&#160;year have a maximum contractual term of ten&#160;years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected volatility of stock options is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury (&#x201c;U.S. Treasury&#x201d;) yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_L6Aulrv6skCjIRhGAQFN1w"
      id="Narr_QpXkLOqLsUSOk3cq4YaIsg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_9A8pPY0sZkKAAfp8PB2l_A">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(p)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;"&gt;Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss (&#x201c;NOL&#x201d;) and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company records uncertain tax positions on the basis of a two-step process whereby (1)&#160;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_6SG937B5Vki5UoHZXIUn_g">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(q)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="INF"
      id="Narr_zqquROffpEiU4uEjT94qgg"
      unitRef="Unit_Standard_segment_4id_vXrVjkay3ChrkF2qUA">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_vLrC1klqqkeiGfJ4Ok21-g">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(r)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33pt;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#x2019;s potentially dilutive securities, which include convertible preferred stock prior to the conversion of such shares to common stock and outstanding stock options under the Company&#x2019;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;"&gt;The following table summarizes the Company&#x2019;s net loss per share:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,511)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22,963)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion of Series A redeemable convertible preferred stock to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,511)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22,985)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Weighted-average common stock outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,472,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,293,629&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.87)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,454,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,139,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,454,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_JYNSM2sqv0-5gb3WLyBbgA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;"&gt;The following table summarizes the Company&#x2019;s net loss per share:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,511)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22,963)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion of Series A redeemable convertible preferred stock to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,511)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22,985)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Weighted-average common stock outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,472,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,293,629&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.87)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_s3NXbCEMeEKfOdTYiT9KSg_4_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-51511000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_lmuhCG_pkU-V-weAh1ExHg_4_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-22963000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_qthA2_MWG0-O-o6csyodmQ"
      decimals="-3"
      id="Tc_WESrCxMEr0yjUVURVCcJOw_5_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">22000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_q-V-3FlhFkSgR6uUxsl2zw_6_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-51511000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_PhkL6HYgZEWCoCvU-7VE2A_6_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-22985000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="0"
      id="Tc_6Re2y1MiAU-N3uQjyLn97w_9_3"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">24472104</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="0"
      id="Tc_6Re2y1MiAU-N3uQjyLn97w_9_3_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">24472104</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="0"
      id="Tc_KTNpkwlx1UaADcensl1RtA_9_6"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">12293629</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="0"
      id="Tc_KTNpkwlx1UaADcensl1RtA_9_6_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">12293629</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="2"
      id="Tc_wfT3I8Fpck2BJWjZArHi5g_10_3"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">-2.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="2"
      id="Tc_wfT3I8Fpck2BJWjZArHi5g_10_3_2"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">-2.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="2"
      id="Tc_en7aWYAIQki8saHDe8rAhQ_10_6"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">-1.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="2"
      id="Tc_en7aWYAIQki8saHDe8rAhQ_10_6_2"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">-1.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_wof_PKN-ZEyZC46_H7EYBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,454,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,139,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,454,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2u36RAc4eEiBYcmpsvX8AA"
      decimals="INF"
      id="Tc_-C_40fK05kKV5MweZSwMmQ_3_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">4110219</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_rJ1OBbHLXUyHKgkaKxW57Q"
      decimals="INF"
      id="Tc_I4ocL8XFekK0TRisz-alSQ_3_4"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">3454374</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_o4StUCQIc0a31cjpbHrNkg"
      decimals="INF"
      id="Tc_ZCJBpVCU_0COyIvwqDpftQ_4_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">28881</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="INF"
      id="Tc_FJlWEHxa8k-CAW_Ot0UnkQ_5_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">4139100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="INF"
      id="Tc_L-nW507IGESA2cP9Ow0Kzg_5_4"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">3454374</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_0dLiFzCxKE2HjXWwp4WWJA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:16.55pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(p)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard will be effective for the Company on January 1, 2024, and is not expected to have an impact on the Company&#x2019;s financial position or results of operations upon adoption.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_39-M3jGLWUWUnU5xreYtvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;"&gt;(3)&#160;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;"&gt;The following tables summarize the Company&#x2019;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,823&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,982&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total fair value of assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 125,259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,982&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,653&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,653&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,448&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,448&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,101&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,653&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,448&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 113,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total fair value of assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 167,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Cash Equivalents and Short-Term Investments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Financial assets measured at fair value on a recurring basis consist of the Company&#x2019;s cash equivalents and short-term investments. Cash equivalents consisted of cash, money market funds and commercial paper, and short-term investments consisted of U.S. Treasury bills, agency bonds, corporate debt securities and commercial paper. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The following tables summarize the Company&#x2019;s short-term investments (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:36.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_P4znHQF3GUSWjTutnltemQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (267)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:36.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agency bond&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,536&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (484)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,823&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113,237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (68)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The following tables summarize the Company&#x2019;s short-term investments with unrealized losses for less than 12 months and 12 months or greater:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:71.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than 12 months&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12 months or Greater&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,971&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (267)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agency bond&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (223)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (484)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:71.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than 12 months&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12 months or Greater&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,194&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,194&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (68)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (68)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#x2019;s available-for-sale securities as of December&#160;31, 2022 were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. The Company concluded that an allowance for credit losses was unnecessary as of December&#160;31, 2022. It is neither management&#x2019;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. &lt;span style="-sec-ix-hidden:Hidden_NQg-uPEboUy3bkc7fClBSQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Accrued interest receivable&lt;/span&gt;&lt;/span&gt; related to short-term investments was $0.3 million and $0.1 million as of December&#160;31, 2022 and December 31, 2021, respectively.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_aAqCtuZOTUaBTLQCwWuL8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 33.1pt;"&gt;The following tables summarize the Company&#x2019;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,823&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,982&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total fair value of assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 125,259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,982&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,653&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,653&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,448&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,448&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,101&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,653&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,448&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 113,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total fair value of assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 167,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__I6MyJ-3P0WLSD1L0CQLMw"
      decimals="-3"
      id="Tc_TJyPB8IFYk2h0LGcdh63gQ_9_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">18436000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BZC2smINzEqMpJkFZy61dA"
      decimals="-3"
      id="Tc_pc_hpmf0XkubShY_YUFKLA_9_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">18436000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CkuAokZFEE6-3rAKVgGLlw"
      decimals="-3"
      id="Tc_1KC6mySGWUS6sZ8lCAQpuA_10_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">18436000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ydsgvjwLrUe_yWrw82jE-Q"
      decimals="-3"
      id="Tc_wsGOo6UTOkChc-haWx4y3w_10_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">18436000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_USRDgmPtwkOyBzlosVP3AQ"
      decimals="-3"
      id="Tc_7-phMTskKEi9G4dB3l7MfQ_13_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">55577000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VJ2CIL3_20mu--166dWxVg"
      decimals="-3"
      id="Tc_u48Q47sL4Eu9IP68tueJzA_13_9"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">55577000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_zqKb8DAZgESt_eax0wleGw"
      decimals="-3"
      id="Tc_0pDbo9EeCEe5RB9XH3SN2w_14_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">26841000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_zemR5DkqREKFgJjFkN8qqQ"
      decimals="-3"
      id="Tc_bxducuXdiEq7y_JSfb7zFw_14_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">26841000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_aQq0ijr06kSW_SZprlK7sg"
      decimals="-3"
      id="Tc_MxaUQaa9V0CG6H9ml8pyqg_15_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">24405000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_rPrkP4ujk0W_7H8LCrqXLQ"
      decimals="-3"
      id="Tc_rUyTQ0pXbEifm867jcq5aw_15_9"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">24405000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CkuAokZFEE6-3rAKVgGLlw"
      decimals="-3"
      id="Tc_feQ1ov9kkEKIq-HNJ6taTA_16_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">106823000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ydsgvjwLrUe_yWrw82jE-Q"
      decimals="-3"
      id="Tc_8rkGlTruoEGags2fvWZVlQ_16_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">26841000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6Vn0yOonI0i5051pthm-IQ"
      decimals="-3"
      id="Tc_qc_yjBk3I0mRgal0cjFt5A_16_9"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">79982000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CkuAokZFEE6-3rAKVgGLlw"
      decimals="-3"
      id="Tc_OQ75s_2mCUmt7GVAtUuQPg_18_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">125259000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ydsgvjwLrUe_yWrw82jE-Q"
      decimals="-3"
      id="Tc_-HWzGNrNqk2eatujt028iw_18_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">45277000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6Vn0yOonI0i5051pthm-IQ"
      decimals="-3"
      id="Tc_jJgRdjTlpkmnyitewxDSLg_18_9"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">79982000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1EYoksMxjEatDkF4HraTtQ"
      decimals="-3"
      id="Tc_dIFQbTEhAU-tpJAiGoDaQQ_9_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">39653000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_btTJ7hB3m0msnUE_XEjudA"
      decimals="-3"
      id="Tc_7lQJa94slk-QNQW3j_bz7Q_9_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">39653000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_X-cBBwKLukqd96ZZFzoANQ"
      decimals="-3"
      id="Tc_GICQ4trp302cz5f0WbG7Xw_10_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">14448000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XKXReW8Iv0iqNoVsfOn3wg"
      decimals="-3"
      id="Tc_NQguJQM4LUylZg62AHl72Q_10_9"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">14448000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_h7PXcaYot0um0bjFUh0YmA"
      decimals="-3"
      id="Tc_FS1WjlQ2OkevDqWQUUEVsA_11_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">54101000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fkQ2x2flakWcJsOn3HTX-Q"
      decimals="-3"
      id="Tc_uPARljEulE2JFBNPPcJsHg_11_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">39653000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tuJ-pg1BnECbTpf6Uk40Bg"
      decimals="-3"
      id="Tc_XzhsHS3NGUePoNPzUjR-sg_11_9"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">14448000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_RR9WWKOeMEOQdAup8Pv4AA"
      decimals="-3"
      id="Tc_U-TytD5Mc0e8hlsT3YSGAQ_14_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">25135000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8VmyKaoxLEOzzbfyzwCJ2g"
      decimals="-3"
      id="Tc_UV5Lf5UYbEuEpn94oOkVcQ_14_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">25135000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_y6dmyknKUU-SGERHF0Dc_w"
      decimals="-3"
      id="Tc_6uoFrjiAc0GiyEvphSVjLw_15_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">10715000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_tGjRsdl680qEsQ3mUldJJg"
      decimals="-3"
      id="Tc_9dpjWf3d_kuzvw1hpbBuJw_15_9"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">10715000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_X-cBBwKLukqd96ZZFzoANQ"
      decimals="-3"
      id="Tc_BIjYibUTwUCSbtN_aOL3cQ_16_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">77328000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XKXReW8Iv0iqNoVsfOn3wg"
      decimals="-3"
      id="Tc_aqxw7-ClQkuIC1A9_XE1xA_16_9"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">77328000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_h7PXcaYot0um0bjFUh0YmA"
      decimals="-3"
      id="Tc_jY3RpkHHeEOjHM5jImpgrw_17_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">113178000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fkQ2x2flakWcJsOn3HTX-Q"
      decimals="-3"
      id="Tc_Pcl1Lh-vPkSeRyfKtAJkxA_17_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">25135000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tuJ-pg1BnECbTpf6Uk40Bg"
      decimals="-3"
      id="Tc_3ZqdXuaopU-NB3Z_nZfQ4Q_17_9"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">88043000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_h7PXcaYot0um0bjFUh0YmA"
      decimals="-3"
      id="Tc_0JMD-pFQ6UOvFZTYNVU29Q_19_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">167279000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fkQ2x2flakWcJsOn3HTX-Q"
      decimals="-3"
      id="Tc_LRKgdGCy50CyrJyII_pf-A_19_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">64788000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tuJ-pg1BnECbTpf6Uk40Bg"
      decimals="-3"
      id="Tc_-ce0_HQpIEyMMMnlnGgwWg_19_9"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">102491000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_-BMOIaXxm0qqmhA6tg0NVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The following tables summarize the Company&#x2019;s short-term investments (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:36.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_P4znHQF3GUSWjTutnltemQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (267)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:36.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agency bond&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,536&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (484)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,823&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113,237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (68)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xiCQZvKWqESmhAB-Ehu1tg"
      id="Narr_6G0dg6TpAkimUZ6qzVbGnA">P1Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q"
      decimals="-3"
      id="Tc_JKsxK7pW_Eq8ZnF4oNKiWg_5_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">55645000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q"
      decimals="-3"
      id="Tc_ltXTQ_tTSkmt0uFZqLpkOQ_5_8"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q"
      decimals="-3"
      id="Tc_10NcrVwO2Ui8ardk4D_UNA_5_11"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">84000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q"
      decimals="-3"
      id="Tc_lJiznXRccEiRP_RwE2xwGw_5_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">55577000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_PvqmJS3bP0uIcfv-_n2kqg"
      id="Narr_lrVUMVBPW0aO5odqIDT2nw">P2Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ"
      decimals="-3"
      id="Tc_nn22DjA1U0u9nR850fLlWg_6_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">27108000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ"
      decimals="-3"
      id="Tc_kjUogDnZwUeLi5hasW2msw_6_11"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">267000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ"
      decimals="-3"
      id="Tc_ln1Udo6HckqxuQgY1y3A3A_6_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">26841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7ZoMrQXRJk2hJ6cbQPFKvQ"
      id="Narr_fKErKTfLTUu8071JUTzE8A">P2Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA"
      decimals="-3"
      id="Tc_NXTnp3AaZ0mq71EW-m3UVQ_7_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">24536000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA"
      decimals="-3"
      id="Tc_SddZsyORh06nlYc0js2CuQ_7_8"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA"
      decimals="-3"
      id="Tc_ej9epzaNuUiDkBnEs7VQdQ_7_11"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">133000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA"
      decimals="-3"
      id="Tc_tBm6ksEo5UStbaq9t201qw_7_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">24405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_jWtpH0CJDkyY-j8rzSBehw_8_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">107289000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_lxI5XrSt_0C0tDJ6b5I0WQ_8_8"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_-Oei1cmotkuNy3LpMXcOgg_8_11"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">484000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_czWur5KjfUOI3uBE_qj7Gw_8_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">106823000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_j8WxaSALUESwMgXMefh0UQ"
      id="Narr_IowvwOG6fU65Jeg7_oqMOQ">P1Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA"
      decimals="-3"
      id="Tc_wU7MM6fx1k6kRWXTgrWRYg_5_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">10726000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA"
      decimals="-3"
      id="Tc_4zmgcDZlQk6o4nx4rgTn7A_5_11"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA"
      decimals="-3"
      id="Tc_FaQty5sF0kWDvUoWhFwC_w_5_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">10715000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_mt2q9GoKi0-AvNO-EXkZnw"
      id="Narr_EoyjfYxWZ0aqO9YxOFEjNA">P1Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg"
      decimals="-3"
      id="Tc_w0Ss-t_Va0WMkXXitlcukA_6_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">77328000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg"
      decimals="-3"
      id="Tc_K8MzSbhAdE2FVDfd2zTOhA_6_8"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg"
      decimals="-3"
      id="Tc_CIQBoEs5xUmcNbFwvRtO3Q_6_11"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg"
      decimals="-3"
      id="Tc_XaDOvs_0PU-byA8Z-wS62w_6_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">77328000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_7nzerVxUhkyRb7q9DTrxjA"
      id="Narr_x-n9lXX2rEC8lYKKqAf_1w">P2Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA"
      decimals="-3"
      id="Tc_fbouYxiNUk-LuMHAd5Ss0w_7_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">25183000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA"
      decimals="-3"
      id="Tc_x3mFjHO3VUO4NhKB8PSX5g_7_11"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">48000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA"
      decimals="-3"
      id="Tc_GGv8bGda1EyWnHKoKi15Rw_7_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">25135000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_hdiKwDnru0aVmtgAOUGzqQ_8_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">113237000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_R8e2-rWLj0mQvDBQCCs9PA_8_8"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_E0agcq1oBUK63DDNppdhVA_8_11"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">68000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_PRTSf6647EeYcChZJuvv8w_8_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">113178000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_6DQQM50ii0qRv5uKBoNWhA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:71.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than 12 months&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12 months or Greater&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,971&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (267)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agency bond&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (223)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (484)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:71.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than 12 months&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12 months or Greater&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:26.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,194&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,194&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (68)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (68)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q"
      decimals="-3"
      id="Tc_CF8p4hsQH0aWfsZRzC--rg_5_2"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">34928000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q"
      decimals="-3"
      id="Tc_v_NysTEh00GEzCuHtix8cg_5_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">84000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q"
      decimals="-3"
      id="Tc_D1r68Zfdc0G4JvfqFl_Spg_5_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">34928000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gM1HxMSd-kCI0ZrCsb7w1Q"
      decimals="-3"
      id="Tc_JPj9Moy8J0yoZgnG260izw_5_17"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">84000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ"
      decimals="-3"
      id="Tc_-OZXp1fnykGizYTCVV2g6Q_6_2"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1971000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ"
      decimals="-3"
      id="Tc_sMCbT3Yow0y4iHUTpQhwfg_6_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ"
      decimals="-3"
      id="Tc_SydZw-KmPEKJo0fO50W6QQ_6_8"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">24833000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ"
      decimals="-3"
      id="Tc_4JuNoM2VcUqgL0o27LFqxQ_6_11"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">261000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ"
      decimals="-3"
      id="Tc_rSs8AXLrN0u9Y9nuHHptVw_6_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">26804000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YelENWoM3U2vnXHkvAXFRQ"
      decimals="-3"
      id="Tc_Nk38dYpOGkK3aRembqR9AQ_6_17"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">267000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA"
      decimals="-3"
      id="Tc_QAYnKIavkUGtlNQhEPvjdg_7_2"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">22964000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA"
      decimals="-3"
      id="Tc_4lW6BZWjbU-d8DoRUYQsZA_7_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">133000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA"
      decimals="-3"
      id="Tc_DRt52gzza0W4GloDgkVoZg_7_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">22964000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_hn0lEDXv6k-2CQMPbEINJA"
      decimals="-3"
      id="Tc_JUQaN2lpiE6A5bNPH-Okyg_7_17"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">133000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_lJu18a54CECkTOtxBOAj9g_8_2"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">59863000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_uoaPPZrs40-_yFaXIiCIog_8_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">223000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_gaWITSgFk0K4TTZ52MMFLw_8_8"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">24833000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_g5GsXBPRSkGf07EE28nF7A_8_11"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">261000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_uHruFW88PUmup6gd6tg1pw_8_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">84696000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_54Lf7VS170KXv3Id1mAxAg_8_17"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">484000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA"
      decimals="-3"
      id="Tc_PuOzqx_C8EOKSOEVuo6G_g_5_2"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">10757000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA"
      decimals="-3"
      id="Tc_oIw3IzRX0Ueqj1HrmC42AA_5_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">11000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA"
      decimals="-3"
      id="Tc_9ZFgDk7RdEm26yLhvegIcw_5_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">10757000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_clR4KbydnUiOUqEnLuOFcA"
      decimals="-3"
      id="Tc_TxvIgd89UE-qx0OEyYS7zA_5_17"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">11000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg"
      decimals="-3"
      id="Tc_xtmVPEUh1UiCOJP-xg4AQA_6_2"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">33204000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg"
      decimals="-3"
      id="Tc_FIIebe9ZCkKf0NzNPVivFw_6_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg"
      decimals="-3"
      id="Tc_E4s0zLdzg0yoKdc_kHnynw_6_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">33204000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_HCb00QichUOhHPjTe2g7Wg"
      decimals="-3"
      id="Tc_suFmpe2qdUKoNQntycKbWw_6_17"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">9000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA"
      decimals="-3"
      id="Tc_R9LVoDzqK0uNdLAwTzKduQ_7_2"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">25194000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA"
      decimals="-3"
      id="Tc_0uJyun5YYECWSUJA-rmnSQ_7_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">48000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA"
      decimals="-3"
      id="Tc_g2Wj5-D6vUaIho9rdoHBVQ_7_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">25194000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_iV61_Vb3tUqz6GzFWmL7IA"
      decimals="-3"
      id="Tc_AMPpsOaM4EyS07hCNnqSDQ_7_17"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">48000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_oE_Sg_u_sEqxgNPiCtcHQA_8_2"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">69155000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_5V1G4XGHDU2qFNyZ4rwNNw_8_5"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">68000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_xy8QuW5dE0C-8JwVRiB8vA_8_14"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">69155000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_F3sHH8fddUmGmrB2qypy3g_8_17"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">68000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent
      contextRef="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_3BpSFz349EKBC1pez2vW1g"
      decimals="-5"
      id="Narr_0GX9frt0cEOWsS0SmMOQuQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">300000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent
      contextRef="As_Of_12_31_2021_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_uqnI7J_-ykeUEvSi8eqaBQ"
      decimals="-5"
      id="Narr_2jV6GHeil0ayp0AxSxTvxw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">100000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_o-7r-PrNy0edP38Dbkf5lA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(4)&#160;BALANCE SHEET COMPONENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Prepaid Expenses and Other Current Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,958&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued payroll and other employee benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,691&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <avte:ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_LACHwZUuOkSercxES6DpWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,958&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</avte:ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_ieEHNRVF00S343Qq9U7Ejg_3_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1503000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_EYesuGUMhUCgbcDSogbxoA_3_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1485000</us-gaap:PrepaidExpenseCurrent>
    <avte:PrepaidResearchAndDevelopment
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_fZrKITdblUKr2Tbjj4yM8w_4_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">478000</avte:PrepaidResearchAndDevelopment>
    <avte:PrepaidResearchAndDevelopment
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_qMhPVWTU0kGdUTXcQ1-qIg_4_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">5233000</avte:PrepaidResearchAndDevelopment>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_g2F5HWz07Ei5Xf_eqfLU4g_5_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">295000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_KSrwUMAv3Uuphy8xIkXicg_5_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">240000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_yBuJ1A2aXUGf770wb7jkxA_6_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2276000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_x2KXQ7V67k2pVp6moR7H1Q_6_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">6958000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_v0r-wjIUB0ueBpeRrztr5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued payroll and other employee benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,691&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avte:AccruedResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_ulmhDh9BDkyImhQ__7x-Kg_3_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2751000</avte:AccruedResearchAndDevelopmentCurrent>
    <avte:AccruedResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_VJHM2VfKnU-s7qh8gf74Lg_3_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">217000</avte:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_7m0BC00rREm8_tYvdNbI8A_4_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1691000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_53P_4LpJ8kyRy3LYd6UzgA_4_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">790000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_g8JK6iafs0y9DlZNQgtN2A_5_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">380000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_CXIv_wDCUEmF120cGqQqeg_5_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">143000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_9CIuU6sK60SAXJ_YLmRITg_6_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">4822000</avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_L8GpetrY7UqrlTq1pahRag_6_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1150000</avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_hBDakIE1rEy4UrV2oWCwuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(5)&#160;COMMITMENTS AND CONTINGENCIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;In August&#160;2021, the Company entered into a lease agreement (the &#x201c;Waltham Lease&#x201d;) for approximately 5,000 square feet of office space in Waltham, Massachusetts for the Company&#x2019;s corporate headquarters. The Waltham Lease has a term of thirty-nine months (&#x201c;Lease Term&#x201d;), unless extended or earlier terminated. The Company has the option to extend the Waltham Lease for one additional period of three&#160;years. The Lease Term had an initial abatement period, and the initial base rent payable is approximately $18,000 per&#160;month following the abatement period. The initial base rent payable will increase by approximately 2% per&#160;year over the Lease Term. The Waltham Lease commencement date was September&#160;1, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;In April 2022, the Company entered into a lease agreement (the &#x201c;Foster City Lease&#x201d;) for approximately 3,500 square feet of office space in Foster City, California. The Foster City Lease has a term of thirty-nine months, unless extended or earlier terminated. The Company has the option to extend the Foster City Lease for on additional period of one year. The base rent payable under the Lease Term will be $22,600 per month and will be subject to annual increase of 3% on each anniversary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;As of December&#160;31, 2022, the consolidated balance sheet includes an operating lease right-of-use asset of $1.0 million and operating lease liability of $1.1 million. The total operating lease expense was $0.4 million and $0.1 million, for the years ended December 31, 2022 and 2021, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;As of December&#160;31, 2022, the future minimum annual lease payments under the operating leases were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:24.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Minimum&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease Payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total operating lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (86)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Present value of net minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The components of operating leases for the years ended December 31, 2022 and December 31, 2021 were as follows (in thousands except lease term and discount rate):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 192&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 574&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average incremental borrowing rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The Company may from time to time be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December 31, 2022 and 2021, and no material legal proceedings are currently pending or, to the best of its knowledge, threatened.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_I5wcShJpG0OhjXjvlcq-_g"
      decimals="INF"
      id="Narr_uODXJHW3UUaURzFrAIIPNA"
      unitRef="Unit_Standard_sqft_UveSBE_izUeNb4VPRsSftw">5000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_I5wcShJpG0OhjXjvlcq-_g"
      id="Narr_ouN4A2OFa0Os1BgkSH8dvQ">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_h_ieJm0F5UauCwtcprOqhQ">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_I5wcShJpG0OhjXjvlcq-_g"
      id="Narr_pYAh2kpEsU-9IEqe6W09JA">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForRent
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_YaLLcUjHZki458JcBBF_AA"
      decimals="0"
      id="Narr_zwcHSTLKPUudtycbDDdumw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">18000</us-gaap:PaymentsForRent>
    <avte:LeaseIncreaseInRentPercentage
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_YaLLcUjHZki458JcBBF_AA"
      decimals="INF"
      id="Narr_qLwAz2I8e0KZ1qZgdMZ-dA"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.02</avte:LeaseIncreaseInRentPercentage>
    <us-gaap:AreaOfLand
      contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_nM5HHKPZJk6bkcFB2fyHpw"
      decimals="INF"
      id="Narr_kDEYIaU3lkaB6qAfzJ1mpA"
      unitRef="Unit_Standard_sqft_UveSBE_izUeNb4VPRsSftw">3500</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_nM5HHKPZJk6bkcFB2fyHpw"
      id="Narr_oeas0g0lnk-pTw11PQTUdA">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_nM5HHKPZJk6bkcFB2fyHpw"
      id="Narr_F_HYHfJ5YUmgem7rHwYQcg">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForRent
      contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_mp5ueIyU6EupPXatRN7igQ"
      decimals="0"
      id="Narr_Sqg7s0QjYEKnBswRln8_Xg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">22600</us-gaap:PaymentsForRent>
    <avte:LeaseIncreaseInRentPercentage
      contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_mp5ueIyU6EupPXatRN7igQ"
      decimals="INF"
      id="Narr_WQGN4uMhgEesc1NUMtmdAA"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.03</avte:LeaseIncreaseInRentPercentage>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-5"
      id="Narr_YRfEgYfYBkqJai4VTgszeA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-5"
      id="Narr_XKDrkZO-4Um8sWfJxogbDQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-5"
      id="Narr_4NPmbh5Z_0a_toFe-OSKeQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-5"
      id="Narr_vS7WInFbykW01fOHLF58xg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb__NIO-hqCDEiClYrxVFsUVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;As of December&#160;31, 2022, the future minimum annual lease payments under the operating leases were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:24.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Minimum&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease Payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total operating lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (86)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Present value of net minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The components of operating leases for the years ended December 31, 2022 and December 31, 2021 were as follows (in thousands except lease term and discount rate):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 192&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 574&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average incremental borrowing rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc__puXVc-y_Eiw_k8LYo158Q_3_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">426000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_EJh22mERDk2DiHVZY3jOyA_4_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">508000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_7AKKb0MTf0mtfQxe0i9IVw_5_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">242000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_SWGcXjFvrkiX8MUbDESXBg_6_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1176000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_XHQ7wMeJ-0KgtlK-2CSKDw_7_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">86000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_xGBYlqLsTUGy79sFIoStAw_8_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1090000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_gXyaHqOC20C_UrVoS54WDA_3_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">385000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_4XUA4peJOU-MIVqbXcmitQ_3_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">192000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_aevpghVU-EKUrOhXQmB-jw_4_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">705000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_FFim2YocF0iAUW5J863_UA_4_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">382000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_ryC-19E4XUyejWdTBFlvdA_5_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1090000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_K1IMuG68D062xkaqa0THwg_5_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">574000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      id="Tc_iBAP1fQJ0EyDC2TEyPPi6g_6_3">P2Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      id="Tc_YezS8xTEw0uAfil1on7Lvg_6_6">P3Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Tc_FLPX6Jc7p0WvdNET1MBifg_7_3"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="INF"
      id="Tc_M1HMlDWJ_EendVGIRSYu1w_7_6"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_bK4MJQqeW0G-Lpi5nFVDIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(6)&#160;STOCKHOLDERS&#x2019; EQUITY&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33.1pt;"&gt;Under the Company&#x2019;s Amended and Restated Certificates of Incorporation dated August&#160;3, 2020, the Company had a total of 94,052,154 shares of capital stock authorized for issuance, consisting of 50,000,000 shares of common stock, par value of $0.0001 per share, and 44,052,154 shares of convertible preferred stock, par value of $0.0001 per share. Shares of authorized convertible preferred stock were designated as 4,000,000 shares of Series&#160;Seed redeemable convertible preferred stock and 40,052,154 shares of Series&#160;A redeemable convertible preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Following the Reverse Stock Split, the Company filed a Second Amended and Restated Certificate of Incorporation, which provided for 150,000,000 authorized shares of common stock with a par value of $0.0001 per share and 10,000,000 authorized shares of undesignated preferred stock with a par value of $0.0001 per share, effective upon completion of the Company&#x2019;s IPO.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&#160;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;In August&#160;2018, the Company sold to RA Capital Health Care Fund,&#160;L.P. an aggregate of 4,000,000 shares of Series&#160;Seed redeemable preferred stock at a purchase price of $1.00 per share, for net proceeds of $4.0 million. On August&#160;5, 2020, the Company entered into the Stock Purchase Agreement. The Company&#x2019;s initial closing of its Series&#160;A redeemable convertible preferred stock occurred on this date. The Company issued 3,468,536 shares of Series&#160;A redeemable convertible preferred shares for gross proceeds of $6.6 million at a price per share of $1.893. In addition to the cash proceeds, 3,020,998 shares of Series&#160;A redeemable convertible preferred stock were issued in connection with the conversion of the 2019 Notes&#160;and the 2020 Notes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The Stock Purchase Agreement contained provisions that potentially obligate the Company to sell, outside of its control, an additional 33,562,620 shares of Series&#160;A redeemable convertible preferred stock at $1.893 per share for expected gross proceeds of $63.5 million, upon the occurrence of three subsequent Milestone Closings or earlier, at the option of any holder of the Series&#160;A redeemable convertible preferred stock. If the defined milestones were not achieved prior to the Company&#x2019;s initial public offering, the holders had the right to purchase these shares prior to the completion of the initial public offering. If the shares were not purchased prior to the completion of the initial public offering, then this right to purchase these shares would have automatically expired.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"&gt;On February&#160;1, 2021, upon the completion of the First Milestone Closing, the Company sold 4,224,274 shares of Series&#160;A redeemable convertible preferred stock at the Series&#160;A Original Issue Price for aggregate gross proceeds of $8.0 million. On June&#160;4, 2021, upon the completion of the Second Milestone Closing and the Third Milestone &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Closing, the Company sold 29,338,346 shares of Series&#160;A redeemable convertible preferred stock at the Series&#160;A Original Issue Price for aggregate gross proceeds of $55.5 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Immediately prior to the closing of the Company&#x2019;s IPO on July&#160;2, 2021, all outstanding shares of the Company&#x2019;s redeemable convertible preferred stock converted into 14,182,854 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&#160;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;In August&#160;2018, the Company issued 241,467 shares of common stock to RA Capital Healthcare Fund,&#160;L.P. at a price of $0.0012 per share. On July&#160;2, 2021, in conjunction with the Company&#x2019;s IPO, the Company issued 9,984,463 shares of its common stock and all outstanding shares of the Company&#x2019;s redeemable convertible preferred stock were converted into 14,182,854 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;As of December&#160;31, 2022, the Company had reserved the following shares of common stock for future issuance:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options granted and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares reserved for issuance under the 2021 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,077,557&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reserved for vesting of outstanding restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reserved for future ESPP issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 216,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,432,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <avte:CapitalStockSharesAuthorized
      contextRef="As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA"
      decimals="INF"
      id="Narr_rxpxBh7co0CQegOi3RfLGw"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">94052154</avte:CapitalStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA"
      decimals="INF"
      id="Narr_EWYEIKTgeUeffA3gXvlsqg"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA"
      decimals="INF"
      id="Narr_Niri3TMFD0ewGSvuKwDfeQ"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA"
      decimals="INF"
      id="Narr_9OVwWoggX0WsmWitNKCteQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">44052154</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA"
      decimals="INF"
      id="Narr_MnhPi1CPNEqwa4dRoLGE5A"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_crMw-EmKcUeuKdVO9DDyyA"
      decimals="INF"
      id="Narr_864Jr6_IS0-VSDfwBZ3FJg"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">4000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_No7St9Lvr0y96G_5EWC44g"
      decimals="INF"
      id="Narr_2xDZHN8Y0E-BMADuN3gWfw"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">40052154</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_22_2021_zuE5gWkeyk2gMuDMHkgnlQ"
      decimals="INF"
      id="Narr_DOJIEB9coEWFivY_YLzK5Q"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_22_2021_zuE5gWkeyk2gMuDMHkgnlQ"
      decimals="INF"
      id="Narr_57GSPKpXD0qwWwsvFV2Jew"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_6_22_2021_zuE5gWkeyk2gMuDMHkgnlQ"
      decimals="INF"
      id="Narr_w5whNIyxRkG3oVpecyBWjg"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_6_22_2021_zuE5gWkeyk2gMuDMHkgnlQ"
      decimals="INF"
      id="Narr_I3WXKhPtZUGAN72tK3MnCA"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_W0a55wDra0WelJUBZUsesw"
      decimals="INF"
      id="Narr_Jm3gkYeG3kqzGBxCeYOjTA"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">4000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_W0a55wDra0WelJUBZUsesw"
      decimals="INF"
      id="Narr__uwuIOYqn0-tU4Erf9hPCw"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">1.00</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_vnUkVXoGN0-57YWUs8EYpA"
      decimals="-5"
      id="Narr_jYF-EFI2Z0OM27TYOEoKcQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">4000000.0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_8_5_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_pNNDYw-rNUWvdmmuAHZlsg"
      decimals="INF"
      id="Narr_Zg8-cSKMNU2QWoLXsOq9Kg"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">3468536</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_8_4_2020_To_8_5_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_KQ7-UIfWqUG1_y4Ju1lXmw"
      decimals="-5"
      id="Narr_9ZuVLI8nl0aPYIdie0DmOA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">6600000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_5_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_pNNDYw-rNUWvdmmuAHZlsg"
      decimals="3"
      id="Narr_cjo5xRMBmUiYzYWBbGitxw"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">1.893</us-gaap:SharesIssuedPricePerShare>
    <avte:TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes
      contextRef="As_Of_8_5_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_pNNDYw-rNUWvdmmuAHZlsg"
      decimals="INF"
      id="Narr_PILz7vMtA0CHfdUWx1Ck6g"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">3020998</avte:TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_8_5_2020_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_oObJ-Nmc4UqeH2X0G6kfiA"
      decimals="INF"
      id="Narr_NKA8QoUV1k29Xq5Pc6gXUA"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">33562620</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SharePrice
      contextRef="As_Of_8_5_2020_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_oObJ-Nmc4UqeH2X0G6kfiA"
      decimals="INF"
      id="Narr_HrX71w2AvEeevbAOV_c1MQ"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">1.893</us-gaap:SharePrice>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_8_4_2020_To_8_5_2020_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_Dv12U9pPlk25gS6TpZJscg"
      decimals="-5"
      id="Narr_3zbhSUZ3BkazM4fuhiu8vg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">63500000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_2_1_2021_avte_MilestoneAxis_avte_FirstMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_wwresvhtM0-V7mH5Vgo-hA"
      decimals="INF"
      id="Narr_8xeRmuC7rE6qpsj281x0nA"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">4224274</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_30_2021_To_2_1_2021_avte_MilestoneAxis_avte_FirstMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_hfGGAslhNEeVOwN6WrF5gQ"
      decimals="-5"
      id="Narr_577DBj8KKUujeGgbuoPrhg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">8000000.0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_6_4_2021_avte_MilestoneAxis_avte_SecondAndThirdMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_GDEihDdvTUyXLABx1mfHnw"
      decimals="INF"
      id="Narr_esGDggMWE0-3vWjC7SNzgQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">29338346</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_6_3_2021_To_6_4_2021_avte_MilestoneAxis_avte_SecondAndThirdMilestoneMember_us-gaap_PlanNameAxis_avte_StockPurchaseAgreementMember_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_rGO8UuK3d0mu99ddFv5hjA"
      decimals="-5"
      id="Narr_c9aUsGHJUE2S_aXGPvZcCA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">55500000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_xbOuftPGHkeAHGLhw_3HrQ"
      decimals="INF"
      id="Narr_Y3Vvrgtd7k2G2g3qKUx0ow"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">14182854</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_djafJWnh40CLwBS3AvdTBQ"
      decimals="INF"
      id="Narr__0vlyfl860iQMSTNNPYLUw"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">241467</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="As_Of_8_31_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_djafJWnh40CLwBS3AvdTBQ"
      decimals="INF"
      id="Narr_pU3jULeTZkmCLy4GT90PPQ"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">0.0012</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_f35-tn37YkSEpT0jtT5KhQ"
      decimals="INF"
      id="Narr_Wc1gyIeRwk2stIJb9_XsuA"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">9984463</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_7_1_2021_To_7_2_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_xbOuftPGHkeAHGLhw_3HrQ"
      decimals="INF"
      id="Narr_P10QE8LVnkeABuTk2TpCKA"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">14182854</us-gaap:ConversionOfStockSharesIssued1>
    <avte:NumberOfVotesForEachShareOfCommonStock
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_avte_RaCapitalHealthcareFundL.pMember_PvcTYb2K9UG6ACE8durCkQ"
      decimals="INF"
      id="Narr_XRP-d64lQkivNpFzT_dTIA"
      unitRef="Unit_Standard_Vote_U58quFcv5ki9AFPMBo9uqw">1</avte:NumberOfVotesForEachShareOfCommonStock>
    <avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_Z0L6wBHZsk2KX8wx4klaDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;As of December&#160;31, 2022, the Company had reserved the following shares of common stock for future issuance:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options granted and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares reserved for issuance under the 2021 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,077,557&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reserved for vesting of outstanding restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reserved for future ESPP issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 216,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,432,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_CommonStockMember_aFm9TwWFNkWt1zWekbZnjQ"
      decimals="INF"
      id="Tc_-K-reKipTEiWpmQM0FOcNQ_2_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">4110219</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_TXk4moIa40GbN1BvRlu_JA"
      decimals="INF"
      id="Tc_c213H-BezUWja3zvJJCLtw_3_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">1077557</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_7kFZeYf8XkSj3t3wwiM5lA"
      decimals="INF"
      id="Tc_TDKTxnhXyECyedYS8DmfRA_4_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">28881</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BFKtiMbYKEWGiX8enBMhZA"
      decimals="INF"
      id="Tc_9Qg7lCV1W0q4K-aS4G0Kbw_5_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">216131</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Tc_bpYtMVH2wkeVbsfWhztHEQ_6_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">5432788</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_zVLzJvvhjk2npb8bfYnvKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(7)&#160;SHARE-BASED COMPENSATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&#160;Stock Option Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The Company&#x2019;s 2021 Stock Option and Incentive Plan (the &#x201c;2021 Plan&#x201d;) was adopted by the Company&#x2019;s board of directors and approved by the Company&#x2019;s stockholders in June&#160;2021 and became effective as of June&#160;29, 2021. Upon the effectiveness of the 2021 Plan, the Company&#x2019;s 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) was terminated and no further grants may be made thereunder. The Company&#x2019;s 2021 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;As of December&#160;31, 2022, a total of 3,576,415 shares of the Company&#x2019;s common stock were authorized for issuance with respect to awards granted under the 2021 Plan. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;4% of the total number of outstanding shares of the Company&#x2019;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#x2019;s board of directors. The number of shares available under the 2021 Plan increased by 976,415 and 988,918 shares, effective January 1, 2022 and January 1, 2023, respectively, as determined by the Company&#x2019;s board of directors. Any shares subject to awards granted under the 2021 Plan or the 2018 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;As of December&#160;31, 2022, 2,467,977 options had been granted and 28,881 restricted stock units awarded under the 2021 Plan, with 1,077,557 shares authorized for future issuance. As of December 31, 2022, a total of 1,642,242 options had been granted and were outstanding under the 2018 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The options that are granted under the 2021 Plan and the 2018 Plan are exercisable at various dates as determined upon grant and terminate within 10&#160;years of the date of grant. The vesting period generally occurs over &lt;span style="-sec-ix-hidden:Hidden_uKh2d8qoz0GftAIlA0yOkQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to four&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the&#160;year ended December&#160;31, 2022:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,454,374&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 954,557&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (298,712)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82,490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,044,465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,682&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82,490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The weighted-average grant date fair value of stock option grants was $10.48&#160;and $4.46 per share for the years ended December 31,&#160;2022 and December 31, 2021, respectively. All exercisable options are vested and all outstanding options are vested or expected to vest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;As of December&#160;31, 2022 there was approximately $17.2 million of unrecognized stock-based compensation expense related to nonvested stock-based compensation arrangements granted under the 2021 Plan and 2018 Plan, which is expected to be recognized over a weighted-average period of 2.7&#160;years&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&#160;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The Company&#x2019;s Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) was adopted by the Company&#x2019;s board of directors and stockholders in June&#160;2021 and became effective upon the consummation of the IPO. A total of 230,000 shares of the Company&#x2019;s common stock is initially available for issuance under the ESPP. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;1% of the total number of outstanding shares of the Company&#x2019;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#x2019;s board of directors. The number of shares available under the 2021 Plan increased by 247,229 shares effective January 1, 2023 as determined by the Company&#x2019;s board of directors. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of December&#160;31, 2022, 13,869 shares had been issued under the ESPP, and 216,131 shares authorized under the ESPP Plan were available for issuance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;As of December 31, 2022, 28,881 restricted stock units had been awarded under the 2021 Plan. A summary of the status of and changes in unvested restricted stock unit activity under the Company&#x2019;s equity award plans for the nine months ended December 31, 2022 was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 21.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 21.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Stock-based compensation of restricted stock units is based on the fair value of the Company&#x2019;s common stock on the date of grant and recognized over the vesting period. The vesting period generally occurs over &lt;span style="-sec-ix-hidden:Hidden_gWG-e8KNUkuG8sHbxrnFJA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to four years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;As of December 31,&#160;2022, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock units of $0.6&#160;million, which is expected to be recognized over the remaining weighted-average vesting period of&#160;3.3&#160;years. The Company did not incur or have any unrecognized stock-based compensation related to restricted stock units as of December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&#160;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The Company estimated the fair value of stock options using the Black-Scholes valuation model. The Company accounts for any forfeitures of options when they occur. Previously recognized compensation expense for an award is reversed in the period that the award is forfeited. The fair value of stock options was estimated using the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.2 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;73.5 - 76.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;68.7 - 69.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.6 - 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.9 - 1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Stock-based compensation expense recognized for stock option grants has been reported in the statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive (loss) income was as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee stock purchase plan awards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock awards and units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33.1pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_TXk4moIa40GbN1BvRlu_JA"
      decimals="INF"
      id="Narr_WcMJ2vsasEGr3vqKwzlWzA"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">3576415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_U-Vimp94EE-Vhg_ROQBzFg"
      decimals="INF"
      id="Narr_3ZL93hmtjU2gLh2Ya3v_lw"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_1_1_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_hoI7V65KHEG5GkLS5GdTEw"
      decimals="INF"
      id="Narr_e6BYtqJI30CI_TATXNdWMQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">976415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_1_1_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_KW9jG2TQGUqptBykLu-x_Q"
      decimals="INF"
      id="Narr_Qbz1VJUFxk6u1pb1XNbRCw"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">988918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_U-Vimp94EE-Vhg_ROQBzFg"
      decimals="INF"
      id="Narr_E_-9Eb2i5EGmdfgsvhed-A"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">2467977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_StqYaHLjzEKZmEQ6yLvUGA"
      decimals="INF"
      id="Narr_n_UbqMtTTE6m2-CT2D6wQw"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">28881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_8KFv4vg0cUCOT78XuWQJLw"
      decimals="INF"
      id="Narr_K6QK-pZGPkmGEg_16VKPtQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">1077557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyEighteenStockOptionAndIncentivePlanMember_xoITfiC24kGgUX1H39EHoQ"
      decimals="INF"
      id="Narr_VF9UXMT-HEyZw9u7f29ZyQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">1642242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_Cyq09hAZqUesspxvNiCeCg"
      id="Narr_080p8yaVNEWyVH-R1cyctw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_9FuVdbUhV0uvrx8hBa_1RA"
      id="Narr_Ijxpoj-1Hk6x8fZ0AX37ug">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_P1XVjdUuhkmKOliY9Ef2VA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the&#160;year ended December&#160;31, 2022:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,454,374&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 954,557&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (298,712)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82,490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,044,465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,682&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82,490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="INF"
      id="Tc_dmRXkRp_AEWcYbtGi-XkNw_6_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">3454374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="INF"
      id="Tc_k49KRWwUa0ecnq3NbsAkPw_6_5"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">6.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      id="Tc_USTuOt2UDkOdgVwksejHZw_6_7">P9Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_VgwWDAnCvEqwEOUGtcU7og_6_10"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">19378000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="INF"
      id="Tc_AQZD2vvSf0CQH-LDLZcUKw_7_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">954557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="INF"
      id="Tc_bT8V-0WIZk2O8U7Se-lQRA_7_5"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">15.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="INF"
      id="Tc_Os09JbQB2EKbOLcSNpAAEg_8_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">298712</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="INF"
      id="Tc_fk-MJ_579E2w7BAJtRwthg_8_5"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">2.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Tc_vtIQ3bjhw0O4WyEcmsh3Sg_10_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">4110219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Tc_LY9yN_w2Dkqi0J9ku63Ucw_10_5"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">9.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_q5lyUXQ890CoL95V0NruqA_10_7">P9Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_LPGlAK18MEmdVIESFe72IA_10_10"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">82490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Tc_Zwa4Dm8Cp0SPF5Mq3IFAlw_11_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">1044465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Tc_6nopaVCNhk-k0hX7cCCuZQ_11_5"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">7.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_kFLeHgo67kajMjiaaaTZyQ_11_7">P8Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_8XwAkSeot0qaTGmaXW0ILA_11_10"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">22682000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Tc_vc_6x68X70OehbSUrt3tIA_12_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">4110219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Tc_ElkSg1Ul5kiVznC69-mc1w_12_5"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">9.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tc_qTQ8xI1uu0a-JAb2_DH4Rg_12_7">P8Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_HySWU0C12Uma4I01yUvQKg_12_10"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">82490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="INF"
      id="Narr_RV-MksCrdUugMi8XAfYAwg"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">10.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="INF"
      id="Narr_WT8G21KiQkapldm-vkAlmA"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">4.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-5"
      id="Narr_Nl1y9JTY90epD7TQaHKPyA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">17200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Narr_kxJ0LQuBz06c50_exIJ7qg">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_VdsnaK6Ohkqmx-_Z9SCPxA"
      decimals="INF"
      id="Narr_wc7lZb9YiEKUNINcZML1UQ"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">230000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_vrB-dEU-EE2kBgR4L-Vkig"
      decimals="INF"
      id="Narr_qNk_70orKkyjEJb7tg1G6A"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.01</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ZEq1R1quB0CHCsbXWqAwWw"
      decimals="INF"
      id="Narr_bRjAWz8ymU22Y37lGueNmw"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">247229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_iezkj5eDqUCfolKO8YRv0A"
      decimals="INF"
      id="Narr_n2m17Ht5TEeMK7475xcJ2g"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.15</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <avte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_0fmPIdzRUE-bEqICdqsXyg"
      id="Narr_fy2yRw72E0e82RmpHgJnMw">P6M</avte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_iezkj5eDqUCfolKO8YRv0A"
      decimals="INF"
      id="Narr_7p2r_Tjc5kicQh2qnobdnQ"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_0fmPIdzRUE-bEqICdqsXyg"
      decimals="INF"
      id="Narr_CIlL0daiXUutCy-MKFeW2Q"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">13869</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BFKtiMbYKEWGiX8enBMhZA"
      decimals="INF"
      id="Narr_9zh9UnwSkkGFh9hNvuZbMg"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">216131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_StqYaHLjzEKZmEQ6yLvUGA"
      decimals="INF"
      id="Narr_x33hDuesrkGSibGHpb6n8Q"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">28881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_0mVZv9y3tkyYJ9QaLZyoLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 21.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 21.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="INF"
      id="Tc_fgJFPg2M10KBUnon7q7Qww_6_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">28881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="INF"
      id="Tc_w1BuKzWMjE2s9AJIq3-fQA_6_5"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">21.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Tc_GmhQi37eeUGF1JQNFm9Fkw_9_2"
      unitRef="Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg">28881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="INF"
      id="Tc_z5cp_w3VF0KMQWWcDCnrfQ_9_5"
      unitRef="Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA">21.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fJh_ywGZikyIQAcBTW536A"
      id="Narr_Ehw5nsHqYEy5pa-VhnPWOQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_7kFZeYf8XkSj3t3wwiM5lA"
      decimals="-5"
      id="Narr_UpNqqWcuZEm6XHfLxy_-vg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ffQ1QIahIk-nBDBoGTbC3Q"
      id="Narr_LoznO9AfOkK603M_VLagNg">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_e3CQPQAO7kGieDZpznXiZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.2 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;73.5 - 76.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;68.7 - 69.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.6 - 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.9 - 1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_aiS3g6rqK0C4IYQ7jBBLcw"
      id="Narr_x8V36iuU7EC5jfEG1KAMxg">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_L6Aulrv6skCjIRhGAQFN1w"
      id="Narr_xmNYUKkCgEG3rSmNWOctIg">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_jKuzK2N-lk6r-oAi8Vk34Q"
      id="Narr_lAMLghS35Ea8dFmNrR6hNA">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_tvsHVVkheEq71hXbwUCgSQ"
      id="Narr_t6FUGrRL_kuVgRQ6lWoRIg">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="3"
      id="Narr_Y2ZssEejsEugYANpqYOolQ"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="3"
      id="Narr_09fp_NcMtUuh7GBYXozBCw"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="3"
      id="Narr_bHuS3TAlDEW8omesUaP5Iw"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="3"
      id="Narr_M_jgJDDjTECgeQBEK6LKMg"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="3"
      id="Narr_a2g6VJAmbEKu45gZ0WPp9w"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="3"
      id="Narr_8XiNi1iHZkK1DhDZXNQw0Q"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="3"
      id="Narr_HnbWlc-plUWnI9IklIsKbQ"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="3"
      id="Narr_uh-MlFdtr0ClB70P9FbpvA"
      unitRef="Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_txAc4B8X7k-_wku7oUoX4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Stock-based compensation expense recognized for stock option grants has been reported in the statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive (loss) income was as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee stock purchase plan awards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock awards and units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_fPutlC_Wlkew2sr7ZE8ROQ"
      decimals="-3"
      id="Tc_TNLfqhLqYEi1wllRcKqAQw_3_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">3347000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_PUAKc7nXUEaEH4mxzoylkA"
      decimals="-3"
      id="Tc_-rk1N-bKNUKIHgMyoGKeUw_3_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1673000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2skYMq1PvUmc9GZXaVoMzA"
      decimals="-3"
      id="Tc_U6z2ddyAOUulYyPbsJoa0g_4_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2129000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_BRUvW3FPrk2wFPzvj1avag"
      decimals="-3"
      id="Tc_lSxUWjeL9kil7JycBTd4SQ_4_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">370000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_qa8X49mTNUu9p2D21Jfk9g_5_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">5476000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_cXTG5xkTTEOhOvS0oEC11g_5_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2043000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8pxhy8PI8Ei91_HCoX_sIg"
      decimals="-3"
      id="Tc_wt9P60nKy0OV9efk1EapLA_3_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">5316000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_38m67FS0GEuKtolLvc65gQ"
      decimals="-3"
      id="Tc_jm0LYUCQbU-ZFiqiwBTWPg_3_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2043000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_0fmPIdzRUE-bEqICdqsXyg"
      decimals="-3"
      id="Tc_7puJD3IJsEaoNMQBhlkPgw_4_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">98000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ffQ1QIahIk-nBDBoGTbC3Q"
      decimals="-3"
      id="Tc_BgaAz3xyokG3_QuoOgZ8Xg_5_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">63000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_DQ2mR4db2E2AZtwDqUTzYg_6_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">5476000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_tsHYz1rER0WLhoZ2mnsFyQ_6_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2043000</us-gaap:ShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_ZdNH_3r4lUqvJLchQSuI_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(8)&#160;RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Services Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;In August&#160;2018, the Company entered into a services agreement (&#x201c;Services Agreement&#x201d;) with Carnot, LLC (&#x201c;Carnot&#x201d;), an entity owned and controlled by RA Capital Management,&#160;L.P. under which Carnot provides research and other services to the Company. RA Capital Management,&#160;L.P. is a related party due to its equity ownership of the Company. The Company pays Carnot for services performed and costs incurred. The Services Agreement is for a term of two years. The Company may terminate the Services Agreement by giving 30&#160;days&#x2019; prior notice and either party can terminate the services agreement for a material breach, if not cured within 30&#160;days following notice by the nonbreaching party.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;In July&#160;2019, the Services Agreement with Carnot was amended whereby research and other services are now performed by Carnot Pharma, LLC (&#x201c;Carnot Pharma&#x201d;), an entity owned and controlled by RA Capital Management,&#160;L.P., and the term was updated to the later of (i)&#160;two&#160;years from July&#160;15, 2019 and (ii)&#160;completion of services under the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Expenses incurred by the Company under the Services Agreement with Carnot Pharma totaled less than $0.1 million and $0.1 million for the&#160;years ended December&#160;31, 2022 and December&#160;31, 2021, respectively, and are presented in the statement of operations and comprehensive loss as research and development and general and administrative expenses. As of December&#160;31, 2021, $2,000 was due to Carnot Pharma, LLC by the Company for services rendered under the agreement, and no amount was due to Carnot Pharma, LLC as of December 31, 2022.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <avte:RelatedPartyTransactionTerm
      contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_efAf7fiBWUqdDgHCEPGdfA"
      id="Narr_QsHWsupPTkeRlF4AvFuFgw">P2Y</avte:RelatedPartyTransactionTerm>
    <avte:NoticeToTerminateAgreementPeriod
      contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_efAf7fiBWUqdDgHCEPGdfA"
      id="Narr_VJso7Su_cUG_kL4L_y5iRw">P30D</avte:NoticeToTerminateAgreementPeriod>
    <avte:MaterialBreachCorrectionPeriod
      contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_efAf7fiBWUqdDgHCEPGdfA"
      id="Narr_1UpBbpjRkEeZE8-pAk8R_g">P30D</avte:MaterialBreachCorrectionPeriod>
    <avte:RelatedPartyTransactionTerm
      contextRef="Duration_7_1_2019_To_7_31_2019_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_524LLIpT_U62C9wdu6QZ1w"
      id="Narr_8R71rxe3TEKXEEKQu4zYrw">P2Y</avte:RelatedPartyTransactionTerm>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeStatementLocationAxis_avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_6iVtOxWY10m-DhjKq-psJw"
      decimals="-5"
      id="Narr_i-FD3-X4pUCJw2K28N3cWg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_qimOehD_5ke94_ayOtSdCg"
      decimals="-5"
      id="Narr_DELGy-CuD0WyvpNzHCWrKg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_VCaJi4v2YU2yhYi2bTbHgA"
      decimals="0"
      id="Narr_HjtdPuqen0Cf25yr_1MfEA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">2000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_KRknw7U1FU-LFYLG7DaGWg"
      decimals="0"
      id="Narr_kqiz5VK2BkSeKoGyg5xTEQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">0</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_JYRFgSrC5kKNm5obA7qisw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(9)&#160;INCOME TAXES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred income tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;NOL carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,781&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,498&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_E0ae-PWvkE-yL5o9JZGx5w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 615&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,643&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,283)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,517)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 302&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred income tax liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (302)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (126)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (302)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (126)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred tax assets (liabilities)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_nezSGvSzDU6xkqS5dwZsuQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&#160;ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,829)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,821)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,828)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (520)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent and other differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (787)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (757)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (392)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,618&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The Company had federal NOL carryforwards available of $46.6 million and $32.6 million as of December&#160;31, 2022 and December&#160;31, 2021, respectively, before consideration of limitations under Section&#160;382 of the Internal Revenue Code or Section&#160;382, as further described below. The NOL generated from 2018 onwards of $46.6 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each&#160;year. Additionally, the Company had state NOL carryforwards available of $34.4 million and $20.3 million as of December&#160;31, 2022 and December&#160;31, 2021, respectively. The state NOLs may be used to offset future taxable income and will begin to expire in 2038. At December 31, 2022 the Company had federal and state research and development credit carryforwards available of $1.8 million and $0.6 million, respectively. The federal credit carryforwards will begin to expire in 2038, unless previously utilized. The Massachusetts credit carryforwards will begin expiring in 2036, unless previously utilized. The California credits carry forward indefinitely. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"&gt;The Company has established a full valuation allowance for its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred since inception. Such objective evidence limits the ability to consider other subjective evidence such as the Company&#x2019;s projections for future growth. Based on this evaluation, as of December&#160;31, 2022 and December&#160;31, 2021, a valuation allowance of $23.3 million and $8.5 million, respectively, has been recorded against all of the Company&#x2019;s net deferred tax assets, as the Company has determined that none of the Company&#x2019;s balance of net deferred tax assets is more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted in the future if objective negative evidence in the form of cumulative losses is no longer present and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;additional weight may be given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company&#x2019;s projections for growth.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The future utilization of the Company&#x2019;s NOL and tax credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold 5% or more of the Company&#x2019;s common stock. An assessment of such ownership changes under Section&#160;382 and 383 was not completed through December&#160;31, 2022. Utilization of our net operating loss and income tax credit carryforwards may be subject to a substantial annual limitation due to ownership changes that may have occurred or that could occur in the future. These ownership changes may limit the amount of the net operating loss and income tax credit carryover that can be utilized annually to offset future taxable income. The Company will examine the impact of any potential ownership changes in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The following table summarizes the activity related to the Company&#x2019;s gross unrecognized tax benefits at the beginning and end of the&#160;years ended December&#160;31, 2022 and December&#160;31, 2021 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&#160;ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Beginning balance of unrecognized tax benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 529&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 276&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Additions based on tax positions related to the current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 253&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Additions based on tax positions related to the prior year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_8vjjWyCvikyedSLToWmJjA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ending balance of unrecognized tax benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The unrecognized tax benefit amounts are reflected in the determination of the Company&#x2019;s deferred tax assets. If recognized, none of these amounts would affect the Company&#x2019;s effective tax rate, since it would be offset by an equal corresponding adjustment in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve&#160;months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The Company is subject to taxation in the United States and various states. The Company&#x2019;s Federal and state returns are subject to examination, as 2018 was the first&#160;year of operations for the Company.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_XDo211gxuEKnYDaj25DLTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred income tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;NOL carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,781&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,498&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_E0ae-PWvkE-yL5o9JZGx5w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 615&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,643&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,283)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,517)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 302&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred income tax liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (302)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (126)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (302)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (126)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred tax assets (liabilities)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_nezSGvSzDU6xkqS5dwZsuQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_6v6x1gFlsECwS7ky0yDyOg_4_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">11781000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_dp-LLsIXrkqUzldfrda_Fg_4_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">7498000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_yOxDnP-2jUmstFf9-53tEA_5_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1601000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_6NwV0V0yyUmshm_vINkPdw_5_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">530000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <avte:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_UT0nnhlLsUGa_VgfHJVGww_6_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">8490000</avte:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_ULB74I1QAUWM1PjbXh3MQQ_7_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1713000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_Er4qVao84EmpmbOHl3GgKw_7_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">615000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_LNqVjhi7r02rWwYmRIp_ag_8_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">23585000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_I763L93SEUKEAKssXU4HRg_8_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">8643000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_kcfsrp8d5kyY_N3oZJMiZw_9_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">23283000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_dVU-2wYGJUObvgX9BGWs6g_9_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">8517000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_8QyZ_DHAukq6qN_aZ-cVVw_10_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">302000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_05acbkki-E6BCHokjMHp3g_10_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">126000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_GQs38gtDN0KlV3e0kuNZWQ_12_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">302000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_KWKLgPzrwkiT5tcCcC2PyA_12_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">126000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_Utck1ThWmku7UUjijZkB5Q_13_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">302000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_yOMDFeQRgUGy6DV0F-z2Rg_13_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">126000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_grA669EFjkGNr9NoCceaaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&#160;ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,829)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,821)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,828)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (520)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent and other differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (787)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (757)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (392)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,618&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_ewdtZ242JkitGzEQ4eDklg_3_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-10829000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_ZingQ7-Z_UOig35Mfatc3w_3_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-4821000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_aR4ItJQ1mkGBmMGBSNWYqw_4_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-2828000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_zuYpbR8azUuiI56CtlSMIw_4_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-520000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_jCwthPTy20iNBtGuRsCI1Q_5_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">563000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_AjTI0p1rLk2J3-1UgdcD6A_5_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">3000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_hUk0QS6Vq0yjqExa7mCmJg_6_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-787000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_qU4n7ToO8UaHtHzBRGs_Ng_6_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">115000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <avte:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_7ALV_3iZ6Uyc8pNsFWhL0g_7_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-757000</avte:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits>
    <avte:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_UlYXiOzmVUS1ed9rSp44Pw_7_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">-392000</avte:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_qtbkMVwyA0euG0NgpmtEZQ_8_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">14663000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_YxjK3b6bF0WBjqOD4Hcpxg_8_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">5618000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_GF7XabABfEa7GLqSLW1azA_9_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">25000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_JKzf0oDUC0qC7LhzmLhNiw_9_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bX05x-nRLk2IigYinMKBjw"
      decimals="-5"
      id="Narr_nsRwifj8C0mzMUBNAz9Hbw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">46600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_gjNW4nJ7gUG3lYvOm_OCOQ"
      decimals="-5"
      id="Narr_xTeS6qGCm0-XlhYaeObEgQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">32600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bX05x-nRLk2IigYinMKBjw"
      decimals="-5"
      id="Narr_3Q45e_qgoEeaWxX_PZnW6w"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">46600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember__U571LHq90ebMUCnu-8gKA"
      decimals="-5"
      id="Narr_hQLYCZH8hkysqe2A-jJ-cA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">34400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_c5GfZjqasEeR4_aZW3f6NQ"
      decimals="-5"
      id="Narr_zMlwPQJGIEOxXkz-C0k2ag"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">20300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_rRDeb8AKE02Eu6qsh0BInw"
      decimals="-5"
      id="Narr_CEf9f15k70qbuqBBt81FwA"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">1800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_Gyry4bLRNEOzHxfxq7X4iw"
      decimals="-5"
      id="Narr_km5G4IPY3EylVZnQwJojvg"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-5"
      id="Narr_bUvxS6H-kECPr7hJrUxKqQ"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">23300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-5"
      id="Narr_VP13bagYQkSC8nhW3S3Qmw"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">8500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      id="Tb_sHnfWcDim0CRreeNVbNKvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 33pt;"&gt;The following table summarizes the activity related to the Company&#x2019;s gross unrecognized tax benefits at the beginning and end of the&#160;years ended December&#160;31, 2022 and December&#160;31, 2021 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&#160;ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Beginning balance of unrecognized tax benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 529&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 276&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Additions based on tax positions related to the current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 253&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Additions based on tax positions related to the prior year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_8vjjWyCvikyedSLToWmJjA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ending balance of unrecognized tax benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_QLxocEOyOUCGelnNbeSz7Q_3_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">529000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020_lex_lE13Tka9RtZYzaRxrQ"
      decimals="-3"
      id="Tc_cH8nRBBfxEOW_Qtdo2Fuig_3_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">276000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_NAN2yHYIakWKJSBPf_FZng_4_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">461000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ"
      decimals="-3"
      id="Tc_plowHCivrU23GDJgPo0MrQ_4_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">253000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA"
      decimals="-3"
      id="Tc_Ay9yuC_dskSEUDJPcOWYvw_5_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">3000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ"
      decimals="-3"
      id="Tc_5T5dTIgkXkGtx_Twmzv_-Q_6_3"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">993000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA"
      decimals="-3"
      id="Tc_j8Tw9mEX_UuXsHf7n2sjAQ_6_6"
      unitRef="Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ">529000</us-gaap:UnrecognizedTaxBenefits>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MDHA]5N)VK)FG"   Y#4  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RU
MFVMSXC@6AO^*BNF:FJD*P3<"Z4E21: SRW8GPP:ZNWJW]H-B"ZQJVV(D.9=_
MOT<V8)R2!=X27Q*,?5Y+#Y)\7DF^>F'\IX@)D>@U33)QW8FE7'_L]408DQ2+
M<[8F&9Q9,IYB"8=\U1-K3G!4!*5)SW.<BUZ*:=:YN2J^F_&;*Y;+A&9DQI'(
MTQ3SMUN2L)?KCMO9?O%(5[%47_1NKM9X1>9$?EW/.!SU=BH134DF*,L0)\OK
MSLC]. D\%5!<\8V2%['W&:FJ/#'V4QU,H^N.HTI$$A)*)8'AWS,9DR112E".
MOS>BG=T]5>#^YZWZ75%YJ,P3%F3,DN\TDO%U9]A!$5GB/)&/[.4?9%.AOM(+
M62**O^BEO+;O=%"8"\G233"4(*59^1^_;D#L!0R; KQ-@/<NP T: OQ-@']L
M0+ )" HR954*#A,L\<T59R^(JZM!37TH8!;14'V:J=]]+CF<I1 G;\;LF7#4
M15_G$_3;A]_1!T0S=$^3!'X4<=63< MU82_<R-V6<EZ#G.NA>Y;)6*!/642B
MND /RK8KH+<MX*UG5)R0\!SY[AGR',_3%&AL#K_'_!QY@R+<UX1/S.'_S#.X
MNZ.[>ZTV_@ZW7^CY1MS_&3T)R:')_U='N%0(] IJ'/@HUC@DUQWHZ(+P9]*Y
M^?47]\+Y0T?'IMC$DEB-7+ C%YC4;R8LS&&\D6CQMB8Z;.9PU^E^UO$Q1K7E
M8TFLQJ>_X],W5G $<*("T%V"5SI YO@E3H2.Z]@8UI:0);$:H8L=H8OC6M H
MRW*<H$>R9ESJ2)EU),^UH(Q1;4%9$JN!&NQ #8[L:AS# [YX/C?#,FLU-BMC
M6%M:EL1JM(8[6L/C:,T(IRQ2#SX$CV+M&'5 :?NH:WS6&>/;0K,D5H-VN8-V
M>1RT.RI"Z(L;=G?PM3;K,*O=_=#!,L:TA65)K ;+=:HDS6F%ZP?!O!G6 ;&F
MQF4.:PO,EEJ=V%Y:ZQHK.<XY?P_,U#,/R'6[KM?U72TV8V1K;);4ZMB\"IMG
MK.>G3%+Y!M02@A[R](EP+2RSB..XW<#I!X$6ES&V-2Y+:G5<53;O&E/>+:Y'
MLJ(JH8?V]H!3??LR"XT(9\_0--$B)ARO22YI*,[*DDZS\%Q+TFIN;TNM3K+*
M[EUS?KXA.88^RZ&_3L$]OJ+/Y$W+TBSE0/L;7 X'P:66FM6,WY9:G5J5\[OF
MI'U#;8%?T30"='1)0USD:X;.:Y8<^EW7'PR&PZ&6GE4W8$NM3J_R ZXYD=_0
M@_[%.&2W!;@S-)>J'S*.QBR'Q@AMDD7Z+GW ;GS2 K3J$FRIU0%6/L$U)_<;
M@*,H G5QMOV OL!UZ*],3\TL>>D[Z#O-).'P0W!"=)9C;-9H#?$4[L&M[(-K
MSOJ-$!<O3 O1+#G/J21E$>^[?<?1,K3J)6RIU1E6;L(U&X#W#,?J"+KP@KUD
M6GYFN>\XD3%.M=BLN@I;:O69U<I6>&8G\![;;NB;039"LU#;@0]HWH^TD[16
MO84MM3JVREMX9C/P'MN,"0DYR[_INO%9<4#1\8*^UER8XUIS.X6Y\"ISX9E]
M0=$K1YS@9DQF@0MWH(5DU5+84JM#JBR%9W8"7U@Q'Q*SS.3 #H@$@=_U OW
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ML(*M!=3_&Z;ZD?I&'^(VA_;+?P!02P,$%     @ DHA]5K[D.L#) @  U@D
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M_Z)(M]5S Q_3HD@WU>::!'2Z73:@GS^E:?'VHGP4X>$!G==_ E!+ P04
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MF9_W.3^W3,]5H.=2$@3*C!/7/(;5-*[8&L'.M&^L$A@KF4%,EAG044C8$F%
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M?1<4 P  ZP@  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULQ59M3^)
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M;P2D >#^7 B]$<P!U?]-[R]02P,$%     @ DHA]5E*\)+,+!@  NA   !D
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M!OWF+99A<DB2*%$X!AZ JB!E*#:^7]#.!V8[58J7+PQE7=J0,X.VT8$1,C[
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M=N&+ /BQ:N&&#*]WL@2%!FN6<;P=AVJ\.?I)I=[SXN2<SS:Y4)6IK\FFF*E
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MVU/H+#SO'E#/YLWIQK)E4ZSQ/$LM% X_\3Q!&["('MLS83H/]L;"6?3#FQ3
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M-ALPXS]M^1NG"_J<M-3.Z9PNUX*#"W "/$\UL'MU@QLTWQ>O_P-02P,$%
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MF^N;CP_B]%Y795XJ,WIS9F$E2.\L=[.^YUEG!V:=SL1ONK8K(S[6A2JZ!,Z
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M [$5I%B1NUI"R',N4QO#;$N@0CFF(N<,%EB3#H!5MNNV(KXU3-?0XT:M$/V
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M(0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6SM6NMOXC@0_U<L%JU
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MA00B!$H!,5.W44A4RVM0#K!FF;K6M-C )UJH&;85*EA\OH./'[J.Y7[Y8]]
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MC0/9]T+HT\0DZ+Y9T[\!4$L#!!0    ( )*(?58YVD4R_04  " 3   9
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M4';8TE.ZIMT\=N3L?R G-_*<W#B<D[M?^[V[;WV5E.]N[_N3*121R738_1/
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M-C6C430C-]%M-)E$-P8ZZ4^GT6PO_A]X8$O.%BRF7)-89+G@P+4B8D'T"L@
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M6AO+,<_;PWPBV59W6"],8K^FAQ&VU,"5 7Y?,R;?)FJ#HDD?_ =02P,$%
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MF= P-A"_3QGC'S=Q!YM3M9W_ %!+ P04    " "2B'U6MPEK,#X%  "7(0
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MQO:",IJ,\E]M[L<ZM]WA&#QW1],!>+P%M\.'[D-OV!V!X8,Y&4_O!P\3$]2
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M6,M T4Y(EI1@I2 A:?'%+V4>3@!VXQV 4P*<SP+<$N#F1@MEN:T^EMAO<W9
M7$<K-CW(<Y.CE1N2ZEN<2ZYVB<))O]<==<=!B.:#,%R@8/(TG8S#\6*.OJ-Y
M, C[RU&()H^H&P2S9=A'W7$?31:#<(:"Y6RF M%HV.T-1\/%,-28ZSY(3*BX
M4>/EO(^NKV[0%2(I6L1L)W"Z%FU3*MGZ<#,J)?8*B<X[$OL0W2+7_H8<RW%J
MX,'GX?8YW%3)JC+F5!ES<C[W'S-69ZQ@:M0SZ0)]$!F.H&.H"A3 ]V#X7[_8
MGO6CSN9_(CLS[5:FW8_8_6X4\1VLD6;&/(J1NDI5+7O5!3)5T[+.?,'8RAEU
M,]G[3JNI;F!_:JHFR&Y5,6=:&Y76QJ>T9OC(&:6Y5"9CX B2C+(C %I!"ALB
M:_^,!;EWHLCV[M_*O@QJW5OULIN5[.:'LB=:8IV@YL59[IWU1L]EC-UPZ_5X
ME1[O0ST+)K%*7IG,OTF,=IRK&T>4X!6A1!*H3:-W<;&-.UV^9[(O@VR[^3:/
MYDEWTR_+$^9;D@I$8:-@UFU+F>=%MRXFDF5YPULQJ=IG/HS5 P=<!ZC]#6/R
M=:)[:/5D^G\ 4$L#!!0    ( )*(?59']2)%] 0   LA   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;+6::V_B.!2&_XJ57:UFI$X3.US:+B 5DMFM
MU)O:SLZ'U7YPX0#1)#%KF])*^^/7N33!$%PB>;Y $GP>V^])G//*##:,_Q!+
M (E>DS@50V<IY>K"=<5T"0D5IVP%J?IESGA"I3KE"U>L.-!9'I3$+O&\GIO0
M*'5&@_S:/1\-V%K&40KW'(EUDE#^-H:8;88.=MXO/$2+I<PNN*/!BB[@$>2W
MU3U79VY%F44)I")B*>(P'SJ7^"(D>4#>XJ\(-F+K&&53>6;L1W9R-1LZ7C8B
MB&$J,P157R\P@3C.2&H<_Y90I^HS"]P^?J=_S2>O)O-,!4Q8_#V:R>70.7/0
M#.9T'<L'MOD3R@EU,]Z4Q2+_1)NB;<=ST'0M)$O*8#6")$J+;_I:"K$50'H'
M D@90(X-\,L ?S> ' CHE &=8P.Z94 ^=;>8>RY<0"4=#3C;()ZU5K3L(%<_
MCU9Z16EVHSQ*KGZ-5)P<3>YN;JZ>;L+;IT=T>1N@R=WMT]7M'^'MY"I\1)\"
MD#2*Q>>!*U5G68@[+<'C DP.@#&Z8:E<"A2F,Y@UQ <?Q!,#P%6SK*9*WJ<Z
M)D;BY8J?(M\[0<0C!'U[#-"G7S^CN?SM%]P_^[UAA),/>.N%XN&<AX_A!69>
M -.*5XVO 1,>C\'-&$T^O[I3_)SK'^!>@Q  )^@:U'-Y@@(04QZM\J?][VO5
M%EU)2,0_37=* >XT@[.E\$*LZ!2&CEKK!/ 7<$9*Q)[7F!2;L, F++0$T[+3
MJ;+3,=%'9598D1#)$+Q*2)N>N[$1U#8;-F&!>8J2KZ%)=DM#T&3O5K)WC6.Z
M6P&G,DH7*,X2@'CV7OK"YE_6ZH2J!T:*IA08H6U38!,6%+!^#LN*C)<1]CS?
M\[R!^[(M^GZ[;H=L-]/D[%5R]EK)&4?T.8HC^=8DHA'55D2;L*" ]301S[U]
M$??;=?N=@R+V*Q'[1A&?F*2Q6@ET*>%5U98"&F]'(Z^MDC9A07_O-LOTV1-R
MOQG6FVE"GE5"GAF%_$YCN:1)\<9KTLT8WE8WF[# )BRT!--R<%[EX/QG51WG
M-K-C$Q;8A(668%IVL%?;!\_XC%PJ=XK8',4TG:'_3-7OV$QJFY"2IBV>>PM#
M8+7/T!9-UWK+JN%6;T<)/&D4VHAI+;1Y4/XY2G*?UFCQ;(XDM$73Y2>U_,0X
MTP=(8:/>K =E-X:WEMT\&!^] >7-HML<1VB+IHM>FTYL=$VC>_J60"K1G''$
MU4&C\%;]94G3BHFSAI7%JG6T1=-5KLTC/L(]YOHBM<9,U3==-%8\9DYKJ0L:
M)EM:>Z<>V97:9J>A+9HN=6T8L=DQ?F5"+2!HHDS-X<+2S&@MLU6':)46VJ+I
MV:C])N[]K/(26_6?5FF!55IHBZ;GJ+:SV.QGVY28_;VBT._N+MT3<W^MM;9)
M"VW1=*UKQXO-EO?H$M.,,16%$W-L:_FM6EU;-%W^VNQBHUO[N,0TA^.\*&S4
MW*I_M4H+;='T3:':P1*S@SVFPBP1VS4A(;V]A<7<4UN5K=)"6S1=Y=J[$K--
M/+K"+#F[-:&_*[5-9QE8I86V:(74[M;F;@)\D>^J"S1EZU06NW?5U6KG_C+?
MK]ZY/L87$]QP/< 78;$O7^.+OPG<4+Z(4J'>!7/5E7?:5\4:+W;>BQ/)5OG6
M\C.3DB7YX1+H#'C60/T^9TR^GV0=5/]_&/T/4$L#!!0    ( )*(?5:KXV/3
MP0,  !H-   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;*U7:V_B.!3]
M*U9VM&JE+7D"@85(3* S2.4A'CO:CP8,6)/8K&U@^N_W.J$I3=)TA/H%XMCG
M^!Q?V_>F<^;BI]P3HM"O.&*R:^R5.K1-4Z[W),:RQ@^$0<^6BQ@K:(J=*0^"
MX$T"BB/3L:R&&6/*C*"3O)N*H,./*J*,3 62QSC&XODKB?BY:]C&RXL9W>V5
M?F$&G0/>D3E1R\-40,O,6#8T)DQ2SI @VZ[1L]NA[6I ,N(?2L[RZAEI*RO.
M?^K&<-,U+*V(1&2M- 6&OQ,)211I)M#QWX74R.;4P.OG%_;'Q#R866%)0A[]
MH!NU[QJ^@39DBX^1FO'S=W(Q5-=\:Q[)Y!>=+V,M ZV/4O'X @8%,67I/_YU
M68@K@%-_!^!< $X.8'OO -P+(%DY,U66V.ICA8..X&<D]&A@TP_)VB1H<$.9
M#N-<">BE@%-!.!F-AHO18+R8H]ZXC\+)>#$<?QN,P^%@CA[0//P^Z"^?!FCR
MB!Z7B^5L@$;#\7"T','P\;+WA)X&O?D 37O_IB2/DQF:3 >SGJ9).^?HKD\4
MII&\!\;EO(_NOMRC+X@RM-CSH\1L(SNF C=:D[F^*/^:*G?>4=XGZQIR[;^0
M8SE."3S\?;C]%F["&F8+Z60+Z21\[BT+62NSE_)YY7SZ^+;E :])UX#S*8DX
M$2/X\P^[8?U=9O:3R-Y8=S/K;A5[ "OHEAE,4<T$I:^34^ YC8YYNM9=R7RC
M;B_3[7VDVRO3G:(:5[KKEI_37<E\H^YZIKO^D>YZF>YZ0;?C.3G=E<PWZFYD
MNAN5NA=<X0A!!A)84;9#$8'[%QWP,Z0%57H#- J.;+N9WT*5D]YHJ9E9:E9:
M>B)2ME$OYD>F(*LE,[#$'&6*0$N5V6H6;#WX>5>5\][HRL]<^96NIJD-=,+1
MD2"^10SJ"4@^-#[&OQ$UOQ@UJV7E_/F%RZ'>]+(Q;V2W,MFMRBMXDMM9$<4K
M&E%%B6R7Z6Q]Y@7\261OC-O6:Q:W*B,6'H6 <)1F4:L0#M>OYZ)1,LAN.>7A
ML*]J"[M2U9BSAW6%,KNP!YI605EQD.N_I^PU6=N5"3'XD91W9/. 3[!G=@3.
MKJYY7_<.'-X8W4&%\DRPD/>E\JNG<%(H\E#,F=I+Y'AH@Y_+3DSX 96;4E7M
ME-=<;5<GZX)SRM9@'D($=_.*"R#4JP 'B92:3MEMYRH>5LW*WUX?#DO5FU>%
MJ_YJ&&&QHTQ"#+8 LVI-2%<B+<33AN*'I)9=<065<?*XAX\7(O0 Z-]RKEX:
MNCS./H>"_P%02P,$%     @ DHA]5EE]]!0S"P  $I0  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&ULO=U_;YM('@;PMX)\J[M=J8IAP+]ZB:4TS,#,
MMM=<T_9T.MT?Q)[$J+;Q DZVIWWQ-V!B//XQ@?39K+0;VV$^X/7W:S,\AIP_
M)NFW;"9E;OV^F"^SB\XLSU=ON]UL,I.+*#M+5G*I?G.7I(LH5W?3^VZV2F4T
M+0<MYEUBV_WN(HJ7G?%Y^=AU.CY/UOD\7LKKU,K6BT64?G\GY\GC1<?I/#WP
M*;Z?Y<4#W?'Y*KJ7-S+_LKI.U;WN5IG&"[G,XF1II?+NHG/IO!7>L!A0+O$U
MEH_9SFVK>"JW2?*MN,.G%QV[V"(YEY.\("+UXT%>R?F\D-1V_%:AG>TZBX&[
MMY]T5CYY]61NHTQ>)?-_Q=-\=M$9=JRIO(O6\_Q3\AC*Z@GU"F^2S+/RO]9C
MM:S=L2;K+$\6U6"U!8MXN?D9_5[]C]@90)P3 T@U@.P/&)T8X%8#W*8#O&J
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M@_AR2?",L*B#?#ZG5.P:T0397RC]_P%02P,$%     @ DHA]5DX.)ZO6 @
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M%<D3.6>[:RSU7&B\D"7"?&%7^M8M"',A65H&*P8IS8J1/)5U. AH.J\$.&6
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M:+W64;^+%]VU,"3;F(ZV9%+U1S.-U8.$7#NH_15C<F_H!-43Y_X!4$L#!!0
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MF J0]Q>4BK>.FJ X(OH_ %!+ P04    " "2B'U64.7H^DX#  "6"P  &0
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M. .5!F)_1@A_G,@#FE;<_0U02P,$%     @ DHA]5M*VNRR, P  \PX  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULQ5?O3]LZ%/U7K+SI:9. _"HI
M\-I(:9L)M %5 ]N;GMX'D]PV$4F<V2Z%_?6SG1":$K(Q1>(+M1W?XW..KXWO
M:$/H+8L!.+K/TIR-M9CSXD3761A#AMD!*2 77Y:$9IB++EWIK*" (Q64I;IE
M&(Z>X237W)$:FU-W1-8\37*84\3668;IPP12LAEKIO8XL$A6,9<#NCLJ\ H"
MX-?%G(J>7J-$208Y2TB.*"S'FF>>3$U;!J@97Q+8L*TVDE)N"+F5G;-HK!F2
M$:00<@F!Q<\=3"%-)9+@\;T"U>HU9>!V^Q']HQ(OQ-Q@!E.2?DTB'H^U(PU%
ML,3KE"_(YA0J08<2+R0I4W_1IIIK:"A<,TZR*E@PR)*\_,7WE1%; :;S0H!5
M!5B[ 8,7 NPJ0#FGE\R4K!GFV!U1LD%4SA9HLJ&\4=%"39++;0PX%5\3$<?=
MX-1;^/L3+_!G:'IY/O<O N_J[/("[:-@>NK/KC_[Z/(C"JXNIY_:IOG_RK:/
M)M_0U;>YFNM]]1:S +V? <=)RCX(J.M@AMZ_^X#>H21'5S%9,YQ';*1SH4#R
MT,.*[:1D:[W UK30.<EYS)"?1Q U 70AO=9O/>J?6)V(,P@/D&WN(<NPK!9"
MT]\/-SOHV/5VV K/?FD[8DQA7^9EA.;X09P7CCQ*<;X"V=Y#_KTXP/*K,!!-
M<9%PG"8_(-I#7D;68O9_GP4D.N.0L?_;#"[7'[2O+R^-$U;@$,::N!48T#O0
MW+__,AWCGS9S>@)K6#6HK1ITH;L!)^%M955(,FD+5C<#E!:UB2\1API17G!W
M[N%@Z(STNVU1SR=9QL"N)S7('M9D#W]-%I%"$FS-^\[PUVY+3V -I4ZMU'GC
M#';ZM*HGL(95P]JJ8>\97"(ZVQELF[L9/'Q%!A_59(\ZR?I9D9(' ,14*A=K
M&L:".2I2+/X9;S!MO\\[05^[63V!-?0?U_J/WSBOC_NTJB>PAE6F\?2H,'K/
M[ IR.[6/CW82NWO9/Y6U]58R.V4M@'&:A%RH*D]!F?=JQ]=YPMM?-)V8K]W7
MOM":#EA/#EAO? HJ GW9U1-:TZZGUYS9^0+ZLW-@/[N]'7OW'/3Z\-*WRH<,
MZ$I554P0%OM5OJ3KT;IR\U2]LC,^D16=*DN>8,IR\!S359(SE,)20!H'0_%$
MH66%578X*521<D.X*'E4,Q95*5 Y07Q?$L(?.W*!NLYU?P)02P,$%     @
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MF90L+0Y70"/@J@'>7S F]R?J ?4.<_\;4$L#!!0    ( )*(?5:P":D::@,
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M4U7Q M<&:G[+F'SJZ)JJK:'C;U!+ P04    " "2B'U6."(-CF,#  "T"0
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MJZ9.&I'WJ'RB>)J5^3E7NFEDPTBW=10F0+]?<*ZV$[-!^:'@_0502P,$%
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" "2B'U6K"Z5 00$  !N(   #P   'AL+W=O<FMB;V]K+GAM;,69WX^;.!"
M_Q6+E^X];!/ F[:KIA(%;X*:0 [(ZO9>3FSB-%;Y$0&[V_:O/T,NVD%-1O<R
MY8E@(O@\QO/9P\>7LOKV6);?V/<\*^JIL6^:P^UH5&_V,D_KM^5!%OK*KJSR
MM-&GU==1?:ADNJWW4C9Y-K+&X\DH3U5A?/IXNM>J&L&3LI&;1I6%;FP;[I5\
MJ5^OMZ?L6=7J466J^3$UNM^9-%BN"I6KGW([-<8&J_?ER[RLU,^R:-(LWE1E
MEDT-\WCA7E:-VOS2'+>02?I8=RU-^ABE&F1J3,;ZACM5U4WWC^[^J69\EOK/
MQ[.GIKQ362,K+VWDK"J?#JKXVMY&]V($NM'%X70\!O&V^C]A+'<[M9%>N7G*
M9=$<XUC)K 4LZKTZU 8KTEQ.#;=\EE7;'_T ?WOL6Z.A0*2J6Z4O5/ZVPR-$
M"8,X7/B>DPB/?7863N *%L^%2&( :"& UF" [&J5 D@;@;1_(V2<Z,-2!!HP
MO&/A2D0 DB.0?##(2'@"0-X@D#<#0OYC <@) CD9#-)UXCF ?(= OJ.%#*.9
M$_A_.XD?!LP)-.AZN72BAY8R]F< \CT"^9X6\K,3^UW<5I&(=0P!K3\+? #Y
M 8'\0 MYY_@1NW<6:]&2WOF!SD&^LV!^$"?1>@D3^1C+Y&/J6(+DR-QPN0J#
M]K6$?*AIR%6S7/K)<::T(ZQG4>(',Z&#*7J0F&U,8MW$2>A^F8<+3T3Q&R;^
M7/O) V3#)&,26R:>.Y&XUE-&>-WPBB#NY@ODP_QB$@LF$HLN(ZZ<*'E@2>1H
M/K<%[(TN)A>3V"Y^H.,F6.+\U7_C,)>8Q#)!4V#/>"9F$Y-8)SBF#3$QGYC$
M0D%S=3^:F%%,8J5<RM7L2F]76I+7I3>F%(M8*6C*9E<0$S.+16R6<TG[OTC6
M?T!(=!]#;98+V?O,D&.2L8@E U/DV1ABAK&(#8.N:7NSV\(T8Q%K!L^5'&)B
MYK$&-<\-Q,3,8PUJG@G$Q,QC#6H>*$@+,X\UY&:F]V[:F'EL8O/@F/#=M#'S
MV,3FN>CQ:Q:[<UA3L3'WV,3N03%[>=-&JVCD931DN=''Q"QDDQ?2L%71-<3$
M+&036^C\JLB33:JRGM)M3$(VL83.4AYGC[=>]&80)B&;6$*75V]=0"$F)B&;
M6$(7,7_-1YB$;&()H9B]B<XQ"7%B">&84.D<DQ"GWOZ@F%#I'),0'VH#U&%"
MI7-,0IQ80I>K6-U<AYCHQQQB"?7W:6>R.L?<PW]CH:T=W]=M6K?X@)B8?#BQ
M?"YC1L+M%58Y)A].+)_+F+,HC&$EDV/RX9U\1J?OVUNY4X7<!OH1M6[?I-EF
M5;'V<*S"\YNV1+9[RC)7MX7%HDRWI\_EIT_]G_X%4$L#!!0    ( )*(?5:2
M+*"6N $  .<<   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V3MN
MPD 4A>&M("^ X3X@(8)4:=)&;,""X2$>MCP3!78?! 4<E"(-FE-9,Y:O_^J3
M-9Y\Q5V=-\TAK3=MZAWWNT.:5NN<V[<0TGP=]W7J-VT\G.\LFVY?Y_.R6X6V
MGF_K50PZ&(Q"=S^C>I_<S^S-3FW\S\1FN=S,XT<S_]['0_YC</AINFU:QYBK
MWJSN5C%/JW#<W;93N%RD?YY<]3X7TZK[7$@52@<I!&GY((,@*Q_D$.3E@X80
M-"P?-(*@4?F@%PAZ*1_T"D&OY8/&$#0N'R0#E'% D/2 -8'6@EP+@=>"8 N!
MV()D"X'9@F@+@=J"; N!VX)P"X'<@G0+@=V"> N!WHIZ*X'>BGHK@=[Z\+%-
MH+>BWDJ@MZ+>2J"WHMY*H+>BWDJ@MZ+>2J"WHMY*H+>BWDJ@MZ'>1J"WH=Y&
MH+>AWD:@MST<EA#H;:BW$>AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z&VHMQ'H[:BW
M$^CMJ+<3Z.VHMQ/H[:BW$^CM#X?=!'H[ZNT$>COJ[01Z.^KM!'H[ZNW/U#OE
MTRZF6\]UC>]_)M7Y_&R\O?ZRO&ZBA,,+S@'^:[[_ E!+ P04    " "2B'U6
MC$_JC[H!  #N'   $P   %M#;VYT96YT7U1Y<&5S72YX;6S-V<ENPC 4!=!?
M0=DB8CR4#@(V;;<MB_Z FSQ(1!);MJ'P]W7"(+6BJ(A*O9M$B>UW7VSI;#)^
MVUKRO4U=-7Z2%"'8!\9\5E"M?6HL-7%D;ERM0WQT"V9UMM0+8F(X'+',-(&:
M, AMC60Z?J*Y7E6A][R)KWUIFDGBJ/))[W$WL<V:)-K:JLQTB.-LW>3?4@;[
MA#2N[.;XHK2^'R<D[&1"._)SP'[=ZYJ<*W/JS;0++[J.L]BF8CYL*_+I^1(G
M>C3S>9E1;K)5'9>DWCK2N2^(0EVENZ+]\\DA[C#MKOSJ_*[,N< X<^:,]?'$
M'%T>=SB2=O7 QD+D0GG^$X^)L?35WT?M:>>4_S([;N^'<<ON/#SK;M?O\=<S
M/M:_L \!TH<$Z4.!]'$#TL<(I(];D#[N0/JX!^F##U$:01&5HY#*44SE**AR
M%%4Y"JL<Q56. BM'D56@R"I09!4HL@H4606*K )%5H$BJT"15:#(*E!DE2BR
M2A19)8JL$D56B2*K1)%5HL@J4625*+)*%%D5BJP*15:%(JM"D56AR*I09%4H
MLBH46=5_ROINS/*O_\"U][3697/(9]UOSNDG4$L! A0#%     @ DHA]5@=!
M36*!    L0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q0
M2P$"% ,4    " "2B'U6CSP_;.T    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "2B'U6F5R<(Q &  "<)P
M$P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( )*(?5;B=JR9IP@  .0U   8              " @0P(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "2B'U6LJSGHJ(%  # %P
M&               @('I$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ DHA]5K[D.L#) @  U@D  !@              ("!P18  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( )*(?5;TN:ZGS@0
M % 3   8              " @< 9  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " "2B'U6N*,O.N4(  "L4P  &               @('$
M'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ DHA]5A4=
M.:?# @  > 8  !@              ("!WR<  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( )*(?59K[_[>/@<  *0@   8
M  " @=@J  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "2
MB'U6E/?4O$ (  # $@  &               @(%,,@  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ DHA]5@1646F\&   L$@  !@
M         ("!PCH  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( )*(?5;2K5_4U0@  *0F   9              " @;13  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ DHA]5FSP?1<4 P  ZP@
M !D              ("!P%P  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " "2B'U64KPDLPL&  "Z$   &0              @($+8
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( )*(?5:&PIKJ
M& <  (P5   9              " @4UF  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ DHA]5H6!Z(FM"P  SB<  !D
M ("!G&T  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "2
MB'U629 4-6X$   7"P  &0              @(& >0  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( )*(?5:E-Q;R?@D  &L<   9
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M970R,"YX;6Q02P$"% ,4    " "2B'U6WYX=7:X#  !["0  &0
M    @($>L0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M )*(?5:0/,D0#0,  +\&   9              " @0.U  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ DHA]5CG:13+]!0  (!,  !D
M             ("!1[@  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " "2B'U607PF41L%  ! #@  &0              @(%[O@  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( )*(?5:<UC!%700
M ) 6   9              " @<W#  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ DHA]5E\.)Z]/ P  00L  !D              ("!
M8<@  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "2B'U6
M7GOV_:$#  "P"P  &0              @('GRP  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( )*(?5;=\P*6< ,  " ,   9
M      " @;_/  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ DHA]5LK[^E)7!@  X3(  !D              ("!9M,  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "2B'U6&$9_,>@&  !A*P
M&0              @('TV0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( )*(?5:W"6LP/@4  )<A   9              " @1/A  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ DHA]5J^(X_:Y
M @  .0<  !D              ("!B.8  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " "2B'U6EQM>Q\<"   ^!P  &0
M@(%XZ0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( )*(
M?59']2)%] 0   LA   9              " @7;L  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ DHA]5JOC8]/! P  &@T  !D
M         ("!H?$  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " "2B'U667WT%#,+   2E   &0              @(&9]0  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( )*(?599QRC$+0,  #$,
M   9              " @0,! 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ DHA]5KCQ20S>"   2F   !D              ("!9P0!
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "2B'U6,"S,
MDU %  !.&0  &0              @(%\#0$ >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( )*(?59.#B>KU@(  .X&   9
M  " @0,3 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
MDHA]5J9\5GZ0 P  +@X  !D              ("!$!8! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " "2B'U64.7H^DX#  "6"P  &0
M            @('7&0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( )*(?5;2MKLLC ,  /,.   9              " @5P= 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ DHA]5B&:QZ4C!
M;18  !D              ("!'R$! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " "2B'U6L FI&FH#  !=$   &0              @(%Y
M)0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( )*(?5;.
MC8;:6 ,  $\+   9              " @1HI 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ DHA]5C@B#8YC P  M D  !D
M     ("!J2P! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( )*(?5:2+*"6N $  .<<   :
M          "  ?\[ 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( )*(?5:,3^J/N@$  .X<   3              "  >\] 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     X #@ /P\  -H_ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>148</ContextCount>
  <ElementCount>293</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DocumentCover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - BALANCE SHEET COMPONENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>BALANCE SHEET COMPONENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensation</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>20202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30403 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>BALANCE SHEET COMPONENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30503 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30603 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureStockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30703 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30903 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureIncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40601 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40701 - Disclosure - SHARE-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40702 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40703 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40704 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40705 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40706 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40901 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40902 - Disclosure - INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40903 - Disclosure - INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails</Role>
      <ShortName>INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40904 - Disclosure - INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. tmb-20221231x10k.htm 136</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. tmb-20221231x10k.htm 136</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockSharesOutstanding, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  tmb-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  tmb-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="tmb-20221231x10k.htm">tmb-20221231x10k.htm</File>
    <File>tmb-20221231.xsd</File>
    <File>tmb-20221231_cal.xml</File>
    <File>tmb-20221231_def.xml</File>
    <File>tmb-20221231_lab.xml</File>
    <File>tmb-20221231_pre.xml</File>
    <File>tmb-20221231xex21d1.htm</File>
    <File>tmb-20221231xex23d1.htm</File>
    <File>tmb-20221231xex31d1.htm</File>
    <File>tmb-20221231xex31d2.htm</File>
    <File>tmb-20221231xex32d1.htm</File>
    <File>tmb-20221231xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tmb-20221231x10k001.jpg</File>
    <File>tmb-20221231x10k002.jpg</File>
    <File>tmb-20221231x10k003.jpg</File>
    <File>tmb-20221231x10k004.jpg</File>
    <File>tmb-20221231x10k005.jpg</File>
    <File>tmb-20221231x10k006.jpg</File>
    <File>tmb-20221231x10k007.jpg</File>
    <File>tmb-20221231x10k008.jpg</File>
    <File>tmb-20221231x10k009.jpg</File>
    <File>tmb-20221231x10k010.jpg</File>
    <File>tmb-20221231x10k011.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="617">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tmb-20221231x10k.htm": {
   "axisCustom": 1,
   "axisStandard": 19,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 617,
    "http://xbrl.sec.gov/dei/2022": 40
   },
   "contextCount": 148,
   "dts": {
    "calculationLink": {
     "local": [
      "tmb-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tmb-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 427,
   "entityCount": 1,
   "hidden": {
    "http://aerovatetx.com/20221231": 3,
    "http://fasb.org/us-gaap/2022": 81,
    "http://xbrl.sec.gov/dei/2022": 7,
    "total": 91
   },
   "keyCustom": 27,
   "keyStandard": 266,
   "memberCustom": 14,
   "memberStandard": 26,
   "nsprefix": "avte",
   "nsuri": "http://aerovatetx.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://aerovatetx.com/20230215/role/DocumentCover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstruments",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - BALANCE SHEET COMPONENTS",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponents",
     "shortName": "BALANCE SHEET COMPONENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - STOCKHOLDERS' EQUITY",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquity",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - SHARE-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensation",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - RELATED PARTY TRANSACTIONS",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsTables",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avte:ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - BALANCE SHEET COMPONENTS (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsTables",
     "shortName": "BALANCE SHEET COMPONENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avte:ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CkuAokZFEE6-3rAKVgGLlw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "avte:ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "avte:ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "avte:AccruedResearchAndDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
     "shortName": "BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "avte:AccruedResearchAndDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "avte:CapitalStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_8_3_2020_xGeNQl9YbUe6-ziAovZsMA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "avte:CapitalStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
     "shortName": "STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - SHARE-BASED COMPENSATION (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
     "shortName": "SHARE-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_U-Vimp94EE-Vhg_ROQBzFg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
     "shortName": "SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
     "shortName": "SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_pRuJeuHwHESGL1VRGyJylQ",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40705 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails",
     "shortName": "SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40706 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
     "shortName": "SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8pxhy8PI8Ei91_HCoX_sIg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_7_1_2019_To_7_31_2019_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_524LLIpT_U62C9wdu6QZ1w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avte:RelatedPartyTransactionTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_7_1_2019_To_7_31_2019_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_524LLIpT_U62C9wdu6QZ1w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avte:RelatedPartyTransactionTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - INCOME TAXES (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bX05x-nRLk2IigYinMKBjw",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails",
     "shortName": "INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_uX0H7egMsUSZNoWpEFnyzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails",
     "shortName": "INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_fKTXq4X7-0-hUSZV_W00gA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_lex_lE13Tka9RtZYzaRxrQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_9gGeJ_r-oESMCylkTiaQrA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_9gGeJ_r-oESMCylkTiaQrA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVBHb787MEOjMaNn9i_4Fg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_W2E30mHD0EGlI5pRGGhQGQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjitDg4W4EOE9Yf-R3ycdQ",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_sM9yjzv2j0OApDlf_9IrWA",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_j11XPcsa8UeeqriZClNpsQ",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fFhlPjb7N0KE88mjnhmJXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 47,
   "tag": {
    "avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet": {
     "auth_ref": [],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of discounts and amortization of premiums on investments net.",
        "label": "Accretion of discounts and amortization of premiums on investments, net"
       }
      }
     },
     "localname": "AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities and other liabilities current.",
        "label": "Accrued and other current liabilities",
        "totalLabel": "Total accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avte_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research and Development Current",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avte_CapitalStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital stock shares authorized.",
        "label": "Capital stock shares authorized",
        "terseLabel": "Capital stock shares authorized"
       }
      }
     },
     "localname": "CapitalStockSharesAuthorized",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering.",
        "label": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOffering",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avte_ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering, shares",
        "label": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering, shares"
       }
      }
     },
     "localname": "ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "avte_ConvertiblePreferredStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock [Policy Text Block]",
        "label": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockPolicyTextBlock",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avte_DebtSecuritiesAvailableForSaleMaturityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity term for debt securities classified as available for sale.",
        "label": "Debt Securities Available For Sale Maturity Term",
        "terseLabel": "Maturity term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleMaturityTerm",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avte_DeferredOfferingCostsIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs included in accounts payable.",
        "label": "Deferred offering costs included in accounts payable",
        "terseLabel": "Deferred offering costs included in accounts payable"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedInAccountsPayable",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.",
        "label": "Deferred Tax Assets, Capitalized Research and Development Costs",
        "terseLabel": "Capitalized R&amp;D"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits": {
     "auth_ref": [],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Research and Development Credits.",
        "label": "Research and development credits",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avte_FirstMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Milestone [Member]",
        "label": "First Milestone [Member]",
        "terseLabel": "First Milestone"
       }
      }
     },
     "localname": "FirstMilestoneMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_FosterCityLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foster City Lease [Member]",
        "label": "Foster City Lease",
        "terseLabel": "Foster City Lease"
       }
      }
     },
     "localname": "FosterCityLeaseMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability": {
     "auth_ref": [],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease asset and liability, net.",
        "label": "Increase Decrease In Operating Lease Asset And Liability",
        "terseLabel": "Operating lease assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseAssetAndLiability",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avte_IncreaseDecreaseInOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in other liabilities.",
        "label": "Increase decrease in other liabilities",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherLiabilities",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avte_JefferiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Jefferies, LLC.",
        "label": "Jefferies"
       }
      }
     },
     "localname": "JefferiesMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_LeaseIncreaseInRentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease increase in rent percentage.",
        "label": "Lease rent percentage",
        "terseLabel": "Lease rent percentage"
       }
      }
     },
     "localname": "LeaseIncreaseInRentPercentage",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "avte_MaterialBreachCorrectionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of days in which material breach must be corrected or agreement will be terminated.",
        "label": "Material Breach Correction Period",
        "terseLabel": "Material breach correction period"
       }
      }
     },
     "localname": "MaterialBreachCorrectionPeriod",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avte_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "avte_MilestoneDomain": {
     "auth_ref": [],
     "localname": "MilestoneDomain",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_NoticeToTerminateAgreementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of days in which notice to terminate an agreement must be given.",
        "label": "Notice To Terminate Agreement Period",
        "terseLabel": "Termination notice period"
       }
      }
     },
     "localname": "NoticeToTerminateAgreementPeriod",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avte_NumberOfVotesForEachShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes for each share of common stock.",
        "label": "Number of Votes for Each Share of Common Stock",
        "terseLabel": "Number of votes for each share of common stock"
       }
      }
     },
     "localname": "NumberOfVotesForEachShareOfCommonStock",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets [Policy Text Block]",
        "label": "Prepaid Expenses and Other Current Assets [Policy Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avte_PrepaidResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research and development.",
        "label": "Prepaid research and development",
        "terseLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopment",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avte_RaCapitalHealthcareFundL.pMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RA Capital Healthcare Fund, L.P [Member]",
        "label": "RA Capital Healthcare Fund, L.P [Member]",
        "terseLabel": "RA Capital Healthcare Fund, L.P"
       }
      }
     },
     "localname": "RaCapitalHealthcareFundL.pMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_RelatedPartyTransactionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of related party transaction for service agreement , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Term of service agreement",
        "terseLabel": "Term of service agreement"
       }
      }
     },
     "localname": "RelatedPartyTransactionTerm",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avte_ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to research and development and general and administrative expenses.",
        "label": "Research and development and general and administrative expenses",
        "terseLabel": "Research and development and general and administrative expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAndGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse stock split [Policy Text Block]",
        "label": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock shares reserved on and as converted basis for future issuance [Table Text Block]",
        "label": "SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE"
       }
      }
     },
     "localname": "ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avte_ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of prepaid expenses and other current assets [Table Text Block]",
        "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "ScheduleofPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avte_SecondAndThirdMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second and Third Milestone [Member]",
        "label": "Second and Third Milestone [Member]",
        "terseLabel": "Second and Third Milestone"
       }
      }
     },
     "localname": "SecondAndThirdMilestoneMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Redeemable Convertible Preferred Stock [Member]",
        "label": "Series A Redeemable Convertible Preferred Stock",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_SeriesSeedRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series Seed Redeemable Convertible Preferred Stock [Member]",
        "label": "Series Seed Redeemable Convertible Preferred Stock",
        "terseLabel": "Series Seed Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesSeedRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_ServicesAgreementWithCarnotLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to service agreement with Carnot LLC.",
        "label": "Service agreement with carnot LLC",
        "terseLabel": "Service agreement with carnot LLC"
       }
      }
     },
     "localname": "ServicesAgreementWithCarnotLlcMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of offering period for share-based compensation arrangement by share-based payment award.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avte_ShortTermInvestmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term investment [Policy Text Block]",
        "label": "Short-term Investments [Policy Text Block]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentPolicyTextBlock",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avte_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement [Member]",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of temporary equity shares issued in connection with conversion of notes.",
        "label": "The number of temporary equity shares issued in connection with conversion of notes",
        "verboseLabel": "Temporary equity shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssuedInConnectionWithConversionOfNotes",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avte_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of new shares classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series A redeemable convertible preferred stock per share, net of issuance costs, shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "avte_TwentyEighteenStockOptionAndIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Plan [Member]",
        "label": "2018 Plan",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "TwentyEighteenStockOptionAndIncentivePlanMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Plan and 2018 Plan [Member]",
        "label": "2021 Plan and 2018 Plan [Member]",
        "terseLabel": "2021 Plan and 2018 Plan"
       }
      }
     },
     "localname": "TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_TwentyTwentyOneStockOptionAndIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Stock Option and Incentive Plan [Member]",
        "label": "2021 Stock Option and Incentive Plan [Member]",
        "terseLabel": "2021 Plan"
       }
      }
     },
     "localname": "TwentyTwentyOneStockOptionAndIncentivePlanMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avte_WalthamLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Waltham Lease [Member]",
        "label": "Waltham Lease",
        "terseLabel": "Waltham Lease"
       }
      }
     },
     "localname": "WalthamLeaseMember",
     "nsuri": "http://aerovatetx.com/20221231",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DocumentCover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r244",
      "r250",
      "r463",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r273",
      "r410",
      "r433",
      "r458",
      "r459",
      "r473",
      "r477",
      "r486",
      "r530",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r273",
      "r410",
      "r433",
      "r458",
      "r459",
      "r473",
      "r477",
      "r486",
      "r530",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r265",
      "r273",
      "r300",
      "r301",
      "r302",
      "r386",
      "r410",
      "r433",
      "r458",
      "r459",
      "r473",
      "r477",
      "r486",
      "r526",
      "r530",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r265",
      "r273",
      "r300",
      "r301",
      "r302",
      "r386",
      "r410",
      "r433",
      "r458",
      "r459",
      "r473",
      "r477",
      "r486",
      "r526",
      "r530",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r152",
      "r153",
      "r244",
      "r250",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r485"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r98",
      "r106",
      "r118",
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties.",
        "label": "Accounts Payable, Related Parties",
        "terseLabel": "Amount payable to related parties"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r133",
      "r429",
      "r438",
      "r439"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r141",
      "r142",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r18",
      "r21",
      "r91",
      "r373",
      "r434",
      "r435",
      "r505",
      "r506",
      "r507",
      "r512",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r5",
      "r485"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r512",
      "r513",
      "r514",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r81",
      "r82",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of land",
        "terseLabel": "Area of land"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r113",
      "r129",
      "r149",
      "r188",
      "r196",
      "r198",
      "r209",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r339",
      "r343",
      "r357",
      "r485",
      "r528",
      "r529",
      "r570"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r125",
      "r135",
      "r149",
      "r209",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r339",
      "r343",
      "r357",
      "r485",
      "r528",
      "r529",
      "r570"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total fair value of assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r52",
      "r201",
      "r216",
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BALANCE SHEET COMPONENTS"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES."
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Purchases of property and equipment in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r39",
      "r127",
      "r461"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash and cash equivalents and short term investment"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r33",
      "r39",
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at the end of the period",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r33",
      "r96"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Total cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r149",
      "r170",
      "r171",
      "r174",
      "r176",
      "r180",
      "r181",
      "r209",
      "r235",
      "r237",
      "r238",
      "r239",
      "r242",
      "r243",
      "r248",
      "r249",
      "r252",
      "r256",
      "r263",
      "r357",
      "r460",
      "r499",
      "r509",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r108",
      "r117"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Note 6)",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES."
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r229",
      "r230",
      "r455",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r512",
      "r513",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r4",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r4",
      "r485"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 24,506,390 and 24,410,393 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively",
        "terseLabel": "Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 24,722,974 and 24,410,393 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r22",
      "r137",
      "r139",
      "r144",
      "r425",
      "r430"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r111",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of stock shares issued",
        "terseLabel": "Conversion of stock shares issued"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r474",
      "r476",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent": {
     "auth_ref": [
      "r202",
      "r216",
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss",
        "terseLabel": "Amortized cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r207",
      "r222",
      "r470"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentWithUnrealizedLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Short-term investments, 12 months or Greater, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r207",
      "r222"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentWithUnrealizedLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Short-term investments, 12 months or Greater, Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r207",
      "r222",
      "r470"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentWithUnrealizedLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Short-term investments, Less than 12 months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r207",
      "r222"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentWithUnrealizedLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Short-term investments, Less than 12 months, Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "SUMMARY OF SHORT TERM INVESTMENT"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r205",
      "r219",
      "r470"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentWithUnrealizedLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Short-term investments, Total Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r206",
      "r220"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentWithUnrealizedLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Short-term investments, Total Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "auth_ref": [
      "r218",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesTradingUnrealizedLoss": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Trading, Unrealized Loss",
        "negatedLabel": "Unrealized loss on securities",
        "negatedTerseLabel": "Unrealized loss on investments"
       }
      }
     },
     "localname": "DebtSecuritiesTradingUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r90",
      "r562"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "NOL carryforwards",
        "terseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r90",
      "r562"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r88",
      "r90",
      "r562"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research credit carryforwards",
        "terseLabel": "Research credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred tax assets valuation allowance",
        "negatedLabel": "Less: valuation allowance",
        "terseLabel": "Deferred tax assets valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r84",
      "r561"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r90",
      "r562"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r37",
      "r58"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r277",
      "r305",
      "r306",
      "r308",
      "r312",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r145",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r167",
      "r170",
      "r174",
      "r175",
      "r176",
      "r178",
      "r348",
      "r349",
      "r426",
      "r431",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r145",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r170",
      "r174",
      "r175",
      "r176",
      "r178",
      "r348",
      "r349",
      "r426",
      "r431",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r558",
      "r559"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Stock-based compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and other employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized stock based compensation",
        "terseLabel": "Unrecognized stock based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Unrecognized stock-based compensation weighted-average period",
        "terseLabel": "Unrecognized stock-based compensation weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r65",
      "r123",
      "r141",
      "r142",
      "r143",
      "r154",
      "r155",
      "r156",
      "r158",
      "r164",
      "r166",
      "r179",
      "r210",
      "r264",
      "r309",
      "r310",
      "r311",
      "r329",
      "r330",
      "r347",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r373",
      "r434",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r350",
      "r351",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r245",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r351",
      "r383",
      "r384",
      "r385",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS."
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r245",
      "r266",
      "r271",
      "r351",
      "r383",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r245",
      "r266",
      "r271",
      "r351",
      "r384",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r245",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r383",
      "r384",
      "r385",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r354",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]"
       }
      }
     },
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r203",
      "r204",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r221",
      "r223",
      "r224",
      "r247",
      "r261",
      "r345",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r470",
      "r521",
      "r522",
      "r523",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r37",
      "r57",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r23",
      "r101",
      "r109",
      "r120",
      "r188",
      "r195",
      "r197",
      "r199",
      "r427",
      "r469"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r150",
      "r318",
      "r322",
      "r327",
      "r331",
      "r333",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r151",
      "r165",
      "r166",
      "r187",
      "r316",
      "r332",
      "r334",
      "r432"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes",
        "totalLabel": "Total tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r314",
      "r315",
      "r322",
      "r323",
      "r326",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r559"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r559"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Permanent and other differences",
        "terseLabel": "Permanent and other differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "U.S. Federal statutory income tax rate",
        "terseLabel": "U.S. Federal statutory income tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r559"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State taxes",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r508"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r508"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2Imported": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Total operating lease payments",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2Imported": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating lease term",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r149",
      "r209",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r340",
      "r343",
      "r344",
      "r357",
      "r468",
      "r528",
      "r570",
      "r571"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r9",
      "r103",
      "r115",
      "r485",
      "r510",
      "r524",
      "r564"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r126",
      "r149",
      "r209",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r340",
      "r343",
      "r344",
      "r357",
      "r485",
      "r528",
      "r570",
      "r571"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r33",
      "r35",
      "r38"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r24",
      "r38",
      "r110",
      "r119",
      "r124",
      "r136",
      "r138",
      "r143",
      "r149",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r165",
      "r166",
      "r172",
      "r188",
      "r195",
      "r197",
      "r199",
      "r209",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r349",
      "r357",
      "r469",
      "r528"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r167",
      "r168",
      "r173",
      "r176",
      "r188",
      "r195",
      "r197",
      "r199",
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net loss available to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "SCHEDULE OF UNVESTED STOCK UNIT ACTIVITY"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of Operating Segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r188",
      "r195",
      "r197",
      "r199",
      "r469"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Total operating lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2Imported": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of net minimum lease payments",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2Imported": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liabilities",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2Imported": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r371",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted-average incremental borrowing rate",
        "terseLabel": "Weighted-average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r370",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining lease term (in years)",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r501",
      "r525"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other current assets",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payment for rent",
        "terseLabel": "Payment for rent"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments for deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r3",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r3",
      "r485"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2022 and December 31, 2021, respectively; no shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2022 and December 31, 2021, respectively; no shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r134",
      "r225",
      "r226",
      "r462"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from issuance of public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from sale of Series A redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r31",
      "r79"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under ESPP"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments",
        "terseLabel": "Sales and maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r79"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r124",
      "r136",
      "r138",
      "r146",
      "r149",
      "r157",
      "r165",
      "r166",
      "r188",
      "r195",
      "r197",
      "r199",
      "r209",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r338",
      "r341",
      "r342",
      "r349",
      "r357",
      "r427",
      "r469",
      "r482",
      "r483",
      "r507",
      "r528"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r59",
      "r116",
      "r428",
      "r485"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Leasehold improvements are amortized over the remaining life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r272",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r122",
      "r376",
      "r377",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r272",
      "r376",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r374",
      "r375",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r83",
      "r121",
      "r578"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted stock units",
        "terseLabel": "Restricted stock units",
        "verboseLabel": "Restricted stock awards and units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r6",
      "r67",
      "r114",
      "r437",
      "r439",
      "r485"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r123",
      "r154",
      "r155",
      "r156",
      "r158",
      "r164",
      "r166",
      "r210",
      "r309",
      "r310",
      "r311",
      "r329",
      "r330",
      "r347",
      "r434",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r369",
      "r484"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate amount of shares"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "SCHEDULE OF NET LOSS PER SHARE"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r77",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED AND EXPENSE BY AWARD TYPE"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "SCHEDULE OF FAIR VALUE INSTRUMENTS"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.",
        "label": "Schedule of Fair Value, Off-balance Sheet Risks [Table]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r274",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "SUMMARY OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "SUMMARY OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r481",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Vested term",
        "terseLabel": "Vested term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Discount percentage on marker price",
        "terseLabel": "Discount percentage on marker price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of units, Granted",
        "terseLabel": "Number of units, Granted",
        "verboseLabel": "Restricted stock units award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted Average Grant date fair value, Granted",
        "terseLabel": "Weighted Average Grant date fair value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of units, Ending",
        "periodStartLabel": "Number of units, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant date fair value, Ending",
        "periodStartLabel": "Weighted Average Grant date fair value, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility, maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility, minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional common stock available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Common stock available for issuance",
        "terseLabel": "Common stock available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options Granted",
        "terseLabel": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "weighted-average grant date fair value of stock option grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Common stock options granted and outstanding",
        "periodEndLabel": "Options Outstanding, ending balance",
        "periodStartLabel": "Options Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Outstanding, ending balance",
        "periodStartLabel": "Weighted-Average Exercise Price Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "periodEndLabel": "Options, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Options, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Common stock available for issuance, awards granted",
        "terseLabel": "Common stock available for issuance, awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted-Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted-Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Expiration period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term (in years)",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted- Average Remaining Contractual Term, Outstanding",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted- Average Remaining Contractual Term, Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted- Average Remaining Contractual Term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Percentage of common stock purchase price",
        "terseLabel": "Percentage of common stock purchase price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares issued, price per share",
        "terseLabel": "Shares issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r104",
      "r105",
      "r112",
      "r502"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term investments",
        "terseLabel": "Total short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r452",
      "r453",
      "r454",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r149",
      "r170",
      "r171",
      "r174",
      "r176",
      "r180",
      "r181",
      "r209",
      "r235",
      "r237",
      "r238",
      "r239",
      "r242",
      "r243",
      "r248",
      "r249",
      "r252",
      "r256",
      "r263",
      "r357",
      "r460",
      "r499",
      "r509",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r17",
      "r65",
      "r123",
      "r141",
      "r142",
      "r143",
      "r154",
      "r155",
      "r156",
      "r158",
      "r164",
      "r166",
      "r179",
      "r210",
      "r264",
      "r309",
      "r310",
      "r311",
      "r329",
      "r330",
      "r347",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r373",
      "r434",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r179",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "ESPP",
        "terseLabel": "ESPP",
        "verboseLabel": "Employee stock purchase plan awards"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r16",
      "r65",
      "r66",
      "r67",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Issuance of Series A redeemable convertible preferred stock per share, net of issuance costs, shares",
        "verboseLabel": "Number of shares conversion securities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r3",
      "r4",
      "r65",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Shares issued",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common stock under ESPP, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r65",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock upon initial public offering, net of issuance costs, shares",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r4",
      "r65",
      "r67",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Issuance of common stock upon exercise of stock options, shares",
        "negatedLabel": "Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r17",
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Issuance of Series A redeemable convertible preferred stock per share, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r3",
      "r4",
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock upon initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r4",
      "r7",
      "r8",
      "r51",
      "r485",
      "r510",
      "r524",
      "r564"
     ],
     "calculation": {
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r148",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r264",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stockholders' equity, reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "BALANCE SHEET COMPONENTS"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Accretion of Series A redeemable convertible preferred stock to redemption value",
        "negatedLabel": "Accretion of Series A redeemable convertible preferred stock to redemption value",
        "verboseLabel": "Accretion of Series A redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r235",
      "r237",
      "r238",
      "r239",
      "r242",
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary equity shares, value per share",
        "verboseLabel": "Temporary Equity, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary equity, shares authorized",
        "verboseLabel": "Temporary Equity, Shares Authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary equity shares issued",
        "verboseLabel": "Temporary equity, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary equity shares outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary equity shares issued .value",
        "terseLabel": "Temporary equity shares issued .value",
        "verboseLabel": "Issuance of Series A redeemable convertible preferred stock per share, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r203",
      "r204",
      "r247",
      "r261",
      "r345",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r521",
      "r522",
      "r523",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r466",
      "r474",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "Agency bond",
        "terseLabel": "Agency bond"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r466",
      "r474",
      "r476",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury bills"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20230215/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r313",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance of unrecognized tax benefits",
        "periodStartLabel": "Beginning balance of unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Additions based on tax positions related to the current year",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r182",
      "r183",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r169",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares of common stock outstanding, diluted",
        "verboseLabel": "Weighted-average common stock outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r167",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares of common stock outstanding, basic",
        "verboseLabel": "Weighted-average common stock outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://aerovatetx.com/20230215/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20230215/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL121698322-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r489": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r491": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r492": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r493": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r494": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r495": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r496": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r497": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r498": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001798749-23-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001798749-23-000015-xbrl.zip
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MFF$W@LC@#T?6:5M/ND#/>CIG!2;>-@</:&:%-IU+;ZZM@7VQJ=GO,A!,=T-
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MAG;/,I^1G<L260OA)SZ5X33QUW$=Q$X<-E?%4/>0XZAS;8/^("ZX6\C?+EC
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M<@<7P#$KY**!F:C+!@0EXJ(<MYM-]@OO-KIPQ]UY6;]CVQ3A+@AQ PZ& !9
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MJQ@(5MQD)W0\,T:W9[,LJ\'?4PA;@)FF^X<:C]3(# 6(/".'(F3ZAN\809K
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MMPPS$7UN-KDO6H?_0F,U;D9P89,<]:4](![\2[ R;RE(\&W;!N2")CVO*_H
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M(I>TBX%VXI2_8.?YA3 ?ON+ >L:S WTH<[Z]J#93-F+6I0'<@954DG7K6@0
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M.0+-\8+'AA,W<&&B'6UPV*[O/=]$.-C!"@)DIL'F%@OK2 LG2*OJLE_O'%\
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M,V6QPTCHH#=,HV/%P'G1"+CK%X/*NG:^!6#7%0BJG.FNYZ/_^GD^O1LO5W]
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MK4>AI]8N.=FMT;V'/M#&_"[FA1@SE.4&:\;;J4Y@A8B)M_%W>&V]2>]CEO<
M'@(DX&9=OJ0Y8!>7D5K5?"<SDJV-T7KX5T-;!@7@J@:QBB[],]G28:JL?;^,
M5E_0Y<01H0YKX&D7M&E7C2^%G%W]./+_2]['JNX,W'WK*:'@CE5%3\ N71.
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M_3)9_XP>9\OQ<#KY;Y)CT_Q:K?BIH/Q/#-O?RMP8*PTM.N@!#3#:5'4J)M2
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M!&-$?N*<3 ?PD>^188;=7*5/OFRPP^Y>K0/+"ZU-04*J2@.X;RBI1!#_JPD
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MW8'[=%U%Y(=BN;Z /;TV!/6RT80X&:]\S]"500A(.RMZ2Z85YW5.Q4LTI1V
MNV\UV/,BML6M ;NHA-"-B]2R'S+43:[9G$Y8%",O_JOD@2PEDL!]0(?"BH]S
MU:<'V(^TP&K!TTRNLSSX'CX^6,'O.+H_>':Y%PD; _>/<I!9RR]N"=BF*P16
M+N1(R:(=HXNVE+"A)8;=#@=T97)A[7%0L;10W!:X;99"S"\E%#0$;)GE\JI/
MHA.JB)$UOF+0,L@])6OV>,;M,5,%_#[ _SC0Z4W9CJ]43^!^60-^X6$)<3?
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M]$.4FLG$+$%4FI1=-.J)M8F3L7R+'EB<IB0L8W/:$[!5Y&]^7Q#P+X35\#G
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M^C6LO+=- "!WX8&.3OI7'NO?1.UX)T!-P#Z,6E!TU=5.@()TT$<S6$HRL!,
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MW#UR<$I.3-BM##>F24=#R6E10CDEI6,#)WRY\09,0M;@C-E R\6)0\)66YA
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M0*P;H1PO0Z$>I-I8%NH$OS.-8/)]:#T%/LY^MG"CH'$AMJ"X^1/F4JTJE.7
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MY%E+RX#;N6$#AD4"J;R\Z',M$KC$4QMY+!I>!*,M<8C+U#8<ZBZ14D,^]+F
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M8E=$57^JG#1"DWPXL4^-+260K[#>*5*'106"DJ#G.>';)0T,4-<MX\FRHY5
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M49Y9)#WTSX1O!\O+,^/9M"1H.7.86KD%PF-EX[L!Z(_[<Q9GF;.NP_JQ72^
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MLC*P!&NY7N)OV#/Q$&>(R ,52T03AU]J 6NFB  KF@.LD/F-B8"48Q0@\ 0
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MI?J<#>S0V:QWA^\R]/_4ASN7_F_]8$M(R?Q%&%Z!GBY%Z(<S!:\JS"F<I$)
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M3*K5S.,<MZI<=R;INIO,]S4[M++^#:O@LD&3\\0 @?+IB,CYQ'#>E6*O7;1
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M6*N=;+.MOW\-/A)')TRSQ::Y9J%=8%M8LIK!V%XZGZSF6"Q=JU0*K5:A5OW
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MZ;*[EL>:\:'*CCZ>=[;;3&BR9.PO&W. !B8CTP"8X46R?F*0O#07$0 F6$"
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M[1V^ 11H3ZP],+%_8]N/""[^K'9F@PX%[*2>[E\B3CS0D7\_R?M?__A&KFL
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M[O5".;Z^0FINMW/=K[T-W7/@^.7R=X3U3TR1-W&D!ZQBVIY%X'%-,"D3ZH)
MF6TZA1,9(@L"[4$!&[86_5TG W&V9/KK!KLJ9&V#;\,"V\7<^>G.3V_Q$PHR
M^?RDH#UOR?>UMDSE/X>T/46%Z&4%;5*.%$OR'4Y@^[0WF2 QKOD.L&EX9M)A
M;WEC.^X%MFP4S4?:9;=KR,NF[EE&OOF(WK)-1+8>8_C#0B,.-ER;WQ V+A0#
MGAVUM</6K!_,$]J)BA&LV5.98 &=< 6==T1Q,$B3>J CD:\)NW&\[=N=X?S1
MEIXLV3BGZ^VVB1<!0.RU$Y*SP-15K* F,7I] S7;19K94[M3O_B_9X\B18I\
M>*\C#_;0PEV;QQ:<)SH&Y@=5' 3YG\AWGWL*]Y3HR%U$W$7$Q43$OF (',C
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MJ<_$2B*$MI&5/I9Y[I9=G-E:(K@XM_ U^6<Y73Z+V#K_;&)H@_CB2\N0#6&
M!@%^S06NRP4;%SQO@5CFD=4(_RS\/1KEM)XL5QS.J,XPT7@T+V>9X:J:)8$'
M?$Q_)9=CG@W=5,$O:P]M-#M]A%393L'QY2Y<)V:^U3UV-WZ;;_QY9RMLSR5^
M*TF .TT"C%3P/0(%IQ_&"*$CP"D#'@'CO]IHT#1+9RQTHJ,S%KX_.=,9"]V-
M7VXL?)/6PL>G#+?@8M]5?/$JYKF2'VY3T+.X VB)9?%/&2$29SXPT9D67X;Y
MOAO9TUD;W[><^JJ4Z*3'-R8]SO_5"81O3"!<A,9(G;$%TJA2Q-C;Q= &R@KQ
M5UMZ* D4H"*))1,U6D_0,K;L,?T(TTJY>Z2PA9F^.AIH<<F8S!A]N%HY].^'
MWM+AEDB&T!DPQ%O);=%J0G6R:KFLLKUAWU0U9M!@D:#,=;A80/%!+0H7A;F.
M4T;_TTY?<.%OV=14M"J,'OEJI=W!N)&D&.W,8@P#,*4T1I2"824UPPLHKJ,D
MOLIRGID!%,GJ!GA1![N]W=U=WL^A_/,6>(0LBG5D&/__RCXRX7M[=-"8BIY*
M#];QT8^0(J>[/TK=-_JA_4H&AH'&\JG)I!+9O)>ABVV"WZ#LF.XA5^$C^_HN
MPVP#.%%)Y7$Q+26XLQ+0*KK-O5U\<+3/.+EE-$,)-' U4=7]"@))H!P]CM96
M=H/M==U@73?8Q^*.KZ'U2YNCW#R!D5DUV6,5=IU'6@AFBJH)(EW2@41 /XGV
M90]XN(B.:710+R(OI1^<01[0#\7SA_[[N+\7#:S$^'V2I#H;9.@!919P]:0I
M)EC87/&[M9T%_3,6R6IDAC&0:ED"<3/W",TM=J!>61?7R350%!LB74)&8S)5
M&G/&;1ORH*;;F6E_K9G*#-D1^F2T[8..?F?. 2%]?H0&-R9%9F[2>2"I]2$L
MEH/ 5:!*CO=^M!*_'ST%\_'07!TF4;.VY.$1^G@/V$6/4#AS1,%:@]<WV"Y8
MU:CN]J4\M2[LW,L N[E-5]MNQ1@B9>4&JFG?57/T,=V !FA(<-,$#0V"Y#V?
MW[0NAZF_%.WV=FT(%TNE, ,TV-%ULUB?(W,%Q/N%+E >8RA=;/WH+!7@Y@8V
M]<+^<',2!G\FZ\(AW0,TU*&TB(1@.>G[YS%55L:@ZC46>MQG=K.&8@.H@(6F
M^N6#G;7!U;UDV5QH,7MTIHSKQU)&4RH DK0,)\4+Z/2ZN ]':5O)VK@SCH4D
MG[YZ_8^!8P<$&_*,&"-GAK'1/)4IQ\Q..D<R58DYHOP][$.<']DIF*Y7VS<(
MP "QR' .0)^RW\$Y=Y@V/_SMN6>L-Y:QSCQCK0FQYBWD53 <P-^-!N*+>D7O
M( BX_=K*T-@U^_J+L[/7<^.C^?8YB9H7/=<L2B:J*11:&4,-[KIW@-Y]<R9X
MFW#K6'VXAMP< 9@XZY$Y,TPJ_K>\:3HH$OD;9'FJ4TX<Z(BBZA>&!T7R'"V9
MSLM]L&S9B5D4-C.'>"=8^\C0UZ=LY1%]IF0.D9AE*30!#, \HU,<ELYZ7 *)
M%31^.VR_>(A V*RNK-[CDO^4761:@:Y+CHVH9M[#E"UMRR^]1Q?BNFE']A4R
MG==:5<"0)C7YCG%0(Y8*\%F3G-4;^J"C!X#]_&F3 +LZZ;99TNW7.[2BY?V+
M9\^/ &J>#!*G+<N73^W<CC5)P<;J&8$I@ZG$ B$?0B9"WMFI(')_$@2J1L '
M(7F5DS\$]"5@=TP!S!4+('P<Q,<&@M8Y]#CE/%^DLI9<$_^(;KC8N8(2#-?J
M.HG%:Z'W\6Q+^F:&04K#EZ\N6C C<>;BX/C/ !XBNKS)%=$ !X3&?!AU-7EW
MP!/@F-ZRP^0%,1P3/<_95'#LHXM)7LXF](&!W,0K ?\7';'0QHGWPB.'8\?S
M;"8"I/!NA. :+&G:AC!$GM:0)U=UG,T9# *F%$^ 4A0E]@8P%]BS3L]O6+'U
MX5E;M"@\&AFFF>$T$SX+=TF*T$YMP?\PEWK5X$(#/@)0)BD])QXG NQ>Q41(
M_!<I&8?VEL[I4))\F- ^F%\8<ADX$K3L!?VZ2=)UMQ.NFR1<+P)W8HEP79/0
M="D\AYKN(]KE!'>ZTM%&['6C3 DA./'.@AWU5HC;-)DE&DB;Z,P-,Q[S0."Q
MR$9KA);3''/';32 C!X./#-*C,.Y:XC'4'[13D+ZQG1S\ZO:!,"J29KS@GN1
MF<F_3):G8LJ2[<R?D-&8"AJ)N]A5.S0#*9.:]\DLOF(MDXFT"8FQDR;OQ"I=
M%!#A+"IK@PXG1#5H@7(!?664EPP_%3[>C<[2P2&C9#Q.AA#J>![I-X3D^$7-
M\>@@ZF!8DUHS><V >'7I(>9+8V.-."@Y>T4$<M\LDXJCF*:@;[,"L',S<"1D
M#0_S"D:R!E\AZS7'*^'#!4J5@BG$#!8SU P4 !2E)'( MA,/)T8SQ'%1T"?D
MOD/9TO^]SJ=)Q?3A(21I74[XO\34!GD ^\43H)!=!I)/+=&WC0"]_+"48AC&
M95]'YCXRI*1RBY_CQEC +?^(2-0,HN(II.3!(3)\6!PY-[S$?Y,XB@&!\6BZ
M*VD\]-/,)-KEXF=R.0%9GO#4%AM(ZT<N$XD,@YLY@+0[HZS*0)RD(,>%<Y1E
M7A=#W. ;XV+R^C)R$/_(&2 )8B@DBLY\:$S#Y"$U]A[ZX7?+(O!HR>"9=B&)
M''(42@2&13+ =7:#[7H!"34TJL$[HA4YN[ROIL5,]D7IEVV#?QH 30H_*E-A
MH'J")NH% #C;OW5@].P8;E-(R%>Y&?@4FTKWM43*6Q]9?5#,)9K!#Z?7_Z=F
MZ"=L"@'&7N#].F10MODF9#7OP(\.\@^9YT47>PV"%1K,BV5Z.N)N?B3H5#'!
M&#TUS1U+2@U)-,N!RD4?RRM!2,XM?_8,P/V'WYV!STAB]1Q,^5=+] /GNVA,
M&U108&8+\/V.CK8/QS!:,&.^6  [O.:YAE,,(D@&?K!#(UP")X:'+:KNO?2V
M>B,]0!Q48@*C7%,8=0(+YQXOB&TZB80#N>#N//M#D<7LE(41."V_ ;Z<#'DL
M(MG+(B*[[H&9]8YM\(NG9(),K=,43\GFJ&QFP^7IB,PRI8JQ(S%9$^F\K<SX
M[W<9_R[COT49?P1RZ7H*5"'9[%/R]LU[6ATGP5X(,#/LGEY[,)N5!&R06$'
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M/.^F<+ DO >-*;?2L['WH_R:?\FTUIB:JAJ$0QB0OV4F.@ERT8S/N4&T"5?
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M1WSY_"DN=_3V]6\O?^D.>X49\XT<]M_IL.EF/__?B_,W+-/_3W?@R^V9;^'
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M19+ OQ]G>3&-4WGLC:Q7/_KA;Y=@23#L4_HK<4+I@"7BOP7'OHI9FZ1>H&!
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M;^VP;A'Z(-JL62W\DFD2!W;4?,D.E;=A/@\GT%B:&\;GOG1$\[,^@F4E.6M
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M/RS9+T_(%S0HM^( G6-KDL..X]GE;O [/!1VZLG2&77\VO'KK?RJ)C*;Q1P
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M*+_<0BQ-7(BE ?B*[*Z@[!(*Q>_+S9:C)/H*'#>.1,+E__ HOWI\E5]<?3,
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MRX:=.3&"BV,K%'N)+3EW< G< 0KR@:HB\>"3VP5C)][.O#3::6TSSODH07^
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M9"I)(QM9Q%2#V4HOCLQ1(DAVM0Z 3.'!AO!2':!C,4Q]??'U@]G#!U<2L=#
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M0Y*Y_Q2*I3?[;E=NX ?_YYL\V<3I91E9NM;K'4T-BR!,ADYX[8;A6%OU%S:
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M^OI4\SK5O+Z@FI??S3'D*:6FT,Q E!VBJ*)=H\P^Y62<I\&D6D1O4(.M*Y7
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M,I&AG78D<P4PEG.QW'(Z'73&Y7BBT^4C/XIV6I Y+%@&:L+!YVA+_5 )[(;
M7*;L%*X-NE02I!6)(3HTB^PX1NCA\("[9ZS"*]^S.J!ZS$R)C 7_E+#764J
M B(OJI)0_&Q42:ZEVNA@0>?7$D">(3R4U5X"<ZZQDP(@AXF T:W\#G<!QWGV
M.S)^TN:\O#BX;RR@# //UI^XGF-X)J<U[00YIY?5,OC!](E<,(V>[L#.]PG#
M9HX<.6$1A!A.,-_ R/W6?&4GAIT<;)T[Y->8KG"&X: 20@,]Y$F +\QT(:(8
M4P;F>H<%0(7CG-,, YPKBZ@?#*B3U?Y%-DE^=RJ0G@JD7Q#]XO21$LP5^IW
M<D1NJH,Z (>I5BH34<'.G6-K"CE6-T,PKCL$[;/"GMWFQDD0Q;XCU;57&.SA
MG+3<7C5(8 V+#/%.R*8H/;F]T\$STWDOWR, JS[M9NPOX1BD=GF,QJ&;'9]Z
MWI$_?09Q2/ MG4[!N'3 ;$--@LSU7,G"DNQYH'#<V>MZ?NL)OK/"?31AO08
MFLGO7Q"/$NDZ+!RQE$. Q[&U!DJ1C7CR"[OXX1+$']9E&IP3_%I8Z96)@-XY
MF D^-2TB5RI]19FGSVL;>)";BQSO'%-$:6E G>2APN,Q.[-TPR@OO5XM4AA@
M!I1'AAH5L66=$J"]A/R;7MC2XP*J=<D%?:LAY1U82HHY<ZM$GKM!9%XL:/K/
ML^=]N[M1A=_T8949* [69'6%G5*$JY;\Q;!HDJ:3&6"W:P>D/MSZI/^#F&E[
MX2%WCE8B4Q'B V_N^AHZ K0B;ZKUHBVE*6I27RL5(G!WL+BAF<][\NIK5GG$
M"+FESSV^EGDRO+_&N<:4=;AU, H*I3JQIG@V"!FT$2 $V+39Q)J2MS]SP=*(
MQP@3GU*+DTO+NS]N;UL,UB679Y0GXG>LRQ4.V7PX7H-&E>"OGXFVR<<$,1C$
M-Z^>N!#H@;7D332#(D\2/RLY/HT+.,0CS"4J:FL-U>D&PRLE23YZ=':\N5N+
M.C,:%]JYE <_[)9H41YR\DN(KH3G_] I!<TXJ]G%5U##(%^;"""=V!:DP^."
M:,L[ZLE*==2,C\51(*(X('H6_8Z;HEFBQG)JF&5LS ,4EF1_:.%HTPE7"Z,N
M][%./D>[C\?>\R-3=IU*^QZ5NR[NM!U=53TP=5$Z;J3S%^F3A-Q*A.22A#%6
M99QGT&W*DD&."F ;RTGQOAU>>ERBB1=$:AF9+VDZ-+JWG&I\X07W4I#?52$J
M:MM^J]E=5M%&POTCB JY\8^,!)N\*.Y".Y]5!LB,ME#+7D=Z'^72C,H#<Z1X
MU<> V *2F2&"Z#ONNXD-'Q^:!2YT^A;36'%DG3@EB&Y+6MA=_$!75O]D5J*N
M[[:\Z7+W-;HV$><FAS[=8=?LBD1O)GX?D\77Q]4\^?1H7D>R&>%UF#H4;.ST
M3=5I).X\$VU,;Q=F+OR#7F.)SC<A2AU.PY%<84< BN N:K%\#B6[8 I41J:S
M!L%@QJJY#.2$DQR9ZW+#.2VJ)8 .N\CY!\K\,(6]:%*:LJG?:VZ#H4!^2^<A
M5VJQ0D0:;L_]0*1I<\9/-Z5J<TZO8PK,)D."IF3.>4D'H2-^:Q5X+R \@C0X
M$X#V]+NF?0<Z87^8R;.LJ?;@^N.\KJ\:":B<C /!.VM?EU?2$1I_5*DD2!'3
MJ%CH5JO69WFGOPR&194*.H 2+<@B;[CR15U]1#M,3N Z>4!HYR27BZEM6S><
M:Z;)U&C*GSWD@W%4Y::>R(YG>\^52TH+7WW[^&NCGG@I]W@J:]/SZK*S*H(-
M;GF%O[T,5OOJ&[#=7D[SYS;!K 33'7ESOWOTU>.KKYX]>W+PWIX$,7(03(S"
M9 YR/(-.PBE[4)ZOSJD,>1:<M#4F["8\;]L]S".E!TKAJ)+)8I-N78)D!@>_
M=/&%XHI'SJD7LIMX4$Z]\!%U8(XYW0S"G<FE%MGUPC@/#G#'#'J>_=C<4?^B
M0H:NATXH99?]B5ED3YXEZ7[7#%W-RT-K_)XE))5:VF/ATG!@%L!K<346K?&B
M_\>WI8E91FQ6:A)][PYJA/;@M;%.H#Q>T!WY:K.&)(]J/>YIG4AKD;S4 Z9M
MP+L^61==E[T =3>9EXJ8@.D?'!B#O()?\J$XQ@#KNCWG)H=2(8>'YG?S715#
M$M9)6,WA^^$#<V/J-UNG9Q.X/2U-EDKM34-[R8&K-MM"3+UPI^<#K4!."*!.
ML3[,*=:! (VQ>+M21<P'CV''*&&%FS,!'+FLSGC72= TS= A=J;G\\=K%,OQ
M.'E_A$#R2<0UVPGEK(D(]^"[Y[[$Y[\ /%K<*78?):EU&WOBS67ICZ=_;%L?
M= ]YP-V4RO<G9O6KIHT3>Y D#CFJY%"**FM*LZ]Z<TLA0^$%>;]/$J;N2RPU
M/;XXE9I.I:8OJ-3DA"_%[)K8[\CV3B:@6M#'KQVP@M IIG%@+/L;N&V-E).<
MM$(FH@I')7)'/.>9B<G?'L9UDQ2@ [F+35E*2*1\PUPD6/OS4DB7X&8EMG-=
M5(L0M-P!T7==U^7[X*U8>_1!7P-&&+3\I*M8B *-=ULJ?:VA0ZI8+(8Q2 9N
M2/ M2#PB>)32(@<J#+[:,'^-I%PT,1'SXI1CM2*!)IPM2'##HE(Z2SJK6T<X
MV"&*U.,S]SXK:TVP\RXU)1M;%U6J5^\"6-54T#?/D]<6S+BN?_ U=KU@,#8D
M;-/"E_&UD:D4Y[\]^Y)0/#S[^6A*DR@= P2O==6PIH7ZR(Z1Q[54\GZE]!6Y
M8 @'D/-NDHS"1%A#]>8'U(WWD)2ANXZ#C(HE7.^]J2D9(#V?TI59,MD65DG>
M$?*4:T+;,(DMLLRC'#Q&.VR+,\N!4Z&Z9)I-CV33JG@$ADH3J48JY]3)I6'$
MNKD[HQ<=&8@'GQ!@>-<T6994[NK*]3(X1Z348IE,%]JXTG[WKRTU'Q6A1E&T
M.^D3$2UBY/WQ"K@I4$PM^%1)_>9#Z\A;4Z&9-'SP<AB_$6 M_E-5MWSG@5=F
MZCP>/>QKZC,,#M4."S:5,Y\*"*WRPJ76*9L.+1S&/%<>\155S2. @:[?Z>[X
M5VR^,+LE\:R1!_M@G9+8]CZYJS0FJZ?O&.U8"&H//C>5M.\HL$FD?^+5Y #Q
MU]G UFN3&NXC$;Z^+ ^G/D@X+YN[SEMFB6:FSDS)?FJ9_=FO1SO[B=_)9HN5
M@:)%'XW3V/*9$%/5#NSNO[0M]31&9\Z]Y-UI([091]A!Q\4Y.&']C=.*?:?=
M8>SM^DH?G\>D\QVC8;3>)^N%GCP%"LBNT2."SVA6?K)SV3_0!QX@CY<D26_F
MV*.=W)4E9\6#299\N4#!PSR4&3>$LJ=*<?Z&>7'I4T!&QU(E_'WZF\C"TJT\
M%]VA)]<<O=1[PR:K-EI%GNDB]V\ZQDWH( & L14YO-D^NAQZZAW52QYDN\EI
M=CI[K:WUD1(2=OFSZV/5DGYHR_?5SI*OKV.=XKG6*09=47\-*W'1;(XYV.F3
MP%_^]:](A&. *4;7R.,!T=L"58*^6>ER":> @.XS'@"!V#\\I&MW$8M-4NK&
MB/Q5!-4:A7<4I*&RX&4\;YQH(:&O:'G@8=\^,=K>.Q6>[RK6@_'+HZ.>E?1Y
M+EWAP<I1]N:C[[XLTN_Q<1;N'Q/QEO.SQ^B4C!M>0))E-U5)#V>;("()>_?/
MQ*L?C,66<2B"V/?%VO 3N5 *EI_JNP]O&:YCO,G*<<R=SX;^4; 4PXR:L.^*
M]:''"G/&@DO#^H$^@3O 6HLD.F#%!6.49W\FT%!8.A5:%&@>#%S&F]_+E"4'
M//27*2ILC P5#SN=8/:<#RQ;$#408IC346WK*GM OLT&)O@A:05J-O[G!BBS
M.GO10J. JL2[9MZL<UW/4]5)-(54=2^>(UR=\*[#BXE:P<2S)ZB'584DQV#@
MZ$KL<4*AB18P68'.,"5N O+LAFLZA\B4H6"^@NE!!+Z@,NJJ9*1NJ@@5;KWL
M$1R%TY(OD#R88\>V=Q!!5&#6HO=MS /.*M#NFER:G[@@DX+6VP^650QRE!PO
MZ8 O&_)%:>\-[/Z\;]-2.U\OD>4PL:N#Q<O?K[EES"Y#UHY?:K@]$]9K$(RR
M Y&VZ'4?N66&W])M(DY]2G4TL5NN-7N6[A9M,$_%%^X /4TP9.CH:Z4W)7U1
M>ISA^65V__F /X.:BDO^C"/1F/IN'K,L!H;Y$?FH>=$Z+]GY#JS/PLH^/[Z^
MSO6TC%S2MK-R@4&M4:LL',M]\2X<;4IH,*$CTU@7LE,(PAZY-IC@M#(-\5VU
MF&OI>@YQQOQ=> +%/-%5AF-+G7I:E$WPC61MS#H1?*Q2O5/6H#R?2*ACE3.%
M52:I\E]BVO?J,4;^D8Q\&,&,(/I]/=>8FQ^Q2A1VO5V)9EQ)(K8]$K((.I.Y
MEB3S8_-(#&?!Y2J&.<_%,Y@8=%IV\.B'<S74ZV&O2%1:.'2S9= ))%(8[ ^J
MDTS.S!=9#KL\E<-.Y;#/39[.O\VL64^23=Y#(8(]G>I^,]M7!Y?JZONG;;_*
MKM5XO.(N\B-V\: 3)#6C[*<'=V! -9F,TW_\'P)5$0%DGCVY"4<Y'75_*<(<
M/W0=94@Y:2<,'(*$621C(5N5D.7.T]CYC^H2-\T(#]AU I08:M".>HANJ.QE
MU.G<\T^="2P5VFPC&J7<D8I2%9,NPZ]:JS ?:9$.B3XLV'_M*;%CP>N?<Q[Z
M?UBY]M];O:_::JX]3:_+:C/KVZ[\#+K,TC7#S$-NP:X!35ESZU)*@W\W+,5R
MU,.YC*8/\Q7)*ZQA"W0E%/8U4MW$Q7/I1I# !SZ4;[2A*HEE8*4TQ=>F>T$L
MBY6(W+AJ]%2UBS,F[-@6>W(%E)^CVZF<\[)<(%.\(O>]ENI &'!4(-4-I4!+
M:J-A?=Y""CPJM9,<R'GVAHD/ #$G?PK.R&ZOC"Z%*UCX)V6Z&4#'RKOU/A("
MWDPXPO"#AB]U;,Z4=!6%@*@/<T?049:PYVP^D;JM2D&U)C-%]$MDN^TE><"@
MI\1U4%J'T4^,4"<':1O>H]B051BOBP':2RMQU._3MSYF8M<6SB>"!PPUC;_\
M0'4>$G#AQ3"QTE@XK)' 6"); #SD,3$ZE>R[\"4\']A8)?4"J8R=5A2J%N6D
M]'5:J1D62KO!9+$EY00YDP7""\8VVS68W*>;Y%T)OR#<-/://;/ZSI:P8H F
M]9?D\8623]GU0&*Q@V(7=72=$92WMP[/>3@-UB86*;:%!E^+TWWG>Q:]3HSG
M-QL*#0GLT,TI57@7U<(4W5F0AZ;2PV$1*]<H9\KF%GHBO[1$_'HP%;IDM(<O
MQ,7@;NIT02B&F>;5!R/I96BX+3<2 A<I0WG4\DE/Y//E$/^].;N+F':2'E1.
M-5'53) ]=#Q]?Y@$^[2.3NOH/_X/%49SQSIA#2'(#!JAW6D=G=;1_?;(M?X;
MA9&5 1F&>%I$IT5T[R(BI_#,;!%H,C^C)7-Q6C&?W8JIA8N6L:8"Q:[1^>)X
M:XKUER<&\H*53B4*1IR9)7$F4)L*$6"NWK![YKWJL _C;5848;92)%"8B07A
MBZ\X+AKBT4ZR.TH.H @-X[X2.OT-J297"N;GA H#K4)\WZDJP+I94;-4#/5
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M.[%:ZAV21D\US$T)Q^2^T5^KGK07PO8,6[^J)9(%$X5L9O*.P_673 M1L$3
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MJ;8<8BU$6GJWM_C;@Q<O7UW_^.3M0WF<J]E7_,.CX7/1A/*#L><,IP2[(5R
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MSH3(@$/EO>\%[[J8\<-FG/(.XW_=:0X" ^$.N,R^. [M)&ZFE?$/#\_Z>N\
M6T;[SZD]E,HGR%8LE/1FX^W4+#?)1,!K9DDF.*%C;?"X+4_=$"]UCM8OGQ'.
M>7*8'-SINA&V.-,Q S T/=;E5H:;JILG*392X!'S^?N-;LSXV#UIMT@_$?M%
MR=J5^7/YJ4%="9.S;&J_,T#ULDZO7]<]9YPF\9Y@OXO\O0X! KZ>ZAV!"HOK
MDHT0F])NV,(0Z7<@G*KDT!.%@9$6"%>BA)/QR4"8%Y67&-5[C?02^FL&C$YT
M^8*?G.5S!;N$B*DS*+\--HH4%Q!2LD :OWWY1\ N-Z'"WC^K),*STQFU?[J7
M\T3K<UH%U_#1ID&K,V('#P@$0=:Q"ZMLY%M)W4D_^@Q]_80'E/,T1I3/R=7D
M#2<.3ZA-M/;ARUBH9J:VBC4DU##C4)'^54JRSY(0\?W5RCW-KQ[.E !;) (,
MEK'"R)@D9)(@B=97M'[Y F*7(%TGH?)BQU+0A-6/SN)&&/']B ,DOVCVN"7-
M,J@:S5*O0F+NW9NQT@#72*)C,,K]G3P>^9J"'B^1XF.>;NB!6Q;:G]%OE9UJ
MBAB#.9\_)%+5>]%YDC,]Z/.PX*B0HG?1%=%>H.GHF3,(:,O)+LO[?V[*17#$
M3^5O'E)UV18=4]/A/^AHB!:<@FIZK<_(U3I:.USQ__KTQ>^?OTBB+]^;/ /<
ME$[P_J3+B[: 1QS2R30($STDX)*N'4U'D&@UTY+0B":!\JL]W65\U,]HF"5^
MVD#MD$O)A('H@M$N_]C<DSS/>C0I@W_U1'RC(<]#DE?M].*POQ]BZ,OR\DEJ
MBT6 ^$B+/O$'?PK3 W:KKFEJ5 UC+"1/.MHR<IGQU_4PE:V\+^Z:%CY7ADM,
ML96)]2%:=P-]#R=0W/&P!ZLVJ/O7X\F]#[[7O4B,VY*:DL!X<9]RYD$QT+(^
MK=.W%/0^A3#^-;J39D'D+VEA/C,.^N2U\("2#&4?A/7PIH5>L@Z9*46H$1\>
MVY!@(TPOMYJRC(])RB$O_A.I8SXTE.JG"TIU0:DN*-7%2?]<)RV#>#G=_44U
MUGO,OLI,+C-]+>V.Q=:NXJ+M)44Q<L)=V:%7ZTF_%_ZWQ=9^F> SCRSS6M/Y
MFL2X*&7T\XOI+:9W)8_\VLL?N$J<JX+RY-Q(5?;GY#"+#2XV.-8RV QEQ81K
MANTL]ONB;+NQT\MT<QU1F\CJ,A(&D"NI/TO9]D(M=['HQ:)_68L&&ED<Z[CU
M--LDNLX$LU;28H^+/5YICQW7,P,3AZUIVM[86-N&)'FYLB_S2<=CI238:X.M
MZA<8;*C\8P_B#!F/R!W>F8\^0[TG+'C$Q::OM&DO)5 98YV)ME3%?3<0X% -
MRWB)EU-^L<!?!M/O8#L$F:EO&6"EW6MJ!IVZ/APZTUK_B7(P'B!C?\D0AN,Q
M_OX%:-!B[(NQ_QWKH=<J9RP6MEC83[,P%5G!]/&S&)"&N@MRR"^>;+&SGRO+
MEGA%LN&\;,P=)* )=R5(:,K!@81>C&XQNJLS\'$=:!.X;,DTRTSKO<B;+29U
ME4DE#1T7@0$$WP&QS6I_.IM1[/!BI&3C\P6&PG[DRN@Q91 ")$V@#_%R,??X
M6/'HRDAK@WZF<+(,XBWF>Y7Y&M229K:.7"YGJ#X&$-#(>60JFY7&/[P)O9=C
MU/CL8)92]C/@_#8<UI#KAA8W1GH*EH^QT2V&JN>C6T8SP#]$7\%8H/T*OL7T
MYS(!"/4(PZEO@N<(_B?'4_]NV=O7[VV9Z0,=_OQHWQQ<FG,Z:_LF@!5C7@S6
MXLL*\7O_\TZ:Q19_45L<UW$M(9P9]L.1Q(FBDIB.62?9C)VYPB.+P\P&T.;G
MGD%2S7=),RY5^+%,<D&R(Q##M5E/CCX\=WLR#W3Z\,["[P.K#&UU:-@STF-(
MBD^N_K9MAIO;&:;/E,2+S \SU:4WHB/3 ]Y\C'3+.OY%?/72N:0?$B04K6\?
MMK=U4S4W\JIU_%:G:%E:AW[CGJ:@I3@JXVG-?3TO>=(&-H!,668<_,C\[W3D
MUM4AUJ*,,A))T2MTYG7C4=YC'GE]3@9'L3$\X>KF)-FP:'1M(A-#;R/L1@/F
M]G:.+8VK!DHU3,:.T#@U7 \]S[$-^]#2^X5NT3K[Q[AD8MH8: X[X27FYG.)
M'$A2Z&8?+X.X,C[2Z[=OL.HZ>CBQH=&<GLP@8ZT'$T9/TW_4O:YY<)UL(SV>
M_'9K#TH_1!U)N9N.Q:,WO8YWQ[^*CTC:6IBOJYJ":DQ;YTE U;@A)R4PI7FJ
M!KEKF<Y^?L7(Q?LW'_1BF0]:YH-^ZGS0DS&I,-G%9-)W$]U$UPVT*<4)$+2&
MV=%Y"!D.[K:I=G0:P371"&X,&W9E-9CC18J,I$YFXLUS\ S]+GK'CO*R E/[
M0K^$@TL.+/\[HV%C##O;Z#!F8R#DAE!G_$220!K)@RKGT6VP8/E:P@Y$.3?Q
M(,;I(G?3#=#P:[ETU'2P!ALESV_R5>8B^733E'1-AUA5_D#/'"\5[Z.I0/42
M@YP23(U@TJM!,(6(3R.C41A%SSVPBJ4\D[+)N, -C[36TX .YYXE##OZU7H;
MHTKX<WN/*4XY%B7]%YW6]L]*]#&V"&6LX>+&CH1-J&BG+A^Z?^VQ846UK@M0
M@K071-038Q'C>(>JUK@&:T)@@!:M$\9:!9)50D?EEE!7? S)0O,RT;O$&HZ1
M"\)EF)]E,QV2]T4/[\PNQ;9+8^)&NK)."PG8!L)YFQ\_")<9]R=9U_'4"+R#
M&%3:IHKO)R]3T0_27< C2*:!K5-2?(.OQNL6'+N:WD(9W4%Q(O'.'>UV9Y>)
MLV?B T;ORD:41BP6P63P7I5=.QR5;8$#'^.?X6@/_\#Z>!)C(@(ANT5,Y$A*
MSA:%HY6&AF1E>R'LK?<Q7A)PX+SETO.!PE^V#%<$,J,[,-,-L1<0:8,99_)&
MB$P+(Y#2!1.BD]54#Q'2I7 9[J51H:U#'"E\(S=# 1\G%#KB1-*-:;B9JFFY
MT)82DE!.HI6[:<'.(OM?<BMI9.(+:!>WUVS6SL?^.?ZJ?_G/K^2HB.<@H:*Z
MY,N<ABFENI9HQ6QI"W(?_Y$,^43I5,'P .=)B6ZIAN_G+@:%X*-/?DN:GB]O
MVA"8&&>LU^NVJAW HO(>#RZZ/'&SQ@0NFLYM>9P[766'T769TL8^(/JK8.Z@
MTJM%/[_$&_WM_,M+\?)__.L>__?@^S3[0.+=AIMX$ 4D8[=%&SH=G;!WITDO
M\UO%UQQVMNGPQQ6E@VU&\JBOC%\4F%-HG[#H5WH'_./", _56<D7Z]57,:A<
M??OL=YPW\SWZK\K->@.@M_AO__J[%R\^^9Q88,@*:OSYT\\YY.G@^]S=\DV"
M\;GN^"Z$2>;E-I[%9(QT['+Z);^(BKMM=F5W4H\:\^':E(.%T)+N[=T0/_/I
MKW^]BH',< A\WJIB-,.OM7>W)[ V=S@<*R;^*1XV%) Q:Y6$0JHY7<5W]6R(
M!X!:__C"_BG&@86K*=V ^1/L-%7E;&*RI\=[[PT]^C?,5)/O0]T(,3J<FN)G
MSW]#CHDDBS4!0@*@==5QP;(Y$@?;-_&:P_$!\T9=@-[*V"U$:T:B"HI1PB!1
M#>E_!23P\6G_]*<OR 1?#C=QEZT^_8P)EY0&C];%KBS,/' >T3-UMEM2^8 _
M[PG6[$R86=5DG;(#?A7?0:CV9_:*U;JH#K7.;NE:0>E$XTB"TB\YZ@&EUJ:Y
MDW!8E<^S#T\9&M>8+J!R%^40%ERDY(/1KZ);OO?5(V:84HJP\S>/4 =W_OP7
M]:^/#SXSVR/GPJ'%?]R6NUVH42;_W8M/?O7Y+W^;DU/X_$V^*[L?NM6[!(VG
MU7TU!R!^CWDOWS@3H\20HH"60F$.ZO$8['Y3!=.WE-:SJJ4/\+VI&F]UFC:?
M99>ZGWBR%.C[?PSQI#)!]FTH>OVWMR__J"E*C.>D>^UT/-+IF"NO#\0(^(56
M6M>N;GUAR85^S73*!2!*]0@&CN[6#!TE?R4Y]CGP*&[,<SEY#J<0C6. ,1#9
M9-FE] 3<MDIR9^34C.,"'7:IM&]=/-ZK0O_1>D.X^4/T?N419?#)?4$F!2'N
MF 4 WZ?'X5J#U%_T;-\$@NS$=]\)Y?$^!B@#%X^+515 $RB_ @I-W2EJ',F#
MIS!\E"]Y7EE]:+JS2RKPVKF@Z&^]PA/$!3W&S+%?:TINN_GOL8<=Z2W%A*MF
MNQU:Y'>6,\;',H"$;0MK[Z7] 5S5'9; VD'<$LB(3YG%4LA8]2&E;H*ZG2>O
MDY-6]1;5;.9T%^,RQXQR0K[IZ=$SH!>1F14'3T6F"!.8 X?54RGGL03D%;<D
M7(-D<GP\Q].:FY%LM6E[$^<VUP%4<$5WD983'J!_S5@8TV[0GYXO?'PUM/31
M-9?&CC1]8XE?*SX0$<GF].A'I_NXHRXO?6&TSA<(JHVCL>RQ+LGD2^.,9$<]
MJ_[.89KN\52IF_NEY,.Y;#FIDT"(A&LE9=S5J5:2>+>_3(R268_P_,]BNT@D
MZL]3]0]:-K$3'.574G):,\\G/ &]1=DBKD EU?*VC+^H*!&;(K@Y<T.(WOV%
MZ 00*ETZ,NFO-':G%*^/)R[WU0TOU664YZ !-@[:C&7</*+_O#QY-]OU79M!
M.$3;!]C=^]72W5NZ>Q]0=^][KB4:1F#.@9XY5]03_:4N*=S\MK=V"Q6  \V]
MAZ2@#!+N%N?W=SY:&'&=N*A,G7;>O"B4%R]^8DIU*\@1T:_X)P=J+C#LGS,-
M);VRO'UEF!EE6KXL#+',KBQ6]Q#XG_'D0KJOS$QC,8:4I6U&!<E5%WT9:]&
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M\0/NU;0:3#]??4,LS_WIR''^VK^$\5:CFB*K15UW*]B,S2'TL$6WS'TB ^&
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MC%(+H]\QD T:@"CD)QGG&:S-+^F(?^E%_TGVF8A0+TK#,):3QI82:20'D0I
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MW 6!5=?*Z[,V HCXEBK7LBJ[N7M_+UA^YQZ?UE JA4[V>A9C/DDWQ#]W(?S
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M'?U'2<#G'=-PH1D9W^UY:_S0P/N_7\#["WC_IX+W%]>[N-Y+KA>HCZK8A,H
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M=--B)]-EO[8<=/5RB\B8?O -C04%^MI.4X,]9><4PW<6O(@ODGL7K<2B9.U
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M9*"S[=XSS)H_2=63?P;QGI!Y;E'PF[E^3&GGZDUX&]%,G[)Z*W<B*4@W.Z_
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M$\]R#!0]I+FA.XARW@8ULYL6=(NB9>$:9BM8\(ZW%$I[X4>@3.YH,<48^+=
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M^6S#Z+4K*H_U.>-2<=%DUYZ>S>N1F_JXF-&KMZ\];A:041*BD%J,*JH7VQ\
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M7ADW+<"'[E8S93ZUX4$DSH,Y'HAJH00)'\>__...HK/8W4H"+@X19J@C2/&
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M*IJ%=OE#H_K902DGKY)#(%J  63YS5Q7!X'TTP6N;]+6&<^(4GYI1WBJ<ER
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M7+QG!ZLMWAFSEQIYSF&BK6#9+WVR+E)G@QN7H7-*KU"4D.O$Q2;?=VPQXH!
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M+).494OF?2^"IB1;;LMDD)+U\48"2!323&3".118_>O?V6L/9Y\<4$5-17;
MT6VSJH <SK#/'M9>*TS DR^X,RC$&_V^\T"Y))\,F07%^XZ;3V,/&]?!DS[2
MA<;1R)<:#1U_'E/3B88=#<? ME- >F_KYB3]Y9:4,DO.!X!865;-+>;8#Y'K
M;G89PQ=S+XOC\79CNBEF!7$VSX0'9K?"AYP3484BD$?-<,^<#U%11YIT8DZ;
M=\^0N+AZ[+TSIIQ8Y-6>WOR$;7X2'IT/H&O[&]#Q9+'T84SONX3:#T2SO&QE
M5%-ETWN,L263PKWVY;H4I\W8=6(WTEV3RA2==G\/KTV-BQEA@/,+RW\(KSD5
M1T[J3)@'.KW.F=YN/,H49"U&0%?J>6JZV8YOW&#^84)H)6J=U>V2MZ$@JY1"
MC?%6C/VS[+9V],S,[.+(LD AW*OP8I+;9@N9M-:A+BD=*]-[<>YJKK'+'*UD
M73W8+GDQ0E5H F_<E;NPV74U,".<"W>F)3='8,:Q 7'%Q1;09!V.L1YA)Z'J
M:*>!2Q_:C-!P%VU;B@"S/2/<^\GS<!E4#)\"0H%![R@?VJ!P+#CWV;7Z?8HJ
MYR(,MQNQ?N\X*IAGY+P['>GV0&10 VNF06^2;5$<1AWBT8<^%3-3-6*.D3XP
MPL7F[;@3WKV#Q'"_SCM,MG;7N/=YR,[57]T\GB7$".ZA=O)SJQ46=U%+(H=R
M%L[!#S<DZ ?/:6QU3D_!NXXDC5/U75.[!0@&NXW=;=<7AS@XCM,G+J@J(0IP
M'Y&! TZ2ZY]N:SK__JX<OM_AWH''D>C3%8D'G4C&'HAQO^P=/)Q\98$ 4]/B
MA(QAMCSO=OF4276X5^5^]8U'CB!^FBXY+ %ZI"'$G:VF&P 6I&7$(A[LZ1M2
M"X(QJT-8\9R,T]A:%F527$DL\X&7G]X[-G;BB<?5]Q&MRERYW=<?HD)K^&Q8
MU/BS^Z52'C72"KQM-DPD_ZTJ5B=K+C9^:V>]"L*C(AR,45WLRIXC=QH*RCX>
MV".>IR!BV K?Y/;1^O:1_%/U+B2>ZL!V>89;43-$TA9I)4@I4Y+R)O2^PT>=
M([39-[2(:9LLDB3Y'>L&0Z( "S@XY85J.,; ]9.EU^+"MU[HMZQM)LO.5X[.
MKK$E0S5ILQ[W9';";'5#"6_0>'DE@[Z7WG!NSL3.'7&$:?X@DUL1&=W,'N@!
M<4 (7SBLH79I>X(?;N6F!3![Q3'GI5Y726IBQ@]?#EN@>3LC92\Y_DD6.\D2
M*VQ+NMO)L RE$SG2<G[D(-'\N\,"'\($4E!URELH:7,C=.:=@X^RZO?9I>IW
MJ?I]5%4_EWN/!%6C0\?;P/<"U3&D,69'%$16F\RRKQF,%%<5RF+\5-9]LG!7
MM4"_@A3 +]YQYA6+9CKWXL'+/AN]]%_S?K-_]&/^+CSPZGGP@K:QVT5A%7K@
M$52J$]3%^I9#BJTA;&;[ I6S(]$"D E3^!,$>=I@O!\L[OJJ4)RA:JJ3/X7L
MGC&38$"X87YCL1-GV$G#U?6]<[O66&TXG%RC3(V,F"XP2E?(R!3AN4OML5&?
M4C]>M =HZ*F03IS+K]KA>O4*74(O'$D6/;G0_7Q/7W[MOOR<&1N??/G%[ZD^
MOBM:J0A*H+BP/#@L6UP[)'C#L#B$ 5 KFS"5,-D4+:&%M3,<F0K\IDBHS9C%
M,KB^N7W2#TU%1:>(2I^H7*O_0),VY?02O_EJ]15?H:>H+1B"DM5[C3PM2QD)
MO$]K)&@:?T]>7/@A^)>H8#_4PO>TMR1*3O&'RMHMK;<1MV"J@@:$(-5E=].N
M!.449J4LBDS*VG,I;8M\2V5O:FA(/LKM"2J?9/O*.CK&57ID\/02M$PZZC.(
M-_(-+^-ZF/L86EAU[MO1A$]6++/@%=M1YER[ONB>81!'8CII,G,RU')7_%XE
M_QPIO?\H+;N9^\WS+<+C9%!Q1%MJ<M'A3+JFJ?%!OB9%,YOR:&[X""YB*G8J
MLQ#%4:.E'ZM7_;)6_U>HH1DMIS:LV+*;DBF)%B/@0DTKE% 6<4DG);YMA+(C
MB:]F-R9XXZF64CN7_\<"8/,R'@FNUG&S+#2F/* >J&R&ZR$';FLJR"*#P'1)
MVE]*O;=I>H<2[G2AD?V5F5-XP8SER.1RI1WLMM%''W59Z926+395G+%0F=.;
M56AZ@WI?1IW/ )Z<BDG?EM88]$7"JX$Z6VAHV]NY%<.]2D+1ZYFR9^E&N761
MKUAU!=<VE(0GKO@&F2UCM%*@P8QHJ<FF2D3ODR6CM./\$R79!X8Y"*3W'\%:
MD\@M>P5/O\Q63T.TRS9,,4_3+S.A)EX)R*](JZMRR?C8<D64X0H)UB+X7GU9
MV>9'H>/*J!7O G"$4?]A-.*T/-#-WNT+\1'>:<8PQ7'8^X0UE[=52;TF(A 3
M@1=&/TBI9Z:2SER?Y/B+&!?.&C$^'="IB4]H5^6&MN\C+?1<XNA\SZXK-,L<
M&X1&D?ST/8*$A+].V83/J>A%J620E,=Q#7?//*6FKAK8#65[H@,<+=GY@3$F
MB":9*W@EB@?<7TRZ!Q'EUD?&+97M>YX0:8]=Q\2N\"+KDJ<+C].W@W@9G=D=
M'BPAQ< !DUBB*C_QG4YAKJCYQ>D8)'3B29>GP5U\#VWP@<E'YM[%^;O9L3;Q
ME&))@'J7YRR2Q>]R9B;2O<*70.>H,,"DA]VY,\TW2\3SV,:/9U'-E'+#WA1"
MW#%[#L^<[]*R:])["1(UCN?,B\/Z,-VWE]/P!P>&D0?^KO.&\:P[UV2W8'7H
M5\'RD E.33T '<)N9T_PLV;'(X=EIG13O 1IB;6H)_W <\[3Q-O_F0_PL+0(
M&IVX-]4!\$GZ&0_B-$<*/ .@5[70&<]*"S4)PX53:NN*OJ]&\#A5WIWR7.GM
MW(MYCEHCYW')*"9#D;-*(*P$9 Y'#K=H27+?OVU?$$8F;Z$%38VA;9@: 'D,
M%448SSFZ:B>?"@\:E0&%EF;GX+3.ATE,_Q0ZV]T;-\M2OR:) D1"%UD+E3/#
MU0IC6WMF92;F]N2:L125?,4I\HB,6'=&^M76[AYGVJV*L'N:&0#K!QRPO=CG
MF(PP8[/)MG J&DD1*7QW>T7!#@G*-WQ?N/6CH@P+4:HKXXR,@C%^8\M"HLD0
M9&'2TE4[5$QO%".B\*NB8[?1TMSIN+P9CI0)6;V@2V3L+BG%\YTI#^,"\D5A
M"#C00E3NFE.1OT47HH/,Q^LA19@ 0:QC.<4&"/\4(?'IU3[*2M[O+Y6\2R7O
M(ZKD>5X(:?BEYF ]$9P-3#*9%N]JYUW/X*?#VKFO?/"1MI1(N*8T%./^XCDS
MG:T:A!S2J'.UBH4<<HB+3<F"($K#EUB^,$W7+? 4>-)PY+> :A#_<X09B :"
M@>:<% @NS>@AC_:6L! '$8U#0NJSH@TJ1R\^Q\9Q830A+Q(SBZ,JZ:0;,I*N
M.SUEI Q3A#;/RD,*WJ2(\.<'TF_)@['G)?%\TYL&Q?-OGULO%9BONXYC\3?%
ML?=IH,=/GFB')W\@*?R*6Z"(Z:@:+:A"""[$/A6;O1XQ961R#(_#'/8YT9G@
M'/N.DI+\$$_^0+FH)Y]E,\NM#QXX;VIU4_,518=/P]%,5<1@#A\QR!N_??*,
MQ3[&'Z$LB7Z 'UV(^#8EUKTD?N"%=GO-K6A#;![SR:2'<VJX^6J!5B4V&)'\
M4KE#YWYOV!XX_EK^E?XU :E?A9??(A:^^_DS*'';A13,$TLTKL3G&=(.A4BT
M<1%6!5RB?/#,.SG!)(V Z('[2A)<YI34@@A0R8Y4J,!"_5HQEG+O?;YEX'[Z
M;4ZTM6&1K1**.]JC]*S=@JBAUQT9YR_748MT4*/3:RI..]>V?LXM$\>$IO)L
MG&+O?/PQ\P91]91V(3X@.\*]D(!<11+=1RB4T6ZN25PR/,=U(Y$?/: F,J(R
M0;PISR2L^6Y^A!A2%^R.9#N6);(9CI\ZIPI<&Y'JAO\Z4EAY1F^[4?$.;<IX
MN HNA,([X9Z)&VAC@="<"4,90FTB+2G&V4H26LGU.?9.-U,2^A-&3QN2;]C^
M-.!O&VHF N4"P0@0&&D+*4F0= <D2UZ6$[=O,I20E5]HZ)T)U^"9(=AR/5FP
M,\;Y:N6(L/(0QY^H4_Y&<OKM+?'_U5M:FA1$8N^E7*HA#&QC=6GQF_2 J5>1
M:H%$8*;;HF12LW$S.R]3UQ6O<&.^]T82NN-G3;A3&R?I!":"AGKWA-I*.3!U
M& D1$#L']";6A5;6:5N%>Q-4@_B:.S',)'A0*!U#+LRO&PU:'YCT/$&DI<,.
M?HJ>TDZBWN/)9##*6V@WI0,P;6!QSIXAHU&0\,A<&RVG'S8UL,R0%DD/SPRH
M:&(CITUA1MC;>1\AL9(M57L DXTGDY-/"('M?'#=RW_U&H$P)B(E2MQCL N^
MC=MHAE$7,?]>FQ\9&=T-+:)>Q];DR3\7,<GBHR>='"V/3V>\OFG[T4/6N3F3
M>59);9DAR<NC.1VTJ5K960&T&-@XQC)4##PIVJP\[;T4R9SUT4RED4AK)BD3
MOFQ9_-GL4PJ$;'QT3-A'7)-Z,^J'>P!QK@7^L271K0?L,VMC&2%IZ I;'"]8
MQT#)=\T(9UKDKX]_##^LFZU,U$3C;2Y_2)D/.DSH*&,\T5+M?<>4X6Q(*%EP
MB$$N<'2N@)&QE10%9;HQT\,?F_#?MX[>#.CA$]UP7^05U=\HF]#^LL[<+YW@
M?HE(7ELOJ%BL/WOISSC&2M7'E"C!>*)(BYUP(XJP>I91KGO;!/^87;LH+;@K
M"MLJL3TN"=% U<%G5K(BU&Q;M]6H4=4]J2.F87\5!<H29D;8.XBB<OP6O;#L
M.TC?;YB _W[O)<<819/7;I1& V!QT?@U\E4]4#;#:*9'$Y(3/<G\1#CVNQM)
M>&T5O3H7V$>0:]H"!:1CV"A85$6-9P-4M:X'LH%,+U3/>.U,!%U(I'?,2_..
MWVML@*1 IJW<%0@(7=QWM?IQCTBD!M*?*EYP;!W+.;55.EHO'$C*B21BC7H*
MZ&&E \8B'])]2#2L"%D'A0)X^1N[?@Z ""8EW$"!*VAXX"9]^);)2DU0J$,E
MU7@!_L2ZQPJZF93(F5OQXV>7>%L/+MQF'4:YJ=4CJO)CY/V-2(;ITG 2SW3H
MLM2"X=54.732$><0(/T(Z?6/] 4DZ>OP,_'!EQXZ/_O(*Z5F<RN!Y4,X38U
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M\MLE(A[N[K-6Z[@22I[.:5K#3R;%8SS:DKV( 6E<WLX1T<,4&F'#5I[0R0W
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ML<"NJ_(#SFZ]])IZD8J$5Z,('M"_!?'$QWOXP+X\2N$NT1G-0K2;5_V>BF0
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M,">AQL'H16[X(OP0'6_N"'KO S]+47@7F<_+VGO_M3?*C'8%,\Z4F]B5K.T
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M_+=B=1G<P,]V4_AWPYGL6IM0I<:H82V8.BE))I( !B">B0BY,>#&9U.$$4?
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M;JX)3"E, )42N<UJ)SNZK_G*:4RZ9,+[*NY'+R!]@J9S6):QQQK##B^%/,K
M&YJ[5&P]5\W"( ^QX+- BWJ6]11A*GF.2VZB^&7F>=@A36,H)%0&3W(;%AR!
M7DM!DN,RKA[QKE$'7,2,:0'33YN[*7Z[E$#H3]=5LT;LTA,VG_Y0-:='I'FU
M]3[4R']2I[!X5QR.4M-0+P7:$:5^,GRK/ P'4=%"^JR5?]=VF?[V6 B=)4?
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M ,8AI55F8:6HMQ(Z$IU'Z3VG.<>ALJ>$:6NN/0!SW-TH7I_69.]<' #.X^N
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M&B+4/#9>5R \>7Q>52UKF%T&GE.T3!PPX$4F6_MA"+$TFB!BK-4W.4S8!YS
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M^472_(F0L.% /-)ABQHNV._*MT4E\%F"&\:,/=*$RF70%84 DNBTI6<M.SS
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M5-EKG\JJ F\)<4WV7E7$QHGC:XP=)_E""6D Q4(BDC FO_YT]\Q((RZ^)-B
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M$VZ="8W<*T:H'BA)+5%^-\*V70]8%,X<"UR6$B.(N]@4=''9ZRI='DP8)R6
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M2^DY01D5J19[V C*I?R ,T(8:<M$"Y%\S0&I592AN9[N^!P\9Z2I> R"FV+
M/565$CV;>6M!4< ,F@6<23"4+F;S$$2BK(+=MGA/+8_WY/&>]<9[5BT=SQF2
M/1C='E<%T9.?U'O-&3[K=^=OYBI><J>/<#<*;!<4F:+SS"E"PPIQN0EFQ*D/
M]IPW%2:$;.^.>3,>06"(&I-,(SY1H\Y!UT&!:!0:]7*A7#450R(+J)9M/<UN
ML1DN=UOVQGA2\:1%LETG0%_"0.$)!P).$K5"J:3P)NA&P=1+!;-DJ(4<RT:
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M*F9:(/$ZX$DA@M Y(S2:"W##;1%$&W:^FUC>-0$QX*NYR$R& R(EP"XC4VT
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MV1O-G+"4<!&RY*(H!L6916DV$B[S?Y!$_D-DEI-\3O*<Y#E^EW),I1Z0-$U
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M2) U=HN(H?*L=B,$;;,Y&:JXK@+VCKI+#D=>,&5,_) (7,11+6B3@0LD.6%
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M-KOR#9F<I?).N9)^)QM59\Q2N*:RF-_H*W1(^?&;HKALQM #J3GRK.D;U_>
MP(M=+["OR305R$_*L\6#R*LP#Q6$D#.-:JTA(6=&(L="I \1MS)?GK5<8XRD
MLJK2D\/@/@^W=(R*B\>#.^CJ)Y6%YXR2]HB9 );-?;R4.PIS$4:D4F?P=MT;
M5MV2#;N+M6F?L@L>,DWJ_2C>I!K(DV(P+RY^$$_?S[WT;BKD&@E?*,_,=>-$
MS>-I9U0.1YKM@H=:8V#^4(!<$'DHYPVG'B$)W^+'YR::%T@SZ7$ = !*JPS2
M)-91+'+E82_&OMP?R@$!&XGS<4&C2&JH\K8\300J I&'K<0LET6/EA15S'L
MDUU !265^&M0BRZ7: 9$L'?;'H\S=1]LE4Q8FMU)N7<9U\]2*^7!>IG&,3AD
M@#>TAFP2A-=I.8$[K\V2PEMZBU_WR=;5]I/[1%J12/G=#88@EV)&9U ;]<N
M0H.G8=_R5=F %V/*@S.QIOPNRJK%M[\NZ8:9ON%O:>W0D-UHSM91Q,P"J^7A
M"X,EL(KMDK&_$A"R34AZ<$FJ#WC.(>5WR-J4AT\6BU,P2BPD!TD DA<:[D3*
MONA0_,[L],CWIS,DF25'.)MZ8ZKGEVZGF6(:TEPQJ4*(%6%(XGBZ<-H-T<1(
MK(UN.FD%I"8MC1/>.V%G.@SC3Z)4=P3*<7(V$1-+I902,1.=E.KW,,_<I02=
M3;9 F\!842QR%(3IR3GIG/41@P?=7F<\-52)M>V[X7!]T>,'%/@Y 0P B5%F
M=H'8LY2YALE<.<)$,E>1!JND-/9@KK)PG5*CV5 @"DCK-I5523(K6CW"4[TX
MTQF3CH6#>CM#A-4\1)B'"-=;J;1J8:AD'VR\\^T"SVK2+_Q Q3=[E'IRKY.Y
M-^]D[MWC9.9:DKT4<,[&T4B)^0!)3L]#O[JT$)+L-1%I([^C,&6FH+M<,U[D
M,7=]X7&KDTV[:1AETV:5CF.5G$[9L:J=>M=P.@V]7G$LI]PME^SY8/:[4W3'
M':1QO4[#,$N-^@;$L=_M:#0X31G=VA314Q_SX>V!5JJ12FSR'%CFN9Q6)B$:
M #X>Z%CJ!IO[D1%Z#@SIZ&B7R"#YII $12ETP,O]TCC6Z8CY,ON^;8&8:\H,
M(XTG?#7'?2QNPV0NU,Z3:&Z;$-N2JPL$R0=\T67QA#'$UJ*/RCAF-7^+WH ,
MBQ%/TC)]++&(0XL,/0=.O!0GQA&5=6(9I@5NX,CI *?LH7*I-3U/ZFP<9V-,
M1N-<9?R".? ZH6ZZ2-PM)&VIF5<5A'>9ABV\LFCAB=)%JGEBMR,L. 2>B\9@
M^MXHZX_(%U'&)EPP(LHV1?4>=3=%Q:?2,.5)L(F6-YN63PY&Y2(QC[E7G*%B
M3C>D%U-0-AI8H9+GG0'G^4O? ?7%0,-=Y"V/L(@2[RAP2HL0BBR;H+C@Y1)T
MR Y&TR4C)+'.\QVM2&84:L9.4O+#=7/AI$M3"V753KMH:J_W,2/@)-C13-,L
MEJK5>MW\6SPTL5_:K5U*HLM2?$;P=2N5>MVJFQV[:F&V;*W2:92J1J>JLXIC
M.V;-<18(OMTTE^1<>I1@:""D_(]P(D2.:V^ #-S=47->DH%J8J2:'*J"DG,F
M;-L#G\J.UXJE<A(DY8%)P9S8M7J%6=TN;%/#[I8Z9:M;A5UKV!VCVK-[3K>L
M5TTKLVMGS?.+@X.#CFE6&XW&T^[-4CMCP1QQ7!+JY4"9(>ZBH>])]V]+.L5.
MN<\+L\=VL4!F_50&AH2VEP;LDI%J<J@<CB2IYGF/^@C%7-::G[TP&4GJ;.KL
MDC-$K3*D=#)4+%V:ZED8W$X50:5F=*?"*%O!E&B5J2>/CF*0686D3GXDC@=\
M'^H-4IL\9BR64&\HOA$E4BZU2P61<KT=#15I&'*7 E7H +.SO&18C5K#Z-8[
M)> JD("LU.G6&JQC5.J57J]>J;">,R<!#2/9Z%T%FKACU*OEV@80I;&C4*(Z
MPJT@.F-U1 <GX',24[?>:UB]:J]C.J;=*3<,J],PF0G2V2JSNE-FW6IMGIA*
M@C>FIQ,?WCQP1T%OE\=JWU%&ENUN $V5=B0/3[5DH.1%$&%E.5984_X[+>%Q
M-J1W+O0Y9:GA$DR66]])^QC:+&TM;39J>JU1Z94Z>JT&@J[;JW2L<J77Z96Z
M9:NL@])0,N9ITQ2[>ZZD!.+Q*_;Q(K0VH+3$,'<2*LP,-$-R%TJLO" *4/C!
M#?J>PZBP:%O.97-[R=#4[;K!] Y08;E3-LHZ4&:IVV&F52[5ZK5RJ;S@O"V?
MR0AH&J;89XR*] 30S0:089F,3Q&I5>,I3&@]<JSK<\60BTP2>[PL'@*;>GAV
M_%X[.CHK@/GJ Z>P?J BLFNOSW:;I^_ N'1<XJ"]-]I_W=LW?N"?C(<P4)O<
M%3"V<W16[XU#H2'!_Z,5VKD(.D:I8XI/O?V!=_:]6SO1#UOU^O"[/QA^_-)\
MI?G6$),EF/M&O A#4P?.*Z*,$RL,.^;127!P_N7HR^6P&7[[=%G\=/'E_>35
M/T:]\M__9 ;TS]];P=KE[6/MK8MNU?+H5A[=^LT"N&ZU4>]6C6ZG5*OHG7+9
MJ7>ZA@U'&K.J7;U:[U4KYKP3YG.G5#:K3QTC^$4?S.=9%TQ%UCO/U\?+0N<-
M.'8K.TE==N'NHNSUH$[=G_@WE^?'2;#.;^^N.IRZ@'UH"B :0:!W_Q$<@Z&'
MIX8]?N Q*I;B8= "P/M-%@8$G(:!5&O$QK%K8\D@D;EO[V#F?)]1O",Y+D72
M"'[)>'@AU8$L/Z,VW9M14J HAWJ TS%O\4,W7!8-[<)S?2J?P" ('"O\M_WB
MNG#]MXAT2RKI[L_3A19)*; ^^D6.2H;!<V.[&%P,* 722;+7XF7Z(M?SL D)
M@B(/.+$B6@]/ATKC!2)T'@V"B2^#<0_@G)!C[_/GQD%.=?=1G:E2G3R%UD=?
MFN=R<!\F@4J0"!)R$3F\8IQ2'"(Z2@()Y4T)MI<E14-8&&7Q_,Q$($EHD_OD
MV:\X"!Q+KU1LL EMW;([95UW.MV26>N8I1*KE<IZI6>6YAT$57RSH1^V.8YA
MIU:N@5ZV <I)=6=V4<00UVF+2B!<*F@5D*@H/PC,C6=42D!(]VD22'Y5&BQ0
M^1_;:UL*%#_PV5N2*<+D>?12SH_L%Y8#'_70=NK;9F?7<SL[M[-_T\YV$/JJ
M43<[Y9()=G;=-#KUDL$ZE4;=J35Z7:MBZ>NSIO'0;9V??FY>M+2+#ZWSYEGK
M\N)@MRUMC9/=)Y6:CS'T#T[V6E^TBU-M]_2D?7ITL =CWM/V#TZ:)[L'S2.M
M?0%?'+=.+MHTXICV5W(JL15RJ6>-(O9&_J$.$ E;$#5NK\W)(E-59XWC0'[!
M68B^R7":KM39A8E<SK)'',J!B1<:G*IC1WY/;=YLRQ.+P\6B>$K#W*F!J% V
M4;Q/;*A*L\KS,7,#>[%($2T_%[$.[PV72Q-8IWOE@5)RF%QJ=4$U'\=L9J**
MZ/SO?V+GH3.L[I2J6SK!_\0A[N\C]S(]2=[\R[89Z_7NF/UJ>%'5'(R=4BTK
M%%(!>]XZ.SV_.-U']CMKP3\G%^>M]P?MB]9Y:^_L\MW1P6YS=_?T\M>D<%K5
M<Z#X)QY0W9/(:NVUC.'@#Q3(,>J5O[D(?RS);<(^*#*1Y$=V8_:+I71JOT9L
MFT)9[YI'(+I;[0^MUD4;<]5+M5\CHEW5,?#.\J@,KCU@;,&AOCHAM*;M-W]W
M^S>!QI=0Q.[I\=EYZT/KI'WPN75TVFYWRD:U5ET!5;0S[M73%,F7IS<.1R$;
M()[Z#=..@NCWR683%OD^2BJ_%$'2!B/@\,/IT5[KO-WZ='EP\;53-_2:8:R<
M<,[37KR[2B_>LZ07+P6A>:Z$$HX6^$E:Z\<8T\]>[U&B6?SWRY-.E9<LG9KM
M#_M'IU?M3KU<;M16<5AEJ6L7,>;WL0?1'R%_JB]%_IR<7K10!BEV:6*6IE9I
MYQ<)YH1'- (M0SF+D-1?GCBIS9#(?\BJ7[U_:=89^EB?[-.YOQ>Z:?F]HUD0
M( *7>=:A__8*;IE+>+]HY"[AW"7\FRYAO6?V;,.J='K5AHV]QIR.9>G5CFWH
M7=-Q3*=4RH8('^&#64N\D(]/.]W7E!%JZ1 U/D:-!GER<7#R7ML_.#]^*D%T
M(8I;9Q-"WTF(RJ3B[4E&,(=B<T\RSYLG1>"Y(YEZY/I4B.P+)*M[U8NUX:MS
M&#;T\PG@8LQ7HABP: Z;CKPK_#\1^7^6)U-IN/2\B].X&[F.B]'BUW$:79Y%
M)-8RK7RP<4]!HI+2BS.CR*9S!5E_@YWQ-W@!MA\*4\O25BS+46)91HEE&2VP
M+)FP+!UA6?("$6I:Q?NOB_['&N]4%&/'3P$'+^%2Y3QX!LUK#)%P? !/%/??
MFW_S-T+@4HIVP$GK@??A+"-J%4^0G-3XWO*\%'5/)(!'_'GI(U3\/F7G'K!Q
MZ:23]DZ8;3*S4?C5@]:08W1AI@'N0@HYJ;2T BML%,^VHZ1BBQ6G=#U&!+RC
MWFDX+R$,UIC5\:#61E;(Y+YQ+.<$#5C9_P2N.@7*XSCK,W>Y9%8)4 C,D0PR
M$O%! TK !0D_$B54E*!$6,OJ4Y3\RR1]4P0Z) DK 8]3ZG0(Q[ XP%Y?^F[B
M/(C^%J4L'#::8ZAFLNW4Q,_9<@J5:18@G.+/1,<]D$XA3CRM@O:L292PD9*X
M1WT51'^&_MC+ B#>7T6=/)(FM;:*ERL5E#+=VF6+E'9U%A/EHX<3)]OS66Q-
M@@$S\BP^8Y [*#WX8N*KJ-BE2R6!"Z%0+>K3.ADP 7KR4.;I"<# 1+:JZ(>%
MY($"40Z.'NS(CCW1852\I7)"+SQG4Z4V/*81JB3DD",P0>;W@0,=@>"+4Z1D
M9#[%!-GQP0CKS8B@21.\5MH4WO1]AO#%VL&["%^&MD 4"CT".126&.<H!;\
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MU.1^001,?XY^VE;MTY=6<=0^.!R8N[4QFF4FU^M !%2?L.'=UHH 4O7^$UM
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M8-G0,\W]65(;=*<.V<]BPJK3[AC^N,.#22!BD1/XO.3"YLNUNEU?<A28+6N
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M)KZ3[ VMR[U^;BZT*L)VL<EVNH/Z((^R:=H;NG1NJYL-6[V3&-74SBQ?<#7
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MU=N7?^8YP)[E.<#.%DRQ[8)BW9-5&ZGSLUF/)&<EL?/Y#<XBF'H](/N.YFG
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M"_3A!)3^">AX5@PX :4%V)+-#$>$AXXXTY?QT8ZN]5 [53L_,#403 UTEM1
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M.HT-5V\(C5U]!OA&,P)K=/T7]L!0YTE4?X]@O;+-H-/N]ER[6,4J41*%.&=
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M57.1:+I"/#>^%#7G%N4YKE2:#:Z'.N*PBSCM32X0L?W%%1CUP!#)3(^0-:
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MR756[X]6Q"B71;)SH3<9B$,$42_D;_^:1HN:N[1=R2B'([<,_R+\.6J$9OE
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M>.&-,E!6?*/Q5ZPLMGTG7&VXX?/L690(/%QP>-MX"S(Z,K&,MBS/ZD)=37=
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M4,+K2/QY*Q=.] 05WC.OP"25@P*4[U#T3#$IP$EPJ-L]LX-\QXA%\%*=0)F
M(V&D6@_J?#@S:0/@W@6#B$H'>PY05 K:D"@$KH,I#H)%H*RRPV'$+(?&L_O)
M B<#HF M";<[4!0U2QE#^*,<(0I=+YTD ]CA',WP7#RB8MH>A>/KZ"&(N35V
MHE\V%1X\#&]A#]B9\),BRC6< D7 R&.VH@YW;GB10J")/\>:PK.10^=N18CZ
M$QUAQ1*Y%N#' HFL3P3)HSEZXFB$N$[?QM-][^K9;.+HY3P<9RP\R[H0U4'[
M0 (;N!V[J%;904!#:PA];C@ZI7 6\OC;HC95<<*"#63"*=!OAWMW^ITUUD )
MF5#(]++OA:-F";8E=ALM"\7-.75\$CY_SGL2-[DXI);9HE]5Z.::>^1[,7D:
M*E_75K[&7T3YRCFA=?R#A^""IX7EGLT"<)RP]GO@*(MI+"'+:RU("BG/F0%1
MMADIUAPB4.BK8&>+!CLIP*D&0$8JRLJ"-T@_3I00[:Q? ]MEMLA4<(K<2?(!
M<D$CH2;!XV 19")/[XYH2SHXSA^ W%M!^6-N'H&C6+G6-.2"(^ [^0W\NF>2
M>)[C36E1?RJSPU62%LRGLIR<E?M5X4Q3F?/CGHF AISLPIP,?!%.UCVD 7GR
MRX+!QFA/?NKY;"7,6 R3&&!V@Q*2<&6X,:*(CSEACH4MR)Z.S9,=!14OI":*
M"M2TI(ED._D<1HA]M2C?WS.MG0"Z!@Z3DD@ ;(JT<9PYCBK23WF6/^73N^0A
MF_;,TH=S'^WBD.]E*Y3:&;W9CGM1Q@R@(2,@"D@%M=/;2)TEYM!P[#%[/CDP
M&GN0#TA_1O,@ ]W>Q'/9K:*@XSH<LJ1W5M.K11/G(C)7#6A3N7FU4VCJV*JR
MG1B+3"N#^!:PTW0)Y1+I5P)EE86[FP"G* W]60<SU*\$H@O-0/:&T@EQ(Y=C
M@L'-8ASO(W8F+I!!O7>]&*YX@;,N)&MA@P8:%< 9<JB5P[X((L7NJ"[R7!]-
M=_Q-Z?@E06R/0:3C_CL+<-8D\AA"1^:M(Y9])^\\"U3DZ<5%+<C'[L$0-G[1
MW</>W?,9>9\]0R\=9NB%&7H7SM![.4?M'1EM[/-KO*@%WL;BL S'SX+".2CW
M#VX6@AUG >*]+X YT\8VLT<12,+N"+>V>=U?MO_E[P@N47Z1];V-\[F,ZV/3
M(G/(K:?:K78ZDB'GH)253/23J_,_2=-,JKD5&)F=)I;URB.0K$[HC[BZ%C_Y
M(EK\$8UA3H=IC$)$%@Q=WLL@W"ZK\%8;D+1MCREQ/2XUQ**)1]FP1G,G).$I
M-A!/3RN2T^KPM!'7)ECJ$MP#<FB@$8(QB[RG$.)8>W7*T(SW3T2<&FNX$\TR
ML'+M;'=E":A3-U3.5=G;0V%R!![)M A7.Y=Q9VN48X#%DH&C"2.L)X*MB%PC
M\.@3,+:3]^!T%BXNDQ:2^<:J$J22HN0'R(TU@T3CC4-&MQ?RU)B4[9""#N<(
MCKQT8U]DJYJ^\YW.<3VC ()[(AQC <K8;SC9NT)URI <QM@E?5!DW0E.2^-N
MXYWV2J,*%G OIRZG&['I=M-Y7-'197-<&4PJL4P[S ZXND"8?AF!X%5_:O!:
M!$\,Y'PJFL.[#1(N-<F'B#/Z? '(]^M>]A>])2>LW*[&,,YHB"2X15K1$7\"
M=C2@!@EGP_7O-;UOPGJ*@J0_(-]*G43B#Z[GYWA/_VDUB!4YFNY;O?OF)!-_
MR"E@$_*>:_.>V1?A/8CB*$QRE(?F LB >B05P F23RUXKY&R, 83E#CB\4MZ
M.A, W$F:\"E<&*O#Z[;1=!F["DFZ"YKMQ*D)-14!!<L\64-H/!"@RK,0YLC+
MB-RW1UE#R&MJ@BG2E>PTFO&)NQ3R/B"1$F)/V@.<#+*4Z.$#G+EY1Q4/7Y0,
M^Y3$T8WT1<DD_1=1=HB=,NGF2^"\(:(;;G#VQPAG$>#N/5@EQ%DGJGT&N/Y2
MD/ ?< 7&!._O<"J</T!JN)6C(@TXK;E!R:!V?!%Q7IQ)A+DX9^#,WZ.L"]S7
MFXRV$S06!Y(C&X9JN;UCCQ.3C-54?U+8F:7M,]N>;@0DTI[B<%SW;'B7 @$X
M1K#C6,=M$;'W][!@Q$E&\5'@,;7A*$+4E)!M<#CZ#/Z.$E=VKN6$>CE"97M/
MW.QPKTL+N='M?.CSI(EVJ:">$C]OU@>@AI)N*.8GU1S!Z=98K-A[MR$&327<
M? 33IT$>B,<M,9P4I1OOG?U)5?"&([8)9P=_P&L;/^21:8>SVS?Z?(+;K8\:
M^PDM4,V'*&_FD(ZO);P-)O*Z(E[D7"J2GTX&VGF;)RF+B.F8V,BW4[%(4X'-
MT46]'0QPU$C0=?PDF"</$Z>Y2N-#/N;!FC^.SD7<5 K(878(@A&2C0;\2:;'
MWS_Z*T[($@R-]&(X9&H1+54ZXA,>L]SCH5#=%RV<'A=D6S?(C6@1X!5LV''J
MN(E.GB,'YS#<GM-5]\,\VRVVAMD^**?XFCB3*J80.DZOKJM*7T17M6F/*G@O
M+B8_RJ8_BA!@\+17SN[FA+>-#W'4S-DIT4&<&@L?>!@2X'=20''8!9=G'3,O
MVZGHYVDZ<'XY31PE)47X3W8,&[>QNJ,JD]._X8"ZLRO(2M9$-UI8BHF*C9UT
MT@AJ+ 6'NPL>)WEA;N:<; 2F$HFDH]F\^[*M=F<U%P1_$<W,1,V0W+\Z2;"3
M,S ;NXFPR.UHJ\Y_W\:B;]EMSU K.1-R2Y1^N'PIHRR9'K7I\7V*[;-/+6E8
MS@^ZN=3&'X$\/R[,*/L8ECK_,BS5[LJ'G_AP:#,"]Q7 "N.CS8+#9HF.ZDDO
MPRGZ,]08U'[>R0Y:32Q=E; J1:I)MNAG4G)"R@H\DR*7H&7B-%CL(,3!+VSX
M1B&(X:Q3'<5L$)?!KD5L[>,D)9SFZDUL&B,3'3W.@$,K^M'?O/E%=U3>.Q)G
M&WG3CR04T5)$^YN>R#UDC;A8 ;6L<>+U+G=U%$YL$T\LY?#,%39H;4W7UO-1
M9S,[1_<-%=JCK+!?"ZO$HM^,Y5/IC1@#VK!]BPIM;'4?UV<CV?J&,Y2%:*56
MFSX,^Q:(JJGRMA<KLS<YPT1R6J[A?HTGU>94[2Q1DR0_0B7 @W4=+.Q.G(HT
M<0O82.W*!.=BGY^-Q!-))VV'/!#A+15!=+J4VQ+WF79OOIR-3Y=>E@G3R\+T
MLH]++V/?E5X6>WZ-%U7"6V1351;0*-'Q0SQZ7C(@O 2E.:EIZK2&G-$O>POZ
M.7IJ5:?E06&7SE:T<K,HIONAM^#JJJW\153; _&AZXZ(+JK@$$A0?01'_DJW
M3E4Y;-S1U0[UL<MG-.*CLE,D[J4#,#8SH*)&'!1J?VWBX#QYV8_4[DLZ5$Y1
MMQCB Q^C-%!PR#0B"@%*74*V-8DLX0)T"#94UNI="8?I<7=8MX05+4XT#,TD
M;X@>U%.[1!7*53L?'XP];;0C=C=LI\D(+M1V_0S6X8&S0V@.>:/Q(5'Y\!CS
M'[O)-H(/5M.Q[Q]G$1P[BM'#6\XY(LC+(*@H=.,$I] :AN$JX6<W[.D8C!Y+
M6NKH%:]#B3U*]G+]OBCK@30@?J'+-DJN$@S2@.5:+Y*\D]T?6F?3[WE1PB,7
M3J5!&2CCHJ;WC?,/J8W+BK#=JZEEH=O7:Q.F$%-& G?V*0D2CSHA1V <O&GV
M.Y=VKLEMW$,U1$8 J_;/"D)S/#$&XN)![;/Q..@DU=ZH'0K"ZPM"Y8L(0D)=
MP9-WW*&3&$H*Q7?4*0H6B(%ZW#[.E2.&OPF#&ZBTLR%.^IN[76;(%Y?"SM/Y
MX5RG!Z<E9J?9MS\ZO+%^9B4\!6Y'3RKU2%MZA4@4+) \35_('E!DCV2['1\&
M9_%Z4TA,TIH'KW50"X[.<;#[O7-SQMD>/G@(_--NB:ZPLJ/&&A;F3B-Y 0MQ
MU//91'WE3I!@D< +4D)(X@:4K9"IZ-H&'0]7^+GY&B2QX=!$Y5",:!^+[-9'
M 00L+NA/ 8*\;(['RJ[ <Y(HR$/+WK22(\_' <:D-0893L+U[H,%]JL>Q^+!
MS@NR%R.S23BS'7G3[@Z;-8Y#-JA2YJ2QB'?HN7XBKT[@&1LYA*QQFR#5^?5<
M"<YQ8>DMDQ,<&B5)\$YO T^+/=Q;:(P;YN L(">,1 " M4@2<G(CZSO*;NKC
MSXK'+8+<=W#QGS7[Z97F"6@]L2^/UHI(]\3+2I*&SEZ[T]QW8/?(07<,>\_L
M0ECR'1MO4?<JN,FLI._381_G* 6.\9 3TO0]:0/V12?O 6-HH\O@?]K!;LUP
M@VP"SRNH+:?Y(7E2]QE=R&IK@K(:;U<RJ- #FAO(W$!JA[K0M76AQ1?1A3P$
M1[D41QI2!D]!ZIWH/M"6>K%?J"_=U(G DV?;[7=J28FFYP/[^5>JO[2_@IO#
MX3ZHN!K+9JNVN^"0!&>9*%GRN3:!IJXI1_W5*/20-,Z<0KT*B$* YXQ0* Z!
M(FV'O/UGSXB>_"3]$-#+U"3'C.1N0L,;\U[X!4T'+W=6E8Y:.3@G097TZ,_V
M=IS7T5$" =*%;.B<M&<0#!<R4 F<@H.6YSGGTM-9ULE+@'(9->-#W-D6UL]
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M/G 0S*T^(8TFC]47)UG&?>@/?]WQ-!B'3 Z<PX<@;6XTR+/ $H48<"_>#5)
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MI>DY\D^7F*?J2)XS_9QP#_KQ7N7)>$+D[ZS^_B3$%](*7S25/\#5*\[ V%)
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M-2IE^RQX#16R:])#7]6>H8A0(PO<5;@-BV/O$M?532Y,TGD@XOZA!!HQ)N*
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M* (PF=SHZ$F\1%U3P8Y:X&)%:@)W=3F#(C GO:V-$3 P7.0Y<&)(W.!DK[X
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M\@DQ :*#4+$8/B\J%:,\M6(4%!84>=,+I0-1E9-"B _ @F^/;M,7VW5&+8@
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MO,/PLW/Y$6N6R^]3$0U#B&?QH1QOS=FI,N/[\<6V/<AJ[*\_A*L&&R :.TY
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M!_<ZW!T%0WS?=RP@"E/^MD[X=@QK5TE^*][%9007>(_0WI<)WHK@PBU */
M"9R X_<WI/-=B7.FI<Q07;"+<"-1,<)CA-!1OA-/Z_C?\[5_N-TCQ5U[A%O!
M^*\)]VR.]0U+6M)-*Y3R1YRR&Q:R+"K:S<1M0RE_4<JJ;IH@%//''.X;EO-2
M5&T0NN#G=L&/&">N3>*;THVY;L"=5V0(!E;$W+.VA"3H=]AOC7C6;XTX6[^U
MO1:=Y.N>,)VUV&1+/-=<E>5N&8S&..]SD[6\OEJNJMGXB(_'"D"F!7U1KM9_
M_2&>FJS]H!YK5R,#OO*XSTC_>U6SORYS&'$F')#4!E4<;(8:KU3Y!:>5[&I&
M"F!/M!5/E\OQT9J8QJ>-3K<E&YU&3Q9B+FWP TW><4^TJQ&,W@%2O-IZ*$!(
M@<1'D.?)C WU-=37&R2]#>ARYA=U+K6=R5*ZK]:G<9W2UI0AMS2:A:N9T__J
MN%'Z_;2_NAJ9[AU@P^N=K0*TF(4X\3G:W8Q8MS8Q,X-/.^DEKW?&F55*6"$H
MH%S/EO"I715^'54Z6TC0YR#@A2-^LQDPD#9'YN(<&+<0Q_<]JA>&\)[4HH:T
MPOOVS"(7B:Q>5'",75:J&->=]K65OZ$[3M],1KUUIX^+BVJBMZYFN$F%O5;H
M[NX]EHL7^YW-="]3J'B3_L@I6\ZE!CA>5Z0Q7QWG:I,6(&6Z(P<P_(8W3<P2
MVB+>*4^[7<52)7O*"G$4?J/IAR@9-O/QBXXOR-;^'H-=:.U^6KM?7;N*3'G;
M'(S9(4=FVNG1D-RVJF-D[,RO/V%SOM#.PQ!D@(W[O=!C*E]/ZIP96_,SJ3+(
MK)8-JQJM0^-&H<=CZPY[=@6WQOM\^^W+%&N'Z_C9HX==,5U=F@)>X['!AF7Z
MV*H9)U?(FBD_'?,;RQZ\\WQ!_K'Y&&G!!<"TC4T$#E2]GRRI,%/0_S CW]PI
MS]$Y":UM@=%>\^/IIC&@%XETRUA/6']CC6M,2ZC=+FEP*4;M%8L+%D+WZM<?
M\BG6:(9Y@M?($[QB[KSO(<L #O<&_:4WH$1IQPFA/8A:_&(;SVXSG5F)S@<P
MTW TT.W>6JGP4ZQDEW/L,-8T\95 HU G&7L@&%^ZH/Y@K#F=[W1MX_,SD!+
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MA<8>YA&&9GZ#9GZ1F&! ;/N]@!Z'B[*T(/0D7XQ'T^G*?#X<MY%MHX!>W,^
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M"KC@X<.U+<@W:J!K#^Q'N01?C>S'J-*(;C<)&B]VE]'\D)BQ:Q;M\5%DG_H
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M&]]4HT-,^<P4A<[7?:.H/VEPUU;Y2\G]^CAYS=63\;=%T7<=IZ?,]-!=.H_
M+]N;]9++7 @"7]6)N+\MO$(0")K ?=XS?5?@+1UNE<XDZW G%+"=T%F4(_(:
M)H1[G2]QQ5T\FO9L1MQ3@^-_S[;+N>'08494C$A;5&UPOL7/7T#\FGC/M9FY
M85&C*EMP,V<&UQ/S4>'[34DY-.C/;4QN6-2A07]\.W+#8CZ[18=[EJ_L66Y8
M@TX!Q0?[8!YN8Z[-X)_2C;ENB!:(#,' BIA[PI&[:89R)D[KZXPD,'17Q(>9
M\/<:=9+^7E(;5'&P&6J\4N47G%:RJQDI*,WC3O#EU.SJ=K$64@Q7+3:K7-O6
MXUE!%F*("YO '^C8<6/<L_F'U[8<WUMGW1P.O-ID\KZYK7Z$\;_/G:7G5]'\
MMM'%>;"8$#ECEJ)(EH58@#I'^DF9>6W3N0IY+G']<9\',HC3K<("Y#J<M?]=
M !:N:Y$]WX6ZOM+.\5[5-0#PZG^[QAM4PU<:+ 9(#4.?Z^LLQ8E^1DY/Z<:0
MFY'Q36F\!')>6D%7"K$4^[>O"KLF?@U67NF:>'.P\GJ?PW #=R-@\OXVK;5>
MYN4AD^ Y;+'&J]RFUZ2W:)OF-"]\<Y_VA0#NA:.ULQDPD/@B<W&."I*"?T;E
MH[]S\7SXVW$)=GI20VKB66\N-<#QNB*-^>HX5YNT "G3'3D@X9<3AKRV9NT:
MQX\)7DE5"S5L+5-LG17B*/8:C3Z0N"^=E:^06GS>0.N=;[7?8US]:>OUS5GZ
M^RMX)I\' Y#HIZ;%$5[95FIM99E90<./_?J3N)?61.<T^C<)5^_$ZM\F,[WM
M(%2XX 1:]=YFJ[QMU;MAV/L!3>+?HR,,=SC7\WL^'.SD*!/?EH9;&=_HQ:$D
M3'/:1D/N# IV^K>1^5$IB=^);-XYAKS+&QCNF *!'._OBTP[,YL#<C'DBWJE
MKED;J3CH.$!"O[,QNL',5/ZQ^1AIP8DR;6,3@5:B^IJ3>L549-\CI $<[@VZ
M''QSIXU'YR)*.TX([4'4XA?;>':;Z<Q*=#XHB6TG@*21*+7U]'91Q.W*L,2N
M6MOBT*X+-(JLDK$'(N%C9/7:N.)[5NNU3>OJ6Y97<F2O/2^WXJ#<*LZ\[[_@
M=F%C:[%>CTMUFGR!Q8R9UD2P$T.]9^\X@?;,L=X &M?50>>5+-MKS\L/SL(-
M%]I+Q*4#."]A*J^/J;S7%N[5E?Z5Q.!KSTNXH?4_D"Z3G4D,2\>7O)@?ZPEC
MJ.>2;>0_HD"Z?_O6,&OXK%G#U[;48(3C S@QX0;Y,F%\MER;FU6Q3'&;)DZ/
M4Q5MT4P[,$:_MP_^.%?>JW[2M>GSKD:8%X4&-=1M*+_K0,T9B2BN/:X .3NC
M8JN[H+HTAF-COMEO"QT<EX,2$CM51,X)35FP!9-;K.5*34E94J[."@P*O<<3
M#T0L=B=)S=<JPKVV;?A%.G'M<5W;.PBTH;^_Z,?:1);J9G-IGEQD*IL^9:PJ
ME16T^QBT>S]CW_=O]$<-^N[#ZIV(]K7']5,RHL/5ZKP$$M<>UT])I[Z&WI)'
MW)_WH;C4C0'N77E<'PX"KS=,W>[$AAR>PIC"JMU0DLP2;:!0$-B_'5283?W1
MB.^U+<@WUHAK#^Q'[<"^&ES-1,U<CAD-A_PL.S.2Y&(SWT1E! _T>QLM)[CZ
M'PN]1'#6:O=U*_8,WE_R09,FMFDIH\WA,H/^(TBTWD2=]VZ-022ES^ [;9""
MF HT S.R&@-K# RH93M!152'$SDR%I<@8@#35J&8(B-#GT7$B&2 H6(YEZ".
MNKKSW1$4@FZ8CQ'TB.,;01VVGI[M^&GT/V9$W*D*!G4-,Z$"'/ 61T3XO5'D
MJ,UY!*HP&5D! T0DT3;A0P:;R$BU)<L6D2*8$46+P$F8 BNR1,3@$6@N\#,+
M?L.T(H@2Q;FWZ(T,/02]'( SHL\4*0*TI6+H&CJM<+ZJZ=9NT(9B3MTQ'DRC
MI-I#^!;66$371T15U5>B)@%D0(>S!1^[@L^U-0T.R31%8_/F$!\C>2NBF!$-
M*,X40W4098#>:C]_:%":@Q"6#F=.5>&[&N@[\(DS'4Z0JDR!NG$;8Z-A..]X
M((G(2H%?&B A+VS%0*/P;@0O,@%\P!+.&7JF&9D;"KPY_+L!9PH"[\:;. 4.
M4H<3.Q!-Q=&(P[^/$#V[(X7'@[9!$5E4H)S0Y'H3(QKH8=Y,0OF)3_#@:9@$
MW]@ 8P"U%BHE^MJC8U?7L",(7H8-#I4*2E!9(DU&L[^""@P% \>/)LC0;7D,
MI8BN\H;_-*W>3/SM3L._(YYX+/BRS@^*:=IP\)Z*#G0X8T,P$J':.E,-'P;6
M<R!9KN2\/R%SFXL;=/_'R#.L@DZ%A"EKS 6JWSGG?T*E+F-VC1OH_"8ZF$KT
M**4FF_4W_9;/SJ_[*[H1!$&XK*C/V@UZ'[TYL7LL=?X'_^ J!]+7L6Y8&/S"
M[)F^(EO[/W]74G)_DIG?/[BUF8-GAYQ-]'HM^'9/U^P..:/)>3.SC5()KIA,
M$7.P)9<=XGFM4NQLZ[ WMWEO:MD1_#^[PRIX3<I!*K085R"FV88!7W2_+,?=
M9;DB&H: 9[N)D6'A$E?MF$V\.2M7ZW;]UQ_\,7JT*$>@NJAHXI&M^RP-XIO2
ML!=:GBX(V&8*>&[95!BP$)/UH$N#G+3CV1Q05%S<S'%VW5RWENL5DL8Q0=:3
M--Y:6I&H=G^*>)_"?^%K(J2!Z*MN'O<NC>3&UT5W=W8!,#X)2^YW]V[:/O."
M_/B.Z0JO_O67%1WY"]0@AI,2( 522C "-8R/!"9*) 1&BI+T8"0-8_@0/O,_
MXNX;T*UN=V(;1JJQ%J=4MRDN4]"S<ZLN$.C8\OF56%U3V6$MV9K&#6K>;BQ9
M5<%9@3R^<B6J6FF>6>-XD\]@E,2/5T1O!:^,O;QR5(G:?*JJ<E.2F1DJT63R
MAEP7H@+^\DJ556/;>-$JX1LIEF\0JU$_EUS!*X^>KL6+W'8]MRU\(4<7:BDS
MS+0RZ)Y'3P?K8G:CCXDN5YS&!TMBO5VLQ;I '3]]52#98C^)Y? F:!#1*MDW
MA]VZ$#N^4N$4D=/548>W1Y4LK; ](561A?CQE=VB!4KY D[CV<&43LZ[Z5Z_
M4W=9L)Y?F9YLN=K<TGK\C.CK6#L[9CND1YOC7/EL+_$,$].VX=@B%*BW1+7T
MPP5KE!FKM<F KN!%CF%F$VT\*W39E]C5M.=SU?$U134IJ@B3FF, K+1B2M!5
ML2$6M. 3DZHN3;T-VT#0,=K :D9E@X-A+<JD!]-13&5=R(80 8:L]<9U KJ,
M^!4!$./F\%4L"(]GVW ?.AM.VY=3SIUKH7]3_W;Q,,F6V$J*BS1S'->*I*KE
M6K7"55K-,Z+%@5>DP)E6I.,7_:!CZKY[S0!S41E&..@3:HY;#:&\ZKC/*7<)
MB;#0S[3<^EN_E$A<6N!W4QJ#H:T"?>2]U.Z=6&WHO)'W0N[[M-#*>*Q1)3:5
M6_5YNSIM D-:<\UX>HYJN5]JU.GK?-6HSVT8=H(!AX+Q]C6>8$1G(MQMN>EL
M>UR??Z0CKT#1Y,C?"MI%Z[8)OVS^^[<C0R?&L1N0%]>2X#?$N0E^[WXX?/<X
M?)^QJU\S<8TY4M?VZZ8*1M9OT;;TW0=.>,K]Q(N$N=<<A,:\:] G7OP]\9A(
M_(46.\O8O9KW2,)=!#]0NQXG'XDWCV"&RO+$S='&<P3G:[=Z[G['4!3P]P#N
MP*;8"D[3/W,O#O7;V4A I^;%/?=_%P>FKMH6^ >^V\$@"1S_ZV+1XKU[\]%8
M$QS(_M]O14RCC^2;M#4^2\%SC9P''PGD1PF"?,3?)$D*!7$A01#11_Q-EKY0
M$B$V_2Q!A-@4$$&$V!0823SB;U)-AH+XG" ^7B[SL=W#Y4;-7"IIX[WE\.S[
MWI.==L\V"?O6Q+&OMB:.1D\D@MU4:V+V=)A^5YL^.$^NS]M(=4MJ$Z+$]5'B
M6IWLB=CC4?G 31D[BJR>R:9#(0=8R,2M /<K0OX:%^DUL/9EU/T6+"L(A0'O
M[>>#FMW[WN[WSO+Z2<'NXCD:R&63;_8K>F?.9;3-MO[E/-[G)W6I%TDG3YFY
M"N!RE48[@^/-*!6M+Q(\S4UD(2I$?_TA'F+X<1I0:'FAY=V1Y9T]@_ZCEL?U
M@&EG^?*83\D#*=W4Y<%:9Z'EQ9'E48PO!3.7V2&>Q_*^X))<FPYJYZ48P 2B
M(8V=W( A6 )5GZ,,G+-AY[4'>BTXO?:XST<EZ,)LL)K>WJC/XR0I>:;7\"R/
MU8;I)[L[ ;^COE',MX8#E2\:9&LPF5";,K,2*.3X4/1Q25)HNJ'IAJ9[;J?I
M2Z:[*(]K[4Z+QZ?9(=_J2G4"6^1E:+K0<XH]D%%?]BRNYW1M);ZD,W71@55/
M)%"&.\U/X>L/9_#T4#FX=)TWZEWM]K6.A7YT<RN3F5BNL\5I3HEU1P)8C$H\
M)0LQY%V1"5^VMJ&IAZ;^,TW]["&L3YEZL6FL^#*[C/+V?+QAUOEI5Y&0J4-O
MC*3P,(IU6U&LG=I&XL[]6[HEJI'Y1VM>PEWR^7?)5Z>X\>N,(8AC#0RH^WPB
MN"O=<VOV7D?W3=(N$"PI=OGLB*;QU8">3->L$'<<N0>2CH>!LA "0@BX#;_N
M:Q"P)HO=.MV.TU-RWI['9WJ#SA&HUATZ>/&'1,R76/D]A-L"SEIV]+N3HG]0
M>2"I0#20I,8ON#BBZ"7\*#UX-1V/I X\4W<*,AA!O2PP^-__>58YL=<>5$>M
M&[]W"'(P,*]B@W3420:86Y@A(@J7WZ*Z$C>F-U Z\40-_'L/0F@F(@3^&(W]
M%3GX&<W(T72B&NV#27M6@^U][7D9]N[#=PI$/-F@FF:2>$1N^PS^Z@V,(A[I
MF$_2>K%IB#[)YK]B9&P@1/M7JYHZF2B-?GZ3/LJA$4 I\XCU'3'[[%59/*PK
M>4U=GT_UJ1GT>%<8$9>BPX0DT"0Q$J@!( 51I!-"8B22!,,D8L3PB'NDGF8+
M2Z.\;4R5PGJEZR6]N\9/\JZ,X]N$V8FMFMQ,SA;U1KS'YWOR*=Z5]DK=TK1,
M9*?V*)HM,.GV>LK(IWA7$GPTDVD:A02/M2BJHJM24U^RIWA7A%8MVV\VRQ5^
MMLBDL@V:2"[C\BG>E;)-I\5MUU[A8LS.,N4M46*S\BG>E5Y>EU1>E%B.S-F9
MA)GJ=VQ[=8IW124HHKNE)0TOZDRU4TGH8I*33_&N4-R*JH^%N,'/JA359!,F
M2*57IWA7:KE1>T N!W-N,]6B<7)9J]H$>XIW1>C:75Y.80*^ 45UG*U7VFU+
M?LZ[<DAX]#;SB<<_\>JWWF2M^',==J67C"*O6>%K="5/%&['U",E1716' 68
MATN,[UPV'A-)=>2]VL%[O,([LL0-;#7)\TG<!LDY:!A;RXC5 \$D<CB]SX,I
MZM.P0A:1'\XBXKH\CWCL+4,."_<O7AP;;+G\W#K^8,OE!Y?U!ULP(9 %4RXA
MD 53+B&0!54P/Y:NY")R"3HOP8<GX;YH"MXJY#Z>DL^5N-\Q:\D);0E)3'PS
MH1 [?AQVW"\]QB>AX]8H44*EN(Q2W R%2I"7C2O6[AR/>G>LX7L1=& 6QKOD
MDS@>\SW12QR.ZU8R.9UB2<^Z3A=+OI[$9:NS<7J<2*:GF_QL7!<$>HT5/9X7
M\H&.'3<8"LTT--.?9*;GK6G^HIFV"[DRV1X5-1XSZ<68D4<T59)=4AB2H.^A
MF.:,1GJ;M36G?*6YN#%T53U(!0&SN:IO (@,@ 9&RKV4U@0'HG_\- 28Q^(6
MO;-=CAKG&6[#[6IZD*'V.NS3,SR9PG&CP<T8P>HMAY5!GF%=,AKB(9[PT3O[
M\680?#1X]I04'-7 4.!=<T!= C12] 11,S'O,2%XW)[/^!WPB$5K E6:%YCI
MIK&)EGK#.+^569<.AT[X6( =9)NYX_B:DXD=[LZ_ _:!X<]X[23A![%DW+*O
MY]9/'I4BO,&+PQ2*<44<F?@FD5;[E;IL54C6Y<6),KY@=6CFH9G_+#/WAP_G
M,V:>ZN:7PBJ=XKE9AB!Q*;NH+X#'B4-0/O(3WJ29WW(8[Y E1_Q(/5>X<?])
M;!F^GLX$<>A!6@=\.7@]P/\=@<:'EH1$*F_S<;,8QYMLMR#T2K-&OB6[1#K4
M X.2H\(07X@4(5+<M,=X#J0H,=DYL(P>S2\,M;4@YN*X(<HNWP[Q0,3"B-[G
MZ'=>\MQ<H-3_[=*3YV0ZB!'@PS%[GW@DOLTMY)&I1'& @\1H)("A1 L4"7\:
MT%%*&"6B@,1C Y*A$R^).I+Q-2>UQ!Z&QQM%#71C39!O(S(5XH@FI-<@TNG!
ML,5C,R!::6UM9J9U@3R^LALMKFBZ/^M/L2%&KG*I&L"&JU,4*2G%K$VJL686
M[XC0#HL]8LOPJU,4*=MEH;=>@?F* ZVY6!CD,XETJGZ*^*0S3F=G]45%X*MK
MC!LFFSF@$ZM3Q"?MI%IL&V,JA\\V_7A/Z>;+%>8D\8F24H1DE>HGI^+8*$VC
M^G1&UNL"?7QEUEBUDNW:>#@E-:*7*&3&]E);"<SQE58^VL]4*[S-D4NS#\1)
M=#N+RO#*W=C]IO-(Z;.98J&,&(20*4>Q9:!)$![3BBFINFD;)R@]QLFT.,US
MA,%M*-YHDWHGM;)7+L!#RP!#UGKC.H^4Q1\"D*,<Y]?I6/Z._=L- J6JY7*^
M5>8JK6:$K:0CJ6JEE:]DN4HJSS4=Z[H&.4E>B["V#*]S7Q(MD@\._0@4&C3[
M3<1)?X:[746S](@848%H@H@H&P @@4;^1M<BI"#Q?SJB:HW%6:2$KG$^(_[Y
M-UI,(^)\;NAKN():0-U\=)$W%R-+X)>@F>0$9<N#RH!JUQIF<V2M3JWRS'Z1
M]_1.<-X#J1MZD"VJ+6#,V+5B"FCY%KRW=2XJ.X5.0CZVDIKCPCR+5\>3[F2I
M2@M,D ^]@WPE\XF $FL L3HJP?'LUW_<5>^*:!B"74UW"[E.E.=%OK'-&&P^
M7ZNPJ+D%=,R.5O^(N;!% T1& %BH/$L?C10)1)Q%'DHGXHWG(5(635.4QK8)
M+,MTIO] GD@L!/T/XILQYCJT;A 9 W&(;@WE;#Y&6O#:9X*,C$43"A[^=88>
M^P9:^"Z'@XG'3"#]'MH&*E8U@?9RYDO - &HS@'"+TUV;HX>6QWMWN- #KI=
MH5BRFA'QJDDDY6DSQPR7]5]_K+%B6!M,4S00F<&OC<V73D;D;T_UW9E"3]CI
M_0-4:Q6^103.#M"&B-?'B #14!5@.).I:.CHUYWPG;&AJ4;"TN>.84"+<[_M
M?/A<*DBN/B#WH6X/=!V:N^8@YP?FEULC_B)- M51U7G_ELXY;W\PU6-! 849
MGHGQHIU:6=+<J"[&<*IU#1S-+7)#T6T0,37\1!_>MOHU@ 96[M,/)F3>8\?D
M=,Z9/);(<PL0[^") HMT#R*LB\D;J#5'FN?JS9/:0=5!$4D(!'#.4)!R +7+
M06AW[AZ<<"52H]T5 _15)VPY%S<.FY1BO@#J_SOS=FROE(S@R0@JY1D$UA-+
M)8F?Y/I3A8HQ!2F9S CLLUT=_AGZ5''C^"H9W6@<;MT.H7N[DG+-5JE8X^VA
MM9$&Z?30GJW@QHTYC=WS71FM@R,'W%Y((B]EY<KV=3FM%%6%?Y8,1_J#S=>6
MUSETNH1YPRX .[?*<<ULB6@WLIO"1@V,U#ZVVCJ;<>?&>6].\AH27 T8J'A+
ME,%>A!AY(,-%:<5NR3P#\&*?6/3E8;F/#:'I'8?H_GJ2'S+&"&)-<"3W9'^G
M%DX)^KT(#QW1#M%2NX+XW@1SZZ"N&KI;:!H?K^H!S@U%1:]!?MGWR^@0^XU(
M"NX@K^3_47!;ZH6#/Z21[ANC%SY42JT<R^6*M7YA&A],I4R2'&UR\Y5O+N T
MS?7R(A]5IV(ROF!'VP(QFT,=C#[$ON "'@CA(8(R".%K:HKHZN:1A#[KV/D[
MP7[Y=O"ON(RKVA2;MU8$4:NW^"'[$=_N_ [<L020;<#+ON;I!%D>IYV=C)#K
MY4:%6(^?R6!&&[E5KR[)CO<70<!ZVLDY7@!M*(Z7 .RNB@/@G]-"'7C2YYG[
MV3QF@_R&CW/VO-85K4:%5N2ZGWY+<R'3)EZ?]+BBEC17#55CA"Z4 $3^^"M^
MBVL>CONXFV+3'DR 9"'U%C4-#O;)&WE2W//[']<0@+\N2*>>K5!V>2QSP)2(
M"E^V9D,6P?\)%P3.)!"=,FM-@?Z'*1J;ZSD-KS#$'/@0B,\6I28AC(0FK(H:
M6JG&:.6"RJ+:0Z>]$ 1*#S8\[\(Y(\+T$68C5P.U+$ /.K=-?^4$.?:93*+G
M8(C&5!WQ)G!Z,.Q5(7Z@";W&B)-[HUYRNBB("M5NR>860$T@'D]8)92PBF;!
MR4!Y,8&[')3-[<_;[AAM<W+&NL6T,>U7,8J?,69G5%CK\B!=1S-V7$:SFS%W
M0;&<-)Z7$^<UO7)\=-_6D$]&8\XRC5X?D).32%5JL\$XUA=P4;#T#,"JS2*
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MP<7^-M;!HH8ZZ+ ">8*L."F#5+&S9J987JWT]4PR:0Q7\,JC>VID(TO$,('
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MC??BW=F+/])WQ87Q"DOC+J'P+-08/U;E/IA,]@ZZ!>S<L?H**[("S-]G4Y:
MC?D[1\Y[T"&_"CH$!)W3>G _.(2BNV>%F\MJT.=GXT/,+&?1G<3IQ*:[TAWB
MAG7GZLG,@?2NG0R%7W^\)L_WYX5<*G')7T+$ ([YW6A*F*G\U4SEUSNNR]V-
MF%M44R2>$GBCK3=C5"?-NHQ,42;F1[KRS[3G'S?D'VC.A# JMKH+JDMC.#:&
M%MT6.C@NLY<S9ZK+L]0<%*H\5LZW%X.N-%,LE  4__6'2/C"]W##YGQGVWS/
M\ZKH&B:=V?L*S!BOZY %:S<6P&GR0#^ \Q2D=>)2;A]$ NG5I4($R[D\;O,8
M5^2-ZKA;GR6QR<HEA*-Q'SV_$$L>3\_"M4TD6+,40DF07,XWH223469D3Y<R
MN,+RG5B!B4<%'B63Q]$FTD>O\UZ@Y);C?>XC7.:QHX.EG[V_^*ZW>>VB?M_)
M"SR(O_8X@P3H5R0O,#8IC$AP5)??@$EGV$IFU.60=<DB?2,O^)GF30= ZT/K
MOE]W[81U%XE\V<[&F30>)]=3<2'BK=Q*AM8-G;08?=S:^&?;]IV%!MU'=)S3
M=S#$1#@64081 \Q$17M*"7**[% 1GE/,=PZ2L?ORT\\?/KP/\L%7M^J!PO8W
MVH=_V D[ &;,!-+OH6T@6WD;EG=VQ[IFU]A9G?/'%K0Y8H_22I*M$:-Z ><V
MZ139XC:UFA+W*&(CY%,'^B<2A]!$_8W*A18:1 M]W9'RVT)[8-MDUBUNA=OL
M2%$)7:-+2V2AT(^*0%L*+?3N@UU'?I2B2="5 AJ*@<']CJ&OD$^%" I^MA=]
MP_EOYX;>0.'L1W>Y<]L PKQA%X"=6^6X9K9$M!O936&C?C^(E:]DOKS/?0'7
M:8\2I $-K@8,Z?"4 B.?CBE*M6Z\(-%SO+,<5K@644XJ(]GE6/:%>O_ZEOO7
M/>2NA:;X#5/\2,3I\J98)G)E-=TI"!S0ANULOM'LV00B5HK_!%/T@<CQ=?[
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MK 5F"*F,C;OZ?$C1$M7VJJ/+<A?OF+..8E6**0O-$?4QX]4UQV='1_]S XP
M=!^&=Z-W+^;S4[I7UL8UA4C5*MQB)5+#AE[*<C'V [KW&&GNI_< #=^8:9=Q
M=0A,N"8ZZQ/T)WW776^.!&<^4)34G:/4GE>672NF@!84H0G7<6 VH9_9 $,
M9FB+E'H:3FTW&L? RXX'*TA&>85QLZ+$ [LX;%<3Z?1F<V'38.)4P8@+^2:.
MM9OIT2K9CV8*$(.ICT"P.VC/+X)#CQC[L;\IRXL SZ>%QWY<<A6=;EJ)TM+
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M\ %/:8G/9#0&ZM!9HB&PS "PW"/ED?M73[B/OK+K.%/2E,9@:*O/9\"UK :
MNKH$PZH&-^:LF=KA5%(T%31[&=NR#9#WB$2<$.@Q$4\?+\57R5S?G)+%+K-:
M4U-53-=]HM;YG!6QSGSOJ)T\TAF/W^F8=<;P9L/YPVA?&OR*DX:$/W+F9\^T
M\ML1ID-CMH_YN\T>)'@W<6Z"W[L?#L>%0N1>>!P%BB4WP+P[XW#B\>@D>_>!
M&XQW/GD6LS\@<?.N>3H681*/B803:K>,W:MYCW29?MXGDG-/'?!'AGJ+-NX@
M_GUP?QW><P2G<T<QM?L=0X1TO]TS#F3-[YXM> <^SH-WEXH#4U=M"USB3.%U
M%MB#[\$_?I1C[NFHZ-MT?HEX*)?@R85\ARPTE,N5Y/(.GW(HEV_)Y7U*\\\M
M*U>;!.83D^ K@'][!IBW\AE.3\G@V3,/ Z,[#N+C?__[G\%9^,Y/M 2[:&/3
M,T_7D0^ZB\"2Y+EFS&^&>%\4Z/G@O]D)P8.1@/6%2!WN&MST83,BPZVSY7$'
M'02=S@8D 9N#LS&6D]?J2N,+A_FG#U!.!&38%;Q3:S,'SV*V!UM]+\XB9F:)
MUJJ3J4P[%K'M@.F@KTW.<S"R8SU]%E,X"A^\#+JT) $K8@8H*O,6IW3FLWH9
MSU2E2AW%+5%:+$'@#R21\(/]/)#MQZ[50"8 WI='V[B/P!SRUSK42\:NFI"(
MH!R16W"X+@V*/Q8!CY.&6BOHG&S<?ZL:<$"JZJR\K#;,:\AU@7LR]#T/'%O=
M*373\R*%9P<5(KELJ+90. _K[I?!42*): Y+@BW?F8C1[;)02)6L%<JY<KH/
MT_1#+'9\IGP+GF30D3!@ZT+C$!678$_D?7A8"77+,A2GHM%U-)&]G:?;? #=
MR2OTWPK]S@_YG8V]'CK@AQYK-IJ\![/T--,'O1'3G38G42NZ6BGEF'IEF&VE
MBZVU-NYNN-0&#'M-)CT;-5B4SOKK#\D\,,PQ=6'H@-Z= _H,8[UC/:Y9J^V]
MT/-AZ1VYG%>,S]TB.+I I<_F0#.=4_T##S29*5I*>= K<IVLTF6 EBR/^U>&
MQD1=IM54F^C@"ZJ(B4TJBQ<'J%X'02,1?R"B/F+C/0-A@)W-%FJ\<Z]^H_]A
MR.>(&(6(.-1ME _R<R'QS(U/SP%L@WG/*K=SY&H*V@-SU!EOK1Q71[S:O_[$
M'J@H^4 SQ\1:H=OW:;1[;SX"X/D='_SNGI*"8Q@8"KQK#JA+@,:%GB!J)G;\
MF,^<EM^X$WEK,W:9\.A=S5BP/+#+S=BS1K0O"2DND,'Z=C;.<]8+E.CZX<'Y
MU%?T4X/Y^NO[W7WTJ<^HDR2]WY]Y*>TIW;1,Q\M((@ZKFKA!M<;F<2KTMEW:
M%I;+\61*:O,!,QCUM&5Q==R3]/1U@>E)2N]ZDN;8!H<EV2:7CJ2JY1I7:;*M
M?+42U)++7><-E^S3/?#QC@L#TQ9Y7V?BG&4^>U.4"[(_G'+>._(W.O5$7R&=
M7"'W\-/YG?CGWT[S8W&HSU'4?[ Y6<TRT*'_C@X+AHH!)$LW3+?6:8[83E__
MVF&) JIL>^+_<=X"W6( )&A#!ZU;1"='_N#*A%L:]QCA=U1!^XM1(^<GZEAO
M7 \G7P55'4;<HOFW9P=>=C0[%C!FBM?8SVWB/+(-^"W#3< QG2;5 P#_-W1H
MY S@'#:?II??ORBJZ-!7+I,X>@7G7DY=V?[]GF7[/, ':]C"AOHR4IX8YG=_
M]"IZH$C@CL>E,W&V;OL_#73--@'\]>4IS^X"Y[#'S25R!H<V4VX31!2'0A*4
M5-LY)W*(F[U/+=TIA--'(T6"<GYXTI&'")C-57T#T$-1]UA;M9SI<G1G"%%;
M-ZY(Z/MV6<<%F@??QB'TTXIUN*:Q!M16V6'+2&Z.%C4G<+DKHOI0"YF.5"Z0
M2U,TN:P172Z*JZW:V2**W8<8'7^@B!.D%!\OP'/K)U]I;.S6V,([S7>=WUV]
MWN76G<@;<0W;+==2E9EBP7NHZ@NB2&@M!D"\DAYJC1P.1LL0'0L:BAL'$47M
MB<D1C@35@;F_H*[RD;_1*( FH6\XKXF4Y=\(;A%\S.#>WXH A @[.@P5(J++
M)/HWX2UC']3>.71;A'G#+@ [M\IQS6R):#>RF\)&?9UT[Z2O=$95YK&V,ILG
M*([#VF-9:%3KR6WF&VTEOJS*-6"@MQ-EZ-E5G\[+W<0X<:W,[-E>JS'RD&RV
M7TI$QS-KPI-R:4SVQ.A24%$;S"-U_FNGR"[L:([QO#R?_X3*>UJGBL=*]QSR
M%/="AU7E2?4>$&OMWZ2G0Z8MC7>ZY;T97!:'P%T8/^,WN*;S-#IO1.)25%2G
MXNV$N>U-R7F.;V@LG%^!QWJ>;L=CQ1R7C66GI68L.VQQWV"<N@P6@WBR9RT*
M^2B>R@LMMM6M##N($COQ&A+[V0C2$TOTG&(I=A*3+-FJ9_G%'$[9M&1C:^&[
M)!&^BZ4^V!+M I]93^,V,1\0W<J@@9IG)1CF(4&\VL'AL"^BM]Q$/"_'$=SS
MSZ(/NZ407J]N'KYNYRPBJ'.MV[0'DP\OKA%]]X'GBKM]%,0=![2H#*&/"53X
M?DYC)<3"#N%9<> !0)DY+OB.J!G]'7U50DN]ZE[_Y,X[*.<XNROX_<@(@A!Z
M290=Y8Q\!="R;N[&89MNF?Q<=*=A3QU]\!)/1"H.:'KCA1<8;A0@8HEK9RU'
M^R(G!<MM"N$Z\8X? ?=$.MP3/6&BV_ULY=YLM^<XZ9<$U)GVD:OB!WDAS]O
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M5Z4;+%'7%[?!":JVB,IL'A1%VW1O/!DJ^(PB)]<3#Y>W"P\,A(>!;J,*<Q?
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M&(90FF""?H@DR2!-\&[N*-U7[!1,POJ=@(3W0JZ5N_*CW)*B]1.=)BZKL]J
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M:=0@($'=EHF3Y]-L;Q:._.YMQ$V" F?#IXZ(:W<P/9?G\>H+\P^@?SZK]#(
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M@3Y:4%C)V<R<K!2E5F@TF<QZ_5HVUD0%A0]71.>?)$H<]%HQ9M2?A:)1(U9
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M7'N]]Z<<O.X"13)[[/@O/<8C>:K&MCI/5'7<[XZ8IQI*Z,9>@SAUEOK9@=?
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M'L6OH-5HT&KT!VU$T,[/+QL1M//SR4X$K49]LA$!-OEE(P)L.NU.!$T5K^\
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M/2>)GQ98JWX1\&1O/C6'N8[8,$R;3/- =/?&LZU!T7M]/X6.!]XBT3W5K<K
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ME$]USDL['Z[&@;J/"C+O.7!RY"[$G!W2?.J7;FOV)*D<:JWJJZ-CB+*G(5K
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M3]C]KV*EPT(#CMI9/ ETS]IN.>V*%]N:G.:P:(37'6TN& T0;IN\ 6ODKDI
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M^-+"35'K; =A981D-8*;]>26IG>MI\S4T,-D^>S%]W-T!"2"HM:>L_#'Q22
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MD=HBM&TE)&X*MLUI=3M^'Y<Y>&O0%41?!C;'.>AB1,(9X&K?.Z^OQ(AHT7>
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MT4];IE$TTN"']B4.?#]+/7'TEQ[%N@Z]'%$3KFV]^O=(F=FPN)3I32B20<:
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M<PVYMS]<8%19Z6:7%(HEH3\U)WEZ\IXS5B+=NSD]UDX6"$XXQ(KR(P[Y$!:
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MD8R8%B[N+L\48JDYV_FU[&3=O#/1\"S];C^29WG>@*W16>_+P3<K"1//:D&
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M5+)PQ:-R41Q4]83'1F/WE\&VJ\!7YZ]W2'<(:%!=IE= +'M8WM"9&50? \]
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MC1!NYW'[XI'GTD C&@<R:%F42?'6&F]Q_-E@Z,NU^\O)YVT:^<>=!AG[#)A
M(P+[]!/4M?@Z":[2U=S5(3Q\8%F5P:2YZ\L0L:YN;.1I7F(7P80)+@G\ T!\
MDSTM9,XG-CSY S"CU)13DXP;I<BVI@.S:;=^6CB&SW.'1SZ+"V6QJ:UX6,(;
M?M>&RT.TX\Z3((7H>)@REBC=\SQHZ:S<404RFLB6UP1%*B$D:DXLOO M ?FH
M>&G;F/=M;#-'N.A0-M% $&M4?B#)JFGJNI*8-/H$<<HL):&DY\>E+BG_P0;3
M$XLHOKO<!8,X"1^O/Q+BOXB<S#3C_6WJ!\9_%"/"\T24CJ$B5Y\T;]2L0-6Q
M[^;B:13B;9S)L(P/"G\XBKFIE37C;>GZANVWXM4P)PM$MXT'?Z(4^2_>G(CS
M>S'X]Q(II:SL)'!U6*K^^0-&[ K8_X<7ET&::??8&X)5>)"$]A@J^-VOC.@U
MF6]F:H2=]^"H#>M5=]DQBNWWCSMSGNN]5-??T@ DL)NMEVY."IB%[XN>X=QR
M+M:\O,GP+T?ST@A45WCGVX]$S=$_E'H@W8)S='9S0<R!%A':P #W_$P?ALE!
M*;Y!SX-8WNL=O3)9(@+\I9CLYQ%"V..]09]D1<*&$)*FG)V!ECN@P/6&7VG!
MU%F0T:F!]-T8N]*Z"%',>H]?D,Q))GF3#3-4/^:EO[.9Q2CW+@/EP+<G%IB?
M VOX_8VK^A7[SU9D$&(^).DTC;*11^6PA+:RPX_^W7MIN.+A=3Z,_9!1<GME
M?GO$;YVWC&]DOG2=CKX,E&AU)"9X6,2^NTL78^)^HXQE@#55@T$#7E445J?F
M"R?=BW6AF03/!F?K9][WYAAF;)('J@@A9>SCUQF6E-6#)JYIUP]-^267*"GW
M?MQL.A:)<S0]1D;1X9P'J4/-?PN;1%>HK&\:?,S#=B:2$T\I<%"5_AM37LLQ
MR38D7"/78N;LFG5NX_$<SV*S?+-<'M1VDMN]Y"4W>:A8DN>>_U5SWO9&JATO
M=MO*R(VQV'&KPX<.:&:LS3/:<C2L9]-"Y#UG0U'AWR9SS%K53T5\:&PQ%KIU
MJ< ZS)>X]D+VO8XB_^PKTV "5L/I^"CZ!9G96AMWQ@_5H=D3>\??L#O.._*C
MO2Q#3+9Q>45&Q_B5'MW<G1C^ C<5Z/X2=%P$S=0PONX]NK;@*F>27N\;'H-J
MHP* _P"&&%'<F%NG?IHE>H2\-&[K6*K(SAH6X]."!'_D25!P\NT1(Y(Y4X67
MK!PT61J%>.9.O!0K]IY$*LAFMT81+$E5__6^)B^?NWM)Q_",M0J)<S-[B18]
M24H]U]VX6S1)XY<PPZ!+8X]]$$CRFSA1YR5A.0&EM?_^W$C[MHX*2M:<A3UR
MP^K"*-%.O!6+C).MQVHS%+4$\&6GYWZUKLG3%5A\-<T>8'S 11&A4(T>\@LH
M0TU(!QM5UM#OWVZ 8?=NQGKKZHBT&C%?LT&50&3#BH5522H;.)&&/A ?E3AO
MQ9T*/'"/T7G (>A!\3]2(.9"K1[@$4_RHX+^)0BL_?ML+$Z;_U<8R2/]-WE.
MKI=B*D#]/PD0XUW_U?C?*;P@V %<>'8'[U\5V/Y.7QAW^+3L%5O<H0Y5W>V0
M3X'_=V#L+?B?^D.U_P\:M'',;?._-9Q_H?Z_$N3]K_VO_?\RHC\K_P%02P,$
M%     @ DHA]5C]^9L4#>0  O9<  !<   !T;6(M,C R,C$R,S%X,3!K,# R
M+FIP9^R\!UB3R[8__"(("@*"($6:@-($I$DGHM(%!*0WE=ZE=R(H(*%$1$""
M]-YK0&J0CDBOTGL'"5("A.0?=>]SS]YWGWO/O?]SO^?[GN^^9)+GG7=E9JV9
M6>4WLP)V'#L'7%:65Y('\,X! ![N#\!. O<!_'/G?KQP%P'N=?["^?,$!.>)
MB8@(+UPBOG2)A)B$A)2,\C(I&049"<GEJY<IKE!14U-?(J>AO4I%2TE%3?6C
M$3Q\W'<(SE\\?_XB%2D)*=5_^<(V 107\-;P.?#Q6(%S%'CX%'C85H 9Q^=Y
MO)\7\-N%=P['(R'1A8O$)#@"^&7@'!X^_CD"_!]<XY[ZXYX#!!3G*:\+R!)>
MT7A*Q.I,)1@8G7:![5[9)VK-@5UVH6<N01>)K]+0TM'?N,G!R<4M+')'5$Q<
MXOX#.7D%125EK<?:.KIZ^@9FYA:65M8VMJYN[AZ>7MX^+U\%AX2^#H.\C7D7
M&Q?_/@&6GI&9E9V3FY=?7E$)KZK^6%/;W-+:UM[1V?5Y<&AX9'1L_.O$_,+B
MTO+*ZMKZ!G+O^_[!X1'J^.2'7'@ /M[OUU_*18&3ZQP! 3X!T0^Y\,YY_B"@
M(#A_78"04E:#Z*GS%5;!P M4]Z+3RCY=9!/2W*5^YC) ?)5=>/X&\H=H/R7[
MYP0+^F])]C?!_DVN"> 2/AYN\O I !!PII4.X03^KN#1SFFY<!E9*!9S+%@=
MQB5E=!=,H%)1/I^;Z6[4M+WRO/F(4%XTF9P6<&?74MYI53;*/ZR9.">TKM;9
M64(_=,#/.#6!,I2M'4TK&X.K^"8I[QQO44Q,4'%2,O-?5\$@[S.-B_49;&/H
M4)#35@F"E(D0CN%")S[ATP06X^C.W4[=+]I=34]?1GW-?UY5+11IXA&C\%2.
MZO&U8"J-N^?_OUQ<9D"[;1WA;MTDM,M1DA;##L6.@W?5$R^Y7*0CE'Q;, ;9
ML$Y5-=:;K[>;][<\U1T4F24W^CJY4>NCZOAL6&/B8EJ\XYPRXV=9N2<*:80E
M:-!N_<R5_F#X\J")K2B-D,GTE'PBI5*62Z^VDAB=&'Z_KM9,C=/K2]V9=^_?
M!MF_C!4#@;,,''7"PB.>36&!DLW[>9T'&2+M%7<"D,SW;$29OXFNV.R1/MZ3
ME!J +?Z\M9X"U\\F9+R1SHG^NA(Q1O<1"W@CA.07SU;0/0R!VU)1?<*6'WLZ
M3GN.8;_HE\AMECR\<8TZ@F:<O@S\HE=@\55GJ^BA*Q9RQGP/L(S\22^./^'-
MF&S=XYP(/4K\+OR+OI-IJ'/KN[Q=Q*]^?Y)'W3U,5K"""1E9_NSVVD]R%Z+*
M_V7S?]G\'V$3%:/R[D>CJ\+PI'2&<7[Q8^CW(OJ7VOG$G.F!_ZP-NOA#]4![
M1"\QB"=8H'\S[YM1=2O_,;XL%C M!:^YS2,3AE'ZVG5:-CT3:;6UD,^C=F'C
M[+<S%+?7@"Y0K.-1_TK#6_-W.A)>Q9_E+E6=Q'#1$=A4$S"C/9*PP$6Y%/2I
MK2F*%R?#@FT-G<R@=(\M#QN&,ES]^' 8L6OHC 5:!_Y$9[WT=)MM=E=DK1"*
M4KZ%!58G-;' )X<.+'!% 7WC:LKW[3SP7-4B%@C+B ZMA(*;QM++0?.<%5@@
MQ4$%"YRO9D:K,N^^T\<"?5596"!H$HJY&27/-"B-!?!-()U8X%5Z'\8?SH^^
M.@5&"H.;-6RP@,Q$/(;$$82"B=/Z*AZA27UX.'!,@OZ-R<%_1,?V1[K_4!A>
MT+]6EK;$MM$[R/KRMEPYXDL5C4EBVHQ=-[Q.#HO>/5DKS.%NNNR?)U9I9$%G
MSTNEH8CS3(_P_E5%E@7O+:&_&F?Q_7;013\N)/ZCH"/3P<BS+P+'/!P3V>$D
M'Q8OS 6(Y4-4OT:+WKCVR?AD<M_*N$%-Q@(+- 9+-(+/$ALI43JK38W7D \F
M[-_:#:A+A7D<N5ZIN1G]>'NV<NZ2BZ0NXB _C_;3Q*T.4AWMO+P>@U/<>M5/
MNOXG7H@4TL"=TN!94&_EIM ]L:&QL^_H3>52WR25I];ID/LX77CQGQ8N<F6S
M3@HE]D<WMT -+K.7$4ND1&<!G[! VBA:(H*&@NY9,A<KP4M6,8O%$K8H'ABR
M9\K3A[KR3>?;=B>6EG9/_.\G$&=5Y15M^F7KR#H==0AB27<4O-GK=';53O]/
M]QEY/?ROO@D[NA7P@9<AX#76$FU&&HRLCNE!&VB?0K<@:<>CPYQ*0XXU",*9
M>@["5=@6\.Z".]4[S8]MZ3'"D%;8$PF('>6%IC1#-NE<O&$-.0!'#+AB9-B]
M>$R7L$#'J]D3W@+*(8S4-A;8A&&!ZX8F,E@@FL<4YTHO(O8-=7AST-Z36&!,
M!'.O.K2YUP8-9C7@3$_X\\#^7Q4U1KD['R0@$L2&3,:GPN"NJ_W@V5HL,)A@
M-[3Y!60)/6:=(#\],CW1XO7Q=S)%E1]8\5TYFV$*W\/-1ZE$\T_1?RM!]R)B
M C>L"YGI42Y8H$WB>MF0GQQXWC>&&S&YWQ]B=&E9QCF"X?M^=M%P6./CZ9(E
MSPFVP&>"SB'B= PZ[QR9"1A>#C8^VLUY(>5:C%9!6@4G+I)#MK<K#25)WJ\J
MSO%?3S*_14O5]$DVPKVK)->-5,*80ZFL(OG00=Z+13%YQ^\BAX41C;WSQP.Q
MW (RA8:6B\:CD<?B#ME'D_>5(9R%:G-_"DK_JN"14Z_,,O/M\/KA+4UF*%?#
M@K,R.RN.)1>]8_5Q>G[!J58]@WX_9K "/DW6T0HS;D_,,U3P-'M>=R-$=J]T
M$]TDSG@A/[RB)DFQ1JZ-66IZ_?9:M:X,=4/_EK#(L @IQW:_]1BE/V1A4"GI
MML8+@3+S"^/M<[+%[VQT AB0II#*2.[I6_N5,4IU5]]$ELE))MR/U6A>8J4D
M&FOPK$JY4"]@DV$K87KH:V1H*QDP/*9+V7.K+F#%W(-W;\[ATR+<<L.$<-"/
M9AX+L"D'#A2[T[+#;+*\LQ.. )*ZMSTO #HI/,.\[%X.>6>UE0R/PA1J<&=)
M(6Z!?9@]N34Z7UX#VOO&L:POPU/^T93$CKUYSA_BBC/#V0Y*PE\=3#CL,AAL
M=,"_5G\Y=U0D%F I )TL,F.">#X@L4 $G)_$/\+FY!:L--$#9S8>NIWF^XPJ
M\[F42Q@-LWZ(:LA\K/FE"6\8]O)4>1@+='\!'2'![?5L"_QMIA0F7D2MI2KS
M7'-1QH++]$9=>_A7SLVZP@.>*CCSQZ4TOD%GH/JR?-[;UVH/N<06^JV8)2O@
M<\K?7D%T?U?8;A5]U)?"]SB&T>.V&#K_4=,'2X0,XJD3O6TCW9#4LUN5WO!H
MX<.Z3D]6J5OOU\B-,+$'L\&8&W:UHP@;"\_Y,'O>%4ORYVV[[S5EE^]N"*#&
M1/S8UWHZW* JY]\KT,B+&%3$EZSXZ/CS]#4*]MVBOPEY%KUH.5;9>H,VZ/%4
M*LMB&0/%3 - J?H,E=-R-9D+7A6$S'Q<55_=J,[[0L9<\.)E)@G*#)'6I.2<
M+.'EJ]'+U<R4:-O!L]J)27D)<Q@:1O5(925,[[B(_J$1)4!P*5O\TY+YXVI3
MJGJ%#&M8(7W2S$N[@O636IL^,/?GJB]0XL^%;\Z9>QY7;1'-BE%/<K1$"MPR
MJ[IBY*U4R&C-N"@#?F_>H5[WUBL?-M:LRF]46U=G>':OY5$<VE;)V^JV$DM\
MUV5T@B;Q.]KK@=3PN2,%CAOFQ0DK)4BV-A.^P7W1\H;2D(W)-@&;[T:\13WU
MNL[OJ_/V$E[F2D8MB_>.=!!6%4HY+."[6V2N73UQ;^C-*MCH;VC;C7L<]@3<
M2'5'"33=22?E;/P ?%ZX4WA].V/$_17,09G7<+O(<T6MFC/-,\1"?(J()<('
MX-%20]EEKQL4):=1Q516Q8O&*]*UDQA?-N]C)!3+7B9[K9&C6R#5\1@YDU5L
M74ZJ/#/#J\;+;UH%6QE8DJ,TI%(=")HBG-N[:/1<060(1=.*X1QR!UVR,;E.
M[U8%:PCT-3-G4'%@UV"C>E?&^K#@RD>\SO4@'GLTZ\ J#2ULS;L[-ZVEY-S!
M2Q5H?!DS?X[?,.8J2B,;I?LX"".YK?(H;G1JXFMVAINEBEB48/2E2U;6=.)B
M@&6V9B0D@CO/N*(Z'<)SY2-G.@18K??' JPZ""Q@<@6\5J%7E8)<=<("1F/'
MQ!,XM4"'^1R=>?5A@53Z+Q5E'^]XH(+N2<%7G4J+4L>XNB5/U=],<(-+I\!]
M%T'?8#(MN-A$BAWG>VVF+P1!4K9$F;\WJY^N0'\GX'OQG]>6&?WSM/_]6MW_
MH7;_.2D\95V(N5W-7$#+KU*.>IB?XD*X9$JS,9LL-VF=M9]?H.MX>WRB<7@-
M>CS/<?;]GLWK_S%1<.XS'M<?%M# =:1\JQBT&O'!!^*I<V5\#_HU Z-8]1)S
M-H9YUVV28N)P*F2@RO%)G;R\=8MDVH7H3*K;).V0YQ>/AKIV$]TCF%\.]B_9
M;5[;9$G/.27M0._&8(XS?G\>GOJ/:ZG_25HI+#"?@OZ@T(IPX)##X0NK$GO:
MOG/UNO/Y@@$#X"O4@9K"230L6*!&VE?S;(,';7KCF$V*N>G,XAB*TP3\^A^:
M\,\4M8,>KSGR4ER@/':&P(3P9'TSFHT"+39W8Q"X,&A?0(V9.B+?[]9:\#.O
M6<R#'E],/1\(%PJ-%ZI?PP*="27@L> .3+CMU65$</R^1A)W'^9C#B:(>_V1
M;7+X+X>TD')RH6 X>9XQ.JEDS0/#.B!"RK>&^.I4M%25V.U05#9<\.10[&:C
MIRF*8[8YZ]&YS7%\YCU*$%K5GT^)\$VCY.CPYG"6NYHJ [S438!7HE^SVK4'
M0X8^MXMH6A-1]!,Z1#)E(NL7#I>Z/Q.21!'*($N4+H@M8=P"J]V$MY#ZO9H?
M/F3N]*QK!M/F:NFHI#ZKGUW,KI,)G(^4T3L(VZ>U'"G<WG':_JJ]$#Q+)FOQ
M]$0WDW[%SV$>A%))&V(599VVAU]SN+LB?8K.F:Z@H^U[>)A^555@6-/95C*9
M+=]KY52]>FRLA4EH6$HC1RY#Q5EZN;E]]MD'Y2"6M_F<-P*=*SXX]'@FBZ+Z
MG.=4E=<Y!HIZXVT'PAP=X8IS'S_<$1S=O?SPQ=4=778&M^*A]AEJ=1HO2:T!
MRJ?FU?WO'W8F5IE')-70K6^:>"^ 7X@RL2"05*5V_0:&=IITV?Q9'2*#XL1W
M;BU77\"8UA+*JY':9UWT4[B2HY/2Y*9K>D4DP;W[U/]:\YX=O4FB2UQ\O(U;
MV><;UU5>I_-\?T665=X]2]?FJH49]#&28;>3KG6U"<L%6U9V:+\V29#JN_41
MWKY(ZQJQTROH'&A\?K:%\:F[PSU5_C8MZQ/+')?J^,-2@[S8+#S\]]G3[ZM?
MT<TWE&D_0<EYYFSR'S)?/HNY]Q8U"W]1&E9,G8!NCW0D9[WS3.F\TB<6>J66
MW-EJ._7^S[O?VI@OVY#D3=G"'L37$DB<];R"54RSO*46O<EYV!)1::N<)T[4
M3V&PB[9H?*LGPK&[F/.*H_$JQ086L-/B6^1_>^.VPP(;2[NG%9%8[CP*E%LY
M=F<(E;:T>S":?U)X8JN?Z^%Z^_V#FU.*T.=TM%T=&NK5*&D?CG#UF%9-T*NG
MC31=&6?14DW-IF(/K*9C+L<DU;D&1BR$S%%HC\(PN-4=O^ #^Q!E8T-T+JY4
M^D<PBI^,/.X(@G\[029B@;NV8T.(Q>9)3 W_'G4T#HD>4\*QP,]'<G"[=01R
MT0'G=.*/B?TO82;W;RU$: XH]C_4@!APX@G(<UFG$K319J6_N$+U+ X"_!>K
M'\G;6*>2N78DGQ]J9/5R<:#1>KO'HZ1O#&O>WL[Z_"%"XK("HLCOT_RWK]];
M8*$XS$R#4G-0:+62'W+SO=;MU5[GPF@>NT0>/_U61B-PHK&YA&07C$[J:P6=
MT@B7G)$9;&:(RREQ#!THQ$:D*;OF<,E_2]RW*D:9MAS.4.,"YW#1I&W[-#TV
MNP28C7)NTZWM;F9-G]$JKGSQG#%ZAXT^C1M4;W]R:O8G,6PNXA<!!,X:B&F0
MLD)M\(T]V&/*V%N74Q*9/NZG+1E']GJEJEMZ@[;2^II*R'$&205QQA77X$F]
M!"J/"4;1S.\J$BAY8H$LS;&2<^3*,PBD.?IKUTLLX)D3T/ECE K)/OW%&*HH
MS> 0S"<BC*#A0NA9T+[3&:'/(?6FB>0<]%C<"<)\2#* V*?;'(^#%R#YY8[9
MH"2[?6A-=,> ''7T.-5O,/&/1>DNB=Q3KYQV"?67]J0K97F&Z_U7QT/,NJN/
MM.7UH:4$8[PVR-5F&E$E@K$C ZOWGYXE/AXJOC4?(WVGBYL;8Z[-J:R\3J=<
M)"9"IZ+C(T+-<.46,E3^4LZ;EK0\;M5[O^#KQ:,V@'$S$=F!]M('_[+-&40S
M-7T,X([@^#,P#H>N/?L@PY/P&*4_0-R*1*##8+BXQ@B\5E54II<LB@.N0B8X
MX$H"/;LZS-L-)N%?RZ'73CESAF(!62I;@^FHF(IM3X');[W3JW09\G2#]CC0
M&P$^N9!?>Q2\)75_V;_,N+Y^>WS9YR ?RB_:4/;N> 0T_6W%RL[T\KXTL\K'
M!M^UY<MI3GRBW:)/B!KM6G; UE!*E5SA4EF+\XU;KTT$.^AVOFZ:Y"U 7\%,
M\M)-#+X>OS%6HMO+M+GXJ"7;;K6N)&2&HQ)QRF.M"^6TM^0\DO?>:HGPMUO?
M^ZSO%^-N/)L<NOKUD$,\2\(YO3!E;W//:@!S 560Y95Q+VK/>W%HYSX5;$;G
MM%!:6G:#)ZL">2?!_WFIK.^EM]73<O8Q)IZ[BW-;$J:A_7:*/6 A.D96/P(&
MH-Z=A7C;K0]O74(;+>J!5*YXH*0Y2"E. &:U:VOM(*7KTG3L&)ZSM13*4AV+
M<'+P1"RYA6:Y@"D.(GWE^IG 9.LO=89)\B^(/ID[>-I.=MOGC?CF1.T7UVU%
M,ZUARX]7*FIVNEQYF.[GHW+:)DK"YP:+1!QX6@2*H81I@B9?KV4+2M:^(ZCW
M:M*8+,DRV=5MZR0+],*P(\KM)HW5_ 7IW/:?U89!;68)[KL*')?>V_E$!*LK
M\N,<DM)%4OI;F0Q63INI8KY >FE+GE*6*Y;7">"% -=#U977^=%$\YMG-V<?
MQBM47KV#!398(2#^SJ.(8F)F=Y;1*(VJCEMFFMO9+CY'T(,D34;Z#OFAS'XX
MX[,]0Z^;H]M'WH\4**)7]F+W7%^DT;Z,B8%\1;F7;!BT5159%)XEP559S[8X
M8"/$"G<H&-FUV;<_=PH*WF49E:_9_:8UM+T?CB#?$#3=\%'=BK^Z7CPE#!E0
MHHB<_P[<(KS K:;(%@.IF^LCMSNY4%/;>)6&/JHD3V0EO;1S0=+KBRVDS-RB
MDR)UE>Y&)-DH_>K*\/(^]+4,9PVF!7FC97UV-V+3!S(N]Y2ZKJBMWG$K6MF"
M-^3&.PN/%_CN"_FH^PLXP!OF9W?H[:>;96#8F"9U>6T[2VE5B<KQ,Y51/$E#
MT$X3P2E]0R9:!"E7">-[Z2J3@ 4N5(7GAI_ZOH;=]Q3,J&@CX;JF>SY$[\J;
M# A<-,C/K&C&QB  [IG9DV$S@8L99R<+LJ8PAO&1#V7OR;O<M21Z0\X 0[AU
M'$%K-JDTR=[!>WU^;/X02?\'YK_S)^8PP )G7CU8('T"OC^+0E9A@6(5=+!,
M"-CAY&IN.D0^\+^S5V1",X?K5S+E=<HAGXWI"0-\)W8^ &<X8VI085C@V4HL
M%DCK-J;R2,DY9A K6@>'[UO5\!NXB_@,%238>Z2F0[@B?H6!B2D^NGC#8WU4
MA<^%C! 0F>O6 5?/.SF]ZP4MSS GWT>1I41QOW7Q".-3YM[S$.NQFK]3!$:&
MC+4-H" ;I!+G]1)5#<,(EUB$YJ"U68NOC\V6[06DQKZD5%FU8P%&%/ZBI(T,
M$U)Z)S8[4G#&J>+NY>)#04?'Q\G/>=9'D4X1?BX>:_16AR(O=_E+B'J@C\CW
MB39-:) QA^Q(T58$':.SE+&EBJ$"0Z3WI8CE>/%/1#E2NB7![[A&U"^/Q-]?
MKI#0MIV?NATVW64\F_8]_A,T"@,:K->>YR>;\$H_)*4X4/$R^'P[D;A+3)"\
M[@-E3[+OV$;MG>4%A$3 14P;# M$W)*27J254GEJ9<LO-<O>P@%K?+AL2. <
ML_S!WV[+":4@PX*RMU(=8QE]PGB]X:$ 4X(T%J ?$SBDYKZAK"3B^WY)H.U1
M.J:"QLJ.*4_.6P^5M\!( KV,TEFA[3 ,?UA^Y@L=K=H'1\C0CG1JY)Z]U<("
MMW;>M2LL#AV47!^$C78,Y^_/1([O6.>/'O7/M)<;/HQIE[__8#YT7>MEM%Z#
ML.6FL8*&:M^\6NK/K6BEF;B8!L!K-@BTM-S("1[GE_\)#YX9(&<)P%W=?H^P
M0*D)3C=2^TQ:X46F83[\70Q>IB'@A?@5&0AG85337VVU90I7AF8!SBE7^(E"
M_"1S4>E#*B\U1MTF=>^T:R_+LGGHG=,&A95UD1@=!1_T4=J=!#<T%BR \#=.
MM)M+XX8>ZC/I/\Z;]U3^%%JLP 9W0.N5J5]!@0QVVQIZ/HX<7!,]%<FL/G>%
M[\+&<[4O<W?PYJ)G:D"$7II8H*6V(?8P:W?Q4\"UZFIY(=M:AW'!NW?FWA%.
M>VUW7R)>"U)+_+8GM5'_N5S%*>7@*+DF^ZMLCH&<@P.EK!/EJRC.=NK'SP'&
M4+A!/LSXH#''@G&DL,O9@3LT2N^]H$3R*XIAWY':57BE]/E2#3FJ2_>;BLW:
M,2*F%]IR;ODXS)3Y@ET/[7QY>)/-WD1L!7C@XSV.Z7%;32L10GVRRU3E"Y5I
M2-LP*$X@*(]/41-$?$W(8*%C#5]U?QK;V4D0<9 /4=VPT/C8OH;P1DJHBJH,
MF6RV^%3ZM&<(OYFTSEN6[MZZEM!%7LK)L%3MO*G1O5#G1(LR:,9,<&U7;3C+
M\L('[6$7-8U+KD5\N*R0URM;(ME_16/W72W1:\?]Z:=H<3O/W$F#R2Z":AJ/
M.-<+Z#@OC,V=G<@7#&^*:XH36W2.B%IH?"+;BMI>C_BI'*(<=F+,\ZXHY@?'
MHY1(ZHBB/UK"RQ\N:-_@93XHVTPODW+" JR6#5C A(;YA+? WOU/^*W-T8?<
MTMH:L4=<@3-- KC@@K7X\M\@W(\]1>X#OC3&:*:A=>4K1-(V^X\D22=G&VC%
M<S3N_MAT)F#T>80+2@FW4X-4)7!1E[FK_(3!WY87+G#^QT;0W L+8!X4@3'U
MEEA@P,'@Q GM-0D>NX&YEW(?5'5&\EA#CNWN/[%5_._*[V&M^F]A[9'R;@D1
MN&L*_0 +E+DJX[1FN1@BJ3Z$CF+0V4>TG0A-C15)P!IL1KY423["=<J@15N9
MD"^176&187@M?/-]T5-&$]T)T,G!Z@2T_>;P#GU'\\3#DYX^=;$\O5!$'MI9
ME]XUN?L^G?8K8?O]KIN*;^I*'YBH"#11?T*%+Y*%9ZDYV*MLTJP&!WUQ), "
M#1BZ0J]&1B]HN^9%/_TB)>IJTU+]RP70^U&@>W:UNUC@I1OTDN&K(?N,:L<]
MO'BG B8[E7O).UO=L"SCAI&I>?FDQ3[&[^X27J:JX&,+)K\5IC,L("@3.X"R
MFI<)GJ^B#'>J-GY9MRUJY6LU[,$<OVB<2GLN+J;@9F&EB5S^9;5ONBNW^0#
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M[7CD8TZQ&0A;%D%,A&OL*C1UFU)MT/M''KW66>$1K_ST?$"L5SL)(_O=\5Z
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M)=MY6<L[KD_(P,L)S'W4^=-Y\ %?H=B" O)!#)O7,UZ) 6;C,AV]-]2"T)W
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M;E8D(KMA[(E$PQS'T?@)GM)9B3<6D(:>[7%7>&2/]O"\O[G/BP7L9L!]9EC
M#P*"?P.MEF&!1KG'Z>'7-PPQ8_58(+D#<TP%_AM-GMQ5V3RG4Y/O&%_FTR6-
M?VLQBTJ?, NQ[=MWO 7^%JUPV+"*/@0==>:_TS"GC\,"?VN:>>(HY?LX%IAE
MS=>0>V/[OYW\Z$19Q.Y' A\219QCU &M?S!Q,W+9\*T[2<O29'Y$LM<MF03T
M1AJ91[1@"NN*_>>Z^L0%4%2&@BL?-*-*J:.;/0$-9=NC_682(6)7*O8.F@Y9
ME;H^?[#;&TI:C/?1*=ES0[_/Q+\V@+K"8.2=48U9.2OD+51H^D^R>-.]/V!N
MYLYR91+9=3@*/Y\SCM8M1)EU3M>=7L]@\G"./!W>[[#7T8 X::XLI4]1SYHE
MH_#SU$FA41XJD1B^8:CLV5*)%FX0FLZ0':?I]::R9RD[]7>."%L60.$L*HG9
M#4D4<^=L](*V9CF09A]T2SR85V4.LAR5U&%\JS?))^3?!BM.S%C#_S9&G'\;
M4&I-2'OG]G#U7S^Z]5)S]O=)ROA]J+65.<M)5<!_FR+H[T.MS9G>*?*/5GW4
M8QK_[G_[4DTDT:,D/_>%',JG7WD%GXL?,Q6@CMI5YAIHMN]=EQ[N69:ED+JZ
MH72(#_?"Q"--]4K'^. <AKXOW4M5+ZNFY@<1#DHP,,$WYP5/X.MJSPT,T=#X
M+]\C^$@HU&+U)7,\G83'-OR91'P;U3_\_4(K3&)['&HXN.VTW26@3NM..NP#
M;1JIW6/P-HR(RSVQ[E'CUO"Y^H_68;3!OWJ)AO^N!_ 9[_<_FWID7<YUQ[7Q
MRC 'M-U$P,)/R,@P3HP!LU$[^SNQD6XP8LD)"3[S,\0":_D;#78YE/&5QPI8
M0$DA(;YJ#8%4^9%]^U=*IBL2O?8_9'HL[9)Y1O8_SMNIRFQJ6[$+3E)I,3.J
M;5D6:AYB 9E8C66U;2,(1!-ZR\)JJFTP@-..'IK\!@72JGU+%R%8WG-Y;_9E
MY?=QBB&1M<-V!6VK\X(UG#Z0A0":P!54!O0XO L+I _6P3>X%KS91&GE9W<[
M._"V;RBI91Y7K]6-^_\6XB]+WP\>!BV56\\>$M5B@8&R,9>&S9 _UVPLE^^+
MKSOQ:[1D\;*LJSQR^P-:N$Z7E=D#>#EMX\^3XK<GL^U.1Y5YE]P]1!J;"*Z[
MM%?U3[9?[I)N5BPLQK?7IN6X]9SGRKQV#R9Q@9Q,U==U48671./SNDW>S'B7
MG;AU=[K*)8&"!\I!GX6&GRRF'?0QH"7+D)55%5V>_EFS$TZ*3F['VNP4'\\I
MC@N6U]XAU'X7A;=06D^]*S_4K.MC?F1R?:S^GG!I<S.IIMOMB66/90T*ET]*
MCPS%B")T-7-KQ VE8.]M?,$VU*CD>)I[OL.Q#,:D2D8YA;_O&7'X+#>R8(%.
M)O*3LY<X%%Z<\R,-![1$009>W2,_(_X0P&X!"HXUA-])ZDACUH()PNNF/KE=
MDY/DD=<)C$Q/BLW@N4OZK_A0:[H#\=")*&+YU?:+GQ]R@*""WJ*5"S45I=X^
M?DTQ?@OGC C2?Q0A6%9:X72SA]QU$SJ&/"Q 7#[P9C_E#]V2]9W\'CJ!^LKD
MW3=VC&\L'YEEN.9CT1!9&TW%\T*IRVPJQ<4%S+T&W9D/*%P!U\.@#PR9C4X'
MU(X5; 7AO6['D5GXPC4&G\<JV<<HJ47'JDPTS!*YZLN_TJZ^A.5F<1FHM;LS
M9%S[9'S6GDV>AL[CZ:L'S5N.6([$&;L::%@%'.:5[Y)^IE;D6#XJN6><:D:T
MH::N/%HD-NA7YGDLE$ABXK[8P^E2#,LYOOA3RE))^0&USP.QJ82_/LRL<\YE
M(A^9F!KJW;7X^$:!=F<:DUPYZ/"5]<8-JJFD:%X+VQFVZJ$+D>!!/G42*BL.
MF0-9.,^WRV51[7<J*WKIYQ,)H$X8N*T-C#HY_KM\B)*ZOKFX&89ZH(O8]H I
MAPB>%Z:3E@E.P(0?B$'IO80,D,5Q-[VO2N8:?@GJ_V 5)>_KO&EBG.-%9#SL
MKB^\/[048JWXW6^*NY6<I6R?A2EVO]M!&F&P4BF=L@M#)1)[VL.[^D[)3;)I
M!(OD*95X;F !X'BJA;5E@:<Y<[(^*1$1 TXS51B (TC6<;'9X"=OIW/G+\C/
M%@N]'"V"4O79M*=E]SAMK'>>V64<6Q^K>?7:];B_FW1G\USR)[CMDD;-(#6A
M8GX@;UP2)CS9>'5= X'34*X35P/.9MG8Z_$CWF>V23.A.2:K/97WP/4I7&<\
MPBAYSFON2=,]%>[X 7+JO'3VQ_[N_"G4Z@N0^(SJN9X3'GP,QR$C@4$0^;<[
MM(/D5\,])\$Y/?;3G?^GN>^.BW)9$AU$04%$!"2#DH. Y,R(2I8L.:FH),DY
MCH!($!A)@N2<84!REBR@Y#CD(#D-,## A#=X/>=ZPMV]N_O>[^T?K8[=75U=
M755=55]U][+F8V9X1+:/(\E0AN6I;ZZ,K$8%[%JB!YAG 0?8QF0#++; TZ%Y
MW7,:(?N"74FBD,X^GZ"N9=J&;+M73B?=NLPK/&WX4\4+KX%#>N@I;>J?-?"'
MO:;AQ5V*!57?0;LH0S'4J,L3L-)&.P9 ^IT!Q4+_TAB)C^8 K3^R(=LJIC+X
M+G6[0@L+S0+G3W\U-O=G\^@$!$RD=I&Y8)V6KX5[;2B[4. 6+QOZG=+.>/50
MC=I;9H\FMM9(+&@/@3ZGLXJ2;7'B[#MJ,-/>?3E1XF/WT^9OX)SJ!ZHY*;%^
M:TD\Z1@ 2S36XRZ5&D>'1]3'[AI)H8$+]FM([[F)8\E5=$(7M#YP79<[+KU?
MV<,S@H[#$E_)("#M#P'TW&+QA-D*G$ZD@;&J6I#O;16JDC@MX>)E5(AB4@I_
M?H0;R7N^@??6_=(TD^Z.0-+U3_H(M<5KB=XX4]+U+)N&MZ%.*QY1G\RK%"3'
MB]S?M2:8!^-*IQ^]ENYGJ>4S[KU,TB3BTTD)9&]SH0LNX?J<0HKPK/M6E;XP
M8Z(BM\/$_LZV60I:-<V%#.?BLIG&6?*7M<.+,1#EE*DK^Y Z_@5^^2W.8E:6
M.F#Q0ZG$/Z*'#P;&>9>(@V]*$WFQF_L?JS<U<A]Y$0E/]TNFXQG[@Q?4Y12E
M.@0A&2S=LL;)\E@5>1OTA?JGABSJ!8<9<*Y!;>!9!F_3A=/OE,H\-7\Y9!P7
MC(8;\!#$H.\LT7H."X%O3+HWM[B*YZ3L')6;W,>/#Z334ZR,C=DONGPK8%V;
MLI*KPHRC4\/U1>>V2JZ(E8W5L<!_*;D&U^1AB)M$ ;&.*#G%U+8\LJ%5SIZ/
M$0,(9TW/-=BH@MAX7#":JB*4O]43):Y+;KU 1()T\[&":N=7JTA3W>1.97^V
M3!JZGDW@I.FT!JE&DO:WCQ4KJ3\>LJRWLW'Q235KD-<GXR]](?E6Z[U\GF E
M>7&1L/"@X51G:<N-0(61)^QT@'SKY$DI8AD3Z YV([E% ,F;;<O14W.S=VTC
M^$AYAC,,$V4(USLUDX:WN(^YP>2#N25YK;IZ=$A-OC0"NM1ZX8P5N?26'B[\
M^=(*Z(=-@+)$G:9&F- I^G0M?GL$7,M0O8R_8-S!/WMY:WO)GXRD@_J--AV
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M <FV414YGOW26CX<:=M7OU#]1K?5A,9_5J;NR&[.J'NZ=CM59OB@I/S"^^N
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MM*:33)*:3C9<1^,FK$E*S&_27;QRP>/8?-=(N==K::B:T>]IN*8024'8)1,
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MZ\*A=[&U5S6PLG?IW\QX^N\47,SD_P%02P,$%     @ DHA]5O$UQ[YG?
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M(?5%:9^B6@^?:]!6FDSFGCGM[9WWZE79> KO:351L@[DMKF#C-Z^)65,!V5
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MP$DT"?C-80'B: *AQ^&V0Y0PPV+Y5&*][9V+O0NI7I_F(JK[+=_ N3/QY$/
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M0'Q?)=ES\;K61]'2KNBUZF.]U/-8,?1L<>ER&T.NM*@TXW<XX)YW"+J&[<(
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M]MS36D\Z;IW=&S4C8SMA/-MKCYTUG69[- A[KAT?Y&3E;WRQ>3\;!]IN.,=
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MF>^L);NNW1VD2:'L&X!HTH&9$;ZO2=4KW^C>:\!CGK;G?QZ-7![+::N6HXD
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M\>JV>G,UY<>5,LPW_*Q30C5DW*R=7^ST8$%\6XBHHF2DSWGB?2L;+YFMW*/
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M+NK)@$_9.,]OR;2\DQQS=8+,1$?A$5@K.[AIJ35J-F#GF[E%%^?/W/B*V2%
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M,>J\.O"V_^7S G\3.)0*W1X@>J]BGX:UO/.-P!-#OU@_X#QB3L%A3@%R>DC
MC 3<4,NA_LV6O1]0K X(N6\SPX:+))L\/R4(IH@L^G51MZ,<MR/8VBB.5QMS
M%P\,*Q&:;Q$C((<$M*,/ZF!S)L1F<[(*Q@D$@;,^L#^7/Y9<6R3^#=I.+ ?M
M;#^!G?OWV83UX*C4,7>YUQ!DPX/G8K]J+I:5QC(++K>$;X?F9RZGI3G(]UV=
MNA*%'>CZ[7S1$"H+X,)JZ,VEZ<UQ 6#X2DNEZ#DS-0QS ,(#3.I8^91CPHK^
M])J \(&VA(WO0')&_;]G4M9%R"DZ!$>E@KFK+?&X$>JA_(A^U_8(#WBU>./8
M-VO,]SKV:#:EOWZ W3R<]5V-(S1;^2CQ=#5(-O7_%P^<_CH=QX)ZD%+#21\-
MGY"DI_7I/NFD1KS*W+FV_#7CE6-E._\#I<P7B;QF )U8*N9)X_>>18:C)K9N
MJ69NY'&X8]&B]K-)F%1VH,B3!W1,3DAM*=T74P$.),5(EHD/ ? TX6C0_12U
M+W%,/.^/\Z>75]8($TC9[^'Y#FXQKVXP[.PB"=%^Q75B:%=3E3D03:>GWCKX
MT^(!\%#'1*MRXA#SC@OCL[N]IL+]1:LA:>R(U)O%)1)8PUY=4B!I/:ZP6/>S
MY'QN=,>7U.QJ+SM9!'\Z';F?B2"*@P)[HR4LW:.9L&)&[&'W89*_JW#1?ZKP
M(8I<(5*J?? ,G.C\0_/5%WC@UB]0C^$\&L?\NG17BP<2GZ&3\, CN<QS8(CB
MP&'MAN,UBSU.K3\-H/ V 1#YXP9WH/G0J=L$)Z7,@@H-(%1&&D^HI&44O,U!
M6"Q9D<#YQ$/ (V]&08CGF@.1U.N9*'IE;57@DKXLE1CA6T"H2X09^"V'N5*?
M0F0)S#2(^$TRPH5/ ]=3;#G54P&^K39EZ#X7N2EF2=$V>$J!3L-U4^^=<UB_
M5J*,_%_E9Q2N.621;W-L:+_>(&1(% K&Z_ZCC\C%6'OU=UV*3(G=3GM+J@>X
M,7:Q&C93&_X!-K18(PTJM1=M05"R.'&%G@YE$/9*^/T7)57!25\@'Y?[IK&*
MC[@.:JK%9^H'(V=FIGQ.VI)3FS][V% /3#(.BKW@-A'/LKG.81I%=JG"_:0\
M9CP1#F(P[T#M!@BVG_5-2' UB>V)[EQ*>E8]ND97 DHV>;- ;2<^[J[$N])T
MS9$M3]5;--&5_[79\37GHI,T[J4 !V(GX0$<L_\#:$0LXF&B2M-0[G 5R:/'
M8X#94R(2BNOB0=XT-*D_=YL5G/2W#@9!X0^QEUW+:,F=[\_%WM'5,+H4"]KL
M^%JTIG!F#_#"$"VG+%6Q9P=I>$!),@E9@M,L(&S@;2X*7-#UM:@C:@LPM5/[
MJ[?9(O92PWRA@BN*5=IP%7*T(]S?'0\P3H$/B91XK *)H&UZT)4#>=?#:@(.
M"=NT5*%_7;F4)\SP#U3+R"S!&Y8!_D5_(>]()S)1*!"FXS02E]9,"^V[AO0^
M#Q:!'NK#5M5&<8I\>, '*F8SZMT&.[VJ2$=PF*HP7"0ST<S_'XJ<R$8X</R8
MQ 35',]\[/> P=QQQTU21*M;._CB0,3U;!/][ =["KV\XT<Z_GT8D\'2#=PE
MY-&ZCO'RW>B<3D[M0@$;&?]!R9?4U]ZY]? 11 W3L6VM-(BB4HVQQRUR5*U"
MF3+R&LO31YR2_!_?V')/EDQ^Q%ZP4@[D<@3/W#LM^"'&5]^0*S?5^=DDN$V#
M@KR),8C*MI?O[H^[Q5$)ND#A[L]D]JL^M@=Y#Z[:]G+%W.'8L08MXP$>IY1
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M8:VBZ&MKV S[:%SRXME5!Y*?6G\1$1.HQ .Q;_'  NB'R>$\$H+3U MIV6:
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M$YW:XP&Z!^A(Z*H'$GUVH^67&OT)?MMR*(N&XDY3"&H4-@4?(72?&PS_!F6
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M+HCT\'&4V429PX+]'9<A'UE']G1EN\OLG$8A,TF]%S<F3G\\F^+]*KUPZJ9
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M>XLTB_JCSE@7N*=(S$2FO3AUK.@E11JPU(_X=%27WT__/HR:SSL#9$$7#\@
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M:Y,219?Z$QNI=2EPQLK\(7])26'=S!1#-_>M\3+&M"K"?9O5%*:TTS=:M)Q
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MY@7DF2)F-R^%-42;X[0 6WAK-QIQ0IVF>W#\S!SW4!0GA#@/_I4JD8F[$$4
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M4UP@8?K$"OI.'*?VS2R:M[/)2<4K,S3$[OC9:"GZ?E/Q$'TKH<=D1:M^\ET
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M\)[M\1'_B+T A$JL+!W3( D"^B5!ZB) :&W8]_-7E3<"E^NAYSRMA1PU*A<
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MT(,%DRGH3J6ANF5$UV6^7.B ] B5(==168P;WZDM.H[*! ]1^6@L3D5>WM(
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ME4"LD_L%H/O3!8#\!*US'$40O*BUWU)\-!;EU=94<9L@F7THWG;I>N D^ )
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M OEP[[/?]]U[G_.=<^\X]QOC?N.LY/DC8ZW,^?SF_,VVLH*;Q"T E&K*JLH
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ML[/*7H)N,)= 98P.7D\N$8G]/DQI:Z86E*]?RZQX->ZCL85:@KQJC"O448+
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M8NLVC_DE^#@+H;UZ"FHK^-VOA$L(0W;4XJ+Y/V/1?=(QYGQ$-N4A<C#Z@,Q
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M]FP>_D;B?CH,JWDWSYVW3>B:4;Y*W_WI*-B^OLA2 3_<T;ZA9?U&-28\1U)
M'2]ZW#Q27N)F5(G16JI!V"&("A.IKM>4I59)53+]8):T;(M6=1DO0;4PFNN$
M69U*3:9O<-DG>4-C.;&;K>:GQT7$$D9(M/M!.Q,,[<7;[[V(TQW.C]#?F5/B
MO)/$PW@]\(KD]</2?D[TNV$Q#6'C\:P'XZ40D7S#LPJQDJAGM4>15W0^+?^,
M?=C]Z(RO.4;=;.Y!DQZM=7\#O*]^FSEB#22-;U/CO1K0PFN.J=UYZ$Y!N.G/
MJ,FS365BS\\8^>#KPEN/Z5ET)CBI^:S@94[DT9,*9$M],4:Y2R5VM</CS<>
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M*?POE464V]^V.^=%+E/;[:U5B<\462M;1ZM0':=+S@3B;8!'X"_,K\Y[R2Q
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M<LV*&\V+/L^<(Q$"+2QJ\W3E6+"?5PK960;;>PO["LLMU,X\)W6F81K+PC.
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M-Z1GE[7/IS 1. #$=M%3?%&/.Y<Q*G8H21_N4!8:MRD:,C,\JT)1G_O+BN"
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M>"9,.",NQ\WT^4@'DUQFD:5PAJ7WM4&"=ZU6%F]>^85C-]89-K$E7:+QOCB
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MSX="K)= K^?)#AJ=J+TX\KX?% 8;2"=G%7:+5I0MG;;329/&'N;Q*GONN"+
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M_TD8,I]&HA=7AHNO2'5D.4>>T>I!*"1?2%[ )2M#Y.5S'O2OP&.U@H%+#[
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M_NODE8MOG@S8Q0%#/0VSP<RM"9/+)0Z\@E.BZ!_97/K6^ZOGV*$R7 U9\K;
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M!K-LP_5*SFS^,YF5:@\K=X-""QX^LYO:3:6)A8G=R>M%L+>5HHE0;O!KK[&
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MCZB8\C5]"23ID,87JOS1UR9QJHDV7 !=0VEH5XP6F]UEFYIJ=KQ18QY_]U-
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MUO1:>_.P++AC4%C@D4 \=\ZE\8HH@96PHE, *6<S:&?)[>S,*_3G\5KHI5,
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MVL:/5KGZ7"T:'O?;:(_*KQ%[UV!89Z*#<:S'_%:^+(-"U;SPM4N[XUAA&="
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M+*OJF7,+6T6"R=23:PWA)-_O5SXTV D9T<S\^3#]I][H>$X;Q(:QA9$B* =
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MG +IMQ:H7T-_N1+XR[$2RGJ6&@<@WS7D.9KJ%V^M'N(NV=?5R=*,1NH3UDR
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M:\(&G@[??65KVMIN:ZO)7#S@\S"S6T-)B.F3)X0Z?[I_21#O<^E3G_^JQQ]
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M:\-$3)[FO#L+^$+AK472K'!U[F7Z;/6W5M6+:*'639&KX<R;F?-E2Z IG;<
MQ\.X\028CQ<].GJF]ZJ+G[440W]J?XUT7F_.Q$1#KBO,>I&R(GLA%,UJ'SY<
M@C$YOHTFT>PKC1FH$3SGUC+!7\,GL.W-\;KY_N%7*6-RAYU6P8*I*JLZN;.9
M6@67'UTN;W'8+*\&OX-?=%C>2QK5D!U8,D09H%UG7\]E68R7S^G!OVW6@MY)
M$:'%9A>^1[99V"BQ9'8XO;N*9BTP;S(B*SJ)A[ZL5=NT2?XVE-H_NC7&H)0W
M8F34,J:JKI,%H-B;\CB+=$@D1C]$2+(XCMN31]2L0@-T^=E@#0G^YIHMV1U6
M\25B]W[$9BOR:5G10OWAM]QN#&3GW%<IN#IVZ7;*)V)JM0>G&YM#>IIMU)D6
MC#0.\"'P]"U4;&2OX9=EKF!T( YPG9($^O,-Z(0CL?KA#\W:\-[3A;ZH)KP?
MS9N39' MPL:X6O42DV:FKZ"UFA ;0W6!KP,NEA[XZW5.";<>OV5Z7CD>8?^V
M<VEMMZ7#YA.X=CP(.4TUC3$?*A'?HBSW$R"R=R8=*RN+S>".UG7Z+!%1O>/C
M!3;:*R5GC\/T&+QYDS%36&@&C0E? 9/)^$$I)819/KM5?4R@33KWVC#7]$F0
M]WG, Q*6O24QFHX1', :?.5PHL 7T65M\9"9K)^!.;#R4 YA>- (.\O;! S4
MHPM0=ZK$=I?IZ)E@;"*^>P;,_MPO!%4\0SIO&-)\3TN'!PM0%K<VSP@.%7_D
MPA<F[T%(1KMRB8W1GYV%PM]2%LOLX)/8E[ 6^#6KJ?/8 =^':$B62_1F_O<!
M\-A=8]HW0N&L/?N-WBXD;$'IQ]P61ZSHRYF6'\7BQ89*0M_PC%*EI'T3%_BP
M_B*:M"*$R6&E^Q4ZLAE*(Y!OC"7G;ZA2J<VL"5S7#LX^B6_-I+_*5J! (I$\
M[SZLW3A]0>$8Y,&!HDV?%:^PY4W4S[=_*G1(E7MOP@0F,0.@UDRKC>'5+RC'
M 0+X+4\LE5<C+"?U1C";RL=L8 4[I/:3DNBNLCA[Q\P T&20LR8FYFQM2DW,
MOA[RI"VP[B+:E9<J?V]6(4NU@LI9E4VAQQT1N&!4:K!GT[/N_#SJ(PO3^,_;
M*4'M&_^R]XRU4+U"1YN$1G;$[5?FI8#7>N6M6Y065='=H2T%%0/C[2;VY]\[
M<YJRO%YCT&*9&0*C+2A)<8#>PG=09!+A7W;-'U9P;LP7!WKLHQS3X95';60)
MUL??P,X8:M,D&):>'9I"P.'%M6FLH#(85D??<6ND650J$7AZ[U=*J4';GM>>
MJ_D4S<+OL&8'T/U6.0SO]&\20,A$PE7/<E''C6M)NV J?!$L25@7(5?_5DAL
MHHX3,PKXO6X+^[,#!*SA@2Z,-X/0JJ?+6$FCCIM(L(8UTK!CND+"TC3S?9&/
M0N@>X  64$O/Z9.B""F0BPG6TP,?-7Y[6S@ 8RJ6#I^^<8"E$<)#"*M^Y Q&
M: 9Q.#_/^1*A,W,&9C28S?GD[9QCA!"#EL8'.9-8CR)/XFY#S_0#: ,?% %U
M 8-0*[- # =A*1RBN8. ,S@ ["]#!N.';/!U77P6])DP 'RN)C^#@!WNH2BQ
M5T?@&"O87PQ[JK9F;J2LLKCT5V@)E.\8?FS"A64D:L0!=M8(0@A* 9$_6/"#
M3OJ+$&V\$&Z*!@^Y'=YJ'*",#X[X(L&+ TC57<?/6MP.<(!0M5.YT'_(+7UC
MT9'R8YVN^?])^;]?RM/I$A+_=K;U?YS1*E"^+2J"%P2:Q@%.)776**%RFT9
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MYB)-L;T1UPBFN00G6BV<=<X,1Q"S<!8F?E#R!'#Y&YFFA#'#B^SD!26XX T
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MD0_/7\=)_:^FWMJTA\ON^Q. P%&T1>=N!L]P?=R1RRE^&B> WP#,^*N9<_H
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MD\V1#!+A<YA&&+YD!D+="KH"9%VI#82SFD?E8-J35W!;VW?-&-<%W;PB9D0
M1OJO[835[,+RY P/9N+*3': STD_F AAP.Q*Z-,I%NIR6U/6Q64WC^M\B>B9
M<S$7%!!P-"NUFU.>OM+7%5GZ.6;)WKV1=54,J8C )WN&O1_%P.4$%<XJHEP&
ML"7,5=^EM!I'STU!?VE<DW "(/.E"*_W0V^2H-I=$2O#AY9N38D<'Z8E(C\
M\L5U@*.[[>S2.!/"]2GJP8K=TD3]J Y2MV'L9;994D$UZ,QC(OTLO +VO/QN
M/6D1]&,AC96OQM,BXKB8<%]ZFJC1K;?/]YL7%49JCV/9U-6/N+M"KZ5-=\6P
MX-\5,P;>&=IJ$8L8 >/)';,TC%(E8C6L_">;;O=5.%GY:90.%L[1H"9;$J^
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M[++EZ311+P9:9\/ 6!P/IVH*S1R8M0MN1F>9+IL4/8UY$^]]K]W'COO%7H<
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M4]O6+QR:=)".5)4J57H'$0$! >E(50$I$9 >(("(]"8@(%UZ!Y4J50A5I$.
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MZQF+_#,L(*3AU_XP85>YI5RG7W8S@E58'UG+Y'8;0:XC[D@)B!<>>/%$BAH
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MDZD[\1J@<O3O,!I?F G='8"3SJZX'-+L(C" 4RZ(; P@F !^P(S4U 3"Z3
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MNZE//8B'U!TZZKU\'=MZN_JW#B 4?@%PV]"J,'4A;,NWLU7C_]0X3.+-TQU
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M0_?W%FS*"V+SUCUF%K[*\1^BK?(R0KLV_N[")4-?Y3P^FN;IK<B0[1**3@R
M8E>0VN&MF8.>6Y_;Q<\L@MS/"(C8GSR02E4N,<;%C2>=J%9N#* Y?@P#8"G6
MN3BRZ?8A^R9,2V\/ WCD,S(97'48MG&. ZW]W&J'_6Q9IR(C,^7:G1Y\[3:$
M&D.LV)VBR#HRBMM*KF;7 \Z!U="/W2$S'6L80"1NLU=0BV'G_KTOP#W*>@Q@
MOG)$?,-=T%Z_B!Y;-\-22QVS# RZSX]_N8&G="Y0B(9-59%<[C01:>HD+]S
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M$%<8KMM"G\K]"CTXCSX4]G8YP7;53>HV_Y('S/V;=,6H0MP:FOWACS-8C3$
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MWT'@ (Z:+WWLQ^[NY5((SA@E?6V([A4I)XJ]%\WC=N92W*,L*M?'J57=**]
M/A<&/U;E$2OMN5KD;1K@1/>*";15D :L= .Y@DB0L3E0?SN2-<SF&7LXRN5K
M76,Z:_B6F*@@RB2)ED>5N:<"M2YA>6DH?WUA9+QJ<@,^_;7LLY\=,G=?\!12
MLRV 82S#]!H&8#J4X20WV=_.7QD[=Z.N]HR^A+15:OQGL-"\9I TI&C2WH?H
M&7\5B]SDK>+3A'>ZR,5R9L1*P!-UM-LCU2F$V<>R=H4<Q&C@,)I=B2L-O^>X
MICSV@!B GO=K(Y\Y'JOR4ZBL*3O)"* 4:=!JYKM1T'Q<!7C9QB-W%T*\NV&D
M^H+JMN_Q].-X:5/#'EAQ&E?:G!-+[O, "3![B\]'F$W^G#B_RX7Q_6"#A1A^
M-_&=%)TBK+/=#QU%"+9-DX&OD:KL-3[LTPC<%$N8,LQJ^9#W^LN+W0N"TC[A
M^A^!I'%:K^404V%Y*,4!/SX/V*<W(OY"ND/IL98LGSALO6G*RRF#P@%7305R
M9QJY^MI %:4A68UA;4>FZ75T!VYYO&[Y#D;< -?'P>REDS0I9UP?8MUOMO1P
MV:AC] 5S4;TG;+NZVFDC?RW1O!+XZ'*#3,Z:.SAUPOXH8:O\6B>[BNS0TW$&
M4Q0K!6O\:P317'9J&9R[7?8R7*\V$6C[-F6CM-C[:E=0K44KWN?07F3$?*.\
M"C(S$ZPDKXZG *T=XFSR=S=]5JL</W+KZL5R9\L F\.W "+"!M_6&INE&<@&
M*9\#G5'"AMS7I"UU30&8HNA*8H3;9_SCY'F)Q1>\-TJ\LI/6!M&!A6%Y62M;
MF8T)O7P'T!E_BYFUPRH*DN5$_6N,7$D=)-8QT.<P$0ZT35VC^7S-8P]^9U.N
M@[:'\"GYB\T2L TR*F8+CA>\-ZUB6J^L&361ZX/(/2@9VG)5:\;7_>+;_<K@
M31W^[C.+9;,;QG,V(;.U1KYKIHZJPQ[+ZFW7I$L;4Z9N&T3+$[+G7!VL"!;O
M[:[)L%4P45#5RF4H-I+-072V;9&A)(<V-E'R1?(Y[6['%\@8%UZ5)5_DN3SA
M@V<&@;?.O08?S!U$7'P[IJT#;R]Y;243_2R(V?D8-91\C_6*SF[G#9,783E(
M[OG25NLQ3[L2X3P_7L[45X7FUSII:O@JW FY3Z5*4_:I+A5M748IS;M$E2-9
M9E)*A!GH>"MG3O>XEBL\E)-%='7,#D<VZ':\\#;:K#E,KKJJRSSOR*<ZNKI!
MAP$(37EL1:()1CP_>X294QGW> MW3%%7M0FIBE_-RGXH1>;?WS8\=1DY- ,E
M,#/]LF9VL;KL7=7VQ^IIH8]B@?K$;RKNG083,2PV><&GGCO-;P4%T UN-O';
MB3())MI^_:R4TTS;7HDHISS'9=IR?=[^T$USM)&[6=(I97I#'G%QSH M:?4L
MG\;-^&%ZA;NS;WWQ'N^U4V43UY1,P\]:A):*G.<H&5L8/R&OWMD/0[KF&*W4
MT+->*3NW2OG\;CRI<C;)>-V'H*\E;M<^+S M^UDC0"WHTT,;6R*3#E,MI''5
MTQSO^CH";MXVK%UZ; [RD^H7[H+:0L+Z6"+*7XFPV'/P,:&:A2JIE^O$62J,
MCKS:^-54X0?-6Q0KCIFPU:.F9YSJ7J;R''JKT3D+U\\D>'7-N\&E!BY=;4SO
MO]VANV"R/V)>ZFMP('C:[P8< VA3Y]\#4CB\7:VV9WL^=>%&1*>NM?@E125\
M_5N2^I^@%;03->:4LOR51ZDIA1]=BCXF^NC(ZC9$+;SEU'>WRJ'@YM ?4+U"
MX#X2^@2FE/ZD:&U0EP-:VF;$DU$N]?L-AG_W1^S\=^^27^$KJO_EA6[L:)[O
M3P7W'?&X!FDSB]J51+N:F2+4YE@;+>9,J9NGSD5^1(;IZ:>4[!'8!'Z:E-T-
MI@E<X@#4X<DX#I=M+S;=0_;--I+C7CM1@6Q:-!:D<&"ZN1]3U^2K?"_YB@5U
M??D2>TK63NAHX)VTQD6W>6YQK0;)JL/4H9FS8AV2)F):R K3H;TY9=$=0X/S
MBEJH&QV+1-5733H[^B@=U/*14BWU"KLP__W&_ PU5^?Q>Y&PJTUW<JOEYA$E
MH!G\ATGF[2#F%59J:!*V)*F.&3]DWU!WQZ>WE;6\N:[)T'R!ZE1QVO/7Q1 [
MEV"O.]B:[UWQ7GTL>,?H<E0G8"2OU+'4<<,Y)=+%T4_,='#JQ*DN>]Z%%5RH
M@T %$,!O)8CJ#QB13BKI#5O8#PY>>YB1=3?B4Z>,!H"F27!(VM,*'F(J-L4>
MN-2FI^J\X;);:%,YE?^4^(\EX;ZV)FIX2?JQ*C)TO%-,W<DJWUYTYXN";"9G
M,CT!"3GYV.WUND_DKJ-5LF2KKI^10G-/]+R&5F5)WM8ER5R<FW.7/+1D7[RD
M_.7RXUHBKFK7<,LZ'\.-HY>7RN-5%'/U!L<<O0-RZY!$[93@L68?@3J*#S7[
M,1-.P!;EA0"BB_6<*V:&QT+&ZHYPL>8>'K:D;XO#EM!TVM6PKA+&0I7,L=;N
M3^&<_##SZ$HM!95^W&,2V'[N(_SS1;-FH3Y,.Z4AD&T9W%L1<7=$\N@*/C4?
MTR9!/<"]0DA@PC5TQR5\^ER5.2',#@8)F0V$4*[5%%I8"FQ;A*<:*>'%TIQ^
M0-SKH^@S%HP>T*=$^K9#R5#J?FB-J)PU*4&!\YMRY6RW/_J2I>:4O-#)>='P
MT=7M!8\8BRC*Z#+2O6-*#.[5ML'>8B8\[-'K/&9<DV#,HMK2#RM78^A17*E[
MC.\AXSB>*7';\;VT5K']E.Q)NBP0MBS6[P#]_'9BVJS7GB>>35$]C_%%-"GU
M^]* < L"7?/R#9L!<;UIR<9!']&M@8#,Y8S0]UN_[JRC9LC^;0NN_5T*DSNQ
MQ"6"'0$,U2,B/"6<[T;XIWO&JWMT:JMOV1Z7U8<?[Y5 T.?"!(]('+]@D=I8
MPFVRH]%>=5?-&BJ/6D(K93LP>::6VHID[U7J)U3PJEQ(P<O,7]>!*Y7E6X3R
MV=WAB59B A0\NT)##L"K\@Y!L8F:[U*-0>'^WM\7 9YP]: #C3  -(4+"+DA
MJS"1ZCV%2DL[9 EYWL2"-.X0DA>MF]T0,DA@?C:U/\!IS?KHK;2O[@B\(XZE
M.+Y^I3K,Y=X:9Y$<P1<\\F#"*UG8DH$  R!63SS!QW:A*-:I;QM<B,LQ@#<)
M4&P1/]Z';2(25B?:3',AMJ5]J"B%QL'+GB3\V?653Q>-#:4_L]XCLPQX_2(U
MA*7=.R0$3;12#B[L](D*%=X0-"T;$U'V)!47<&K+ 407V4J%D"G+2.F6(N4N
M0Y<YL2W"S/[.]T:16.'7^?/,2+*Q_<1L5]H6)Z/J>9_]&N=.B,#C'!.8L9%Z
MKK&:X_UE> L\7_F+[*QNQRFS-H_\3>%"J=?CCMW%&0FKXUYQ0F\$Z6:?PGS"
M(\DEQY(Q@!9*:PS@!C\$VR/5I.%ZI.\"0+[//^QV$%-:F3"! U$/"A]K,>,>
MMH2.2HMD.R26/2Y?W/P@<8\! [ +'RW=%T@ZH-,6B:B+;:/$1G-W0L6ABJC$
M2/&-]@= ^!-#2+^:.:YO7?JV)O&=!1@ 4J8!MW:MAT:0?*E.A^Y]WFA0FVG$
MZ]!J9:W+-'! O!^?-Q[W3.QQT9T@OV2 XLUHMW:_EV2:9#@)*:TQ]B 1 _BM
MA8L!R'W/S/YN&244&QV.'MCFSA?'#WNW%6>+':D=7YD R(+/_8?]S32N2DR=
M5("\T"LTI]X#/&@_KDZ3HH EJX4%#K(,@RY[M"N>[M;,L8BA179N1(G5#Z&G
MO\M<"?D-N6!6TRP)]5ZCV]!IM))3*5+^)L(FM5KR4XQUP>=\ J>M"X96=R3/
M$<_#\W?[SJY(\G*UJE>6?W0D=WIC\*G]T\@,.:$&T?TQ@M\-_KM:ZDJY5Y)?
M^TU@P[F9TJTTT@86UG<GY4UT V.Z@HOG!ZR K]\=CU<OR9XX^K!PM9 >O_Z\
M81&Y[:F;-&MU6N7T27_O\..X\-U2*:RW7/S56WZW47K'<1=-70#3PV-LM-N:
M@Z,3':U=K>G2G%A26J5Z3\NE<]H<MR<R<!ST&647@>E;4R\.OAD2D:'0A X5
M(Q9@$^/LG72$A"/LI(]73%Q^,X7=[Y,S0Z?(;4;JA \Q@)AE)J60RD8B\%#E
ML3%@5C>XDH]U)O,,.6#FWOR02 YQN[?M/QOMX/M@ CH'UHI9&47IN5B7U.G*
MO-A0^O>F8_']8;I(A8F 44@/;O;55S3W].-_NL4?O_CN%NP_W6*@ZUU(5=HV
M&DND' 5&VJ^0;^ IF?U.\)\3N@G,;MBBH&F'K/DQB@K>YM\TH,1&KK\H(/E#
M >:P6E]##$ 0&Q$+[FG%F.G_X(3GUE\H$=GXD^D7-UG_&\17^TU\XK7_,?'+
M<(S^[Q#?'QL@E>+29K&5FF8PF!5OZ)'$J<4-#$ ]M>Z5-(7UUQK4+<_YYK42
M[+P?EII8D=<^N1#;;[/(F\CY33S;>U<%7$M[&T=SDO35>5&C:%)A<]<?U1#U
M\(YH:!>".[@20O?Y-8OCK<J1^R^_OFD(MI;S?_ ^= 8;?;^[9.,OD48>;?D'
MF\^0R# Z9V45\]ACP23S.A(,J822K71;97TVMD]P/?G,SV80#7FO<\JDIAT8
M4@Y>[5&)[=@3/C%6&6:#5M;%D!:4I[U29H[NB4&.:F*'5OISZ*]L</5HX/8O
MW->J@%ZE]NM?>/!MB_K#U(MPC>!Y/KLW8[N^9VUX(A?4QCU?LNV=?]QN <;*
MC4!PMXY#2>VTC>WT#BY5+[234XFKG!^A=0U45+B'A9W".NKPS[!<28&/8[4Y
MT-0'!WM_G+%RPG#)!%V]V='XI@RIPM#= >%"==D!Z7>.!G<8XEAH%8F6^6X0
MCYL9_K3XSR!F_EM:&W157^V-5U'@R#SQ[_S?Y3C($?05A;N%XU;H-;X//ZT0
MV?B7>/\G*Q=,6V%]AQ#0MLRMF" S+_@6$)X,1@7%NLSV 7>[=/%FOE'\CQ34
M"19LWG=#YG84N%1E;6_-WK8:=7Z1-K%T^>8KE_SN@MLFY<,?=&V6*+R@ 7U=
M1R2N.GOJ7)V&Y0F#1Z-\XX:*7W"U"H5<;B#?)^C?)"*L#25_TD/SDJDZBXJ(
M+8LL9.%A*B/</*2!$3]Z69(_,HHFQ+TXHKZ-X2CEC4W-\*,KDOH)V%AU#[3(
M_H\5P0^@G'G?U5&?B0VMM"S^BF7;OXI'?SIT';W;21$&D(@=D'WD&D]7*=]O
M/@S\?8 8+XJ_A3_AW\.O?3$\=!OZ5Q<>!.(;S*/E_BYD!*4>9A=%D:Z4K?C<
M/*? V99W2FJSA-6;7-/+306U9E:VZM$^:8*M.,_\K$6O^"F@FP0/*':*?#XC
MZ(^0D G0I[(U@W?LJ7IU'_P,$)YCCYJ8D'%M>EKR,E.O[QU0*KC&AK^/?,-\
ML&%"[:>&& NTA3<NA3EYG)6_,592O'[KZ$J2Q/K"JQOAY5#R.G'Q!?T;QRJ0
M;GS$E _$NDMS1J_<CP_NLZ6O>6:UB1=ADSEG5]DUT_AVR&R*S]<N>[NC\V[0
MM6M!'9I-?-6)W!6+\34G%/24ER*AG-P#(/XC5.20$;(0&T3(S<_S:[<E><;/
MU!NSXU=$H'UYK*-8W'1?G!#O92/$V@6)D6)WC,\ZMM$9><Z>_T@M<?F9C] &
MT=V#^Q0^,[+T8,BM1N00PE>[MBQP#BVC.CII\PJO/+U:\8*M>/?""8%; "#*
M_!U"J>U8!\$=XE%8)[(650USU&/UV+ZN0_S:-=Z=4@[ \'XQ7SMHK5SN:$0G
MKGRDZL"OSWNLP>D-TEPY3&?$TU>-7]8R@W$ACN^J130UHX#R @%1:)@Z,FBV
M^*Z]38])>1UZV)N]G(2[5TKQVFIFR5<6_;Q2KFJD0Y)2D"RKD;VL]"!HE@.^
M4ELWZ"*H:S2X+3I1\EILR:$P>"(K?JZB067.<>O9--$BPH_)J2KMN1]MB<R4
M\(ITCV](C<52)?](S+S-0=>2\ C/KH\)9W@^\#G'AL>[ PS@J<S<01M,(R5?
M(,T]S[C9;W30C-0VFNA*[G0<<)*E]VXG(NS]]NJ^D1&X5-5?;D^K>,;XT:W'
M'=I$.0;,CQXHEXK X]>!5)S(> 05]>)*(I/O,DP^-<TVDLZ; =+(1XD! $JL
MC/J%QX&?"Y5281U34UJV5OZ+60[,&K9R]_B':\1[.15!9%/U%UFO96K<KBJ:
M[C;>D7V,@+11D(,)&:P1Y!7V69<_ZK&Y(>V)5VD5#>8_6TW%:CX+8 AIR6PK
M+5U9>W-MD^EYK3E'^'Q0JH;;U=&&*=CB!R#,5RO.-)9X 7+6& .X)[.B*R?=
MNA]UN>9\187X$FT:XC0&T'H'I8$T%GN=4_.$ /VF^+(40=I^9//;,B#7QGC=
M2GVPZJ7N_;K"]F&_0;V!;.>FII BL-(<\&F#+\TVV->X8B2XKJT'/TU:Z23[
M NU1C&$BA E%8"'R0HQ58- R=N?EJ5JB!Y.55$J3^('7/B_H4WMS!B]M2&6J
MI5=2J1,^]A!)K+RDWR/0=#VZ]'R-\WOI>9%F/Q$H_":H?"O4JCY.E5[*DV#8
MRBW5]Y9IFR'1(O>F4R=KO%8F44DC2%O"ZA)WC^>86>2HC\_$$:@M]<J -$LN
M/[HF?]R^.K*9RG!ZJVRY@%"->OE-DM?3!L-,9*>&&(PKTR4?1LASK\9OPV+$
MP%-[7=%Q<;GSF9.T/MQ)T-/X+-,2FM)66<"SQUWXXA9)G6NC*V\4@'F)L=00
M:3Y+FG*^HXEOU$5:/<O1"Y9D3%IH>G%"+D;2N2V\R0KUD?S: XU+G"IR]"[:
MJ@P?XG,R,HJSL7F5YC@U18%&G[-/;QD;903H;RC0:#VHQP::L.!^+04:$X'
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M.PA/JN.9T]UNV_?:]Z8.-7?V?3 ]!)W-W;;Y>>YV<3OP?YJ[K6?TUWF#%8C
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M09J>L);B!+>XY5= <X0_G4TI4Z;U+/B9S<L$@[9WNE(^'QC\G[F\(I1"<N$
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MCQ OLU\8[K0&WG1XVY"-^-6O@7AEU^_HX*T^4!D=?4 QKV3=/9%=5[>)W:U
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M9(;(H<[\%R['"\T-?5)7Y*??Q33WG5[$SCX1%A\9^]Y#.CJP*?CRU >)YH'
MGT^4X;9+O?HVD+<8;;".B$B%2^LOQ-;<WVQ4/-T?6:SX-37P K_Z<LF;5;?
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M<XD)T3+WFAR8RX\ ,]H)?)LS>\!8Y"#&[][6BT@/D@J/><X1@?AT-\*1-T8
M_OFYKU>BA9,5"_?\2]S9V"AZ$FUH23)OZ;'OA%5#V@CB;<JRI\F[-=]U-1 S
M6+T]I4)S=-;=Y)H,SA,4WTO#*C]$W(<"M?/WGM#=,=3Z<?V= K5GQW&\V@;R
M09\!?,^I1"%9F\1\CXI_T5?(,-S+WX0KX[Q=)7:4/>2RH=!%C557& ^=C^8T
M&FKD\I.DF[@QZ0\GM5K!I21,JT\:NQEK51<&]-G7E>ALU BR_-J^3A7&7,01
MI_K:4%A^'W%LW.K<'?/2CI+'#<,L=]Y7?6B_'#[[4H_4%#T(YUP9P/B115)_
M</.Y+$X+Z1N-O EV[36Z=C-YAS\9H!#8:?(CVM )K:YI_3RG] =XI\^N+>*/
MZJL5S[\&,R\P5=7,+;KF""WR"<T,1#UW66I2&ZIPM<J;WC'J=Y]XY^T%(TYT
M7>LJBMQKY15]:L48IN#&5!U\&%NR(TGZ :E/J/(=B0$(%YZWOUM==9Y-V>=I
MZL7=64W4:["/K.4"QI)+6N 257F</S9<>^"D*W=HY0?&&Z"50^[CQ2NC+FG?
MOCT3L;4*NG+>.UV7K=WU&$]Z0FR'SX-S8;N*K*0>[)8]6%0(KG1ZM^1M)7 D
MD#[.-SRT'U9V0'WDF>,5N*8'A AAVQC J[#D:MQM'#=-UFBSIF?F-LUL(J=C
MX)B(^MH5GO3VA:+(E,9(5!_-A#+6/"U,D1/GP),J5#\ZWH^^]^K+D5IK5CW#
M8(-^"!<E8[9B(2U*#:W;46GGQF7ZLJF.4/NU6^;T;0_@ZZ,@)!O-@M*X6M>"
MYZ.ID+T[>/2I;5H?MNJO1(=LB;\+R*4;3FAJ%L+F#&=Y49O/IWW65$9/7LZ1
M"I;B/0&UO5"-W&<H%DCB&+-O$S^..D/M+:P-2OHH3=U:0*0!F&\DV#B^ZZ@X
M TB@RV 0P]^K&8" Y5,7IO;)?&$L=VO5UFRO@H%SY(O/<%8T5Y<T?_]:"64M
ML7!LL_&XAVZ.K]\=DTMONNX^C"+W1GGU1 QJE@+21KXMP]N%4"%P@1SF .;,
M8>-V&F\/F$+B0[V;ZIVAJO&:A6I-?ADMT%OZ?6WX?32S(?Q\O"_&M +I=[3S
M*)'_ZBID9K1Q]GWAG.&@=C+$-MM8VI6J0],:CMI/@PT8JI1U2^:.N@<^D#,_
M$G;J$^(^7I.":V8 207LX ,\$PI5WY9,3J#S3%1+GOI=HR_K-7<5I(T%0=A"
M2(UC]F V<5?A>./(CYJ;IZH_'FY(^I$:W27Q575P2BN+0ZFD]JWE??YS_N_G
M@C/[8XUA,N@76[IC 4TLJ&EQ-S\55*?X5AU'7=ER<-<WN4'EF ?G(0"@KF3?
M@7C%/MI(M?>9X;/;$NR7\0D,+'\U^>U=O'SZ4=9CG9R(N$CG-Q&CWHDT$R]B
MQ1%_<]OZ]-[>_>(61<?V:64L= #HKC:UZ(F$^ WKE/HK+[2M(:FANY9VL1\1
M-Y1BXGC6QG1ZZ9W(UP$$LG17!S]8_&-Z^]QPP32G.VNF5 /?79.^ZX_R=EPD
MXK(.13;'?^5;&_HU_/CW$F0:RE(/KKA+[U:&(A*SIESKXM)Z.I_Z^E506X*T
M320S^WG9+4F$VS"Q!@TF'W1&Z8(WC\:/P@_&3XM8G<E:^<9]#3(\-EI\'L+V
M<\FI0(42E3/;J+[LTK&A'WFKOG.H]]KCI-94:A8[@'9LM1[_V;&.<4TA)71(
M18U=H @U9KX>JEXY=M1UZ<,,IJSOD_693+>U535RERU81[[>+BTTZ'X,7\,Y
M(AONNN_-1>P=O%U\2(%@IJBF?CS/,O3TC<U-F M YC&8=:]!44W1EEV!VI"S
M@Q@Y;3'/OMZA@&Z/U0LSJ4TL3%V&;%_C1[<1C]:5C'>1<&I4>\MADG+FIQ<Q
M^KH7YDJ7D";HR:X)2-OJ@>6H R,5(2G[B8;4LCV'O?JY"ZS\?.H[BAN+7)8=
MM(IZ\C_LE7D _; <P6<,DU^!5:6_\"?;M;4==6F/P"56&MH&DJR0]F_<;LV;
MWC$@!@?%-'=$E*3"H7[U#&"5:]9:ZH3RX1*?&R)'AV1WMWSWS,%R;MKF1*(,
MK,?*-R56/KK>+"VY-W#K3.8;+PF^1T?U)6T@V31-T.@YB)BK8YHPT:D&.U^Z
M NK$U<0H'UKIUJ,Q':HEAIO2UXZ7IB$HYK=TJ('0&?!RR</>@H.*F?>YS4SH
MPIU[5_-V$!$+8J5?[[.S23<-LZR')1 N0P7!"1ALA0'PZWR&=18<'L)6D7*M
M[ X.5<1?$\ ]E(O7P^LW[F9$:8&QK3NZ\34\-]MVHF*)2Q7SMWC@'?Q6UMUW
MA'XBQ>S3T;VH51PW.'2:XKK,>H9P"W2ZT)@_EM7\2[-DVFQ#IEYJF8E@'V'"
M< Z:76Y7G?0ALGM=\8SO3L6S&W5-DF.S J[-RQKSG:['EH,YM*;?4-4^*SF2
MU]K2A$*L!=M0%(CY:-'8:JBL'\\KP]B%&CZ!ZI/HU4Y]QTD@=O!>-#P(="5_
M)'VIO_?Z.<UXK/HUU^?NR]Y/?!V2,R$>&7K/FCW#EP;?$%BBNJ?ER9W9Y( )
MTO((KF6BIO=Q>$W3^BE7ELA?0EM"@BP_%YK7HB?&V@(3</M#E'[-%LRUBQ<_
MOAG@B3A23HSF^?73_7(@51RL.\X4.X-K;?6KE3D4KI;:K(F]EV];^8=S9VE5
M*T.-@_56D#ZVQM(B9-EFF$!UOM>Y,;H,>*MUWK7:J:+:ZLB S*T^R*'8:+'N
MOHAM'5'!:AL64\'_.&S<RC,"%>-NG3X7IZS)TM*U8C_D>B=H-!IAT,2.[NHB
M<-;T3;!V1BF-5/<XGAP(*,I;'YS@< Y0'57NJ$HB&G@UH5Z_ R<I*T1<_ 8T
M"7Z,:<)N_&R.N+W% *X.?%=Q5OU^,#_'MJ&MY4#]0OKFVQ)ZK[OV,,:9DMU:
MWY-V"V3MG'>]'YKHC?"+]Q(]*8VLZEX8++4DJ\V9M_<(F(.7YW('5N&P)8'F
M*Z/EQ6KASSM8.9+$-=4?3+R%3V^P;#" =O\;<R:@/\DJH+NY8,RJ8)[#*+G3
M&6N+S)MF&0HPM"+K6^]?@;'\P#@_]4L<HQ^@'%KMG3J^=#_KIRO+^_-2>E+Z
MCLO"186NJ"CI^D'5)SR7KP>,]HD@@NZ6P3+Q60= "PJUF2Y& ,\3X_M_8*":
M1C6Y297?E,*]_+ZEMW 2/\16BP,[UK/^G7&1Y(36=?#*.HEJC&*C2FZKU-M+
M'^.^IFENW=IT IN.J$:DA!"2IF7((POQRM4PCN4P&VC=I%9/F*3YH6.S'N;N
MFUN.K3C &:,"!CY&6UI?05G)#_AG3K[PRII)DAM+ +EF=9,-$>3L.=[8,*$W
MPQCK4C\1X2-9MXHN0Z[,??Z:#/P4P_KTI4TX)F $*(AS2.@DR-4>$9>3M:C1
MVH-.,KCJJ+G1&]YQ0QS704C%BD;)@D.6H$70X\5ZD=L!A->5"J.K>=Z-[\24
MDTU^G?,2NMZ)>]V5JD,8OTDLB:GPJ*%/]8>JJ/Z@B%\U$]X;UEU3U2=UQ,B>
M".W(B'6'4P+PY(*94V/:.-$ON[5;0PZ/6J^J)K9]%(.AI=\8=0!!TUJ[+PU#
M@ZAP-**]27*HG$GQXM/@<S4>/V%='W>^H\ZBO+/\A=1](]:),](8=DI8FSL'
MI19/;+2D"UCIVHA?[LV_\OZJJD>2DP@;[6,N+<@.1:C:3JS&W\9"&_2*OG2\
M6,G#IE;0+"K</Y$TU'I[#B,O!#1+->/MP1IRACLE8Y6'C.V8B#BQFT',&3%=
M>4<<ZTO627V^_<T*P%@2WP5*.4>UPH0"0G?MK8=#.D?N.[<$\EF8]C<AU5]+
M/W<5E8J[.4ES 5?("4@0=7,N)8-G&FW9OG-7W&2P^N,-UY031V@)GXR".M'S
MK\JQ5QA BOFL2#LV7D3?(5.J8KIL:U=XRZ"\FOJCO5+.#GY!4><[ ZAV;"'P
MT4X--0F9/#%GK4O F%XN<__U:K5=8Y=4\K80FD\SI5ZDG1FE*Z!?6 PTG"="
M(1^?^JGY^A*1_&;=X:7*5SF(!V?#\P6IVW@,V$.26!/SP^ZEB41Z'2JD\/0/
MAZ;XT(,$';H7A)0-Q(0@TD\KPA'M:^,O2/G,X=%L?:$)#8<IK,9CWN$5H6D8
M9=UZX^L?7AQ@O[4IIC=7$<$ FM6BZ;+@3=)Q0\L;]1WW,IZT//-U7/_D[FQR
M:"$8.M5]L?!ZZSZ '"A 'V_2H"@D-=C>) 9*H:&M$](ID49I36GX'ZB/:X=>
M?CI%C4D\&)4SBB9LO:(04FE29"][T)LGKI$!I*MZ5Q>H6'&92V;^<#BPV1RB
M\,4AX 55"W,:]"5A!5IFU?8Q!2E<BL)#F[@K C]89W+]6;?6O<L7;ETZKQ!M
M%:'3]WV5]"[2<1:38G3O*0/@3-L8<ZGX%%3T*FLYF%\;N"C<Q5KKP\K5AI"$
M*] .@ \JT-ZD;S_2\"XE"?)C_JH;EM?WFDCL?]]2OP#!19#7)B"="$F,/WG?
M4,?T 7I;X)Z5G;A'+WV%,]7?O;S=RQW0-_"&%>&R4T)R;%8Q)XETO:]Y]\8S
M<)\UT36?_UO[_3L6LOR<2&.#L3ATR5;H;J$._C<0[JU;? TBC]?'E&^6*3"
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M(._SUFAX3M&3!W(Q^OVLBZ6I;\0,H2ZV^IEW@HU, 0M3C<L.<JQ9AS=8OLU
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MKF>D]*Y2=LX+'1<EB"X$K2YC^5,.PYM?1E_HR<CU,;P2C5!&$A4Z<;>%+1@
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M!WJ&N%6"I<#H_(W6'?KE-R+JX@NFN'TE]KC-=ATI%<G.6+!J8@!Q5523%9P
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M]M?Q63+/TAZ_U!-:@U65W*9YA%-822+M2"%T,((3GQA7+9QG<M?PP\M*PVZ
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MWEHG( [@\-&,0';^L9QBC:LJL-M4I1H2(\/.H?RJ.(P0+J%4@;3F]/(C@1Q
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M:D5*5.T)).NQS]P+[1V^QR=66W.E5GJ<1=JO#XC5KC<1V L%U&\E5*#E1&>
M#^9+R4@29Z&YV'UU/<_5M9C9:!IA/@\:W;\?#FI-ZKTY.X?X'2EM3;D+"QC1
M.GSNS)+?/24ZD9\9DG#&O#]%+%.]%V (+0D:C8YP'KT0N ]OJ1V_.NVH!DJ&
M>V]D&+@-0I,^BWG<VL)UWGCL2W;XD&V?E$\M%OS>[KCHT1',,1R?$@G<>Q+M
M+.(8(Z9><[U3$\7FBV*7[-N.S\:DB!&NABFO![2P25G[Q_R4O9///VL),'4C
MO=".GX R\L@C;*+H&+H)@=(FD;^+=*2/_-Z82?1Y,_VD@VUYGW&Z6D=W0Z%4
MSZ0?G2JEB&>V1O-& 1#Y5T-?(]!LHB!KSU#!@R.+:64$9I:]5U H]VOQB:3U
M@O:9NH3)!?:8+CUI,JMH%.MH,^(-;8"B?0H@+DS%(LL"HVQO,ZNP=\@I\>L.
M>R*N>G:[B%]Y5R[5I7VP!0.[T]AQV0;]2$X=C+-/TV*65GN?AFYD;YT%[%8]
M)X?OTZA=4C?\^*]PZ:WV87)63!-+X6A)RH6E^[7WN(W0B3>^[ 5YFU@9[&"*
M(;:5\\[A_%,J,L8:?NQ5QE9.B>/<6;E3[-)2N^),,'Y-U, V^T;$)>5MYGL5
M0)KA+KM39^PGGKJ=K*K+^ BT]T-LDV=?!Y;'H,"@<H'M:[>F(SSEJ4AC^FK$
MD$H.B(V.6(E@IL,FM\.A@>QFA%!NTA&8;TNF4F5WI*#LP!7R<85;GYOU3:%Y
M\AX=,;DZK6P5X8 !KILMS+8D<$QUU=;"[9O8ZWQ^RB]U=5Y$E0!":KJ.'H;>
MHA 2Y7UECDTV/-P]+$9(WV0TA*?9;%(J?S(U"AO<M\,('0Y6PL] %T3;#Y]T
M0VL)RK?4]I[0<HHV _R?(\AA%;>GU62KGD] /C\& 27B99*3#^%R$<24 #M\
MN/1F@)T,5?BU#S%,<."[6_6VH'B4ETM'.+0K+3EDC'4ABNRM&>Z+#$S*:'4@
M!!C1CVG1Y8%%1).WE%/ ?7PG'+-H2VOY_<WFSH)M8Y3B$TXG';R@HO?Y[S*-
M^$8R^WNL8.&$&\2]AO:E;U^8JZVU<SSER.[2Y@,V+GF3_1%]0%@);V];S_+>
M:/#.U'%QIR@T05[9V'DWY\L;3XZ7&7,;&88>U\XP=SN# C^.,MCP?E@-ISAO
MO2EHC0@VC?(0R$, !>Y(8']GCURM3#?C#/0(JQJN@4@6,Q+>[EI**#?5X&'W
MU(1E^N^4X^^5M0LVANJ7=!_/76F!@'5@8#U:T5XIA34ZU#P@?[/]]:#M+,3+
MSI3C7;KUEYNHOPRE;*N^8.Y.87E/QA>9*? DV4Z-RDVR<)E_G?I.OE.LQ%\D
M,?$7[C!<:3 A@0;O%Y1_2[E)VD.10%5:0L'6P_I?ZSN?-_Q(A\Y'E7T33V<^
MX8VD*BP?G^10)DRID=/?ZC1CTTJME]9W8(*(JC>PG4NJF\7=8\'4;,#A:!_V
MLK("#ZW,FG*2$[2'-M!W'J=)"Z4UI QVM%^.1KEN>=F?I7/1LAC];)RP<BWE
M^./8:E,W5<SET>L\T)&%X9S2MO<:I%S#'+> 4]G//GD V/P?;PF"@_Q<0><:
M&NV!+B?"S4>JN0C>W#;_C,$8W9IO$@GO?QA*4M&:>N,O-,C6/8+R=:J%^]E^
MZ#Y71?:0!G'8VR*!WI;RU2D%SE 9"O:E0Q-2'R_K^[49?F>@4[KC#VI;H!"G
M3 _$DRK6?\)R7-JI7YZS(4^__+1T [_Y".&(KA\<X1@,^"CBR#E[JR(3R]O)
MZ*G62 NC,8VT3J<]!%E%UDW!3Z4I2KWX18.2UD4?@M!/F/ QT3XFCX\BL]@<
M76CE\FRW93XLCZM0[P?KY*2V(,V8"&;=Y#N,3<J?<=EOF3VZ.TV15GX+64/Z
M'!!B[.A^M(J 94]^&T3W;^.0BVZ_/EUKFBR<)G5=M>L;,G\5!JR1>76<UVE:
M.4QE7NEKAR:%PD /QDX6KM)Z55\E]7JUSU]YIJ@AK;X! S]P1EV 2.2[4EVS
MG\4X.%7HL\Z.?Y-Z<*=B';A;ODK3(5[_MZ1EN[^NRD$"'I[GYQF: (<(OX,/
M8X$.6!J"NF:,OTK-2FSR*@_:JAPBN25IO56\P X+9)5(9=H8"(OQ&""=&6,I
M0@[QC[C\,H>Q39<C-(52L4_W[NDN:E4]V9!\+1UK.]CSU_(A%Y#XB,>,58"$
M>BG,3:VI<"G?"CX;6Q;BK!,5\H9W$7(E^=*MH"H[.1J"B!7>P,_0D@P:ILA/
M'E,'_+B>%U]T= QFLKW'PS2JMVQ[:>)(O*_,>N XO4165X1YWGU.-S4Z.M$8
M=<8Y2S"\S.4:BJEE\MV0;\XY"1_DVSB?]_2JF.,JE5NF!C1>DG$NV"S':#*J
MOW;Q?;BS8=KM[7"VE:[ M=03Q<#([DM#Q:YJHZ6T)=WI7UO&:TW>L8&.;_V-
M6LE7=P'+5Q(!$^W'Z70#$E# ,* JL.IN.WZUT^JK[[BY0EF4*@</A]0M)I:\
M3OCD>F6TAR*KZT%1_](5[1O.<V1RWEL*]O:DF_M\M9H/+>^\G;Z0P*OD"NW8
MLN-";<7 C+N4&$QLI[I8+;4976H<XO])=7><G*XT;@0J<$M6P)C#P+='+YDH
MF@KUK(<W#=%"B*:Q$,G*3<',I,*9C2S"FM_ <*,T4G3K$PLAFP+EI\61>+#U
M'Y"5M AX(CXN+F:ZJ-KDD76AKF/08RXUU7 J!(X'<WJ4=E& L3_DQ5W*<DPC
M%PTT9.\^3K\',&NFZ1&U%'COD9R5Y;05N(S3#Q._8+(-^275-PV"9T\!+Q_U
MNZ(K#KAS8?TB:A),$;)7R*-E3>[FL"N$V'!A9V'.](-?MM*$>VH3H*0,=WX]
MF5- 4-UT^]V+%GB8@&!<K#+9^'[3I+R<0^8>WM9]S6\>'P=09VU^#I7NC2/R
MQ<C1X0H)*V/?Q:AG4"'FECQ&)C=RW_OMUXPG E84NKD#C>]3'PA+=(S)2A(>
MX[+"QY WO,;6IIL<*1Y(R;W\D/.@(T;PA4;O+U\,7>Q\.-\VXT5H1JQBX[ \
MG?>(J*0\Q9.%2;NC'OBB9(9!K-5,1JG-@5>C&/3G\(X!A 7Y"+!O&H^Z6$A5
MB G'%=KHY6_]UOQMR63R);ODK,Z!E2Z*^/3@SB^,*DWL2,W5'DCWDHQO&K8V
M[LB6,6AHJ!]7_MH4*[>JG!K1^=F :!,7'2X7:H@/54#/!T;T40*_^9 01P&V
M<$MC:,,']$XE'_^?WS7A!8'0E;B$)Y2XA%!]*JA/,"+:73F>/JD:7&D?U"?0
M,XOO.+L-$U[&LWQ8>><@I._#D!_LG7+ )%3_1L%,3?=6W?;XV4MIHQ9:/Z>[
M@V@2)-/X<"TJIE^G&B%V&SNI?"33I?D9J2HG?YWE+,A;Z2M,$K*V 8<(+'<A
MB$ <%+C>#DY1V>:O05^<0#2WDS_ERA5>J<;GQ1O3"\*D6!;\L/\F+%\".E2G
M(C#"M&O:W6MU<9BYL2+UC7I-W /*;FIM<]3.HA:R?E R;AC4K'[FG,#V)[2H
M,>S*)!0(@0*33!.R#!M.EFX<&)CO9(U<3W;POSF1N''=^7__0D]K%WPDQ?(9
M'<YW!_4;Q)Z$(+1T3*@,*WTQ5;W;)G(;Y$\<BP*!<Y_;7X ZDB5[""=:S823
M(1*2<PL^9K.Q)_@R_,_&5&51!XWER#SU=9GUE/QD"_*5$#/6%%K'WB.*<!GQ
MEL$]O#((R+E@6F_YH_'(-SG!P4L\I%;#=MDQ@/>C"XJ)'K:28B&D1XI+4&YI
M&R>7-N-_A%Z_F%G?^]2LYL=GRS6 @Y &IOCCQ_QR,584&A!*)(XRA#HW1(\$
M!;;T(WE=VDL3B%5U(24#Q>^I-J9*%0]"LMQB>S/>,:6'P/&OF.M>A-Q_Z<HF
M C#U,OGOEVR^%:<7->'70M4GZ5I.7D+%^[>5&HR4JIJFL"5!2SC,[/M0&V'!
MCEJLK9CE> UZ-7,9F/YM0<"J,'R5D2RY9);NL*)%8;<Y $'#V]^W*6OPCO2]
M4T!/MMS7[_V-#4//8G*1%B8R[V@91]=I"CC#RD4<0CNW>L&ES"25-+YYA]=,
MU++G@0BOP#IB;N/\,""P-(LB;WMYSQW*X;8-:].TG[DW_WE<REO#(PC7%(R*
M;DQ0!E]PGG.L$4\?')%YYK<^P'5=; >=4I@(>/2/2BZ6I16XE;UC?X'.V1)M
M1(LL0Z#/%3F0PBRLE^,U])WQL%- ( _K#L96[);S "#TF!*Q]Q /D5D."E5;
MD0F!"M:[JO'5VFXJLMFP@<3\B?MU/34XJ^/L[BN;)[]U4/;I5_<>:MZ;K% >
MFRE+ZQK[:BB3JK-A5Y HQ?(MQ'X684:1C*>[D\!,FZ11RRG?C]6-'Z9^2+89
M!]C$.IWM_C,:5Z*U#.ZU3T9Q^+4Z4,]AEH?U;N=^SHZ9RLW%[;W^LA+K8AL/
M.4QF>H\I28R>>]%Z"M@:8\;_XX;X=/9?4$L#!!0    ( )*(?5;D[V J[J$
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M^%1>4?FYZDMU34MK6WM'Y]>N[J'AD=&Q\8GODP@D:F'QQ]+RRBIF>V=W;_\
M>WCT4RXB@(3HC^/ORL5P*A<Q*2D)*?E/N8B(/7\68" ENRARAE'%@-S:A>F2
MZ L*YINQ667-9WG$[J)9'KH.4I[C%4?P87Z*]IMD_S[! OY?2?97P?XFUR1
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MT7=7-V7:[/#LHQ\9')\DUBE7M3^*TM)E95*-&,/W\2D$0&F, !R@#4X:WQ&
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M?W41'))_\1X&SKQ?T=&4O?N;7_&OR(( !,)1W0?X%E;PD41A9@F\N1&SZ$,
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M"^)T6 2.N1IQZ!C\(8L$,Q%1>>#OI?O0)[E"[Z[<R%*TB3:"0\=JGQ?-T1*
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MU(?^BLCRT:=[9S>S/M<$(R$F#/V<3N>S'Q)1-KE+7Y@_&OV V?INJUD3@PB
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M^LZ2=EQEU'TK>++(<V"%-6"Y9$OP:Y>195W1['UY=)M+\J[E<R%)5#NX/&N
MFMC(-M9L) :[<\PP$]?8G)9JRW6U3W7%X&IL*D;GQW6Q=,$FOXMF#@V"V!.I
M$-:VR;&H;/[ A7J([U7,QH[+?EK!];T%%NXW_:K)VT)42%!$G1R: ,P?1)7(
MFWQP8*\*+7GR<>0N'I$\B#RW\PG$OUDH>"L?2A3-P;N92?<9U[Y71 #HH?$Z
M/X/AA1#9H(:D=V;Y;Q5FI@.DL\'&-DTLVU+K2X5K?DK8H'E=)SH&:,/J($R!
MKS],:"]-W;TBWB"^Y]'V@^>4W6*2Q#3AM0IJGJ!*4(2)/B:IM3^D.-_!.SWE
M/9C+UB)$NRQY6R5_BOI#A<N5IPJMRF=7_'WM2.9 [4><\._FE1 )_)C<4[%3
M-SLOK;;1L[]W>Z?3(0[.9"]9LU$2(9GCR%WJ036M\G"(2+PLBVC&L$#?5(7G
MG1K,!&%4@^%?[RE887_6&-(.IM@KE>U04)]!U$ =,WH#O:6IY7O<JF+7K/+0
M$6V?"0"SWP5L*_)'FKUBK;VC#233KLPL81H39!X1ES)!_99/38;G#?P"G1]&
M*F)7B6R%R2$97VR;8U_V0,O35[:=?>F=:2AS^D5,< A"D&*KLMBL7[LB-H!W
MW.V:P[HWH&>X6YH!?^I,NZ(H?9("NX?D\E%.[S$<VNV:[9LS<+]\[F%F \-;
M*9NL/HVG)CJHKA"<N$;S1*EV95C9Z*RP&!G-1#A-W>[,QYYH N##3+2JA0&U
M?((:.S,)AU:T(B;NI5L:;F@*#5QI=8J79KL0&&\NZU1@6V2_/[XO)6+YW:*C
M7-6%ZHP6@__5;@U2>I5>F$\QE$<5HQ'0:+>6TJ/I+.Y#HWUTK*N,K6+5R4=J
M4"H:7^Q2:'J:3N/+@"9JPK*@L<32 ]<T2.']I)FT&1W<TH/R)%D-9:5@&J4[
M6EE5]I%WL'&FQ@(=S$P]-9$H$AEI('G2U"#IF9,"! &*9!WWNX$5+,;FW,?<
MR7'\0,<]9=^J(?72C")K=/Z6OWE\Q8U;C)LDGKQ+Y-'#*.=VF[S9GB*LX5V,
MT<$1?VB1>TJ!\7'/T+U)(U.AY.DOC#2E4;/FW,=?,NE*VL)]\ DQ2#UV.RNZ
M@/.5]6;#VN%/OG/,=-.+>1-#%O4886J8Q! ,Z#Y6U,/W%B1Y*\S1N4)(7WL6
M)LL;^N3+Q1JDS(5TD/4E.NTC6Z14Y*G%#N$F&\-I%8!VA2YWZQ2<Y7C;<N6B
M;U>'8OZ8_W6L82>> S-B<A?J8U$V%C>DPM)<EO9X&WQ^<N(XGY23&P(O]A)>
M[T?C#YJ5J.=KQNXWAN%47"[7%FEJ*-E_<;Z1/\A<9/.=S/OKO#[QX+_M3;'^
MXDWM_NY-[9$0 *:9&_#AGP'0K#\'0%^\^#UGX:+?=S\ \_A');QDV8_"F7/*
M09;7S(S**%BG6-1N\^7L0]X,+TLM<OOY[%23\<J=C XZ;C",$[MA@SQQ5AO?
M@Y/J9<%MBSLB;/F0$Y9G(VI[F+V>RCXE"LBH53[7<#8_HLX3$]$&HJ_LI[#
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MKAJ7DRR:K2&L/?Q9#J$A(;@4IT'50.UCI(;HXGNG6N> =((.0<IR3/(]HX5
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MK,[A"G?!#[ K]9FE<SB_GC&#T3W>2)TO ZYC@@I&$;19]J/#U6L>6*%@4E4
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MR[3JA4*>BM>VP1[%."]3?'"%$^M1[5B:=@7CP,Z+FR_<K&)_>5'M>EM5!I<
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MK_Y'"3A&#?U;I7Q8$C9=N::Y@;3;?2)95FV40'@TUF+* =B)JLZKKMGP[*G
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M&G:[U_6(AQ7?##[P \8ZN?*R@UC9'B5' 7<,HBR66@3MK<]B0.&QL'!%=0)
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M=O3A:6#F*<?HX+@<$GI$B_7'(_3PT8[ 2KB1CI9\JL5O_/_9TCM$'+G7B@D
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M.@#EZO1Y%U:S 8B2DP/<)TR/;<W>[.M''2?^RMLT0@SQ03G R]9E=JF8/0+
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M3IU#1_)A00L"=ZPSDZ\D0+U&2(:(GG(E905QB#,V$_'"%N< K;'$OQQ''&Y
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MM16O"0!%YXC(7+Q?BDCIA$%,7J[14W-UM]<02W3?2#$?3^G['5D2P:;0MZ>
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M&6*':_% ,=+!C,PPS$;7Z;AH*>_D7;T]BD5T<2"2_4V]AI(FZ*1=K5*9_Q3
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MVMA>Z/N:VSH5/ E2%W*]DLJ)^8!0QJL'8([315; WGEFYI;-*)<EY$OP7J=
M4"=/WC"RX-ZM<(6K\%1]6W-]N,"'B>]^S-<UEAOL?+([_&1#BK/K)J0I/-8=
MW-B[;C7?\#>L%8J2@M%W" SOR6ONVL:Y+)D056MJ!":D,V)J,'T]GNY:*!-6
M7GK3VH%@!2":@EHN-L;6EVU3NK9JMP0UG/)ZUO/1F$RE0Q@>M@_$<G^^#M>!
M[BA7*[)WH()X0I_5U  =8!%$.GG"%1P?:LS7PN7!+9L\^8E=IMU2QVD)[3O2
MPY^-4K:;2IO>66XK.=A$ +G C&[%^'L3;5ZKXZ#+._3KVXF$(AV5D\^[K [,
M\]<'*W2H9W?MI00Q/!&M@<F[K'>!1V,9Q7AW#1RUDG9>[O0:/<1K2=#M"(IP
MU;#A E:#<?[9[[%;'4WG?8H>CX#5;6_ #NQ\0^X<B3R>>,K5HA$\&*XOP<I-
MXTL7"7RJ$Z[$M\-QS(2<LB&:KVZ__4:X8]-KPB*^T8X>N'!9-JB1U\;\PG&E
MR?>WQ->P,Y=L0>J5+KSU*CR-Z\.^P_#'+S.,-8AWV?A.G"OJXTV?UJ_ F?VB
MYE&/TF)%=5T3I;;K^Z6A]T[*P?0!UT*-M-3N5O>SO=B,N@8T[#H1?OJFN)')
M\T=^0_IJP98 .N6S@BQ&\7)[Y;I,?)'9FE[\^YE'B",'OLKUY#PNP8]O]50$
M :+_S;U>%*INUBZ84T!(F<^!F=4]*V_],KY;K&'S.G'VU5Q%P_E%KW]H[3Q8
M1H3G1(8+.LYQ7SD%4#<YG0+N&W\^!02(\F![]N&[TB">@^&)JB$KB%4;Y$[K
M26(H4:?]+,!#_^[QT!]?] ]@#/"F)Z!.DO]:=AE"%TBO@MW1SUP3==4=!:\0
MOC"-A&3'N0?/-X)/"AKE\53W\9M8K_[CMLJ4 VM.'/7.VM"EJ2^JY<E&<*IF
MP:#U^<8.X8OG]S_1%^ZREIJ-)JN[:\UE[#H:M+8FI)4K:4T0KZQ R('.6O<[
MB8)U,M87<=YO-C8W/!>NS\_J4,?.FPG3#O=<$\FL+FW=5Q[>>CI4[XV>B;J^
M(:I@AK;(,&_A2'+\#M)GXH\K>ERZF![F]A7Q 9S4(1.MOT%:\>P%F+[4A_Q!
M_<F[4X!3B;8+Y;2+G0V]<VF5N.N[;_=94HQ@_.0"CP\0.CBU4*3K!8(77LQ#
M\>K,PTBP?(DR<-+>U%M5=/&I*J]]"&O(7%^ UG>A [42DU%DCXN.=DUY351O
M9>;5L ==;*KG;Q(B/]#U+TS-Z ^![<5;N"2M<#RA4NDV=&LN^69J+A=:UE*K
MGI>_J4I3BU:IDTCHC3WN#@'T!? ?/UOS^UFT:$6%6GB3595J@ZO,XTY3&K:R
MBQTCSWAIE<10J">SS,4*'1N"/('3K=I,5LIR"^.L2U 9##X.(_72D(#+IA9O
M']X$, C&ITB0#?[THSRP$;4X'XWY^($NSD/DS/<0.BD$WRK&5^E@3U)B,%JR
M1/HE&UK+62UV2XN0_4VA=PR/DV^$LJUN6C:U!W ?M#:Q$O2PWCI5-;"'^")_
MI\)V-\XG[<^#WHR:\ ?7V).3'Q/W#B3O1=\TY';?56HR-V!/H8F]V^%(&CJF
M< MCNK=YV\>U34XU'N7OB([<[8FYGOLNV>?*T\O7+*-)MM_;U7/LI^(/%NEH
M":YX%?M\?.;X\$[K/&\FQC"R=6F(1[OZ@4-+?$A_*/&"C05),-0AX2WPVC(4
M<"BDAJ]#N09#N(C7UY7$&A.U!^N=TUY4?%BS?I"@%ACI6-;%^)2D)R3HS>W;
MG@5$+GRV)I[_6%#=&[.>C'U/O))H6!\V?6+&Q;UFEAO+5_W-I?3V!FB=E+)2
M0D+MGA.X0C&?=!D^J89F":^W/;[M(_1H:.\A K%KQ3<^HA=R\[Z%YH_H['-D
M=$R[*E)\"&6HY[\$'XK3;78B&(_HL&'8W O0G]#&7[ MF2HN5[M F+]2$6%9
M^I(K.4OPOB?O]Q/0*%$0?'M$Z1K>^YC#J&:T1!0\EMX[C%@J3Q<9](V7J+RS
MFK:-P-MMD29 T &86.#:BU$@?@_@"?^B%E0!#VNZ*!5#9Q,RW*-O]N(%ATY9
MP/[^]1L#?!:JDVRF8R&AP2.Q(F.@=V=+,(@NG)N]8A YM?7S^69/N6:!M;KG
MG=GVV%4!P?3$#AVFD3_M$DN-=<T:7GA8GQ&B[/IJNXZ[F^\5)-FS F53,;8Y
MAVB]ABD7L)RSRBG?5,A8C*;K1^9<D(N/6C,TD?P<>GQC=<2GM<U:'!\5F),W
M^B)M?K#*,;BKDR@'I#QH8L"_Z&SW$YU/+/BZGTZ5,W7C07RUYQJ%8A$5RN2U
M+=X?NZXV?.F\S/[:<&*'9?1G8*1T-X$'7U)(T,)Y0SL3*?'N.DG*#L*E7),,
M%X4:W>!M)H:CZQJ>MD@7XL/N"M.=?,V"U2/F2 ?4G/"$ULCF^'CW]"U./2$5
MO6GDM:QJ#I>Y%$8]E9N_]OS]ATOC%].)BB@C24PI7D<-IU5DX7QDE9M]<2U5
MMSATC],D#A^^+X>]6B"BE9?S,_2.0/CG:D&3%0[IG\UV(1=+KICG $.TF/.N
M;0RD<2Q.M&^%:]6U<-\ASI5;I\B5W>E\RA%%]ZWDA@TR/*:>@J@#"^295[MT
M"D@]D6*^I_CP!P2W=F3!Z:Y745N+"GKL]YW4XL0^7:-,9^"9DC_A(:Z)CC@.
MIZV84$DU3%6/PQH3R>[2U5%#]S)$+$<J9J1J1[9<MEQFGSZMBI.+WV,:\$E$
MD8?6F\;6PL.+Q<QJN[Z_@1ROOE1&\(]!GCP8*IT_:)X7&:V7=L_HH8^K]]W%
MD._T*5DJ$)DQZX54RIL?=\V>ZB5,$IS()&VDWT$<>4A>VHTH.#B^IW[\4*UI
M]@Y!2\OEV&S!Q\LHO"/S_)B4 3S-Q[ V>)<7(J=#I;>NE;=#KK5P;V)3$\,F
M14?N7"N:VE> #UFC8HT/W&\)JCDY=Q9*%(T367PD@  ?N@>#NN?&4[K+RU:&
MZ5.!4<\:W8:EBW2F^?<31Z2Y)'L36].HJ7PZC&8:M;+9N.NZH_VN@M;C!XV,
MK;O?.Q(FO]?H1WA+(?4L597_JKSG[%*@UTBIVI5HAP@NN3+PDDF5?',&CIXD
M#_YJ1>4CD[@U2#G+&_--,:3FB4GKB,B3@!3,2QZM*6")_S?6W6RF(1UZ8^B/
M/!'QYN6">QE6SRI$)BTXY*_Q2BAT"% \B?N13LHF-#H1C9_8AU;C_=%1)4!S
MK%=QK=2C\W+UY'X:-^^LD!,5T_8)AA+F D-)\4:C>\9L9+E)']FLBWU32\+U
M+R>Y:%LBAI?IL!B,R1LE(1W1QDCP@"^[+PRD\.S.N>7SBWMK<B;^#7?7 ,4N
MXE_3KD;E:T)L<\RFYKOKK'UX#;W8^B^>^XCK@!6N![(VE@]YWO_D_"KW2OW%
MZH]]E_=?P7_NPM[I+4<K;MK$-U0'7#<,W;*1/5LE"3YX'R_+:5/\<!_PQR=3
MAGB\"_ CPAL;B @H]?'J.-8?@:LW9M[<GOKV:HA'H[;:5U_#LBMOLC_#4Z]Z
M*M=EV/@L=H;N9DCJ:G*4J([/XR9>?;W17=KZ&3">\(B']2OY1Z;^$7/DBT^9
MD0F7:&Q]0IOG>7"&=+0E69-K%*K 85YCX#LVIKHT2?U/Z"V&4O#)642YT_K*
MDF. RMD<]L;U:[<BLG<E#R??A%OK46(X^:! Z[6:R3=",'&$>[H"=B@.9DD&
M"!03PQDK_%?K^*$%R.'4TEQH]IX22&?:H).;RHTG5HG+6H7R9'WN-L,'/\R2
MP9G?0[E1?_W8"*R DRKB<.[+T9X\E&;M?<RC18"--P2C&,X5DUXG,K,QM>,1
MBX@0 HA#K 1U?#VCZ0?2[? 5W<N>4)UI77@G60//"N>0/Z)Z_;FTO)7VG)BH
MF&UM<(>Q*:=<V=YYHY!61="RYM84NQ6E5S76)$9:AZ[FSJ6ZU+N!V6P$=R.%
M@6E2U.J5[)%ZT+,&UL?JP>L'%L"#,>X6!B+CQ(!ROM 7I?@F_@U9SE- SY^
M&1 9L$W;?,>X'E?T*8!DK5:2D;>'(46O\R,@L&*7_$T%184-S:IWV8OM%Z+9
MR;+1G$SGGQA+7^M/;8M(LO26=LR"ML5E06-R /&=C*7GDPS.)X7HI?D'"S(.
M+^HBZA2!<B9WY1)?DK,M#\>G<WVQ)C]^&#@B"68>DPJ05!WBQW%GN]U@6+NV
M\W:X95@]A2DN+N]&_X)PYD?3_5SRQA":JWNLWY],0,%:^ FT%A#-A0AJY,8[
M=[8U"K-#]DL.]G-PR(HO50*%+SR-[?J;%^TY+Z>A-YJ>BVS1._I=??<1KR6$
MAQ<X>YL_R.2JK]]>1*9,/O/E?OSI\*X+[V;7[#72->JEE/JHQ?".$ATTV6<T
MG,JGZ%YX:Z8D=G1(<"^CI*NZ*N6."=A Y8J1X,-OWU\:3FAAQ&,"R?#>WHI5
MD02C'$>32\VI$BH!'I_+VWJ-;,C?,Q23#Q[IDKNJO+P)]L=[NY>NLM^PEAP2
M&*OP20A0ZA/7^U2CQJ8?Q/WJ#C?29QTST+H09@Z=]"EJ/])^X_=-@/D@53CA
MN1#)YTD&.G/ 5GYQ'T>;GW>$AZ:5O58==$>S-D*'9E;K[1S%M\<!BNM)V(%.
M>'BC%.[&//=@O7VV<^UW^:I)\WG^[EL30;Z=X&=!\FOW7DJ HD(Q:L$_Z]5H
M@^F@'@6>-3DI%+N[M0:2"O<E:&K6/G">"(O3@5]@6:+!FK)ANZ[,J^R9-9?L
M]IDGG 2"KK>^I+N]!07\9!K[$OK><S_/)(DX\.LD'1!J'"B;;A R33:D8)#O
MZ'4*>$8M>Y_TC:I+&Z%3 4,ZW?"77>__[*8'ZJ9+^-2'V)*(AO$*3<6K R^5
MW?SE6M)ARC41;$K)N-A4M-9E]$*TTA5G)6'\83Y>/T#(*&%&>\0#>$G% 43S
M0<4QA_13>_ -]SA:E0 C7+AJ[80"G^A&O= GG_[OEBVMC\;GC!=>8+D?E=^>
M+30-CO4S&6B\CA6/V&T(),YHG60TLED[18J(EHSU9U.+2]TE%!MLG *N\U<
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MG0JC5Z]>WDI<U\M)KG]A]3C2,F,F!."^?I?[PC&7LF!C.LY4DZ/# DU6OMY
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M*T7?S@X>2F#T;I^0NF;E%Q;9#PI%7=.,*3P1YP.E]?1>:6A_ZRC.8[UC8!+
MXAZ+@[33V*-ID?-LV,M,*O(O*H+C/L<>Z^P1"ATA#B(E#T1 F;=&MQ;PR:SY
MP'?$Y%4B#58[=3%&6!&H665Z15=6UCC^<TRO?]H*8,#2Y/EGR\P?%YXN%&!:
M14UA\_8!JTII4[[<%CF!?=:4(]BG2+BNJT7!V2PVZ&:E"&^!4)@&\6'W@F8&
MD5=@2Z"2G%(GXP+%[_U'/M2BXB%I-OQ\=!=7QGLBD$77.H]E5HE,@?*L?*P/
M[74.#"D_JSSUGMW0C0YDLI..N+ZI^0.FK).5^ZU<7&B!L8#"<CDM 6I7[A?7
M!6*L66"_?0IP4B[4036(W4\9*>%8/P=?-?<PT"IY)T:?LK:DZ6.BYA::,Q6_
MXC)"$'[3V0JCGKN\M&(.#MJ762<R#0]I:6L^^^9Q71'=^/WE!/!\_67O X*\
M(W ]\_M93QX6TQCL/\-:'=*XNKKGEJVX. "/94#CUTJR(TI8/*^^ZA%OT3(;
MALW"+KE.E5I(0+XHV!>9BS\5?Q^(',+:=,J$R\#IQ1I>=W<>)@ U#MB=.(T7
MK$KVTP(+.+>NMYPD37Q*.]$YL_77'.B3*$@V?KP?I>:4S08\I!ZJPSQ[?Y-_
MV/.F?$(1? PT2TD:*Z>KZ\W86"54;W!(?Y)Z 6MT-C=4-?4O1]!Q$BS++"WQ
M$M/K\VSDQ.Z.U_A5= 9G8K$/V3X]08MLFWP%DN'O-:MK&#]*] BP2\<7B#=D
M->9$P+Y&IO;WXGITIK-;J;WF39V]Q&A9-2EX Q^!GDWLQV&YN@!K""J(EZ83
M.;''.M0[;]J:VM)"Y>9N/ G1$^:&76^ILE1'S8F>$#M9@9G7C&X.S]/X 7?H
MGK[M1!6QK+,<28HM8+Q#Q-RJVF2@.@YV3;TF:KD^=2KC=X]I"QR\=!R?&0/C
MI/OFP(Q8Q:G>3(YR\L\J(K!O$[*%Q%YKZE$)6^AV>X,MG'_[I0K=&N+9Q.PI
M@,]WYUK 6\VEB67W<4R& )LQM6+!HR#(7E$;$)7./6JOB<NM>"S/==AYLMVC
MC!?!%#$H=>*N[C\*&'H).['*WS?D:34*Z 6Q1-MPLQ%R+C>.US_-P5];]\LL
M>%G67,(]-M"[^0.6K/8*U".%)WCB6K:U5$7O02[ZN*G.>,"V>N7A$ 3W5%$C
M#_Y*/BA3-.6@XVB!(,#7G-4)T*>/U%?=.'*H\/\D@_O*T,D)XG2^69@-H-,H
M]?, AAWFS,\$+"EUTL,@FQ=;X-L+)FL3*/N.DE/ ,R[A[PXF$YY:6I%=<V*#
M$-*T5>1"$#?YR+G-(?[JE[<:T6JO(-287<1]<T^'&T;>>?+RUW^\E?/K2&C*
M;'K79T&0Q;9_)..BTHFF;9F#M%1<P>ZGN\*$6\9O0%XQ\0PC'4L=[BA.S;%+
M96/;Q>,99K+$QHR,=DD9-T,;E*")%M3;$X-Z921!M_.&-+X]L5977#7FE=O9
M*[B6*\)W\?F']X';K&>F$$!2O$JXDC5'K95C]A X766#+8%>SQWO3:701*N_
MS^AL@5/,,3S![F>JKSW@Y1DN_]E(ZL.^)8^D,#SZ5"X&O(JXFX4T*E13$3IX
MO_T5]:-!^H"_RQ7X3/S\7, WL<VF]>@S[YA&-W7?:DB7YS,HK0&>.Z7<N6H]
MHO+B<_+$C(-(=YD.T8J_%;9Q@G#ZE,'?F99$LRJ&@7<5A+;8L")#5*J@-Z2O
M=2K+!77NZ*Q;+ZDZ2[SK]S\:"WB5C2\^T9<D=G_D<JI1&]8A7D23FN G\BIY
MU(81AA"&\I"%7S@6C"4X$73,F1>BCF70)I_?MH3WG)^HPIR+S6X0+Q;"&2B?
MP(V!9'R@)?@2C)X'&3 ?J[9_$"IMP<3)$OT$@IDD>N8X'>OA)5SW.H@C$WU5
M_<"M!-#X:\UH)M;=XF,$K9-<,-!I1%0,N(ZD/ 7TZFU> T+3K6&$]HU;V&&F
MQ#W8H22LXN0#@=P[IA:MEKG=R@>1+M%TC>:FJ3\%&*$YR(YZ8,L&EH0;V(!)
M)8<P9"O\YXSP*>"*&0L/"8'*K6N0]_Y:;,^)H^M9[>\">KUZL\?I3@'G;)8\
M]C-E!L4G11N_V$IR!XM=2L0_JVAON=U=9KM&"^I& )_!26=)RSO04S#5L!_5
M!%H5>]F-&9FS6(1O*WK/Y8K: ]=W$$$1]?LTHH72:TW?M!MMZ:#0U$\EA]G3
MXM_[H@GV!RX3JUI#,W(N^6?^JSKAC4].9\M Q+[,-@<D0E\[6%U$RN7;V5I<
M-%DOSCBX8GS1C3?%LRI:_A3@L\DFG6SN]J;F6<Y!QENPBD9?8=)[T?F![6<5
MC'JF7%__ =A@LC_D\<<2"R#?W,_693^=$\!XQ6^)UBNK9J*G /Y[D(D\XH!Y
MY^]S_ #0T'_RB]?D#OHLS+K\[V3V7'\B=OQ &^$I91<\.CSX]TAYSB[Z-X+.
M5=5?Y+(=CNV_2#NYD^Q2H( _H";_!X"5).1_#9AY$?J+I?;JM>;=G+_^,OYK
M0Y0'BP%A&-CAL_^Y]'+_H3],2PO,1$ES@G@ AW:HRBA8#ZWU0@VF-;A;DNEQ
MS.(1:S9E1*\F&+F_!,>Z8D3A[456SL"-]%, +:A6=&&R0NNR 840,BG_:=<]
MH^2D$%9.=L"N\[*"5G\!ZF?-L=-_-I3ZPY3F@-]CM/V]5]<(\+MD$:3AKTAN
MK3'_'F7\0Q_R;S("0OY/ -AZ"_]-'O>(LS!Q_I\*_/_\$0X[T?L->7B._2*\
M"9KGDO7]7$=9=K&23SDG,Q&+L:O3%^G-!BC-[%Y*;ND3![S',\7P>[BJ]C3I
M4;_P\!=YP[OK_L<.=#1M^_M;RXRVK?:]*@)NR?P5_JF18/Z/^ &-Q$<X,IAM
MZ6KYI0&' @O!MAMJO$DOE3N'\P;!BCEX"XVJ$2D7N0GU$9>.R><;'TUM(QQN
M&^J>B_6G!#3*479/[/*7"'Z.7=U8KDSLBW4<O45^GIN.ZV*)\S72]%_'5,\"
MSX\I9]9'DGT*H 2BN,8A*\^J3P'-CJ> EEJ-WQ5*^]]"_^\7LL&K><*/V%X
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M_6CWZ7/:OG></G>,^][_QMO4@E'LO=:<WS?#FFO5WH6>1"\ 9&I*JDH !B8
M8%S^ .@90 ' PL3\\;H\L"]?.%=P<+"Q<0CP\'"O$!$0$1$2$!(2DU"0$9.0
MDQ 2DE&3D5^EI**B(B*EH:6FI*6@I*+\,0@&UF4?;!Q\'!Q\2F)"8LK_^$!_
M <BO8 *8;E@8K  F.086.0:Z#6"YU!,'X^<!_'Y@8%[JB(MW!9^ \/*"2C(
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M</IKC://@X)[IFZ[1(L[Q[X5[Q>((:7:G<<J8C!/=K)E"5*'S76U/2(WGU;
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M1E3+3$MW*'5UAW_>1L[]ZVV)AG]Y_J\R:/A(',YP^5^:C0%]$W<1A[%$O<K
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M&-BKQ+=(\83=5<G[>5%MN4C3L8N?0[;=\_OIGPJ&UN9A6?4X:$#>_S)3O7!
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M)_OZQ+71^M@:0W#'62G6<LH<5ZI)Y2#&"^B0C.41MR"(\$ZP;][$\(2.O+G
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M+7P<(NG5==_M%-H>L4P6I'\*I8,^WUD?HR!R?" :0F)!WBIP02P?_N[2P[W
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MSOE)K[K[\&-/UFHSG4N1V/Q S,..AGL/_7?*1DP9%CJKP+"=DJ;XO=E)0QS
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MVS1]AMM+_ O.P3ZY"237]7G_O5GNX$,B_"@DLG2:(JR@P^]U6QH&/M?&73V
M>7VXMB9>,1CV._)Y?PSZK^!!4-ZCWHKKWF7%K&/N8,#]=_B '/S1RLH_:I6^
MHKODO9V! [!4KZ-9"UJD;VZGL[<@*K66)FAM/<@\/D(6JX[8A6DBVY;XS#24
MLP[?'R@TI$VO&+UU^>PR>AI@&_<N(Y+^8LYXK+'J2+M3C%<J!0DG?X+.T<C^
MTP!Q*Y P$ZKS><!W#;'?Q<QZ+)#LGKXX&R+CSB,G50_Y1GJ58T<'B]^.5/WU
M.44;)"[UBEU)'%\6:5\1L8XVOJ!LZ_C\P- /P)(/\L!D$$I2/*GL (9<+$#;
M5LI1O<*H8.G(#U,L.-,]RNE-/U\\:!B5G5\SI4&\XUT]G9 >@*5?4-6:4'!Q
M-!1*3AU_=1O@?R/*9)-O6&/T\EF*PR5S@D4TQ2.UL$ C^_48/HD/ID0[*=\A
M!=L&;@9ST%FV\%XVYYZ5F]8$#T\_JN$+STD)?D5^FS')_4I-,F%/Y+D^TDDC
M5!RH<PMV#5G2' "D-C,@%SPC7+]?V0L6V9]7*.M])3M(]>*6Q_ C@M<L\X1A
M=P:F-L5%"7L"2=J1'8589N3:^RRY]+%%M7%=F6<[5*B5TF*NA+<S^@X?UP#!
M_:FA+X)M!QDR #5;1\U-TC.2P8$A/>ZW:1A$NO"<X9&&/'T1[ KIW$X&^KB"
M$X@:J7.)FX%45AC.' .S&!._#'"V07ZO-.Q%ZF*<5HSHDY6L(4>]STW"(UX1
M)0S+4.1 != /(YZZU#4R-BR3H2MC%S6(+*2Z3JQ2RQ)4ID'#E+D@S48H0_$D
M<I(TS-W)%+XWOY'A-FS-*]$Z+[.3$&<346ISZH-U\T-39HGFKB[:<$2@&DJ&
M,?+XT-MDBDHGU>94@HRWJ<RSH'O7Q-ENC(!7[URH"KEZ&'43?24YHO7@ 7(>
M"[^* Y!L!VI&8ML4@)-QH7>> BVJ]Y[+X@ AK8>6_>@MZ++NB+QDQ(F)_L7E
M[E/^U^4]%J6)4Q\Y6%QE:^0A3J5FC#R1]"10;?)K:P[XB[R,D;:+MRQ^<\39
M)L%)[Z*"E@O9_U[0=^F#DV:4RWUC W_@*3?%AJ42\$UFX,)SC2T)P4U,L)C>
M8=2AX5YR'ZK]*GM[X%8[*^,;G_VAE8$#/WSCQWDI;&^=^HKBV]&O!W_P-WTK
M$_X#Z:7D/"0TC=@&C2F#W4-4CK</8FEY->BN32#]1UR&CXKBQ%W751_1L3.]
M>*6B=W#5+7#+!1\1^&CYZ+SB,/9%X2A@ )-(_EKL?7<%,CR;G T8UP,],/]4
M1_:+BYEI:+\M4;ID0U>$LQ6CMEVVG-=3XY>HD#?5&IRA.2=9R*6<Q5._4.V$
M?AF]%WUQ\W(;?7ZQ:E^@#W$I\X<NHE**1TX:BLW^3Q^C6'3."X\(:OBNJMVF
MP0'4SSKXOHB/O! JFD\,F)QN+3(8):P5H?)[6G@HJ8RB#/9S!0N,VE#JF6TT
MIR@^T[7(^G*MELB3\+ WT%-&@& 5S1CY2#/610V]F.K"5>;3HTC6H'^U3Y_0
M\4JTKT KKY$G:=B<7,DKXC.!'XH':B9CBB9Q@*!J*K0'<F"BV8TA3D^WOB=9
MM%(U3.#2J?,G C&UD5YOZ/=-+[]R7T.*L]5L93RU@6Z+LO&LFL@'F'?)4W07
MSX91&VLQ3GKB^P&==(0[X(1,B6#7,*0YQV5^EL'R'_]OCHQ_G/2[HG$FE@;/
M>3,3%'XM0/MMQ40D9#)A<-=R*MX[1K2B>:K*L)G6/K<@I(SKIHG6Q&'X4LK\
M03)JO[P,XC=Q1H WH/I4GPLW0MZFR%SX4V)=\6!0Y)K<.5^.I5$MX:PN8H4'
M"O=2SKQMNEX+G*'=,YA>\^:&K?(?W%S8IQSJ)M6(V886HNJN"+44%R^1<"+O
M>7B4G@OE.SFY/^\C1H Z?:<P0*X2'7:Q*$4Z\>+:O)1J#L6"\)>]<7EZ@J@-
MOI?K[0]0CC7I*-9&7M_J:\6#;C5QI,%KG+JGN#Y/F%&=S+P4+LETLXZ4WI[E
MP[QO'QDE<K<93HVYB8QN/B.J-7 5%94\"3NGO:BCE/R2])PRG_[+DYZWDFX,
M-?7.LYHQD8;IP;Q9T;UI&+FS,29PQ\D#*-_,6'H SU9Z^,@>>5'%[1WACE:R
M3TLR;>Z:] ,?L9]HK3/@5%8N,E A:"I&)H[S?9L9MT3'P'/IK/Q"Y:HR/?_;
MS)?<Q6]DNE&[=6*YD?:Q#1*LZ()<\%AB<?BHG+!#6!V7)#-36'%X3TMB'LW[
M08\/?4'TO#43_L*@<V(/3OAFN$BB>+RFS0J'HQ\B;5YS0:WF?6:2/.Q-%*MI
M!:S0-';&SSZG>.D!5VXF+PGA "<,X=4H"5CNWGX4]/SHDLD)67\+1PX][<O:
MIR6$A78>A]MZN(M R#"G^G/%[*=X*<$3#0/5;'V5[%:"U>\$T\)VV(TV5=5D
M2B%"RM?>$)/$Z7@VA"HK*GM,$-M4DPY9E*NB%)O*DN1<7SBF:\E;T=]I98V=
MM^>Y&1H=EM<0? VPKG#6LF%<O-_%\4#R"X:S9SL;?E9KD99DV<DG,?UU=;\M
M2_A;A#?MW4>O >,-9YH]:HB ].C'&>B0FHF3( O7>_4&82YRR>  K7)?3:%N
M?CDNH99E9NG[:;IF+:=+(MPY1[%L;IV.$ASH=ZDN4DA(@+7+Z6E14>65T>R6
ME?"UT\OBC969CY\3<,AQU,S8AMIJE[.N5-@F@^D0Z;ZZ3=&:G=/+[S/78#PY
M")N"/=3><\H'QERCSC.\]&Q-[-QO@WD;)Z@QDHDN?&A)!!FY 3BJM\ZIV"=:
MGPD%],F9BD&,+";Z)84;7Z\>.L47Q59&Q./V<!XBATYVALHCDVM%#$*"*_$F
M2\V0F^9DFSK_9624[\U].K'"-Z_RLUWBV61JB-88?-XC QJQ%Y'SKP3@9&!$
MQ[   ^O!57 1 \4778N30ES/Q>Y,D91G&5Y";3(V4S8M0_+=W@C7XP"G%]T8
M4-*)4S87P38J9?T"< JMNO=3I67/!PD_41NPMS9'G00<WQ)@(J,#%R"(:^)/
M*J8O8=E+4 R=K\4TC1/!EAIQ8Q*]IC9VDQ?+'MR7 ==$LC=19ZW-Q!3EHI,;
M02>PHA@0<FS0KPAX$6S:#++,!XWDUUC;'0PEFD=IC;#ULDT^#O4D)GIDJ^OD
MN]))%>!VT0"LV^3&TX]1A(ZWGQE%OQFXP6.U]MBJ2X[(0N@N,[/WO.C;<#EH
M)QF&M7\>)>2' -&"_7L;]L<]K 1$[D>-F Y?\DC5"U=:G&O1-[F=]\98)65*
M6B[-7W:O0@7M@=+8W7%&)T^7NK&,C5BX$:,8"\[DV"X6I_(^+BICRU=^NZ<6
M$,BD'B['9=EE#Z0%+]?":=W.C.FAJZT,[J(]=@(LQT[(WS L*K@\VAF48&QP
MC1Q\9:S$<858DFJER"[^!)8) XIN7+Q2$FA_>E5Z[E @1XZ@(K25+VDOA?S4
MI1<MZS&C*&"-*'X,O3Q!4B2'42;E!Y\:D4T.4;ABHY>X$;P^X0)GW7W1H>1,
MU+KT4MG73O<0N-.-SLY4GF9XF=#K(IBVQ%]WOB7@=4D'#F!JL^7RNJGG1#NL
MD\>"W8W5Y1:*>*5(N+F*L_&"KL6S445HR)F3CZRNKSQYLZLKW#H7O1$6\JZ2
M86::<!9FUNUV:GP10E>IBB*Q(:]W982GCRXZTDHNIAH&GY3CT%#FOQ(\UW&;
M6/SX\Q&9E9Q]JE>"-KY1^ISA(&^GP W1!67C]Z67PMK:+"DGW@*\_6Z>$'I$
M[5XOP'M]L6NF"$*+/D#$-T&9Z^.H487CY#UB4DC4-CK?D*C=\)FU5:2(\6W#
MXCOPZTS&>?R>S&B9J7AR'>PPB!RZ#6*TC$DI-_%(%IN:+M*RWF6I"&V>B><1
M'WW+97Q6:S:FZJ7;:64K5/T]M)<Q]+:IY>.$$E]U*451]AV3-RR@RDT^:@%+
MKT# =2\% T]A#1#0!GO%?)RMO'>R7^# F5O]KKS9,$_@\4"%*R ^-E))CL!X
M_2(YBUS6U,X'2?[L7\NDJ[@M[JO>/DA?O"5OV HWANQ=%@$=NDY %HVVEP5G
M)G[>AU&"8GG^" <8R]QG2O+GO)!SM#W_!!_?,WY]4Y3-C@_2MU;T4**S86*4
MT1YCQ04:CA'LW_!6]RJMI[.:3Q"W[.4/]B4>>9\/*0?Q%!+(W!I8=5%,-!^I
MBGZW(WH 7DO<3#)+&5JB<60&?!IBYKC%-$/;E7SS^]O_WRW+@#WX_?+(<=^F
M:DA8<P"6J@,4(Z[ASY9KGS_<AT?YZ.L+[QE]X&%FY2D$Y'7V9 #50$>Y-4MQ
MPPCEC,;!]%C%[BIY")"]=LRKB4QPN3!V$POII  4_E)$YM]6*R[ZXVK%*3=7
MV,T6NR9W6!,29,+=NG0H]+G0QIDN@CU/2A3E&QTVS)&U!3-%'BW:N>]DD$VY
MNN*C9AU:IMT8W@1=M'R]DW2 F9%0N7&*1NB[EZYA":H5?9-D'94<!SNVZ'A0
M@"#4H7-Z/#U-,?,3S91O_4Y@7D/9QM2=F= ,,H5MEFW!-?T+W:;(09^M,;YI
ME=(!'JC5 #MLK31\MGD\++^&RUG-F6 :5' UQ45OFBQ8Y'"!S!$'.!7;]$IX
M<W9D6(K"5IHL35^Z.3M>9_ PL9+!%&5:%S5!LKJZ*Y4M;WD%Z0W0DZAC)ZQ\
MM:5AP_N$-%S>Z)GO>31Q[6X\J1L[YE9QT ,!9>KQ,R^4JYHT1*=/^B-8::@[
MH^FS#U<[^$[F\@SN/$''FSMF/1S%=NFT5RQIGA'OA?FN"H<_OT8=?DO56[6C
MG_#86\9-!(.!(M(DVC7G2UWBIR1*/X*8Q::+-WR!_.>?)?>%."$@IB'>FYCK
MZ)?B<:D4URUB.I)?YEI<S'MQIG!070Q*8NB90<U*SU#MDR?!@CF&2@\24TQ>
MBN%MS,9W!R/F%[./Q\8L=(U3NJ;JF[STX^8\)KU"ROY( M6I.5E%K(&6GZR2
MPB@B#F6:R]^]2:/2%&JE"-GPH">OIZYA@3UNM6D*'_:8C\_;]>/9-O!E9.^R
M3C%_@BP)$!0_VR-S$P>0D2N1+MM2.9!)4!'5[ ;,$.H;'HA@."*F>.LC\ZJ,
M75^H5Y</%&E*AEJO&?&)>'UAXGBW7B"^W+M854.LL_ 4/CW F_JB'FHG!$$M
M4_6D1OHM)/E+?HV'UOZ64^0=IUBK+#5/HUBGQ.$-;<XW<NT/'24O=G30W:VX
MN'KU%O63!Q]O9 7!<IOLZ:?I:O7VA[I;MH&Q-(S)FS ^',#G7B]H(0%]@ ,0
MR^, 39F@J7"[SGTV"0D<H/83#H#*FHAZ/P[QQ5P(&4& Y@>Q"O"6K940U;WN
ML"60R"80;13+C_4G"X$CG\./"GS]<!JL8]")AM226;[& >(-]OC$19G[W.R,
MG$(Z*INQ-*P*.$"2U_0ZAA[VK9K83Q>BHC>Q0*3D]V9#E'Y%?1V/6NY7U)S?
MBUC]=&4V%8,#^&+(=TI#]K9Q@ CFWH_B,O/2,AF8Y<^0W^C8<Z0CZ.<+-]DA
MH"D<@$@\EQGK"IGYOZ7R]%]X-OR_1-?,GZ3KT\]T??JOT77OC^GR_P^?^]NI
MRL0K7_A;URC_G:Y??M65]Q\@[> 8ZY ?3W^'65AB>C,ACHPY'?HR&L.G\0X'
MD")NGD"+&&"%%6V&.154E#%<0* =#I#PM6&72'@\$@?PE,_\+H#3K8W>Y7P/
MP>1AU@'LT$U1/_\(Q=[['?#AAQ470V2\?#\+*CW0KCEJ#G6F.#8S1^5,M%K"
M)053(N_6^4R)HD7#'?E>,DP?&1 RN0A!]UMJJ[^1TW=UAM3>S'O#F45^+RK*
MP.PWIOS7ZN5_=Z$+L%]X5?P7>6;A!Z:_7OF]"S[_U07A/P5H.>B_T2R_NE(;
MEH;S%\]AX#UZ;_QG ^>HM#1^$-"%EFO! 4*A$]BP5G4<H/Z*N1?6XKL/6U=.
M(T K\X\3,9)HR_3T0(SA\YBTY!>GVU]D$8<#BCOV7J_0R3$=>XDH2::]YZB^
MWMO6-]-X/W=QN&>I>C!&(I*(\14P,1F/U7YV\>"J>17V$AB]#VF8Q1M2]#>X
MOWI\SDUS\9<X !F:5;.H =()P[QCC#VBAN\(JB$.0!J1!NF^C=K%GM7\7@WR
MQPNM\GM'3S/_A]G!_']%,OT[^@]]JZ,1'T/VQ@TD-!VR[UR&;RC@YY9S3_3N
MV.1'3T=E)\;3HEMDR'RM<ALG^V5&M(H^+^?'FY"<>4=(?][5TL(V+1(J$0N?
M_ #V?S.:[F1@N1=MXDKS@V&BTR[@1[??TX*@#(9/Z3=I0E!KHP<+J<>>&EE"
M\&)X_ZI5V[Y9]?+?E/,1%-NU7_UQ#H1L%3$]I #B\\J1.P)_/*4O_);'& ?/
MX0 2\ TC)T>\51(FI],9./]'^QJQ<_B')HH1 UPX@)WF:^&5B'0(60,(R(X#
MY'UM:@=TQHRY7A^8UQ.^A-CFFM*ZB%C=;6=2=>\8HC'\,O!"56/642A5)-PF
M[N+>ESY]3W_B>YS,&3J_7:_TVQ]GK82@RSUT +*D1H(7E7(.#%YTNCNI8[Y[
ML:"RM\$H^%K[Y<]9Z3Q*Q^( ]*;,UHK.".-4SR6J\V"'>?GWLG$K#T>UE>FC
M=CG\49S,2K6A09.A-3,D12?Z/X]).3/62KWLK(&_II*00,M-KCIKQ0S;N^HJ
M!:]I3=%1%)#&9BG9ZGTI3_U JB'_-MGXDJPIP%.)PE6.B.SA_<)>LU26'N-R
MCIR1V-3*;BGN!MLV]LL"C@3Q#,]$L10/EQR*G^T-4IVKI<)LA7G"YLPM1)/Z
M*3^AEQ$2WLA-F9(^^X ^3[KL4BZKOG/EYJFAESG.SG-'!+M?T#L)N2[)/AF<
M@ /H"!+U.DC%< 8CC>*8/0W(2_Q@6VUO?9(O]6+K4L7>*V:H7FV=4YB)6)"R
M\WI08.1(I?)&N7*TB2IPP_G9[7U:VB=J"A52SQF%J@;6"C- 4Q1] A7."^L)
M5&09UD;D+[TZ5$M"#X0)XM ='$9HCV10,%V=^4OZ\L\.!M91QQ\IV$8/552=
MII]T=F5/&7K!G)F4*9%M<M494G3'^IS\6Y=:.&/IUFZ.."_B1% N.EL;N1TT
M\\)"Y%Z#=3\UD#V%] '9@=;#L 6S@K-&]@*:K)/O7.X4ZT1C6 :=7/M;X!]&
M)3[DG.-VQ"X:@)JHZ*J6DXO[H+R$[YW?II]T*(F<*HZ7]*?-NQI39N*?ME\4
M^910[TX*/(IO.AJ[/C@"S2:F(68>B:J2CG$^+46A<NWH#7*:W*YR5^_BU]*
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MB0WTO:$2OX 1I7\+@XJX;0;E5NS*9,!6J9#UP T)-*0/TE G =&!_)R1L_&
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MJ%FQH7+]F_M'V#^-=D(<@/\_[3<,ZG" OZ'C^$-% _X7]&A'GV9V"G9QG<)
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MHOQE#SU'Q?%+Q.)R^RI*\X^E7D+<(>; 8YB[J+,5B>8CWG/QV0O%.(!51>'
M2EI>] I\$YE]3:W[N83;!Z_Q5&3SZNDILHN6C R].3/5 =CS E%Z%]?6VJ=*
M^J)8>+#R8:TG3S]V9WEQJU,^J3*@WHT#:?T.!41TI)MF+I<X5;\[$V!9?*'1
MEN7BX\>135:($;>-[*BAL^"M9.G#K&K&94>)\[JZ;9NFB+1@<7YU5R'CCU&F
M>FUD<?>90MW=%+:)&*79=#R6"U4_=-\Z+E@.3!6)&2/K\1 /83^,@L_X'=4_
MW?Y>_U0S MMFL'%W"[*___TK]IP6$XUAK5XX@$/Z@J<_6XY2S;=RH8!.);?8
MC%\_A07C0F?_5+E49*/3'_X'A4NUOA4N[>O481,WR[7/']G]EHR^%@.(^?7?
M0ISM*SC S+2@S?^A[:W#VHRZ?-%0:"GN[L6*4[1H"BU>H$"+2RE.D.)!@Y3B
M!*=%6Z2X%??B5DAQEP0KGJ I!+CTFYGG.>?[SITS,\^]^3LK:^\EO_7;>=^]
MUA65,_#T^U;[H[85V(V6J/XMH$9_\A]/W!S]M<>S/L7!__X9E:A$J2_D[=4^
MIZ/T6$;UZ1 E(,5@Q**N\P[^:<$>/^1YT"7.*&"OGTJT)X&O%P&3C'8SV0Y^
MI'O:**C1Z>?PO;2 M'>J^,+YOV$/'.GCJ]8.\"\,ZDT$S'?[\:H$4AB51%D%
MOS!_>J<"UR@<L+*-/H8] *]L(PQZ;P$,/2YP,9*'9BH%W=&0]6V=X][:VMS#
M_N^*I< V,RBK ?3F%S,.:K7[B!C2/?ZK@QV=JXNJJ#C+RR49]<JF/]40478F
M_P4HE7]7.K?T)&M;[+* L^0LFVKS%D I3[*[2BWXDX99 L7RH2X3;# 4T7W1
M/V:7FS2AR7H_.J0.!X>8@/&0:CAHU.!& !V&5#Z>[;W<F+WL_URV2V\&C7JK
MPYA>LV@J^VJ9\7U7-&-80L_[M\\9PVJ./ VR,0_0Q;DT'4S&>R+*U8X-%Q0[
M&=DMI]''*\\I?_A3,T1<\?.-/R;U!JKO\$/6)X0N0)G[0:D3AK> @0*+PZF:
M 7>_QWF)7_[1E5._^>+=Y4R%#2C76ZCBGJTFI<[KV.Z_#6G-;=8SR_ Z!-"\
MW?N^B1H.)<]YQ;2&(N)9J2)I&9H!%*-^SESC<P Y7.V3(<P.D42#_*OKK!L*
M<"U\(/:LZL'>O,7'COO3=E,!DE[<0)!)_2I^H$#J-BZ3L<)OOC"TPQ='XZ-]
M/=2>0NVDJXE1^W3]'^=RFX8DJ2(U6C&GZ&&"!XRATK/+8-K^!W(\BYFYGYMI
M=_V\OIWITQ\&?+H%D'D>,06\N,XX,WLTHI^I^1UTVM$2* &>F%&96'G"</C*
MQU7&'>L5F#MC^_!1$W*@MP3S')EI/@5OG@HPG%FX8QARQM,%]:T)*[2'0E\$
MFR,X7R*4.($D*=<%\N813'Y!%L/A?^1_$YS27GQ)_18QP$+2P:V"U!X 4G6P
M!"@@&QJ+F2"]DL9C4>)I4 $,_10-#^UQV"-*8@EG><O7V"4_*M-[_4K0OE?&
M8.[>'+:)K8FZS%L -A.]Q.2!37,HWW3SB?Q/V?JGW=4$"2*X5&=D=)=^.LEU
ME5H/N^CV%D)JU[CK.UNO8R#V5U@%CFZ.TA'17LT"Y06UR6,I&I[A]QZS2#Z_
M<)?7&_7;:BQ91K.L-W97L5@H> %##C&<DA&5KGGA\V*M:?9%:K:O)!\-;48V
MD@4_&P.,!CX_^G5Y^<I72DIV._G/KSHRU'9D %D>J(,?O;T.(9MWE+0@EM4D
MCL@O=4 -<^>\3J4ZLL*7)",8_/ 4=MG0_ZQ\SPAC410@@IZ&2V'TO%"2W7AK
M?^Y2NDW)PU;I$L:AFS<G\RA$AO@A*SD!X?JCCDE6YB\L/9C+#%TL6E:RWRJ4
ME $Z5Z(@^L8?#%4/Y] )CO2-X1BW/&--YQ*8#7^ZM, &]6^HC11!LZ7L'U]:
M?7YB$>.2';_T#P%4ZYU1\MCHBK5.,L>+C(;VP!+["PEO@T9]O^F*J?#UX(=J
M2C8X;.3W38E-*@)[ ;J]  +&A@<B@=I5KH.O?DC]"7:M FX7,K];^A-],^19
MM;"XMO_>?L*A)3 ][&C_YY-^&%$F!4DZ5G(J[L-G0]M4FRL/VI%!D1V/T48H
MC1_,[-,8_9:*=:,OM6W-WU$X>J:ROP8KZ)YPKYCU*Y8^'/,+N?BX#ONY%,NL
M#31^/C1$Z?Q%#O9);&]]#;I(T+?J..$R+V[QP.'73H*",T?"4ANY9@=G E&^
MB[)/XDR;$[HB0/L+AA3%.).QX1>?O>[O*VY&/:F:L:J-W/TCJ>Z\'FX%2-CO
M;)-9.N3FI14("LG1TC:UDL^?Q%S]>MK_=$#QZ<#D1(CIG]6N\J.K]^#+O?T+
M'I#0A],1^RU_G]>^Y Z??SUAT.#]GB2:XPA<?'=#)-H#(:P\3-QH"!NXY/_.
M^\+F7=D3[H?Y C>_<7)23]_2 HC#OE0)H ^0T-?H1I(/[R;/1C1IKG M:F>C
MFJO]J^K$6P\-;XPH[.5@7 G3B9LY4HT0QJ!?=\A.VL;V#1A9'L"SMJRULF=M
M\V[JD+/K8^\3; C67,C%>ZP]<PLXA,)D+^CQ=6; JW63-$-Q@N(S&57/F$Q_
M(JI5K1SQ[Q^QF*=?>\^W;@<0UJY37:38!]23.]OA8UNZC6'),JM( 6<*.#)D
ML.U^!C&VQ\^N%QUP>KA1[MWO3RV(M$E:T$S^X]W(Q_J\<9O73 &;FZOM\)!N
M\ESG^G-YQY#O^370XI?YX=S"T+8)ORK"-E$1$V*XEB0#-;X*9K0JPF5G?_HM
MF.H] /N7'BE?%*7P;V4E 3I8YTPT@*?BUS7/U,SOH!2\?5_M_?I; (>VRBV@
MJNSHFC^G_5U;[KGQ+2")._\6,#M]<9.F;5YCHG_#'_^2Y:H>^()21^F=]S_J
MHZ]*/S0LAQN=6[R33H_;)T0:(!\]P1UO$DC].%M035;T"#?A:95!7K!HF]0W
M4_L.YDFQJW;E0//#B9G'7%,NP>3+TL5$?"']6ZPU W1<=?;_<=/FG^ITE=Z_
M5W.5?[YHT_?O%VU>GN6%S?QM.U[U/B^:)_@?[QE%H^W6)&,]A:+6^V@@= $Z
MY7<G+H<T"%K9)2_2V"G@ ,KJLM!,^_?MN_I_;_OSCQVUYV*R;"MN >\JBOX^
M<"HPR)R_!0SU._Y'SU!G;0<_T62R-N#?6S9WO*#O<*RQ%5_QO;1M6N@_$$'9
M'GO+E3YH8@4P@[&32*W*)14,^[KR@+H:K:?7K*FU)8)?X]EH+9Q/3 .4*>;&
MS_?YU4$SF]PGSS1Y%GE0Z83H"'$A)^A],E:\5'DJ6T8V1L(NNS;S[8%'O%OL
M15ZZ!E$N,&CDO H.(<-X3KCFCK3&#$AFE%F3:]9//=&@N(K%?:5R05+HD7X+
MJ!<*EGV.J#H0\ 92<<:'>;!-G$:V\92J;8\UZWCO-VSB_9!_M1K,XF%93?%;
MK8W!MD/D%O A[V=@LD$&3EUK(B[->W9J);>EK[:\_B[L7Q\UGE<* P"> [27
M>M0#80%OK[^>:A./%*'-KZY\%)NF]F<0EX<C+]H[_&FS>(1+&J.53B(Y[)Z^
MTG#WGO5!6O7G,*!<PR(PCXQM#M/A<0+IVG4F!](@HN'(@OUH&P-\+((T;$[M
MJ4NL=X&MJ+,QD*3IA/6,YY"35;/_XZWGE$G=N)]J$I[C +M5G\(<[VV'!/7X
M"8SF!K>Y5JC'I@6QHKY5E1J6$6)CY8X8,/^TLCKJJLH/_M&G-U[G#R1QD/"S
MS;YG/&?476W20]M=X"C\)1! Y1Y,/+!CQ@G%^"G=''@$0B=:-%C0IS'7"VE/
M#__V]_ZWWF_P&U9T^BOD07O^/-A*'R6JOL_D6<7M^8RXG",15WXE=4E/<;WZ
M6W:CP2,W][CDQK,M<"Y&@ AR$V47"SF* =ZH_9U5%@G\G08>N$'7WA'(C//V
M%*<*7S@F!G4+$(7NGD&V]Z[2_S#S_!URULMRJB%K=0L(,+H%'&O^'1=V=XY_
M4=L/O.C+O4O1V?K]?!OF">!@)\L)B:7!35!G,R01D?O/7QO_UY_R-X<5,LBG
M^*M"'F$@/^6K_D>RMX#_H?#C\\0;)?0MX%.@>17F&O)WQ$K?W\EI8?^IF7+5
MGS7G+ZC\H5F_L3SSZSPYNQ[!0*G^CG-#D%QRYCRY!73PWP+^</T=L\9Z"\@S
M6F>Y0L#N8 NT<![X>/[T/V3W>6\!L-D+H6-9O7]6\D^+J +-*P_+%4 2@X!;
M+ 9WB .T6.H<1&G_LP+[?UU$>Y7E7]>P_,,U9=.W@-RJ0XL-<!%&@(04,LZ/
M@EZC[.YP1 S2_0N%>TT.NP.>56H()ME\]GO<_]BTPQ(Z!^S_""3ARW:+/Y<W
MFS<JT?^L0>7?XM'B?]GC@A3\7Z5@LP.8B<Y_2%G\0^I_6[CX@?_C>159X%_3
M,'?_U[U8KAL^RHCZ'W@_Q:GP@.W_MC?550J,HL) =R>MYV':7VO.WUGSN@#X
MOSOPC\?:6"WB*,*"I%R,Z3D<&NWB<K#5E%C80%V(/R2;!)#4(L&:\MP'-=VY
M-;\J]T_A_^I6A_,^!MYL&VX?JKLM?!;NGBJZ_W#:V]CIOQP7-@R\_Y[M(NWA
M_XF3_C\Q]YW9\G/^1_@P+)$A5_ _T\?R?]$W2[-NYM&7PXY*#SGS=_UHSAN_
MJMB>LX602OLE%HT4>RO(S2[E=&*A?0=NKQW[!7<)_B*C]">U*2A_::O?7=YJ
MWU!#(TFXX1:Q"K*Y:3]O 0>C0O]J,-%5%G6)UU>J9]%WJ33]JZRS_K^XB;RF
MPKG XFWHL=  9NB<ZK\+R/\1WC?_/V7O/^W3QDTM^E\QRN*_$HMESH+#<O^<
M'?\:QJ"D1A1--!Q=$8CP0/;T65CF*H5I&@;7G\CVYA@1D&VOTR;X[(-VXG+5
M95N:9G06_OI+A/-#UL'HFYW*.XRF_$<>;=^H_:=Q<WGGJG^#O?%?I<O79?\-
MFU_JU.YH_!NZO_OOF,Y?_D[M_]GHL[> WZGH_T)=^$^SXV/GW4JK_H_1\=\$
MOW\I?!2NT?*L_4#X&_1 [KG3P,W2; 7:^]CL^?/O+3EC@=)&>4;T$WNNF7CL
M,@P.[.Q?NX#&XWCJ-*AB=VT;*[_7V[B^FIU[@SH3T8^+I>__[S/CGS]CAJ"X
M$;D8MCO.'XZ1L[+-@$;*JKCQ4TN<P#84\Q[_3))-<GX'N/MP) &*?C,_13&N
MB-YQ11\SY(8^[KX .",[=3O7^8D1&1TEI;X^PW<%QGO"VD]_H,^0^3U >N5D
M^('^S;8:"N>!IH;*E.>?@-8R ^B[UG[_6T#%R]B3@<+WG7AM)BB&+B!U,MRG
MUR3&@N*YU[=1_SSTMQG@'7A&I9IQ*UQ8$!8D^*TGS]3'^N9[OMT<X1-="J *
M1,34E+-0S#N<RYM_%?,#UZ1T?K9_>)SS\M1=1)710)F6(KA'/A79WS#[*F@D
MMXY );"XK<4NNEZ\_M.*.L<;C0]OS*ZB^&(KB57J_=C!WD# S3@$5U L9O29
M!L)$0%' K*@U[4T'V8)OL9%1Y'W#>Q+!  #Q?:#MZMFFF[^)@^ONN7R>".#9
MTM]A02+H$)2*/A+:9Q%A3MM879>IB9*=U='T/GZ2)L1UEV"\\5(P74UP;HRG
MF7^?.3&ZHHA!4_]HX "!UUE=;R:L_NWQA;*SODS*CRAV1>S*32F1]QK6ISE2
MOV ?@_AO8/0@33?^!--=]2,O7X&IV%N C6[O$)]HXVB633SNO<B>5ZF:)(4X
MRR+/N+\4VO(60'465SJ4)V2ERH-^95A "RW('#)L6VTJE^<Y-ZJU9A=X0E\J
M;(K\S!.?(T-2/N!?;/2PT$:_4SMLXRD4GS[U*^QM2*1S?:M';OI$H44).Y70
M%[O!D=&I42SV3W;Y&^2;BVC!C5D@G*MV<C])3O'%I&9L(691 2JP 5.1W2"^
M[YGWS(\LIZDJ0MRUKFI__DKE0_L4O:9D'_V7^I25T0[A^)#7$HCW6/V3B0=F
MZV _(:P /S2W?Z'9+HL]2KSBE+X5YLM?YE=F;:,X_/,9V[3JPEWL/2T[]]F[
M-H0M+&I #.2_B3@_Y9=D#FTN.2.A)(FD3ALWG&-Y6!\+E5M_&335J/#CQ>N=
MZF]J\O4GLSUQ[%K77VXH'>6Y9KPRXVCZ-"I,1R1J0(]-LCDKBIZ&X,'9R4H_
MFD>X<9![F!%=C^S< AJXDOD-# RH3\#TA_ OODL%L8W"<=TBWA]9O0!>XK)I
MWC92.YY^V@/0R(S<;EAX$!M**]4&5&RVDW8##CU4?L'^'@>N;%+U,CY;R<>[
MD0OTV-:]V(RJO9D*Q=QN4Q2@?1V)>8["?6.7V^<7UW;YX0+A0ZZ(".RTQ<E-
MX]39_'1)-D0G5:4T<^1ZPX;QG@F@\/4JB!&0[&E(E\CPKG'EJ(%MTU!H12>Q
M\K>^<I'BP\BX3P>-C;^X,G,)E+8H$BN%UX82R_&M5U&@6=X@T[*1H!Z_W#A7
M604?UW4\L?FJ_4K;!DO'F0ORAPP7L1JL^'F*/@# (/NCT?#KU2X(W<TO?6::
MI$TGSUR219"$/L72D'OU4ATYM8T(M>NGTB11Z%AZ;<MXZH&T6*#7%F%BD[47
MY;=G#'0,+>NRLZ%@[BYFNBE/8 2SW(3757'ES,.MI!N"N(.*.I1E?C.WO-V8
M#^'U!+$$HFVRFYEQ5EX:(YS;5PUN5/]5_UO<)*9$?*8N0^- 0E700KC6=Q?G
MG3C!YII@SX6:%%^"7%[-^3,INKL\JT?-JJ"52M'J(Z\)1Q%$:DXX8>'U>L=_
MQOQ9?:+PGE[=3/^>T=+,>GG(\>Y++5:PEO1ZXT2'!3H"'FBPWA^"PEE VUWI
M:<V\N_DY[@4Y>(@X3IL?4K/2&Z-?][!FR7XC5_HV.:U0<T&:1=/1P$#_G'S4
M#L>'HI0\48,MSO!\)-PI2+G-'RXTP$(;\!;M8X4XX.XR-J5N#+*/7]CN)=G:
M9$H(BU%\H'YV5V%K?7H;T9E(*\V.#AGQ19Q (?T0V"C3!I C^/H]K;]P%<MU
M$H8% 2$-&L[@]U.)X9IXT;UCU6CRU%#H\L5GLPT7P$GRE&V% L>@AT\<M%3V
M2;DI2)Y^HIYA3_2;V?+"<]D9E\58XM]T^=S8G&KLR JS-2]VW*]5.3=2 PB"
M=KL>X\/P/!.,(O(\+?V]8P>M1FJ\K?MNWA9KD$&22-)C7!R7IZS'$D$L:-=N
M%IH@*C#UB5K+C.5X'>BH84'Y0M=D246,7(U!P2TL;6XQ-16*/"O_8U9I &RW
MFCO#.[2L_;R_%K^U^?H3(NTY>:U5L"'?6_]@T,^@>QBG5O1HX5[MBCT/O/6:
MY76F>DNU9*=CDI354YD:>BLI'*]1OQ9!FIR@^F,H%*,(M,U=T%WOG>QC14*@
MGML:G]:@WN(F-C\-6583\72N$=J%INRCX(H^7=.&S+D+5WSPR6N44+RL00'$
M>K&OT-YC '1=R 3W$!LE']8;>1*,7_9-ZV0$:XK^(.W9/%:(Y>Q"V_/^BY;9
MKJKYB-Z,Z0P2M+J Y_R95 % 0G#3BB,^4+$VR]KSU9.0Z)/.J$M[M =R%EX$
ME:7Q$ 6'7:F\##6!B1<DFWS<+QUNQ,E=J75=PAO"/3P8($BZPI5KE*\3N<^8
M\&0V0[8K@0 K)_A,_(0X%3GY$AV&@J[;QI2/EBXYD$%L1IDR=@T>EK OM%+?
M-Y5P5R/(S@?ZL%J-YOV:"_JY2B3/J5GJ."LO4M<Y\16JD_XJ98NK3<,[\MM!
MYDOKC0..'#7NC$*MP]D#=-1TH]8M(.2<:?,B:AUU4%@GX></UBSG\#U<T;_2
M7<9E>,6MF8DGM9>K'HP>;]. P\BTX;AUT_6:4H?\<"/3<A)?>FOEGS(/>,M5
M.@M];1N=(/#J4S#A!8F#[]I56L;TM@>!<-.;0<4Y7%RZ>VU%<+L/IQ4RYU;H
M27\KU^OL8H5 A&I>4^UG>"(YMW?LO0*RT+(;3?7PB2FM;PWRG<CVL3*W+SL3
MH(3%A3T2EX^'!/I"Y"]5?I)!W^ ^%2^OI/7"W;%@W/-.<DP#?E^0+RHVR58*
M@GF?7TST3Q2=^S_!)8K=!@K_^>@W<Q3L>?"\FUGD^FL $YQOR,GY]$!Z^$3I
MX_'.1OS$(6(BH.,/;4+ANJ([N-^AR:%I6OO7Y5=KPMX'./%-!YK-3?$3-!E&
MU(\3J.VL@K^XJ\E_JDIVEB7S78_L(-+(GP-'J&9P$"%B4II;)X/&L<+X:S49
MV+(SWI87B-Z3]'8RJ+B9,D[=2KR2QB@V38X0%)\Z=).- %Z'0AY!>+6H'7SH
M2SQ7K6J10K$0N/2XU:S O<HXGY,YU=='33%/*?SYO,RE=$GH*O4&6*CJ+0@P
MEFA_^$-^IZW)-LWS5>F# ML,=AP%)"DAX2%C4E!J5X #J@+6?0N8]W\&(5EB
MDF;X=%K!XYHON["HN=D_P;.O:(T]E^ WHQW71I8'?G[^"<W$%>4B0&[O9;],
MKLS#9F)X/M@C.^C#V,E9C<<QJ:.VMR7DX.5Y1ZS"73$Z'A7H)#GO$>WZ2;:6
M-Q.<=:DY:FMS!&)?D.4,[/%/S'@'*\9#+NG_ +NEM>I+1Z]4[3.(2\\O$V=T
MF:0UKH;P7XPZTY$=<J3J<U3AQBT9R GU0=$*L@(HP:W5;DD+D@[..; ?S];X
M"%ZY=12G]957+58]:BL)<\];<']=7"NGA6"AH%Y^G/Q>KS6Y=+!?H+T(H$L-
MJUUT%)P;$42/=A30^+$B-NZU6$9Q#A14:FQ::IG+$'YN2J[]Z4<<_!)J:I *
M]IX1BE[]?M..PK_< EDP2BZ>W9^V:K)IFCQD3=(6I!T+>J%#7P(-5E;#R9IZ
MO%3E %JZPFG"3HX>0%G$B!T]0(-T9KU,"NHGRUG]H[8XWI>*#I0\7?,1/][,
M,,-HHFN1H8%^)E=V*)*0[99I)X&C;Q\EDTDE),J(P@1_["^H_I!B-"! Q'&1
MH&U6H2TX6Z!1H1YFKM8(]>A#_=0*=@.H8\D[K0<7_=I^A=JPR_8H+W^AW5GY
M491@(2*R7HCX%O!V;L[,8=+L8+J@+3%)5:#AR3(IBV^C,ZU<G.?6J[(T-K>E
MC#^-Z_)Q(+@V8P!^X\3+%J\:%$]XQ9?F1#8O81G2D5:B$X_!\C)@A+1!? =_
M@/M$?6:<UK9& WU ]?PMP&'I40$4Q+;T, #Y(Y6.E5EQJRA9HW')?-+$+XA[
MVHC2MD-THG[Q6KN+Y7M#A9?_^\O4PWRJ]N6AE(C/\B-"Y(PG2<$G2_HW)8@X
MC:Y.*HC]Z'.-),U+BX_[50?.QR]!;N<.GZKU^M4(<LU/ER5KS*>]Y<O(^<BQ
M[ZGH[)@"^W-9+##B:"L$D,*A(6WVPN]-2OJ[E5T]>F&='.]0[4EH!7CV0Q#3
MZBXN?!5:!Z.Q/_=&_1%9,C-:7*(3;[)]1<^SO,TV_SF$<%B]^F#T??IY Y &
M8LT2F2,U8VRR2KD<I[F1-;CBDKNIOD/U_>W-P0L0\ZOWBU%2RZ^_)%.6V@<^
M8>G=FMB7Y?2MY*<^#V+3 %LU0]G86I.$1QBL<Q@W>&"FV%E;K6<R*2S&?ZK.
MDS@A[W9<$O:;ZR=/RS*]]4)K.<XWA0/= 1C0;V=R^-9$^4;F9BI<Q>UWGP*P
M1#Q9WX!7Q'G7G86A@]L4PXH&E:,[!'@%W@GPLHDU?#>[_O3]$/_](LNL;(BA
M]%'?*BW:HFL$<9=T@ '?PL*FUF:HTO3-M >AC(^HKRNAY7F\JO[0 "!C[+IN
MCF4>@J =A)V[:E_9UZ_*UQ3]MB"X!=352R4Q2<^J4FBS9SU6BA#([2[E<5^.
M-]CZ+H8A67=F1["$BZV2_?:)"BS8%8[ZDBT3-D4V%Y:@L$&J4+&,Z"!!:R!'
M>D6#^EM4(D^O\.);\W9KT9DJU3+I!]ZA[[:6DUN&0R+UIKYG7+@2@Y-FUU.,
M8;%M4GX97FW&=)-UHUJNJ>RM:4 1(]$EI18.F*V1BJ-[>$[LIZEQ,^9C#IS$
M)G(9[&<)U.SOGQZL=!BA.2%<(>O.,CWF7,C @= ;MH$";=?[^Z(,<4#3UP_-
M7471A7H?9;H"I(9D\;<\@02@%2FT"EQ&=6W&$AW.$N51!FHX65+8?B;$02-T
M/O?91_'7MF/9^3, *WT0S,S0WTQ,93Z.5<LH%.KWWM*"9\0N$&6!@/5V8H_Z
M?BM@9FZLK9[</_-JRD'0<C08$?UTXM(7-.N<86P<SF?/6HQ1FI:E6K>8OU*;
MPFC? O $2UQ]2W<:,[YCD[63S6O66YMFI;(IJ\E650AJUI,XS Q,R43(3M%0
M=,X7@@*A(B5SY6"!>*S3K0[;YO&S;+N^W#JM,'BVR16#[F>QWW7;:7;QCVV3
M1M4 8:DKO?<,LCI4''VZY;1ZWLP$:'[9[2#N1'NL _<M3BM$5MXY57[5YQ5T
M+E3$9H)]9'VPZ9%3YR]IV[/ M>\_&RR$4?.%R\F[TBP8&8)#$N.6.[+9DG#>
M]A*5^^Z$>BQE_)X.$U0@)%'D6^\,-VA8F-V?1AI/ZK=/G?&-[,W;Q"B'ATE\
M_SW9F2HC-9#21-P7A?L6AQ'1CGUNZG\@V0NDJC/IU9 )E.S%;[AT;A^!W<\8
M<J:,8U1*537[J74O)&OMU4X]A$VYU/M$_F/>I\JG3*./]XR8L(O_7ZY#\Y"(
M/?EQ6HF-B.BO(@E@D19%9Q_R\]>;3$VN=9*YAMA"6CC>!BD$:ZG^)BD4RQS'
MJTN=KT#< CXNL,2="0B]FF;]?.39*3R_9+(TA)- LT!;ICSLKAARRO4%>=&]
MS-"SL+0PG-G^W#B-I58BO\1,KA?!O_V.^JD2C.,QW2ZHC!R;-O!'K)U<S9XI
ML(<D]H8)W<K5<$.7A+@<4>M(ULQ!]U,_R!8V>K4MT,,S2-M#8@SZ[*2QN3M,
M?C-F?C^S.X<=N;CC(Y2'CC[4.-"=KY?)/X_*;I1Q.9$41&"QJ>*$#%"5!2+]
M>PP6MC]ZE1Q4?IN6%8O/L-ZZ>6])G,G"*L_"U[5$Y$.IJPE-9:$V1G.*,X$,
M;@$?PN #O>T,?1<+X7U3QV@+_20Y7GT'VOR"7'NRX@5EP])&O?CI4\%PI/>
M3@-2\Q80S=DVW:8)!W>.>SWH^*S>^MB GRS5FO.9KI'O@ MHHM=1OJ.N]*O?
M&ZG&&GP\T:&VYU<"&#F49-PFRFPF6<RXHNL!TFA5VY7H\ %N+J,+M3::=+M#
MA6H7Y)3XH[H?QZT82Q$5+$.B8-@AATIA!B#3*A ,K:"8,CF)^<-O\7,\"7FQ
M#=BD3YG/K+J9.</ZY:G'ST;L5_B<M<88YI)>29:JADPQ^O003C4&CHP#]6*
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MJ<6G7.YC;@'MQ[\*P&97>HY)#W[QD77:Y>)T!M?= NYGR^_=D)7AW2UOT-'
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M(JNAX1AU61G)B'J>NCB)^PW1JEO-T;0; NYC\8MT!3H?\!6/\99UEM';?9?
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M9\J-D:6Q;Y!H^5JW3+7<F58S1#CN.C;[D(0H53:ZK,=USTK>Z.P$,Z9^"T!
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MQ%%Z ^3@&,2W<$NYHZA*,>='JSJ_;@'UY>SUS4EJ[,D;UG'L2X7)L<5RI;>
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M;DH0J--G @\S?GKN*KO.+5O85^(KI2=C4]C2%C_"#_/79]2UR_T#*)I*FVA
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M%N9\D'34N_(P*EIKE"<U*/54$,^[?[50O@>;]QS&P]8'<#&U7F_,SO37MUA
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M@[JASY,$3?[<&0B9L ;=.?[=H:G;ZR@L\(E4L>8;$W=U-W_NZ>>F='$.;1C
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M24Z*SR0+S>TG(NGJPS]2HGWA=>OU*P4$6RF@TI&F:1\^'5!>F0^M$N9 Z.A
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MO*7; 907\0G?\)!&#\[@+1.J&^"" "7\;\NU=,H+\ X5+CN!',NZZ32BA;'
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M'?1M[,JC$WCL3N64"E($?N16MW?[WNVG3$(<<;$Q==N)$A;8I@%MW80.0K#
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M8VN^L&?I;<RG?BRPS&2-!7SIT#P_2;PGU :D4;)!H%%&R F^'7@3MS$'_"1
M4H,OS(>;!>Z?CL,"U\8UCY$PA,J/@MYR:KL4^^C[DV>XI*178@"#%D)I_2CH
M'/$44ZCN\_QH'/4OEO+[___#B%G,952[.QUBL2!;H+'!W>RR(=4GX;<HD[0J
MYG)9ZN0A$9MS3C[DUK=U;)03M6NL?9;4_[2SN[X,P[-;0H$NW8;,'F[E?1.
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M6I+W[$H1HC#)]-#"U9P)=TXS'13R&CL2/^Q%Y7Z$/KC;^ G? &1T4#:DX'9
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MY+ML\ B@N*5"=&D5N)Y, S<;,'L%JD[]8+$CKAE6,B&%8J:SL1HGNBF+('D
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M%80TN'$\Z _1_L<FX 7[PXTT(?OKB2 A0T'7Z;'+B@:)PHUP98/V!=="FEL
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M>KW_3BE:JGA6#5ET4<A'*M\7 DY4 4R*(SVO1 >322"$K'Y3MH"($@L=V'/
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MD)4WQRC1KIH\02H9\JF2<869EP>M[C(L^::V2Y'].YKNI<_C_P-02P,$%
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M)['S59%BZL4_"Y.G'" ^Q<1>0%X>+';JXQO;:PY<#(E,K@*K$CU?B,[U_4T
M5T3&&7AGYISC/P$XWQ0;SWANSQA-D4@BJ=37*C!.4X;G+]@<G5\H7%YV%?F7
M@N%@(AG2L0+YV">(.'P$$0W?JAC55U[7SUTIXTOUG<D-MR/QQ[D4RSS1_$[(
MH"GI6U>.NPTUR]-%AR/1M>IW=X?KU?>:.VQO5[:Y1RW(G%HS2<E'BZ1(Z0)R
M)UA28^;-F>UO]IY*Y!JJ6EW/FOO>_A]02P,$%     @ DHA]5I['EE_5!0
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M\"C"<DRGK$K?#<^$202ZD+34Z+9U,\$*&;M1O?D(=ED@RV7;]$I8CK6VEN.
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M,#(R,3(S,2YX<V102P$"% ,4    " "2B'U6TJPU-O00   EYP  %
M        @ $G$0  =&UB+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "2
MB'U63'=(S48I  ##IP( %               @ %-(@  =&UB+3(P,C(Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    " "2B'U6$MA/+45>  "49 8 %
M    @ '%2P  =&UB+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "2B'U6
M7#[GYB9'  !N*04 %               @ $\J@  =&UB+3(P,C(Q,C,Q7W!R
M92YX;6Q02P$"% ,4    " "2B'U6YF;)BP\"! ")?"0 %
M@ &4\0  =&UB+3(P,C(Q,C,Q>#$P:RYH=&U02P$"% ,4    " "2B'U6_^M@
M"V^8  !EIP  %P              @ '5\P0 =&UB+3(P,C(Q,C,Q>#$P:S P
M,2YJ<&=02P$"% ,4    " "2B'U6/WYFQ0-Y  "]EP  %P
M@ %YC 4 =&UB+3(P,C(Q,C,Q>#$P:S P,BYJ<&=02P$"% ,4    " "2B'U6
M\37'OF=\  ! E@  %P              @ &Q!08 =&UB+3(P,C(Q,C,Q>#$P
M:S P,RYJ<&=02P$"% ,4    " "2B'U6#9DTA:"I  ![R   %P
M    @ %-@@8 =&UB+3(P,C(Q,C,Q>#$P:S P-"YJ<&=02P$"% ,4    " "2
MB'U6QCJ=,!P] 0 B> $ %P              @ $B+ < =&UB+3(P,C(Q,C,Q
M>#$P:S P-2YJ<&=02P$"% ,4    " "2B'U6$V]X%)?(  !9\@  %P
M        @ %S:0@ =&UB+3(P,C(Q,C,Q>#$P:S P-BYJ<&=02P$"% ,4
M" "2B'U66J,#!$%4  "\7P  %P              @ $_,@D =&UB+3(P,C(Q
M,C,Q>#$P:S P-RYJ<&=02P$"% ,4    " "2B'U6Y.]@*NZA  "YS   %P
M            @ &UA@D =&UB+3(P,C(Q,C,Q>#$P:S P."YJ<&=02P$"% ,4
M    " "2B'U65LR&Z\^$   $LP  %P              @ '8* H =&UB+3(P
M,C(Q,C,Q>#$P:S P.2YJ<&=02P$"% ,4    " "2B'U6%5!) 8_R  !T)0$
M%P              @ '<K0H =&UB+3(P,C(Q,C,Q>#$P:S Q,"YJ<&=02P$"
M% ,4    " "2B'U6HZQ;V$5D  #@A   %P              @ &@H L =&UB
M+3(P,C(Q,C,Q>#$P:S Q,2YJ<&=02P$"% ,4    " "2B'U6W\ER 5<#   <
M#@  %P              @ $:!0P =&UB+3(P,C(Q,C,Q>&5X,C%D,2YH=&U0
M2P$"% ,4    " "2B'U6;C7B6B8#  """   %P              @ &F" P
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M,2YH=&U02P$"% ,4    " "2B'U6GL>67]4%   R%P  %P
M@ $4) P =&UB+3(P,C(Q,C,Q>&5X,S)D,BYH=&U02P4&     !< %P =!@
&'BH,

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
